#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau



# 

#### (43) International Publication Date 9 October 2003 (09.10.2003)

# **PCT**

# (10) International Publication Number WO 03/083047 A2

(51) International Patent Classification7:

\_\_\_\_

- (21) International Application Number: PCT/US03/06025
- (22) International Filing Date: 28 February 2003 (28.02.2003)
- (25) Filing Language:

English

C<sub>12</sub>N

(26) Publication Language:

English

(30) Priority Data: 60/361,196

1 March 2002 (01.03.2002) US

- (71) Applicant (for all designated States except US): EX-ELIXIS, INC. [US/US]; P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BELVIN, Marcia [US/US]; 921 Santa Fe Avenue, Albany, CA 94706 (US). FRANCIS-LANG, Helen [GB/US]; 1782 Pacific Avenue #2, San Francisco, CA 94109 (US). FRIEDMAN, Lori [US/US]; 113 Arundel Road, San Carlos, CA 94070 (US). PLOWMAN, Gregory, D. [US/US]; 35 Winding Way, San Carlos, CA 94070 (US). HEUER, Timothy, S. [US/US]; 581A Paloma Avenue, Pacifica, CA 94044 (US). LI, Danxi [CN/US]; 90 Behr Avenue, #302, San Francisco, CA 94131 (US). FUNKE, Roel, P. [NL/US]; 668 Sierra Point Road, Brisbane, CA 95005 (US).

- (74) Agents: SHAYESTEH, Laleh et al.; Exelixis, Inc., P. O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

/083047 AZ

(54) Title: MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

(57) Abstract: Human MP53 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MP53 are provided.

# MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

# REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application 60/361,196 filed 3/1/2002. The contents of the prior applications are hereby incorporated in their entirety.

#### BACKGROUND OF THE INVENTION

The p53 gene is mutated in over 50 different types of human cancers, including
familial and spontaneous cancers, and is believed to be the most commonly mutated gene
in human cancer (Zambetti and Levine, FASEB (1993) 7:855-865; Hollstein, et al.,
Nucleic Acids Res. (1994) 22:3551-3555). Greater than 90% of mutations in the p53 gene
are missense mutations that alter a single amino acid that inactivates p53 function.
Aberrant forms of human p53 are associated with poor prognosis, more aggressive tumors,
metastasis, and short survival rates (Mitsudomi et al., Clin Cancer Res 2000 Oct;
6(10):4055-63; Koshland, Science (1993) 262:1953).

The human p53 protein normally functions as a central integrator of signals including DNA damage, hypoxia, nucleotide deprivation, and oncogene activation (Prives, Cell (1998) 95:5-8). In response to these signals, p53 protein levels are greatly increased with the result that the accumulated p53 activates cell cycle arrest or apoptosis depending on the nature and strength of these signals. Indeed, multiple lines of experimental evidence have pointed to a key role for p53 as a tumor suppressor (Levine, Cell (1997) 88:323-331). For example, homozygous p53 "knockout" mice are developmentally normal but exhibit nearly 100% incidence of neoplasia in the first year of life (Donehower et al., Nature (1992) 356:215-221).

20

25

30

The biochemical mechanisms and pathways through which p53 functions in normal and cancerous cells are not fully understood, but one clearly important aspect of p53 function is its activity as a gene-specific transcriptional activator. Among the genes with known p53-response elements are several with well-characterized roles in either regulation of the cell cycle or apoptosis, including GADD45, p21/Waf1/Cip1, cyclin G, Bax, IGF-BP3, and MDM2 (Levine, Cell (1997) 88:323-331).

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms.

Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as p53, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

10

15

20

25

30

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

#### SUMMARY OF THE INVENTION

We have discovered genes that modify the p53 pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as Modifier of p53 (MP53). The invention provides methods for utilizing these p53 modifier genes and polypeptides to identify MP53-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired p53 function and/or MP53 function. Preferred MP53-modulating agents specifically bind to MP53 polypeptides and restore p53 function. Other preferred MP53-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MP53 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

MP53 modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with an MP53 polypeptide or nucleic acid. In one

embodiment, candidate MP53 modulating agents are tested with an assay system comprising a MP53 polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate p53 modulating agents. The assay system may be cell-based or cell-free. MP53-modulating agents include MP53 related proteins (e.g. dominant negative mutants, and biotherapeutics); MP53 -specific antibodies; MP53 -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MP53 or compete with MP53 binding partner (e.g. by binding to an MP53 binding partner). In one specific embodiment, a small molecule modulator is identified using a binding assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate p53 pathway modulating agents are further tested using a second assay system that detects changes in the p53 pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the p53 pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the MP53 function and/or the p53 pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a MP53 polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the p53 pathway.

25

30

5

10

15

20

# DETAILED DESCRIPTION OF THE INVENTION

Genetic screens were designed to identify modifiers of the p53 pathway in *Drosophila*, where a genetic modifier screen was carried out in which p53 was overexpressed in the wing (Ollmann M, et al., Cell 2000 101: 91-101). Modifiers of the p53 pathway were identified. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MP53 genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective p53 signaling pathway, such as cancer. Table 1 (Example II) lists the modifiers and their orthologs.

In vitro and in vivo methods of assessing MP53 function are provided herein. Modulation of the MP53 or their respective binding partners is useful for understanding the association of the p53 pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for p53 related pathologies. MP53-modulating agents that act by inhibiting or enhancing MP53 expression, directly or indirectly, for example, by affecting an MP53 function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MP53 modulating agents are useful in diagnosis, therapy and pharmaceutical development.

# 10 Nucleic acids and polypeptides of the invention

5

15

20

25

30

Sequences related to MP53 nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) or RefSeq number), and shown in Table 1 (ExampleII).

The term "MP53 polypeptide" refers to a full-length MP53 protein or a functionally active fragment or derivative thereof. A "functionally active" MP53 fragment or derivative exhibits one or more functional activities associated with a full-length, wildtype MP53 protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MP53 proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan et al., eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MP53 polypeptide is a MP53 derivative capable of rescuing defective endogenous MP53 activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an MP53, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods for obtaining MP53 polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of any one of SEQ ID NOs:57-112 (an MP53). In further preferred embodiments, the fragment comprises the entire functionally active domain.

5

10

15

20

25

30

The term "MP53 nucleic acid" refers to a DNA or RNA molecule that encodes a MP53 polypeptide. Preferably, the MP53 polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MP53. Methods of identifying orthlogs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA et al., Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as Drosophila, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul et al., J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is

being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

5

10

15

20

25

30

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 Nucl. Acids Res. 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of any of SEQ ID NOs:1-56. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g., Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of any one of SEQ ID NOs:1-56 under high

stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100  $\mu$ g/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100  $\mu$ g/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500  $\mu$ g/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100  $\mu$ g/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

10

15

20

25

30

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

# <u>Isolation, Production, Expression, and Mis-expression of MP53 Nucleic Acids and Polypeptides</u>

MP53 nucleic acids and polypeptides, useful for identifying and testing agents that modulate MP53 function and for other applications related to the involvement of MP53 in the p53 pathway. MP53 nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may

require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of an MP53 protein for assays used to assess MP53 function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (e.g., Higgins SJ and Hames BD (eds.) Protein Expression: A Practical Approach, Oxford University Press Inc., New York 1999; Stanbury PF et al., Principles of Fermentation Technology, 2<sup>nd</sup> edition, Elsevier Science, New York, 1995; Doonan S (ed.) Protein Purification Protocols, Humana Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MP53 is expressed in a cell line known to have defective p53 function (e.g. SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

10

15

20

25

30

The nucleotide sequence encoding an MP53 polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MP53 gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the MP53 gene product, the expression vector can comprise a promoter operably linked to an MP53 gene nucleic acid, one or more origins of replication, and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, etc.). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MP53 gene product based on the physical or functional properties of the MP53 protein in in vitro assay systems (e.g. immunoassays).

The MP53 protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences

encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

Once a recombinant cell that expresses the MP53 gene sequence is identified, the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MP53 proteins can be purified from natural sources, by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MP53 or other genes associated with the p53 pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).

Service that is set the first of the first

# **Genetically modified animals**

5

10

15

20

25

30

Animal models that have been genetically modified to alter MP53 expression may be used in *in vivo* assays to test for activity of a candidate p53 modulating agent, or to further assess the role of MP53 in a p53 pathway process such as apoptosis or cell proliferation. Preferably, the altered MP53 expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MP53 expression. The genetically modified animal may additionally have altered p53 expression (e.g. p53 knockout). Preferred genetically modified animals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into

the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford et al.; for transgenic Drosophila see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. et al., A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer et al., Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. et al. (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

10

20

25

30

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous MP53 gene that results in a decrease of MP53 function, preferably such that MP53 expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MP53 gene is used to construct a homologous recombination vector suitable for altering an endogenous MP53 gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner et al., Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, supra; Pursel et al., Science (1989)

244:1281-1288; Simms et al., Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH et al., (1994) Scan J Immunol 40:257-264; Declerck PJ et al., (1995) J Biol Chem. 270:8397-400).

5

10

15

20

25

30

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MP53 gene, e.g., by introduction of additional copies of MP53, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MP53 gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knockin can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the p53 pathway, as animal models of disease and disorders implicating defective p53 function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MP53 function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MP53 expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered MP53 function, animal models having defective p53 function (and otherwise normal MP53 function), can be used in the methods of the present invention. For example, a p53 knockout mouse can be used to assess, *in vivo*, the activity of a candidate p53 modulating agent identified in one of the *in vitro* assays described below. p53 knockout mice are described in the literature (Jacks et al., Nature 2001;410:1111-1116, 1043-1044; Donehower *et al.*, supra). Preferably, the candidate p53 modulating agent when administered to a model system with cells defective in p53 function, produces a detectable phenotypic change in the model system indicating that the p53 function is restored, i.e., the cells exhibit normal cell cycle progression.

# **Modulating Agents**

5

10

15

20

25

30

The invention provides methods to identify agents that interact with and/or modulate the function of MP53 and/or the p53 pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the p53 pathway, as well as in further analysis of the MP53 protein and its contribution to the p53 pathway. Accordingly, the invention also provides methods for modulating the p53 pathway comprising the step of specifically modulating MP53 activity by administering a MP53-interacting or -modulating agent.

. . . . .

As used herein, an "MP53-modulating agent" is any agent that modulates MP53 function, for example, an agent that interacts with MP53 to inhibit or enhance MP53 activity or otherwise affect normal MP53 function. MP53 function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the MP53 - modulating agent specifically modulates the function of the MP53. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the MP53 polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MP53. These phrases also encompass modulating agents that alter the interaction of the MP53 with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of an MP53, or to a protein/binding partner complex, and altering MP53 function). In a further preferred embodiment, the MP53- modulating agent is a modulator of the p53 pathway (e.g. it restores and/or upregulates p53 function) and thus is also a p53-modulating agent.

Preferred MP53-modulating agents include small molecule compounds; MP53-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19<sup>th</sup> edition.

# Small molecule modulators

10

15

20

25

30

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MP53 protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MP53-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the p53 pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

### **Protein Modulators**

10

15

20

25

30

Specific MP53-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the p53 pathway and related disorders, as well as in validation assays for other MP53-modulating agents. In a preferred embodiment, MP53-interacting proteins affect normal MP53 function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MP53-interacting proteins are useful in detecting and providing information about the function of MP53 proteins, as is relevant to p53 related disorders, such as cancer (e.g., for diagnostic means).

An MP53-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MP53, such as a member of the MP53 pathway that modulates MP53 expression, localization, and/or activity. MP53-modulators include dominant negative forms of MP53-interacting proteins and of MP53 proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MP53-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3<sup>rd</sup>, Trends Genet (2000) 16:5-8).

An MP53-interacting protein may be an exogenous protein, such as an MP53-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988)

Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MP53 antibodies are further discussed below.

In preferred embodiments, an MP53-interacting protein specifically binds an MP53 protein. In alternative preferred embodiments, an MP53-modulating agent binds an MP53 substrate, binding partner, or cofactor.

# Antibodies

In another embodiment, the protein modulator is an MP53 specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MP53 modulators. The antibodies can also be used in

dissecting the portions of the MP53 pathway responsible for various cellular responses and in the general processing and maturation of the MP53.

Antibodies that specifically bind MP53 polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MP53 polypeptide, and more preferably, to human MP53. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, antiidiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MP53 which are particularly antigenic can be selected, for example, by routine screening of MP53 polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of any of SEQ ID NOs:57-112. Monoclonal antibodies with affinities of  $10^8 \, M^1$  preferably  $10^9 \, M^1$  to  $10^{10} \, M^1$ , or stronger can be made by standard procedures as described (Harlow and Lane, supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MP53 or substantially purified fragments thereof. If MP53 fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MP53 protein. In a particular embodiment, MP53specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

10

15

20

25

30

The presence of MP53-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MP53 polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to MP53 polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing

together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

10

15

20

25

30

MP53-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

Terror Pitters.

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may

be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg—to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

# Specific biotherapeutics

grand the control of the control of

10

15

20

25

30

In a preferred embodiment, an MP53-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

When the MP53 is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MP53, as described in the previous section, may be used as biotherapeutic agents.

When the MP53 is a receptor, its ligand(s), antibodies to the ligand(s) or the MP53 itself may be used as biotherapeutics to modulate the activity of MP53 in the p53 pathway.

### **Nucleic Acid Modulators**

10

15

20

25

30

Other preferred MP53-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MP53 activity. Preferred nucleic acid modulators interfere with the function of the MP53 nucleic acid such as DNA replication, transcription, translocation of the MP53 RNA to the site of protein translation, translation of protein from the MP53 RNA, splicing of the MP53 RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MP53 RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MP53 mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MP53-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

1 - 1

1, 30

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred MP53 nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known

in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem. (1993):36:1923-1937; Tonkinson JL et al., Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, an MP53-specific nucleic acid modulator is used in an assay to further elucidate the role of the MP53 in the p53 pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, an MP53-specific antisense oligomer is used as a therapeutic agent for treatment of p53-related disease states.

# **Assay Systems**

5

10

15

20

25

The invention provides assay systems and screening methods for identifying specific modulators of MP53 activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MP53 nucleic acid or protein. In general, secondary assays further assess the activity of a MP53 modulating agent identified by a primary assay and may confirm that the modulating agent affects MP53 in a manner relevant to the p53 pathway. In some cases, MP53 modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising an MP53 polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates MP53 activity, and hence the p53 pathway. The MP53 polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

# 10 Primary Assays

15

20

25

30

The type of modulator tested generally determines the type of primary assay.

7. 34. Marin

March 1. 1

# Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS et al., Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicty and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of MP53 and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry

provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MP53-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MP53 protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate MP53-specific binding agents to function as negative effectors in MP53-expressing cells), binding equilibrium constants (usually at least about 10<sup>7</sup> M<sup>-1</sup>, preferably at least about 10<sup>8</sup> M<sup>-1</sup>, more preferably at least about 10<sup>9</sup> M<sup>-1</sup>), and immunogenicity (e.g. ability to elicit MP53 specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

10

15

20

25

30

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MP53 polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MP53 polypeptide can be full length or a fragment thereof that retains functional MP53 activity. The MP53 polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MP53 polypeptide is preferably human MP53, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of MP53 interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MP53 –specific binding activity, and can be used to assess normal MP53 gene function.

Suitable assay formats that may be adapted to screen for MP53 modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (e.g., Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, supra; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate MP53 and p53 pathway modulators (e.g. U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); U.S. Pat. No. 6,020,135 (p53 modulation),

and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

Protein kinases, key signal transduction proteins that may be either membraneassociated or intracellular, catalyze the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. Radioassays, which monitor the transfer from [gamma-32P or -33P]ATP, are frequently used to assay kinase activity. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from [gamma -33P] ATP to a biotinylated peptide substrate. The substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M et al., J Biomol Screen (2000) 5:205-212). This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from free ligand. Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA) assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133). Another example of antibody based assays for protein kinase activity is TRF (timeresolved fluorometry). This method utilizes europium chelate-labeled antiphosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using timeresolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

10

15

20

25

30

Protein phosophatases catalyze the removal of a gamma phosphate from a serine, threonine or tyrosine residue in a protein substrate. Since phosphatases act in opposition to kinases, appropriate assays measure the same parameters as kinase assays. In one example, the dephosphorylation of a fluorescently labeled peptide substrate allows trypsin cleavage of the substrate, which in turn renders the cleaved substrate significantly more fluorescent (Nishikata M et al., Biochem J (1999) 343:35-391). In another example, fluorescence polarization (FP), a solution-based, homogeneous technique requiring no immobilization or separation of reaction components, is used to develop high throughput screening (HTS) assays for protein phosphatases. This assay uses direct binding of the phosphatase with the target, and increasing concentrations of target-phosphatase increase

the rate of dephosphorylation, leading to a change in polarization (Parker GJ et al., (2000) J Biomol Screen 5:77-88).

Endogenous protease inhibitors may inhibit protease activity. In an example of an assay developed for either proteases or protease inhibitors, a biotinylated substrate is coated on a titer plate and hydrolyzed with the protease; the unhydrolyzed substrate is quantified by reaction with alkaline phosphatase-streptavidin complex and detection of the reaction product. The activity of protease inhibitors correlates with the activity of the alkaline phosophatase indicator enzyme (Gan Z et al., Anal Biochem 1999) 268:151-156).

Fatty acid desaturases catalyze the insertion of double bonds into saturated fatty acid molecules. In one application, radioassays for inhibitors of delta-5 and delta-6 fatty acid desaturase activity use thin layer chromatography to detect conversion of fatty acid substrates (Obukowicz et al., Biochem Pharmacol (1998) 55:1045-1058).

10

20

25

30

RNA folds into a myriad of tertiary structures that are responsible for its diverse functions in cells. In most instances, RNA is associated with RNA-binding proteins (RBPs) that protect, stabilize, package or transport RNA, mediate RNA interactions with other biomolecules or act catalytically on RNA. The structural information obtained for RNA alone and RNA-protein complexes has elucidated a variety of RNA tertiary structures and diverse modes for RNA-protein interaction. The specific interaction of proteins with highly structured RNAs makes it possible to target unique RNA motifs with small molecules, thus making RNA an interesting target for therapeutic intervention.

Assays for RNA binding or processing may be based on homogeneous scintillation proximity (Liu J, et al., Anal Biochem 2001 289:239-245), chemiluminescense (Mazumder A, Nucleic Acids Res 1998 26:1996-2000), gel shift (Stull RA, et al., Antisense Nucleic Acid Drug Dev 1996 6:221-228; U.S. Pat. No: 6004749).

Adapter proteins are involved in a wide range of signaling and other cellular processes and generally facilitate protein-protein or protein-nucleic acid interactions via certain conserved motifs, including PDZ, SH2, SH3, PH, TRAF, WD40, LIM, ankyrin repeat, KH and annexin domains, etc. Assays for adapter protein activity may measure protein binding at the conserved motifs. For instance, exemplary assays for SH2 domain-containing proteins have measured binding using fluorescently labeled peptide substrate and fluorescence polarization or laser-scanning techniques (Lynch BA et al., Anal Biochem 1999, 275:62-73; Zuck P et al., Proc Natl Acad Sci USA 1999, 96: 11122-11127). An alternative SH2 binding assay uses radiolabeled peptide. An assay for protein-protein interaction at the LIM domain has used fluorescently labeled LIM-

containing proteins (FHL2 and FHL3) and the fluorescence resonance energy transfer (FRET) technique (Li HY, J Cell Biochem 2001, 80:293-303).

Transporter proteins carry a range of substrates, including nutrients, ions, amino acids, and drugs, across cell membranes. Assays for modulators of transporters may use labeled substrates. For instance, exemplary high throughput screens to identify compounds that interact with different peptide and anion transporters both use fluorescently labeled substrates; the assay for peptide transport additionally uses multiscreen filtration plates (Blevitt JM et al., J Biomol Screen 1999, 4:87-91; Cihlar T and Ho ES, Anal Biochem 2000, 283:49-55).

5

10

15

20

25

30

Ion channels mediate essential physiological functions, including fluid secretion, electrolyte balance, bioenergetics, and membrane excitability. Assays for channel activity can incorporate ion-sensitive dyes or proteins or voltage-sensitive dyes or proteins, as reviewed in Gonzalez JE et al. (Drug Discovery Today (1999) 4:431-439). Alternative methods measure the displacement of known ligands, which may be radio-labeled or fluorescently labeled (e.g., ScHMid EL et al., Anal Chem (1998) 70:1331-1338).

Transcription factors control gene transcription. Electrophoretic mobility shift assay (EMSA) or gel shift assay is one of the most powerful methods for studying protein-DNA interactions. High throughput gel shift assays for transcription factors may involve fluorescence (Cyano dye Cy5) labeled oligodeoxynucleotide duplexes as specific probes and an automatic DNA sequencer for analysis (Ruscher K, et al., (2000) J Biotechnol 78:163-70). Alternatively high throughput methods involve colorimetric assays (Renard P, et al. (2001) Nucleic Acids Res 29(4):E21), or homogeneous fluorescence assays for the detection and quantification of sequence-specific DNA-binding proteins (Heyduk T, and Heyduk E (2001) Nat Biotechnol 20:171-6.)

er begin

Reductases are enzymes of oxidoreductase class that catalyze reactions in which metabolites are reduced. High throughput screening assays for reductases may involve scintillation (Fernandes PB. (1998) Curr Opin Chem Biol 2:597-603; Delaporte E et al. (2001) J Biomol Screen 6:225-231).

Assays for ATPase activity may be performed as described in Blackburn et al (Blackburn CL, et al., (1999) J Org Chem 64:5565-5570). The ATPase assay is performed using the EnzCheck ATPase kit (Molecular Probes). The assays are performed using an Ultraspec spectrophotometer (Pharmacia), and the progress of the reaction are monitored by absorbance increase at 360 nm. Microtubules (1.7 mM final), kinesin (0.11 mM final), inhibitor (or DMSO blank at 5% final), and the EnzCheck components (purine nucleotide

phosphorylase and MESG substrate) are premixed in the cuvette in a reaction buffer (40 mM PIPES pH 6.8, 5 mM paclitaxel, 1 mM EGTA, 5 mM MgCl2). The reaction is initiated by addition of MgATP (1 mM final).

High throughput assays based on photometric analysis of the activity of decarboxylase enzymes have been described (Breuer M et al (2002) Anal Bioanal Chem 374:1069-73).

High-throughput photometric assays for peroxidases have also been described (Smith AD et al (2001) Int J Vitam Nutr Res 71:87-92; Smith AD and Levander OA (2002) Methods Enzymol 347:113-21).

10

15

20

25

30

5

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik et al., 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara et al., 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). An apoptosis assay system may comprise a cell that expresses an MP53, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MP53 function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MP53 relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MP53 plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

134 14

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA.

Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino et

al., 1986, Int. J. Cancer 38, 369; Campana et al., 1988, J. Immunol. Meth. 107, 79), or by other means.

Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specfic to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL et al., 1998, In Vitro Cell Dev Biol Anim 34:239-46).

10

20

25

30

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with MP53 are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

1. Sec. 15. 15

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with an MP53 may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses an MP53, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MP53 function plays a direct role in cell proliferation or cell cycle. For example,

a cell proliferation or cell cycle assay may be performed on cells that over- or underexpress MP53 relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MP53 plays a direct role in cell proliferation or cell cycle.

5

10

15

20

25

30

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses an MP53, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MP53 function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MP53 relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MP53 plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MP53 in hypoxic conditions (such as with 0.1% O2, 5% CO2, and balance N2, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For

example, a hypoxic induction assay system may comprise a cell that expresses an MP53, and that optionally has defective p53 function (e.g. p53 is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate p53 modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate p53 modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MP53 function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MP53 relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MP53 plays a direct role in hypoxic induction.

5

10

15

20

25

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a

microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

5

10

15

20

25

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigel<sup>TM</sup> (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4°C and forms a solid gel at 37°C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF-alpa. Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing an MP53's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an

upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing an MP53's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

Sprouting assay. A sprouting assay is a three-dimensional in vitro angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900µl of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100  $\mu$ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

### Primary assays for antibody modulators

10

15

20

25

. . 30

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MP53 protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999,

supra). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting MP53-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

# Primary assays for nucleic acid modulators

10

20

25

30

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MP53 gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MP53 expression in like populations of cells (e.g., two pools of cells that endogenously or recombinantly express MP53) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (e.g., using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MP53 mRNA expression is reduced in cells treated with the nucleic acid modulator (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al., eds., John Wiley & Sons, Inc., chapter 4; Freeman WM et al., Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MP53 protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, supra).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MP53 mRNA expression, may also be used to test nucleic acid modulators.

#### **Secondary Assays**

Secondary assays may be used to further assess the activity of MP53-modulating agent identified by any of the above methods to confirm that the modulating agent affects MP53 in a manner relevant to the p53 pathway. As used herein, MP53-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a

modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MP53.

Secondary assays generally compare like populations of cells or animals (e.g., two pools of cells or animals that endogenously or recombinantly express MP53) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MP53—modulating agent results in changes in the p53 pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the p53 or interacting pathways.

# Cell-based assays

5

10

15

20

25

30

Cell based assays may use a variety of mammalian cell lines known to have defective p53 function (e.g. SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA). Cell based assays may detect endogenous p53 pathway activity or may rely on recombinant expression of p53 pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

#### **Animal Assays**

A variety of non-human animal models of normal or defective p53 pathway may be used to test candidate MP53 modulators. Models for defective p53 pathway typically use genetically modified animals that have been engineered to mis-express (e.g., over-express or lack expression in) genes involved in the p53 pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, p53 pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal p53 are used to test the candidate modulator's affect on MP53 in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4°C, but rapidly forms a solid gel at 37°C. Liquid Matrigel® is mixed with various angiogenic agents,

such as bFGF and VEGF, or with human tumor cells which over-express the MP53. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

10

15

20

25

30

In another preferred embodiment, the effect of the candidate modulator on MP53 is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a preexisting tumor or from in vitro culture. The tumors which express the MP53 endogenously are injected in the flank, 1 x 10<sup>5</sup> to 1 x 10<sup>7</sup> cells per mouse in a volume of 100 µL using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

James Barrie

In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral

red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorogenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

20

25

30

5

10

15

# Diagnostic and therapeutic uses

Specific MP53-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the p53 pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the p53 pathway in a cell, preferably a cell pre-determined to have defective or impaired p53 function (e.g. due to overexpression, underexpression, or misexpression of p53, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MP53 activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the p53 function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored p53 function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for

treating disorders or disease associated with impaired p53 function by administering a therapeutically effective amount of an MP53 -modulating agent that modulates the p53 pathway. The invention further provides methods for modulating MP53 function in a cell, preferably a cell pre-determined to have defective or impaired MP53 function, by administering an MP53 -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MP53 function by administering a therapeutically effective amount of an MP53 -modulating agent.

The discovery that MP53 is implicated in p53 pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the p53 pathway and for the identification of subjects having a predisposition to such diseases and disorders.

10

15

20

30

Various expression analysis methods can be used to diagnose whether MP53 expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al., eds., John Wiley & Sons, Inc., chapter 4; Freeman WM et al., Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective p53 signaling that express an MP53, are identified as amenable to treatment with an MP53 modulating agent. In a preferred application, the p53 defective tissue overexpresses an MP53 relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MP53 cDNA sequences as probes, can determine whether particular tumors express or overexpress MP53. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MP53 expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the MP53 oligonucleotides, and antibodies directed against an MP53, as described above for: (1) the detection of the presence of MP53 gene mutations, or the detection of either over- or under-expression of MP53 mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MP53 gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MP53.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MP53 expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MP53 expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 2. The probe may be either DNA or protein, including an antibody.

### **EXAMPLES**

10

15

20

25

30

The following experimental section and examples are offered by way of illustration and not by way of limitation.

## I. <u>Drosophila p53 screen</u>

The Drosophila p53 gene was overexpressed specifically in the wing using the vestigial margin quadrant enhancer. Increasing quantities of Drosophila p53 (titrated using different strength transgenic inserts in 1 or 2 copies) caused deterioration of normal wing morphology from mild to strong, with phenotypes including disruption of pattern and polarity of wing hairs, shortening and thickening of wing veins, progressive crumpling of the wing and appearance of dark "death" inclusions in wing blade. In a screen designed to identify enhancers and suppressors of Drosophila p53, homozygous females carrying two copies of p53 were crossed to 5663 males carrying random insertions of a piggyBac transposon (Fraser M et al., Virology (1985) 145:356-361). Progeny containing insertions were compared to non-insertion-bearing sibling progeny for enhancement or suppression of the p53 phenotypes. Sequence information surrounding the piggyBac insertion site was used to identify the modifier genes. Modifiers of the wing phenotype were identified as members of the p53 pathway. Modifiers (enhancers and suppressors of the wing phenotype). Orthologs of the modifiers are referred to herein as MP53.

## II. Analysis of Table 1

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. The columns "MP53 symbol", "MP53 name" and "MP53 name aliases" provide a symbol and the known name abbreviations for the Targets, where available, from Genbank. "MP53 RefSeq\_NA or GI\_NA", and "MP53 GI\_AA", provide the reference nucleotide and amino acid sequences for the MP53s as available from

National Center for Biology Information (NCBI), and Genbank, where available.

Nucleotide and amino acid SEQ ID Nos of the sequences used in the application are also provided.

Names and Protein sequences of *Drosophila* modifiers of p53 from screen

(Example I), are represented in the "Modifier genetic Name", "Modifier physical Name" and "Modifier GI\_AA" column by GI#, respectively.

Table 1

MP53 To h	MP53 name	MP53	MP53 3 945 8	NA :	MP53: 1	ĂA	Modifier	Modifier	Modifier
Symbol		name	identifier	SEO	GI# AA	SEO.	genetic	physical	GI# AA
		aliases	NA RefSen	ID.	<b>344</b>	ID.	name (	năme	
		420	or GI#	NO:		NO:	1.30	<b>人名霍</b> 克	
ΔNY Δ13	annexin A13	ANX13	XM 052383	1	4757754	57	AnnIX_(A	CG5730	gi 17136266
VIAVVI2 6	illicalii Alb	MINIS	22141_022303	•	[,,,,,,,,,,	-	nnexin		ref[NP_4766
							IX)		04.1
ANXA4 a	annexin A4	ANX4	NM_001153	2	4502105	58	AnnIX_(A	CG5730	gi 17136266
AIVAA4	aillicaili A4	AUA	1414_001155	_	1302103		nnexin		refINP_4766
							IX)		04.1
AXOT a	axotrophin	DKEZD	NM_022826	3	12383066	59	NA	CG14518	
AAOI		586F11	14141_022620	3	12303000			0011010	gi 7301726 g
		22;					į.		b AAF56839
		axotrop	4 3 2		; .	٠.		,	.1
		hin							
TT 7000061			XM_053238	4	15308522	60	NA	CG7983	gi 7294806 g
	hypothetical		1		13300322	00		CG/703	b AAF50140
I	protein FLJ20085		.1	r ·		,			11
		1116015	NM_022567	5	12314287	61	caps_(capr	CG11282	gi 3885974 g
	nyctalopin, alias:	.2,CLR	14141_022307	۲	12314207	01	icious)	CG11202	blAAC7814
			ŀ	ŀ			i Cious)		4.1
		P, CSNB1,		ļ					
	night	CSNB1,		1	<u> </u>			}	
	blindness 4;	CS14D4							}
	Congenital	1	1		1	}			
	stationary	l		ļ			ł		
	night	ŀ	1	1					
	blindness-1	]					ŀ		
	(CSNB,								
	complete)		·						
	hypothetical	<del>                                     </del>	NM_022901	6	12597641	62	caps_(capr	CG11282	gi 3885974 g
	protein	F	14141_022901	۲	12377041	2	icious)		blAAC7814
	FLJ21302			<b>,</b>		İ	,		4.1
	glycoprotein	D11993	YM 006108	7	5031707	63	caps_(caps	CG11282	gi 3885974 g
	A repetitions		ZEW_000170	ľ	5051707	ال	icious)		ЫAAC7814°
	predominant	515			1		101010)		4.1
	glycoprotein	CD42b	NM_000173	8	4504071	64	caps_(cap	CG11282	gi 3885974 g
	Ib (platelet),	CD420	1 111 0001/3	۲	7,5040/1		icious)		b AAC7814
	alpha	ļ	ļ				1		4.1
	polypeptide								'
	glycoprotein	CD42d	XM 002075	0	4758460	65	caps_(caps	CG11282	gi 3885974 g
	V (platelet)	724	25.1.002313	[	7,50400		icious)		<b>b</b>  AAC7814
	· (platetot)						[		4.1
HT017	HT017	<del></del>	XM_054557	10	10190722	66	caps (cap)	CG11282	
uliul/ "	111011	ſ	PAMI_ODIDD/	Į.v.	1.01/0/22	,,~~		1	
	protein	ł		1		1	icious)		<b>b</b>  AAC7814

KTA A041	KIAA0416	L	XM_003637	11	7662102	67	caps (capr	CG11282	gi 3885974 g
	protein		Mw_003037	••	7002102		icious)		b AAC7814   4.1
LY64	lymphocyte antigen 64 homolog, radioprotecti ve 105kD (mouse)	RP105	XM_003933	12	13645378	68	caps_(capr icious)		gi 3885974 g ЫААС7814 4.1
LOC1126 84			XM_053144 .1	13	15301270	69	caps_(capr icious)		gi 3885974 g b AAC7814 4.1
ISLR			NM_005545 .1	14	5031809	70	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
Unknown (protein for MGC:171			15489167	15	15489168	71	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
unnamed protein product CAC2178			12226531	16	12226532	72	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
KIAA146 5		,	XM_027396 .1	17	14752075	73	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
LOC1150 25			XM_028612 .2	18	15294652	74	caps_(capr icious)	CG11282	ЫААС7814 4.1
PAL			NM_015613 .1	19	14149694	75	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
KIAA124 6			XM_046690 .2	20	15300859	76	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
MGC265 6			NM_024509 .1	21	13375646	77	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
unnamed protein product CAC4997			15132048	22	15132049	78	caps_(capr icious)	CG11282	gi 3885974 g b AAC7814 4.1
, KIAA191 0			XM_055514 .1	23	16163269	79	caps_(caps icious)	CG11282	gi 3885974 g b AAC7814 4.1
KIAA091 8			XM_054870 .1	24	16188327	80	caps_(caps icious)	CG11282	
ъG256O2 2.1			5531259	25	6691962	81	caps_(capricious)	CG11282	gi 3885974 g b AAC7814 4.1
KIAA084 8			NM_014926 .1	26	7662336	82	caps_(capsicious)	CG11282	gi 3885974 g b AAC7814 4.1
CASK			NM_003688 .1	27	4502567	83	caps_(cap icious)	rCG11282	

· · · · · · · · · · · · · · · · · · ·			7 5 0044 50		4500100	0.4	(	0011202	-: 2005074] <sub>c</sub>
APBA1			NM_001163 .1	28	4502129		caps_(capr icious)		gi 3885974 g b AAC7814 4.1
LIN-7-C			NM_018362 .1	29	8922944		caps_(capr icious)		gi 3885974 g b AAC7814 4.1
	tripartite motif- containing 3	RNF22	XM_044513	30	5453569	86	brat_(brai n_tumor)		gi 17136846  ref NP_4769 45.1
		none	NM_014552	31	7657297	87	grh_grain yhead	CG2094	7302703
PTBP2	polypyrimidi ne tract binding protein 2	PTB, MIBP, nPTB, PTBLP, neural polypyri midine tract binding protein	XM_042972	32	14722543	88	<u> </u>		7302108
ROD1	ROD1 regulator of differentiatio n 1 (S. pombe)	1	NM_005156	33	4826984	89	heph_hep haestus	CG2094	7302108
PTBP1	polypyrimidi ne tract binding protein 1	PTB; PTB2; PTB3; PTB4; pPTB; HNRPI; PTB-1; HNRNP	NM_002819	34	4506243	90	heph_hep haestus	CG2094	7302108
P4HA1	procollagen- proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), alpha polypeptide I		NM_000917	35	4505565	91	none	SD05564 <sub>F</sub>	15292529
Р4НА2	procollagen- proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), alpha polypeptide II	prolyl 4- hydroxy lase, alpha polypep		36	4758868	92	none	SD05564p	15292529

		hydroxy						İ	
		lase,							
	'	alpha					1		
		polypep		l l		i	į	]	l
		tide,					l		1
		type II							
none	metastasis		6539605	37	6539606	93	none	CG9469	7302324
lione	suppressor	110110	0557005	Γ΄		_			
	protein ·								
7.000015			XM_043228	20	14779986	01	none	CG9469	7302324
		none	A1VI_U43220	P°	14117700	3-4	Hone	005105	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4	Unknown								
	(protein for	]	Į.						
	IMAGE	ļ				25		CG5447	18488547
LOC1236	similar to	none	XM_063793	39	17478005	95	none	CG3447	18488347
76	hypothetical			l I					
	protein,								
	MNCb-1213		ļ			ł	-		
	(H. sapiens)								
LOC5112	HSPC041	none	NM_016099	40	7705821	96	none	CG5447	18488547
5	protein	[							
WFS1	Wolfram	WFS,	NM_006005	41	5174749	97		mod_@tra	
111.01	syndrome 1	WFRS,	1	`				nsmembra	
	(wolframin)	DIDMO			•			ne	
	(womanin)	AD				ļ		wolfram	
		AD						syndrome	}
ļ	İ	ł	l		}	Ì		wolframin	}
		}	l				•	•	<b>[</b>
	, .		1	1		]	<u> </u>	transcript	
	ļ		1	1		l .	'	_3	
		·						translation	
PPP1R16	protein	МҮРТ3	NM_032902	42	14249672	98	none ·	CG6896	7293882
Α	phosphatase	,				1			
	1, regulatory	MGC14					}		l
	(inhibitor)	333;		ļ		ł		į .	ŀ
	subunit 16A	likley		1	ļ			ļ	ļ
	Buouni xorr	ortholog	,[		1		1		İ
		of	<b>'</b>	1	1	ĺ		ŀ	
		mouse				ſ	į	ļ	
		1				1			
		myosin		1		1	İ		
		phospha	1		i	1	į	1	
		tase		1	ļ	1		1	
		targetin	1	1	ļ	1			
}		g subunit		1		1	1		
	1	subunit	ł		Ì	1	1	ļ	
		3		1_	L	1		00000	7002000
PPP1R16			XM_028840	43	14770818	3 99	none	CG6896	7293882
В	phosphatase	ANKR	1	1			1		
	1, regulatory	D4,	1	1	1	1			]
	(inhibitor)	KIAA0	1	1			İ		
	subunit 16B	823							L
CXorf9	chromosome		NM_018990	144	9506363	100	none	mod_@ki	Exelixis
C220117	X open	753P9;	[	1				aa0790.tra	
	reading	likely			1	1		nscript_11	
	frame 9	ortholog	.}			1		translation	
[	HI allie 3		5			1			
				1	1	1	1	1	1
		of	İ	1		1		1	1
		mouse							
		mouse SH3							
		mouse							

			77.6 044015	15	14751637	101	none	mod_@ki	Evelivis
LOC1349		none	XM_044015	45	14/3103/	IOI		aa0790.tra	
	KIAA0790								internal
	protein (H.							nscript_11	ŀ
	sapiens)							translation	
SAMSN1	SAM	none	NM_022136	46	11545871	102		mod_@ki	
	domain, SH3				l l			aa0790.tra	internal
	domain and				4			nscript_11	
	nuclear				l l			translation	
	localisation							ì	
	signals, 1		/						
MGC956			NM_080669	47	18087847	103	none	CG15553	7302010
	RIKEN		14141_000000	Γ΄	1000,047	105			
	cDNA								
							ļ.		1
	1110002C08	•			1 1				ŀ
	gene			10	16416764	104		CG15553	7302010
					16416764		none		
	BCL2-		NM_004281	49	14043024	105	none	CG10745	160/6828
		BAG-3,			l i		ļ		1
	athanogene 3	CAIR-		İ	1		1		
	_	1,			}		-	1	
	ł	DKFZp		l	]			<u> </u>	
	}	434E06		Ì	1		ł	i	<u> </u>
		10; Bcl-					ł		
		2-			1		1		
		binding	T				1	ļ	1
		protein;					1		
		docking		Ì			}		1
0,0				, ,					
		protein	`					l,	!
		CAIR-							1
		1;	,					Ì	
		BCL2-		Į.	.	l			'
	,	binding		1		ĺ		f	
		athanog		٠		1	ł	İ	
		ene 3;				ļ	ł	1	1
		BAG-	}			ĺ	1	1	
		family		1				ŀ	
		molecul			1		}	<b>,</b>	
	}	ar			ļ			1	1
		chapero			ł		†	1	
		ne 1			ļ.	1		i	
		regulato						İ	
		r-3							
BAG4	BCL2-	r -	NM_004874	50	6631075	106	none	CG10745	16076828
μα04	associated	BAG-4;	1171_004074	٦	332073				
							1		
1	athanogene 4	Sucher		1	1	1		1	
1		of death	1	1					
	1	domains		1			Ì		
		; BAG-	!	İ				1	
	[	family		1			1		
		molecul	ļ				1		1
		ar							1
	1	chapero	l	ł					
		ne	l				1		
		regulato	1				1		
	1	r-4		1					<u> </u>
FLJ22944	hypothetical		NM_025145	51	13376733	107	none	mod_@dk	Exelixis
	protein	1	[					fzp434a20	
	FLJ22944	Ì	1				}	17	
			1	1	[			flj11142.t	rl
				1	I	1		anscript_3	
1	1	1	ı	ſ	1		1		

		<del>r</del>	· · · · · · · · · · · · · · · · · · ·		·		<del></del>		
			İ	1			1	translation	
				l					
			ļ	ļ					
TT T11140	1		D. C. 010000	50	0000007	100	<del></del>	(G <sup>21</sup> )	IZ
	hypothetical		NM_018338	52	8922897	108	none	mod_@dk	
	protein		i			l		fzp434a20	internai
	FLJ11142		ļ					17	
								flj11142.tr	
	1							anscript_3	
								translation	
	bromodomai		NM_013448	53	7304919	109	Acf1_AT	CG1966	7302099
		WALp1					P-		1
	zinc finger	,			}		dependent		
	domain, 1A	hACF1,	f	ļ			chromatin		
		WCRF1	]				assemblyf	:	
}		80,					actorlarge		
		DKFZP					subunit		
		586E05		i					
		18		<u> </u>			ļ		
	bromodomai		NM_023005	54	14670390	110	. –	CG1966	7302099
	n adjacent to						P-		i
	zinc finger	R9,					dependent		•
	domain, 1B	WBSC					chromatin		
		R10;				ŀ	assemblyf		}
		William					actorlarge		<b> </b>
		s-				Ì	subunit		
		Beuren						ļ	j
		syndro							ŀ
	,	me		ļ	,		· .		
		chromos							
		ome				}	} .		
		region			•	<u></u>			
		none	NM_021929	55	11345464	111	none	CG4065	7291750
	protein								
	FLJ21613						}		
	similar to rat		}				ĺ		
	corneal							1	
	wound						1		
	healing								
	related								
	protein								
		none	NM_015176	56	7022998	112	none	CG3428	7294925
3	protein								

## III. <u>High-Throughput In Vitro Fluorescence Polarization Assay</u>

5

Fluorescently-labeled MP53 peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MP53 activity.

## IV. High-Throughput In Vitro Binding Assay.

<sup>33</sup>P-labeled MP53 peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl<sub>2</sub>, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate p53 modulating agents.

10

15

20

25

30

# V. <u>Immunoprecipitations and Immunoblotting</u>

For coprecipitation of transfected proteins,  $3 \times 10^6$  appropriate recombinant cells containing the MP53 proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at 15,000 × g for 15 min. The cell lysate is incubated with 25  $\mu$ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

## VI. Kinase assay

A purified or partially purified MP53 is diluted in a suitable reaction buffer, e.g., 50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and a peptide or polypeptide substrate, such as myelin basic protein or case in (1-10  $\mu$ g/ml). The final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by

increasing assay throughput. A 96-well microtiter plate is employed using a final volume  $30\text{-}100~\mu\text{l}$ . The reaction is initiated by the addition of  $^{33}\text{P-gamma-ATP}$  (0.5  $\mu\text{Ci/ml}$ ) and incubated for 0.5 to 3 hours at room temperature. Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg2<sup>+</sup> or Mn<sup>2+</sup>) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

## VII. Expression analysis

10

15

25

30

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, Ardais, Genome Collaborative, and Ambion.

TaqMan analysis was used to assess expression levels of the disclosed genes in various samples.

RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/µl. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis was performed using a 7900HT instrument.

Taqman reactions were carried out following manufacturer's protocols, in 25  $\mu$ l total volume for 96-well plates and 10  $\mu$ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a

mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., Tumor – average(all normal samples) > 2 x STDEV(all normal samples)).

Results are shown in Table 2. Number of pairs of tumor samples and matched normal tissue from the same patient are shown for each tumor type. Percentage of the samples with at least two-fold overexpression for each tumor type is provided. ND indicates not done. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

5

10

15

20

Table 2

SEQ	Brea	# of	Colo :	# of	Head	# of	Kidn,	# of	Lung	# of	Öväry	# of	Pros	# of	Skin	# of	Uteru	# of
m-		· ·					ěy:	Pài		Pairs		Pairs	tate'			Pai	S	Pai,
NO:		rs		rs	Neck	rs		rs.			100		16	rs.		rs	為記	rs
1		33			1. 1				7		3.8					7.		
48	_	21	6%	33		8	12%	24	5%		9%	11	17%	12		3	11%	19
52	5%	21	6%	33	12%	8	8%	24	0%	21	9%	11	17%	12	0%	3	21%	19
4	5%	21	6%	33_	12%	8	8%	24	0%	21	9%	11	17%	12	0%	3	21%	19
6	33%	6	17%	30	ND	ND	ND	ND	8%	12	20%	5	ND	ND	ND	ND	ND	ND
55	33%	6	17%	30	ND	ND	ND	ND	8%	12	20%	5	ND	ND	ND	ND	ND	ND
51	33%	6	17%	30	ND	ND	ND	ND	8%	12	20%	5	ND	ND	ND	ND	ND	ND
7	0%	12	50%	30	ND	ND	ND	ND	0%	14	14%	7	ND	ND	ND	ND	ND	ND
8	33%	12	10%	29	ND	ND	ND	ND	21%	14	29%	7	ND	ND	ND	ND	ND	ND
9	8%	12	33%	30	ND	ND	ND	ND	7%	14	14%	7	ND	ND	ND	ND	ND	ND
10	100 %	1	0%	8	ND	ND	ND	ND	0%	2	ND	ND	ND	ND	ND	ND	ND	ND
11	0%	12	7%	28	ND	ND	ND	ND	7%	14	14%	7	ND	ND	ND	ND	ND	ND
56	0%	12	7%	28	ND	ND	ND	ND	7%	14	14%	7	ND	ND	ND	ND	ND	ND
31	5%	21	6%	33	25%	8	12%	24	5%	21	0%	11	8%	12	33%	3	5%	19
40	17%	18	22%	23	25%	8	20%	20	6%	18	10%	10	0%	8	33%	3	20%	15
38	17%	18	22%	23	25%	8	20%	20	6%	18	10%	10	0%	8	33%	3	20%	15
12	25%	12	17%	30	ND	ND	ND	ND	21%	14	0%	6	ND	ND	ND	ND	ND	ND
47	14%	21	18%	33	25%	8	29%	24	5%	21	10%	10	8%	12	67%	3	0%	19
5	8%	12	14%	14	ND	МD	ND	ND	18%	11 .	14%	7	ND	ND	ND	ND	ND	ND
42	10%	21	15%	33	25%	8	12%	24	14%	21	18%	11	8%	12	67%	3	5%	19
43	10%	21	15%	33	25%	8	12%	24	14%	21	18%	11	8%	12	67%	3	5%	19
34	10%	21	15%	33	25%	8	12%	24	14%	21	18%	11	8%	12	67%	3	5%	19
32	10%	21	15%	33	25%	8	12%	24	14%	21	18%	11	8%	12	67%	3	5%	19
33	10%	21	15%	33	25%	8	12%	24	14%	21	18%	11	8%	12	67%	3	5%	19
30	33%	21	67%	33	25%	8	83%	24	10%	21	36%	11	17%	12	33%	3	58%	19

5

#### WHAT IS CLAIMED IS:

5

10

20

30

1. A method of identifying a candidate p53 pathway modulating agent, said method comprising the steps of:

- (a) providing an assay system comprising a MP53 polypeptide or nucleic acid;
- (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
- (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate p53 pathway modulating agent.
  - 2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MP53 polypeptide.
- 3. The method of Claim 2 wherein the cultured cells additionally have defective p53 function.
  - 4. The method of Claim 1 wherein the assay system includes a screening assay comprising a MP53 polypeptide, and the candidate test agent is a small molecule modulator.
  - 5. The method of Claim 4 wherein the assay is a binding assay.
- 6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
  - 7. The method of Claim 1 wherein the assay system includes a binding assay comprising a MP53 polypeptide and the candidate test agent is an antibody.
  - 8. The method of Claim 1 wherein the assay system includes an expression assay comprising a MP53 nucleic acid and the candidate test agent is a nucleic acid modulator.
  - 9. The method of Claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

10

- (d) administering the candidate p53 pathway modulating agent identified in (c) to a
   model system comprising cells defective in p53 function and, detecting a phenotypic change in the model system that indicates that the p53 function is restored.
  - 12. The method of Claim 11 wherein the model system is a mouse model with defective p53 function.
- 13. A method for modulating a p53 pathway of a cell comprising contacting a cell defective in p53 function with a candidate modulator that specifically binds to a MP53 polypeptide, whereby p53 function is restored.
- 15 14. The method of Claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in p53 function.
- 15. The method of Claim 13 wherein the candidate modulator is selected from the groupconsisting of an antibody and a small molecule.
  - 16. The method of Claim 1, comprising the additional steps of:
  - (e) providing a secondary assay system comprising cultured cells or a non-human animal expressing MP53,
- 25 (f) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and
  - (g) detecting an agent-biased activity of the second assay system,
- wherein a difference between the agent-biased activity and the reference activity of
  the second assay system confirms the test agent or agent derived therefrom as a candidate
  p53 pathway modulating agent,

and wherein the second assay detects an agent-biased change in the p53 pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

- 18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.
  - 19. The method of Claim 18 wherein the non-human animal mis-expresses a p53 pathway gene.
- 20. A method of modulating p53 pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a MP53 polypeptide or nucleic acid.
  - 21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the p53 pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

- 23. A method for diagnosing a disease in a patient comprising:
- 20 (a) obtaining a biological sample from the patient;
  - (b) contacting the sample with a probe for MP53 expression;
  - (c) comparing results from step (b) with a control;
  - (d) determining whether step (c) indicates a likelihood of disease.
- 25 24. The method of claim 23 wherein said disease is cancer.
  - 25. The method according to claim 24, wherein said cancer is a cancer as shown in Table 2 as having >25% expression level.

5

15

# SEQUENCE LISTING

<110>	EXELIXIS, I	NC.				
<120>	MP53s AS MO	DIFIERS OF THE	p53 PATHWAY	Y AND METHOD	S OF USE	
<130>	EX03-018C-P	С				
<150> <151>	US 60/361,1 2002-03-01	96				
<160>	112					
<170>	PatentIn ve	rsion 3.2				
<210><211><212><213>	1 1587 DNA Homo sapien	s				
<400> gtaaact	1 ttg cctgtag	gag gactgatete	ttgatgaaat	acagaaaaac	catctcagaa	60
aaaggaa	aat gggcaat	cgt catagccagt	cgtacaccct	ctcagaaggc	agtcaacagt	120
tgcctaa	agg ggactcc	caa ccctcgacag	tcgtgcagcc	tctcagccac	ccatcacgga	180
atggaga	agcc agaggcc	cca cagcctgcta	aagcgagcag	tcctcagggt	tttgatgtgg	240
atcgaga	atgc caaaaag	ctg aacaaagcct	gcaaaggaat	ggggaccaat	gaagcagcca	300
tcattga	aat cttatcg	ggc aggacatcag	atgagaggca	acaaatcaag	caaaagtaca	360
aggcaac	egta eggeaag	gag ctggaggaag	tactcaagag	tgagctgagt	ggaaacttcg	420
agaagad	agc gttggcc	ctt ctggaccgtc	ccagcgagta	cgccgcccgg	cagctgcaga	480
aggctat	gaa gggtctg	ggc acagatgagt	ccgtcctcat	tgaggtcctg	tgcacgagga	540
ccaataa	agga aatcatc	gcc attaaagagg	cctaccaaag	gctatttgat	aggagcctcg	600
aatcaga	atgt caaaggt	gat acaagtggaa	acctaaaaaa	aatcctggtg	tctctgctgc	660
aggctaa	atcg caatgaa	gga gatgacgtgg	acaaagatct	agctggtcag	gatgccaaag	720
atctgta	tga tgcaggg	gaa ggccgctggg	gcactgatga	gcttgcgttc	aatgaagtcc	780
tggccaa	agag gagctaca	aag cagttacgag	ccacctttca	agcctatcaa	attctcattg	840
gcaaaga	acat agaagaa	gcc attgaagaag	aaacatcagg	cgacttgcag	aaggcctatt	900
taactct	cgt gagaagt	gcc caggattgtg	aggactattt	tgctgaacgt	ttgtacaagt	960
ccatgaa	aggg tgcgggg	acc gatgaggaga	cgttgattcg	cataatcgtg	accagggccg	1020
aggtgga	acct tcagggg	atc aaagcaaagt	tccaaaagaa	gtatcagaag	tctctctctg	1080
acatggt	tcg ctcagata	acc tccggggact	tccggaaact	gctagtagcc	ctcttgcact	1140
gagccaa	agcc agggcaa	tag gaacacaggg	tggaaccacc	tttgtcaaga	gcacattcca	1200
aatcaaa	actt ggaaatg	aga ctcccgcacg	aaaaccctta	agagtcccgg	attactttct	1260

tggcagctta	agtggcgcag	ccaggccaag	ctgtgtaagt	taagggcagt	aacgttaaga	1320
tgcgtgggca	gggcaccttg	aactctggct	tagcaagcat	ctaggctgcc	tcttcacttt	1380
cttttagcat	ggtaactgga	tgttttctaa	acactaatga	aatcagcagt	tgatgaaaaa	1440
actatgcatt	tgtaatggca	catttagaag	gatatgcatc	acacaagtaa	ggtacaggaa	1500
agacaaaatt	aaacaattta	ttaattttcc	ttctgtgtgt	tcaatttgaa	agcctcattg	1560
ttaattaaag	ttgtggatta	tgcctct				1587

<210> 2

<211> 1982

<212> DNA

<213> Homo sapiens

<400> 2

60 gcagaggagg agcgcacgcc ggcctcgaag aacttctgct tgggtggctg aactctgatc 120 ttgacctaga gtcatggcca tggcaaccaa aggaggtact gtcaaagctg cttcaggatt 180 caatgccatg gaagatgccc agaccctgag gaaggccatg aaagggctcg gcaccgatga agacgccatt attagcgtcc ttgcctaccg caacaccgcc cagcgccagg agatcaggac 240 300 agcctacaag agcaccatcg gcagggactt gatagacgac ctgaagtcag aactgagtgg 360 caacttcgag caggtgattg tggggatgat gacgcccacg gtgctgtatg acgtgcaaga gctgcgaagg gccatgaagg gagccggcac tgatgagggc tgcctaattg agatcctggc 420 480 ctcccggacc cctgaggaga tccggcgcat aagccaaacc taccagcagc aatatggacg gagccttgaa gatgacattc gctctgacac atcgttcatg ttccagcgag tgctggtgtc 540 600 tctgtcagct ggtgggaggg atgaaggaaa ttatctggac gatgctctcg tgagacagga 660 tgcccaggac ctgtatgagg ctggagagaa gaaatggggg acagatgagg tgaaatttct 720 aactgttctc tgttcccgga accgaaatca cctgttgcat gtgtttgatg aatacaaaag gatatcacāg aaggatattg aacagagtat taaatctgaa acatctggta gctttgaaga 780 840 tgctctgctg gctatagtaa agtgcatgag gaacaaatct gcatattttg ctgaaaagct 900 ctataaatcg atgaagggct tgggcaccga tgataacacc ctcatcagag tgatggtttc 960 tcgagcagaa attgacatgt tggatatccg ggcacacttc aagagactct atggaaagtc tctgtactcg ttcatcaagg gtgacacatc tggagactac aggaaagtac tgcttgttct 1020 ctgtggagga gatgattaaa ataaaaatcc cagaaggaca ggaggattct caacactttg 1080 aatttttta acttcatttt tctacactgc tattatcatt atctcagaat gcttatttcc 1140 aattaaaacg cctacagctg cctcctagaa tatagactgt ctgtattatt attcacctat 1200 aattagtcat tatgatgctt taaagctgta cttgcatttc aaagcttata agatataaat 1260

1320 ggagatttta aagtagaaat aaatatgtat tccatgtttt taaaagatta ctttctactt tgtgtttcac agacattgaa tatattaaat tattccatat tttcttttca gtgaaaaatt 1380 1440 ttttaaatgg aagactgttc taaaatcact tttttcccta atccaatttt tagagtggct 1500 agtagtttct tcatttgaaa ttgtaagcat ccggtcagta agaatgccca tccagttttc 1560 tatatttcat agtcaaagcc ttgaaagcat ctacaaatct ctttttttag gttttgtcca 1620 tagcatcagt tgatccttac taagtttttc atgggagact tccttcatca catcttatgt 1680 tgaaatcact ttctgtagtc aaagtatacc aaaaccaatt tatctgaact aaattctaaa gtatggttat acaaaccata tacatctggt taccaaacat aaatgctgaa cattccatat 1740 1800 tattatagtt aatgtcttaa tccagcttgc aagtgaatgg aaaaaaaaat aagcttcaaa 1860 ctaggtattc tgggaatgat gtaatgctct gaatttagta tgatataaag aaaacttttt 1920 tgtgctaaaa atactttta aaatcaattt tgttgattgt agtaatttct atttgcactg 1980 tgcctttcaa ctccagaaac attctaagat gtacttggat ttaattaaaa agttcacttt 1982 gt

<210> 3

<211> 2728

<212> DNA

<213> Homo sapiens

<400> 3 60 ggtggctggt tctgcgccgg atccgggaga ggggcgggcg ccattgtgct tcgctgccga 120 ctgcatttcc tcagtcacgg gcctagaact ccaaggagaa aggcggcgaa aaatctttaa gaatggagtc taaaccttca aggattccaa gaagaatttc tgttcaacct tccagctcct 180 240 taagtgctag gatgatgtct ggaagcagag gaagtagttt aaatgatacc tatcactcaa 300 gagactette atttagattg gattetgaat atcagtetac atcagcatca gcatctgcgt 360 caccatttca atctgcatgg tatagtgaat ctgagataac tcagggagca cgctcaagat 420 cgcagaacca gcaacgggat catgattcaa aaagacctaa actttcctgt acaaactgta 480 ctacctcagc tgggagaaat gttggaaatg gtttaaacac attatcagat tcatcttgga 540 ggcatagtca agttcctaga tcttcatcaa tggtacttgg atcatttgga acagacttaa 600 tgagagagag gagagatttg gagagaagaa cagattcctc tattagtaat cttatggatt 660 atagtcaccg aagtggtgat ttcacaactt catcatatgt tcaagacaga gttccttcat 720 attcacaagg agcaagacca aaagaaaact caatgagcac tttacagttg aatacatcat 780 ccacaaacca ccaattgcct tctgaacatc agaccatact aagttctagg gattccagaa 840 attetttaag atcaaatttt tetteaagag aatcagaate tteeegaage aatacgeage 900 ctggattttc ttacagttca agtagagatg aagccccaat cataagcaat tcagaaaggg

ttgtttcatc	tcaaagacca	tttcaagaat	cttctgacaa	tgaaggtagg	cggacaacga	960
ggagattgct	gtcacgcata	gcttctagca	tgtcatctac	tttttttca	cgaagatcta	1020
gtcaggattc	cttgaataca	agatcattga	attctgaaaa	ttcttacgtt	tctccaagaa	1080
tcttgacagc	ttcacagtcc	cgtagtaatg	taccatcagc	ttctgaagtt	cccgataata	1140
gggcgtctga	agcttctcag	ggatttcgat	ttcttaggcg	aagatggggt	ttgtcatctc	1200
ttagccacaa	tcatagctct	gagtcagatt	cagaaaattt	taaccaagaa	tctgaaggta	1260
gaaatacagg	accatggtta	tcttcctcac	ttagaaatag	atgcacacct	ttgttctcta	1320
gaaggaggcg	agagggaaga	gatgaatctt	caaggatacc	tacctctgat	acatcatcta	1380
gatctcatat	ttttagaaga	gaatcaaatg	aagtggttca	ccttgaagca	cagaatgatc	1440
ctcttggagc	tgctgccaac	agaccacaag	catctgcagc	atcaagcagt	gccacaacag	1500
gtggctctac	atcagattcg	gctcaaggtg	gaagaaatac	aggaatatca	gggattcttc	1560
ctggttcctt	attccggttt	gcagtccccc	cagcacttgg	gagtaatttg	accgacaatg	1620
tcatgatcac	agtagatatt	attccttcag	gttggaattc	agctgatggt	aaaagtgata	1680
aaactaaaag	tgcgccttca	agagatccag	aaagattgca	gaaaataaaa	gagagcctcc	1740
ttttagagga	ctcagaagaa	gaagaaggtg	acttatgtag	aatttgtcaa	atggcagctg	1800
catcatcatc	taatttgctg	atagagccat	gcaagtgcac	aggaagtttg	cagtatgtcc	1860
accaagactg	tatgaaaaag	tggttacagg	ccaaaattaa	ctctggttct	tcattagaag	1920
ctgtaaccac	ctgtgaacta	tgtaaagaga	agttggagct	taacctggag	gattttgata	1980
ttcatgaact	acatagaget	catgcaaatg	aacaagctga	gtatgagttt	atcagctctg	2040
gtctctacct	agtggtgtta	ttgcacttgt	gcgaacaaag	cttttctgat	atgatgggaa	2100
atacaaatga	accaagcaca	cgtgtccgat	ttattaacct	tgcaagaact	cttcaggcac	2160
atatggaaga	tctcgaaact	tcagaggatg	attccgaaga	agacggagac	cataacagga	2220
catttgatat	tgcctaactt	catataagac	agatggatga	tctgtgaaca	taagtgttta	2280
ttaaaaatgg	caattaaata	taaattactt	ttgtggggga	atgcctaata	aatacattga	2340
ctatatataa	aatgaatata	tacatacaca	tgtatgcctg	tatatatata	ttcattctcc	2400
agtgttgctg	aattaaaatt	ctgctggact	ttttaacata	gcaaatccga	tgtttataaa	2460
ctggtaatca	aaaaggtttt	ttcttttagg	tgagtgggaa	agtattaccc	ttgttttaaa	2520
tatctaagca	atgcctatca	accettttt	gtgttatgat	tactgtagtc	atatttatga	2580
aaaaaggttt	gtgttttact	cttgctagtg	agaaaagtgg	gacaaaatat	acttttgaaa	2640
taaaatgcta	tatggcacct	aattatttt	tcttttaaaa	tgccttaagt	tgcagtctca	2700
ttttgataat	catttgcttc	cagtgttt				2728

<210> 4 <211> 3441 <212> DNA <213> Homo sapiens

ggagattgtt gccagggctc tggtgagttc agaatgaccg aagaagcatg ccgaacacgg 60 120 agtcagaaac gagcgcttga acgggaccca acagaggacg atgtggagag caagaaaata aaaatggaga gaggattgtt ggcttcagat ttaaacactg acggagacat gagggtgaca 180 240 cctgagccgg gagcaggtcc aacccaagga ttgctgaggg caacagaggc cacggccatg gccatgggca gaggcgaagg gctggtgggc gatgggcccg tggacatgcg cacctcacac 300 360 agtgacatga agtccgagag gagacccccc tcacctgacg tgattgtgct ctccgacaac gagcagccct cgagcccgag agtgaatggg ctgaccacgg tggccttgaa ggagactagc 420 accgaggece teatgaaaag cagteetgaa gaacgagaaa ggatgateaa geagetgaag 480 gaagaattga ggttagaaga agcaaaactc gtgttgttga aaaagttgcg gcagagtcaa 540 600 atacaaaagg aagccaccgc ccagaagccc acaggttctg ttgggagcac cgtgaccacc cctccccgc ttgttcgggg cactcagaac attcctgctg gcaagccatc actccagacc 660 tetteagete ggatgeeegg cagtgteata ecceegeeee tggteegagg tgggeageag 720 780 gcgtcctcga agctggggcc acaggcgagc tcacaggtcg tcatgccccc actcgtcagg ggggctcagc aaatccacag cattaggcaa cattccagca cagggccacc gccctcctc 840 900 ctggccccc gggcgtcggt gcccagtgtg cagattcagg gacagaggat catccagcag ggcctcatcc gcgtcgccaa tgttcccaac accagcctgc tcgtcaacat cccacagccc 960 accocagcat cactgaaggg gacaacagcc acctccgctc aggccaactc caccccact 1020 agtgtggcct ctgtggtcac ctctgccgag tctccagcaa gccgacaggc ggccgccaag 1080 ctggcgctgc gcaaacagct ggagaagacg ctactcgaga tcccccacc caagccccca 1140 gccccagaga tgaacttcct gcccagcgcc gccaacaacg agttcatcta cctggtcggc 1200 ctggaggagg tggtgcagaa cctactggag acacaaggca ggatgtcggc cgccactgtg 1260 1320 ctgtcccggg agccctacat gtgtgcacag tgcaagacgg acttcacgtg ccgctggcgg gaggagaaga gcggcgccat catgtgtgag aactgcatga caaccaacca gaagaaggcg 1380 1440 ctcaaggtgg agcacaccag ccggctgaag gccgcctttg tgaaggcgct gcagcaggaa caggagattg agcagcggct cctgcagcag ggcacggccc ctgcacaggc caaggccgag 1500 cccaccgctg ccccacaccc cgtgctgaag caggtcataa aaccccggcg taagttggcg 1560 ttccgctcag gagaggcccg cgactggagt aacggggctg tgctacaggc ctccagccag 1620

ctgtcccggg	gttcggccac	gacgccccga	ggtgtcctgc	acacgttcag	tccgtcaccc	1680
aaactgcaga	actcagcctc	ggccacagcc	ctggtcagca	ggaccggcag	acattctgag	1740
agaaccgtga	gegeeggeaa	gggcagcgcc	acctccaact	ggaagaagac	gcccctcagc	1800
acaggcggga	cccttgcgtt	tgtcagccca	agcctggcgg	tgcacaagag	ctcctcggcc	1860
gtggaccgcc	agcgagagta	cctcctggac	atgateceae	cccgctccat	ccccagtca	1920
gccacgtgga	aatagtgcga	gccaggcccc	gtggaagacg	ggctccctcc	tccccacct	1980
ggcccctggt	ctagaaggac	ccactgcacc	accctccgct	ggctcgggaa	gacaccgtgc	2040
ccgccccaag	agcaagcacc	ggccatgctg	cagaggcaag	acctcaattc	ttggctgcaa	2100
agtttcatca	gggctagggg	gctggtgccg	cctcataggc	agacgaggat	catcgctggg	2160
ggacctttcc	cgtgggcttt	cttcctttct	ctctttgcct	ttagtttgcc	cgacaccagc	2220
agaaaagtgg	accttggggg	ctggttctgc	tcctggcccc	cttgttcagc	ccctgccggc	2280
acacgggcgg	ctcaccctgg	acactgtgat	gcgcatgggc	aaggccagcg	cccggggctt	2340
ctgaaccgag	cggggtgttt	cattttttg	cttttccctg	tcttaggctc	ccagtctttg	2400
actgccttcc	catggcgatc	tataagttga	aagattttt	tttttttaa	tcacctcatg	2460
atgatggagt	taaaagtaaa	ccgtgcagac	cctggggtcc	ctgttgtacg	ctgcatcatc	2520
ccgctggccc	tgtgccctgg	agggtgggcg	gctcatggtg	ccacagcccc	tggcagggac	2580
ggccggcccg	ccccgtgac	tgactgacag	atgcagggat	ggccgaggca	gcccțcgctc	2640
cagctgaacg	cctccattgc	tgcttgttct	ggagaccccc	gccccgcac	cttccagact	2700
tagcagaaga	acaaactgaa	gaacagaccc	agccagagaa	gcagggattc	cagaagctgc	2760
ccattaaggg	agaaggagag	gatccggtcg	gcagcagccc	tgagcagaaa	gctggagggg	2820
ggactgtcgc	ggggttttc	tgttgtggtt	tattttatta	aatttttcc	ttttttctat	2880
tcatttcgat	ggacgcaatc	ttaagccacc	ctggccttgc	tcctgggagg	tgagcgtgca	2940
caggtgtgtg	caggtcagga	ggtgccgtcc	aggtgtgcgg	cgagccgctg	cgcacagatg	3000
tcaggatttc	cgtttgggtc	tagtttagaa	cctgtcctta	aacctagggg	ttgctgtcag	3060
gatttgcttt	cagacttttt	ttttttttgt	aattcccttt	agagtctaca	aaaatgtttt	3120
taaaaggatc	aggtctgctt	ttagtttcat	ttttgtttct	ttcccgtccc	actctttaaa	3180
aactggttcc	gtgaggaaag	gcagaagccg	ttccgtgtct	cttgcaggct	gggccggctt	3240
catgccagtg	cgagggcgtc	ccgtgcccac	gtacatacgt	atgtctccat	gagttctggg	3300
ctccactggt	tccaattgag	ctccagccct	ggttttccta	cccatgcagt	tagggacttt	3360
aatttaattt	tttttttgta	gggccaccgc	cttcaaacac	aactgctaca	acattctaat	3420
aaaggctcat	ttaaccccca	g				3441

<210> 5 <211> 2713 <212> DNA <213> Homo sapiens

<400> 5

60 tggctgcctg acttgggaga tggatgggct gagggagtgg agggggacct cagaggagca ggaccaggga gactcccagg acggtaagca acatttgagg accattcact aacgcttctc 120 tgcaggggtt tcctctccat ccatttcctt gctgggttgt cagtgatgcc atctgagttg 180 ctgtcagggc tgtagcctga caaagggttt cctaatagat ccaaactgtc catttgtggg 240 gagettetga ttttetgttg ttaetggttt ecettagece aacaccaggg teattaagaa 300 ggaaggaatg tgaggaagaa agaaaggcag ggcattcagg aagaagtgtg gaggcatggg 360 420 agggttetea tggggeeete etgggeaetg ggtgaeetgt eettteteee eteaggtagg ggtcccacgg ctgggtggtc ctaagccact gggtggatga aaggccgagg gatgttggtc 480 540 ctgcttctgc atgcggtggt cctcggcctg cccagcgcct gggccgtggg ggcctgcgcc cgcgcttgtc ccgccgcctg cgcctgcagc accgtggagc gcggctgctc ggtgcgctgc 600 660 gaccgcgcgg gcctcctgcg ggtgccggcc gagctcccgt gcgaggcggt ctccatcgac ctggaccgga acggcctgcg cttcctgggc gagcgagcct tcggcacgct gccgtccttg 720 780 cgccgcctgt cgctgcgcca caacaacctg tccttcatca cgcccggcgc cttcaagggc 840 ctgccgcgcc tggctgagct gcgcctggcg cacaacggcg acctgcgcta cctgcacgcg cgcaccttcg cggcgctcag ccgcctgcgc cgcctagacc tagcagcctg ccgcctcttc 900 960 agcgtgcccg agcgcctcct ggccgaactg ccggccctgc gcgaactcgc cgccttcgac 1020 aacctgttcc gccgcgtgcc gggcgcgctg cgcggcctgg ccaacctgac gcacgcgcac .1080 ctggagegeg geegeatega ggeggtggee tecagetege tgeagggeet gegeegeetg 1140 tgtggcgtcc tggagcatct gctgctcaac gacaacctgc tggccgagct cccggccgac 1200 gccttccgcg gcctgcggcg cctgcgcacg ctcaacctgg gtggcaacgc gctggaccgc 1260 gtggcgcgcg cctggttcgc tgacctggcc gagctcgagc tgctctacct ggaccgcaac 1320 1380 agcatcgcct tcgtggagga gggcgccttc cagaacctct cgggtctcct cgcgctgcac 1440 ctcaacggca accgcctcac cgtgctcgcc tgggtcgcct tccagcccgg cttcttcctg ggccgcctct tcctcttccg caacccgtgg tgctgcgact gccgtctgga gtggctgagg 1500 gactggatgg agggctccgg acgtgtcacc gacqtgccqt gcgcctcccc gggctccgtg 1560 geoggeetgg aceteageea ggtgacette gggegeteet eegatggeet etgtgtggae 1620 1680 cccgaggagc tgaacctcac cacgtccagt ccaggcccgt ccccagaacc agcggccacc

accgtgagca	ggttcagcag	cetectetee	aagctgctgg	ccccgagggt	cccggtggag	1740
gaggcggcca	acaccactgg	ggggctggcc	aacgcctccc	tgtccgacag	cctctcctcc	1800
cgtggggtgg	gaggcgcggg	ccggcagccc	tggtttctcc	tegeetettg	teteetgeee	1860
agcgtggccc	agcacgtggt	gtttggcctg	cagatggact	gacctggcca	gaggggggaa	1920
agtttgctta	actgggcttg	agtgtgtttg	tggtaagggg	agaggagccg	gaatggaggg	1980
cagaggtgaa	aatcccagtg	gagggtggaa	ggaaccgttt	gcctccagag	atggccccag	2040
ggagaacaca	gggacgtgcc	actcgagggg	gaggatggta	tggatttctg	cttttgtcac	2100
acgggcatcc	attggaaaag	agaagcaaga	atgaacgtgg	gccctcgggt	gggaagacta	2160
ggaatcggaa	gcttctaggg	cttcacatcc	cttcccctcc	cctcccttc	ccctcatctt	2220
ccaggcaaca	gtgcctgcaa	ggcctgaatt	agagagactt	ccattggcta	agtagttaag	2280
agccgtccca	tttctcctgg	cggggtaacc	cattacaccg	aagtcctttg	ttttctacca	2340
caatcctcct	cetectec	aggggcctgg	aaacactagg	attcaggaag	gtaggcagga	2400
cgtgagagaa	gggagatggg	agagagattt	aagacaaagg	gtggcggtgg	ttcctggggt	2460
ctgagatgtg	ttaggaggcg	tttaaaacaa	agatccagtt	catttactcc	acagttattc	2520
ccagggctgg	ccctagccac	aaaggaactt	tagggcaggg	tagggaaaaa	aggggcagca	2580
gggggtgtgt	ttgtggacaa	ataaatttgt	aaagtccgag	gattaaaaaa	aaaaaaaggt	2640
taaaccggtt	tctctactgc	tggacttttc	agagtctttc	atatgctaac	attcattgtg	2700
aatctcccaa	gag					2713

<210> 6 <211> 3160 <212> DNA

<213> Homo sapiens

<400> 6 atacgatgta cttttttaa tgccgttgaa acagagttaa tttcctttag cacacaagtc 60 ttagagacaa aagaaaaaaa ggtctgcaac atgaaagtca caggcatcac aatcctcttt 120 tggcccctct ccatgatatt attatcagac aaaatccagt cttctaaaag agaagtccaa 180 tgtaatttta ctgaaaaaaa ttataccttg attccagcag atatcaagaa agatgttact 240 atacttgatc tcagttataa ccaaattact cttaatggta cagacacaag agttctacag 300 acatactttt tactcacaga gctctatttg attgagaaca aggttactat cttacataat 360 aacggttttg gtaacctctc cagtctagaa attttaaata tctgtagaaa ctccatctat 420 gtaattcaac agggtgcatt tttaggctta aataaactaa aacagttata tctctgccaa 480 aacaaaatag aacaactgaa tgctgatgta tttgtgcctc taagaagcct aaaacttctg 540

aatctgcaag	gcaatttgat	: tagctatttg	gatgtaccad	cactatttca	tctggaatta	600
ataactttat	atggaaacct	atggaactgo	: tcttgcagtc	: tatttaattt	gcagaactgg	660
ttgaacacat	caaatgtgac	: attagaaaat	gagaacatca	ccatgtgtag	ctaccccaac	720
agcctgcaga	gctacaatat	caaaacagta	cctcataagg	ctgaatgcca	ctcaaaattt	780
ccttcatcag	taactgaaga	tctttatatt	cattttcago	: ccatcagcaa	ttcaatattt	840
aatagctctt	cgaacaactt	aacaagaaat	tcagaacatg	aacctcttgg	aaaaagttgg	900
gcttttcttg	ttggtgttgt	tgtcactgta	ctgacgactt	cacttctcat	ttttattgct	960
atcaaatgcc	caatatggta	caatattctg	cttagttata	atcatcatcg	cctggaagag	1020
catgaagcag	aaacctatga	agatggtttt	actggaaatc	caagetetet	ttcacagata	1080
ccagaaacaa	actctgaaga	aactacagta	atatttgaac	aattacattc	atttgtggta	1140
gatgatgatg	gatttattga	agacaaatat	atagatatcc	atgaattatg	tgaagaaaat	1200
taatttcttt	caaagtttgc	ttttaaagc	aaagttatca	gctcactcag	tttagatatg	1260
gagattttgc	tatgtgacat	aacaaaatac	agctggcagg	cattcatatt	aatgacaaca	1320
tacatgaata	tcataaaatt	atgttctttg	cattatattg	agcaagcagg	ttcaaataca	1380
gtaactgaca	ctcctcggta	gttgacagtt	acatagtcta	caatactagc	actactattc	1440
ttagcagtgc	ttgggtgacc	atacgaacta	gtaaaaaggt	ctaaattatt	catgaattaa	1500
aatgaatgga	ttctcatatt	aacacaggta	tttgacataa	tatgtattaa	gttatactaa	1560
tgtttcaatc	agtaaagaaa	taaaagttta	ggatttatta	atatatggaa	gtcaaagtga	1620
ggaacagaga	tagcttaaat	aatacactaa	gattgatttt	atgctcccag	aataaaatca	1680
tagagttgga	aaatatttt	ttgaaatgct	tcctgaaata	gcacaataaa	tttcccttaa	1740
aatttcatag	caatttaaag	cacaagcaca	atgttcaggc	ataatcccta	ataagtcact	1800
attgattctg	gttataaaga	aaggctgtca	ccataatgca	ggatcactac	agtttaatgt	1860
catactggct	tccaaagtgg	gcatcacaat	tatctataaa	tcttgtttta	aaaatacata	1920
tttctacctc	tctctgggag	atttttattc	aaattggtct	gtgctgacac	taaggaatct	1980
tcatgtggtc	catggacagc	tatttctatc	tattcagtag	atagagcaat	gtttcccaaa	2040
ttgtttttct	agaatactaa	tttccagaga	gacattcaca	agtatttaca	gaagaagaag	2100
gaggtacatg	gtcaaattac	tacaggaaaa	actagtagtt	taaacaaggt	gaaacaagat	2160
tctttttctt	tttttttt	ttttttttga	gacaaagtct	cgcactgtct	cccaggctgg	2220
actgcagcag	cgcagtctca	gatcactgca	acctccgcct	cctgggttca	agcaattctt	2280
ctgactcagc	ctcccgagta	gctgggagta	caggtgcaca	ccaccatgcc	tggctaattt	2340
ctgtattttt	agtagagaca	gggtttcacc	atgttggcca	ggctggtctc	gaacgcctga	2400

2460 cctcatgatc tacccgcctc ggcctcccaa agtgctggga ttacaggcat ggagcaccgt gcctggccaa gattctttac aataggattt atgtaaaact taactaagct aaactgctct 2520 ctgattattc aagagcaaag tattaaaaat ttctcgaact tacttgacaa caaaacccat 2580 tctttcagtt acatctacta agagctcgta gttcaataac attccaaaga acgtagtttg 2640 gaaaacactg gcctatcggc tgtaatagga agggtctaaa gaaaattatt tgctgagtcc 2700 2760 tcataatcaa ttggctataa tcacaattta ataatttatc aatgcaaaca gtacattaaa 2820 aactgtagca caatctataa tttttacctt catatgcaga gaaattaaga atttacatct tttacaaata tgtgtatctc tgaaataatg aaatatattg atgggtgaaa taatatttct 2880 ggtattttct tcattataac acgtggaatg ggacagtggc tagaggtatg gatggagcaa 2940 3000 ggtcaaatat gagctgatgg agctgggcgc taaataaggg tataatatgc tacttctgtg 3060 tatgttgtgt atggtatagt atgctatttc tgtgtatgtt caaattgttt atgtatataa 3120 taaagtttta aaaatttgta tgtacttgac aattccttag aaaaaagagg ctaaaataaa 3160

<210> 7

<211> 4158

<212> DNA

<213> Homo sapiens

<400> 7

ttgatttggt atagtgggaa catttgcttt ggagacagat gaactggatt ctgatcgtga 60 120 ccctgctatt ttctccttgt gtgactttgg agccatgaga ccccagatcc tgctgctcct 180 ggccctgctg accctaggcc tggctgcaca acaccaagac aaagtgccct gtaagatggt ggacaagaag gtctcgtgcc aggttctggg cctgctccag gtcccctcgg tgctcccgcc 240 agacactgag accettgate tatetgggaa ccagetgegg agtateetgg ceteacceet 300 360 gggettetae acageaette gteacetgga eetgageaee aatgagatea getteeteea 420 gecaggagee ttecaggeee tgacccacet ggageacete agectggete acaacegget ggcgatggcc actgcgctga gtgctggtgg cctgggcccc ctgccacgcg tgacctccct 480 540 ggacctgtct gggaacagcc tgtacagcgg cctgctggag cggctgctgg gggaggcacc 600 cagcctgcat accctctcac tggcggagaa cagtctgact cgcctcaccc gccacacctt 660 ccgggacatg cctgcgctgg agcagcttga cctgcatagc aacgtgctga tggacatcga 720 ggatggcgcc ttcgagggtc tgcccgcct gacccatctc aacctctcca ggaattccct 780 cacctgcatc tecgaettea geeteeagea getgegggtg etagaeetga getgeaacag 840 categaggee tttcagacgg ceteccagee ccaggetgag ttccagetca cetggettga 900 cctgcgggag aacaaactgc tccatttccc cgacctggcc gcgctcccga gactcatcta

cctgaacttg	tccaacaacc	tcatccggct	ccccacaggg	ccaccccagg	acagcaaggg	960
catccacgca	ccttccgagg	gctggtcagc	cctgcccctc	tcagccccca	gcgggaatgc	1020
cagcggccgc	cccctttccc	agctcttgaa	tctggatttg	agctacaatg	agattgagct	1080
catccccgac	agctttcttg	agcacctgac	ctccctgtgc	ttcctgaacc	tcagcagaaa	1140
ctgcttgcgg	acctttgagg	cccggcgctt	aggctccctg	ccctgcctga	tgctccttga	1200
cttaagccac	aatgccctgg	agacactgga	actgggcgcc	agagccctgg	ggtctctgcg	1260
gacgctgctc	ctacagggca	atgccctgcg	ggacctgccc	ccatacacct	ttgccaatct	1320
ggccagcctg	cagcggctca	acctgcaggg	gaaccgagtc	agcccctgtg	gggggccaga	1380
tgagcctggc	ccctccggct	gtgtggcctt	ctccggcatc	acctccctcc	gcagcctgag	1440
cctggtggat	aatgagatag	agctgctcag	ggcaggggcc	ttcctccaca	cccactgac	1500
tgagctggac	ctttcttcca	atcctgggct	ggaggtggcc	acgggggcct	tgggaggcct	1560
ggaggcctcc	ttggaggtcc	tggcactgca	gggcaacggg	ctgatggtcc	tgcaggtgga	1620
cctgccctgc	ttcatctgcc	tcaagcggct	caatcttgcc	gagaaccgcc	tgagccacct	1680
tecegeetgg	acacaggctg	tgtcactgga	ggtgctggac	ctgcgaaaca	acagcttcag	1740
cctcctgcca	ggcagtgcca	tgggtggcct	ggagaccagc	ctccggcgcc	tctacctgca	1800
ggggaatcca	ctcagctgct	gcggcaatgg	ctggctggca	gcccagctgc	accagggccg	1860
tgtggacgtg	gacgccaccc	aggacctgat	ctgccgcttc	agctcccagg	aggaggtgtc	1920
cctgagccac	gtgcgtcctg	aggactgtga	gaagggggga	ctgaagaaca	tcaacctcat	1980
catcatcctc	accttcatac	tggtctctgc	catcctcctc	accacgctgg	ccgcctgctg	2040
ctgcgtccgc	cggcagaagt	ttaaccaaca	gtataaagcc	taaagaagcc	gggagacact	2100
ctaggtcagt	gggggagcct	gaggtacaga	gaagagtgag	gactgactca	aggtcacaca	2160
gtgatccggg	atcccagaac	tctggtctcc	aaattacagc	ccaggacacc	tttctctgcc	2220
gcctgctgca	tcagtgggtg	accccttcc	cgggctgcac	tttgggtcca	gctgtggaag	2280
ccagaagttg	ggcggtttca	gggacagccg	agaataatgt	tgacctgtca	gatcaacaaa	2340
tcttcactga	gcatgtattt	tgtgccacac	cctgctctgg	gcactgggaa	tgctgggaaa	2400
tgagatacat	tcccgccctc	aagaatctcc	cagtctggta	ggagagagtg	ctgcagagcc	2460
acgtggccgc	cacgcagtgt	gcttagggcc	tgaggtgtga	aagcccaggg	ctccagagct	2520
cggcaggccc	cgctggtttg	gtgcggtgag	tectgeeeg	gctgtgccag	ggtgagggag	2580
ggccaagccc	aggaggattt	gtctgagaca	tttccaagca	gactgtttgt	cacgtcttct	2640
gagaatgact	ttcagtctct	ctgaaaatga	aaagcttagg	accagaagag	agaattggag	2700
ctgtacgagt	gtgtctcgga	tctggtgttg	ttaggtgggc	cacggcggct	ccagcagggt	2760

ctggttaagg	ggtccagccc	agcactggac	cattccgtct	cctgctctgg	acttgccctc	2820
tecetteetg	gcactctcat	gttgcatacc	ctgaccccag	tgctgctcta	agcaccgtcc	2880
ctgcccagcc	ccacttctcc	atcgcagccc	caccttggct	gctgagccag	gagctaaaac	2940
cttagatatc	tggttctgtt	ttgcacccag	cttggcagat	gtggatttga	atccaagcct	3000
tgtgtctgcc	cctatgtgac	agctctatat	tttatccccg	ttttataaaa	gaggaaactg	3060
aagttctgaa	aatctccttc	cagggcccca	gctaactaat	gccataggtg	agattcaaac	3120
cttcatcctt	ctgtctccag	ggcctgatct	ttaccactgc	aggggctgca	ggccgttaag	3180
tggacaggaa	gtggccccac	atagcccgag	cagggtctgg	aagcatcctg	tgctgtgcac	3240
acctgctctc	tcctctctcc	caggcaggca	gctgcaggcg	ctctcctcct	tctctgcctg	3300
tttccctcct	cccttccttt	ccaccctggt	gtgggttctc	ctgttctctc	tgtgctcttg	3360
cattctctca	ttcccttttc	ctctattgag	cagagcctgg	agtttgagac	tatggaatcc	3420
aacctcccca	ttgcacagat	ggggaaactg	aggcttagga	agagaatgaa	acttgtggag	3480
agcttataca	gageetetgg	gggaaaaaag	agcccttatt	tgtggggtga	gattgggggt	3540
tggaccagag	tgatgtcctc	tctcagctat	cacatcacaa	gataatgctg	gctccaaact	3600
tcctttctgt	gcctcatcat	gcaaggatct	tttttccctc	ttacaaaaac	aggtaaaaag	3660
cctcacccag	atgaccccca	teceteatae	catggagtca	tgagctgtct	gggaagaatg	3720
gacgtgctgg	gaccaactca	agaccttgtt	ttgctgtctt	catcatctta	cctgtgcttg	3780
gcccacagtc	tggctcatga	tgtgggctca	gtaatgtgcg	agaaagtgaa	aatgccactc	3840
tctccacccc	attttacaga	ggagaacacc	aaggcccaga	ggaagttaag	ggagagtcaa	3900
tgggcagagc	cagggctagg	ccctggtggt	gtgtggagca	cccaggcaga	cccagtcctg	3960
gttgggatca	cacccacggg	tgctactgca	cgtaacactc	ctccttaggc	ctggaggcca	4020
aggtgtgggt	ccccacgcct	gatctttgaa	aacactacac	agggctgctg	tcacttccca	4080
gggcccaggc	ctcagcccag	gcctcgggac	caactctttg	tataacctac	ctgaatgtat	4140
taaaaactaa	ttttggag					4158
<210> 8 <211> 248	0					
<212> DNA <213> Home	o sapiens					
<400> 8 gacgctctgt	gccttcggag	gtctttctgc	ctgcctgtcc	tcatgcctct	cctcctcttg	60

ctgctcctgc tgccaagccc cttacacccc cacccatct gtgaggtctc caaagtggcc

agccacctag aagtgaactg tgacaagagg aatctgacag cgctgcctcc agacctgccg

120

180

aaagacacaa	ccatcctcca	cctgagtgag	aacctcctgt	acaccttctc	cctggcaacc	240
ctgatgcctt	acactcgcct	cactcagctg	aacctagata	ggtgcgagct	caccaagctc	300
caggtcgatg	ggacgctgcc	agtgctgggg	accctggatc	tatcccacaa	tcagctgcaa	360
agcctgccct	tgctagggca	gacactgcct	gctctcaccg	tcctggacgt	ctccttcaac	420
cggctgacct	cgctgcctct	tggtgccctg	cgtggtcttg	gcgaactcca	agagctctac	480
ctgaaaggca	atgagctgaa	gaccctgccc	ccagggctcc	tgacgcccac	acccaagctg	540
gagaagctca	gtctggctaa	caacaacttg	actgagetee	ccgctgggct	cctgaatggg	600
ctggagaatc	tcgacaccct	tctcctccaa	gagaactcgc	tgtatacaat	accaaagggc	660
ttttttgggt	cccacctcct	gccttttgct	tttctccacg	ggaacccctg	gttatgcaac	720
tgtgagatcc	tctattttcg	tcgctggctg	caggacaatg	ctgaaaatgt	ctacgtatgg	780
aagcaaggtg	tggacgtcaa	ggccatgacc	tctaacgtgg	ccagtgtgca	gtgtgacaat	840
tcagacaagt	ttcccgtcta	caaataccca	ggaaaggggt	gccccaccct	tggtgatgaa	900
ggtgacacag	acctatatga	ttactaccca	gaagaggaca	ctgagggcga	taaggtgcgt	960
gccacaagga	ctgtggtcaa	gttccccacc	aaagcccata	caaccccctg	gggtctattc	1020
tactcatggt	ccactgcttc	tctagacagc	caaatgccct	cctccttgca	tccaacacaa	1080
gaatccacta	aggagcagac	cacattccca	cctagatgga	ccccaaattt	cacacttcac	1140
atggaatcca	tcacattctc	caaaactcca	aaatccacta	ctgaaccaac	cccaagcccg	1200
accacctcag	agcccgtccc	ggagcccgcc	ccaaacatga	ccaccctgga	gcccactcca	1260
agcccgacca	ccccagagcc	cacctcagag	cccgccccca	gcccgaccac	cccggagccc	1320
accccaatcc	cgaccatcgc	cacaagcccg	accatcctgg	tgtctgccac	aagcctgatc	1380
actccaaaaa	gcacattttt	aactaccaca	aaacccgtat	cactcttaga	atccaccaaa	1440
aaaaccatcc	ctgaacttga	tcagccacca	aagctccgtg	gggtgctcca	agggcatttg	1500
gagagctcca	gaaatgaccc	ttttctccac	cccgactttt	gctgcctcct	cccctgggc	1560
ttctatgtct	tgggtctctt	ctggctgctc	tttgcctctg	tggtcctcat	cctgctgctg	1620
agctgggttg	ggcatgtgaa	accacaggcc	ctggactctg	gccaaggtgc	tgctctgacc	1680
acagccacac	aaaccacaca	cctggagctg	cagaggggac	ggcaagtgac	agtgccccgg	1740
gcctggctgc	tcttccttcg	aggttcgctt	cccactttcc	gctccagcct	cttcctgtgg	1800
gtacggccta	atggccgtgt	gąggcctcta	gtggcaggaa	ggaggccctc	agctctgagt	1860
cagggtcgtg	gtcaggacct	gctgagcaca	gtgagcatta	ggtactctgg	ccacagcctc	1920
tgagggtggg	aggtttgggg	accttgagag	aagagcctgt	gggctctcct	attggaatct	1980
agttgggggt	tggaggggta	aggaacacag	ggtgataggg	gaggggtctt	agttcctttt	2040

tctgtatcag	aagccctgtc	ttcacaacac	aggcacacaa	tttcagtccc	agccaaagca	2100
gaaggggtaa	tgacatggac	ttggcggggg	gacaagacaa	agctcccgat	gctgcatggg	2160
gcgctgccag	atctcacggt	gaaccatttt	ggcagaatac	agcatggttc	ccacatgcat	2220
ttatgcacag	aagaaaatct	ggaaagtgat	ttatcaggat	gtgagcactc	gttgtgtctg	2280
gatgttacaa	atatgggtgg	ttttatttc	tttttccctg	tttagcattt	tctagttttc	2340
ttatcaggat	gtgagcactc	gttgtgtctg	gatgttacaa	atatgggtgg	ttttatttc	2400
tttttccctg	tttagcattt	tctagttttc	cactattatt	gtatattatc	tgtataataa	2460
aaaataattt	tagggttggg					2480

<210> 9

<211> 5223

<212> DNA

<213> Homo sapiens

<400> 9

60 agagttatat tgtgccattt atggaaaaac tctccccact gctcttggct ttgacagtag 120 gaatcaggtt atatatggtc tctcggtttg aagatatttg tcattaaaaa ccagaacaag 180 ggctctgaga tagggtcctt tcctgaccta ctctggtaaa gtctttatcc tcaggatgca aggataccac cctcttcctg tggaaagtgt cgaatcacat. gcagagctct aagtctttca 240 300 gttactttgg agtgcagaac catttcagac atgctgaggg ggactctact gtgcgcggtg 360 ctcgggettc tgcgcgccca gcccttcccc tgtccgccag cttgcaagtg tgtcttccgg gacgccgcgc agtgctcggg gggcgacgtg gcgcgcatct ccgcgctagg cctgcccacc 420 480 aacctcacgc acatcctgct cttcggaatg ggccgcggcg tcctgcagag ccagagcttc 540 ageggeatga cegteetgea gegeeteatg ateteegaea gecacattte egeegttgee 600 cccggcacct tcagtgacct gataaaactg aaaaccctga ggctgtcgcg caacaaaatc 660 acgcatcttc caggtgcgct gctggataag atggtgctcc tggagcagtt gtttttggac 720 cacaatgcgc taaggggcat tgaccaaaac atgtttcaga aactggttaa cctgcaggag 780 ctcgctctga accagaatca gctcgatttc cttcctgcca gtctcttcac gaatctggag 840 aacctgaagt tgttggattt atcgggaaac aacctgaccc acctgcccaa ggggttgctt 900 ggagcacagg ctaagctcga gagacttctg ctccactcga accgccttgt gtctctggat 960 teggggetgt tgaacageet gggegeeetg aeggagetge agtteeaceg aaateacate 1020 cgttccatcg cacccggggc cttcgaccgg ctcccaaacc tcagttcttt gacgctttcg 1080 agaaaccacc ttgcgtttct cccctctgcg ctctttcttc attcgcacaa tctgactctg 1140 ttgactctgt tcgagaaccc gctggcagag ctcccggggg tgctcttcgg ggagatgggg 1200 ggcctgcagg agctgtggct gaaccgcacc cagctgcgca ccctgcccgc cgccgccttc

cgcaacctga	gccgcctgcg	gtacttaggg	gtgactctga	gcccgcggct	gagcgcgctt	1260
ccgcagggcg	ccttccaggg	ccttggcgag	ctccaggtgc	tcgccctgca	ctccaacggc	1320
ctgaccgccc	teeecgaegg	cttgctgcgc	ggcctcggca	agctgcgcca	ggtgtccctg	1380
cgccgcaaca	ggctgcgcgc	cctgccccgt	gccctcttcc	gcaatctcag	cagcctggag	1440
agcgtccagc	tcgaccacaa	ccagctggag	accctgcctg	gcgacgtgtt	tggggctctg	1500
ccccggctga	cggaggtcct	gttggggcac	aactcctggc	gctgcgactg	tggcctgggg	1560
cccttcctgg	ggtggctgcg	gcagcaccta	ggcctcgtgg	gcggggaaga	gcccccacgg	1620
tgcgcaggcc	ctggggcgca	cgccggcctg	ccgctctggg	ccctgccggg	gggtgacgcg	1680
gagtgcccgg	gccccgggg	cccgcctccc	cgccccgctg	cggacagctc	ctcggaagcc	1740
cctgtccacc	cagccttggc	tcccaacagc	tcagaaccct	gggtgtgggc	ccagccggtg	1800
accacgggca	aaggtcaaga	tcatagtccg	ttctgggggt	tttattttct	gcttttagct	1860
gttcaggcca	tgatcaccgt	gatcatcgtg	tttgctatga	ttaaaattgg	ccaactcttt	1920
cgaaaattaa	tcagagagag	agcccttggg	taaaccaatg	ggaaaatctt	ctaattactt	1980
agaacctgac	cagatgtggc	tcggagggga	atccagaccc	gctgctgtct	tgctctccct	2040
ccctcccca	ctcctcct	cttcttcctc	ttctctctca	ctgccacgcc	ttcctttccc	2100
tcctcctccc	cctctccgct	ctgtgctctt	cattctcaca	ggcccgcaac	ccctcctctc	2160
tgtgtcccc	gcccgttcct	ggaaactgag	cttgacgttt	gtaaactgtg	gttgcctgcc	2220
ttccccagct	cccacgcggg	tgtgcgctga	cactgccggg	ggcgctggac	tgtgttggac	2280
ccatccgtgc	tccgctgtgc	ctggcttggc	gtctggtgga	gagaggggcc	tcttcagtgt	2340
ctactgagta	aggggacagc	tccaggccgg	ggcctgtctc	ctgcacagag	taagccggta	2400
aatgtttgtg	aaatcaatgc	gtggataaag	gaacacatgc	catccaagtg	atgatggctt	2460
ttcctggagg	gaaaggatag	gctgttgctc	tatctaattt	tttgtttttg	tttttggaca	2520
gtctagctct	gtggcccagg	ctggcgtgca	gtgggccgtc	tcagttcact	gcagcctccg	2580
cctcccaggt	tcaagtgatt	ctcatgcctc	agcgttctga	gtagctggga	ttagaggcgt	2640
gtgccactac	acccggctaa	tttttgtact	ttttaaagta	gagacggggc	tttgccatat	2700
tggcctggct	gatctcaaac	tcctggtctt	gaactcctgg	ccacaagtga	tctgcccgcc	2760
ttggcctccc	aaagtgctgg	gattacaggc	gtaagccact	acacctggcc	ctcttcatcg	2820
aattttattt	gagaagtaga	gctcttgcca	tttttccct	tgctccattt	ttctcacttt	2880
atgtctctct	gacctatggg	ctacttggga	gagcactgga	ctccattcat	gcatgagcat	2940
tttcaggata	agcgacttct	gtgaggctga	gagaggaaga	aaacacggag	ccttccctcc	3000
aggtgcccag	tgtaggtcca	gcgtgtttcc	tgagcctcct	gtgagtttcc	acttgcttta	3060

catccatgca	acatgtcatt	ttgaaactgg	attgatttgc	atttcctgga	actctgccac	3120
ctcatttcac	aagcatttat	ggagcagtta	acatgtgact	ggtattcatg	aatataatga	3180
taagcttgat	tctagttcag	ctgctgtcac	agtctcattt	gttcttccaa	ctgaaagccg	3240
taaaaccttt	gttgctttaa	ttgaatgtct	gtgcttatga	gaggcagtgg	ttaaaacagg	3300
ggctggcgag	ttgacaactg	tgggttcaaa	tcccagctct	accacttact	aactgcatgg	3360
gactttgggt	aagacacctg	cttacattct	ctaagccttg	gtttcctgaa	ccttaaaaca	3420
ggataacata	gtacctgctt	cgtagagttt	ttgtgagaat	taaaggcaat	aaagcatata	3480
atgacttagc	ccagcggcct	gcaggcaata	catgttaatg	aatgttagct	attattacta	3540
aaggatgagc	aattattatt	ggcatcatga	tttctaaaga	agagctttga	gttggtattt	3600
ttctctgtgt	ataagggtaa	gtccgaactt	tctcagactg	gaggttacat	tcacatcagt	3660
ctgtcttccc	ctgcggatgg	cctcagccct	gggtggccag	actctgtgct	cacaatccag	3720
agcaatggat	cctccaacac	caccaggtgg	atgtggagca	ggagagcitgg	atcgtggcat	3780
ttgtttctgg	gttctgcagc	tgtgggagtt	ggtttctggg	ttctccattg	gtctacttgt	3840
ctagtcccat	accagactca	cggtctccat	tattggagct	ttaataattt	ttggtatagg	3900
gtcatctctc	caccttgttt	ttcttctatt	cttggttctt	tgcaattcta	tgaatatttc	3960
agggtcagca	tgtcaactcc	attgaaaaac	cctgctggga	ttttaataga	acttacagct	4020
cacgcctgta	atctcagcac	tttgggaggc	tgaggtgggt	ggatcacaag	gtcaggagtt	4080
tgagaccagc	ctggccaaga	tggtaaaacc	ccgtctctac	taaaaataca	aaaattagct	4140
gggtgcggtg	gcaggtgcct	gtaatcccag	ctacttggga	cactgaggca	ggagaatcac	4200
ttgaacccgg	gaggcggagg	ttgcagtgag	ccgagatcgt	gccactgcac	tctagcctgg	4260
gcgacagagc	gagactccat	ctcaaaaaaa	aaaaaaaaa	attgcagtaa	atttaaaact	4320
aatttgggga	agaatctgta	ttttttacaa	tacctagtgt	tcttgccagt	aagcatggtt	4380
catcttccca	tttatttacg	tcattttaaa	tctttcagtg	atgttttaga	attttttta	4440
taaaaacctt	cactataaga	acagaaaacc	aaacaccgca	tgttctcact	cataggtggg	4500
aattgaacaa	tgagaacact	tggacacagg	gcggggaacg	tcacacgcct	ggactgtcgg	4560
ggggtggggg	gctgggagag	ggatagtgtt	aggagaaata	cctaatgtaa	atgacgagtt	4620
aatgggtgca	gccaaccaac	ctggcacatg	tattcatatg	taacaaacct	gcacgttgtg	4680
cacatgtacc	ctagaactta	aagtatataa	aaaaaagaaa	ccttgcactg	attttgttag	4740
atttattcct	aggtatcctt	cctcttttt	gatttgtcat	tgctattgta	gatggcatct	4800
ttttaaaaag	ttatattttc	taaagaaaaa	aataaaaaaa	gttgtatttt	ctaattttta	4860
ttaccaatat	ataagaatgt	aatttattt	tacataatta	tctțatgtct	agtaataatt	4920

ctgataattt	gcttcttcct	attaaaacct	tacacccatt	attgatttat	ttttctgttt	4980
taaaatatct	tcctgcactg	gctaaaacct	ccactataat	gttgagcaga	acagtgagca	5040
tccttagaac	tatcttggtt	gcaaagggta	ggtctctaat	gtttcatcaa	taaatgtgat	5100
gtttctagtc	tgagtttgct	aagtatattt	taaaataatc	agtaaagtta	gattttatcc	5160
atttttatct	taactattga	gatgctcata	tcatttttct	tcttcaatgt	gttaaaatgg	5220
tga						5223
	s sapiens					
<400> 10 agaaaagcaa	gggcagggtt	cagaaagact	gaatgtaaag	ctgggctctg	agtctgccat	60
gcccttcgtg	tgttgctctg	cacattaatt	aaagggtcta	cgaggtcagc	aaggacgccc	120
aaggagactc	agtcatgaaa	ggtgaactgc	tcctgttttc	cagtgtgatt	gtcctgctcc	180
aggtggtatg	cagctgcccg	gacaagtgtt	actgtcagtc	atctacaaat	tttgtagact	240
gcagccagca	gggtctggcc	gaaatccctt	cccatttacc	tcctcagact	cgaacgctgc	300
atttacaaga	taatcagata	caccatcttc	ctgcttttgc	atttaggtca	gtgccatggc	360
tcatgacctt	aaacttgtcc	aacaattccc	tttcaaatct	ggcccctgga	gctttccatg	420
ggcttcagca	cttgcaggtt	ttaaatctaa	cccagaattc	actcctttcc	ctggaaagca	480
gacttttcca	ttccctccct	cagctgaggg	agcttgattt	gtcatcaaac	aacataagcc	540
accttcccac	atccttggga	gagacttggg	agaacctaac	tatacttgcg	gttcaacaaa	600
accagcttca	gcagcttgat	cgagcgctcc	tggaatccat	gcccagtgtg	aggcttttac	660
ttctcaagga	caacctctgg	aaatgcaatt	gccacttgct	cggtcttaaa	ctctggctgg	720
agaaatttgt	ctataaaggg	ggactaacag	acggcatcat	ctgtgaatca	ccagācācct	780
ggaagggaaa	ggacctcctt	aggatccctc	atgagctgta	ccagccctgc	cctcttcctg	840
ctcctgatcc	agtgtcctcg	caggctcagt	ggcccggctc	tgcccacggt	gtggtcctga	900
ggcctcctga	gaaccacaac	gcgggggagc	gagaactctt	ggagtgcgag	ctcaaaccca	960
agccaaggcc	ggccaacctg	cgtcatgcca	ttgccactgt	catcatcact	ggcgttgtgt	1020
gtgggattgt	gtgtctcatg	atgttggcag	ctgccatcta	tggctgcacc	tatgcggcaa	1080
tcacagccca	gtaccatggg	ggacccttgg	ctcaaaccaa	tgatcctggg	aaggtggaag	1140
aaaaagagcg	atttgacagc	tcaccagcct	gagagctttt	gtctcaaata	ggattggtca	1200
ttgcaggcca	gaagatagtg	tctgagtagg	gctgatgtgt	ttcctgttag	tctgattttg	1260

cttttgccaa aagac 1275

<210>	11	
<211>	5568	
<212>	DNA	
<213>	Homo	sapiens
<400>	11	

60 ctcggaaaag cttttcagta aatgcactca tgctgctcca ggagctcttc tctgcaacaa 120 gccacccatc tgccatcaac aagttaagac caagagaact aacggctgcg gaaatgagac 180 tgaagctttg attaaccagc tgagcagtta gaggtggaga aatttaataa cttatattca aaactgattt agggatcaga gcaatcacag aaaatgaaac caatgctttc cagagggata 240 tcctaaggaa aaaacaactc gtcctggtgg attcaatttt acttggaaag cctgggacac 300 agaaaacagg aaactggtca aaggctccta catgttagag ccttttacag actcactgcg 360 420 ttgagtctaa caaccgcgac tgaatgcagc ctccaatgtg ctcagaagaa tgggcttaca tttcaagtgg ccattagggg cccctatgct ggcagcaata tatgcaatga gtatggtttt 480 540 aaaaatgctg cctgccctgg gtatggcgtg tccacccaaa tgccgctgcg agaagctgct 600 cttctactgc gactctcagg gcttccactc agtgccaaac gccacagaca agggctctct gggcctgtcc ctgaggcaca atcacatcac agagctcgaa agagatcaat ttgccagctt 660 720 cagtcaactt acttggctcc acttagatca caatcaaatt tcaacagtaa aagaagatgc 780 ttttcaagga ctatataaac ttaaggaatt aatcttaagt tccaacaaaa tattttactt 840 gccaaacaca acttttaccc aactgattaa cctgcaaaat ttggacctgt cttttaatca 900 gctgtcatct ctgcacccag agctcttcta tggccttcgg aagctgcaga ccttgcattt 960 acgttccaac tccctgcgga ctatcccagt acgcctgttc tgggactgtc gtagtctgga gtttctggat ttgagcacaa atcgtttgcg aagtttggct cgcaatggat ttgcaggatt 1020 1080 aattaaactg agagagcttc acctagagca caaccagctg acgaagatta attttgctca 1140 tttcctacgg ctaagcagtc tgcacacgct cttcttacaa tggaacaaaa tcagcaactt 1200 gacatgtggg atggagtgga cctggggcac tttagaaaag ctagacctga ctggaaatga aatcaaagcc atcgacttga cagtgtttga aacgatgccc aatcttaaaa tactcctcat 1260 1320 ggataacaac aagttaaaca gccttgattc caagatctta aactccctga gatccctcac aaccgttggt ctctctggca atctgtggga atgcagcgcc cgaatatgtg ctctggcctc 1380 1440 ctggctgggc agtttccaag gtcggtggga acactccatc ctatgccaca gtcctgacca 1500 cacccaagga gaggatattc tagatgcagt ccatggattt cagctctgct ggaatttgtc 1560 aaccactgtc actgtcatgg ctacaactta tagagatcca accactgaat atacaaaaag 1620 aataagctca tcaagttacc atgtgggaga caaagaaatc ccaactactg caggcatagc

1680 agttactacc gaggaacact ttcctgaacc agacaatgcc atcttcactc agcgggtaat 1740 tacgggaaca atggctttat tgttttcttt cttttttatt atttttatag tgttcatctc 1800 caggaagtgc tgccctccca ctttaagaag aattaggcag tgctcaatgg ttcagaacca caggcagctc cgatcccaaa cacgactcca tatgtcaaac atgtcagacc aaggaccgta 1860 1920 taatgaatat gaacccaccc atgaaggacc cttcatcatc attaatggtt atggacagtg 1980 caagtgtcag cagctgccat acaaagaatg tgaagtataa tatctaccca tcatcaaaaa 2040 tcacatcaga taagtaacct attttacata gtagaggcta aatacatatc taatttttac caatggtgac attaagccta attttccaaa ctaagtggag acttagtttt tgaagtgttg 2100 2160 aagtattttt aatttttaa atgaaaccat attttaagtg ttaaatgaat caatgctcac attaatttgc actcctgttg gaaagtctaa aatgcttact tcaaaataag aaatgtacgt 2220 2280 aattatatac aatcgtgtgt aaacctttac actaaggtct ccatatacta tttttttcta ctgaaaacaa tttagaaaga agctattggg cagaaacaga tatagatcaa tacctgtttg 2340 2400 atcactgctc tccatcccat gtaccacaac tatcttgctg cttaaaagga gacttagtaa agttetettg tatgataatt tggtatttac teaaatette aatttettge cagggtggga 2460 2520 agtagaattt catgtatgct gaagactggt aaatattaaa cattctcctt ccagagtttc tgcctgggtt agtagatatt atcaaagtcc atatcatgaa ttcagaaccc tttaatgtaa 2580 ttctaataag ctgagtgact ctttaatata tttacacaat gaatccaagt gactgtgaaa 2640 2700 aggictcatt acaatgaaac caatcctaaa taattacacc aacticttat acattictcg 2760 tttgacttat aatggacatg atttttgtgg catttagaca actgttttaa actagcatta aactgtcatt gtactaatta atgtactaaa tcctatgttt acattaatat gtgaaaaaaag 2820 atttagaaga tattttggag ataaacaaga caaactgagt caatttaaca atcctgacat 2880 2940 gctccctcca atttaaaagc acacacaca acacacaca acacacaca tctcgcgctc 3000 tctctctcaa ctatcatgat caaagatgcc ttgacaaagg ggtttaaacc tctttcttct 3060 gctttttcct gatcttcaaa cctcaaagag ccaagttaaa aataattggc tagcaacagg 3120 cttaacactg attcttattg tattacaaag gaaccatgaa aaaaaacact ttctaactat 3180 tatataatac atttcgatct ttcaataaag atacgcattc acgctgtaag tgtagttcag 3240 tgtaggtgaa gaaaacagca ccactgagat gaatctcatg gcagaacaac tcgacatgcc 3300 cagattttga aatctgactc tcaggttagc tggagttaca aggcagccaa caatgattat 3360 3420 acacaatctg caccaaacag ggaaaggacc tgctgctgaa aagggaagag gggtagatcc tccaatgtaa atataaacat gccatagtta acaaatgata aggatgccac atttttcatg 3480

cacatattga aaaaactgta aaattatagc actaacttga tittagaaaa tgagcattit titacaactgc catitactgt atgtagaaaa aagacaaaa acctiagaga aagccactac 372 catititicaa gitatctitt coccaacatc aacatcaaca tgatatccti caticagggc 378 atatititic titccaggat caaactgaaa acatgitaag gitatagtit agccagtaag 384 attitaatcac aatititict cittaatact aagagatggg tacctiagta cocticacct 390 aacatcicic ggaaaaaag agacaagatc acaaattaca gtaaaaatg gitatitititi taaaccagac agacaagatc agacagtic aaticagitig atcicagatig 402 gigagtatit titgictitigi taaaccagac citgiggctig tetigggcag gacagaagct 408 gattiaacag catagagcac agagccaaca titcccacag acaggctgaa titagaagccc catatacaaa taagagcacc acgagctaaa attiaccaaa catiticaa ggaagaacca titcccattigi caggtgacag acagcitigi cacaacacaa citgificctig agacacacaa 426 atticcatigi caggtgacag acagcitigi cacaacacaa citgificctig agacacacaa 426 atticcatigi caggtgacag acagcitigi cacaacacaa citgificctig agacacacaag 426 atticcatigi caggtgacag acagcitigi cacaacacaa citgificctig agacacacaag 426 atticcatigi caggtgacag acagcitigi cacaacacaa citgificctig agacacacaag 426 atticcatigi caggagaag gatgificia cacaacacaa citgificctig agacacacaag 426 atticcatigi caggagaag aaatccccti cittiggctgg gaatctccac citaataccti aaaggaccat aactggcaaa atccctatititicca ticatiticaaa ccacaaacaa 432 aaaaagcaagc catitactaa ticagaggaa cagcatagcc aaggctagcg aggcatacti 450 aaaaggaagaagaa acagtagaacaa attititigic ticcatititi citgigtaad ticcittiaaga 456 aaagagaagaa attagactgi tagtcatctig ticcittiaaaa gcaaaaaccci 462 aaagaacagaa aggaagaatat titticctitic ticatiticaa titgigtitica 468 gaatcagcaa aggattigaag attagactgi tagtcatccig ticcittititi accaactggc 474 tagaacggaa cagcatacaa gcaacacaa gcaacacaa accaacaacaa cacaacacaa cacaacaa	cagaaaagaa	ccacaggtat	tcagtttctt	gtattatgat	ttctaaagaa	aacctattaa	3540
ttacaactgc cattractgt atgtagaaaa aagacataaa accttagaga aagccactac 372 cattrttcaa gttactttt ccccaacatc aacatcaaca tgatatcctt cattcagggc 378 atatttttc ttcccaggat caaactgaaa acatgtaag gctatagttt agccagtaag 384 atttaatcac aattttctc ctttaatact aagagatggg taccttagta cccttcacct 390 aacatctctc ggtaaaaagc agacaagatc acaaattaca gtaaaaatg gctctttttt 396 aaggtgggca gattagtttg tcaaagtctc agcccagttc aattcagttg atctcgagtg 402 gtaggtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct 408 gatttaacag catagagcac agggccaa atttaccag acaggctgaa ttagaagccc 414 cctattacaaa taagagcacc acgagctaaa atttaccaac ccatttatca ggatgaccat 420 ctattacaaa taagagcaca acgggctaaa atttaccaac ccatttatca ggatgaccat 420 ctattacaaa taagagcacc acgaggtgaa gaattccacc catttaccag gattcacacaga actccatcag ccctgaagga cagcagagga gtattttcca tcatttcaaa ccacaacaaa 420 aattcactcag ccctgaagga cagcagagga gtattttcca tcatttcaaa ccacaacaaa 432 aattcactct aaaggaccat aactggcaaa atccctt. ctttggctgg gaatctccac 438 cttaatcctt aaaggaccat aactggcaaa atccttagtg tacggacaaa agcaaattgg 446 aaaaggacagac catttactaa ttcagaggaa cagcatagcc aaggctagac aggcatactt 450 ctcagttgaa aaaaaccaaa attttttgcc ttccattttt ctgggtaatg tcctttaaga 456 aaaggcagaa cagcatagac aggcatagat ttttcctttc tcatttaaaa gcaaaacct 450 ccctttttaa ttgcctgtag aaggcaagat tttcttctc tcatttaaaa gcaaaacct 460 ccctttttaa ttgcctgtag aaggcaagat tttcttcatt ttttgtccat ttgtgttca 460 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 476 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 480 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 477 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 480 gttttttgat ggggtttat cctcttcacc accactaccc actccatttt ttttctattt 480 gttttttgat gggggtttat cctcttcacc accactaccc actccattt ttttctattt 480 gttttttgat gggggtttat cctcttcacc accactaccc actccattt ttttctattt 480 gtttttatat catttctga gcatgacagg gatttcaacc acttcagaa accaagacc aggaagacaaaacc cacacacac	atatttggaa	tttagatgca	agctactcat	tcacacagaa	cttttccata	aacattgttc	3600
cattittcaa gitalcitti coccaacate aacateaaca tgatateett catteagge 378 atattittie tieceaggat caaactgaaa acatgitaag getatagitt agecagtaag 384 attitaateac aattitteett ettiaatact aagagatggg tacettagta ecetteacet 390 aacateetee ggtaaaaage agacaagate acaaattaca giaaaaatgi getetititt 396 aaggitgggea gattagitti teaaaccagae eetgggette aatteagitig atetegagig 402 gigagtatti tigteetettig taaaccagae eetgggettig tetgggeaga gacagaaget 408 gattiaacag catagageac aggeecetae tiececacag acaggetgaa tiagaageec 414 getatiacaaa taagageace acgagetaaa attiaccaac ecattiatea ggatgaccat 426 etatiacaaa taagageace acgagetaga gacaacacaa etgigteetig agecacacaag 426 attecateag eetgaagga cageaggag gattitieea teatticaaa ecacaacaaa 432 atticaateag eetgaagga cageagagga gattitieea teatticaaa ecacaacaaa 432 aattaagati taaactgigg gatgggtaag aaateeetti ettiggetgg gaateeea 438 ettaateett aaaggaccat aactggeaaa ateettagig taegggacaaa ageaaatigg 444 aaaagcaage cattiactaa tieagaggaa eageatagee aaggetageg aggeataeet 456 ettaateett aaaggaccat aactggeaaa ateettagig taeggacaaa ageaaatigg 446 aaaagcaage cattiactaa tieagaggaa eageatagee aaggetageg aggeataeet 456 etecatitiaa tiggeetgia gaaggaagat titteettie teattitaaaa geaaaacet 466 eeettittaa tiggeetgia aaggeaagat titteettie teattitaaaa geaaaacet 466 eeettittaa tiggeetgia gaaggeagat titteettee teattitaaaa geaaaacet 466 gaateageae aggittigaag attagaetgi tagteatetgi tigetitetti accaactigge 476 tagaacggaa eageateaea geaacgetge ggatetiggi taacaaggit eaggatitti 486 gittittigat giggittiat eeteeteaee aecaetaeee aeteeattit tittetattit 486 gittittigat giggittiat eeteeteaee eeaacaacee aeteeattit tittetattit 486 gittittigat giggittiat eeteeteaee eeaacaacee aeteeattit tittetattit 486 gittitatati eattietgia geatgaagg gatticaace aecaetaeee aeteeattit tittaatate eegitaaaate gaaagacta gatacaaace titaaaaate eegitaaaate titaaaateee eeaaaaatee gaaacacaa aecaagaace aggetagaaaaaacee 510 aaagataaaat tittaaaatee eeaaaaatee gaaataacaa aggataacee aegecaacaa	cacatattga	aaaaactgta	aaattatagc	actaacttga	ttttagaaaa	tgagcatttt	3660
atatttttto ttccaggat caaactgaaa acatgttaag gctatagtt agccagtaag 384 atttaatcac aattttctt ctttaatact aagagatgg taccttagta cccttcacct 390 acatctctc ggtaaaaaag agacaagatc acaaattaca gtaaaaatgt gctcttttt 396 aaggtgggca gattagtttg tcaaagtctc agcccagttc aattcagttg atctcgagtg 402 gtgagtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct 408 gatttaacag catagagcac agcgcctac ttccccacag acaggctgaa ttagaagccc 414 cctattacaaa taagagcac acggcctac ttccccacag acaggctgaa ttagaagccc 420 ctattacaaa taagagcac acggcgctaa atttaccaac ccatttatca ggatgaccat 420 ctattacaaa taagagcac acgagctaaa atttaccaac ccatttatca ggatgaccat 420 ctattacaaa taagagcaca acggcttggt cacaacacaa	ttacaactgc	catttactgt	atgtagaaaa	aagacataaa	accttagaga	aagccactac	3720
atttaatcac aatttttctt ctttaatact aagagatggg taccttagta cccttcacct aacatctctc ggtaaaaagc agacaagatc acaaattaca gtaaaaattg gctctttttt aaggtgggca gattagtttg tcaaagtctc agcccagttc aattcagttg atctcagatg gtgagtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct gatttaacag catagagcac agggccctac ttccccacag acaggctgaa ttagaagccc ctattacaaa taagagcacc acgggctaaa atttaccaac ccatttatca ggatgaccat tgccatttgt caggtgacag acagcttggt cacaacacaa	catttttcaa	gttatctttt	ccccaacatc	aacatcaaca	tgatatcctt	cattcagggc	3780
aacatctctc ggtaaaaagc agacaagatc acaaattaca gtaaaaatgt gctcttttt aaggtgggca gattagtttg tcaaagtctc agcccagttc aattcagttg atctcgagtg gtgagtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct gattaacag catagagcac agcgcctac ttccccacag acaggctgaa ttagaagccc ctattacaaa taagagcacc acgagctaaa atttaccaac ccatttatca ggatgaccat tgccatttgt caggtgacag acagcttggt cacaacacaa	atatttttc	ttcccaggat	caaactgaaa	acatgttaag	gctatagttt	agccagtaag	3840
aaggtgggca gattagtttg tcaaagtctc agcccagttc aattcagttg atctcgagtg gtgagtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct 408 gatttaacag catagagcac agcgcctac ttccccacag acaggctgaa ttagaagccc 414 cctattacaaa taagagcacc acgggctaaa atttaccaac ccatttatca ggatgaccat 426 tgccatttgt caggtgacag acagcttggt cacaacacaa	atttaatcac	aatttttctt	ctttaatact	aagagatggg	taccttagta	cccttcacct	3900
gtgagtattt tgtctcttgt taaaccagac cctgggcttg tctgggcaga gacagaagct 408 gatttaacag catagagcac aggccctac ttccccacag acaggctgaa ttagaagccc 414 cctattacaaa taagagcaca agggctaaa atttaccaac ccatttatca ggatgaccat 420 tgccatttgt caggtgacag acagcttggt cacaacacaa	aacatctctc	ggtaaaaagc	agacaagatc	acaaattaca	gtaaaaatgt	gctctttttt	3960
gatttaacag catagagcac agogccctac ttcccacag acaggctgaa ttagaagccc 414 ctattacaaa taagagcacc acgagctaaa atttaccaac ccatttatca ggatgaccat 426 tgccatttgt caggtgacag acagcttggt cacaacacaa	aaggtgggca	gattagtttg	tcaaagtctc	agcccagttc	aattcagttg	atctcgagtg	4020
ctattacaaa taagagcacc acgagctaaa atttaccaac ccatttatca ggatgaccat.  tgccatttgt caggtgacag acagcttggt cacaacacaa	gtgagtattt	tgtctcttgt	taaaccagac	cctgggcttg	tctgggcaga	gacagaagct	4080
tgccatttgt caggtgacag acagcttggt cacaacacaa	gatttaacag	catagagcac	agcgccctac	ttccccacag	acaggctgaa	ttagaagccc	4140
attccatcag ccctgaagga cagcagagga gtattttcca tcatttcaaa ccacaaacaa 432 aattaagatt taaactgtgg gatgggtaag aaatcccctt ctttggctgg gaatctccac 438 cttaatcctt aaaggaccat aactggcaaa atccttagtg tacggacaaa agcaaattgg 444 aaaagcaagc catttactaa ttcagaggaa cagcatagcc aaggctagcg aggcatactt 456 tccagttgaa aaaaatcaaa atttttgcc ttccatttt ctgggtaatg tcctttaaga 456 aaagtgaatg acagtagtac caaaaaggta ttttccttc tcatttaaaa gcaaaacct 462 ccctttttaa ttgcctgtag aaggcaagat tttctttcat ttttgtccat ttgtgttca 466 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttctt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gtttttgat ggggtttat cctcttcacc accactaccc actccattt ttttctattt tttagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 493 cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaaggtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttcca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	ctattacaaa	taagagcacc	acgagctaaa	atttaccaac	ccatttatca	ggatgaccat.	4200
aattaagatt taaactgtgg gatgggtaag aaatcccctt ctttggctgg gaatctccac cttaatcctt aaaggaccat aactggcaaa atccttagtg tacggacaaa agcaaattgg 444 aaaagcaagc catttactaa ttcagaggaa cagcatagcc aaggctagcg aggcatactt tccagttgaa aaaaatcaaa atttttgcc ttccatttt ctgggtaatg tcctttaaga 456 aaagtgaatg acagtagtac caaaaaaggta ttttccttc tcatttaaaa gcaaaaacct ccctttttaa ttgcctgtag aaggcaagat tttccttcat ttttgtccat ttgtgtttca gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 476 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt gtttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 516 aaagataata atttttaag ccaaaaatct gtactaacac atgtaattc ttaatgtgcc taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 523 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 523	tgccatttgt	caggtgacag	acagettggt	cacaacacaa	ctgtgtcctg	agcacacaag	4260
cttaatcett aaaggaccat aactggcaaa atcettagtg tacggacaaa agcaaattgg 444 aaaaagcaagc catttactaa ttcagaggaa cagcatagcc aaggctagcg aggcatactt 450 tecagttgaa aaaaatcaaa attttttgec ttccatttt ctgggtaatg tectttaaga 456 aaagtgaatg acagtagtac caaaaaaggta tttteette teatttaaaa gcaaaaacet 462 ceettttaa ttgeetgtag aaggcaagat ttteetteat ttttgtecat ttgtgtttea 468 gaatcagcac aggtttgaag attagactgt tagtcatetg tgetttett accaactgge 474 tagaacggaa cagcatcaca gcaacgetge ggatettggt tacacagtgt cagagetttt 486 gttttttgat ggggttttat cetetteace accaetacec actecattt ttttetattt 486 ggaaagctaa aggaaaatga ceattaagaa ceagaaaaat aattaatete tetggaaaaa 492 ggaaagctaa agaagactat gataccatac ceatecagaa accaagaact agtttgaaat 498 cgtttatatt catttetgta geatgacagg gattteaate acctttetga aaagagtggg 504 ctgataaact tgtaaateca cacacaacte tgagaatacc cactgccage atcaaaaagc 516 aaagatacta atttttaag ceaaaaatet gtactaacac atgtaattte ttaatgtgee 516 taagttaatt tetgtateaa ttcaataaat ggaattgact gaacttecca acgccactaa 522 ttattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 taattaaaat ceatetgett attetaatge tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatetttee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tagtcaccaa gagetagact ceatettee 528 tag	attccatcag	ccctgaagga	cagcagagga	gtattttcca	tcatttcaaa	ccacaaacaa	4320
aaaagcaagc catttactaa ttcagaggaa cagcatagcc aaggctagcg aggcatactt tccagttgaa aaaaatcaaa atttttgcc ttccatttt ctgggtaatg tcctttaaga 456 aaagtgaatg acagtagtac caaaaaggta ttttcctttc tcatttaaaa gcaaaaacct 462 cccttttaa ttgcctgtag aaggcaagat tttctttcat ttttgtccat ttgtgtttca 468 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gttttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agttgaaat 498 ctgttatatt cattctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	aattaagatt	taaactgtgg	gatgggtaag	aaatcccctt	. ctttggctgg	gaatctccac	4380
tccagttgaa aaaaatcaaa atttttgcc ttccatttt ctgggtaatg tcctttaaga 456 aaagtgaatg acagtagtac caaaaaggta ttttcctttc tcatttaaaa gcaaaaacct 462 ccctttttaa ttgcctgtag aaggcaagat tttctttcat ttttgtccat ttgtgtttca 468 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gtttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt cattctgta gcatgacagg gatttcaatc accttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 516 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	cttaatcctt	aaaggaccat	aactggcaaa	atccttagtg	tacggacaaa	agcaaattgg	4440
aaagtgaatg acagtagtac caaaaaggta ttttcctttc tcatttaaaa gcaaaaacct 462 ccctttttaa ttgcctgtag aaggcaagat tttcttcat ttttgtccat ttgtgtttca 462 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 480 gtttttgat ggggttttat cctcttcacc accactaccc actccattt ttttctattt ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat cgtttatatt catttctgta gcatgacagg gatttcaatc accttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	aaaagcaagc	catttactaa	ttcagaggaa	cagcatagcc	aaggctagcg	aggcatactt	4500
ccctttttaa ttgcctgtag aaggcaagat tttcttcat ttttgtccat ttgtgtttca 468 gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gtttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt 486 ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt cattctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 516 aaagatacta atttttaag ccaaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	tccagttgaa	aaaaatcaaa	attttttgcc	ttccattttt	ctgggtaatg	tcctttaaga	4560
gaatcagcac aggtttgaag attagactgt tagtcatctg tgctttcttt accaactggc 474 tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gttttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 516 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc	aaagtgaatg	acagtagtac	caaaaaggta	ttttcctttc	tcatttaaaa	gcaaaaacct	4620
tagaacggaa cagcatcaca gcaacgctgc ggatcttggt tacacagtgt cagagctttt 486 gttttttgat ggggttttat cctcttcacc accactaccc actccatttt ttttctattt 486 ggaaagctaa aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 516 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatcttcc	ccctttttaa	ttgcctgtag	aaggcaagat	tttctttcat	ttttgtccat	ttgtgtttca	4680
gtttttgat ggggttttat cetetteace accaetacee actecattt ttttetattt 486 ttaagattag aggaaaatga ceattaagaa eeagaaaaat aattaatee tetggaaaaa 492 ggaaagetaa agaagactat gataceatae eeateetagaa accaagaaet agtttgaaat 498 egtttatatt eatttetgta geatgacagg gattteaate acetttetga aaagagtggg 504 etgataaaet tgtaaateea eacaeaaete tgagaataee eactgeeage atcaaaaage 510 aaagataeta atttttaag eeaaaaatet gtaetaaea atgtaattte ttaatgtgee 516 taagttaatt tetgtateaa tteaataaat ggaattgaet gaaetteeea aegeeactaa 522 ttattaaaat eeatetgett attetaatge tagteaceaa gagetagaet eeatettee 528	gaatcagcac	aggtttgaag	attagactgt	tagtcatctg	tgctttcttt	accaactggc	4740
ttaagattag aggaaaatga ccattaagaa ccagaaaaat aattaatctc tctggaaaaa 492 ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	tagaacggaa	cagcatcaca	gcaacgctgc	ggatcttggt	tacacagtgt	cagagctttt	4800
ggaaagctaa agaagactat gataccatac ccatctagaa accaagaact agtttgaaat 498 cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	gttttttgat	ggggttttat	cctcttcacc	accactaccc	actccatttt	ttttctattt	4860
cgtttatatt catttctgta gcatgacagg gatttcaatc acctttctga aaagagtggg 504 ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	ttaagattag	aggaaaatga	ccattaagaa	ccagaaaaat	aattaatctc	tctggaaaaa	4920
ctgataaact tgtaaatcca cacacaactc tgagaatacc cactgccagc atcaaaaagc 510 aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 510 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	ggaaagctaa	agaagactat	gataccatac	ccatctagaa	accaagaact	agtttgaaat	4980
aaagatacta atttttaag ccaaaaatct gtactaacac atgtaatttc ttaatgtgcc 516 taagttaatt tctgtatcaa ttcaataaat ggaattgact gaacttccca acgccactaa 522 ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	cgtttatatt	catttctgta	gcatgacagg	gatttcaatc	acctttctga	aaagagtggg	5040
taagttaatt tetgtateaa tteaataaat ggaattgaet gaaetteeea aegeeaetaa 522 ttattaaaat eeatetgett attetaatge tagteaceaa gagetagaet eeatettee 528	ctgataaact	tgtaaatcca	cacacaactc	tgagaatacc	cactgccagc	atcaaaaagc	5100
ttattaaaat ccatctgctt attctaatgc tagtcaccaa gagctagact ccatctttcc 528	aaagatacta	attttttaag	ccaaaaatct	gtactaacac	atgtaatttc	ttaatgtgcc	5160
The state of the s	taagttaatt	tctgtatcaa	ttcaataaat	ggaattgact	gaacttccca	acgccactaa	5220
aataaaaatg agccctatgt agcactaggt ttgaattcta aaattcaaaa caggcatttc 534	ttattaaaat	ccatctgctt	attctaatgc	tagtcaccaa	gagctagact	ccatctttcc	5280
	aataaaaatg	agccctatgt	agcactaggt	ttgaattcta	aaattcaaaa	caggcatttc	5340

attttcttaa ggcacacttc ctacacacag ctatcagggg aaaaagctat aaatgtcctg	5400
ttctttttct gaagtgtgga tatcaatata aaatttgtta aagaatattt ttaacagctg	5460
acttacatga tcgttttcct aatacaggaa tacagcgaca gacctatctg aaaagtctgt	5520
ttgggggcat acttttcata tcttattgac taaagccctt gagccagg	5568
<210> 12 <211> 2698 <212> DNA <213> Homo sapiens	
<400> 12 gctgagcagt caacagcatt tettgtteea agateacect tetgagtace tetetggetg	60
ccaaattgcc agggccttca cagtttgatt ccatttctca gctccaagca ttaggtaaac	120
ccaccaagca atcctagcct gtgatggcgt ttgacgtcag ctgcttcttt tgggtggtgc	180
tgttttctgc cggctgtaaa gtcatcacct cctgggatca gatgtgcatt gagaaagaag	240
ccaacaaaac atataactgt gaaaatttag gtctcagtga aatccctgac actctaccaa	300
acacaacaga attitiggaa ticagciita attititigco tacaaticac aatagaacci	360
tcagcagact catgaatctt acctttttgg atttaactag gtgccagatt aactggatac	420
atgaagacac ttttcaaagc catcatcaat taagcacact tgtgttaact ggaaatcccc	480
tgatattcat ggcagaaaca tcgcttaatg ggcccaagtc actgaagcat cttttcttaa	540
tccaaacggg aatatccaat ctcgagttta ttccagtgca caatctggaa aacttggaaa	600
gcttgtatct tggaagcaac catatttect ccattaagtt ccccaaagac ttcccagcac	660
ggaatctgaa agtactggat tttcagaata atgctataca ctacatctct agagaagaca	720
tgaggtetet ggageaggee atcaacetaa geetgaaett caatggeaat aatgttaaag	780
gtattgagct tggggctttt gattcaacga tcttccaaag tttgaacttt ggaggaactc	840
caaatttgtc tgttatattc aatggtctgc agaactctac tactcagtct ctctggctgg	900
gaacatttga ggacattgat gacgaagata ttagttcagc catgctcaag ggactctgtg	960
aaatgtetgt tgagageete aacetgeagg aacacegett etetgaeate teateeacea	1020
catttcagtg cttcacccaa ctccaagaat tggatctgac agcaactcac ttgaaagggt	1080
taccetetgg gatgaagggt etgaacttge teaagaaatt agtteteagt gtaaateatt	1140
tcgatcaatt gtgtcaaatc agtgctgcca atttcccctc ccttacacac ctctacatca	1200
gaggcaacgt gaagaaactt caccttggtg ttggctgctt ggagaaacta ggaaaccttc	1260
agacacttga tttaagccat aatgacatag aggcttctga ctgctgcagt ctgcaactca	1320
aaaacctgtc ccacttgcaa accttaaacc tgagccacaa tgagcctctt ggtctccaga	1380

gtcaggcatt	caaagaatgt	cctcagctag	aactcctcga	tttggcattt	acccgcttac	1440
acattaatgc	tccacaaagt	cccttccaaa	acctccattt	ccttcaggtt	ctgaatctca	1500
cttactgctt	ccttgatacc	agcaatcagc	atcttctagc	aggcctacca	gttctccggc	1560
atctcaactt	aaaagggaat	cactttcaag	atgggactat	cacgaagacc	aacctacttc	1620
agaccgtggg	cagcttggag	gttctgattt	tgtcctcttg	tggtctcctc	tctatagacc	1680
agcaagcatt	ccacagcttg	ggaaaaatga	gccatgtaga	cttaagccac	aacagcctga	1740
catgcgacag	cattgattct	cttagccatc	ttaagggaat	ctacctcaat	ctggctgcca	1800
acagcattaa	catcatctca	ccccgtctcc	tccctatctt	gtcccagcag	agcaccatta	1860
atttaagtca	taaccccctg	gactgcactt	gctcgaatat	tcatttctta	acatggtaca	1920
aagaaaacct	gcacaaactt	gaaggctcgg	aggagaccac	gtgtgcaaac	ccgccatctc	1980
taaggggagt	taagctatct	gatgtcaagc	tttcctgtgg	gattacagcc	ataggcattt	2040
tetttctcat	agtatttcta	ttattgttgg	ctattctgct	attttttgca	gttaaatacc	2100
ttctcaggtg	gaaataccaa	cacatttagt	gctgaaggtt	tccagagaaa	gcaaataagt	2160
gtgcttagca	aaattgctct	aagtgaaaga	actgtcatct	gctggtgacc	agaccagact	2220
tttcagattg	cttcctggaa	ctgggcaggg	actcactgtg	cttttctgag	cttcttactc	2280
ctgtgagtcc	cagagetaaa	gaaccttcta	ggcaagtaca	ccgaatgact	cagtccagag	2340
ggtcagatgc	tgctgtgaga	ggcacagagc	cctttccgca	tgtggaagag	tgggaggaag	2400
cagagggagg	gactgggcag	ggactgccgg	ccccggagtc	teccacaggg	aggccattcc	2460
ccttctactc	accgacatcc	ctcccagcac	cacacacccc	gcccctgaaa	ggagatcatc	2520
agcccccaca	atttgtcaga	gctgaagcca	gcccactacc	cacccccact	acagcattgt	2580
gcttgggtct	gggttctcag	taatgtagcc	atttgagaaa	cttacttggg	gacaaagtct	2640
caatccttat	tttaaatgaa	aaaagaaaag	aaaagcataa	taaatttaaa	agaaaagg	2698

<210> 13

<211> 2233

<212> DNA

<213> Homo sapiens

<400> 13

tccggacgct gggtc	ctccgc agcaaccg	cc tgaagctca	t cccgctaggc	gtcttcactg	420
gcctcagcaa cctga	accaag ctggacat	ca gcgagaaca	a gatcgttatc	ctactggact	480
acatgtttca ggacc	ctgtac aacctcaa	gt cactggagg	t tggcgacaat	gacctcgtct	540
acatctctca ccgcg	geette ageggeet	ca acageetgg	a gcagctgacg	ctggagaaat	600
gcaacctgac ctcca	atcccc accgagge	gc tgtcccacc	t gcacggcctc	atcgtcctga	660
ggctccggca cctca	acatc aatgccat	cc gggactact	c cttcaagagg	ctgtaccgac	720
tcaaggtctt ggaga	atctcc cactggcc	ct acttggaca	c catgacaccc	aactgcctct	780
acggcctcaa cctga	acgtcc ctgtccat	ca cacactgca	a tctgaccgct	gtgccctacc	840
tggccgtccg ccacc	ctagtc tatctccg	ct tcctcaacc	t ctcctacaac	cccatcagca	900
ccattgaggg ctcca	atgttg catgagct	gc tccggctgc	a ggagatccag	ctggtgggcg	960
ggcagctggc cgtgg	gtggag ccctatgc	ct teegeggee	t caactacctg	cgcgtgctca	1020
atgtctctgg caacc	cagctg accacact	gg aggaatcag	t cttccactcg	gtgggcaacc	1080
tggagacact catco	ctggac tccaaccc	gc tggcctgcg	a ctgtcggctc	ctgtgggtgt	1140
tccggcgccg ctggc	eggete aactteaa	cc ggcagcagc	c cacgtgcgcc	acgcccgagt	1200
ttgtccaggg caagg	gagttc aaggactt	cc ctgatgtgc	t actgcccaac	tacttcacct	1260
gccgccgcgc ccgca	atccgg gaccgcaa	gg cccagcagg	t gtttgtggac	gagggccaca	1320
cggtgcagtt tgtgt	gccgg gccgatgg	cg acccgccgc	c cgccatcctc	tggctctcac	1380
cccgaaagca cctgg	gtctca gccaagag	ca atgggcggc	t cacagtette	cctgatggca	1440
cgctggaggt gcgct	tacgcc caggtaca	gg acaacggca	c gtacctgtgc	atcgcggcca	1500
acgcgggcgg caacg	gactcc atgcccgc	cc acctgcatg	t gcgcagctac	tegecegaet	1560
ggccccatca gccca	aacaag accttcgc	tt tcatctcca	a ccagccgggc	gagggagagg	1620
ccaacagcac ccgcg	gccact gtgccttt	cc ccttcgaca	t caagaccctc	atcatcgcca	1680
ccaccatggg cttca	atctct ttcctggg	cg tcgtcctct	t ctgcctggtg	ctgctgtttc	1740
tctggagccg gggca	aagggc aacacaaa	gc acaacatcg	a gatcgagtat	gtgccccgaa	1800
agteggaege aggea	atcagc tccgccga	cg cgccccgca	a gttcaacatg	aagatgatat	1860
gaggccgggg cgggg	gggcag ggaccccc	gg gcgg <b>cc</b> ggg	c aggggaaggg	gcctggccgc	1920
cacctgctca ctctc	ccagtc cttcccac	ct cctccctac	c cttctacaca	cgttctcttt	1980
ctccctcccg cctcc	cgtaca atgatgaa	cc ccgccagcc	c tcaccacctg	ccctccttct	2040
accaggacct cagaa	agecea gaeetggg	ga ccccaccta	c acaggggcat	tgacagactg	2100
gagttgaaag ccgac	cgaacc gacacgcg	gc agagtcaat	a attcaataaa	aaagttacga	2160
actttctctg taact	ttgggt ttcaataa	tt atggatttt	t atgaaaactt	gaaataataa	2220

aaagagaaaa aaa	2233
<210> 14 <211> 2110 <212> DNA <213> Homo sapiens	
<400> 14 caggccgagg cagggagaac tctccactcg gaggaggagc tggggtcctc ttccatcccg	60
tetteatect geetggetge gtgacetegg gaggeaceat geaggagetg catetgetet	120
ggtgggcgct tctcctgggc ctggctcagg cctgccctga gccctgcgac tgtggggaaa	180
agtatggett ccagategee gaetgtgeet accgegaeet agaateegtg ccgcetgget	240
tcccggccaa tgtgactaca ctgagcctgt cagccaaccg gctgccaggc ttgccggagg	300
gtgccttcag ggaggtgccc ctgctgcagt cgctgtggct ggcacacaat gagatccgca	360
cggtggccgc cggagccctg gcctctctga gccatctcaa gagcctggac ctcagccaca	420
atctcatctc tgactttgcc tggagcgacc tgcacaacct cagtgccctc caattgctca	480
agatggacag caacgagctg accttcatcc cccgcgacgc cttccgcagc ctccgtgctc	540
tgcgctcgct gcaactcaac cacaaccgct tgcacacatt ggccgagggc accttcaccc	600
cgctcaccgc gctgtcccac ctgcagatca acgagaaccc cttcgactgc acctgcggca	660
tcgtgtggct caagacatgg gccctgacca cggccgtgtc catcccggag caggacaaca	720
tcgcctgcac ctcaccccat gtgctcaagg gtacgccgct gagccgcctg ccgccactgc	780
catgetegge geeeteagtg cageteaget accaacceag ceaggatggt geegagetge	840
ggcctggttt tgtgctggca ctgcactgtg atgtggacgg gcagccggcc cctcagcttc	900
actggcacat ccagataccc agtggcattg tggagatcac cagccccaac gtgggcactg	960
atgggcgtgc cctgcctggc acccctgtgg ccagctccca gccgcgcttc caggcctttg	1020
ccaatggcag cctgcttatc cccgactttg gcaagctgga ggaaggcacc tacagctgcc	1080
tggccaccaa tgagctgggc agtgctgaga gctcagtgga cgtggcactg gccacgcccg	1140
gtgagggtgg tgaggacaca ctggggcgca ggttccatgg caaagcggtt gagggaaagg	1200
gctgctatac ggttgacaac gaggtgcagc catcagggcc ggaggacaat gtggtcatca	1260
tetaceteag eegtgetggg aaceetgagg etgeagtege agaaggggte eetgggeage	1320
tgcccccagg cctgctcctg ctgggccaaa gcctcctcct cttcttcttc ctcacctcct	1380
tctagcccca cccagggctt ccctaactcc tccccttgcc cctaccaatg cccctttaag	1440
tgctgcaggg gtctggggtt ggcaactcct gaggcctgca tgggtgactt cacattttcc	1500
tacctctcct totaatotot totagagcac ctgctatece caacttctag acctgctcca	1560

ccaactggga gaagecteag tggtggaatt ccaggeactg tgactgteaa getggeaagg 1740 gccaggattg ggggaatgga getggggett agetgggagg tggtetgaag cagacaggga 1800 atgggagagg aggatgggaa gtagacagtg getggtatgg etetgagget ecetggggee 1860 tgeteaaget ceteetgete ettgetgtt tetgatgatt tgggggettg ggagteett 1920 tgteeteate tgagaetgaa atgtggggat ecaggatgge tteetteete ttaecettee 1980 teeeteagee tgeaacetet ateetggaae etgteeteee tteeteeea actatgeate 204 tgttgtetge teetetgeaa aggeeageea gettgggage ageagagaaa taaacageat 210	aactagtgac	taggatagaa	tttgatcccc	taactcactg	tctgcggtgc	tcattgctgc	1620
gccaggattg ggggaatgga gctggggctt agctgggagg tggtctgaag cagacaggga 1800 atgggagagg aggatgggaa gtagacagtg gctggtatgg ctctgaggct ccctggggcc 1860 tgctcaagct cctcctgctc cttgctgttt tctgatgatt tgggggcttg ggagtccctt tgtcctcatc tgagactgaa atgtggggat ccaggatggc ttccttcctc ttacccttcc 1980 tccctcagcc tgcaacctct atcctggaac ctgtcctccc tttctccca actatgcatc 204 tgttgtctgc tcctctgcaa aggccagcca gcttgggagc agcagagaaa taaacagcat 210	taacagcatt	gcctgtgctc	tecteteagg	ggcagcatgc	taacggggcg	acgtcctaat	1680
atgggagagg aggatggaa gtagacagtg gctggtatgg ctctgaggct ccctggggcc 1866 tgctcaagct cctcctgctc cttgctgttt tctgatgatt tgggggcttg ggagtccctt 1926 tgtcctcatc tgagactgaa atgtggggat ccaggatggc ttccttcctc ttacccttcc 1986 tccctcagcc tgcaacctct atcctggaac ctgtcctccc tttctccca actatgcatc 204 tgttgtctgc tcctctgcaa aggccagcca gcttgggagc agcagagaaa taaacagcat 210	ccaactggga	gaagcctcag	tggtggaatt	ccaggcactg	tgactgtcaa	gctggcaagg	1740
tgctcaagct cctcctgctc cttgctgttt tctgatgatt tgggggcttg ggagtccctt 1926 tgtcctcatc tgagactgaa atgtggggat ccaggatggc ttccttcctc ttacccttcc 1986 tccctcagcc tgcaacctct atcctggaac ctgtcctccc tttctccca actatgcatc 204 tgttgtctgc tcctctgcaa aggccagcca gcttgggagc agcagagaaa taaacagcat 210	gccaggattg	ggggaatgga	gctggggctt	agctgggagg	tggtctgaag	cagacaggga	1800
tgtcctcatc tgagactgaa atgtggggat ccaggatggc ttccttcctc ttacccttcc 198 tccctcagcc tgcaacctct atcctggaac ctgtcctccc tttctcccca actatgcatc 204 tgttgtctgc tcctctgcaa aggccagcca gcttgggagc agcagagaaa taaacagcat 210	atgggagagg	aggatgggaa	gtagacagtg	gctggtatgg	ctctgaggct	ccctggggcc	1860
teceteage tgeaacetet ateetggaac etgteetee ttteteecea actatgeate 204 tgttgtetge teetetgeaa aggeeageea gettgggage ageagagaaa taaacageat 210	tgctcaagct	cctcctgctc	cttgctgttt	tctgatgatt	tgggggcttg	ggagtccctt	1920
tgttgtctgc tcctctgcaa aggccagcca gcttgggagc agcagagaaa taaacagcat 210	tgtcctcatc	tgagactgaa	atgtggggat	ccaggatggc	ttccttcctc	ttacccttcc	1980
tgttgtttgt teetetgeaa aggeeageea geetgggage ageagagaan tanness.	teceteagee	tgcaacctct	atcctggaac	ctgtcctccc	tttctcccca	actatgcatc	2040
211	tgttgtctgc	tectetgeaa	aggccagcca	gcttgggagc	agcagagaaa	taaacagcat	2100
ttctgatgcc	ttctgatgcc						2110

<210> 15

<211> 2146

<212> DNA

<213> Homo sapiens

cggagatgga tgtctctctt tgcccagcca agtgtagttt ctggcggatt ttcttgctgg 60 gaagcgtctg gctggactat gtgggctccg tgctggcttg ccctgcaaat tgtgtctgca 120 gcaagactga gatcaattgc cggcggccgg acgatgggaa cctcttcccc ctcctggaag 180 ggcaggattc agggaacagc aatgggaacg ccagtatcaa catcacggac atctcaagga 240 300 atatcacttc catacacata gagaactggc gcagtcttca cacgctcaac gccgtggaca 360 tggagctcta caccggactt caaaagctga ccatcaagaa ctcaggactt cggagcattc agcccagagc ctttgccaag aacccccatt tgcgttatat aaacctgtca agtaaccggc 420 tcaccacact ctcgtggcag ctcttccaga cgctgagtct tcgggaattg cagttggagc 480 540 agaacttttt caactgcagc tgtgacatcc gctggatgca gctctggcag gagcaggggg 600 aggccaaget caacagccag aacetetact gcatcaacge tgatggctcc cagettecte 660 tcttccgcat gaacatcagt cagtgtgacc ttcctgagat cagcgtgagc cacgtcaacc 720 tgaccgtacg agagggtgac aatgctgtta tcacttgcaa tggctctgga tcaccccttc ctgatgtgga ctggatagtc actgggctgc agtccatcaa cactcaccag accaatctga 780 840 actggaccaa tgttcatgcc atcaacttga cgctggtgaa tgtgacgagt gaggacaatg 900 gcttcaccct gacgtgcatt gcagagaacg tggtgggcat gagcaatgcc agtgttgccc 960 tcactgtcta ctatccccca cgtgtggtga gcctggagga gcctgagctg cgcctggagc 1020 actgcatcga gtttgtggtg cgtggcaacc ccccaccaac gctgcactgg ctgcacaatg 1080 ggcagcctct gcgggagtcc aagatcatcc atgtggaata ctaccaagag ggagagattt

ccgagggctg	cctgctcttc	aacaagccca	cccactacaa	caatggcaac	tataccctca	1140
ttgccaaaaa	cccactgggc	acagccaacc	agaccatcaa	tggccacttc	ctcaaggagc	1200
cctttccaga	gagcacggat	aactttatct	tgtttgacga	agtgagtccc	acacctccta	1260
tcactgtgac	ccacaaacca	gaagaagaca	cttttggggt	atccatagca	gttggacttg	1320
ctgcttttgc	ctgtgtcctg	ttggtggttc	tcttcgtcat	gatcaacaaa	tatggtcgac	1380
ggtccaaatt	tggaatgaag	ggtcccgtgg	ctgtcatcag	tggtgaggag	gactcagcca	1440
gcccactgca	ccacatcaac	cacggcatca	ccacgccctc	gtcactggat	gcggggcccg	1500
acactgtggt	cattggcatg	actcgcatcc	ctgtcattga	gaacccccag	tacttccgtc	1560
agggacacaa	ctgccacaag	ccggacacgt	gggtcttttc	aaacatagac	aatcatggga	1620
tattaaactt	gaaggacaat	agagatcatc	tagtcccatc	aactcactat	atatatgagg	1680
aacctgaggt	ccagagtggg	gaagtgtctt	acccaaggtc	acatggtttc	agagaaatta	1740
tgttgaatcc	aataagcctt	cccggacatt	ccaagcctct	taaccatggc	atctatgttg	1800
aggatgtcaa	tgtttatttc	agcaaaggac	gtcatggctt	ttaaaaactc	cttttaagcc	1860
tccttgtttt	gatgtcacct	tggtaggctg	ggccctctga	gaggttggaa	gctctaggca	1920
ttgttctctt	tggatccagg	gatgctaagt	agaaactgca	tgagccacca	gtgccccggc	1980
accctttaac	accaccagat	gggtgttttc	ccccatccac	cactggcagg	gttgcccctt	2040
ccctccaatc	atcactgtgc	tcctttttc	ccggcctacg	aggcagctcc	tgccactatc	2100
tttagagcca	ataaagagaa	ttaaaaacct	gaaaaaaaa	aaaaaa		2146
<210> 16 <211> 1680 <212> DNA <213> Homo	) o sapiens					
	gccggtgagg	cgccgccggg	agaggccgcg	acggagctcc	cagaccggcc	60
atgggctgag	acacgtcctc	gccgagcagt	gacccttccg	taccccacca	gaacatgccc	120
gggtgacctc	ctcccagatc	ttccttgtgg	ccttcctcgc	ccactccagt	gacactatgc	180
accccaccg	tgacccgaga	ggcctctggc	tcctgctgcc	gtccttgtcc	ctgctgcttt	240
ttgaggtggc	cagagctggc	cgagccgtgg	ttagctgtcc	tgccgcctgc	ttgtgcgcca	300
gcaacatcct	cagctgctcc	aagcagcagc	tgcccaatgt	gccccattcc	ttgcccagtt	360
acacagcact	actggacctc	agtcacaaca	acctgagccg	cctgcgggcc	gagtggaccc	420
ccacgcgcct	gacccaactg	cactccctgc	tgctgagcca	caaccacctg	aacttcatct	480

540

cctctgaggc cttttccccg gtacccaacc tgcgctacct ggacctctcc tccaaccagc

tgcgtacact	ggatgagttc	ctgttcagtg	acctgcaagt	actggaggtg	ctgctgctct	600
acaataacca	catcatggcg	gtggaccggt	gcgccttcga	tgacatggcc	cagctgcaga	660
aactctactt	gagccagaac	cagatetete	gcttccctct	ggaactggtc	aaggaaggag	720
ccaagctacc	caaactaacg	ctcctggatc	tctcttctaa	caagctgaag	aacttgccat	780
tgcctgacct	gcagaagctg	ccggcctgga	tcaagaatgg	gctgtaccta	cataacaacc	840
ccctgaactg	cgactgtgag	ctctaccagc	tgttttcaca	ctggcagtat	cggcagctga	900
gctccgtgat	ggactttcaa	gaggatctgt	actgcatgaa	ctccaagaag	ctgcacaatg	960
tcttcaacct	gagtttcctc	aactgtggcg	agtacaagga	gcgtgcctgg	gaggcccacc	1020
tgggtgacac	cttgatcatc	aagtgtgaca	ccaagcagca	agggatgacc	aaggtgtggg	1080
tgacaccaag	taatgaacgg	gtgctagatg	aggtgaccaa	tggcacagtg	agtgtgtcta	1140
aggatggcag	tcttctttc	cagcaggtgc	aggtcgagga	cggtggtgtg	tatacctgct	1200
atgccatggg	agagactttc	aatgagacac	tgtctgtgga	attgaaagtg	cacaatttca	1260
ccttgcacgg	acaccatgac	accctcaaca	cagcctatac	caccctagtg	ggctgtatcc	1320
ttagtgtggt	cctggtcctc	atatacctat	acctcacccc	ttgccgctgc	tggtgccggg	1380
gtgtagagaa	gccttccagc	catcaaggag	acagcctcag	ctcttccatg	cttagtacca	1440
cacccaacca	tgatcctatg	gctggtgggg	acaaagatga	tggttttgac	cggcgggtgg	1500
ctttcctgga	acctgctgga	cctgggcagg	gtcaaaacgg	caagctcaag	ccaggcaaca	1560
ccctgccagt	gcctgaggcc	acaggcaagg	gccaacggag	gatgtcggat	ccagaatcag	1620
tcagctcggt	cttctctgat	acgcccattg	tggtgtgagc	aggatgggtt	ggtggggaga	1680

<210> 17

<211> 3737

<212> DNA

<213> Homo sapiens

<400> 17 60 ctcgatctga gccacaactt catatccagc tttccgtgga gcgacctgcg caacctgagc 120 gcgctgcagc tgctcaaaat gaaccacaac cgcctgggct ctctgccccg ggacgcactc ggtgcgctac ccgacctgcg ttccctgcgc atcaacaaca accggctgcg tacgctggcg 180 240 cctggcacct tcgacgcgct tagcgcgctg tcacacttgc aactctatca caatcccttc cactgcggct gcggccttgt gtggctgcag gcctgggccg cgagcacccg ggtgtcctta 300 360 cccgagcccg actccattgc ttgtgcctcg cctcccgcgc tgcagggggt gccggtgtac 420 cgcctgcccg ccctgccctg tgcaccgccc agcgtgcatc tgagtgccga gccaccgctt 480 gaagcacccg gcaccccact gcgcgcagga ctggcgttcg tgttacactg catcgccgac 540 ggccacccta cgcctcgcct gcaatggcaa cttcagatcc ccggtggcac cgtagtctta

gagccaccgg	ttctgagcgg	ggaggacgac	ggggttgggg	cggaggaagg	agagggagaa	600
ggagatgggg	atttgctgac	gcagacccaa	gcccaaacgc	cgactccagc	acccgcttgg	660
ccggcgcccc	cagccacacc	gcgcttcctg	gccctcgcaa	atggctccct	gttggtgccc	720
ctcctgagtg	ccaaggaggc	gggcgtctac	acttgccgtg	cacacaatga	gctgggcgcc	780
aactctacgt	caatacgcgt	ggcggtggca	gcaaccgggc	ccccaaaaca	cgcgcctggc	840
gccgggggag	aacccgacgg	acaggccccg	acctctgagc	gcaagtccac	agccaagggc	900
cggggcaaca	gcgtcctgcc	ttccaaaccc	gagggcaaaa	tcaaaggcca	aggcctggcc	960
aaggtcagca	ttctcgggga	gaccgagacg	gagccggagg	aggacacaag	tgagggagag	1020
gaggccgaag	accagatcct	cgcggacccg	gcggaggagc	agcgctgtgg	caacggggac	1080
ccctctcggt	acgtttctaa	ccacgcgttc	aaccagagcg	cagageteaa	gccgcacgtc	1140
ttcgagctgg	gcgtcatcgc	gctggatgtg	gcggagcgcg	aggcgcgggt	gcagctgact	1200
ccgctggctg	cgcgctgggg	ccctgggccc	ggcggggctg	gcggagcccc	gcgacccggg	1260
cggcgacccc	tgcgcctact	ctatctgtgt	ccagcggggg	geggegegge	agtgcagtgg	1320
tcccgcgtag	aggaaggcgt	caacgcctac	tggttccgcg	geetgeggee	gggtaccaac	1380
tactccgtgt	gcctggcgct	ggcgggcgaa	gcctgccacg	tgcaagtggt	gttttccacc	1440
aagaaggagc	tcccatcgct	gctggtcata	gtggcagtga	gcgtattcct	cctggtgctg	1500
gccacagtgc	cccttctggg	cgccgcctgc	tgccatctgc	tggctaaaca	cccgggcaag	1560
ccctaccgtc	tgatcctgcg	gcctcaggcc	cctgacccta	tggagaagcg	categeegea	1620
gacttcgacc	cgcgtgcttc	gtacctcgag	tccgagaaaa	gctacccggc	aggcggcgag	1680
gcgggcggcg	aggagccaga	ggacgtgcag	ggggagggcc	ttgatgaaga	cgcggagcag	1740
ggagacccaa	gtggggacct	gcagagagag	gagagcctgg	eggeetgete	actggtggag	1800
tcccagtcca	aggccaacca	agaggagttc	gaggcgggct	ctgagtacag	cgatcggctg	1860
cccctgggcg	ccgaggcggt	caacatcgcc	caggagatta	atggcaacta	caggcagacg	1920
gcaggctgaa	cctccgcccg	teeggeeege	ccattcccga	cctccaccta	gggtgcctgg	1980
gagcagcagt	ctagggctgg	caggacttat	gtcccccgtc	cccaaccttc	acctactcct	2040
ccccttact	actccccaac	cttgactacc	agggacttct	attagggagt	gggccgattt	2100
caccagtccc	tgctacccac	ggctgccatt	ctccctgcgg	gctgaatccc	cttccccgcc	2160
aagcacagtg	tttatcttac	cccatgcaag	actccacccg	cagacggtgg	gcgatatcta	2220
tgtccctcca	ttcccgtcgc	gattatctgc	gaaatccacc	ccgcagcccg	ccccaccgtg	2280
ggctctggag	ccagaggaaa	cgagcgaaga	ctttggaaac	ctcgcggtaa	cgcggtggtt	2340
tcgggggcca	gccaaggcca	gtggagtgct	gtggggtccc	acctcgaccc	ctcctcctcc	2400

ctttcttct	ttccttttt	tttattttt	aattttattt	atttatttat	ttattttttg	2460
acggagtctt	ggtctgtcgc	caggctggag	tgcagtggcg	cgatctcggc	tcactgcatc	2520
ttccgcctcc	cgggttcaag	cgattctcct	gcctcagcct	gcctagtagc	tgggactaca	2580
ggcgcgcgcc	accacgacca	gctaatttct	tctattttta	gtagagacgg	ggtttcacca	2640
tgttggccag	gatggtctgg	atctcttgac	ctcaggtgat	ccatctgcct	cggcctctca	2700
aagtgctggg	attacaggcg	tgaggcaccg	cgcccggccc	ctcctccctt	tcaatcccta	2760
ctcccagaag	ccgggattcg	tggcaacccc	tagtttttag	ttccaaagcc	tectgeegge	2820
agggaaccaa	atccttctgt	cctcccaccc	ccaccccact	tctggccagt	tggagtccag	2880
cccggtgcct	ggggcgcctt	tcagctccgc	gctcagattt	tcctgttttc	gttgttttca	2940
aagacagcga	catttcgggt	ctggtgctaa	caccccttc	ccagcctctg	ggaaaatcga	3000
gtgtgtgtgt	cggggggtag	ggagggaatg	cgttttctgt	cgtctctctc	ctaacttaaa	3060
gegeegeagg	accgcgcgcc	ccttggcggc	tgagcctgtg	gacttggtcg	cgggccaatt	3120
tcgttgtccg	tgtgttgggc	tttccggagg	tctgtgcgcc	caacagcgcc	gctcccgcgg	3180
ctccacccga	cccagaccct	agctggaaag	cgccggaggc	ggaggaagct	gactgtggcc	3240
tcccgggccg	cggctctctg	gagggctcgc	gccctagttc	gcacaaagcc	tgctcgtgac	3300
tgtgcgactg	tgcgacggga	tccggatgga	geegageece	tccgtcctcg	cgtctcggtc	3360
ctcgcgtcgc	cccgccccac	ccgcccctgc	ttcggcggga	atcgtgtttg	cccggcgtgt	3420
agtccctgac	aagcgtgccc	tgtaggagaa	aagtctgtgt	cctgtgaagt	gtgaccgtgt	3480
agtgtagggg	ggcgggcggg	ggggcggatg	ggcggggagg	gagggaaggg	gaggggcgcg	3540
gcgcggcgac	tcggggcggg	gttcttttt	ccattttgaa	agaaagcgtc	ggggttgggg	3600
tggggggagt	ttcagtcctc	gggatcagcc	ctctccgcga	agcgcagcac	aagcgcgggc	3660
ctgggacgga	gtagcccccc	ggagcccgtg	cccttttcta	aacgcgtctg	tatgcagtca	3720
ataaaacaat	cgatttg					3737
<210> 18 <211> 607	2					
<212> DNA <213> Hom	o sapiens					
<400> 18	. ataacaacca	tagatecage	atcadadcaa	ccgggcggac	: gaggtggagc	60
					atgggacgcg	120
					ataagcccat	180
2000022002		J = == 200 gaa	J			

240

cttgctgcac caagtggagg cgctagccgc ggcaggcgtg gaccacgtga tcctggccgt

gagctacatg	tcgcaggtgc	tggagaagga	aatgaaggca	caggagcaga	ggctgggaat	300
	atgtcccatg					360
	ctctctgaga					420
	ttccaagcca					480
	aaggtggagg					540
	caccggttcg					600
	atcctgagcc					660
	gtcttccca					720
	tggacattgg					780
	ggcagaagca					840
	acccaagtgc					900
	gcgtggtggt					960
	tccgttccca					1020
						1080
	gggtacgcat			•		1140
`	acctcaacgg	•	•			1200
	gtatcatcat				:	
catcagcaag	gggagtgctg	gcctgacaca	tcagaagacc	ctggacttgt	cattatttgt	1260
ctggggggca	ctgggtgaag	ctgaagctgt	tggacacctg	ccttctcatg	tggacatcat	1320
ctggcaggat	ccctgctggg	cacaccccac	aaaccccact	ccctcaagaa	gggccagggc	1380
cagggctgta	tggaataata	atttaatgct	cactgtggcc	ctgactgaaa	gtcaagctca	1440
ggcacaatta	gggccatggc	tgggctccca	ccaatgagga	tacaggcagg	caaggaggtt	1500
ggatgtggtg	gtgtgggata	caggagaagg	gcaaagggag	ctcataaata	gggcccagcc	1560
tggctctggg	ttcaaaggtg	gaggttccag	gatggcacag	gctgtgaggg	ctaggcagct	1620
gaggaggtag	tactcgtatt	ggctcccttc	tcccagtcct	ctacagacac	gatggtggtt	1680
ttgcagaaga	agcagtcctt	gttgttcatc	aggtgctggt	tgatacaggo	: tctacaacag	1740
gggaggggat	gaggactgcc	ctgcatgtac	ctactgctct	ccccaccacc	: aagctgtggg	1800
gcccacttac	ttgcaggact	tgtggccaca	gggctggaac	acagcagaga	tggggtgggc	1860
atagcagatg	gggcagaggt	cctcctcact	ggtgggctgc	agggaggaga	gtgaagggtg	1920
ggctggagtt	ggatgcctgg	ctatgtggat	gtccgttgtg	cctgtgtagg	g agtgcacaca	1980
tattcaagtg	gcatggacct	gtgcaccgtg	ttcccactca	ccagggagg	agctgctgcc	2040
tgggcagatg	cagaggtcag	gtgcgccagc	atctgttcca	cttgggccag	g ctcatcggca	2100

ctgatataat	ccgcatctgg	ggagtggtag	gtagtgtcaa	gtcagaggta	gctgaggatg	2160
tgatgcctct	tgaatattcc	cagcctagga	ctttgctgtt	cttaaggctc	ctgacccgac	2220
ccagccccag	atttccctga	cctgccccac	cagcccactc	acagctctgc	agggagaagc	2280
gcttccggtc	aggggctggc	agagcagtgc	caggtgctgg	gggctctggc	tgtcccagga	2340
gatagcatat	tgagcgtagc	tggaagcagg	gatctgccag	gagcactgat	gtggcttgct	2400
ctctcctagg	taggggaggg	tgcaagggca	gtcagaaggc	ttggggcctg	gctaaaagtc	2460
tctcttggga	ttgccaatga	ggagtgccat	ggctcgtaca	tgatcacccc	ccctgcatcc	2520
tttccgtctc	cctgcttccc	aaaccccaag	tcctgtattc	tagtaaggtg	ccacacagcc	2580
tgttttttt	tttttttct	tgagacgagt	ctcgctctgt	tgcccaggct	ggagtgcgat	2640
ggcacgatct	cggctcactg	caacctccac	ctcccgggtt	caagtgattc	tcctgcttta	2700
gcctcccgag	tagctggaat	tgcagacgcc	caccaccacg	cccggctaat	tgttgtattt	2760
ttagtagaga	cagggtttca	ccaggttggc	caggctggtc	tcgaattcct	gacctcaggt	2820
gatccacctg	ccttggcttc	ccaaagtgct	gggattacag	gcgtgagcca	ccgcgcccgg	2880
cctggggtac	cactttaaga	aggctcaggc	gaaccacctt	aagatagtga	gagtctgcct	2940
gccccataat	attatcagtc	cttcaaagtc	acttcaaata	aacactaaca	gcagcttgga	3000
gacattcttc	cagactcccc	cttttactcc	ccgaggaaaa	acgagcggcg	gagagctgcc	3060
agccaaaggc	tgacggggac	tttggggttg	gccttgctcc	ccatctggcg	gtcatgcggg	3120
gccattgggc	acaaagggat	gtagccgccc	cgcctcctca	aacgggaacc	aataggagcc	3180
cgggccccgc	ccctgggggg	agtatttagg	agccgatcag	gaactcgctt	ggagagggct	3240
agcgaagccg	aagggagcgc	ggctaagagt	gccgcaccgc	ctcacaacct	gggaaccgga	3300
gagtaggggc	cgtcggctgg	caagaacccg	ccgtgcctcc	tcggcaaggg	ccatccggtg	3360
ccacccatgt	cgcactagag	cagaagaggg	tgagtcctgg	aactgcaacc	tgcacagagc	3420
tgctctgtac	tgtccctggt	ggtcgccgcc	atgacctggt	tggtgctgct	ggggacactg	3480
ctctgcatgc	tgcgcgttgg	gttaggcacc	ccggactccg	agggtttccc	gccccgtgcg	3540
ctccacaact	gcccctacaa	atgtatctgc	gctgccgacc	tgctaagctg	cactggccta	3600
gggctgcagg	acgtgccagc	cgagttacct	gccgctactg	cggacctcga	cctgagccac	3660
aacgcgctcc	agegeetgeg	ccccggctgg	ttggcgcccc	tcttccagct	gegegeeetg	3720
cacctagacc	acaacgaact	agatgcgctg	ggtcgcggcg	tcttcgtcaa	cgccagcggc	3780
ctgaggctgc	tcgatctatc	atctaacacg	ttgcgggcgc	ttggccgcca	cgacctcgac	3840
gggctggggg	cgctggagaa	gctgcttctg	ttcaataacc	gcttggtgca	cttggacgag	3900
catgccttcc	acggcctgcg	cgcgctcagc	catctctacc	tgggctgcaa	cgaactcgcc	3960

1	tcgttctcct	tcgaccacct	gcacggtctg	agegeeaeee	acctgcttac	tctggacctc	4020
1	tcctccaacc	ggctgggaca	catctccgta	cctgagctgg	ccgcgctgcc	ggccttcctc	4080
i	aagaacggcc	tctacttgca	caacaaccct	ttgccttgcg	actgccgcct	ctaccacctg	4140
•	ctacagcgct	ggcaccagcg	gggcctgagc	gccgtgcgcg	actttgcgcg	cgagtacgta	4200
	tgcttggcct	tcaaggtacc	cgcgtcccgc	gtgcgcttct	tccagcacag	ccgcgtcttt	4260
	gagaactgct	cgtcggcccc	agctcttggc	ctagagcggc	cggaagagca	cctgtacgcg	4320
	ctggtgggtc	ggtccctgag	gctttactgc	aacaccagcg	teceggeeat	gcgcattgcc	4380
	tgggtttcgc	cgcagcagga	gcttctcagg	gcgccaggat	cccgcgatgg	cagcatcgcg	4440
	gtgctggccg	acggcagctt	ggccataggc	aacgtacagg	agcagcatgc	gggactcttc	4500
	gtgtgcctgg	ccactgggcc	ccgcctgcac	cacaaccaga	cgcacgagta	caacgtgagc	4560
	gtgcactttc	cgcgcccaga	gcccgaggct	ttcaacacag	gcttcaccac	actgctgggc	4620
	tgtgccgtgg	gccttgtgct	cgtgctgctc	tacctgttcg	ccccaccctg	ccgctgctgc	4680
	cgccgtgcct	gccgctgccg	ccgctggccc	caaacaccca	gcccgctcca	agagctgagc	4740
	gcacagtcct	cagtactcag	caccacaccg	ccagacgcac	ccagccgcaa	ggccagcgtc	4800
	cacaagcacg	tagtctttct	ggagccaggc	cggaggggcc	tcaatggccg	cgtgcagctg	4860
	gcagtagctg.	aggaattcga	tctctacaac	cctggaggcc	tgcagctgaa	ggctggctct	4920
	gagtccgcca	gctccatagg	ctccgagggt	cccatgacaa	cctagactgc	ccagggctcc	4980
	cccacccagg	ccccaccct	cttgctgctc	gccctgctcc	ctgcttcggt	ccagagaact	5040
	ggcagatact	ggtgggaagc	actgtgcctg	gcccccagc	ttcctgtatg	ggcctcgaaa	5100
	cacaatgggc	cttctcgctc	actggtagag	acaggggttg	tggtccccaa	cctgccttct	5160
	gctctgcccc	tgcacaggac	ccaaaggccc	caggccctgc	aaggtgtgct	agttcctgct	5220
	ttcccgcgga	cttcctagtg	cccaaatgcc	ctgtgaggct	gagagaccca	ggcccctgtg	5280
						tggaagaacc	5340
	cctgtagcag	agcctcccgt	ccaccctcag	gggctgagac	agctctcgag	gagtggtgct	5400
	caagagctga	cgcagggcca	cctccccttc	: ccaagggggt	gggagggagt	gggcccacag	5460
	ggaaaagaag	gcggctctga	aggaagatct	cgcccacacc	ccaggacaga	aagaggaaac	5520
	aagcccgccc	tctggtgaaa	tgggactccc	: tccatccacc	aacacccaac	ctcctgaaag	5580
	cttcacaact	tcacgcagag	tccggtgggc	: aggcaccagg	caggaaaggc	tcctcaagag	5640
	gttcctggtg	gtctggccta	agccccagcc	: agaggccctg	ctctctctgg	cctggggcat	5700
	ccacccgttg	ttctgaaggc	agagcccatt	: ctgtgggctc	: acaagacaca	ı gtgaagggga	5760
	tcatggcctg	cacccctgct	tttcagcagt	aaaaagcccg	g aaaagcctgg	g cgagcatggc	5820

cgagctggga gggccgagcc ggaactccac gtccctcgag agcaggagcc tcttaagggc	5880
tggcactggt ctcagcctaa tggctgaggc ggtaccctgg cttcatatgc atctcactgc	5940
teceaetgea ggggggeagg gaaggggggt etgggageee tteatgtgtg ggggeegage	6000
tgggggcccc catggccatc ctggacctcg ctgctccaga gtttaataaa ggtagcacat	6060
gcttattgct ag	6072
<210> 19 <211> 2100 <212> DNA <213> Homo sapiens	
<400> 19 ggccagagag gagccaggag ccatgagggt ggcattaggc atgctctggc tcttggccct	60
tgcgtggccc ccccaggccc ggggcttctg cccctctcaa tgcagctgca gcctccatat	120
catgggtgat ggcagcaagg ccaggacagt agtgtgcaac gaccctgaca tgaccctgcc	180
cccggcgtcc atccccccgg acacctccag actgcgcctg gagcggacgg ccatacgcag	240
ggttcctggc gaggccttca ggcccctggg ccgcctggag cagctgtggc tgccttacaa	300
cgccctcage gagetcaacg ccctcatgct geggggtctg egacgcctge gggagetgeg	360
gctgcccggg aaccgcctgg ccgccttccc ctgggcggcg ctcagggacg cccccaagct	420
gcggctgctg gacctgcagg ccaaccgcct ctcggctgtg cccgctgagg ccgcgcgctt	480
cctggagaac ctcaccttcc tcgacctctc cagcaaccag ctgatgaggc tcccgcagga	540
gctcatcgtc tectgggctc acctggagac cggtatettt ceteecggec accaececag	600
gegggteeta gggetacagg acaaceeetg ggcatgtgae tgeegaetet atgaeetggt	660
tcatcttttg gatggctggg ccccaaactt ggccttcatt gagactgaac tgagatgtgc	720
cagcccacgt agcctggccg gagtggcctt cagccagctt gaactgagga agtgccaggg	780
cccagagctc catccaggag tggccagcat caggtccctt ttgggtggca cagcattgct	840
acgctgtgga gctactggag tccctgggcc cgagatgagc tggaggaggg ccaatggcag	900
gccccttaac ggtacagtgc accaggaagt ctccagtgac ggcacgagct ggactctgct	960
gggcctgcct gcagtgtccc accttgactc cggagactac atctgccaag ccaagaactt	1020
cctgggagcc tctgaaactg ttatctcctt gattgtcact gagccgccga cttccacaga	1080
acacagtggg agcccagggg cactatgggc aaggacaggt ggcggagggg aagctgctgc	1140
ttacaacaac aagctggtgg ccaggcatgt ccccagatt cccaaacccg ctgtcctggc	1200
cactggaccc tctgtgccca gcacaaagga ggagctgacc cttgagcact tccagatgga	1260
tgccctggga gagctctctg atgggcgggc aggaccctca gaggcacgaa tggtgaggtc	1320
tgtgaaggtg gtgggggaca cttaccacag cgtgtccttg gtgtggaagg caccccaggc	1380

taagaacaca	actgccttca	gtgtcctcta	cgcggtcttt	gggcagcaca	gcatgcggcg	1440
ggtgattgtg	cagcctggga	agaccagagt	gaccatcact	gggctgttgc	ccaagaccaa	1500
gtatgtggcg	tgtgtctgtg	tgcagggcct	ggtgccccgg	aaggagcagt	gtgttatttt	1560
ctccaccaat	gaagtggtgg	atgctgagaa	cactcagcag	cttatcaatg	tggtggtgat	1620
cagtgtggcc	atcgtcattg	ccctgcctct	cacgctgctt	gtctgctgca	gtgctcttca	1680
gaagcgctgc	cgaaagtgct	tcaacaagga	ctccactgag	gccacagtta	cctacgtcaa	1740
cctagagaga	ctgggctaca	gcgaggacgg	cttggaggag	ctgtcccggc	acagtgtcag	1800
cgaggctgac	aggcttctct	cagctcgttc	cagtgtggac	tttcaggcct	ttggagtcaa	1860
agggggcagg	agaatcaatg	agtacttctg	ctgagggata	tgcctccgca	actcacacac	1920
ctgcctgccc	acgctccttc	tttagctctg	acacctgagt	acacgatcac	ccactcttac	1980
ctgctcgggt	acctgcttac	tcagatactt	acacacaaca	acagcagcag	caagctgcta	2040
ctgcaacaac	cgctaacact	tgttaagcac	ttactacaga	ctagaaagtg	ttctaagtgc	2100

<210> 20

<211> 3144

<212> DNA

<213> Homo sapiens

<400> 20

gcctggctcc ctctcgctga gacacacata cactcacaca tacacaaccc ggcaggctcg 60 120 tctgaacttg aagacacccc acattccaag atgcccgagg ttcctggggaa tgcctggggt 180 tcttcgatcc ggaaaatcct accggcatcc tcctagggag ggattattat tattattttt 240 ctttaatctg gaagagaaga gaacaagttg tgcttttccc cccttcttct tgctaaatgc 300 catggatata actgaataag cggctcaggg ctttccccgc gtggacgtcc gaggccacca 360 tetgeetgea ttegeeggag eegeeggagg gtttageteg agtetgtete gggeggggaa 420 ggatgegtgg cegageeggg gageeeggge geeeegegga geeggeeteg gtgeeaeeea gccgggggta gatgctgcct cgcccaggcg ctgagtgacc agaccatgga gaccctgctt 480 540 ggtggcctgc tagcgtttgg catggcgttt gccgtggtcg acgcctgccc caagtactgt 600 gtctgccaga atctgtctga gtcactgggg accctgtgcc cctccaaggg gctgctcttt 660 gtacccctg atattgaccg gcggacagtg gagctgcgcc tgggcggcaa cttcatcatc cacatcagcc gccaggactt tgccaacatg acggggctgg tggacctgac cctgtccagg 720 780 aacaccatca gccacatcca gcccttttcc tttctggacc tcgagagcct ccgctccctg catcttgaca gcaatcggct gccaagcctt ggggaggaca ccctccgggg cctggtcaac 840 900 ctgcagcacc ttatcgtgaa caacaaccag ctgggcggca tcgcagatga ggcttttgag

gacttcctgc	tgacattgga	ggatctggac	ctctcctaca	acaacctcca	tggcctgccg	960
tgggactccg	tgcgacgcat	ggtcaacctc	caccagctga	gcctggacca	caacctgctg	1020
gatcacatcg	ccgagggcac	ctttgcagac	ctgcagaaac	tggcccgcct	ggatctcacc	1080
tccaatcggc	tgcagaagct	gcccctgat	cccatctttg	cccgctccca	ggcttcggct	1140
ttgacagcca	caccctttgc	cccacccttg	tcctttagtt	ttgggggtaa	cccacttcac	1200
tgcaattgtg	agcttctctg	gctgcggagg	ctcgagcggg	acgatgacct	ggaaacctgt	1260
ggctccccag	ggggcctcaa	gggtcgctac	ttctggcatg	tgcgtgagga	ggagtttgtg	1320
tgcgagccgc	ctctcatcac	ccagcacaca	cacaagttgc	tggttctgga	gggccaggcg	1380
gccacactca	agtgcaaagc	cattggggac	cccagccccc	ttatccactg	ggtagccccc	1440
gatgaccgcc	tggtagggaa	ctcctcaagg	accgctgtct	atgacaatgg	caccctggac	1500
atcttcatca	ccacatctca	ggacagtggt	gccttcacct	gcattgctgc	caatgctgcc	1560
ggagaggcca	cggccatggt	ggaggtctcc	atcgtccagc	tgccacacct	cagcaacagc	1620
accagccgca	ctgcaccccc	caagtcccgc	ctctcagaca	tcactggctc	cagcaagacc	1680
agccggggag	gtggaggcag	tgggggcgga	gagcctccca	aaagcccccc	ggaacgggct	1740
gtgcttgtgt	ctgaagtgac	caccacctcg	gccctggtca	agtggtctgt	cagcaagtca	1800
gcaccccggg	tgaagatgta	ccagctgcag	tacaactgct	ctgacgatga	ggtactgatt	1860
tacaggatga	tcccagcctc	caacaaggcc	ttcgtggtca	acaacctggt	gtcagggact	1920
ggctacgact	tgtgtgtgct	ggccatgtgg	gatgacacag	ccacgacact	cacggccacc	1980
aacatcgtgg	gctgcgccca	gttcttcacc	aaggctgact	acccgcagtg	ccagtccatg	2040
cacagccaga	ttctgggcgg	caccatgato	ctggtcatcg	ggggcatcat	: cgtggccacg	2100
ctgctggtct	tcatcgtcat	cctcatggtg	cgctacaagg	tctgcaacca	cgaggccccc	2160
agcaagatgg	cagcggccgt	gagcaatgtg	tactcgcaga	ccaacggcg	ccagccaccg	2220
cctccaagca	gegeaceage	cggggccccg	ccgcagggcc	: cgccgaaggt	ggtggtgcgc	2280
aacgagctcc	tggacttcac	cgccagcctg	geeegegeea	gtgactcct	ttcctccagc	2340
tecetgggea	gtggggaggc	tgcggggctg	ggacgggcco	cctggaggat	cccaccctcc	2400
gcccgcgcc	: ccaagcccag	ccttgaccgc	ctgatggggg	g cettegeet	cctggacctc	2460
					g aggggctggg	2520
acgtcggcco	ggggccacca	ctcggaccga	a gagccactgo	tggggcccc	c tgcggcccgg	2580
gccaggagco	tgctcccctt	gccgttggag	g ggcaaggcca	a aacgcagcc	a ctccttcgac	2640
					a cagtcctcct	2700
cggaaggtct	cgaacatctg	gacgaagcg	e agestststs	g tcaacggca	t gctcttgccc	2760

tttgaggaga	gtgacctggt	gggggcccgg	gggacttttg	gcagctccga	atgggtgatg	2820
gagagcacgg	tctaggtggg	ggtgggcatg	ctccctttcc	tgtgcgcagg	gtgggagaag	2880
gggaaagaat	ctcactggca	agtgtttgtg	gagtttccat	ggtgatgttt	acatccaggg	2940
acagtttcgt	ctccctgtca	atggcctcgt	gtcccccct	accccgcaac	acccacatca	3000
cctccccacc	acccggccgg	ggtgtgctca	gggaatgtgg	actcgctcaa	atgccggact	3060
gagccctgag	tgtttggaaa	ggcgagactc	cgcctttcta	atcacaaatg	tagcctacaa	3120
gcaagcggct	ttggattgct	tatg				3144

<210> 21

<211> 2549

<212> DNA

<213> Homo sapiens

<400> 21

ccaaggggcc tgaacccgag tttgggcctg aagtccttgc tgcagacctg agtgcttaaa 60 tctggggctt gagacctccc aatcttgact cagcacccca atatctgaat gcagaacccc 120 gggatcggat ctcagactct aaaccccacc gtttggctgc ttagcatccc aagactggac 180 240 ctgggagacc ctgaccctga acaacccaaa ctggacccgt aaaactggac cctagaggcc 300 caatatttag gggtctggaa ccccgagtat taaggtctgg agactccgtt gccacagatt 360 tgagccgagt caggacacag tccctctaca gaagccttgg ggacaggaaa agcatgacca 420 gatgeteect ccagageect gacetetgae teccetggag etaggaetet geteectggg 480 gctgcttcta gctcaggaca cccctgcccg cgatggccat cctcccgttg ctcctgtgcc 540 tgctgccgct ggccctgcc tcatccccac cccagtcagc cacacccagc ccatgtcccc 600 gccgctgccg ctgccagaca cagtcgctgc ccctaagcgt gctgtgccca ggggcaggcc 660 tcctgttcgt gccaccctcg ctggaccgcc gggcagccga gctgcggctg gcagacaact 720 tcatcgcctc cgtgcgccgc cgcgacctgg ccaacatgac aggcctgctg catctgagcc 780 tgtcgcggaa caccatccgc cacgtggctg ccggcgcctt cgccgacctg cgggccctgc gtgccctgca cctggatggc aaccggctga cctcactggg cgagggccag ctgcgcggcc 840 900 tggtcaactt gcgccacctc atcctcagca acaaccagct ggcagcgctg gcggccggcg 960 ccctggatga ttgtgccgag acactggagg acctcgacct ctcctacaac aacctcgagc 1020 agetgeectg ggaggeectg ggeegeetgg geaacgteaa caegttggge etegaceaea 1080 acctgctggc ttctgtgccc gccggcgctt tttcccgcct gcacaagctg gcccggctgg acatgacete caacegeetg accaeaatee caecegacee actettetee egeetgeece 1140 1200 tgctcgccag gccccggggc tcgcccgcct ctgccctggt gctggccttt ggcgggaacc 1260 ccctgcactg caactgcgag ctggtgtggc tgcgtcgcct ggcgcgggag gacgacctcg

Department and an analysis of the second analysis of the second analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and an analysis of the second and analysis of the second and an analysis of the second and an analy	1320
aggcctgcgc gtccccacct gctctgggcg gccgctactt ctgggcggtg ggcgaggagg	
agtttgtctg cgagccgccc gtggtgactc accgctcacc acctctggct gtgcccgcag	1380
gteggeegge tgeeetgege tgeegggeag tgggggaece agageecegt gtgegttggg	1440
tgtcacccca gggccggctg ctaggcaact caagccgtgc ccgcgccttc cccaatggga	1500
cgctggagct gctggtcacc gagccgggtg atggtggcat cttcacctgc attgcggcca	1560
atgcagctgg cgaggccaca gctgctgtgg agctgactgt gggtccccca ccacctcctc	1620
agctagccaa cagcaccagc tgtgaccccc cgcgggacgg ggatcctgat gctctcaccc	1680
cacceteege tgcctetget tetgccaagg tggccgacac tgggccccet accgaccgtg	1740
gcgtccaggt gactgagcac ggggccacag ctgctcttgt ccagtggccg gatcagcggc	1800
ctatcccggg catccgcatg taccagatcc agtacaacag ctcggctgat gacatcctcg	1860
tctacaggat gatcccggcg gagagccgct cgttcctgct gacggacctg gcgtcaggcc	1920
ggacctacga tctgtgcgtg ctcgccgtgt atgaggacag cgccacgggg ctcacggcca	1980
cgcggcctgt gggctgcgcc cgcttctcca ccgaacctgc gctgcggcca tgcggggcgc	2040
cgcacgctcc cttcctgggc ggcacgatga tcatcgcgct gggcggcgtc atcgtagcct	2100
cggtactggt cttcatcttc gtgctgctaa tgcgctacaa ggtgcacggc ggccagcccc	2160
ccggcaaggc caagattccc gcgcctgtta gcagcgtttg ctcccagacc aacggcgccc	2220
tgggcccac gcccacgccc gccccgcccg ccccggagcc cgcggcgctc agggcccaca	2280
ccgtggtcca gctggactgc gagccctggg ggcccggcca cgaacctgtg ggaccctagc	2340
caggegeece eccetetaag ggteetetgg eeccaeggae ageaggaece ggacaecetg	2400
tgggacctgg cctcaaactc accaaatcgc tcatggtttt taaaactctg atggggaggg	2460
tgtcggggac accggggcaa aacaagaaag tcctattttt ccaagcttgg gcgaaaaaa	2520
aaaaaaaaa aaaaaaaaa aaaaaaaaa	2549
<210> 22 <211> 2022 <212> DNA <213> Homo sapiens	
<400> 22 atgtgctcca gggtccctct gctgctgccg ctgctcctgc tactggccct ggggcctggg	g 60
gtgcagggct gcccatccgg ctgccagtgc agccagccac agacagtctt ctgcactgc	
cgccagggga ccacggtgcc ccgagacgtg ccacccgaca cggtggggct gtacgtctt	
gagaacggca tcaccatgct cgacgcaggc agctttgccg gcctgccggg cctgcagct	
	200

300

ctggacctgt cacagaacca gatcgccagc ctgcccagcg gggtcttcca gccactcgcc

PCT/US03/06025 WO 03/083047

aacctcagca	acctggacct	gacagccaac	aggctgcatg	aaatcaccaa	tgagaccttc	360
cgtggcctgc	ggcgcctcga	gcgcctctac	ctgggcaaga	accgcatccg	ccacatccag	420
cctggtgcct	tcgacacgct	cgaccgcctc	ctggagctca	agctgcagga	caacgagctg	480
cgggcactgc	ccccgctgcg	cctgccccgc	ctgctgctgc	tggacctcag	ccacaacagc	540
ctcctggccc	tggagcccgg	catcctggac	actgccaacg	tggaggcgct	gcggctggct	600
ggtctggggc	tgcagcagct	ggacgagggg	ctcttcagcc	gcttgcgcaa	cctccacgac	660
ctggatgtgt	ccgacaacca	gctggagcga	gtgccacctg	tgatccgagg	cctccggggc	720
ctgacgcgcc	tgcggctggc	cggcaacacc	cgcattgccc	agctgcggcc	cgaggacctg	780
gccggcctgg	ctgccctgca	ggagctggat	gtgagcaacc	taagcctgca	ggccctgcct	840
ggcgacctct	cgggcctctt	ccccgcctg	cggctgctgg	cagctgcccg	caaccccttc	900
aactgcgtgt	gccccctgag	ctggtttggc	ccctgggtgc	gcgagagcca	cgtcacactg	960
gccagccctg	aggagacgcg	ctgccacttc	ccgcccaaga	acgctggccg	gctgctcctg	1020
gagcttgact	acgccgactt	tggctgccca	gccaccacca	ccacagccac	agtgcccacc	1080
acgaggcccg	tggtgcggga	gcccacagcc	ttgtcttcta	gettggetee	tacctggctt	1140
agccccacag	agccggccac	tgaggccccc	agcccgccct	ccactgcccc	accgactgta	1200
gggcctgtcc	cccagcccca	ggactgccca	ccgtccacct	gcctcaatgg	gggcacatgc	1260
cacctgggga	cacggcacca	cctggcgtgc	ttgtgccccg	aaggcttcac	gggcctgtac	1320
tgtgagagcc	agatggggca	ggggacacgg	cccagcccta	caccagtcac	gccgaggcca	1380
ccacggtccc	tgaccctggg	catcgagccg	gtgagcccca	cctccctgcg	cgtggggctg	1440
cagcgctacc	tccaggggag	ctccgtgcag	ctcaggagcc	tccgtctcac	ctatcgcaac	1500
ctatcgggcc	ctgataagcg	gctggtgacg	ctgcgactgc	ctgcctcgct	cgctgagtac	1560
acggtcaccc	agctgcggcc	caacgccact	tactccgtct	gtgtcatgco	: tttggggccc	1620
gggcgggtgc	cggagggcga	ggaggcctgc	ggggaggccc	atacaccccc	agccgtccac	1680
tccaaccacg	ccccagtcac	ccaggcccgc	gagggcaacc	tgccgctcct	cattgcgccc	1740
gccctggccg	cggtgctcct	ggccgcgctg	gctgcggtgg	gggcagccta	ctgtgtgcgg	1800
cgggggcggg	ccatggcagc	agcggctcag	gacaaagggc	aggtggggc	aggggctggg	1860
ccctggaac	tggagggagt	gaaggtcccc	ttggagccag	gcccgaaggc	aacagagggc	1920
ggtggagagg	ccctgcccag	cgggtctgag	tgtgaggtgc	cactcatggg	g cttcccaggg	1980
cctggcctcc	agtcacccct	ccacgcaaag	ccctacatct	. aa		2022
	cgtggcctge cetggtgcet cgggcactge ctcctggccc ggtctgggcctg ctgatgtgt ctgacgccc gccggcctg ggcgacctct aactgcgtgt gccagccctg gagcttgact acgaggcccg agcccacag gggcctgtcc cacctggga tgtgagagcc ctatcgggc cagggcacc ccacggtccc cacctggga tgtgagagcc ggggggggg ccctggcgg	cetggtecte ggegetega cetggtgeet tegacaeget cgggeactge ceeegetgeg gtetgggee tggageegg ggtetggge tgeageaget ctgaatgtgt cegacaaeca ctgaegeeg tgeggetgge ggegeetgg ctgeeetgag ggegaeete cgggeetett aactgegtgt geeeetgag gacageetg aggagaegg gagettgaet aegeegaet aegaggeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg tggtgegga ageeegeeg eeaggeeea cacetggga caceggeeea tgtgagagee teeagggag caaeggeee tgaeeegg agggeggee etgaeegg aeggeggee etgaeae gggegggtge eggagggga tecaaecaeg eggtgeteet cggggggggg ecatggeage ceeetggaae tggagggagt ggtggagagg ecetgeeeag	cettggtgcette ggegeetega gegeetetae cettggtgcet tegacaeget eggegeaeteg cettgeeeege etectgggee tegageeegg tateetggge tggageaggg etggatggg etggaeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggettgge eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegeeteg eggegegeg etggegeg eateggege eateggege eggegege etggegegg etggegegg eggegegeg egggggggg	cetgggectge ggegectega gegecetetae etgggeaaga cetggtgeet tegacacget egacegeete etggagetea cetggtgeet tegacacget egacegeete etggagetea cetgggeaetge eecegetgeg eateetggae actgecaceg ggtetgggge tgcagcaget ggacgaggg etetteagee ctggatgtgt ecgacaacca getggagega gtgecacetg cetgacegee tgeggetgge eggeaacace egactgeeg ggeggacetet egggeetgee eggeaacace eggetgetgg gacagecetg etgegetege etgegetgg eeggeaacace ggegaacetet egggeetett ecceegeetg eggetgetgg gacagecetg aggagacgg etgecaette eegecaaga gagettgaet acgeegactt tggetgeeca gecacacaca acgaggeeeg tggtgegga geceacacge ttgtetteta agececacaag ageeggeae tggageece eggeeecet gggeetgtee eccageeca ggactgeeca eeggeeet tegtgagagae aagtgggaa ggggacacgg etcacacet cacetgggga eacggeaeca eetggegtge ttgtgeeceg tgtgagagee agatggggaa ggagacacgg eccacacea cacacggteee tecaggegga eategggeeg gtgageecea cacacggteee tecaggggaa etcegtgeag etcaggagee etategggee etgataageg getggtgaeg etgegaetge eccacggteae eggagggea gacggeeetg ggggaggeee tecaacacac agetgegee eaacgeeaet tacteegtet gggegggtge eggaggega ggaggeetge gggggaggeee tecaacacac eccagteae ecaggeeeg gagggaacacg ecctggeeg eggtgeteet ggeegeetg getggggageee eggggggggg ecatggeaga ageggeetaa gacaaagggee eccetggaae tggagggag ageggeteag gacaaagggee eccetggaae tggagggag agaggeteae teggageag eccetggaae tggagggag agaggeteae teggageag eccetggaae tggagggag agaggeteae gacaaagggee eccetggaae tggagggag agaggeteae teggageag eccetggaae tggagggag agaggeteae teggageag eccetggaae tggagggag agaggeteae teggageag eccetggaae tggagggag agaggeteae teggagageae eccetggaae tggagggag agaggeteae teggagageae eccetggaae tggagggag agaggeteae teggagagag eccetggaae tggagggag agaggeteae teggagagag eccetggaae tggagggag agaggeteae teggagagag eccetggaae tggagggag agaggeteae teggagagag eccetggaae tggagggag agaggeteae teggagagag eccetggaae tggaggaga agaggteee ttggagagag eccetggaae tggaggaga agaggteee ttggagagag eccetggaae tggaggaga agaggteee ttggagagag eccetggaae tggaggaga agaggteee ttggagagag eccetggaae tggagagag agaggteee ttggagagag eccetggaae tggagagagag agaggteee	cettggeetge tegaceget egacegeete etgagetea acegeateegeeteeteeteggee tegacegee etgetgage etgagegeggggggggggggggggg	aacetcagea acetggacet gacagecaac aggetgaatg aaateaccaa tgagacette egtgggetge gacgectega gegetetaac etgggaaga acegaateeg ecacateeag eetggggette tegacaeget egaceegee etgetgetget tggaacetag eacetgagget etgggacetge eetgetggge etgegetget tggaacetag ecacaacage etcetgggee tggagecegg eateetggaa atgegaagg eteetgggggggggg

<sup>&</sup>lt;210> 23 <211> 5188 <212> DNA

## <213> Homo sapiens

<400> 23 . egegetetet teeteeetea gacaactege ecceegeet eegeceeet eeaegtaatt 60 ccgaaagagc agaagaaaga gaaggagaac aggaaaagaa gagctagtaa gcgagagcga 120 gagcacagaa aagaaaaaaa aaagccttaa gaggaccgaa ggggaggaaa ggaaaaggat 180 240 ggacaaccac aaaacgcagc gattgcggaa attttccagc gccattggct gggcagcgtg agtccttcgg tcgggcgtga tttcagcacc gggggaactg gacagcacct cggggggact 300 tetgggcaac cegcaaccac agcaagaact ccaccagcag cetcaacaac agaageegeg 360 gaaaaccctg ctttgtatca gagaggcaag gtcagtccga cgcacagcca tgcacaggca 420 gtgcgcctgt actacgctgc aaaccctctg cttgtttctc taacatgcac ttgcttctaa 480 ttactagcat tgtttcattt ctgatcagtg aagatcagta gatgagattc tgtaagggtg 540 tacttttaat ttatatgtat atatttaact tctttttctg ttatttttaa agtgttgtgg 600 gggagtgggg tttttttcct acttttttt tttttttt ttctttgctt gccttgcact 660 acgtgcctgg atagtttgtg gatataatta ttgactggcg tctgggctat tgcagtgcgg 720 780 gggggttagg gaggaaggaa tccaccccca ccccccaaa cccttttctt ctcctttcct 840 ggcttcggac attggagcac taaatgaact tgaattgtgt ctgtggcgag caggatggtc getgttactt tgtgatgaga teggggatga attgeteget ttaaaaatge tgetttggat 900 tetgttgctg gagacgtete tttgttttge egetggaaac gttacagggg acgtttgcaa 960 agagaagatc tgttcctgca atgagataga aggggaccta cacgtagact gtgaaaaaaa 1020 gggcttcaca agtctgcagc gtttcactgc cccgacttcc cagttttacc atttattct 1080 gcatggcaat tccctcactc gacttttccc taatgagttc gctaactttt ataatgcggt 1140 1200 tagtttgcac atggaaaaca atggcttgca tgaaatcgtt ccgggggctt ttctggggct gcagctggtg aaaaggctgc acatcaacaa caacaagatc aagtcttttc gaaagcagac 1260 ttttctgggg ctggacgatc tggaatatct ccaggctgat tttaatttat tacgagatat 1320 agacccgggg gccttccagg acttgaacaa gctggaggtg ctcattttaa atgacaatct 1380 catcagcacc ctacctgcca acgtgttcca gtatgtgccc atcacccacc tcgacctccg 1440 gggtaacagg ctgaaaacgc tgccctatga ggaggtcttg gagcaaatcc ctggtattgc 1500 ggagateetg etagaggata accettggga etgeacetgt gatetgetet ecetgaaaga 1560 atggctggaa aacattccca agaatgccct gatcggccga gtggtctgcg aagcccccac 1620 cagactgcag ggtaaagacc tcaatgaaac caccgaacag gacttgtgtc ctttgaaaaa 1680 ccgagtggat tctagtctcc cggcgccccc tgcccaagaa gagacctttg ctcctggacc 1740 cctgccaact cctttcaaga caaatgggca agaggatcat gccacaccag ggtctgctcc 1800

aaacggaggt	acaaagatcc	caggcaactg	gcagatcaaa	atcagaccca	cagcagcgat	1860
	agctccagga					1920
	cacatcccag					1980
	gatttgaagc					2040
	agcatccgaa					2100
	aataacatcg					2160
	tacatggata					2220
	ctagagtacc					2280
	gccatgccca					2340
	gacgtgttcg					2400
	ctcccggtgg					2460
	aacccctggg					2520
	tccgaagtgc					2580
	ttcatgctcc					2640
	ttaacttcgc					2700
	: tacctagaca					2760
		•			tcctgaggaa	2820
						2880
					attecetaca	2940
					gggcccacag	3000
					ataggggagg	3060
					gaggggcgtg	3120
					ctgtgagctc	3180
					gagcagactg	
					tgacagaaag	3240
					ggggcctgtg	3300
					agagagatag	3360
					acgcagggat	3420
					ctgacaaaaa	3480
acaaaaagt	g ctgcatggct	cgcatggaat	ccacgcgcto	cagggactc	geeegeeeee	3540
gcgactgga	g acggcatcto	gttcacagca	a cccaccctct	tacctgata	a gttccatcgt	3600
atcaaactt	t ctataaacaa	a aatacagta	t aatcagaaag	g tgccatttc	g ccattatttg	3660

tgatcggtag	gcagttcaga	gcataagtta	actgtgaaaa	aaatgtaaag	gttttattta	3720
ggacatttgc	atggctagtc	atcagtccat	tttatgagtt	aacaatgtat	tttgttgagg	3780
gaagttttta	ggggttgttt	tgggttcttt	tattttgatg	gtgatgtttt	attttatttt	3840
attttttca	gggggtcttt	tttttaatac	atatccaata	atgccttcca	tctgaatgta	3900
aaataagtac	ccatgatttc	tattatagta	tcagtgtaat	tatttaaaaa	atgattttga	3960
ggcagttaag	catgaccaat	taatgtcact	ctagtgctta	ggctgcgatc	ctatggtagc	4020
aattctgtgc	tggtataaat	cttacttata	aagtaggaaa	agagaaccga	ggaagcacgt	4080
gaaacttact	aattctattc	gaggatttta	taatggcata	ttttttcagt	attaaagcga	4140
aaatgttttc	aactctgggt	ccttaccttt	ttccagcttc	atatttgcaa	gtggtaaatt	4200
ggatttgcgg	tggaagagac	aggggaggga	aacggttggg	gttagatccc	ttcctgagct	4260
acattaaggc	tctttctcta	atcgccttac	ttagcttttt	accctttaag	tagctcctct	4320
tccctcgccc	ccaccctcta	ccccaccccc	accttcgctc	agactttacc	ggctttcccc	4380
agtccataaa	ggtcttgccc	caacactcac	cccttctttt	tttcccctct	ccaaatgcag	4440
cagtgaatcc	ctttattaat	actggaaatc	cctctctgct	gcttttgttg	gtgctgccca	4500
cactgcagat	atattaagga	tgttaggaga	gatttgattt	aattgactct	gcctagatag	4560
gtctcattaa	acagagtgga	gatttcattg	gtcagcactc	ctcaatgaaa	gacagaccta	4620
atgactggca	tttgagatgc	tgctggcatt	ttgaattcaa	catctgctga	aaacggtaaa	4680
actaattagt	gcccacccac	cctccccgcc	ccagcaactg	catattgaaa	tttgttaaag	4740
cactcatctt	tatggaaatt	aatcattatc	ctaaagaagt	gtttctctcc	catcatccgg	4800
atttctggtt	gtggcccagc	aattaacaaa	aacagcttca	actgttcgaa	tttatgaac	4860
caatgtaact	ctggcctcaa	tcatattcct	ctgggatttc	taaacagcag	ttaagctaca	4920
aaaagcaaac	aaaaccacac	atattgatgg	agtctgcatt	ccaccacata	tccacccttg	4980
agaagtatgt	caaaagactg	cagactatag	atttttttt	aatataggat	: tataaatcag	5040
ctagtgaaag	acctcagago	agttgtaagt	agatctgcca	tctagaacto	: atattctaaa	5100
gggaagtgat	ttctcagaac	: agtgatgttc	: tggaatatgt	: attatttatt	ttaacacttt	5160
tttaataaaa	tctttattat	aaaccatg				5188

<sup>&</sup>lt;210> 24 <211> 4331 <212> DNA <213> Homo sapiens

<220> <221> misc\_feature

<222> (2420)..(2519) <223> n is a, c, g, or t

<400> 24 60 cccggaaccc gcggtcgcca ccgcggcggc ggccccaggc tggaggcgtc cgggcgcctc 120 tttcctccag cctctgggac tgcgctgctc gcagtctcct cgccctgcct gggcttgaga aacctagtgc ataccccaaa gagggttttt gtgtatgtgt gtgtttttaa agggtggcta 180 tgatgactgg gccttggaga tgtgagactg ggaggtaaaa tgcacacttg ctgccccca 240 300 gtaactttgg aacaggacct tcacagaaaa atgcatagct ggatgctgca gactctagcg 360 tttgctgtaa catctctcgt cctttcgtgt gcagaaacca tcgattatta tggggaaatc 420 tgtgacaatg catgtccttg tgaggaaaag gacggcattt taactgtgag ctgtgaaaac cgggggatca tcagtctctc tgaaattagc cctccccgtt tcccaatcta ccacctcttg 480 540 ttgtccggaa accttttgaa ccgtctctat cccaatgagt ttgtcaatta cactggggct tcaattttgc atctaggtag caatgttatc caggacattg agaccggggc tttccatggg 600 ctacggggtt tgaggagatt gcatctaaac aataataaac tggaacttct gcgagatgat 660 accttccttg gcttggagaa cctggagtac ctacaggtcg attacaacta catcagcgtc 720 780 attgaaccca atgcttttgg gaaactgcat ttgttgcagg tgcttatcct caatgacaat cttttgtcca gtttacccaa caatcttttc cgttttgtgc ccttaacgca cttggacctc 840 cgggggaacc ggctgaaact tctgccctac gtggggctct tgcagcacat ggataaagtt 900 gtggagctac agctggagga aaacccttgg aattgttctt gtgagctgat ctctctaaag 960 1020 gattggttgg acagcatete etatteagee etggtggggg atgtagtttg tgagaceeee ttccgcttac acggaaggga cttggacgag gtatccaagc aggaactttg cccaaggaga 1080 1140 cttatttctg actacgagat gaggccgcag acgcctttga gcaccacggg gtatttacac 1200 accaccccgg cgtcagtgaa ttctgtggcc acttcttcct ctgctgttta caaaccccct ttgaagecee ctaaggggae tegecaacee aacaagecea gggtgegeee cacetetegg 1260 1320 cagocotota aggaottggg ctacagoaac tatggoocca gcatcgcota tcagaocaaa 1380 tccccggtgc ctttggagtg tcccaccgcg tgctcttgca acctgcagat ctctgatctg 1440 ggcctcaacg taaactgcca ggagcgaaag atcgagagca tcgctgaact gcagcccaag 1500 ccctacaatc ccaagaaaat gtatctgaca gagaactaca tcgctgtcgt gcgcaggaca 1560 gacttcctgg aggccacggg gctggacctc ctgcacctgg ggaataaccg catctcgatg atccaggacc gcgctttcgg ggatctcacc aacctgaggc gcctctacct gaatggcaac 1620 aggatcgaga ggctgagccc ggagttattc tatggcctgc agagcctgca gtatctcttc 1680 1740 ctccagtaca atctcatccg cgagattcag tctggaactt ttgacccggt cccaaacctc

cagctgctat	tcttgaataa	caacctcctg	caggccatgc	cctcaggcgt	cttctctggc	1800
ttgaccctcc	tcaggctaaa	cctgaggagt	aaccacttca	cctccttgcc	agtgagtgga	1860
gttttggacc	agctgaagtc	actcatccaa	atcgacctgc	atgacaatcc	ttgggattgt	1920
acctgtgaca	ttgtgggcat	gaagctgtgg	gtggagcagc	tcaaagtggg	cgtcctagtg	1980
gacgaggtga	tctgtaaggc	gcccaaaaaa	ttcgctgaga	ccgacatgcg	ctccattaag	2040
tcggagctgc	tgtgccctga	ctattcagat	gtagtagttt	ccacgcccac	accctcctct	2100
atccaggtcc	ctgcgaggac	cagcgccgtg	actcctgcgg	tccggttgaa	tagcaccggg	2160
gcccccgcga	gcttgggcgc	aggcggaggg	gcgtcgtcgg	tgcccttgtc	tgtgttaatt	2220
ctcagcctcc	tgctggtttt	catcatgtcc	gtcttcgtgg	ccgccgggct	cttcgtgctg	2280
gtcatgaagc	gcaggaagaa	gaaccagagc	gaccacacca	gcaccaacaa	ctccgacgtg	2340
agctccttta	acatgcagta	cagcgtgtac	ggcggcggcg	gcggcacggg	cgggcaccca	2400
cacgcgcacg	tgcattatcn	nnnnnnnnn	nnnnnnnn	nnnnnnnnn	nnnnnnnn	2460
nnnnnnnnn	nnnnnnnn	nnnnnnnn	nnnnnnnn	nnnnnnnnn	nnnnnnnc	2520
acagcagcag	ccccgccgc	agctgcagct	gcagcccggg	gaggaggaga	ggcgggaaag	2580
ccaccacttg	cggagccccg	cctacagcgt	cagcaccatc	gagccccggg	aggacctgct	2640
gtcgccggtg	caggacgccg	accgctttta	caggggcatt	ttagaaccag	acaaacactg	2700
ctccaccacc	cccgccggca	atagcctccc	ggaatatccc	aaattcccgt	gcagccccgc	2760
tgcttacact	ttctccccca	actatgacct	gagacgcccc	catcagtatt	tgcacccggg	2820
ggcaggggac	agcaggctac	gggaaccggt	gctctacagc	cccccgagtg	ctgtctttgt	2880
agaacccaac	cggaacgaat	atctggagtt	aaaagcaaaa	ctaaacgttg	agccggacta	2940
cctcgaagtg	ctggaaaaac	agaccacgtt	tagccagttc	taaaagcaaa	gaaactctct	3000
tggagctttt	gcatttaaaa	caaacaagca	agcagacaca	cacagtgaac	acatttgatt	3060
aattgtgttg	tttcaacgtt	tagggtgaag	tgccttggca	cgggatttct	cagcttcggt	3120
ggaagatacg	aaaagggtgt	gcaatttcct	ttaaaattta	cacgtgggaa	acatttgtgt	3180
aaactgggca	catcactttc	tcttcttgcg	tgtggggcag	gtgtggagaa	gggctttaag	3240
gaggccaatt	tgctgcgcgg	gtgacctgtg	aaaggtcaca	gtcatttttg	tagtggttgg	3300
aagtgctaag	aatggtggat	gatggcagag	catagattct	actcttcctc	ttttgcttcc	3360
tececetece	ccgcccctgc	cccacctctc	tttctcccct	tttaagccat	gggtgggtct	3420
aactggcttt	tgtggagaaa	ttagcacacc	ccaactttaa	taggaaattt	gttctctttt	3480
teegeeeete	teettetete	ctccctccc	ctcccttctc	attccttttc	tttgttttta	3540
aaggatgtgt	ttgtatgcat	tctggacatt	tgaattaaaa	aaaaagtatt	gtgatcctgt	3600

•	aaaggatcac	catagatgtg	gacaaatcat	taaaattaca	gagctatatg	atccataatt	3660
•	gattagtcaa	aataacttat	tgatgaaata	tacaaatatt	ttattgtagc	acctattttt	3720
•	atatgcacat	ttagcattcc	tctttccttc	actatttagc	ctatgatttt	gcagaggtgt	3780
,	cacactgtat	taggatctgc	atttctaaaa	ctgacgtggt	atcaggaagg	cattttcaat	3840
	cattcaaaat	gtggagaatt	taatggctaa	atctttaaaa	gccaatgcaa	cccacccaat	3900
	tgaatctgca	ttttctttta	agaaaacaga	gctgattgta	tcccaatgta	tttaaaaaa	3960
	tagggcaatt	gattgggcca	ttccgagaga	attgtttgca	agttttgggt	tttattagaa	4020
	aatatttgaa	agtatttta	ttaatgaacc	aaaatgacat	gttcatttga	ctactattgt	4080
,	agccgatttt	cgattgttta	accaaaccca	gttgcatttg	tacagatcca	cgtgtactgg	4140
	cacctcagaa	gaccaaatca	tggactgtac	aagtctctat	acaatgtctt	tatccctgtg	4200
	ggcagcaagc	aatgatgata	atgacaaaca	ggatatctgt	aagatggggc	tactgttgtt	4260
	acagtctcat	atgtatccca	gcacatgtaa	ttttttaaat	agtttctgaa	taaacacttg	4320
	ataactatgt	С					4331

<210> 25

<211> 216215 ...

<212> DNA

<213> Homo sapiens

<400> 25 aagetttaaa tgttactgtg tggttcagat taagetcata gttcacgetc ttccttttta 60 120 ggacaagaat aggaacgcct aacacagggg ctgttccttt agccaaggtc ccggaatcag aacatatatg gaactaaatc agaagtaagg aaaactaagc agagtcacag tagctaccag 180 240 tgccctgaaa cttataacat gtaatgcaat ttcaaagtag atgttttttg taagtcattg 300 agatttgggg gctgttattg agaagaaata caggcacaat acacagtttt catcctgctt tttcacttag tattttgtaa tatatcagtt atctattgcc acttaaaaat gtcagcacaa 360 420 acttagttga ttgaaagaat acatacttat catcacacag tttttaggga tcgggagttt 480 gataacagct taactggatc ctctctttca gcatctcaca aagctgcagt caagatgtta 540 gccaatggtg tggtcttatc tgaggctcaa ccagaggaga atttcctctc aagctccagt 600 ggttgctggc agcattccat tttttgcagg ctatcggact aagggccaaa atttctcaat 660 ggccatctgc cgaagatacc cttcactttt ttgccatgtg gctttctcta taggaaaatc 720 tcatgtcaat ttgctttatc aaatccagaa agggaattta tgtcctctag taagattggt 780 gctatgaact gtggagcatt atcacaataa agatattctg tcacatgtgc tgtattttat 840 tgattatatg aaagccatag ttactaacca tactcaaggg gaaagattat acaaaggcgt 900 aaactccagg aggaagggat catgagggac caccttacag cctgttcacc gcagatagaa

tttctcatgt	tactaagcat	tcttcaaaaa	ggatgctttc	tgcatttatt	aaaatgttca	960
tgtatatttt	tctttatttt	gtgattgtca	taaaatatga	caaatggttt	ttctagggtt	1020
cacaaaatat	ataaatttta	gtgtttacac	aagacctcat	atgaatggat	aataatgtaa	1080
ttaatcagtg	tattgttcaa	taattagatg	gtttactact	tttaattatt	tgagttattc	1140
tgataattgt	gtacatccat	tttttccaca	tatttactta	ttttctttat	attgctagat	1200
gactactaaa	tcaaagaata	tgacttcttt	taatggcctt	aatgaatact	gtcacaataa	1260
tttccagaaa	tgtataacaa	tttacaattc	aaatgcccat	cagtaatgca	ctgtcttacc	1320
gtaactcagc	atgtgtgtgt	ctcttcacta	acaataggat	tctataccac	aaaattgcta	1380
aagattctgc	caaaagtccc	ctagacctaa	taaatgactt	tggtaaagtt	tcaggttaca	1440
aaagcaatgt	acaaaaatta	gcagcattta	gttttttct	tttttttaa	attttacttt	1500
aagttttggg	atacatatgc	agaacatgca	ggtttgttac	acagatatat	gtgtgccatg	1560
gtgctgctgc	acctattgac	ccgtcttcta	agttccctcc	cctcaccctc	caccctcaa	1620
caggccccag	tgtgtgttgt	teceetetet	gtgtccatgt	gttctcattg	ttcaactccc	1680
acttatgagt	gagaacatgc	ggtgcttggt	tttctattcc	tgtgttagtt	ttctgagaat	1740
gatcattttc	agcttctgat	tttttgagat	acgttctatc	aatacctagt	ttattcagag	1800
tttttagcat	gaaggggtgt	tgaattttat	tgaaggcctt	ttctgcatct	attgagatta	1860
tcatgtggtt	tttgtcattg	gttctcttta	tgtgatgaac	tacgttcatt	gatttgagta	1920
tgttgaacca	gccttgcatc	ccagggatga	ggctgacttg	accgtggtgg	ataagctttt	1980
taatgtgctg	ctggaatcag	tttgccgata	ttttattgag	aaatttcaca	tcaatgttta	2040
tcagggatat	tggcctgaaa	ttttcctttt	taattgtgtc	tctgccaagt	tttggtaaca	2100
ggatgatgct	ggactcataa	aatgtgttag	ggagaagtcc	ctcttttct	attgtttgga	2160
atagtttcag	aaggaatggt	accagctcct	ctttgtatct	ctggtagaat	tcggctgtga	2220
atctgtctgg	tcttaggctt	tttttgcttg	gtaggctatt	aattactgcc	tcaatttcag	2280
aacttgttat	tggtctattc	aaggattcga	cttcttcctg	gtttcatctt	gggagggtgt	2340
atgtgtctag	gactttaacc	atttcttcta	gattttctag	tttgtttgca	tagaggtgtt	2400
tatagtattc	tctgatgtta	gtttgtattt	ctgggggatc	agtggtgata	ttccctttat	2460
cactttttat	tgcgtctatt	tgattcttct	cttttcttct	ttattagtct	ggctagtggt	2520
ctacctagtt	tgttaatctt	ttcaaaaaac	cagctcctgg	atcccttgat	ttttgaagg	2580
gattttcatg	tctctatctc	cttcaattct	gctctgatct	tagttatttc	ttctcttctg	2640
ctagattttg	aatatgtttg	ctcttgcttc	tctagttctt	ttaattgtga	tgttagggtg	2700
tcaattttag	atctttcctg	ctttctcctg	tgggcattta	gtgctgtaaa	tttccctcta	2760

aacactgctt tagctgtgtc cccaggatcc tgctaccggt agtgtctttg ttctcattgg 2820 tttcaaataa cttatttatt tctgccttca tttcgttatt tacccagtaa tcatttagga 2880 2940 gaaggttgtt cagtttccat gtagttgtgc ggttttgagt gagtttctta atcatgagtt ctaatttgat tgcactgtag tctgagagat ggtttgtttt gatttctgtt cttttgcatt 3000 3060 tgctgaggaa tgttttactt ccaattttat ggtcgatttt agaatacgtg tgatgtggtg ctgagaagaa tgtatattct gttgatttgg ggtggagagt tctgtagatg actattagat 3120 3180 atgcttggtc cagagctgag ttcaagtcct gaatatcctt gttaattttc tgtctcattg atctgtctaa tattgacagt ggggtgttaa agtccccctc tactattgtt taggagtcta 3240 3300 agtetetttg tagateteta agaacttget ttatgaatet gggtgeteet gtateaagtg catatataat taggatagtt agtccttctt gttccattga tcccttgacc attatgtaat 3360 3420 gcccttcttt gtctttttt tgtctttgtt ggtttatagt ctgtgttatc agagactagg attgcaaccc ctgttttttt tttctgcttt ccatttgctt ggtaaatatt cctccatccc 3480 3540 ttcattttca gcctatgtgt gtctttgcac gtgagatggg tctactgaat acagcacact gatgggtctt gactctttat ccaatttgcc agtctgtgtc ttttaattgg ttcatttagc 3600 ccatttatat ttaaggttaa tattgttatg tgtgaatttg atcccgtcat tatgatgctt 3660 gctggttact ttgaccgtta gttgatgcag tttcttcata gtgctaatgg actttacaat 3720 3780 ttggtatgtt tttgcagtgg ctggtaccag tttttccttt ccatatgtag tgcttccttc aagagctctt gtaaggcagg cctggtggtg acaaactctc tcagcctttg cttatctgta 3840 3900 aagaatttca tttctccttc acttatgaag cttagcttgg ctggatatga aattctgggt tgaaaattct tttctttaag aatgttgaat attggccccc actctcttct ggcttgtagg 3960 atttctgaag ggagatccac tattagtctg atgggcttcc ctttgtgggt aaccccatct 4020 ttctctctgg ctgcccataa cattttttc cttaaattct accttggtga atctgttgat 4080 tatgtgtctc agggttgctc ttcttgagga ctatctttgt ggtgttctct gtatttccag 4140 aatttgaatg ctggcccatc ttgctgagag gtgacagcat gctggcagcc ctcactcgct 4200 ctcggcacct cctcagcctc ggcgcccact ctggccatgc ttgaggagcc cttcagccca 4260 cggctgcact gtgggagccc ctctctgggc tggccgaggc cagagccggc tccctctgct 4320 tgtgggtagg tgtggaggga gaggcgcggg taggaaccag ggctgcacat ggcactcgcg 4380 4440 ggccagcgca agttccaggt gggtgcaggc tcggcaggcc ctgcacttgg atcgtccccg ggcagtgagg ggtgtagtac ctgggccagc agctgcggag ggtgcaccag gtcccccagc 4500 4560 actgccggcc cgcaccacgc tcaaattctc accaggcctc agccacctcc ctgcggggca 4620 ggacttggga cctgcagecc accatgcccg agcctcccc cacccaccc atggactccc

. . .

gcatggccag	agcctcccca	acgggcacca	cccctgctc	cgcggcacct	ggtcacatcc	4680
actgcccaag	ggctgaggag	tgtgggtgca	tggtgtggga	cgggcgggca	gctctgccca	4740
cggccctagc	gtgggatcca	ctaggtgaag	ccagcggggc	tcctgagtca	ggtggggact	4800
tggaggagtt	ttatgtctag	ctggagaatt	gtatatgcac	caatcagcac	tctgtgtcta	4860
gcttggggtt	tgtggatgca	ccaatcagca	ctctgtatct	agctaatctg	gtggggactt	4920
ggagaacttt	tatgtctagc	taaaggattg	taaaagcacc	aatcagcact	ctgtgtctag	4980
ctcaaggttt	gtaaacacat	caatcagtgc	tctgtgtcta	gctaatctag	tggggacttg	5040
gagaactttt	atgtctagct	gaaggattgt	aaatgcacca	atcagcactc	tgtgtctagc	5100
tcaaggtttg	taaacacacc	agtcagcacc	ctgtgtctag	ctcaaggttt	gtaaacgcac	5160
aaatcagtgc	tctgtgtcta	gctcatctag	tggggacttt	tgtggtgatt	gtaaatgcac	5220
caatcagtgc	tctgtgtcta	gctaatctag	tggggacttg	gagaactttt	gtgtctagct	5280
aaaggtttgt	aaatgcacca	atcagcaccc	tgtcaaaacg	gaccaatcag	ctctctgtaa	5340
aatggaccaa	tcagcaggat	gtgggtgggg	ccagataagg	gaataaaagc	aggctgcccc	5400
agtcagcagt	ggcaacccac	tcaggtcccc	ttccacgctg	tggaagcttt	gttatttcgc	5460
tcttcacaat	aaatcttgct	gctgctcact	ctttgggtcc	accctgcctt	tatgagctgt	5520
aacactcact	gcgaaggtct	gcagcttcac	tcctaaagcc	agggagacca	cgaacccacc ··	5580
aggagggatg	aacaactccg	gacgggagga	acgaacaatt	ccagacgtgc	tgcctttaag	5640
agctgtaaca	ctcgccacca	acgtctgcag	cttcactcct	gaagtcagcg	agaccacgaa	5700
cccaccagaa	ggaagaaact	ccagacgcat	ctgaacatct	gaaggcacaa	actccggaca	5760
caccatcttt	aaaaactgta	acactcaccg	cgagggtctg	cagcttcatt	cttgaagtca	5820
gcgagaccaa	gaacccacta	attctggaca	cattgctagg	ctgtggaagt	tctgctggat	5880
aatatcctga	gagtgttttc	caacttggtt	ccattctccc	tgtcactttt	aggtacacca	5940
atcaaatgta	ggtttggtct	tttcacatag	tcccatattt	cttggaggct	ttgttcattc	6000
cttttcattc	tttttctct	aatcttgtct	tcacacttta	tttcattaag	ttaatcttca	6060
atgtctgata	tgctttcttc	tgcttgatca	attcggctat	tgatatttgt	gtatgattca	6120
caaagttctt	gctctgtgtt	tttcaggtcc	atcaggtcat	ttatgttctt	ctctaaactg	6180
attattctag	ttgtcaattc	ctctaacctt	ttttcaaggt	tcttagcttc	cttgcattgg	6240
gttagaacat	gcttttttag	ctcggaggag	tttattatga	cccaccttct	gaagcctact	6300
tctgtcaatt	tgtcaaactc	attctccatc	cagttttgtt	ctcttgctgg	ggagttgtga	6360
tcctttggag	aagaaaaggt	gttctggttt	ttggaagttt	cagcttttt	gccctggctt	6420
ttcctcatct	tcatggattt	atctattatt	ggtctttgat	gttggtgacc	ttcagatggg	6480

gtttttgtgt ggatgtcctt tttgttgatg ttgatgctat tcctttctgt ttgtttctt 6540 ctaacagtca ggcccctgtg ctgcaggtct gctggagttt gctggaggtc cactccagac 6600 6660 cctgtttgcc tgggtatcac cagcagaggc tgcagaacag caaatattgc tgcctgttcc ttcttctgga agcttcgttc cagaggggca cccaccacat gccagccgga gctctcctgt 6720 6780 atgaagtgtc tataaatccc tccttggagg tgtctcccag tcaggaggca tggtggtcag 6840 ggacccactt gaggaggcag tctgtccctt agcagagctc gagcattgtg ctgggagatc 6900 cattgctctc ttcagatcca gtaggcagga atgtttaagt ccgctgtatc tgcgcccaca gccaccctt cccccaagtg ctcggtccca ggtacatgga gttttatcta taagcccctg 6960 actggggctg ctgcctttct ttcagagatg ccctgctcag agaggaggaa tctaaagagg 7020 7080 cagtotggct acagcagctt taccgagctg gggtagggtc cgcccagttg aaacttccct 7140 gcagctttgt tgacactgtg aggggaaagc cacctactca accctcttaa tggtggacac ccttctgccc accaagctgg agcatcccag gtcgacttca aactgctgtg ctggcagtga 7200 7260 gaatttcaag ccagtggatc ttcgcttgct gagctccatg gaggtgggat ctgctgagct agactacttg gctccctggc ttcagccacc tttccagggg agtgaacggt tctgtctcgc 7320 7380 tagcattcca ggcgccactg gggtatgaaa aaaaaaaact cctgcagcta gcttggtgtc tgcccaaacg gctgcccagt tttgtgcttg aaacccaggg ccctggtggc ataggcaccc 7440 7500 gagggaattt cctggtctgc agattgcaaa gaccatgtga aaagcatagt atctgagcca 7560 gagtgcactg ttcctcacag cacagtccct cacagcttcc attggctagg ggtgggagtt 7620 ccctgaccgc ttgtacttcc cagctgaggt gacaccccac cctcctttgg cttgccctct 7680 gtagcctgca cccactgcct aaccagtctc aatgagatga gccaggtacc tcacttggaa 7740 atgcagaaat cacctgcctt ctgcattgat ctcgctggga gctgcagacc ggagctgttc ctatttggcc atcttgccag ccactccctt taattgttta ttattcattt gggttgaaaa 7800 7860 tataattact gaagttttca ataggagtta ttctataaag tacgttgtaa tctttcaata gaaatatgca ctaaatgttt tcttaacatt tggattaatt ttccttggat agtgatatac 7920 7980 ccattgaaac atttttggta aacaaattta gaaaacaatt ttaaaaggta gtaagacgat tgaaagctgt tattttcaaa aattgtaatc agtttctgac ttactgtgtt tgatgtggca 8040 8100 tatgcctttt ggttttctgt ttgttttgtt ttccataaca tgatatgaca gggtgttatt ctcactgttg attgcaggca agagtacaaa aaattattag aagttagctt gtgagcattt 8160 8220 aataaatgga attgttgaac tatagacaat gtctggggtt cactaaaaat gtatacctta 8280 ataagaatct tcttttgatt tgttaatgtt tagatgacag tcatgagaat gcaataaatg 8340 ccttgtgtct ggaggtcagc ggggtatctt tctaggcctt tcttgttttt atggtgtata

aaataaagtt	atgtgagctt	gatgaacact	ggaacaaaat	tccagggtct	acttctcgtt	8400
tgtcttattt	ttagattttt	ttttttcatt	atcaggtttt	gtgacttctt	atagagaatg	8460
agacaagtgt	cagtcaacct	gtgggagaaa	tcctgggcca	tgccttctct	attttcggtc	8520
ctctttctta	ctgtctttta	aaatattttt	agatttttat	tttgaaacaa	ttataaattc	8580
acaagaagtt	tcaaagatac	gtacatggag	gccttttgta	cccttcaacc	agtctctccc	8640
aatagtaaaa	tcttcaatac	actaccacat	tacactatca	aaactagaac	attgacagtg	8700
atgcaatcca	gagcttttta	agattcaaca	ctttcttt	gactattcta	ggcactttat	8760
atttccatag	gaatattata	attatcttgt	caatttctat	taaaaaggct	ttttagaatt	8820
ttgattagaa	tttagttgaa	tccacagatg	aaattggaaa	taactgccat	tttacaatat	8880
tgaatcttcc	aaccgaaaat	caaagtatag	atctcaattt	ttttcttatg	tcattaattt	8940
atcattgtaa	atttttgtag	ttttaagtgt	acaagtcatt	tacatctttg	gtcagattta	9000
tccctaagcc	tttaatattt	ttagtgatat	tttaaattgc	actgttctta	gtttcaactt	9060
tcagttgttg	aaattaactt	ccagtccacc	ctaggactac	cattggctaa	aacattgtct	9120
cttctaatat	agaaacttct	catatgtaac	tgctaatata	taaacataca	attgatttgt	9180
gtgttgatct	cttactttgc	aattttgcta	acctcaatta	atgtagaacc	atttttttag	9240
attgactttt	ctacatatac	tctcaggtag	tctttgacaa	aagatacttt	tacttctccc	9300
tttccaatct	gaatgcattt	ttttttcttt	tacactggac	acaatctcca	gtacaaagta	9360
taactgtgcc	catactggtg	cacatgtggg	tcttagattg	tagcatcctg	caggtaaata	9420
ctcagaacaa	cttccagcac	ttgaatatcc	actccttccc	ccacccacat	actggcagaa	9480
ttcatgttgg	gatactacat	ttactatgaa	catagacccc	tgatttgaaa	caagactaag	9540
atacatggta	aagaaagttt	attcaccaaa	gttttgacag	actgaaggcc	attatttcag	9600
attggaaata	ggaaacttaa	aggaactaca	tggacattgg	gtaaaagaac	atgggttgaa	9660
atttgcctgg	cagtagccta	aaagtaaatg	gtcttcaagg	tgcatgtgaa	ggaactttag	9720
gaggaaatga	gataattcac	atctccacca	ataattaaat	gtagccacac	tagcttggag	9780
ggatttgagg	tgagacatct	aaaatactaa	gtcatggtga	gggctggaag	acaaaagaat	9840
gaatgacttc	ataggaatga	ctgtggggaa	gggcttgaag	gaatcatcct	ctcacttcca	9900
tgtgaaccat	gaacattaaa	catggagaaa	tgagcagcag	cagattagtt	tgggatgcat	9960
cttcagggga	tgctgaaaca	acaacagcat	ttggtttcct	ctacacccct	gtcatccgtc	10020
ccccacaagc	ccagggagtg	gtcagcagtg	gtgctttgtg	atgtctaagc	caccctagga	10080
ctgccattgg	ctgggacact	gcctgtatga	tcaaacaaag	ctcaagagtg	tggctttgcc	10140
ttgccaccag	gaaggtatac	atagggaggg	ccagagctct	gggacatcct	cctggcaagc	10200

ttcaatatag	ctgtggaagt	ctgcagtcta	caagagccta	ctatagacat	tctacaacca	10260
agcagaatca	tggaacagcc	gacttcaagc	accaatgggg	agaagaggaa	gagcccctgt	10320
gaatccaata	acaaaaaaaa	tgatgaggta	agattgttag	gttttgaagg	gaaggtgagg	10380
gtgaaagaaa	gacacacaga	gaagggacgg	ctcaaacagc	aacacaggaa	tactgcagac	10440
acctgtggaa	gtgggggacc	tgcttaatgc	cagaacccac	cgccgcttac	aggctggggt	10500
gcttataggt	atgggtggga	ggggccgggg	cagtatggct	tgctgcccgg	caggatattg	10560
ataagatgtt	tttatgatca	ggctgtttgg	tcctttttcc	agtgggatgt	cattgtggtg	10620
tttcttggaa	ctttgcccag	caagatacca	taggaaagtt	tctttagttg	gacctgtgtc	10680
cgccttgtgt	tacgacgatt	aggcaagatt	tttctcatgg	cccgaacccc	cgtggaatgt	10740
ttcactttga	tcaaggtctg	caaaatagca	gggtgcttac	taaatggtgg	tttggactca	10800
cattcttgcc	ttctacttta	gtataaaagg	aagaggggca	ttgttgatta	tctggctgct	10860
tgctgccgaa	taggggagct	gtaatcaggg	tttgggtttt	gaagcagggg	gtgacggact	10920
tcagagttgt	tttcctggag	gcactggtac.	cggacttggc	agaggagaag	gatggtatca	10980
atgtgttgct	gggtggctgc	ctggagaggg	gagtttagcc	ttcgggagat	aaagcaggat	11040
atgaaggtga	gtatacatcg	gccaaatgta	ctatcaggag	gaggaagatt	aacggcccta	11100
agaaagggac	cacctgctat	cccägtgctg	agtgcatcag	agatgtttag	ttctgctaac	11160
actagaatga	gatgtacagc	ctgcttagtg	tgtgtggagg	aagatgagac	agaagctact	11220
aaaggaacct	ggatggtctg	cttgttaggc	aaagtgttaa	tgtttagatt	gaaacacaag	11280
ggtgcatgtt	cctgaccaat	tggccagtag	gcagagataa	gagtttgtgc	cgcaaaggaa	11340
gaagacacta	ggggtggaca	gacaaaagtt	gtaggttatg	gtggcaagtc	atgagaaggt	11400
gggggttgaa	ttctgcacaa	accctttgtt	ttaactttta	tgtttttcca	agttgaatac	11460
ctgccagcaa	gggtagcccc	tctgaaggcc	tgataggaaa	tgttggtagt	ggaggaggtg	11520
aaggctgttt	ggttttggag	agagagcagg	aaatgggttt	ttgtaactaa	tagccattgc	11580
ggtcctgaca	gcgcagaagg	atacaggttg	cagttgaggg	aattgtttgt	ggatattttc	11640
cagggagcgc	ccttgacttg	gatacatgga	gagcggctcc	ggcagaaagg	ggaggggttg.	11700
ataagaggta	ttttctggaa	tccgactggt	aacatgttta	gttaagaggc	tatgaggtga	11760
aggagggtga	cagccctgtg	tgtgacggtg	tgggtggatt	tgatggattg	gtggggggg	11820
aaaggtgatt	agccgagcaa	gattataagc	aggttttgcg	aatgaattgg	tcaattaggt	11880
gaaatgcagg	tttattttgg	acagggttca	tgtggccagg	ttaacaggaa	gggctgtgaa	11940
ctactggatt	tgtgtggaca	aacaaattta	acagttggaa	ggaagagggg	agtgtgactg	12000
atttaagagg	cagtgaggct	gatgaagggg	gctcatctgt	tagacgttcg	gggtggggac	12060

12120 ttagaatatc ccacagatag agaggacaaa aggagaaaga ggagatttga gtaggagtga 12180 aattttggaa ggtgccctga agtcatatct ccttgattag tgtgacaaat tggcctggac tattcagggt catggggaag ggaaaccagg aaagatctga aataaagtag gagacaaaag attggaaact ggagacagag agtgttatgg actaaggtgt tctggattgg caacttctgg 12300 aattettgtt aagtacagtg aggttggtet tgtcagggaa ggagaataat ttgggggtga 12360 12420 acaaatttct agatgtggat ctggtgctct ttttagtttg aaatgtgcat tcagtgtgca 12480 aaggatgtta getttggege tgtgggagta gttageatea eetggtgaga atteeteeae 12540 ttaggttgga gagcgggga ggaggagtct gtgattcaga cccagcccgc tggttgtagg 12600 gacagggagg agtgttttga ggatggactt ttaggctggg tcaagtaagc atttgcgtac 12660 tgtcttatta gatgttgggt gaggtgtaac gccggccaag tattccatat agaatggggg gaaaatacag ggagattctg gaggataaat ggagcatttg tacatgaatt taaatgggct 12720 12780 taggctgagc gcttttagga aatgactcat aatcgcatga ggaacaatgg gagaagtgaa gtccaggcca ttttaacctt taaggagagt ttggttagtt gttgtttttt ataaaatttt 12840 12900 tcctgaagat tcggagtggt aaggaatatg gaaagcccat ttaatgttta gagcctttac cagctgttgg ttaaactgaa acaaattggc ccattgtctg actggatgca agaggggagt 12960 ttaaaccggt ggataatatg ggtggagaga atagaagcga tggtgtgtgc ctttttggtg 13020 gtggtaggaa aagcttttat tcatccagag aatgtatcta ctattgttag aatgtatagg 13080 13140 aatcactttc tggggagcat gtgagtgatg ttgatttgct agtcctgccc tagtaagtgt cctcaggtct ggtgtgtggg aaaggagatg gtttgatagc ttcctgaggg gaagtttgag 13200 13260 tgcaaaggga acatgcctta gtaatatctc tgagatgggc aaccatggtg gaagaatgtc tagaagtttt taaaagctgg agtaggggca gtaaccggca tggaaatggt tgtgcacata 13320 tgaaagtaca gaaggttttt taaacttggg caagacactt tatcagtgag atcgaactat 13380 tttttcctga atggcaccag cctgggcaag tgggtttttt tcctgctggg tatatacagg 13440 gtgtatgctg ggaaaaaaaa tgagcaataa cgatggggtt ttaagggctg cctgccaggc 13500 tgccgaattt gttgaaaggt ttttctcggt tttggcatct gtagcctttc ggtgtccctt 13560 13620 gcaatggata atggtggcct ttggtggtgg tttatccacc cccaacagct tatgtgtaag tttgccattt cttatggggg ttccttttgt agttaggaaa ccctgttcct gccagatgaa 13680 13740 ggcatgagac tgtaggacat ggtatgcata tttggaatgg gtgtaaatgt tgaccctctt tecetttget agggtgaggg ceetggttag ggcaactage tttgeetgtt gagaggtage 13800 13860 atggggtgtg agagcattcg attctaggag tttatcttca gcactgatgg aatagccagc tgctggacat ggctgcctaa aagaggttcc attaactaac cgtgtatgtg ttccctgcaa 13920

aggggcatct gaaatgtgtt ggaaggggga ggagagggag tctaagaggt ccagacagga gtgagagagc ttagagtcgg aagtgtttac agggagaagg gtggctgggt agagaatttt 14040 atgtctctgg aaggtgatta gagggttacc tatgaataag gcatgcacct gctgtaagca 14100 ggatggtggg agggatagaa gggattggtg gtttatgagg tcctgtagat aatgggaaga 14160 tgcaatagta atgtgttggt agagagggag tttccgtgca tctaaggcca gcaatgtggc 14220 catacccaag atttttagtc agagtgacca gcctcggatg acagagtcca gttgttttga 14280 gaggcgtgca atggcttctg gggcgttgcc atatgtttgg cagagtagtc caagggcaag gcgctggtca gaatgtacat agaaagtaac aggcttggtg aggtttggca gtcccagtgc 14400 cagggccatt aaaagggcat ttttaagttt ttaagttgga gttgatgggg caagctgggt 14460 tcaggggttt taggatgggc ccatgtgagg ctacgtatag tggcttggcc agcaagtcaa 14520 agttaggaat tcacagccag aagtatccca caaggcccaa gaaggagggg aggtcctttt 14580 tttttatgtg gggaaggggc atgtcccaaa ctggctcctt tcattgggtt gggatggctc 14640 gagaattagg ggttaggaca aacccaaggt aagtaacttt gatttgggta cctgagattt 14700 tgtgggttag gcccaatata cttgattatg aaggaagttt aaaacctgag tggtgtgttg 14760 aatggacagg ttaagaaagg ggctacagag aaggaggtca ttgacatatt ggaggagggt 14820 actaggagca aggggaagtt cagctaggtc cttgatgagg gcctgtctga acaggtgggg 14880 cctatcccgg aacccctcta agagtacagt ctaggtgtaa gtccatgtgt aagtcctgta 14940 agagtacagg acatgtgagt attaggattt gaccaagtca aagcaaaaag actttggtaa 15000 gccagattta agggaatagt gaaatagttg tcttttagtt caatacaaag gagtgtgtgg 15060 tagatggggc aatacggtag agtagagtat attggttgag gaccactaga tggattggta 15120 ccacggcctg gttaacgact tggagatcct agacaaaggg gtaagtcccg tctgtctttt 15180 ggaaagccag aataggggtg ttgtggggag agttaacagg cttgagaata tgagcttgta 15240 aaagtttaca gataataggt ttgagacccc ctaagcaagg ctggattaag gggatattga 15300 gactgatgaa ggaaaatgga ggggttttga agggttattt taactgggat gtgatgtgtg 15360 gctattgtgg gtttagaaac attccaagct ttagaattaa cagaaggtaa cagggtggat aatgaggatg agtgggggga gagggaagcg tttgggtgtc agagtaaaat aaaaggggta 15480 gaattgtagg agccacattg catggagttc tggaatttac ttaatatgtc ccatcccaag 15540 ataggggtag gggactgagg gataaccagg aaagagtggg tgaagggggc tgctgaatag 15600 gttgtataat aaaggaccag tctgtttgtg cctagagggg attctattga ttctcacaat 15660 agagatggaa gaactgaaaa aggttctaga atattctggt caaactgagt aactagttgt 15720 cctattgagt atccaatagg aaagacatgg gcttactaga gactgacaga attaccctgg 15780

gttccgaggt ggtgatggca gtaggggcgg tggactccag gccccacctg tcttcaggta 15840 caggtggtga agcaggatga agagtttcag tgagcacagt ctgacttcca gtgttgcttg 15900 15960 tgtccctgtt agacgaactt gtaacaggct cctggagttg actgttgcca agttgaggaa 16020 ttctgtaggc cttgggaacc ctgttgagtg gcagctacca gcatttggta tttagcctgg tccttcttta ggtttggatt ttttagttct tcctctctaa tcttatagat cttgaaggcc actttgatta agtctctttg gaaggtttga gggccaccct ccagtttttt aagttttttt 16200 caaatgtctg ggtctgactg ggagataaag tataaatgga ggtagttttt gcccttattg 16260 gtattagggc ttaaggtggc atatttagtt gtgacttttg aaaggcagga gaggaaacga 16320 16380 gcagggacag ctttatttat gccagctaga aggcatgata tcatatggcc tgatttctgt 16440 ctgtctactg aagttgcctg ataattccaa ctggggccag ttctggggac agctagggtc 16500 cctattggat tatgagcagc atcttgttgg tggagggtgt tctcatggac ctgggcaccc 16560 ataaagatgt gttccctgtc ctccagggtg agggtagagg agaggatgac atatatgtca tgccaggtaa ggtcataaga tttagggaag tacaagaatt ccttgtggaa ggaggttgga 16620 16680 tccattgaaa aggagtcaag tctcctttca atatgggaaa actcagctag agagaaggga acttgaattc agattatgcc tttagccctc gcaacctcct gcaagggaag gactttggaa 16740 16800 ggcctttggg catgtgcctg gttcctagcg aaagggggtt gggtgtgaga cctggtttga 16860 ggtggagaag gaagggggat ggagggcgac agtaaggggg tggaggagcc ggatccgaag 16920 gagaaggtgg aggggaatggg agagggcagg aggctgaaga acgggtgtgt tggccaggtt gaaattcaga ggaagaagac ttgtccggag gaagaggcat tttgggggggt ttctccttga 16980 17040 ggaggaagat ttgaaaaggt gaacaagatt ggcagagaga gagagagaga gagagagagt 17100 gaggcatgaa aggagataag caaagcactt cagattattt accattgcat tgaagaaagt 17160 tttttagatt atgttgaatt tggaagttga atgttttgtt ttttggaaga ggggagtgaa tactctggat gggagtgact acccctgagg aaagtgagta ccctggaagg gagtgagtac 17220 17280 cccaggggtg agcgagtact ccagagagaa gtgaataccc catagggaag tgagtacttg attectectg ggagaaggga cetggagagt tggggcagee cegtactatt catgetecec 17340 agaggccaga gcagccagag tggcaaacgt tttgaaggtg taccctaaga agggaggctg 17400 1.7460 cagtcacctg gtgactgggg agacctctca cccagcactg gaattttttg gagaacgggc agaaatagag aggaatctgg aaaggaggaa gagggagact cacccactaa ttgaagccca 17520 17580 gtgttggatg tgatgtccag aaatgggggt gatccttgtt gcagctgccc ggaaacagga aggaacaaaa aataaggtgg cttgtttgat cactatctgg aggttagccc aggtctggag 17640

aagactagag	aataaggaga	atgggactgg	gaacagggag	tacactcagg	atctggaagc	17700
aggccctggt	ctagtttgtg	ctgcttgctg	ctttccaggt	tgcaagagaa	aacttaccca	17760
ttagaaccca	atcaccactc	caggttttgg	caccaaaatg	ttaggttttg	aagggaaggc	17820
aaggatgaaa	gaaagacaca	cagggggcag	ctcaaacagc	aacacaggaa	tatggcagac	17880
acctatggaa	gtggaggaca	agcttaatgc	cagagcccac	cgccgcttac	aggctggggt	17940
acttacaggg	atgggcagga	gggatctggg	caatgtggga	tgctatccgg	caggatattg	18000
ataagatgtt	cttatgatca	ggtggtttgg	cccttttcc	agtggaatat	cattgtggcg	18060
ttccttagaa	ctttgccaag	caagatatga	taggaatgtt	tctttagttg	ggcctttgtc	18120
cgccctgtgg	tcaggtggtt	aggcaggatg	tttctcacgg	cctgagcccc	catggagtgt	18180
ctcactttga	ccaaggtctg	caaaatagca	aagaacttgc	gaaatcgtgc	agtttggact	18240
aacagatgac	cctacccatg	ctcctcttct	tcttccccat	agatcactac	cctatgattc	18300
caccttgttc	ttctctggca	cacacccctt	cctcaacctg	cattccttct	cataaagccc	18360
cccttgctat	ccagtctcta	ccctattcac	ccaaaataat	gactttctgg	cctctccctg	18420
ttttcttatc	agatgcagga	ggcaccgaac	agggtcttag	ccccaaaca	gagcttgcaa	18480
aagacaaaaa	caatagaata	tctaacaata	atagtgtatt	actacaggaa	gcatacgaaa	18540
ataaattcaa	atcaactgga	gaaggaccag	tcccgagaga	actccatcaa	tcccgtccaa	18600
gaggaggagg	acgaaggcct	agactcagct	gaaggatctt	cacaggagga	cgaagacctg	18660
gactcatctg	aaggatcttc	acaggaggac	gaagacctgg	actcatctga	aggatcttca	18720
caggaggacg	aagacctgga	ctcatctgaa	ggatcttcac	aggaggacga	agacctggac	18780
.tcatctgaag	gatcttcaca	ggaggacgaa	gacctggacc	cacctgaagg	atcttcacag	18840
gaggacgaag	acctagactc	atctgaagga	tcttcacagg	agggtgggga	ggactagtca	18900
aacatggaga	aaccaaattg	gacaaatcct	cactaccaat	ggcgatgatt	acaataaaat	18960
caagtttgag	gagctgatga	ccgtgtatat	ctctgcctgt	tgtctgatgg	tgggaaggaa	19020
gggaagggaa	gaggtaggca	tttgagaagg	gaaggatatg	agatcctgta	gggttggcgg	19080
acagacccac	aggttgacag	tttcccagac	attgtaaata	aggeetgggg	gaggacttat	19140
tcctagagac	aaattttctt	cttaaaattt	tatctaacag	gagaggaaga	aaaggacttg	19200
gtgtttggag	catgtgaata	tgtagaaggg	catttaaaaa	gatctgtatt	ggccgggcac	19260
ggtggctcat	gcctataatc	ccagcacttt	gggaggccga	agcagacgat	ctcctgaggt	19320
caggagttcg	agaccagcct	gtccaacatg	gcaaacccca	gtctctacta	aaaaaaaaa	19380
atacaaaaat	tagctgggag	tggtggcagg	tgcctgtaat	cccagctaca	tgcgaggctg	19440
aggcaggaga	atcacttgaa	cacaggaggc	ggaagttgta	gtgagctgag	atctggccac	19500

tgcactccag	tctgggggat	agagcgagac	tctgtcttca	aaaataaata	aataaaataa	19560
aatacaaaga	tctgtattgt	atgtaggtga	cagtgacact	ctttccaaaa	tgaagacatc	19620
aaaatcacca	cctccaggcc	acatacctca	tagtgatttg	ggttgcaact	caaccaatac	19680
tgtaagcaac	tgaagcccct	caaatggaca	aaaaacctca	ccctacatag	agtaagacag	19740
catgtcacac	acaccaaaat	aatggtgttt	ggaggccatg	gtcccaatac	tagggcattt	19800
ccttgttaag	aaactagtgg	ccattgtcta	ctgcaggcaa	taaatgaaag	catagtctac	19860
agagaatttg	aatataatga	tacaagtaaa	agttggtatt	tttattacca	cttccataca	19920
ccagcatttc	tatagaatgt	caatgattaa	gaattcttcc	cttgaaaaaa	atattgcttt	19980
tattgaaggg	aatacaatag	agtggtttgg	catcaatgta	gagggctgag	ttatatattc	20040
tttgagttaa	ttgctcaaga	ccctctccta	tttatttact	cattcactct	cctttatttc	20100
catgacccag	ttttatttct	cttgtctaca	ttggcaatca	ttgtaatgcg	tttgatgtgt	20160
attcttttct	ctgtatgagt	gttattacat	gttttttatt	gtttgtggac	atttgttttc	20220
aatttatgta	gccattgtca	atatttaatg	tttcactcag	acctgttttt	aagatgcatc	20280
tatttatata	taatctgttc	ttcccttgta	aatggatata	tcgggtacat	ttttgtattt	20340
tgtaactttt	agaaagatat	tttgatattt	aatatctgta	cccaccttct	ggtccatgtt	20400
ttgtttaatt	tatacctagt	attatatttt	ctttcaagtg	actgtaaata	gtatcatgtg	20460
tttaattttg	atttccacat	gttcaatgtt	agtatataga	agtgtgatgg	atttttatt	20520
tctattttaa	agaaatttta	ttgtgtatat	ttgaggttta	caacatgata	ttatgggata	20580
cataaagtaa	aatggttact	atggtgaagc	agattagcat	acctctcttc	ttagttttta	20640
agtgtgtgac	aatagcagct	aaaatctact	tatttaacaa	aaattcatga	tgcaatttca	20700
tcagctttag	tcccctgta	cattagatct	ctatacttgt	tcatccgtat	tgtggcaaat	20760
gccaagatct	cttttcttta	agtctgaata	atatttagtt	ctgtacaact	ataaataact	20820
acacacacac	acacacacac	acacacacac	acacacacac	acacaccaca	ttttaaaatc	20880
cattcatcca	ttgatgggca	tttaagttgt	ttccatatct	tggctattgt	gaataatgct	20940
gtaatgaacg	tgagagtgca	tgtatctaca	tgaggccgtg	atttcatctc	ctttgggtat	21000
ctacccagaa	gaaggattgc	tgggtcatat	ggtagttacg	ttttaatttc	tttagaaacc	21060
tccacactgt	ttcacataat	ggttatacca	atctacattt	ccaccaagag	tgtactaggt	21120
ttgtttttc	ttcacactct	catcaaaatt	tgttatgcat	tgtttaattg	ataatagcca	21180
tcttaacaag	tgtgaagtga	tattctggtt	ttagtaggca	tttctctttt	gattaatgat	21240
gttgaacatc	ttttagtgtt	atctgttagc	atgccactgt	aagaaataat	atgaagagat	21300
accatactgt	atcttttact	caatttcctc	caattataag	atcttgcaaa	agtatagtac	21360

gtcacaacca	gaaaactggc	attagtatag	tccatctgtt	cagatcacca	attttacatg	21420
tgctcatttg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtttagt	tatattcagt	21480
tttatcatat	gcctacattt	aagggacaac	caccataata	atacagaaga	gtttcatcaa	21540
cacaaggatc	tctcattttt	cctgtaatag	ccacacccaa	ctttcctctc	aagttcataa	21600
tccctagtga	ccactattct	cagcctatac	aattttgtta	ttttgagaat	cttatagaaa	21660
tggaatgatt	tgaacttgag	aaatatgatt	taggatatct	ggtaggggaa	atttctaaag	21720
atttctgaag	attatgcata	ttcagttata	tgcattcaca	aagagatggt	ttgctactgg	21780
aacatacatt	tgaaagggaa	gcagagcata	aaagtttgaa	aaattagcag	cccgatgatg	21840
tgataaaaga	gaaaacatca	ttttctgggg	aggaatttag	cacactacag	aaatttgcat	21900
aagtaatgag	gagccaaatg	ttaatcacca	agataatggg	caaaatgtct	tcagggcatg	21960
tcagagatct	tggctgccgt	ccctcccata	acaggccagg	aagcctagga	gaaaaaatgg	22020
tttctctggg	cccagggccc	ccgctgctct	ctgcagcctc	tggacatggc	accctgcatt	22080
ccagctgctt	cagcgccagt	cgtggctaaa	agggtggctt	ccatatgttg	ttgggcctgc	22140
agtgaacaaa	agtcaagaat	tgaggtttgg	gaacctccgc	ctagatttta	gaggatgtat	22200
gaaaatgccc	ggatgtccag	ccagaagtcg	gctgccttct	ttataaaatt	acaaaatttc	22260
tgaggccttg	ccagccatgc	agaactgtgt	gtcaataaaa	cctcctttgt	ttataaatta	22320
cacaggctca	ggtagtatct	ttatagccgt	gtgaaaacac	actaatacaa	atacttaact	22380
gggaacctag	ttcaggtgag	ttgggatata	gtgagaaaac	ataaaactac	tcaaagcata	22440
aaataactag	aattagatct	ttttcctgga	tgtatagctc	tatttttatc	atttggatta	22500
ccctttggcc	atctcacttt	actgtagtat	gctatgcatt	cctagcaaga	gatcatgtat	22560
agctacttac	aaaagagata	acttaagcat	acatatccat	gattaaaatt	gtaactaaat	22620
tcattatgaa	atacatgaga	gggaatctaa	atattgctat	tgctggatta	aacaggcaat	22680
gcatattctt	aataaacgta	actgtgttct	ttgatctgta	tcttagagtc	tgtaaaatat	22740
attaatactt	ctaccttaaa	aataatgcat	tgttttgtgt	agtcatatag	cactggatga	22800
gtgtcaactg	cgaacacact	ttcagaaata	ccaaaatctc	tcacctggct	ttctagaata	22860
ttcataatca	ccctccattt	tctttcttga	tctttctacc	aggttctttc	cattgctccc	22920
gtaaagtaaa	aagttttaaa	gactttcatg	gagtacagac	ttctcctatg	ctccatttct	22980
ttgacctcca	gctcacccca	acacagctta	cagaaacatt	ataagaggga	gaagaagcat	23040
agtgcattgc	agttaatggc	atgcactttg	gaaccactgt	ctagtttgtg	atttggggca	23100
agtaatatag	ccctgtatat	gcttcacttt	ccccacctca	tagagttato	: aggataatta	23160
aattaaatta	atgataactt	ttttgtaaag	cacttagaac	aatttcaggo	: acataacagg	23220

tattacacag	aaagttttaa	aatcaacaaa	taagtctctc	taggcttagc	acagacattg	23280
ccacctccaa	gaatctttgc	ataattttgc	tctcacaaaa	ccaggttaca	tgccccttcc	23340
ccttaaattc	ctcctccgtg	tgctctggct	tctcgttata	ttcatcacac	tataacgtag	23400
ttgtcaattg	ttcttaggat	ttccccattg	gagtgataga	cagggaagat	gttctacagc	23460
tgataaatgg	aagtttcctt	atggcaggaa	ttttatcttt	tttccatcta	tcagatcccc	23520
agtgcctagg	atagtatcaa	gtacagacac	atgtaactaa	aaattttgtt	gaatgaattg	23580
tctaaatttt	tcatctgcta	agattcttac	tccttttata	cgctcaccta	ttatagtact	23640
tcacattata	gatacacaat	aataataata	ttaatagtaa	ttaatcaata	tatacctgtc	23700
atgaactgcc	ttggtctgtt	ttgtgctgat	acaactgaat	atctaagact	gtgtaattta	23760
taaatacaaa	aatgtttctc	ccacagttct	ggaggctagg	aagttcaaga	gcaggtcatg	23820
aggatgtgat	gaaggtcttc	ttgctctacc	ctcacatggt	ggaagtgaaa	ttttctgatg	23880
acataatctt	acataattac	aaatttgctg	atgacataat	gttacataaa	aaaaacctag	23940
agactttacc	ggaaaactgt	tagaattaat	aagtgaattg	cgaaaagttg	caggatacaa	24000
aatcaacatt	aaaaattagt	agcatttcta	tgtattagta	acaaataatc	tgaaaagaaa	24060
attatgaaaa	caatatgatt	tagggtagta	acaaaaaatt	aaatacctag	gtataaactc	.24120
cactaaagag	gtaaaatacc	tgggtactga	aaactgtàaa	acactgataa	aagaaattta	24180
aaagacacaa	ataaatggaa	agattttccc	tgttcataaa	tactatgaaa	atgtccatat	24240
tactcaaagc	aatctaaagt	cttattgaaa	tctgtatcaa	aattccaatg	ctgtttgtaa	24300
catgaatgaa	aaagaaatgt	tatgaaattt	tttgggtatt	ccttttctgg	ttggaatcct	24360
ctgtggccag	gggtgcctat	gctcaagttc	ttgtcctgtg	tccaggaaga	atgaggtatg	24420
cacacaagta	gaaggtgagc	aagatgaaga	ggagctttat	tctgtgttag	aacagctcag	24480
agaagacctg	cagtgagtag	ctcctctctg	taggcaggtc	atcctgtcat	ctctgcagct	24540
ctcagcagag	tgggggcctg	aagtgaatgg	atcctctcgg	ccagcagggc	atcttgaaga	24600
gtgttcagct	ctcagcagag	aggaggcgct	ggagagggta	gcacttcttg	gcaactgact	24660
gtcccagtgt	ctgctgctcc	cagcagagaa	gaggccttgg	agagggtgct	cctctccgca	24720
agcatgccat	cccaacatct	gcagcaatta	gcagagagaa	aaccctggag	agggtagctc	24780
ttctctccag	ctggtcacct	tcatgtctgc	tctgccttgg	ctaagtctgg	ggtttttatg	24840
gtcttcagag	ggagaaagtg	catgctgatt	ggttcatgga	caaccatggg	cgggcctggg	24900
aaaaagcacc	accagttccc	tctctggtct	acagtactgg	cagaggagcc	cacaggcttc	24960
aggactttct	ggcctgaagg	tggggcttca	ccggggacct	gccgtcttct	gcccagagtc	25020
tgtctgcctc	ccactgccat	tcatggtgcc	cagactgtgc	caactggcac	ctgcaggcca	25080

acactgtgct gcccactccc cagctgcctc ggcttccctc ctatatacat cagtgcccaa 25140 aattcagagg gggccaaggt ggcaggggcc tagtgtcagc actgcctcaa gcgtgctctc 25200 acccagctgg gctgcagtag caccagagct cagccccaac tttgttccaa gatcagagtg 25260 ggctctggta gtggggagag gccaagcaac aggaacaggc acttctgagc ctcgagaggt 25320 acggggacct acccaggtcc ccaagagtac agagaatcct gggtctgcag ccagatttgg 25380 atggctacag ctgcatccag ggacctccca ccaatacaac ttgaaagggg tggggctccc 25440 acttgtaccc agctcctgca ggctctgtgg agtgtgcatc ctcagccata cctctgttat 25500 tggagcaggt gtcagcaacg gggagaagcc aggcagcggg agaaggcact tctgagtgtg 25560 aggggtagga gaccatccca ggaccccaat agcacaaaga cacccaaatc tagagctgca 25620 gtgaagctcc tgcctgctct gtggaggagg aggccccagc tccatgggga cagggctcct 25680 gcctgcttaa tggagtgtat agctctggct gcacctccct gctgcagtgg catcttggca 25740 atggccactc tagatgggcc actgctaccg tcaaaaatac ttcaattact atggaaccac 25800 aagagactct acatagccaa aacaatcttg ggcaaaaaga acaatgccaa aggcaacaca 25860 ctccctgatt ttaatatata ttacaaacct acaataaaca atgcagcatg gtactggcac 25920 aaagacagac agacagacag atagacagac aaatggaaca aaatagaaaa cccccaaaat 25980 aaactaaact atttatggtc aactgatttt gacaaaggta ccaggaacat acaatgggga 26040 26100 aagaagagcc tcttcaataa atggtactga gaaaactgga tatacacatg cagtgtaatg aaattagacc cttttctcac accatatata aaattaaata aaaaatgaat tgaagacttt ttaaacatat aaattcaggg gtgtatttgc agactgtgca tgtttgttac atagtaaaca 26220 tttgtgatag gggatagtta tacagattat tttatcaccc aggtattaag tctagtatcc 26280 26340 attagttagt tagctttcct gatcctttcc cttctcttat cttccatgcc ccggtagacc 26400 ccagtgttct ttgttcccct ctatgtgtcc atgtattctc atcatttagc tcctacttac aggtgagaac atgctgtatt tggtttactg ttcctgcttt agtttgctaa gagtaattgc ctccagctct atccatgtcc ctgaaaagta catgatcaaa gacataaaga cagaaatacc 26520 26580 attcaatcca gcaatcttat tattgggtat acacccaaag caatataaat cactctatta 26640 taaagataca aatgtgcatg ttcattgcaa cactattcac aatatcaaag acatggaatc aatgtaaata cccatcaatg atacactgaa taaagaaagt acatacacac catgaaatac 26700 tatgcagcca taaaaaataa atacttaaat agaatacctg aaactctaaa actgcttctt 26760 aaaaagcgta aagaaatagc tctggccggg gatggtggct catgtctgta atcccagcac 26820 26880 ttttcgaggc tgaggcaggt gtatcgcctg aggtcaggag ttcaagacca gcctggccaa cgggatgaaa ccccgtctct actaaaaaca caaaaaatta gctgggcttg gtggcgggtg 26940

cctgtaatct caqctacttq qqaqqctqaq qcaqqaqaac tgcttgaacc caggaggcgg 27000 aggttacagt gagccaagat cgtgccattg cactccagcc tgggcaataa gagtgaaact 27060 ctgtctcagg ggggaaaaa aagacatagc tccatgacct tgctcttagc catgattgtt 27120 tggatataat cctgaaaaca agcaatgaaa acaaaagtag accaatagaa tggcatcaaa 27180 ctgaaatgct tctgcacagc aaaaagacaa ttaaccaaat ggaaggacaa cccacagaat 27240 gggagaaata tttgcagacc atacatctga taaggggtta atacccaaaa tatatatgaa 27300 actcaaaaaa ctcaatagta agaaaacaaa taatgtcatt aaaaagtggg caaagaacct 27360 aaacggatat tttgtaaaag acatacaaat ggaaaatcag cacattaaaa tacatagaat 27420 taccaatcat tagggaaatg caaattacaa ctaaagtgaa atatctcttc acactgttac 27480 aacggcttta atacaaaaga tgaaagataa catgttttgg aaagaatgca gagaaaaggg 27540 aactcataca ctgttggtgg attgtaaatt agtacactca gtatggaaaa cggtattgaa 27600 gttcctctaa cacctaaaaa tagaactacc ctatgaccca gttcttccac ttctggatat 27660 gtactcaaag aaacggaaag caatacatca cagtaatatc tgcactccca tgtccagtgc 27720 agcattattc gcagtagtca agatatggaa acaacctaag tgtacatcaa tggatgaatg 27780 aataaagaaa atgtgatata catacacaac aaaatactat tcagccttaa aacaggaggg 27840 aattactttt tatttgtata tatttaggat gcagttttgt tgcatggatg tattgaatag 27900 27960 tggtgaagtc tgggctttta gtgtagccat cacttgagta gcgtacgtgg tatccattac 28020 acaattactc atccatcacc cctgtattag gccattcttg cattgccata aaaaatgcct gagactgggt aacttataag aaaataggtt taattggctg acggttctgc aggctgaaca 28080 gtaagcatag tgtcaacatc tgcttctagg gacatgtcag gaaactttca atcatgacag 28140 aaggtgaagg gtgagcagct ttctcatata gtgagagcaa gagcaagaga gagtgcaggg 28200 agtgtaccac acattaaaac agccatatct catgagtact cacteggtat tgcaatggca 28260 acatcaaacc ataagtaatc tgctcccatg atccaaaccc ctcccaccag gcccgatatt 28320 caacattggg gataacattt catcatgaga ttggggtggg aacatatgtc caaactatat 28380 cattetgece eggecectee caaatgteac atcettetta cattgeaaaa cataattatg 28440 acttttcaac tttcccccaa attttaactc attctctcat taactccaaa gtccaaagtt 28500 28560 tcattggaga tgagacaaat ttcttccacc tataagccgg taaaatcaaa acaagttatt tacttccaag atagaatgga ggtgctggca ttgggtaacc actgacattc ccaaagggat 28620 aaatcaacct aaagaaagag actagagaca ctatgacaat tcaaaaccca ttaaatctta 28680 cagctccaaa ataatccttg agtccatgtc tcacacccag ggcatactac tgcaaggggc 28740 tggctcccaa agtcttaggc agctccgttt cagcccctgt gtatctgcag agtacagccc 28800

ccaaggetee tettatggge tggageagag tggetgtgge ttttccagge ccaaggtgea agctgctagt ggatctaccc attctagagt ctgaaggatg gtagttttct tctcacagct ccactaggea gttctccagc ggagactcta tgtggggcct ccaaccccac atttcccctc 28980 cacactetee tggtagaagt tetetgtgag ggetetacee etgcageage gettteecag gacacccagg ctttttcata catcctctga aatctagaag gaggcgacca agcctcattc 29100 actettgeae teggtgeace tgeaggetta geaceatgtg gaagacacaa aagettatgg 29160 ttcgcaccct ctgaagcagt ggcctgagaa gtacctgggc ccctttgagc gaagactaaa 29220 gccagagtgg ctggaatgtg ggaagcagtg tcctaaggct atacagggca gtgttaccct 29280 aggtctggtc cctgaaacca ttttttcctc ctaggcctca gggcctgtga tgggagggga 29340 tgctgcaaag gtctctgaaa tgacttctag gcctttttcc cattttgttg ggtattagca 29400 cttggctccc ttttagttat gtgaattcct ctagcaagtg gttgctccac aaagtgatta 29460 aatteetete etaaataaae tttttettte teeaacatgt ggacaggetg caaattttee 29520 aaacttttat getetgettt ettttaaaat ataageteea aetttaaete atteetttge 29580 ttccacatgt gagttaggtc attcaaagca gccaggccac atcttgaatg cattgctgct 29640 tagaaatttc ttctgtcaga tatcttaaat catcactccg atgttcaaac ttccacatat 29700 29760 ccatacagca tgaacagaaa gcaggtaagc tctttgctaa ggcataatat gtgtcacttt tgctccaatt cccaatgaat tcctcattta catctgagac ctcatcagcc tggacttcac 29820 tgtccatatc aatatcagaa ttttggtcac aaccatttaa ccagtgtcta tgaaattcca 29880 aactttcttc tgagacctcc aaactcttcc aacttctgcc tgttacctag ttccaaggcc 29940 actttcacat tttcaggtac ctttatagcc tcacccatct cctcagtata agttttccat 30000 30060 atttggccat tettgcattg ccataaagaa atacetgaga etatatagtt tataagaaaa ttagtttaat tggccgatgt ttctacaggt tgtacaggaa gcattgtgtt ggcatctgct 30180 tctcaagagg tctcagcaag ctttctttca tggtggaagg caaaggggga gcaggcatct catgtgttgg gagcaggagc aagacagagt gggatggaag atgccccaca cttaaacaac 30240 30300 cagateteat gagtacteae teactattge aaggacagtg teaagceata agaggtetgt 30360 cctcatgacc aaacacatct caacaggcca cacctcaaac actagtgatt acatttcaac 30420 atgagatttg gtcaggaaca aatatccaaa ctgtatcaac atccctccca ccatcccacc cttccaagtc tttgatgttt attatttcac tctctatgtc catgtgcaca cattatttag 30480 ctactattta tgaattagat gatacggtat ctgactttct gtttctgagt tatttcattt 30540 aagagaaagg cttctagttt catccatgtt gttgtaaaag acatgatttc attatttttt 30600 atggctgaat agtattccaa ggtatacata caccacattt tctttattca attatccact 30660

gatggacact taggttgatt caatatgtta tcatgaatac tgctgcaata aaccgatgag 30720 tgcaggtatc tttttaaata atgatttatt ttcctttggg taggtacccc atagtgaaat 30780 cactgaatca aatgggtagt ccaattatga gttcattgaa aagtctccat actgttttcc 30840 acagagettg tgccaattca cagtccaatg aacagtgtat aagcattccc ttttcccac 30900 gatctcacca acatctgcta ttttttgact tttcaataat aaccactctg actggtgtaa 30960 gagcatattt cattgtggtt ttaatttgca tttctctgat gattaacgat ggtaagcctt 31020 ttttctgtaa tttgtgacaa catggatgaa tatagtgggc attacagtaa gtgaaataat 31080 ccaggcacgg aaatataaat atcacatgat ctcacttcta tgtgaaatct aataaatttg 31140 tactcacaga aatagagtgt ggaacaatgg ttatcagagg cttgggaggg cttcaggagg 31200 gaaagaatgg ggagtttttg accaatgagt acaaagtttc aggtagacgg gaggaaaagg 31260 ttttgaaatc tattgcacag cactgtgatt atagtcaata ataatgtatt atatatttga 31320 aaaataacaa agtaaacata aaatatctca ccataaaaat aataggtaag agatgtgatg 31380 ggtgtgctag cttgtttaat catgacacat tgtatacata tatcaaacat cacattgtgc 31440 cccctagatg catatattaa taattatgat ttgccagtta aacataatat taataatatt 31500 tttaaaagtc aaaacaatag tgataggaac tagttttcag tgttgtcaca gtccagtagg 31560 ggaatagcag gaaattaaca gacatgaagg aaatttgggg gctgatgaaa atattctcta 31620 tcataactgt ggtggctaca tgatatttgt caaaggtcat caaattatat acaccaacaa 31680 taggtgaatt ttactgaagg taaactatgc cttaataagc ctgactttta ggaaagaaat 31740 aatccagaac aaagagtaag gaaagtaaag attggactct aaatggataa acttttatgg 31800 gatgtagaga tagcagaaag gagtctggaa gaataccctg gactgtggtt taggtagtca 31860 31920 cagtaacttc ttatgtagtg ccattgattc ctggtaaaaa acattttaga agcagttgac agggccgaca gaatggtcag atagagtcat agtatctgag aagcacaggg aaaatgtttg 31980 caatttgact ctggcggtta tgtgtggcca ccaaacgatt cccagtacac tctcagtatt 32040 atacactttt aattatttta actaaggaca tgtagtaaat atgtaacata atctaacgtt 32100 tatacattcg cataatcatc ttacaataca tgatttaatc atcttacaac tgataattgg 32160 32220 atcatcttac aatcatcttc aattagcttt gaagtatatc ttaccttaac aaatgaataa attgaggcta ttaaatatta aataactttt ggatggctat acagagacta agtgctgaag 32280 32340 ccatatgtat ttgacacctc cgcttgagct ccttctacct tgcccttgag tgttcacacg aggctaagag aaggctgggt acttttataa aaattcccac agtactacca gagtatttca 32400 ggagataaaa agactttatc aattatttag tctaacttct gttttttaca gatgaggtac 32460 ttaaatttga aagtgtgtta gcaacttggc caaggttata ggggcacatg ttgaaacagc 32520

. \* : : : : :

tcacttagaa cctagatcca	gtaactccca	atcagttact	ttcttttcta	tttctgtcat	32580
tggaaatcta ggaccactca	acaaaatgct	catcagacca	aggagataaa	cttgactcta	32640
atacacccat agagctgctc	ctcttgcaaa	tatatatata	tagaagtgcc	tctgctcacc	32700
atgggggcaa tgttggaaag	tacaaccaaa	caaatacata	atgtaaaaag	aatttctata	32760
ttcacaatct gctaagcata	tgtcaatgaa	gctatcttta	ccgtcaaacc	acccctaccc	32820
acctaacaat tttactaaaa	gtaatctctt	atcaaggatc	ccaaaggtgg	aatgaaacta	32880
gccgctaaaa aatggttaac	tttcttctaa	caggttacct	acagaatctc	ccagagaaac	32940
tgctcatcat aatccaatct	ctaaaaagta	ggaagatttt	tttgtgagat	cagtgtcata	33000
aacaaataag acatttattg	actcttacca	cgaaccacac	actgttctaa	ggtctttaca	33060
tatattactt tttaaaatct	tcatcatgat	tctatgaagc	taacataatt	attatgctaa	33120
tgttataatt gaggaaacta	aggtgaaggc	aatttaagta	acttgcccaa	agctatacag	33180
tgataagaga tggagagcca	gtcagggact	ttagattttg	cattcctagc	catcacacta	33240
cacctgaaac cttctgatat	atctatggta	tgtttgaagg	gaggttcaac	tcaattttaa	33300
aatcagttat acccatttac	atctattctg	aaatacatcc.	ccttttcatt	caggtttcca	33360
ggtttcctat ggatataatt	aatattgtta	ataggatgta	gcttgtggaa	caagctcccc	33420
ttagaagaaa gagtcaagac	atgaaagtta	aaaaagactt	ttatttgatt	tctagctctc	33480
tcacttactg agcaatttat	ttaattgtct	tagcctcagt	tcttcagcaa	ccaaaccaat	33540
ataattttat tggctttagg	atttctatgc	atgccattca	gagtcctagt	atgattcaca	33600
ctaaaaagga gtgatcggga	agtttcagtg	aagatattat	ttataagaca	tgggaaacca	33660
gcatggcttc tgatcaataa	tgaggaacca	ttatcactcc	tcagctggaa	ggatcaaaga	33720
aaaggagtta caagaaccca	aagaaattgt	ctttcactgt	ggataggata	aggctgccga	33780
agtggagetg gaagetttag	ttgatgggca	cccacaagtt	cttggtgacc	atatgggagg	33840
aagccaggag aacagtttcc	tgccctttct	ctcctccctt	gctacaatct	cctgagactt	33900
tttctgaatc cagcagaagc	caaagggaaa	gagaaccaag	ctgttgcagc	ctatacaaat	33960
cagcccctg gggtaccagg	aaaacaaggg	tgaagaaagg	atccacagga	cacacactga	34020
taacactata agatgaacat	tacatgagaa	aatgctgtaa	tgcagcatgg	gcttaagaat	34080
tattaattta ctttttcct	atagtggtca	ttttttgttt	ctgccagctc	tgcattgcat	34140
cctcttcttt cagtaaaatc	acctttcctt	taataaacac	actaatccca	ggatagtaag	34200
agggttacat gtaaaaatat	gtcagtgctt	gaaactttta	cttttaggga	gagattctgt	34260
agcatagtgg tttaaaccaa	gggatttaga	atgaaagtgc	ctggatctga	atcacagttc	34320
acttactage tgtgacettg	ggtaagtttt	aggagcttgc	tgagcctcag	ttctcatttc	34380

tgtataaatg gagcgtaata ctaatagtga ctcaacaggg tgattttgaa aattaaataa 34440 atcaatatat atatgtatat atataagtac attatatagt gactataaaa aatagatgag 34500 tctgtatgca agacttgcct attattattc catgtggtct tgttaatatt gacaatcagg 34560 taatccaccc actgccttta tgattgaacc tccctttgga taggtatgtg tctctggctg 34620 ggccaatctg actttttctc ctgagaagct gaattatgca ctgaatgata caaggttaaa 34680 acaaactgtt gatgccgaag tcactctgac agcaaggccc ttaagaaact gccaattatt 34740 teteactatt caateeetgg aattateetg gttttataet teeagattgg teacttatte 34800 ctttgatgtt taaacaaatt ttttactttt gatattttaa acaactttat ggagatataa 34860 ttctcatata ctacagttca cccattaaag gcatacaatt taatgttttt agtaccttca 34920 tagagttgca caaccattgc caaaatctaa ttttggaaca ctttcaccac tcccaaaaga 34980 aacaccttac cttctttggt actcaccct cattcccttc aaccacctct ctctagtgcc 35040 tgacaatcat taatctacat tctgttccta cagattttag acaagggtgc caagaaaatt 35100 35160 caatgatgaa aaggtaatat ttttaaaata cggtgttgag acaactagat gtccacatgc aaaagaatga attttgaccg gtacctcaca gtctatacaa aaattaattc aaaatgttaa 35220 aatacctaaa taaaggaagt gaaactctta gaagaaacat aagtaaaaat tttattcctg 35280 tgatttgtga atcctttcaa caatttcctt ttagagtttg ggtttgtcta aaattctgtt 35340 35400 ttgttttatt gttattgttg tttgcttgct tgcaagcaga ggactctaac atatagctct 35460 ccagccgtta ctcccttgca gttagaatat catcctactg ataggagtaa tatagtgttt tcttcctcaa aagcatcccc actaccactc acatttccac cccagataca tgaagatgaa 35520 tgtatggcat gattgaacta gaacatgtta tctcagctta tgtctgattg gatctgagaa 35580 caccattata ggtatcttca cctgccaagt ggcaactgac tattttcttg agtaaaatac 35640 35700 aacactgcta agaatattca tgaaagtttt tattttgcaa tttaactgta agattcttgc ctaatacttt gagcaggact atttttctac ctcttaagaa acagactgga ctccctgagt 35760 35820 tgttgaccct aggttattaa ccttattgaa aagctaaatt taggcttaaa ctcaagaaca 35880 ttttttctaa gagttttcct gagtcagcaa tactaatctt catggtatct aactagtcaa 35940 tctctggcag tgttttggca tgtgttctta cagggctaaa tgaagttgca atgaacttaa aataaaagac aaataaaagt taacaagttg ttcagtttgg caccgtgacc attaaactca 36000 36060 atgtatggaa ctagagaagg ctgctgtgaa ttatggaatt aagagaactt atcacagaag aatactagtg acttgctact tagtgatagt ctatttatta ggcatttcaa tttaacgtat 36120 36180 atcggcaatt ttaattttct aaacaaattg aataagaata tgaaaaccct ttaaatagta aaaccatata tatctctctg tgtctgtgtg gtggtggagg aggaggtgtt ggaggaagaa 36240

atcaatctga tattaccatc agtaatatgg cattcttact gtaagagggt caaggatgaa 36300 catgtgtagt catagatcta aaacaaactg gtcaaatgat gatggtgttt gctgctttgc 36360 tgcttgaatc ataaatggta acattctttt actttgcaca ttgccacagc tgttcattaa 36420 atcgcataaa agaaaatgca aattgccttc cccataaagt aaatgcaaga gtattctcaa 36480 gtttggacca tcttgctgag aaagtgtaca acaactgcag aactcaaata ataataataa 36540 cagtaacaaa accttctgtt gtataggatg gaagatgcag tttcaacaat ttgcagggtt 36600 cttttttct ctgagcaagt caattgaacc acatgcttga gaaaacatat ttttgttatt 36660 gtagaaaaat tattacagat ttttcacatg agaaaagtac agataaaaaa acagcaacga 36720 gtgcactgat atccatctaa agaagagaat aagcttgctg ttaagtgtgg gcaataagac 36780 agataaggat gtcaagtaat gcatcaacat atgtgagaaa aaaagaagag tacgtaaaaa 36840 taggaagtta actaaccatc tecteteetg etttttete ttatatettt tgetgeteet 36900 gcaatgaatt gtttctttct acctaagcat aaaatgctag tctcttgtta tccagtccta 36960 catacattta tactttacta taccttcttc ttgatgattc catttagtcc tacggcttca 37020 attattatct attccacata tacatagctt ccacatgtat aactccagct aagacatttc 37080 ttctgaattc tagaacaagt ctccatttgt ctcctgaacg tgtctacatg ggtacctgaa 37140 aggcatatca aattcagcgt gtctgaaact aaactcatga tcttctttcc ccaacatgct 37200 cttctggcaa ccccatctca aaatggcacc accattcatt tatctgtgaa agtcagaaac 37260 ccaagactca tccttgatat tcctaattca ttcatatccc acatgccatt cattagtggc 37320 agaagcacaa tttaaaccaa tatagtaact ttcagtttag tacaacctca ctattccaca 37380 gagtaataag gaccccagag tctaacaggc aaacatttaa tagatttaat ctcatcagac 37440 ctattttctc tatatttagt caccagtatt tgttcataat gcattcccag ggggagggta 37500 aggggacaca tactaaagaa gaattgtgaa aactgggcaa tattcccaga gagctaattt 37560 aaaaatgtta aaagttetta ateaeettte aetttgaaae ttaatttttt attataatgt 37620 tatgggatac tgagtgagac ttttcctaat tctccagaat gataacctcc agtctacagc tgaggataaa gaggctctaa gaaacctata ttcttaagat acctgtcgaa aattttggcc 37740 caacactttc ctaaggactc actaaaatta ccaagtggta gcacatattg tactagtacc 37800 tccaacaatc atccccacat tttcccttcc tctaacttat cagtatattt ttaaaaactg 37860 cagaagagag agcaaaataa tcaaagtcaa gaacaattgt tgcaggagtg accggacttg 37920 tgtgcaggta tcacccaacc agagtgtact cttgccttgg tgctgaatca ggatactagg 37980 ggcctctcgc tatgccagat aggaccttca tatttgctgg atcttagagt tgagaggctg 38040 agtgggaggc ttcagaggag cactgatgtg agagacggag ggagagaggt gatataaagt 38100

tattggctat ttgccaatga ataaagacgt atttcagtat ttcaacaatg tttctcagtg 38160 aagggaagat actggcattg ggatatcact attccccagg gactgcccat gcactgcagg 38220 acgtttaata tetettaete etggaaatta aatgetgttt eagteactee aagacaatea 38280 atatecette acacatttta ataggetece tgagtggeag ggeagtactg cacacettgt 38340 gacccacttc cacatccacc acactaggga actatacaac taaataaatc cagggagctt 38400 ctgaaaatct aaaacatgag ccaaaaaggg aggcagcact ttgattcctt ttttgcagag 38460 aaacctgatg gccaagacga gttaacagaa aagaagcaat acaaacagca acaaaaatca 38520 tcacagccaa gaagtaaaga gagacctgtt aatacgttca tttgctccac tgtctgtcct 38580 cctcaacacc ctgaaagaat taggtcttga aaaattagga cagaagaagt atctacctca 38640 gatcctgccc tgccacatct aaactaacag cattccagtt taagcttgtg atgaagggaa 38700 aggaaaagaa agaaaacttt ggggattcag ggggaagtat actgcttgag tgatgggggc 38760 accaaaatct cacaaatcac cactaaagaa atttgtcatg taaccaaaca ccacctgttt 38820 cccaataacc tatagaaaca aaaaaaatat ataaaaaaca gacacatgat catcagattc 38880 tccaagaccg aagtgaaaaa aaaaaaaaaa gttaaatgca gcaagagaga agggacagat 38940 cacctactaa gagaatctca tcaggctaac aagatacctg tcagcagaaa ccctacaagc 39000 cagaagagat tgggtgccta tattcaacat tctttaaaaa aaaaaaaaag aacaattttc 39060 39120 ttttcttttt tttcttttt ttttttttt tcctgagaca gagtctcact ctgtcaccca ggttggagtg cagtggctgg atttggctca ctgcaagctc cacctcccgg gttcttgcca 39180 ttctcctgcc tcagcctccc aagtagctgg gactacaggt gcccaccaac atgccaggct 39240 39300 aattttttgt atttttagta gagatggggt ttcactgtgt tagccagaat ggtctcgatc tcctgacctc atgatcctcc caccttggcc tcccaaagtg ctgggattac aggcgtgagc 39360 39420 caccgcgccc ggccaagaaa acaattttca acgaagattt tcatattcgg ccaaactaag 39480 ctacataagc aaataacaaa taaaatccta gtggggcaca ttggctaatg catgtaatcc tggcactttg ggaggccaag gcaagtggat cacccgggat caggagttcc agaccagcct 39540 gaccaacatg gagaaaccct gcctctacta aaaatacaaa attagctggg cgtggtggtg 39600 39660 catgcctgta atcccagcta cttgggaggc tgaggcagga gaatcgcttg aacctgggag 39720 gcagaggttt cagtgagcca agatcatacc actgcactcc agcctgggca acaagagtga aactccatct caaaaaaaaa aaaagattct tttcatacat acaagcaaat gctaagggaa 39780 39840 ttcattacta ccagacctgc cttacagtgc ctcacaagag atcctgaagg gagtgctgaa taccaaaagg aaaaactgtt actggttact acaaaaacac aatcaagtac acagacctgt tatgctatac agcagccaca caaacatgtc tgcataataa tcagctaata acatggtaac 39960

40020 aggatcaaat tcacatcaat actcaccttg agtgtaaatg agctaaatgc cccaattaaa aggcacaaag tggcaagttg gataaaaaac caaaacctga cagtacgctg tcttcaagac 40080 acccatctca catgcaatga tacccataga ctcaaagtaa agagatggaa aaaatctatg 40140 aagcaaacaa acgaacaaac aaaaacagga aaaaaaagca gaagctgcta tcagttttaa 40200 40260 ttttttagtg agggatgttt tttgtttgta tcagttttaa tttttattag tgaggttata 40320 ggaaactggg tatatttttg ttattctcac gggagcatta aaagattgaa aaagagattc aatcattctt aaggtaaatt tgacatcata tttcaacaaa cctgaaaggt acaaggtagt 40380 tgagatgatt tctatccgta ggcatttacc ccaaagaaat gatcagagat gagcataagc 40440 attgttgaaa tattgtttaa acattgatcc aagagttatt cacgagtgaa gaaatttaga 40500 aacatctgaa atggcacaaa gaatgattgg ggtgaatata caaatagagt ttgaccaaaa 40560 agtaagtgtg atatggctgt taaaaggttt tttatggaga atcatttaaa gacattggga 40620 gatattcata agattaagca ggaaaaaaaa agcaaaatgt aaaccagaat atacagtatt 40680 40740 tgttacacat cagaatatta acagtgggga tgcaattctt actattttta catttcactg 40800 tcgtagtgaa aaataatgaa taagtttaca ataatgaata tttattacat atataattgg 40860 gaaaaataaa gaggaaaata gatttctttc agaaatccag aattcattaa ttgaatggtg 40920 40980 ggactgggta catctggata tgaggagatc tcttatttgg taatggtaag ggtgtctggt 41040 gtactgcagc aagaaagaga aactgacaga tctgggtgtg agaagcaagg aaaaagtcaa agataaattt catacaaaca ataatattag cactaacaga tagttaagga aatgagaagt 41100 tagagcaaat atgggaaaag atgatgatgt gcaagatttc atgttctact agtaactggt 41160 41220 aatctaacgt cttggtaacc agccatcgga cagtgtaaag atggtcaggc ataacaaaat 41280 catgacttga gaaatgttca tcaggatgtt ataaacaata cggaagtaga agaggtttca 41340 gggacagaaa tttaaggata aaaatagaga tataagaact acgcctaaag aatatgcttc 41400 atttaagagg tttgttaaga ggaaactatt aaaatagtag ttagcgatag gtggaaaacc 41460 aaaacagact ttaaactacc aaagatccaa aaagacagta aagggctcag ttcaacatga 41520 agacctaact accttactta catactcact caagacagga gcacccaggt tcataaagca agttettaga gacetacaaa aagaettaga aecacaegt aatagtggga gaetttaaca 41580 ccccagtgac aatattagat agatcattga ggcagaaaat taacaaagat atttgggacc 41640 41700 ttaactcaac acttgaccaa atggacctaa tagacatcta cagaactttc caccccaaaa 41760 caacaggata tacattgttc tcatcaccaa atggcatgga ctctaaaatc caccacacaa ttgggcatga aacagtcctc agcaaattca aaaaccagaa atcatactag ccatactctt 41820

ggaccgtatt gcaataaaaa tagaaatcaa tgctaaggaa attgctcaaa agcatacaac 41880 ttaatggaaa ttaaacaacc tgctcctgaa tgactttggg gtaaataata aaattaaggc 41940 agaaatcaat aaattctttg aaattaatga gaaaaaatat acaacatacc ataatctcta 42000 ggacatagcc aaagcagtgt taagagggaa ttttacagca ctaaatgccc acatcaaaaa 42060 gttaggaaga tctcaaatta acaacctaac atcccaccta gaggaactag agcaacaaga 42120 aattgagaca caaaaatcat acaatagatt taattttaat aacaaaaagt gaccagagag 42240 ttatgtaatc tgtccaggac ttcattaaat gacgagaaac ggagattcaa taagtgtggt 42300 tgaaggcaat gcctagagaa aaaattaaaa attattttat gtttattatc tcaacaagtc 42360 cagatgccac aaaatactga ttgtaatgca cctttatcgt ctcatgaatt cccttaattc 42420 agctcttttc cttcagattt gaatataaag ctattagaac aacatctaaa taaagctaac 42480 aattcgtatc atttgagaga ctaacttttt ctccctcaat tatacaggca aatctgattt 42540 42600 tattgctttt tacttttatt tagctttgaa gatattgcat tttttatttt acaaattaaa agtttgtggc aatcctgcgt tgagaaagtc tattggcacc atttttccaa cagcatgtgc 42660 tcactttgtg tcgctgtgtc acattttggt aatccttgca atattttaaa ctttttcatt 42720 agtgttataa cagttagggt gatatgtgat caatgatcct taattttacc attgtaattg 42780 42840 tttcagggta ccacaaacca tggccatata agatggcaaa cttaatagat acattttctg agtgttctca ctgctccact tcatctcttt ccccctcctc tgacctcccc attccccgag 42900 acataacaat attgaaatta ggccagctaa taactccaca atggcctcta agtgttcagg 42960 taaaaggagg agtcacatgt ctcccatttt aaatcaaaag ctagaaatga ttaagtttag 43020 43080 tgggcaaggc ttaccaaaag cttagatagg ctgaaagtta ggcctcctgt gccaaacaat tatccaagtt gtgaatgcaa aggaaaagtt cttgaaagac actaaaagca ctattccagt ttcgctgata tggagaaagt tttagtggtc tgtacagaaa atcaaaccag ccacatgact 43200 cccttaagcc aaagcctaat gcagagcaaa gcccttactc tcttcaagtc tatgaaggct 43260 43320 gagataggtg agaaaggtgc agaggaaaag tctgaagcca gcatgaggtg taagaaaaga agctgtctcc ataacgaaaa agcagcaagt tctgataaaa gttgggcagt aagttatcct 43380 43440 aaaaatctcg ctaagataaa tgatgaatgt gactacacga aacaaaatat tctcaataga aacaaaacag ccttctatta gaagaagatg ccatctggga ctttaatagt taaacaggag 43500 aagtcaatac ctgccttcac cacttcaaag gacaggatga ctttcctgat aggagttaat 43560 acagcttctg actttaaacg gaagccaagg cttatttatc attccaaaaa tcttagggca 43620 cttaagaatt atgctaaatc cattctgcct gtgctctcta catggaacaa acataatgcg 43680

tttgcacacc taacagacta cagtgtaatg caaacataat tttttttt tgagacagag 43740 tttcactctt gttgcccagg ctggagtgca gtggtgtgat cttggctcac ctcaacctcc acctcctggg ttcaagcgat tctcctgcct cagcctctca agtagctggg attacaggca 43860 tgagccacca tgcccagcta attttgtatt ttcagtaggg acggagtttc tccatgttgg 43920 tcaggctggt ctcaaactcc cgacctcagg tgatccaccc gctttggcct cccaaagtgc 43980 44040 tggagttaca ggtttgagcc accgtgtccg gccctgcaaa cacaattttt atatccaccg 44100 ggaaaatgaa atttttgtgt tactcattta attttgatat ttattgtggt ggtctgggac tgaacctgca atatctccaa gttatgcctg tattaaggtt atgagacctg tgcaacagca 44160 tgtatgattt tctgttttcc tctcatgtta ttagctacat gtttcctctc atggtattag 44220 ctatacagac agtataaaat aaatataaaa attcaaataa ctatacaata aaacttgata 44280 ttcactaaga attgcaacac tactcaagtt gagctgatgt ttgactggaa gcaccactag 44340 gaaaggactc aaaatatata atacagtact gattttctgg atgttttaca tccattcaaa 44400 44460 atttgatgga tgatagacag tttagggatt taacagtaaa atgtgctaaa gtgtgaatta 44520 ggcaaaatct gagctatgac gtgtgcatac cacgttgtta ataataacct acctgttgtt gatatgaggg ggagagagca aggggctcac ctgctctgtt ttaccagcaa tctataccca 44580 aatagctgag gcctgaaaat ccacttgaaa gcctttattc ttacagatca gtattggaat 44640 44700 caccttcatt atgcaatcct cactattcaa agagttgcca tagaattacc agtcatttaa 44760 atcttaaagc ttttacattt taagttttaa aaaaattggc caatggactc cattatgagt ctcattaaaa gtatacacat tattttcaaa agaatgaaca tagatacaat tttgattaca 44820 44880 gttgctattc ctggaccagc tctcggacta ttcaaagagg ccaggtagga tagattgtat tttacaaaaa tgacagcacc aataatgacc tcatcctgca tgttcctctt acaacatgag 44940 45000 gttcacactc tgccgttgag aggtgggggc tatgttgact ctttttaatt ctgggaacac ctttgtaatg accaaggaaa agaacaaatt taaaccccta cttcacagta taaacaaaat 45060 45120 taacttgaaa cggatagaag ggacctatat gtaatagcca aaagtataaa acactttgaa 45180 gaaaatatta gtgtaaatgt tcatgatgct gattaggcaa tgacttatta gatatgacga 45240 ctaaagtaca agcaaccaaa gaacaaatac ataagtgaaa cttcatcaaa ataaaaaggt tttgtacatt aaaagatacc atcaagaaag aaaagaaaac ccgcaggata tgaaaaataa 45300 45360 ttctaatcat ataccttata agagactagt atctagaata tattctaaaa ttttgcaact 45420 caatagtcaa aagacaaata acccattttt taaatgggca aatgatttga agagacatgt 45480 ctctaaaatg atataaaaat ggtccataaa gcacacaaaa agtgcttgac atcatttgcc atcagcgaaa tgcaaatcaa taccacaaac ttcctatcca ctaggatggc tataacaaaa 45540

1.1.

atacagatet taagtattgg tggggatgtg agaaaattga aacattgtge gttgttagtt 45600 gaaatttaaa atggtacaac tactttggga aacagtgtat aagaaaaaga acagcaaaat 45660 aageteaaag aatgtggaca taaaaatata ataataataa agttaacage agaagtaagt 45720 aaaatataaa aattaaatta aggatcactc tgggcatggt gcttcatgcc tgtaatccca 45780 gcactttggg aggccaaggt gagatcactt gaggtcagga atttgagacc agcctgggca 45840 acatagtgaa accacttctg tacaaaacat ttaaaacttg gccagttgtt gtgacacacc 45900 cctgtaatct cagctaatcg gaaggctgag gtaggaggat ccatcgtcag tttcactcaa 45960 cacaatataa aaatcataag caaagtatta ccaaagtgaa taaagcaata tatacaaagg 46020 aaaatacact gtaactgaat tgactttatc acataaatgc acagttattc tatcattaga 46080 ggctcaaata atgtaaatca aaatattacc agataaacag atttaaaaac catgatttca 46140 atcgcctttt aacatttggt agaattcaac atcaatttgt tattttaaaa aacagtaacg 46200 atgttaagaa attgagagtg taagaaaaat cctcatagtc tgacaaacgg atgtgcaaac 46260 aaccaaagta aatatacact tatccgtgaa aggttgaact gcttcccctt tgagaacagg 46320 attaagacaa agatgcctgg tgttatcagc tatactcaac attatactgg atgttctagc 46380 cagttcggaa agcaatcaaa aggaaatgag gaatgaagag tgtagaaaaa aaaatgtgta 46440 acatttttgt gtttagagaa tcctaacaaa tctacagata aattattagg attaatgaga 46500 gtgtagcaaa tttgtgggaa aaaatcaata ttcaaatatt aattgcaccc tttccttccc 46560 ttgcccttct tccttttccc tctcctactc tcctttcctt ctttttcttt atgcacacag 46620 tagaatacta cacaatctat agccacatat aaacattaat gaatcatttc acaaaccaaa 46680 tggagggcga ataaagcaag acacattata cactgttcta tttaaaaaaa gtgcaaaatc tgtttaaact aaagtatata tttaggagtg caaacctaga aggttagacc gcaaagaaaa 46800 tccaaaaagt atagatacct atttatttt agtacttacg cattttttta aatgtgctac 46860 atagtactat aaaataactg aagatctcaa aaaaatgtat gtatgagaca gagtagcatt 46920 gataaagagg caatttcacc tttggctctg tatatttctg tgttgtttaa acatattaca 46980 caaagaatac acattttcta tgtatcatat atgtaattta cttttgaata tcaatataga 47040 ttttacaaac tataagaata cccaaaaatt gtttatataa attttaagga aaaaaaagtt 47100 tcagaatgag agaagacaca atgattagag gcaaaacaaa aaataaaaag ctaaaacatt 47160 tgaaggtccc cattagtttg atgaagctga agaaaagggc acatgtgtgg ggacaaagcg 47220 gagetetetg taatetgate tetgaaggge tegggetgta ceaettaaat gtggtttgag 47280 gtcacacac ctgaaccaca tggcagtact ctttttactt tgaccctggt gcccagacta 47340 tgatctaaac ctcatcgtag cttgtaataa attccaaaat tatcagcaat tgtaacaaca 47400

e total grade

gagagtcaaa	gaactgatga	ggccaggaga	agaggtctgc	cctttaatca	gaagctatac	47460
attcaaatca	ccttcaaggc	aattttctgg	ggcaaaccac	tgtccatgca	tttatatgtg	47520
gttaatgagt	agtgaaaagc	cctttggaat	gtttagaggc	ccttttcatt	tgcacacaat	47580
tagggtaaaa	atgaaatgtg	cagattaaca	ttgaatgaca	ttcttctgtt	atctttttct	47640
atcacatcat	gcatgaaaac	caaaggtctc	tttgtcataa	aagggactaa	attgcttaat	47700
ccatgaattt	ataaacttgc	atttttcccc	tcagagaatt	tgtcatggtt	tctgagttct	47760
caaaaactcc	cagaaagtga	taatgcgatc	aattgcatat	aaaacctcaa	aagtcatagc	47820
agaagactag	ttgagaaatt	taagttcaga	ggaggaagta	tgaaaggtaa	atcgtaaatg	47880
tttaatttgg	caatcgaacc	ttaaaagata	tatgtttccc	ggggatgagg	gctactgtga	47940
ccaaaacagc	atggtaatgg	tacaaaaaca	ggcacataga	ctaatggaac	agaatagaga	48000
gcccagaaat	aaggcgacac	atctacagtc	atctgatctt	tgacaaagct	gacaaaaaca	48060
agcaatgatg	aaaagactcc	ctgtgtaata	aatagtgctg	ggataactgg	ctagccatat	48120
gcagaagact	gaagctggac	cccttcctta	caccatatac	aaaaatcaac	tcaaaatgga	48180
ttaaagactt	·aaatgtaaaa	cccaaaatta	taaaaaccct	ggaagacaac	ctaggcaata	48240
ccatcttggt	cctaggtatg	ggcaaatatt	tcatgacaaa	gacaccaaaa	gcaatcacaa	48300
caaaagcaaa	aattgacaaa	tágaatotaa	taaaacttaa	gagattctgc	acagcaaaag	48360
aaactataaa	cagagtaaac	tgtcaatcta	cagaatggga	gaaaatattt	tcaaactatg	48420
catctgacag	aggtctaata	tccagcgtct	acaagaaatt	taaacaagtt	tataagagaa	48480
aaaaacaacc	ccattaaaaa	gtgggcaaag	gacatgaaca	gacactttta	taaagaagac	48540
atacatgcag	ccaacaagtc	tatgaaaaaa	gatcaatatc	actgatcgtt	agagaaatgc	48600
aaatcaaaat	cacaatgaga	taccatctca	caccagtcag	aatggctact	attaaaagtc	48660
aaaaaataac	agatgctggc	aaggtctcag	agaaaaggga	acacttatac	actattggtg	48720
ggattgtaaa	ttagttcagc	cattgtggaa	ttcagtagca	tgattcctcg	aacagctaaa	48780
agcagaacta	ccccttgacc	cagcaatccc	ttactggtta	tatacccaga	taaatataaa	48840
tcattctatg	taaagacaca	tgcatgtgaa	tgttcattgc	agcactgttc	acaacagcaa	48900
agacatggga	tcaacctaaa	tgcccatcaa	tgacagactg	gacaaagaaa	ácgtggtaca	48960
tgtgtatcgt	ggaatattat	gcagccataa	aaatgaacat	gatcatgtct	tttgcgggaa	49020
cacggatgga	gctggaggct	atcattctaa	gagaagtaat	gtaggaacag	aaaaccagac	49080
actgtgtgtt	ctcaattata	agcggggagc	taaacaataa	gaactaagga	atatagagaa	49140
ggaaactcca	gacactgatg	tctacttgag	ggaggaggat	gggaggaggg	aaaggagcag	49200
caaagataac	tattgggtac	tgagcttact	acctgggtga	tgtaataata	tgtacaacaa	49260

acccctgtgc cgtgtttatc tgtgtaacaa accttcacat ttacccacaa acctaaaatt 49320 aaaattaaaa aaaaacaaga aagagtttta aaatactttt cttgtggctc acgcctgtaa 49380 tcccagcact ttgggaggcc gaggcaggcg gatcacgagg tcaggagagc gagaccatcc 49440 tggctaacac ggtgaaaccc catctctact aaaaatacaa aaacaaaatt agtcgggcgt ggtggcgggc gcctgtagtc ccagctactc cgcaggctga ggcaggagaa tggcgtgaac 49560 ccgggaggcg gagcttgcag tgagccgaga tcgcgccact gcactccagc cggggcgaca 49620 gagcaagact ccgcctcaaa aaaaaaaaaa aacaaaactt ttcttaaaca tggttttata 49680 tgtgattcta ggcaactgga cattgaacag tctgcaactg tttgttctgc atctatcctg 49740 ttaactgctt ccagcttacc cacacctagg ccatgggttt catataaaaa acttcataac 49800 49860 tcatggagtt cccgtaaacc caagcccgga gcctcatttt ttctttcctt ctgcagtctt taaaccattt tgtgtagtct cagcctacct ttgtattgac tctggagttg gctgcaaacc 49920 ttaaggatgc tgcctttgct ctaagagtta tctcagttac ccatgtcccc aaagaatggg 49980 gacagggtta gggatgcagt gccctaacct actctctgtc caggcttatg cagggaaagc 50040 50100 50160 acataaatcg aacaatgtct acgattactt caaacttttg aaccactatc ttataaagtg gaggcccgca aactgcagcc caatgtcaaa atccagccct tttcctgttt tcatatggcc 50220 gttgagataa gattagtttt tccctattta aaggatcgta aaggaaaaag gaggaggagg 50280 50340 acagaaagga ggaagaagag aaggcaaagg tggaggagga ggtgaagcaa agaagaaaat gaggcatatg cagtgaagac cacatgtggc ctaccaaatc ctaaaatgtt taccatctgg 50400 ctctttacag aaaaaaatgt ttcctgaccc ctgttctaaa ccacaaactt tgtcctttca 50460 50520 agcccttgca tgaaatgctc ccatggcttt ccatcactct caggataagc tctacattcc 50580 ttaacatagt ctatgctcga tcatctgacc ctaactatca cttagtccct gtcaacttgg ccccaacata cactgcctat tcacagagcc tgaattactt gctcttttgt gaacataaca 50640 50700 50760 cttttcctct ggccctcttg gaaaactctt ccttaaaggc tcagctaaat tgccacttct 50820 ctgaagcatt ctctgagtgc cccgagctga attaagatct cctctgcaca tccacagcat 50880 ttcgttatgc cttctcttag ttcacttaat atattactct ctgagccacc actctcagtt ggggactgaa aggtttatca tttccatcta gctgtttata tcccgcggac agcctaaaag 50940 cagtcctagg tttgaattta cttctgcttc tatttactgt ttacttaatt tgggaaaaca 51000 aaaaagatag accaacagtc ccaaattaga tgaattgtca gacagttgaa aagaatatag 51060 tgcaggccta gaaaatggtt tgagaaagaa tcaaaccctt acctgcaaag tgaagacatc 51120

ttaaagatat tcttgggaaa gaataagttt tcattttata gatatatgag gcactccatt ccaagaaaat tgatgctatg ttaggaagtc tcctacctgc agtaccgaca tgattaaagg gctctaaata acatgatcac tcatttataa agatgaactc aaaaataaaa ttagttatac 51300 tgtacatatg ctatttaatt ttatgaaaat ggtcaataag atgaagtttt gttttgtttg 51360 tagetettgt tgeccaggtt ggagtgeagt ggeaggatet eggtteaeeg caacateege 51480 ctcccgggtt taagcgattc tcctgcctca gcctcctgag tagctgggat tacaggcaag 51540 tgccaccacg cccagctaat ttttgtattt ttagtaagtt ggagtttcac catgttggcc 51600 aggetggtet ettateteet gaceteaggt gatecaceca cettgaceae ceaaagtget 51660 gggattacag gcatgagcca ctgtgcccgg ccaagatgaa gtattaatat ggaaaaaggt 51720 tcatggaaaa gaagtaggtt gaaaaaatat atatactatg actttttatg tcacttattc 51780 51840 gaaataaaag attaaaacac cctttatgtg tatatgtgtg tgtgtaaatg tctccaaaaa 51900 tttacaaggt atgcctgatt agcaaaaatg tttccttcgt aaataaggga ggagagtttg 51960 gggctgataa tccaagagag tcaaagggca ctttaactgt tacctttact tgcgaattgt ttgacttctt aaaaataatg agcatttttt gtcaatttaa attaaagcca ataaaatgta 52020 cattcacctc acatccagat cctacaagac ataacatttc aacagggtct aaatgaatag 52080 gtgatatatt ctcattcatt tagtttttaa attgtctttc ttaggtttta aatatacata 52140 52200 ataaaagaaa atcatagacg ctgaaatagg tattccaaag ctcaaagaca agctgagaaa atcagaatta aaaccacaca ggttaaaaat tattttcttt aagaatgttg aatgttggca 52260 cccactctct cctggcttgt aggttttctg ctgagaggtc tgctgttagc ctgtgcagca 52320 aactgccatg gcacacattt acctatgtaa caaacctgca cattctgcac atgtctcccg 52380 gaatctaaaa taaaattaaa attaaagaaa cacatgaact aaagcagttt ctgttaaagg 52440 tgaatgaaac aaacagtaga tgaaagttgg gttaccatgg aagcaataga catgaacatg 52500 52560 taggaaaaaa aaataaagga gaagattttc tgctcagtca cggcaaagtc aggggtctag tctgtttcaa tgtcagatcc tgtaagagat gatgatgttg ggtgctgacg gtggagcagg 52620 52680 attcataacg aaggtccaga gattgcccta gtcttgctca gccaataaag tgcagtggat ttttttctga gtgcaaaatt taaaataagg ctcaacgtat tcatttcatc tacagcagag 52740 52800 aaggcagacc aagtggtgag acttttgctg aacttgagag tatgaggtca aattggccct gaaaaaaaga caaagaaact ataggacaca gatatgtttc agtattcaag tcaaacaatg 52860 52920 ttgaaatgga ttgggtgctg aagcatagtg gtccagatag ttctgacatg gccaatgatg gctttgtact cccctttgaa tgtagcaagg aagaaattgt tcagttcttc tcatggttgg 52980

53040 aaatcgtgcc aaatggcata acactgatgg tggatttcca gggaaggagt acaggggagg cctttgtgca gtaggcttca caggaaatag ctgaaaatgc tctagagaaa cacaaggaaa 53100 gaataaggca catgtatggg cttatggcca tgcagcagcc aggtccctat gacagacctg 53160 gggctggcaa agagcataac agcattagca gaggagatgg ctttgagagg atgcggtgtg 53220 53280 gtgcttatgg tggaagctat ggaggctata atgattataa tggttataat gatggctatg 53340 aatgtgggtc agatagattt ggaagaaact tcaattatag ttttttagga atgcctgatc 53400 atagatatga agatggtggc tctaccttcc agagcacaat gggacactgt gtacacatgt gtggattacc ttacagagct actgagaatg atatttataa tttttttcac tgctcagtca 53460 53520 tggagagtac acattgtaat tggtcctgat ggcagagtaa ctggtgaagc aaatgtcgag tttgtaactc agaagatgct gtggcagcta cgtcaaaaga caaagcaaat atgcatcaca 53580 53640 gatatgtaga actottottg gattotacag taccaccaag tggtggttggt tatggtagco 53700 aaatgatggg agttataggc ttgtcaaacc agttcagtta cagtggccca gccagccaac 53760 agttgagtga tggttatgca ggcagctatg gtggctagag cagcatgagt ggatacgatc aagttttgca ggaaaactcc agtaatcttc aatcaaacat tacataagta gccaaggagc 53820 53880 gataaacagc agctactaca gtagaggaag ccatgcatct atgggcgtga acagcatggg 53940 agggatgtct aacatgtctg atatgagtgg tggatgaaga atgtaattga tcctcatcac 54000 ggactcttgg ccaacttttt tctaagaaaa aaacttcagt ttaacagttt ttgaagtaca 54060 agctcgtggt ttatgcttac tctctaagtg gaaatcagga ttgttctgca gacttaatta aggeteaatg tttttgaaca cagtacteet etaggatgta acagtgaagt egagtaaact 54120 ataactgtta aaaaagtttt cgtttttctc aagttagtta tattgtacaa tgtactgaag 54180 cagtaaatgt atttaggtta aagcagttga attaagttag ttgttgccct tataccacgt 54240 54300 tacattgaac acagtttgga tgcatgttga aatacatgct ttttttttt ttcataaaac 54360 tcaatataag agctgtgtct ggaattaaag taaaaatttt tggcacgttt tttaattcta gtttcattta ataacctgta gggcatgttt gtttaagctt tatttaagtt aatgggaaaa 54420 54480 aattagagat ccaataccaa tactttagga ttgtggtctt ggtgtttata tgaaattctt 54540 aggcctcgat tttaatcttt cattgtattg tgattttctt ctaggtatat tataccataa 54600 gaaacttgtc aaataaatct ttctttttt taatttttt ttttgagatg gagtcttgct 54660 ctgtcgccca gcctgaagtg cagtggcaca atctcggctc aaggcagcct ctgcccactg 54720 ggttccagtg attctcctgc ctcagcctcc tgggtagctg ggattatggg agcatgccac 54780 cacgcccggc taagttttgt atttttagta gcgatggggt ttccccatgt tggccaggct ggtctcgaac tcctgacctc aggtgatctg cctgtctcag cctccaaaag tgctgggatt 54840

acaggegtga gecaetgeae eeggeeaate tteettttaa aaactgaaag aagaaaaagg 54900 aagaagaaga agaacaacaa caacaacaac aacaacgaca agaaggagga gggaaaggag 54960 ggaggtatta agacttggca caactagtga tatcaggtta gaatagatcg tcagggctat 55020 cacattttgt aagccttgaa aatcagtaaa gctgaatagt aaatttcagt gcaggctaaa 55080 ttaaaaatgta aagtaatttt ctcctctttg attcataaat tcatttattc attcatccgc 55140 caaagattta ctgagtgcct aaaatttgcc agaccctata tgctgggtgt gaaagataca 55200 gaaaagaaat aactcatgcc ttttcttgta cttcaaaagc tcagtctaac caaggccttt 55260 acgtagagtc aatgacttct aagagactca ctggctgtct gggacaatat tgttctcttt 55320 atttctcctt actgttggtt aagatttcct ctaaatatat tacagattca actcctttta 55380 tgtagcaaga actgacagtg tggagtggag ctgttcacca cctgttcacc atctctgctt 55440 tccgatttcc aacatggagg ttggcaaact tttagtgtaa aagggccaga tagtaaatat 55500 tttaggcttt gtgggataaa agtctagggc attacatagg tacatataac catttaaaat 55560 55620 gtagaaacaa ttcttagctt gtaaaccata tgaaaacagg gccagatttg tccaataatt 55680 tgccaacact tgttctagta gaaacatctg aggatcagag agggaagcag caaagttgtt attectagta titaaggica gatataacaa agagcaaaat aggcacggic citgccitca 55740 55800 cagagtttac agagcaggca cacagctagt ccataaagga ggtcttcgta tctagtagca 55860 actgtaatcc cttgagggta tatgtttatc ccatttctct tgcatgtcac aaaaagagca 55920 gctgtttgaa agcttctctt acacctacgc catcattcta aaatgcactg cttgcatgtc tgtatcccca ctaggtaaaa acctctcata agccaaggag tatgttttat ttatctttat 55980 56040 attettagtt cetageacte cetgeacett gegeatgtta tacacteaat aattgettgt cagatgaatg gaactaaact gtttttataa cattatgtgt gtgccttttt aggtggtcac 56100 56160 ttgtcttttt gctagagtta actgtgttgt aaaaaagact ctgaattcaa agccttcact 56220 tttgagaatg aaagggggcg tatattcact gcagttgaca tcaacataag gtctaaaaaa aatctttgtg acatcctata ttttcagctg ggatttgcag caaactattg ttttcctttt 56280 56340 ctccaagaaa aactctgcct aacgacaatt ttcttgttgg tttcacaagg agattgcaca 56400 ctcttcttat gagatcgatc aggtcttata tctttctttc cttattattt cataaaggaa aaggacagct ttttcttatg ttgactattc tgtctctgtg ccctgtgggt aaaactaaat 56460 56520 acacaggtag tgactactca aaagcctatc tggatggctg aaactgacac ttgtcttcta 56580 tttgaacatg tgtgaagcta aatgtgccct tgtaagcatg aaagacgcaa atgcttttaa 56640 aagtatactc tatttttacc agtataaaag gaatgcatat tcattctaga aaatttgaaa acgatagaaa aatggaaagt aggggaatag attttgtata tactcaccat ctaaatatat 56700

ctgttgtaat atttttctca agtttaagct ttatgtgcct caggtttttc atctataaat 56760 tcatttataa atctataaac aacaatacct tccttaaagt gttgtaatga gtcttagaat 56820 aattaataca tgcataatgc ctaaaagata ttttttcttt atttgaaaaa cttgtatttt 56880 aggttcaggg gtacatgtgc atgtttgtta tatagggaaa ttcgggtcat gggggtttgt 56940 tgtacagatt attttatcat ccagatacta agcctaatac ccaatagtta ttttttctga 57000 tactctccct tctcctaccc tccaccccca aatagacccc agagtctgct cttcccctcc 57060 taaaggagat ttttacagag tacatgctca acaaatgtta aatagtactc ctcatactga 57120 atattatett ttagtgeett aacttgtttt gttateatta tateataata acaaatatte 57180 cttatgtaat taaaaatttt acttataaca tatttgggag gccgaggcag gtggatcacg 57240 aggtcaggag ttcgacacca gcctggccaa catagtgaaa ccccgtctct actaaaaata 57300 caaaaattag tcgggcatgg tggtgcacac ctgtagttcc agctactcgg gaggctgagg 57360 caggagaatt acttgaacct gggaggcaga gattgcagtg agctgagatt gcgccactgc 57420 acttcagect gggegacaga geaagaetee ateteaaaaa aaaaaaaaaa aatttaetta 57480 acacaattat ggtccaatgc ctccaacaca ttgttacaat tagtaataat atagaatatt 57540 atataaaaga acccctaact cttgcttatt ttataaaaca aactgaaatc agttacaaaa 57600 ttcataaata ctaacattgt ttgaaacatt gatcctattt aaccacagtt gccagaatag cctagaaaag tctgttcatg aaatatttat agaaaacagc taagttttca actataccta 57720 ggtgactcta agaccactta taaaaaacagc atgctttgaa attgtccaaa gaaatcttca 57780 ttttaactaa gcttcaaata ggtaatttca tatttgaata cttatgggaa ctgaatctga 57840 atattcaact ctaaagtaac ccatcaaact tgccataatt ttcttatatt ttcttgaatc 57900 acagactatg gattactctt catcagttat tagcttcttt aatgatagca ttttttggtt 57960 tatatactgt ttgtcctcaa ccttctacat acttttccat ttcagagaca aactaatgtg 58020 taaaatagcc agtggacaag agttattcat taaaactgtg tctatgaatg caaaatatga 58080 tatgtaattc tggtaactgc ctagatgaga atcacatgaa tgaagaaatg taagtaataa 58140 caccaacttc ccaggcaata aattagcaat tgacttgaag tgtcagttct cacaagaaat 58200 acaaatagta aatatacata acaaataagt tcaacttggt taaggggtta aagaaatgca 58260 atatttaaca aacatgagat gcaaattttt gtacagaaga gaagaaaaaa ataaatgaaa 58320 taagtcccaa tcctggaaag actgaaaaga aatatgctta tttatgacta gcataatcct 58380 ttcaatgaat aatttggtga tgtatatcag ggtagataaa ataattatac cctctggccc 58440 aacaattccc cacatggaaa tttaccctaa gtgactaatc aaagcagcga agctatgtaa 58500 gattgcttta ttaacatgtc catggtggat ggcagagcaa gatggctgac atcaatgcag 58560

5 42 5 gc

ctctcttcca cagaatggaa ccaaaatagc atgtagattg acacttaaaa tagattgtga 58620 aagagagaac actggaatgc aacagagcag tggtgggaaa gcactgaaag caaagaagaa 58680 aaaagaagca aggcagcctg cttggcagag atgcgctggg agctgggaca aggtcctgtt 58740 tggggaaatg gtaagtgaga gcccaccaag gctgcacatt tcgaccatgg cgtcttgcaa 58800 58860 tcctagctat ggggagagcc cttccactgt catgggcctg gagatgaaaa cacaagaagt tgtctagaga ttgtgcaggc attgttccag agagtgtact catgctgagc cccacaggct 58920 tctgagccct gagcagctac agcacggtat cattggaaga tcttggtctc caaaggacgg 58980 tgtcctattc tggggcccac attgctcctg ccactgctga gttaaacaaa caaacaaaca 59040 59100 aacaaaaaag gcagaaggag accaggcaca ttcacatatc ccgagaacaa attccaccac caccactgta gcttgctgtg ggtctcagac acaagtaaac tgtgcccccc acagcactgc 59160 59220 acccactgag agtgacccca ccctcttcct cagtagcaga cccaaagtgg gcaccagtct cagagccaaa cccccgaaga actgcatcct gccctggggc tgatgctgtg gctgccacca 59280 ccaggccaag gatggtagag agaggaggt gggcattttc atgcaccctt acctcttctg 59340 gaaagaggct gctgtgggac tgatgctgga gaagatatgg agaaaaggga ccacttatat 59400 actgctggtg ggaatgtaat tgagtaaaat cactatggaa aacagtatgg agatttctta 59460 59520 aagaactaaa aatagaacta ccattctatc cagcaatccc actaaatcag tatatcaaaa ggatacttgc actctcatgt ttgtggcagc agtattccca tagatttgga agcaacgtaa 59580 59640 gtgtccatca acagaaaaat tgatgatgaa aatgtggtct acatacacac tggaatacta ttcagccata aaaaagaatg aagcctagca atttgctgca acatggatga gcctgtagga cattatgcta agtgaaataa gccaggcaca gaaaaatacc acacgttctc actcatatgt 59760 gggagctaaa aaagagttaa tctcataggc atagagaata gaatgataga cactagaaag 59820 tgggaagggt gggagggtga gagtagagga tgaagagatc ctggctagtg ggtaaaaaca 59880 cacagttaga tagaagaaat aaactccaat attctataac aaaacaggac cactatagtt 59940 60000 agcaacgatg tattatatat ttctggcaac catcattcta ctctctaact ctatgagttc 60060 aattgtcttc atttccagct cccatagttc aaagtagata aaagagaggt catgaaatgt tacaaacaca cggccaggtg tggtggctca cgcctgtaat cccagcactt tgggaggcca 60120 aggcaggcag atcacgaggt caggagatcg acaccatcct ggctaatgca gtgaaacccc 60180 60240 atctctacta aaaaatacaa aaaattaggt tggcatggtg gcatgcacct gtagtcccag 60300 ctacttggga ggctgaggca ggagaatcgc atgaacccag gagacggagg ttgcagtgag 60360 ctgagattgc gccactgcgt tccagcctgg gcaacagagc gagactccgt ctcaaaaaaa aaaaaaaaaa aaaagagaaa gaaatgttac aaacacatag aatttacaaa aactcaaggt 60420

្ទាស់ស្នាក្រ

gaaggatact gtgaataccc cgacttgatc atttcagatt ctattcataa aacaaatgcc 60480 cacatatacc ccgtaaatac acaaaatatt ttgcattaat aaaaaagtca tccatggtca 60540 tgttatttat tgtggccaaa aaactgtaaa aatttaaatt cttagccaaa gacttgttca 60600 gtaaattgca agaattaaat tgctacaaca taatattaag catttatcat aaataataca 60660 tcttgggatc ctgtaaaagc ttggaaaaca gtttggagtt aatattttgt gagacataaa 60720 attggattaa agtagatact atacattttt gaggaatcga gtctaagact aaaaatattt 60780 60840 accttgcaag ccactaaagc aaataatttc cctttaaaat gcaataaaaa taactaaaac atctaaccca aaattaaata ccatttttc caatttctcc gaattgttac tggggtgcat 60900 gatgaatagc tttatgaatt actttttctt gtttccatac taagcattta gtagacttgt 60960 tcatgccaga agttcaaatt gccactgaat tcacacaatc atttattttg ctcaaaattt 61020 cgattttaga actaaagaac atgactttat taaactcctc atttccatca ccagctctag 61080 61140 aatttggctt tattttagag ccttttttt tttcacagag aaacttcatt ttcgtaactc tttgatagct actgtgtgag taagagtgaa tagagaagca catgattggg cagcaaccta 61200 ggctcactca ctggtaagtg gcttgctttg attaatcagc ctcagagtgt gcatgcttca 61260 aacgcatgca tctccaacaa aaccttcttt gctgcatgcg atggaacaaa cgtttgccat 61320 61380 tcttaaaacg tgccaaccat tcatgatctg ggaacttttt tttatacata ctgctccctc tactgggctg ttcttatcct caccttcata tcaaattgct agtcaccact gaagtcaaag 61440 61500 ttgaagcatg actttcttta tgaaacatac tctgacacct ccagggatgg ctattcctgg 61560 tatcttctgc ataatattgc acgtgaagtg agtacactca agtcctgaac tatgcttgct 61620 tatgggagtg tttaatgata ttaactatga aacgtcatga cagcaaaacc agggatctat tttcagtttc aattgaagtt aaagggaatt tctcacataa gagaaccaca catagtgtgt 61680 61740 gatgaatagt aaaagaatta atgtatctgt atgcgtagaa gagattctca cacatagtat 61800 gtgctcaaca aatgttagac aacgctttct actattgcaa atttcagaga aaatggacat 61860 caaccttgta gcattcaggt taagtatggg gagagtcatg gtatcatgta gtcatcacca 61920 gggctggtca gcaagggtta agaactctcc aagattagta attaatgaag acaaagaaga tgtaaatatt cccatgcaaa caaaacctca tggaacaggc gaattgattc agaaaagatg 61980 ggaaatattc ctctcaccat gctgtagact gaaatcaggg ccctctgcag ccccgacaga 62040 62100 ggtgattata gataattata tagactaagg tactgagatc atcagtccag agtgggggaa 62160 cagttattct caacagacct tcttgtcatt atcataaagc ttcacattaa gaaaccctca 62220 aattattatt atagatattc gggttgagga gatcttactg gttacatcca agatctgtag caaaaatatg taagaaagca aaaaacatgt aaaatacccc agttacacat ggatatatac 62280

atatacattg acaacaagag aaaataaaag cctatctaga cgaggcttct ttatgactgg 62340 gtgtgttgca tagcttttat tgttccttca catacttcag taacatcttg tgctatatct 62400 atcgaggcac ttctcagact ccattgtaat aagttctgta catgttaatt gacatctttg 62460 catcctcttt aagaatgtgg gtattttaca taagggtaaa gtattgtttg tcttgtataa 62520 62580 ctctatcaaa tatagccttg tctattacta tagccattca cacaatgagg gtgaaatgga agacagagaa tcagttggtt ggaagacatt tatcctgaga ttcatcttcc ctgagagttc 62640 tcttaagaaa ctgatcaatt acaaggttgg caccttaagt accttgttct atccttcagc cccactgaag ggttgacaaa ggccaatatt ccaaaaagaa atttaccaaa taccagagaa 62760 gaagaaaagg aaaataagct caataagctc agaaaatgct aacagcatca gatttctgaa 62820 62880 gctagtataa tctcattcca catgttcagt tgtgcatatg tgtgtgtata tatatataca catatatata tacatatata tgtgtatata tatatgtata ttcaacctta cttgtttttt ctatgattga acacagtttc aattttcagc tgtcagtccc tttgccttaa ataaaccatc ttgaaaatgt cggggttccc tttgccattg agtgacatct aagttttaga atgctaaaat 63060 ctactcaaga cattgcaggg tagagggcac atattaacct tgatggcatt tgtccttgca 63120 gacgeteett tgteeatgaa gacaeteett gagacaattg tggeeteate agtacagata 63180 63240 aggtgcttat gagatgacct ttgctccacc cataaaaccc ctttaggtct agtgttggca 63300 cacaggactc tttctgatgc ctttctacta ctttgagttg gataagtccc tatgaggctc tctctaaggc cccacgtgtc tagactgact acacagccac ttattctctt gggttttgtg cctccccaca gcttcacctg ggaagtagag tattgaaact ctggctctgg aatacgacaa 63420 tgcctccttc ctccccacac agggatatct aatctagcct ctaggagaaa cctgtttcct 63480 caaatcctca gctcatattg ttctgttttc cccttgtatt ttttttttt ttttactatg 63540 63600 tcaacagtca tattcaacaa agccaaacaa agacgttaca agaaaagaac attacaggcc 63660 atatccctaa tgaaaatata tgcaaaaatc cccaacacaa tactagcaaa ccacgttcaa 63720 cagcacatta aaagaatcat tcactatgat caagtgggat ttacctctgg gatgcaagga 63780 aggttcaata tatacaaatt aaaaaattgt gatataccac attaacagaa tggaggacaa aatctatatg atcatctcaa tagatgcaga aaaaatcatt tgacaaaatt ctacatgctt 63840 63900 tcattttaaa aactctcaac aaattatgta tagaaggaat gtacctcaat acaataaagg 63960 ctatataaca aaaacccaca gctgacatca tattcaatgg gggaaagttg aaagcatttc 64020 ctctaatatc aggaacaagg caaggatgct cactctcgct atagttgcca acataacatg 64080 gtactggcat aaagacagac acatagacca atggaacgca atagagagct gcaaaatcaa tatgagcatt tacagtcaat tggtttttca caaagatgcc aagaacacac agtgggggaa 64140

ggacactctc	tttattaagt	aatgttaaca	acaactggat	atccacatgc	agaagaaggg	64200
aattagactg	catgttacat	cacatacaaa	aagcaagtca	aaataaagtt	ttaaatataa	64260
gaaatataag	actttacact	gtgacactac	tataggaagc	attgtggaaa	gactccatga	64320
cattggcctt	ggcaatgatg	ttttgtatat	aaacccaaaa	acatgggaaa	caaaagcaaa	64380
aatagaaaaa	tgtgattgta	tccaactaaa	aagctcctgc	acagtaaaag	aaacgaatga	64440
cagtgtgaag	agacaaccta	cagaatgaga	gaaaatattt	gcaaactgca	catttaatca	64500
agggttaata	cccaaaatat	ataaggaatc	caagcaactc	aatagtaaga	aaacaaataa	64560
tctgatttat	aaaatgagga	aaggatctga	atagacattt	ctaaaaagag	gaaatacagg	64620
tggccaatag	gtatatgaaa	atattctcaa	catcactaat	tatcagggaa	atgaaaatta	64680
ataccacaat	gagatatcat	ctcccatccg	ttagaacggt	tattatcaaa	aagacaaaat	64740
ataacaagct	ttggcaagga	tatggagaaa	agggaatctt	tacacaccgt	tggtaggaaa	64800
gtaatttagt	acagccattg	tggaaaacag	tatggaactt	cctcagatta	aaaactaaac	64860
taatatatga	tccagcaatt	ctactactgt	gtgcatatcc	aatgaaaata	aaattattat	64920
gtggaagaga	tatctgcagt	gcaatgttca	cggcagatta	ttcacaatag	ccaagatatt	64980
gagtcaacct	aagtgtctat	caaggggtga	atagacaaat	aaaatggagt	gtatatatac	65040
acaatggaat	actattcagc	cttttggaac	atggaaattc	tgtcaatcgt	gataacaagg	65100
atgaacctgg	agaacatcat	gttaagtaaa	ataagcctgg	cacagaaaga	caaataccac	65160
atgatcttac	ttatacgtgg	aatcttaaaa	catcaaactc	atagaagcat	aaagcagaat	65220
ggtggttatc	aggggctggg	gtggaggcag	tgactgggga	catgctagtc	aaaggataca	65280
aaattgcgat	tagctagatg	gaataatttc	aaagggcctg	ttgtacaaca	tggtgactat	65340
agttaataac	aacttattgt	gtatccccaa	attgctaaga	aaatagactt	tatgtgttat	65400
cacaacaaag	aataataagt	gtatgaggta	gtgcatatgt	taattagcat	gattcagcca	65460
ttctgcagtg	tataatttca	aaacatcatg	ttgtacacca	taaatatata	caatttttt	65520
gtcaattaaa	aataagttta	gaaatagggc	atatcattta	gggtttgatt	aacagaataa	65580
atatttttaa	aataggcatg	tcaatttcct	aaaagcttaa	tttttttga	aaaccctagc	65640
taagaacatt	tcatattctc	tgctttctgc	tttattattc	ttctgaatag	tgagcataaa	65700
aatggttatc	tacttggatt	tggggttaga	gatagaaaga	aaagtaaatt	attgagaaag	65760
aggaaaatag	taaatactat	cttgtcactt	tttcaaagac	ttcttcaccc	ccacaaggtt	65820
ggcacaactt	tataagcatc	tggttgccct	ttcttcccgt	ttttgtgata	agtcagatga	65880
aaagttaaat	ggtctaacaa	aattcactct	tttaagcaat	acggcagaga	atacttttgt	65940
agaataattt	ttggtaaaat	aaataattat	cctctaattg	ttcttaatat	ctggaagttt	66000

tctaaactac	agcctatttt	tacctttatt	tggtctgata	cttaggtaat	cgtgtgtgga	66060
tttatcactg	acaacctggg	ttataaatta	taataaaatt	gcgtatgtgg	gttttttacc	66120
ttcattttaa	aagaccagct	cattaaaaaa	aaaataatgc	tttaagttaa	gaaaatatac	66180
attaatgaaa	ctatgctcaa	ctactttaaa	tcaattataa	attttattta	tgagttcttt	66240
gctaggatca	ctgtctaccc	tgcagctccc	gactttaaat	gacatattca	taactatgaa	66300
atctattaca	atatagcttt	tcactgattg	aattcatgat	aaaaacatta	ttattttttg	66360
ttagatatgt	aaaattagat	agaattcatc	tcactagaat	acatctttag	ttacagtttc	66420
attgtatatt	ttctcagcaa	agcacatgcc	acctggtggc	tgaaagaagt	atgtaacata	66480
ataggtttcc	aaaatactgt	ggaaaaccaa	aggttccaca	atatcatttt	gaatccgttt	66540
ctaaaccagt	agcaaacgtg	tattttgggg	caagacgcac	cacagtggca	aatcttacac	66600
cttcaaaagt	taacacccag	tggagtctgt	gtcaaatgga	gacacgaaac	agcaatactc	66660
cattttaagt	attttttaaa	atctttccag	aattgttttg	cattttgaaa	tatgtttgct	66720
tctttatgtc	atgtccattt	tactaacaga	agtaaaattg	tttacatgca	gaattgcttg	66780
tcctggtaca	cacctagaaa	acggaggtaa	atatctattt	tttccttcaa	ctaactaaga	66840
agggaggtga	ttagccaatg	tgggaggcat	ttttttcttc	cagaattttt	actggagtag	66900
gccctatgtg	ttagattcca	tgctaacaga	gggtaaggtg	atagagagga	atctctggag	66960
gaactctcat	tgtattgaaa	ttcagaaaat	ctggcttccg	gctcacagcc	agctggttgt	67020
gtaagctctg	gcaagcctta	agccacctga	tgcacagata	agttacatat	gcaagtccta	67080
cattttaagg	ctttaagtgg	attgattttg	tgtgtgtgtg	tgtgtgtgtg	tatgtggcta	67140
cagtggaagt	ttcttttatt	tttcgttttt	aattatagta	aaaacacgta	atataaaaca	67200
tatcctctta	gccattttaa	gcatatattc	agtagtgtta	actatattca	tattattgta	67260
taacagatct	ctagaatttc	tcacttgcaa	aactgaagct	atacctactg	aattgaacaa	67320
cttttcattt	ccccctaccg	cagcccctca	taatcatcat	tctactttct	ttttctatgc	67380
ttttgactac	tccagatatc	taacttaaat	ggaatcatat	aatatttatc	tgtcagtgaa	67440
tggtttattt	cacttagcat	aaagtcctct	aggctcatcc	atgttttagc	atgtgacaga	67500
attttctttt	taaaaatgaa	ataatatgat	atgccattgt	acataccaca	ttttattcat	67560
ccatttatct	gtcaatggac	atttcgattg	cttctacctc	ttggctattg	ggaataatgc	67620
tgcaatgaac	atagatgtac	atatatctct	tcaagatcct	tttttcaatt	attttggaaa	67680
tatatccaga	agtgggattg	ctgggtcata	cggtaatggt	gtgtttaggt	gtttttgagg	67740
gatcttcact	ttgtcttcca	taatggctgc	atcattttac	attcccacca	gcaaggcaca	67800 ·
agggttccaa	tttctccccg	ttcttgccaa	cgctcattaa	tttttgtttt	tgtttgtttt	67860

actaacgggt	gtcaggtgat	atctcattgt	cattttgatt	tgcatttctg	taatgattag	67920
tgatgtaggg	tctcctgtaa	tacacctgat	agccttttt	tttttttt	tttgagacct	67980
agttttgcac	ttgttgccca	tgctggagtg	caatggcgca	atcttggctc	actccaacct	68040
ccgcctcctg	ggttcaagtg	attctcctgc	ctcagcctcc	tgagtagctg	ggattacagg	68100
tatgtgccac	catgcctggc	taattttgta	ttttagtag	agacggggtt	tctccatgtt	68160
gatcaggctg	gtcttgaatt	cccgacctca	ggtgatctgc	ccgcctttgc	ctcccaaagt	68220
gctgggatta	caggcatgag	ccactgtacc	cggcctaact	tgatagccat	ttctatatcg	68280
cttttggaga	aatgtctatt	caaattcttt	gcctattttg	taatcaggtt	aacacctttg	68340
ttgtttattt	gtaggagtta	cttatatagt	ttgcatatta	accccttgtc	agatgtgtaa	68400
tttacaatta	tttttcttat	tctgtacatg	gattctgttt	tttattctgt	tgattctttt	68460
ctttaatgtg	tagcagtttt	taagtttgat	gtttgtttca	ttagtgtatt	tttgcttttg	68520
ttgcatgtga	ttttggtgtc	atatctaata	gattactgca	aaatctaatg	tcatgaagct	68580
tttctcgtat	gtttccctct	aggagtgttt	tagtttaġgg	cttatattta	tatctttaat	68640
ctattttgag	ttaattttta	taaagtataa	agtgagagtc	taacttcatt	ttttgcatgt	68700
gcctatccca	gcaccatgtt	ttgaaatgac	tatcctttcc	ccattgtggg	atcttcgcat:	68760
cttgttatat	tatttgacca	tatacatgag	aatttattt	ggggctctct	attctgttct	68820
attggtctat	atgcctgtct	ttatgctagc	accatactgt	tttgattact	atagtgttgt	68880
aatatgtata	gaaatcagca	agaatgaggt	ctccaattca	ttcttgttta	tcaagattgt	68940
tttggtaatt	cagggaccct	tgagattcta	tacaaatttt	agaattttt	tcctgtttct	69000
gaaaagggct	tagaataatt	taactaaata	tttaggttgt	aaagtgtagc	agtcagtgtt	69060
ttcttaacct	cttggttcac	tctagcacga	aaagctggcc	actgtatcta	atgattcaac	69120
ttcccttcac	tcctataaga	acatttattc	ttcacctact	cttccatgat	gatcagagca	69180
gattcacctc	tcattttcaa	aatatctcca	ccattcatta	ttcataccat	cctgagccta	69240
ttataggaac	ttaccaaatc	atccattttt	agccattgaa	tctccctgct	gtgaattaca	69300
ccctacaatc	cttgtcccac	tttattttgt	ttgtgacttt	tattctgttt	agccagctgt	69360
ctcttcctcc	ttgggcttgc	cttgtgcatt	atcttctagg	cccttagcca	agcactaatc	69420
tttcactaat	tagctaacca	accactaacc	tgctgcagct	tcctgcatgg	gtcttaagct	69480
catcatctta	tececageee	caggacacca	gatactttcc	ttccctgaga	ctgtcacaaa	69540
gtatgcccca	ccaaatatag	tgactgagag	agtcactgag	ctgcacagtg	caatctttac	69600
atttatagtc	agctgaactt	aagaaacttt	ggacctttcc	tcaggactca	gtgaagtctg	69660
tgctacatct	gccggcagca	agatgcaaag	gctgactaag	ccttattatt	ctgttatctt	69720

caatagtaaa	tgacttgagg	ttacctaaga	ggatgcattc	actaaaagtg	gtaatgaaat	69780
gacttacaaa	tgcgatcaag	aggtttagaa	agttcaattt	tttgtggctt	atgcaaccaa	69840
cccacgagca	gtggaaatag	catcttagtc	catattatct	aaaaatttac	cttagttaac	69900
tattcattga	ttgttctgtt	atattcaagt	agtttcataa	aatagatcca	cgatttgaat	69960
gtgaaaatgt	gcttaaaagt	gtaaatgaat	tgtgatgata	gctactgttt	ggtgataaga	70020
tcactaactg	acaaatagtg	tgctaataaa	caatgaagag	attttaagca	gcagaactgc	70080
atcaatgttt	aaggatgtac	acagatttta	aatgatttt	aaagacacac	aaaaatacta	70140
ctaagagaaa	tattcatgga	cttgactatg	aaatcaatca	catatataga	tgtattgtag	70200
taagcagatc	caaggaaact	agcatgcatt	gaaacattat	aatgtggtag	gtgtttgtac	70260
atgtgagttt	acttaattat	cacaataagc	ctgtggtgta	gatggcatta	ttgtcccatt	70320
tcatatgtga	agcttttaaa	ccttaaagag	gttaagtgtc	taaggtcgca	gagctaatag	70380
aagggccaac	actaacaccc	gggtctgtat	gacagcaaaa	ttaattcgtt	ttctactata	70440
ccgagggtta	cgtgacagct	ttgaaggaag	aaggatacct	ctgtagctca	aagatgactg	70500
aggaattcag	tatgtgaggg	ttgaaaataa	agctgatatt	gaacattttg	aatatttgtt	70560
tctcgaagct	tatatgctaa	agatttctaa	cattaatatt	ttcagtataa	atacatatat	70620
acgttatata	tcttacagca	gcatgaatac	gcatgtatgg	gtcttttaca	taagtgactg	70680
tacatttttt	aaacattcta	tatattttgt	cactctagct	taatataact	tcttaaagat	70740
aaggtccatc	cttgatacac	aattgacttg	gcttctggct	tgtgtagaaa	tgtgtgcaag	70800
tccctcaaat	gctcatgttt	cccgagggga	tagagaaaaa	ggtaagcact	taccgtctat	70860
gtaccccacc	ccagctctgg	acagatettg	gactctacaa	ccccattcac	tcattcagcc	70920
aatgttgttt	gactacctgt	tacatgcaat	gaactgtgct	aggcacaatg	ggaggcatgc	70980
aaagatgaaa	aataagacaa	aaaatggcct	cttgaattta	tattatcaga	tccaccaatc	71040
tgcctgaaaa	tgtcccagct	gtctttggtt	tatcaaatgt	atcacaagta	ccttgtcaga	71100
gtggttaagt	attatattca	ttcattctca	taaagcttgt	gggctccaaa	cttcaaccat	71160
gctgtaagag	catgggactc	taacttcaac	ccatttaaat	tattattgct	gtgacaagaa	71220
cattttaaaa	tctctcagtg	aatcaccagt	ggtagcagct	ttacttttta	acactaagca	71280
gcagttagaa	aatcatatca	aatattctgg	caatctgttt	taaaactaat	tcgataataa	71340
tgtaattagc	aaagtaagga	atatattact	attatgctgt	attatgactt	agctgaaatt	71400
gcacatgcag	atgtataatg	tggaatttct	aaaaattcca	tttagaaaat	ttagcagtgt	71460
atttaaatat	ttcttattca	caggcaccca	gctgtgatgg	aggaagctgt	atttaaatag	71520
tcaaaattga	aggtgccagc	agatttcaaa	cagaacacgt	gaaagggaac	tttttataaa	71580

ctttgttttc cttcttggc	a cggattatta	caacacactg	aaattgaggt	gtgaggttta	71640
ttttaaccat ctaagtaca	t ttaaacatta	catgatgtac	tactttctaa	atgcataact	71700
gtctgataat attcactga	a agtacttgtc	aacctgttca	cctgtgccag	atactattag	71760
cataagtggt cactaaatt	a gtgtacatat	tagagtacac	cgtgaacaag	gttttaccta	71820
aggtgtggcc atagttatt	c aaagctaaca	tgctttatgc	actattacat	atacatatat	71880
attacatatt atatatatt	a tatataaata	agatatatat	gtacacacat	atttgtgtgt	71940
atataataca tatacatat	a ttatatgcat	acgcatatta	tataaacatt	atatattata	72000
tatacatata ttatatata	a tatacatata	tactatataa	tatattatat	attatatgta	72060
tacatagata catatgtat	a catgtataca	ttatatatac	tatatattat	atgtatacat	72120
atattatata tattatata	t ttatatatac	atgtatatat	acatgcatat	atgtatacaa	72180
ttatataata tataattgt	a cacatattat	ataatatata	ctgtatatat	attatatata	72240
atatatactg tatatatat					72300
aatgtgtata tattatata					72360
tatatattat ttataacac					72420
ttatttataa tacataatg					72480
ataatacata atgtatatt					72540
taatgtatac atattttat					72600
acatatcata tataatata					72660
catatataat atataatgt					72720
tatatgtgtg tgtatatat					72780
taaggccgtt tttaagtac					72840
getteeteat attaaggea					72900
ttttctttt ggaaacgca					72960
atttattgag ggccgtgtg					73020
aagtcctcaa aataatact					73080
agggaggatg tgtgactta					73140
aatccaatcg atttggcto					73200
tetggggtae atatgeagg					73260
cctatcaacc tgtcatcta					73320
ctccctccc ttgcccgc					
atccatgtga gaacggagg	ja tgttttgggt	agrgaaacta	cuctacatga	a Lactataata	, 5 . 4

gtggacacca	ttatagtgtc	atatacaaaa	cccacagaat	gtacaacacc	aagagtgaac	73500
ccttttgtaa	actatggact	gggctccata	atggtgtgtg	aatcagttgt	aataaatgta	73560
cagctctggt	ggaggatgtt	gataaagggg	aaggtatgca	tgtttagggg	tagagggata	73620
tggaaaatct	ctgtaccttc	tactaaactt	tcctgtgaat	tgaaaactgt	tctaaaaaat	73680
agtccattaa	gaaaaaaaca	cacaacaaca	agttgtaaca	ctaggacaaa	taataattca	73740
gtcaaatcat	cattaaagca	tgacgaagca	gacctcttct	attcaccaac	agatattaaa	73800
ttgacagaag	catagatact	gttttcttt	taaaaaggca	tatttgccat	ttaaaataat	73860
tggaagtcta	attttgtatg	gtcttgtacc	aaatgaataa	cataaattgc	ttcttggaac	73920
ctagcaacct	atatcagaca	gtttaaaaaa	agaactaaaa	acacacaaaa	aatgggaacc	73980
aaacataaaa	ccaagacatg	tacagagtaa	agtaacatga	aacaccattt	aacagccttt	74040
tagcaaagtg	ctctacatga	ttagctagat	tgcaaaatgt	gtagaagttt	aatctctttt	74100
ctacaggata	gtcttctaaa	tgactgagga	cagttaaact	tctacttttg	catcattccc	74160
ttcagtggtt	tgtcatctga	catggttttc	agaaactcaa	agtttcctcc	tgggtacttt	74220
ctagtttaat	atctctcttg	aaatatggta	gctggaactg	aatacacaac	tccagatatg	74280
ctatgtccaa	cacaaaacag	·aagaaaatta	ttaacactta	ttcattatta	taaagccatt	74340
tgtatgaata	aagcctgttt	tcatttgtgg	caatgacacc	caccactgag	tcacattgcg	74400
cttgtactca	gttaattctg	aacatgaatc	tatatattac	agacataagt	tatcttacaa	74460
ggtgttaggt	aaaagaccag	ccactaggat	cacacagcct	ccatgtgacc	ttgagcaaat	74520
cacctcaccc	tctttggacc	tcaatgtcct	cgtctataaa	atggagataa	taaaattgct	74580
ttttcatagg	gttgctgtga	ggagtaggta	gaattataca	tggaaatctc	ctcaaacaag	74640
gtctggcaga	aggcaaattc	aagagttata	aagaaccagg	gacagagaga	gatcacgtcc	74700
atagatgaag	gttcattaac	ctagaacaat	aggtaaaaga	atcacaattt	acttgaatac	74760
ggaatcagta	tttaaatacg	tctagtaatg	ttttgagaaa	aaacattcag	tgcagaggcc	74820
agaaacagag	aagaaagtaa	gccttcttgg	atctggagat	ttcccaggag	agacgagaga	74880
aatgaaggca	cgcaggaagc	cacttgcttt	aagcaaggag	atcataaaag	taaagtttag	74940
gtgggagaga	gggacataca	gagattatga	aagtgaccct	gaaagagatt	gaaatttcca	75000
caattccaaa	attacaactg	aacttcccaa	atattaatat	aatgatggtg	cgagcctgaa	75060
tctactttgc	accagagtct	aagcaggtaa	acttaacatt	gaatattata	tgactataag	75120
ttgcagtttt	tctgaaacta	tttatttatt	tatttattt	gagatgaagt	cttgctctgt	75180
ggcccaggct	ggagtgcagt	ggtgcgatgt	tggctcactg	aaacctctgc	ctcctgggtt	75240
caagtgattc	tcttgcctca	gcctcctgag	tagctgggat	tacaggcatg	tgccaccacg	75300

gctggctaat	ttttatattt	ttagtagaga	tggggtttcg	ccatgttggc	caggctggtc	75360
ttgactgcct	tacctcaggt	gatcttcccg	cctcggcctc	ccaaagtgct	aggattacag	75420
gcgtgagcca	ccatgcccgg	ccctctgaaa	tatttctgat	atcaaattgt	ctctcttaat	75480
atcagactgg	gggcaatttt	tgtttcgaaa	acagagacac	tatcttattc	tagcaagcat	75540
aagaaattat	agagaaagac	aatgagtgta	ataactttga	aagatggttg	agctctatat	75600
aaccaatatc	atgtgatttc	ctagaactag	aatctccata	agagcaagta	ctgtttggtt	75660
caactaccga	aaccataggg	gttagcacaa	ttcctggtat	gaagtaagtg	ttcagtgatg	75720
acctgttgag	tgaatgaagc	aaagacattt	gtattaacct	attaacctca	atattttccc	75780
catagtgatt	atgagaaaaa	cactttaatc	aagaagggta	tttgggagga	caacaaaaag	75840
agcaactgct	aagtcctatt	ttataaccag	tcttacagtg	aaaaggaccc	tcaagggcta	75900
caaagtattg	cagaaatgat	aaagatgaga	gaaacacagg	gtaatatatg	gaagcctgta	75960
tagaggaaaa	aagatgaagg	tccaaagatc	ttgtctggac	caaaggcatt	taacttgtgg	76020
aagggcagtg	tagctcccct	agatttaacc	attattaaaa	ttttcatatt	tacctgttat	76080
actgtaatca	actagacata	gccttagttt	cttactactg	caaataaaag	gtgaatgtaa	76140
tcttggaaat	tattataacc	actttaaaat:	taaatttaaa	tatctaagca	aaatcaacct	76200
gctgagttct	ccagattttc	caccaggcac	acagacgtgt	gccactacct	atggtccttg	76260
ccagtgtgac	cacgtcacat	cctatgtaag	aacaggccaa	gagattcgga	aggttggcat	76320
caataaatgt	cgtaatttaa	taaactatat	tatggaacaa	tatgcctatg	aaagtcacct	76380
gccattgaca	gttttgtcat	ctcagaagat	gaatcctgat	taccaagaag	aatttttgtt	76440
gctgctacac	aatgtaaata	aaatcgaata	tgttcggaac	tgccttctta	gtacttccac	76500
gctgcctctt	aatcttttca	tcatcaagag	aaaagagtaa	cggaaaacta	actcaaaaag	76560
gaggaaggca	ggactaagga	ttcagaccct	ttgagaatgt	cactgtatag	gaaagaatac	76620
ctactaactg	agtcctggtt	acagcaaaga	aacatggaag	gagtattgga	agaaggtatt	76680
cataagaatt	atttgtaacc	tcatgaaaga	aaaagggctg	tatcagctat	gcctatttct	76740
tcccttgatt	tttgtgtgtg	tacacacaca	cacaaacaca	caaacatata	taataattca	76800
tacatatgta	tatatacacg	gtgtgtgggt	gtgtgcaagt	gcacacaatt	tctttttcc	76860
tctctgcaat	tttccccctt	gttattttat	atgaacattt	ttgctagcag	ttaagtttac	76920
aatgtaagct	ttagattata	aaatgttcag	gcggaattta	aggctattta	atatcagcta	76980
gagatggaca	tcttaaatgt	tggaactttg	tgttaggaga	aaggggaaaa	catctttatt	77040
tggaggaagg	atagaaagca	tagagttttg	ttttatagaa	gttaaatatt	tgtaggaagg	77100
ctacagatcg	taagtaatca	gagtaagctg	tggtgattgt	tattaagctg	ttgtctctca	77160

gctacaaata	aacaattcta	tacattgttt	tgtggtgctg	gcaccaggat	gggactctgc	77220
ataacacatg	teteetttge	tacctggttt	tgccaatagg	ggcactagag	ggaggctaca	77280
aaattgaaag	agaaagaaga	catctgatcc	ttcctgatta	cttgctaatc	ctgtcagcct	77340
tgcccaacca	ctgcccttta	ccctgccagt	agcagttagt	tccagtctca	attttccttc	77400
ccaaaaacgt	ttttttgttc	atccatgatg	actatactag	ttacctgcct	tatagagtca	77460
tcaaggaaaa	attttgtgca	tcatactgag	aaccaggaga	cacgggtttt	tttaattgtt	77520
gtttatttt	gtctttttct	tgttcctaac	ttacaggcta	atgtaacctt	aatcaagtta	77580
gctttgtgca	tttcttattt	tataaatagt	gatgtgtttt	ttataatcta	caagagtgtt	77640
gtaagcataa	ataagaaaat	acctgtgaaa	agccttagat	tcagaaaaga	ataaaatttt	77700
gtgctaagat	tcaatatggc	caaagaaata	attgttaata	ttaagccttt	tggaaaatat	77760
acaggcacca	atccagatga	atgactaata	aacagaaaat	cagtcaaata	aaagtacagc	77820
agtagtagca	gggaaaatat	gtttttttt	cttcccaaat	aatttattta	aagaaaaatt	77880
aaacttcaag	tagattgaat	agcaaaaggg	aatttcagta	taagatgcta	aacaccaaat	77940
attttggaat	ggctattttt	ttggctttca	tctatctttc	tttgtttatg	gaagagagta	78000
caagaggagg	tgggaggagt	ttgtttatat	agtaaagcta	tgaaactgag	aagagtaatg	78060
acaaatcttg	actactaaat	ttctaatgta	atctttgctc	aaactccagt	gcaacaatcc	78120
cataagaact	gtttatcggt	gctgggatga	ggaaaatcac	gagttaagta	ctatgttaga	78180
aaaaaaaaa	cagaaaattt	tttaaaaagg	gtaaaatctc	ttgacatcca	taaataacaa	78240
ttagtagaca	tcactgtcag	gctcaggtag	aagtcccaag	gctaaatggc	tataagaagt	78300
atatttaaag	tctgttttga	cctattaaaa	caatcaaaat	ataaagaaat	ccacatttta	78360
gccttgttaa	aataatttta	gtaggatttc	tctctttctt	gaagtattta	tcaattggcc	78420
catttaaata	ttgaggcaca	tctgtgtata	ctggttaaaa	ataaaaagta	ataatgtaaa	78480
actagacctg	cttatattta	agatactatt	gccagctgct	cttgtttcct	gagaaccagt	78540
tgcagtttcc	tgcttgttat	ttctcaatca	ctagatacat	acatacatat	atgtatgtat	78600
aaagtagaga	agacagtttt	tattgtattt	ggctctcagt	tccactcggg	aagccaagtc	78660
cctaacacta	tatacactgt	atacagctgg	cgctcagtat	cagtgcattc	aaccaactgt	78720
ggacacaatg	agattgcatc	tcacgccagt	cagaatggca	attattaaaa	agtcaataaa	78780
caacagatgc	tggcaaggtt	gtggagaaat	aggaacactt	ttaccctgtt	ggtgggaatg	78840
taaattagtt	caagcattgt	ggaagacagt	gtggagattc	ctcaaagacc	tagaaccaga	78900
aatatcattc	gatccagtaa	tcccattact	gggtatatac	ccaaaggaat	ataaatcatt	78960
ctattataaa	gatatatgca	cgcatatgtt	cactgaagca	ctattcacaa	cagcaaaatc	79020

atggaaccaa	cccaaatacc	caccagtgat	agactggatg	aagaaaatgt	ggtccatata	79080
caccatggaa	tactatgcag	ccataaaaac	aaacgagatc	atgtcttttg	cagggacatg	79140
gatggagctg	gaagctatta	tcctcagaaa	actaatgcag	gaacagaaaa	ccaaacacca	79200
tgṫgttctta	cttgtaagtg	ggagctgaac	aatgagaaca	catggacaca	gggaggggaa	79260
caacacacat	tggagcatgt	tggggggtgg	ggtatggaac	gcatcaggaa	aaatagctaa	79320
tgcatgctgg	gcttaacact	taggtgatgg	gttgatacgt	gcagcaaacc	accatggcac	79380
acgtatacct	atgtaacaaa	cctgcacatg	taccccagag	cttaaaatat	gaatttcaaa	79440
agatcttcat	aaaaataaca	atagaacaat	aaaaataata	cagtataaca	actatttaca	79500
tagcatttac	attgtattag	atattacaag	taatctagag	ataatttaaa	atatacagga	79560
gaatgggcat	aggttatata	caagtactat	gccattttat	gtaagggaat	tgagcatctt	79620
cgaattttgg	tatcctgggg	gttctgaaac	caactcccca	cagataccaa	gagaggactg	79680
taatgttcac	acccctgaaa	acaacatgag	gatctcttcc	tttttcatga	tttgcaaatc	79740
aaatttgaga	agacccttat	tgttttggta	tcttcttcca	ttttatttct	tttgcatatg	79800
tgaactactt	caatttctgg	cccttccaaa	tgattccatt	tcttatttta	tagaacattt	79860
cctgttaatg	tactttccaa	atatgcctgg	cacatggtaa	attttgactc	tatattctgg	79920
aggaatatca	aaaatttgga	ctgtgtcatc	tccagaagga	catacaagtt	gttgaccttg	79980
ccatgtgatg	gaaggcagtg	ttctgatttt	cttaatttcc	ttgaatatgt	gccatggaag	80040
cttaccatta	ttgcctttaa	ctatagtatt	tcacaacatt	ttataaaacc	gagaaattta	80100
gtaaagtttg	agaatgagcg	gtcagtagtt	aaaggacatg	ttcaatcaat	acattatata	80160
gtattgttta	ttataacaca	atacatgata	tagtattgtt	tagtataaca	tagtctcatc	80220
tgctttatca	ctaaactaag	tgatcttgga	ggacagaggc	agtttccttc	accttggcac	80280
ccaaagtctg	atgaattata	ggcattcaat	aaagatttaa	taaactgtac	tttatggttg	80340
agcagattat	ttgtagtcag	tcacctctac	taaaactcca	tatgttcttg	aaattcttgg	80400
agttcttgga	gaacaaaagg	aaagataatt	ttctattact	aggacagaat	aaaacatgct	80460
catttgtttt	aggtgtacat	tttgattctt	ccaatgtgca	gctatcaaat	caaccattag	80520
gatggggatg	gcaagggcga	gtggtactgg	tttgtttcaa	ttctggagag	cttatgtcta	80580
tgtggttcac	aatgtgatat	ggctcactag	gaagactagg	aagtctcagg	attaaatttg	80640
ccctttccca	gaaaagctct	gagtacaaat	gtgtttaatt	cagaattttc	aatcagtgat	80700
aaagaggaca	atatgcttcg	ttttttaaaa	aaaggtaatt	acttgaagtg	gttaatgagt	80760
tgactaagaa	caaaaacctg	cttgagagtt	atgtgtaatt	tagatattgt	gtgcacgagt	80820
atgctgaaat	gccatttgtt	tctcctttat	ccattttccc	ctgtaggctg	gtctgttctt	80880

gccactagtc ttaataaatg ataaaatcag aatctcaaat gaattggaga taccttatat 80940 81000 aatatttaat aatgagetga aaaagagace caaacacatt cactattcac tttttgagec acaatccagt taaccatcag teettgaccg teetttgtta etacaaaaat actgtatgaa 81120 actatetect tacagagttt ccaetgetta ecaaacteaa ettgttttae agtaagacae ccttacctcg gaaatttctc ttttacaaaa tctgacaact ttttacaaat gcttttaaac 81180 81240 caaagagaat ttgtcaatat atttaatttc gtgtttaaat tttggtagta actttgagac cgtcaaacta tcatgtaaat ctttctgttc gcaagacata attggagaaa agatcagcac 81300 aactctggcc actcactaaa ttttagattg gaaaatggcg tttctttgac ctttgtccag 81360 atatcctctt aaagtataca aggagggta ggaatggaag ataagagtcc cagaaccatg 81420 81480 gtcccctcac agggatagcc tgccatatgt cacagaggac agattctcaa ggagaaaatc tggatgactg tcaacaaaat tcctctcctt tcaaggctca ggaaactcac atctcaaaac 81540 81600 acaggcaaag aaatgaaagg aataatcatt atatggtcca tttgtgattt tttttcattg ccctgagtgg ctgaatcctg tagtttggct ttctggatat ttcttcatcc ataaagataa 81660 81720 taaaaatgaa atttcataga atagcttcag ctataaatgg aagtaaaatg cccaaaaaact tgaactatat ggggaaaaaa aaaagttgtc tagaggccat ccttagaata.tttttttta 81780 81840 accttagaat tgttttacta gagaaggtat aaatagaatc gagatgatgt aagttagatg tcaacatttc caacaatgaa tattgtaaga aaagtcaatt aacaatggat acaataggca 81900 81960 ctatatctgt ctgaatagtt attagatgat tgagattgaa ttaatttaca cataatttat cacacgaatg tgatcttagg tataattgca tcacaccttg tcagatctga cttgcttttc 82020 tctaaaaaca gcatatgcta ctcttatgac aaaataatct tagatagaac aatactagtt 82080 82140 cttcaatgag aacacatgga cacgggaaga ggaacatcac actctgggga ctgttgtggg 82200 gtgggggag tggggaggga tagcattaag agatatacct aatgctaaat gacgagttaa tgggtgcagc acaccaacat ggcacatgga tacatatgta acaaacctgc acgttgtgca 82260 82320 82380 ctagttcttt aagtcattaa gtttctaaaa atatacattt ccactggcaa aatgataaaa 82440 ttagtgcccc caactcactt gaactttttt tgcacatata ttacaaacaa taaagctata tacacgttgg ttcattttt tcctttcctt tctctttcc tgtttgcttc cctaaaaaaa 82500 82560 aaccagtgat aagattcaga aaaagatatt tttaacattc tctccagggc cattatgagg 82620 aactttgttg caataatgat aatacccact tttcgtgggt ctgacatgta gaggatgaga ttctaggtta gtctggcaag caaggcacgt aagattattt taaaaaaatag taatggagtc 82680 tgcaatcctc aattctacag agattgttgt taaaattaac ttttaaaaaa actaataata 82740

tgtgaaataa gaatagaaaa gtaagtaaag gataccaggt ggggtaagaa caggtggatt 82800 tatttttaaa taatagttct agcttttgaa ataaacaaaa gatacactga attaatccaa ccactctctt ctactcgcca tccttagact cgagaaggga aataatacat ggtctgaatt 82920 atttgttttt ttgtatatgt ggaagtcttt tctgtttata aacagaagga aataaaaata 82980 ttctgccaga aagacacagt gctaggtgtt tgtcaaacat tatacttgtt aatcctcata 83040 aactcaggac tattgagttt gtcctgccca ctttacagaa aaggcaatga aagcgcagag 83100 aagttaactg ccctaaatca cagaactatt aaatagtgaa gcaagaaatt aacaccaagt 83160 tcatctggtt ccaaatttca cactcctgaa accctgatag atctaatttt atgtttcccg 83220 aatatttaca aaacagcaac aatttcaaaa attctgtaat taattttctg aataattcac 83280 tggagagett acceteagtg agetececat gactgggtgt atteaageae tgagtgttea 83340 tttgataaga tatcagtttt gtgagtgctt aaactagaag aactttgagg ttccttcaaa 83400 ' ccctgtttct aattgataac caaactgtgc acctgaaaga gaagaaattc tctgtgatga 83460 caatttttcc tataccctga tccctttaca tgggacctga ggactgttta ctcacggcaa 83520 83580 ccttacgtgg gtagacatta ctcaatttga gtcagagttg ggaattagca gctccaaatt caaactgaaa aagaaggtag tcaatcacag atgcatgaca ctagcttaca cagatgttct 83640 gctttcctct gactcactct ttgaggcttg gaaagggata aactttattt taatatagca attgcaatac agtcatacca taactcatat ttttatatta tgccttttct gccttgtttt 83760 atgcctccgg ttttgaccca acttttgaat tgttcaagag cctctaaaac aaaggaggag 83820 gagetgagaa caagatcaac tttttatttt ttttatttt aatttttgtg ggtacatagt 83880 aggtatatat atttatgggg tacatgagat gttttgatac aggcatgcaa tgtgaaataa 83940 84000 gcgcatcatg gagaatggga tatgtatccc ctcaagcatt tgtcctttga gttacaaaca atccaattac tctttaaatt atttaaatgt acaattaagt tattattgac tatagccacc 84060 ctgttgtgct atcaagtagt gagtctcatc cattctttca agttattttt cgatattatc 84120 tcactccagt taagatcact tttgaaagaa agatttaagt ttatatttct aaggaaaagt 84180 84240 aatattgtta taaaagcatt gaaaaaaaga ccctcaatgc ttttgcaaaa caataatgtt ttgctagcta gggacaacac tgtggttccc gagatagagt ggaacacgat aaaaacagaa 84300 84360 agatttttat caacttacta tctctctgat aaagcttcag ttggtgttat ggaactttta cagcccataa gagtaattct cacactagac tgtttagcta ttaacttcct atttttatt 84420 ttatgatctt tattatcttt gagttgtctg agggctgttg agcttgtggc tgggccctaa 84480 tctttgacag tgagatttct ccaagttaga gaatatatag aaaagagaca ctattttgtc 84540 agcatccctg gcttagcaat attctaaacc acataggtag ttctagttag ccatagggac 84600

aagtacccat taggggccaa agttacaaag accctgcaaa acaacatacc cctctttatt 84660 attattctag aaataataat ttctgagtga agtgttattt gaaaaattag ccaatgcctt 84720 gctacacaga ctgtaataca ttcacacctg atgcctgagt ttctgaaaag gacaccaggt 84780 taccagctgt actataaaga agtctgagca aaatggaagg tcaggttaat tgatataacc 84840 taatcaaata atcaactagt ctcacatttt ccaattcatt tggtatccta ttttataaca 84900 atccttttgt cttaactgga ataagtctag ggatgaacac tactgctttg cttggtgtgg 84960 tggttaataa tgagcgtcaa cttgattgga ttaaaggatg caaagtatcg atcctggatg 85020 tgtctgtgag ggtgttgcca aaggagatta acatttgagt cagggggctg ggaaaggcag 85080 85140 acceaecett aatgtgggtg ggeaecatet aateagetge cagggaatgt aaagtaggea ggaaaatgta aaaaggtgag actggcttag cctcccagcc tacatcttcc tcccatgctg 85200 85260 gatgetteet geeettgaac atcagactee aagttettta geettgegae teagaetgga ttccttgctc ctcagcttgc agacagccta atgggggacc ttgcgatcat gtgagttaat 85320 85380 85440 85500 tgtgtatata tatattagtt ctgtccctct agagaacact gactaataca catggcttca tttggtgata gtgaaagtga ttatccctaa taaggaacat ttgagacatc atcacagatt 85560 cagaatcaac tcaggtatga gagttgaaag agcagaatgg atagaacaag gctactattg 85620 gcaaagggta aaatcagttg attcaagaga ccttgtcatg cataattgat gtgaactgtt 85680 85740 tttaatgtca tttatttgtt tattcctgtg ctgagtattc atactttaat acttgaaaac atttatgtct caagtattca tctttggaaa atttattctg ctttcaaatc tatccctttc 85800 85860 tcttttttg agacagggtc actctgtcgc tcaggctaga gtgcagtggc ttgatgatgg 85920 ctcactgcag ccttgacctc ctaagcttga gcgatcctcc cacctcagcc tccctagtac 85980 ctgggactac aggtgcaccc cacgatgcct ggctattttt ttaaatttat tttttaaaga gatggctttt caccttgctg cccagactgt ttgtcttggc atcccaatgt gctgagaata 86040 86100 caggogttaa gtcaccctgc ccagctttca agtctattct gctttcaaag ttaaaaattc cctaatcccc ctgtgaaaac gaaaatgtgg tgtactggaa aaacctcaaa gatctggggt 86160 86220 caaatcttga ccatcactta ctcaccatgt gacctcgggc aaactgttta ccttccctga attttatttt attttatttt attttatttt attttgagag agtctcagtc tgttggctgg 86280 86340 gctgcagcgc agtggcatgg ccacagctga tggcagcctt gacctcctgg gctcaagtga tcctcccgcc tcagccttcc aagcagctgg ggctacaagc atgtgccacc atgcaccact 86400 gatttttgta tttgttgtag agacgatttt tcccatgttg cccaggctgg ttttgaaatc 86460

ctgggctcaa gtgatctccc cacctcagcc tcccaaagtg ctgggattac aggaatgggc caccatgcct ggtcacttaa cctcattttt aaaataagta tgataatccc ttccttgttc 86580 atagaactaa gtgaaataat atttgtaggc agcacagcaa agaagaggca ctcaacagac 86640 agtagctact attgaatggg ttaattatga tctgaaaact tcctttcatg ttctaaattc 86700 cagaaaattt gtaaaaatgg gctattagta tgtttttcaa attatataga tagaaaaaag 86760 ggttccattg ttaagtaagt ctgtgaaatg ccacatgcca tatccctttt cccttggtaa 86820 ataaaagttc atttaaacat aattaattgt gttgaaaaat cccaaagtaa aaataaaatg 86880 tttagcttta cggaaccaag ggtcttttaa acttatttga tcatggaaac atttcttccc 86940 agaagatata ttaacatcct aagaactttc ttgtattcca cttagagaaa tagcaagtgt 87000 gtgaccggac gcggtggcac acgcctgtaa tcccagaact ttaggaggcc gagatgggcg 87060 gatcacctga ggtcagaaga ttgagaacag cctggacaac atggtgaaac tccatctcta 87120 ctaaaaatac aaaaattaac cgggcatggt ggcacatgcc tgtaatccca gccactcagg 87180 tggctgaggg aggagaattg cttgaaccca ggaggcagag gttgcagtga gccgagatca 87240 cactaacgca ctccagcctg ggtgacagag tgagactctg tctcaaaaat aaataaataa 87300 aaatgaaaga gaaatagcaa gtttgtaact gttaaaatgc cagaatataa ataaatcttc 87360 aatattaaaa tacactgaat catctgtgat acctggatac gaaaattaag gctgatttga 87420 87480 ttttgagcag cagcctaaga caaggcaaga taaatgagga atacagtgaa agtgaaagac 87540 cgctgactag ggccaagact tggcattata atcactttcg gttggtagtg ttttaatgac ttaattccaa actgccttcg gaacgaaggg tatacaggat cttgttgaaa ttcttagtgc 87600 agttgttttt ttccctgatg gagggagaca cagtatatca gtgtagacct acgattctgg 87660 ttgtactcct aaaaagtcaa gatgaaataa ggtaaaacat ttggaggaag accgtgagag 87720 87780 tattgcaaaa ctcacaatat ttgcatgctt acattttagg aagaacatca attttgtttt tctttcaatg gccataaata gtgctggagt tttcttaaca cttttattta tgtatatatt 87840 87900 cacttccttt gttaagctag caattctgtg tcatttccta ctgttctatt gggatgtcac 87960 ctgtagttct aggggacgga aaagggactg tgggactaaa ggattgggtt aattactttg 88020 88080 ctttatcttt ttaagtagca aaacatttta ttttaaagca ttcatttaaa aaagttgaat 88140 attaatcaca gataagttct taggaatatt atgaattgta atttatcgat gatctagcta 88200 cagtggcttt cagatttgtc tccatatcca tatgaaaaat aacatttcac agttattgca 88260 gttaaatata gccaagtctc agaacagttt ctaaagttga ataaagatag gcatttaaat catctgatat ttactgtcca aatctggcct tttcagttat cacattactt agaattttca 88320

ggtaaacttt ttttgctcat tctattgact cttgttaaca tttgtagtaa aagacaaaca tttcacctat ctggataaaa tatattcagc ttcctgaatt gttagcattt agaataaatg 88440 ccaacttgtt ttgataccca ttactacttt caaactgcat tacacaataa aatgcaaatg 88500 tgagttatta attagcagga tctgttttgt ccaagtgtgc aagagtagag ggatttttca 88560 acattetgea getgttacet atgaaggaaa catcatteae tttgetaaaa ggagetgeac 88620 aattacatac getgttatag acaaatattt tagtgtttee ttaatgetat tteataatgg 88680 atttcacatt gaataagata aattttacca atgctgccca atttctgtct ctaggttgtt 88740 tgtaaaagag aggatgatta cagttttcaa ggcaatgtgg agtgaaggta gagaaagagt 88800 tcttcatgaa cgacacaata tttagcaagg tcataaagaa atatgcccat acacgcatat 88860 ctatttaagt attcatttac atattgtacg tgcatctctg tatacatgtt gtgcccggtg 88920 aacatttgtg tgaatataac ctgacggaag tcccataaaa tgacaaaaaa tgaaaaacaa 88980 tgaaacatgt atatgaatga ctactataga tgatacagaa ggtagaccat tattcacaaa 89040 89100 taatgtaata aatcctttgc ccatcagatg tttctaccta gatttggggc ctttaaacat 89160 caaccaatta tggtaaatgt ttaactgtag gagttcaggc agacagccaa attctggttt 89220 tctggatacc ggttgtgctc tattgtggct agagccgctg ggatttgaat aagtaaattg 89280 89340 ggcaacacac tggtcctgaa gaaatgggcc tggcagtatt acctgaatgt ggcaaataat 89400 aggetaceaa gagteetagg gaaataette eeatttataa ettageteta ettaeetaaa gctagtttat tcccacagac acgaagagag agagagttgt ttttcttagc caagctccta 89460 caaaaaacag caaggttggg ggatgggagc acatccaatg tttatgcctt ttgtttagga 89520 aagccaggta totgaaatac atacatgata gocaactcot ototgotoco otococcagg 89580 89640 tttatttatt ttcttaacaa gcttattaac gaaattatca atttgcatga aactggtttg 89700 aacattggcc cttcctcaga atatttctta tctcttgtgg aagcactaac aaaaagggta 89760 gaagaagggg cctagacaat ccacacgttg gatttgcagc cactggatat ttcagattca 89820 gctgctaaag cctctttggt atacacaatg aggggcgact gaagtgactt ttcttagtcc 89880 atttcctctc cttctccccg tctcccgaag gtactccgtg ggtcccttcc ctttctctct 89940 tcacagtccc tcctgagcag tcccaaagct tcaaaccttg ttctccaacc ccctttccct 90000 aatgtctccc aactaccacc cccttcccca gtcaaactcc cctcccggtc accaccaaag cccggagaag tggaatgcac acaatgcctc ccttataggg cttgagctgg gaactgggca 90060 90120 geggeatete teccagtece aegeetetet tteeteaace cetateceet ateccetate 90180

1.00

-782 31

cccacccca gctccaagat catccggctt aacccattct gcaccaaagg cccacggagt 90240 tctaaggtgc ggataattaa cccgtctcct tctaacccgg ctaaatagtc tcactttagg 90300 ctaaagcctc acactttcgc cttaaagccc ctggcccctt acgcgcagac aggtagggg 90360 agtgcgaata ctactggatc ctaggaaatt ggttcccaag aaggctcctt ccaggatcga 90420 90480 ccgctacqqa qaaqtattcc aggagccctc cgttctgcgg ggtgacaatt agccaaaggt 90540 accgtacccg tgatacaaaa tccaagtatg attgttgcat ttgaatgtca ttgttgttga ctcattcccc tccatcctgt aattattcaa ttccgcgtag actcgacgac cctatcgatc 90600 tccctcggcc cccctcccc aggctctcca gtgtttcttt ggcttttcct ggcttcttgg 90660 90720 tgtgtgtgtg tgtgttcctt cgttattagg ggactggaag agaagaaaag ggctcgagtg 90780 tgtgtgtatg tggtggggg gatggaggcg agtgcgccct tgttagagga ctggggtctc 90840 90900 cacgcctgag gaaaggggtc gctcctccct agggaatgtt ttaggcaaaa agagggggcg gatgccggga ggaaagcgcg ctgtctttct gggtgtgtgg gtagaagagg aatcaaatgg 90960 gcatgtctgg atgggggacg ggggtaggag ctcaggaatg tgagggggtc aaagtggtcg 91020 agtgtcggga ggaaggactg cttgtgtgcg gggtgggggg gggtggtgga gagcgggggc 91080 ggggattcag cgcgtgtatg taaaggtgca gcccgtgtgc taggcgctgg gtgcgcgcgc 91140 91200 ggtgtetget egggtgege egeegeege tgeeegeetg eeegeeggee egeetgeteg 91260 cctgctgggg ctgctccgtg ggtttgacgg gcgagcgggc gcggaggagc tctgtccgga atcacataga taccatcgtg gaaacagcag cgcaggtcac ggcgccgcgg gccctgcacc 91380 agacgctggg ctctagaggt gggtgaattt tcagcggggg ctgcacaagc tgcaccgaca cgcgtgctgc ctcttccccg ctcagctcag tagcgcgtgt gcctgcgtgt gtgtgtgta 91440 gagacagaga gagagagaga gatctcgcgc gcgcgcacgc gagccgaggg ggcaggtagc 91500 91560 ttattatttt tagtttgggt cctgttggtt tggggccggt tgagtggcca aagtggccga 91620 ggtggctaat cctgccctcc acctcccact tgcctgccta cgacgcggtc tcatgccgct gaggaccgga aaggatccgg gtgtccttgg catcgctgcc cgccccccc cgccccacca 91680 taccccaage ggccagggcg geggggcaag ttgtacaggt ctegggtgge teeggetgte 91740 gggccgctgg gctgggttgg gctttatttt tgcaccccac tcgcagccac tttccgcaga 91800 91860 cgtggatctg aggctcgggg cagtggcccg cgggttggtc ggagattgct agcgctcggc 91920 aagactagga ataccagagg aagagccggt gggtaactct aaaagctctg caaagccagg 91980 cgagcgctgc cagcgcgact ttgcaagggg cctaaatgtt gagctgattt ctggcatggt 92040 gagagcagga tttttgtagc tggccaggga gggagaacag gcaaggggga gcctgggccg

ccgctcgcag ccacaaaacc acagggtcac tctgcccgtg gcaagcaggt cagtgactcc 92100 ctagtgccaa cgtcttcgag gcggcctgat ctggcctctc ttcctcctca cccaccgcac 92160 gcctgggtct agagaggtcc actgaaactc cggcagctgc cccttgtggg acgggagcgc 92220 gcggagaaat gtgtgagcgg cgggactgaa ggcccccgcg acatcccgcg cggtaccccg 92280 cctccgctac acggaccgcc aggctgctgc ttgggcccct gacgcggagg gggctgagcg 92340 gccggctccg ggaacaggga tgcggcaaaa cattgcggta cgcgccagca gcccctccag 92400 cetectegee gecegeega ggtagegeac eegggeggea atggeegggt eteteegega 92520 acctetteca cetecatecg ageettagge gggccagegg ggtttecega gggagetete 92580 ggggagccac ctcggcccac cgccctgaag cccatcagtg ttctgccccc ctcaggccgc 92640 ttctctctc ccagtcgcgg agtgccaggc gctgcactcc ggtggatgca ggatttgttt 92700 ttggtcgggc taggtttgtt cagtcctggc tggtcgtgag agccaagggt ctttcagggc accgagagga agacggacag ctcccagcag ccacagagaa ggctcttggt acccagctgg 92760 tactttgtgg gctttttctt ttcttttttg cgtttttccc ttgatgttta aatgtgcatg 92820 tttcagtggt accaccggag tgtgaggctt tattcgcata cattcagtgc tccctttacc 92880 92940 ctctttgtag ctcccttctc cgagttcttt ttcttccttt ctccacattt ccatggtctc 93000 ttgccctttc agtacctctt ttcctctctc cttggtggac caactggact ctttctctct 93060 cttgcctgcc cctccagctg cttgtggctt cctctgtttc acaagagctg catttgggaa 93120 cttcctggct cttactagtg ccttttcccc cccttgctac ttaaagtagc aatcaccagg aggagggcag ctccttatgc attttcagat gtgttgagat tcctggttct tgtttttgta 93180 93240 ctgaattcgg attataagga ttttttttt tctgcgtttg gtttttagtt tggttgcttt 93300 tgggtttctt tgttttgagg tgggtggggt ggtggtttag taacaagaaa tgactcaact 93360 gaaccaaaat agctgttgaa aaccacattc ataacaaggc aaaaaatatc aagtgaaatt 93420 ttgattttac aatgaaagtt gctttaggtg atgtcatagt taagaattat gacttctttt tgcaatgcca atcatgctct catggtgaat aggggaaatg cacgtctata tggcagccaa 93480 93540 atagcatete ageagtgetg getgtattet gaaccaaact aettaàaatg caaateetee 93600 tgggtcatgg ctaatgggtt gtctaccttg agacatgttc ggttttacca ctagctgatt cctcgtgggt aaaataaaca aaggagtttc tgtgcgacac ttctttcttt gcatcatttc 93660 cttgttgtgt gttcctgggt attttatgta tttaattaat atttggagat aacgatattg 93720 aaattgcacc cagcttccca ttcacaatgg aaaagactaa tattgctaaa atagtatcaa 93780 taaaatgcac tctgcttgtg ttgtttaatc ttttccagga agcatcgtgt atgtttgtgt 93840 atatatgcag tatttaagga cctgaaaacg atgagttatt ttgctaagca ttaaactcta 93900

ccaacaagtg attetttatg cgtttacagt cagggacatg gggtggtaat attaggaagg 93960 gcgggtgggt gtttggaact gatgatttta ggacgaaaaa tgtgctgtac tgaacatatt 94020 tggtgctgta gcaaaagcta ctcaaagatt gtgttgtgtg aactcccctt cctcagcagt 94080 tgcagtctgt ggtcaaagtg aaagagataa agcagttaag ccgaggatca gtcggacctg 94140 ggttcaaaat ggtaaataaa gatgtgggag agggccaggg aggcaagaga gccagttctc 94200 aaagtggaaa gactgcctgg agattagcta agcaatgcag gagtaagcag gttactctgc 94260 tgctttcaga ggctccaaga caaaaggctt tttgctccct ctttgggaga tgactgacag 94320 gaaattagag actgtttatt taccagaaaa taaaatttgg ccatccctta ctcagttgtt 94380 tttctagaac cgcacagcgt cgtctgtgtc tttgaaggca gcagtgtaca ggtgtgaacc 94440 gattgacagc aatgatetta eetatgggge tacagcacaa geaaatetet teecaggtea 94500 ctgttcctta gtcttttaac agtcctgct acagcagccc aatcctccca tttccatcct 94560 ccagtgaact ctgggctcta atgtttttgt ttttgttttt ttaattcagc ctctctatct 94620 agctgaagct tagagaatag atatccacta atcaaaatgg ctttgtggta caaactcgat 94680 ggcatacttg atggtctcgg tcatttgaag tgcaagtagg aagcttaagg cctgtgttca 94740 agggcagagt ttgacggtcc acgtggaaaa aatattttca gattgcaaga tttaagcatg 94800 94860 attgataata tattttccta ctgttagttg tgtgttctgc acatgtgaat ttggtataaa 94920 ccacaggtat ggaaaataaa atgtatggca gttttagtgg ttattattgt tcgactgagt 94980 gagactattt ggaggtttga ttgccttaca aatacaactc tggtaattat agccatgtgt tcactatggt atgatttaca tacaagtaat ttttcaagta atgaccattg aaaaaatgtt 95040 95100 ttcttttat tttttagatt atttctcttt attcagaagc atacagttgt ttgctgattg caagaagatg tttctgtggc tgtttctgat tttgtcagcc ctgatttctt cgacaaatgc 95160 agattctgac atatcggtgg aaatttgcaa tgtgtgttcc tgcgtgtcag ttgagaatgt 95220 gctctatgtc aactgtgaga aggtttcagt ctacagacca aatcagctga aaccaccttg 95280 95340 gtctaatttt tatcacctca atttccaaaa taattttta aatattctgt atccaaatac attettgaat ttttcacatg cagteteect geatetgggg aataataaac tgcagaacat 95400 95460 tgagggagga gcctttcttg ggctcagtgc attaaagcag ttgcacttga acaacaatga attaaagatt ctccgagctg acactttcct tggcatagag aacttggagt atctccaggc 95520 95580 tgactacaat ttaatcaagt atattgaacg aggagcette aataagetee acaaactgaa agttctcatt cttaatgaca atctgatttc attccttcct gataatattt tccgattcgc 95640 95700 atctttgacc catctggata tacgagggaa cagaatccag aagctccctt atatcggggt 95760 totggaacac attggccgtg togttgaatt gcaactggaa gataaccctt ggaactgtag

ctgtgattta	ttgcccttaa	aagcttggct	ggagaacatg	ccatataaca	tttacatagg	95820
agaagctatc	tgtgaaactc	ccagtgactt	atatggaagg	cttttaaaag	aaaccaacaa	95880
acaagagcta	tgtcccatgg	gcaccggcag	tgattttgac	gtgcgcatcc	tgcctccatc	95940
tcagctggaa	aatggctaca	ccactcccaa	tggtcacact	acccaaacat	ctttacacag	96000
attagtaact	aaaccaccaa	aaacaacaaa	tccttccaag	atctctggaa	tcgttgcagg	96060
caaagccctc	tccaaccgca	atctcagtca	gattgtgtct	taccaaacaa	gggtgcctcc	96120
tctaacacct	tgcccggcac	cttgcttctg	caaaacacac	ccttcagatt	tgggactaag	96180
tgtgaactgc	caagagaaaa	atatacagtc	tatgtctgaa	ctgataccga	aacctttaaa	96240
tgcgaagaag	ctgcacgtca	atggcaatag	catcaaggat	gtggacgtat	cagacttcac	96300
tgactttgaa	ggactggatt	tgcttcattt	aggcagcaat	caaattacag	tgattaaggg	96360
agacgtattt	cacaatctca	ctaatttacg	caggctatat	ctcaatggca	atcaaattga.	96420
gagactctat	cctgaaatat	tttcaggtct	tcataacctg	cagtatctgt	atttggaata	96480
caatttgatt	aaggaaatct	cagcaggcac	ctttgactcc	atgccaaatt	tgcagttact	96540
gtacttaaac	aataatctcc	taaagagcct	gcctgtttac	atcttttccg	gagcaccctt	96600
agctagactg	'aacctgagga	acaacaaatt	catgtacctg	cctgtcagtg	gggtccttga	96660
tcagttgcaa	tctcttacac	agattgactt	ggagggcaac	ccatgggact	gtacttgtga	96720
cttggtggca	ttaaagctgt	gggtggagaa	gttgagcgac	gggattgttg	tgaaagaact	96780
gaaatgtgag	acgcctgttc	agtttgccaa	cattgaactg	aagtccctca	aaaatgaaat	96840
cttatgtccc	aaacttttaa	ataagccgtc	tgcaccattc	acaagccctg	cacctgccat	96900
tacattcacc	actcctttgg	gtcccattcg	aagtcctcct	ggtgggccag	tgcctctgtc	96960
tattttaatc	ttaagtatct	tagtggtcct	cattttaacg	gtgtttgttg	ctttttgcct	97020
tcttgttttt	gtcctgcgac	gcaacaagaa	acccacagtg	aagcacgaag	gcctggggaa	97080
tcctgactgt	ggctccatgc	agctgcagct	aaggaagcat	gaccacaaaa	ccaataaaaa	97140
agatggactg	agcacagaag	ctttcattcc	acaaactata	gaacagatga	gcaagagcca	97200
cacttgtggc	ttgaaagagt	cagaaactgg	gttcatgttt	tcagatcctc	caggacagaa	97260
agttgttatg	agaaatgtgg	ccgacaagga	gaaagattta	ttacatgtag	ataccaggaa	97320
gagactgagc	acaattgatg	agctggatga	attattccct	agcagggatt	ccaatgtgtt	97380
tattcagaat	tttcttgaaa	gcaaaaagga	gtataatagc	ataggtgtca	gtggctttga	97440
gatccgctat	ccagaaaaac	aaccagacaa	aaaaagtaag	aagtcactga	taggtggcaa	97500
ccacagtaaa	attgttgtgg	aacaaaggaa	gagtgagtat	tttgaactga	aggcgaaact	97560
gcagagttcc	cctgactacc	tacaggtcct	tgaggagcaa	acagctttga	acaagatcta	97620

ggtcatgtaa tcttacttca tacagaggac atttatttaa tgatgaaagt gccttttgtt 97680 gacttctaac ttccaaatac tatattatca ataggcatgg aggcaggtgt ttccaagggt 97740 gtctcattaa ctgtagctgc aaagatgtgt caagtagaag agaatttgtt taatagattt 97800 97860 tactacataa aacctatact gtggagtcct gtggggatac tgcaaactct attgccaaag ggatgettta tacacataat actgaattta acctcaagag gcaaatetgt tttgtacccc 97920 97980 aatgcaaaac cttcgtctct ttgtgctttg taaagcaaac tcaagaaaac tggtacacct gtaccagctg ggtcctttat cttgcacgta gattaagttg gtggaactgg aataatcctt 98040 98100 aaaaaaaaaa aaaaaaaaaa aaaaaaaaa aaaaagcatg caaagagaga acactcgata 98160 98220 gtatttgtaa attggtaacc tttatggcct gcatcttgaa accgctggat ttataatgtt aatttgtgca aatacttgtt taaaatataa catacattac ataactataa aataaatttg 98280 aacactttaa gcattacctg tctatacata aaaatctaaa agaaaaaatc aacgtgagtt 98340 agatagcatt tgtgatgatc tgaagaaata tgtgacgttt atcagaatta aacatggctc 98400 aaattaaact; aacactagag tttgttctca gttacgtgaa acacccacaa tccttcaagg 98460 98520 ttgtccaaaa taagcagagt gcttactgtg tgagcgcacc caaagctatt tttgtaacat 98580 aattcatatt tatgaagtac tttgtatact aaataggaaa atatgtactc cttaatatgt 98640 atttaatatg cctgacttgt tttcctgatc acagtgaatt tatcagtaag tataaatgta gacagaaaga aatatactaa actgaaacaa gctggtgtga acagaaatat tctggacttt 98700 98760 gtgatcaggt gtaacttaaa aacaaaaaa ttttaaaaca aacagaaaag aaaaaaatac aaaagaacag tcaattctgt gctattcttg tgaatttagc gtattatctt cagatttgtt 98820 98880 accaattgtg cattcaaaaa taagttcctt agttttctag tattgtgtct ggggcagttg 98940 ttatttgcca tcggttgtct tgcttttcag gattctatga gcttaattca aatagttttc 99000 gctacaagta tttaaaaaat aatgaataag gttaatagtt atatcttgta tgcatcagta tcctgttctt tcatcattca gactactatc agataatcta gtagaactgt aaacatcatg 99060 99120 gtaatcttgg ctatgaaagc cacactgtaa aaatgcttgc attggtttca gatgagttca 99180 cagtotgcaa ctacaaatga tatgcccctg tgtttgcttt tgctaagatc taagtcaaaa 99240 tttgttaaag gaataaagta actgataatg ggtgatgtcg gaacttttgt aggagctccc 99300 gattaacaaa gtgatattca gaaacacatt gtcttcttgg cctgcctgca tatatatata 99360 tagatatata gatatatata gatatacata tatatatatg tgtgtgtgta tatatatatg 99420 cgtgtgtata tatatgtgtg tgtatatata tacatatatg tatgtgtgtg tgtatacata 99480 tatatatagt gtgtgtgtgt gcatgtgtga gagtgtgtgt cctatctctt ataattacct

tatgaatcag taagataacc aagaaggtaa acatagccat tcctcatgat tgcaagtggc 99540 atattttttc tgttgcagct tccaaaatga tactatgttt atagttgcag tagctgttcc 99600 tttattaatc actaatttca gggctttatg tgtttgttgc aagacaaaaa aagaagcttg 99660 gctttcttgg gtgtgtgtgt atgtgtgtgt gtgtctgagt gtgtgtatat atatatatgt 99720 gggtatatat tcatacatat agataatttg gaaatctttt ttaaatagca aaaaccgtct 99780 ccatgtgtat gtgctggtgc tcttaaaact ttagtgtgta attttaattt ttatgacatc 99840 tgtgaaaact ttatatgaat ataaaataat tcaaacaaat aattgctttc tgatcttgaa 99900 agaaaagaca agatgtgtgc ccaacagctt ttttcatcta caatttcata aggacttttg 99960 atatgccatt accatgcatg cacacatcca tggattaaag ggctcctaat gtatactgac 100020 aggataaaga tgcaaaggct tcaaagaaag tgttttagtt tagtctgtca ataaagtatg 100080 gcttgaagga tcttaaatag acacttatag gaggaatcag aaagttccat tcatggtctg 100140 gggataatag gtcatttgaa tgatactttt attcagtgtg gtgatgttct gaagatgttt 100200 caaggtttct gcagaattct caatggcaag agtacctgcc accatctcaa aagcttgctg 100260 tagcatattg gctatctcat actcttctgc taaaaggtat aaatgttcaa ctttttttaa 100320 aaagtaattt aacatatgtg gttatttgga ggttcaaatt gtaaatgaaa gtaacaaatt 100380 cttggttaag gctaatatat tttccttaac taaagtcatt gtgcctacat tatatagtgt 100440 acacaatttt gcacctgtct ctcattagtt ctagttgtac attttatgat aatgtagtta 100500 ggtataagtt ttgagttgag tacaagaaca gttaaaatac tgtatctaca ttttgttggc 100560 ttcaactata accttgatgt tagtttaacc cctggaggta tgatatgtac atcagtacag 100620 catttttagt ggaacttgga tgcaaaccta taaaatccaa gaagtgctca tttctaatgt 100680 gggctgacac atcatgggct tcttggcact atagtcatgg gtatggacta cgttagaatg 100740 attgcaaaca aatttagatc ttatgaaatc agtgaagggg ttgagataat atattgtgtc 100800 catgtaatat aaatcaagtt ttaaattatt tttttatgaa atcaataaag atgattcaat 100860 tctttaaaag taagactttg tgtaatttta tgagaaagca gctattaaag tagagtgatt 100920 caagtctata aggcaattta tattctatat ttagtttttc attctgaata gactgaaaaa 100980 atatatgaat tagaaattta tttaagacca tctttctttt gttgcttttt ttaaacattt 101040 acttttcttt aagccataag gatgcataaa ttatacaggg catgacctta tgagtaacat 101100 caacaggtat ttcagaaata acagaacacg tctagaaatg tatggtggta atattaatct 101160 ataacatttt ttgcatgatt tgtacattga cattgtatga aatgagcaca ctgaggtttt 101220 tttgttgtta ctgtcgcatc caaagagttg gggagaaact atattaagaa tgtatttata 101280 · 

cagtatttta ggttaatttg taagagaaaa atcaagtaat gctgtaaaaag ctcatgtaaa 101400 tcacagaaaa gaactgtttt aatgactttt gtttgctttt aataacatca aggtattaga 101460 atttattaat tgccattttt atgaaagtat taataaaatt gtttgctaca atgatatttc 101520 tgaagccaca gtttgttaaa tatatttgtc tttccattat ttttcagaaa aatataaagc 101580 agtaaccaaa ctgatcattt cacccagatt tgagggtaag atatagcttt agcctactgt 101640 ttatattcaa cttaactgct aaatctctgt taaaaaaaaa cgctttcttt agaaacatat 101700 tttcaatctg tgttccttcc cactggcagc ccctttggag aagagtctga cagtgccaag 101760 atcaacatgc tttgattctt gcccattctt ttgaatcagt tggattctga cataacttca 101820 gataagcaaa tactaatatt cagtettaac tatetgetea aataetttta gaaaccette 101880 agtacctctg tattccattg ccagtttgcc tggttacagg ttagttaccc acttatggag 101940 tgaattgtga tttgtatttg gttcttttaa agatgaccaa aattatcaat ccatgacttt 102000 acccaaatta ttactgttgt ggaaaatgaa ctaattgcat tacggttaac ttgagggcag 102060 aaatgaatgt aactgactat attgaccaat acggtgggtt taaggttcat atatttatgg 102120 taagaaaagt aaacacagaa acagagagag agagagaata taaattaaga ttgttgttgc 102180 tttacacgta tacataggta tgctgaaggt gtgaacagta tagatagcat atgcaagtac 102240 tatttatgag tactgagcac agagetttgg gttccagcca cttctgttat gtagacaagt 102360 ggcatcaaat caaggtttgg catcatttct agtgctcatc ccattagtca ctgtggtcag 102420 atgggctgaa ctaaaataaa atatcctgtt tgtggcttca cttacctaga ataactggtg 102480 acatatatca agttcacctg ataattgtta actctcaatt tcagatttcc taaggatcta 102540 ttctttgtta atttaaaagc taatgggaac tcaaatgaat tttaataact tactttgtac 102600 atttaatgtc tttttagttt ctactggttg ataggattgt gttttaaaag ggaaaatcga 102720 ggaagggaaa ttgtgttgtt tatcttatag gaaatgatgg ttttttttaa tttttaaaaa 102780 ttattttaac ctgttgttct tatgtctaca aggggaaaat aaagtagggc tctgaggcat 102840 ttgaatattt tagaccaaat aattgctatt gagaataaag attcaagctt ctcattaatc 102900 cataattgac atttccactg actgtaggac ccagaaccag gagagaatta ctcaaccctc 102960 cacttcagtt tacttttgta gacactgcct aaatagaaat agaaattctg gtgatttcaa 103020 taacatcaaa aatgacaaat tacctgttta acttaaaaag gtcatgaatg aggccttcag 103080 agaaataata ttaataatat aatgaataac catagagcag tgcctttaaa ttagctatag 103140 gaaggaaata gtcttttcaa gtttctgaac aatatatttc tcttagttgg cacctcacaa 103200

atactagatc atgtcagacg ctgctggtta atagctgcag gaaggcatgt tgtgcagtgg 103260 atattgctca tggaagtgtg tgaaaatcat agtaagcttt gttctccctg ctaagacttg 103320. ctatgtatat ttccatcatt gtttcatgta aactgaacca ttgtggtaaa cttttggagt 103380 tgatatggaa tcactttaat gctgttttca caaataaaag ttttttctta taggtcacat 103440 ttgtagccat tcagtgtgtt tattagtgtg gaattagtaa agctcaagct caaaaagaaa 103500 tgcaaatagt ctggttttta gctgatgcaa tcaatatatt agtttacatg gctaggccag 103560 gtctacctac acacatacac atgcatacac ataagaaaga tagagagtaa tgtgtgcaaa 103620 tagtgaatta tacacaaagg gaattatcta gttaatgtaa acaaaatatt tctatcttga 103680 ctacctactt gaccacctag atgtttcaaa tccaagtaga ttgggaccta aatattaatt 103740 gtcctttttt ttttttcgc ctacacttga aattaaaacc tgaccacttt gtcatatata 103800 gtagaaatta tgcccagctt atctcccaag acttctctgg gtttcagtta tttgttgtct 103860 tgagatttta ttttgatttt ctttgttaac atttttcatc actatcatct ccaaattata 103920 tgcttaataa atgtatagtg ctgtgtacaa ttttcaggca accagcccag gtgcaaatca 103980 gtgctgctac tacctttcac aaacgttatt cagagaaccg tgcaggagca tttaaatcca 104040 aaataatccc aggatgagga tttaattaga aattattgga acaggtatgt ttttttcccc 104100 ttaaagaagg aaaagttggt tgaaaattat gactaaagag cagcaggaga acaaaggagt 104160 attaagagaa aaaatattta cttatcagat ggaattcaga acttaaatac tgaacaaatg 104220 tatcataaaa taagtcaaat tatagatttc tttctcctta ttatttacct cggctttatt 104280 tcttttaaac agatatgaaa tctaggcttc gtcaacacaa tagtaattta tagcttttat 104340 agaatccact ggtcaattaa aacatttaat tacctttgca acccctatgg atttttttct 104400 tagttgacta acatcaagga ctgactgatt ctcaaagcct cccaatacag ttttagctgt 104460 caaaaaatga taagtagcat ttgtgtttaa tgagaataag aggtgaaaaa tgcatatcac 104520 agaaaaccat catgataggg agcaaaataa attagtacaa acatttgggt tcccagatac 104580 aaacacttgt ggtcaaaaag ctgccagacc ttttgggctg ttttcagaaa tcttattttt 104640 aaaaaaaata tatcaagtgc ctatttcaga agctatttcc tgtacgaatc cccaggaagc 104700 catgtatctg ccatggatcc ccttgctcca tagcaagatg tgtcacattt gccaagtcct 104760 ccctgctgga aatttttctc ttctgctgtt acaagcaacc aacactgtct atggcattgg 104820 ctagcttagg gagaattttt tcactgtttt ttggtagttg gtggtaatat ggacaaaaaa 104880 tctaggagtc tcaataccgg catatattta cctttgtaat attaccatac tggagagcat 104940 ttgggcctgt atattttaca cattgcatct ttgtttttat tcatcagttg tcctccatcc 105000 cacagaagct actagttatt ttattcatcc ctctctttca aagtagaagc tgatcaccat 105060

cctgaaatct cagttattta tagaaataat catcacactt ctatgtgtcc atttccttct 105120 ataacttcta gaaatataga aaatttagta cagtaagtga tggatttaaa aggaagtcct 105180 actgacacac aaaaaaatca tgatatgaag acagagtgac ttaccagaaa aaaacaactt 105240 taggaagtca tttcttaagt tttaggtttc cttgctttgc aattagactt cagtgccttc 105300 gcttgtgagc tggacccaat gaaatcagtt ttcactctgg ggccgcgcaa taactagaaa 105360 tgatattatt gctgacatgt gggcagcttt gccatgtgtt gccataaaca tggctgctat 105420 tttctccttg cactttctac ttcagaaaat attcattctc tcagatttgg cacagctgct 105480 gaaatgctgc tgtatcaatt ctcaccatga aaattcaaaa agaatttttt ttctatatgt 105540 aactgagcag ttacacaaaa atgtgtattg gaaactggat aaaaacatca ggataaagaa 105600 gataactagt gtgttcataa gaaaagaggg ttttaaggaa gtgaaatgca ggcattttat 105660 taaaaattac atctaccacc tccctttgaa cttgtcgact ttttgaagac tccagtgtat 105720 gcattataag gggaatagga ctctgtttat acgcagcatt ttcactctct gctcattctt 105780 cttggttgcc taggctgggc tgcagtggag aatgtgtgaa cagtaacttt gtttttaaat 105840 cccaaatgca tatatgattt cagttgctca tttgaatatt aacacattgg acatggccag 105900 tttctaacat aatatttta ctacagccaa ttgagacttc actgaatgac ctttatttca 105960 tcttaaaggt tatcagagca ggggtaaact aagaggctgt tggtcagttt caatgtttaa 106020 agaccatcac aggaagattg agtatatgta ctccgaattt ccaagtcaga ttatttggtc 106080 ccaatttctt ctcttttgaa agagtaacta gggctagaga gggcaagtga cttgcccaag 106140 gtcaaaaaat tattacagct agtctggtct aggacctgat tctcctcact cgcaggatca 106200 agttattttc attacactgc tttgtttgca agttccaggg aggaaaatga gcatctgtgg 106260 gtgaagette aggeagaeat teeaatgeag cataaggaea ttttetgtaa ggttttagaa 106320 tgctctataa ctggaatgaa ctagatacaa aatgcagagc tcttagtcct tagaagtgtt 106380 caagctgagg atggttctaa caaggaggat ggatgttatt caagaaaatt tatttgaatg 106440 cgagcttgga ctaggtgatc ttggaggaca cttgaaactc ttaagacacc aaggattctg 106500 tagtgtatac actataatca tttaccaagc aagtcaaaac tatcaaatat ttttcatctg 106560 gaatatttaa ttaattgatc tttgtagttt aatgactagc agatgatctc tactagtaga 106620 ataacatatt aataactcca aaaataccag ttaggtatta ggcatcatga taaaagggac 106680 atagagtgaa atctccccca ctatataatg tttgtgtttt taagtgtcag catttcaaaa 106740 agaatagtct ctgatgttta atcttttac aaaggaaaaa caaattcttt tgtacattac 106800 actgaagatg gcactgtagt gacaacccca cactagaaat gctgagacat gccggtatat 106860 gttatttcaa tcctcaattt caattttgag aatatttctt gagcttggaa aacggaacac 106920

. .

aaaggttaat atcttgtaac atcatctttg ctaattggag ttgggtgcat tttttttata 106980 atttactctc aataagatag aactgaactt tattccaaag aattgcagtt caggttgcag 107040 ctcaacagac tatattcaga atagaaactg caaattatct gacctgtaaa aattattaga 107100 aatatttatt tgaattttat tccataaaga tagttttctt ttaaaaaaaaa aaaaagtaaa 107160 gggaaaataa aaccattccg acctcaagga ctgtttgttc tatttatttg ggatgctatt 107220 aatttttaaa gattctgggt acacccagga tgactctgaa atgcaatttc taggttttct 107280 ttattccatc catatcatta actagagete cagegaatgt ggetaccatg caattcctgg 107340 tccctttaat cacaaagagt attccctcag gtaccagcaa ctcattcaaa attagcagtt 107400 ttatactttg gagtcgtact tcacttttaa atagtcacag tgttaaacat atacataacc 107460 tctgcccaag tgattttatg ttttagtaga gaagaataga agggaataaa aatatttact 107520 ttgacttaac actgatgtcc aaggcctgtt gaccctccgg ccttccctct ctcttcatct 107580 cacatgccta tggatgatac cactttatct gtctgctccc tgtgcagtct catagctcct 107640 cattcaaaca ttacctcttg tgacagtggc catatgcccc cacctcact aaaactgttt 107700 ctgtttaaca atgtttttt tttctgataa ttcaaattca gataccagat tcacatgctg 107760 ctaattcaca agecegteaa atatgteagt actetgagae atttteaaga gaggacateg 107820 gccgggtgcg gtggctcacg cctgtaatcc cagcactttg ggaggccgag gcgggcggat 107880 cacgaggtca ggagatcggg accatectgg ctaacgcggt gaaaccccgt ctctactaaa 107940 aatacaaaaa attagccggg cgcggtggcg ggcacctgta gtcacagcta ctcgggaggc 108000 tgaggtggga gaatggtgtg aacccaggag gcggagcttg cagtgagccg agatggggcc 108060 aagagaggac atcgaggagt ggaagaggag accacgttag tcaaataatg gtgtttcagg 108180 cctgggacaa gcagtggact aggggacctc cttggtatcc ttcagtctta accatgggta 108240 aatctggtac agttcagacc aataaggaga gaggctgact ttaaccttct ctcaggaagt 108300 cccgtctggt gtctccttag tggctttcat tcattccata ttattcatat tagagtggaa 108360 ggagtgggag ccagttaggt aaggetetet tgtggaaate acatttaaat gaaagtettg 108420 aggggtgaag ttcatgagcg gctgagcagt agggttgagg agggcctctg aggttgagag 108480 aacaacatgg gctttgactg cagtgtggga attaactcac tatgtggtac tggtcaggta 108540 ggcagtgcct agatcaaggg ttggcaaact ttttcagaaa taattttctg aaatagcaaa 108600 tatttgaggt tttacagacc acactgtccg tgcttcgact agttaactgc tgttgtagca 108660 cagaagcaaa cacagacgac aggtacacaa atggatgtga ctgtgtgcca ataaaatttt 108720 gttgtccaaa ataaactagg ggatggattt gacctacagg ccagaggtgt caaccccttg 108780

gctagattct gaagggtctt gaaggagttt tactttcagg tgctttggga agtcaatgaa 108840 gattttttaa aagcagtgca gtggcatgat taggtttgtt tccaacagac ttccttctgc 108900 ttctggaggc tggactagag gtggtgagga gcagagtata agtggggaaa gaagtcagga 108960 agctcttgca atagtgccga ccaattataa acctaatccc agctaagatg aaggaagaat 109020 agggttgtga gctatatttt gaatgtcgac tccatagcac ttgccaatat actggatatg 109080 aaggtcgagg gtgacagtgg aatcaaggaa aaccctgagt tctgtgccat gagcacctgc 109140 gctgataaag atgccattct ctgagatgag gacctctagg ttagcagtgg ctgtggaggg 109200 tagacattac gagacaaaga gtttcatttt ggtggccggg catggtggct cacgcctgta 109260 atcctaacac tttaggaagc tgaggtgggc ggattgcctg agctcaggag ttcaaaacca 109320 ccctgggcaa catggtgaaa caccatctct tctaaaataa aaaattagcc gggtgtggtg 109380 gcatgcgcct gtaatcctag ctactcagga ggctgaggcg ggagaatcgc ttgagctcgg 109440 gggacagaga ttgcagtgag ccaagattgt gccactgcac tccagcttgg gagacaagag 109500 tgagactctg tctcaaaaag taaataaata aataaataaa taaataaata aataaaataa 109560 agttccattt tggacgtgtt aaatttgaaa tggctgagaa tcttcaaatt gtcagattgt 109620 tgactttgtt: caacaggatc.tctgaggaga agcttaggcc acagacagga ttgagaatta 109680 ctatcgtttt gaaactgaag gtcatggagg aaggtcacag aatgaaaaaa aaacaagacc 109740 ctgcaatgac tgcaggtgct tcagagcttt ccttttcagt gtcatctgta ctgtgcgcat 109800 tetgeateag aateteetga ggtgettgtt aacatteaga etettaggee ceateecaga 109860 ccttctgagt caaaattttt gtggtcagga ctcaaggaat atccattttg aagttcttag 109920 gttattctta tttacattaa actgtgagag tgtctactgt ttaggtaact tagaagataa 109980 aatacctgca aaaaagggaa atggtgagca gacagcatga cagaaaacta ggaagctgtg 110040 gggtcctggg agcaaagaaa aaaagagcat tccgcaaagg acgccgtgac tgactatgtc 110100 cagtgttgct gagcgacagc agtgctattt aagcatgctt ttctggtatt ggcctcactg 110160 agattgcatg aaagactgat gtcagaacag ctgtgggatt ccattcccta acaagagaca 110220 gactettgga aagaaactee acagagagaa gggatggtgg atgagaaatg ggagagaata 110280 atcaggacca cagtagtggg caaagtgaaa gcaaaagatc agtgcaagaa agactttagg 110340 attccagtgg tgagacatgg aaacagcaaa gccagcagca ggattatacc cagagtagga 110400 ggtcaaagtg agcacctaga gtcagcacca gagggcaaca ggggtgggct gtggtggaag 110460 ctcaccaaac tctagcactt tataaatgac tttatgtccc acagtcctgc cccaacagag 110520 atgaggaaca cagagaggaa tcttggagct ttagctgttt tctgtggtct ttggacggaa 110580 acaaattcgg ccaggaaaac ccgactacca cccctactct gtcatggaaa tttttcctta 110640

atagagaatg ctttttaaat tcaagttaat gcatatgcac tgaatgccta ctacgtgttt 110700 tctctgggct ggatgatgga agagacagga gagttatacc aagtcccacc cagttcccac 110760 ggagcttaca atctagtgga ggaggcaggt atgaaagtga ctaactagaa tatcacatcc 110820 ttaatgctgt aacataaagg gaatgtgctg cttgagcagg cgctgagcta tagggcacaa 110880 ggaaggette atggtagagg tacattatga cetaacettt gaaggatgga ttggattttg 110940 atagaagagg gatgttccag ctgagagaat agtgtgtgta aaagcagaga ggggtgggga 111000 agtttggtgt tctcgggata ttaggtggtt cagtgtggct ggagcatgta cctcctgagg 111060 ggtgtctcca ctgcttacct gccatgtccc tctgactcaa agggacccca agctcaaaat 111120 atgacatact gaattcatca ttctctctgc acagaatatt cttctagtct ttgctatcct 111180 agtggccagc ccctcagcta cctggatact ccagctagaa tcctgggcat catcctgagc 111240 ccctctatat ccttcacccc acagaagcaa gacctggggt ttctgagtgc ttcttaccta 111300 ccagtcattg ttctaagcac ttagaaggtg ccatttaaat taactctttt tttgccattt 111360 atactattta ttgaacccca gattaatgtt ttgtagtata tatttgtaag atgtacgaca 111420 tgatgttttg atatacatat acatagtgaa attattactg tagtcaagca aattcaccta 111480 tccatcacct actatagtta ccgtttgtgc gtgtgtgtta agagtaccta aagtctactc 111540 tcttagcaaa tactcagtat ataatacaat atcattaact atagttgtca tgctgtacat 111600 tagatettea gaattattee ttetaataaa egeaagttte tatetaacea tttacetaet 111660 tattcctagt tcctcctct tcctgctcct ggtaaccagg attctatctg tttctatgca 111720 ttagcttttt tttttttt tttagattct ccatataagt gagataattt agtatttctt 111780 tctatgcttg acttatttca tttagcataa tgtcccctgg gctcattggc agtatttcca 111840 ttttaaaggc tgagcaatat tccattgtat gtatatacca catttccttt atctatttat 111900 atatacacaa gcatttatat tatttccatg tcttggacat tgtaagtaat gcagcagtga 111960 acacaggact gcagatatgt ctataggtgc tgattgtttc ctttgagtat acacccagca 112020 caggaattgc tagatcatat ggcagttcta gtttcaattt ttttaggaag ctccattatg 112080 ttttttataa cggctgtacc aatttacatt gccaccaata gtgtataaga attccctttt 112140 ctctatatcc ttaccaacac ttatctcttg tctttttgat aataacaatc ctagcaggtg 112200 tgaggtgata ggttgttgtt tctatttgta ttttcctgat gcttagtgat gttgagcacc 112260 tttccataca tctgttggcc atttttatgt cttctttgaa aaaatgtcta ttcaggtcct 112320 atgtccattt ttaatcaggt tttttttttg ttctgctatt gagctatgtg agttttaaaa 112380 attacattct agatatttac catttatctg atatatggtg tgcaaacatt ttctcccagt 112440 ttgtaggcta cctttttcac tttgttggtt gtttcctttg atgtgcagaa gcttttttgg 112500

tttgatatag tcctacttgt ttatttttgc tttggttgcc tgagattttg gcatgatatc 112560 aaacaaatgt tggcaagatc agtatcataa aacttttccc caatcttttc ttctggcaac 112620 tttatgttgt aggcactaca attgtcccta atttacagat taaaaatgga agcaaaagga 112680 gatttttaaa atttgcccaa acttgtacac tggtacactt gtacactggt tccagtgaca 112740 aagctggaaa acacacccag gcattttgac tatatatccc acacttttct gtatcatggt 112800 gtatggctcc tacaaaatgt aaactcttta ccatggtcta cataaccagt atggctgggc 112860 ctttgccaga ctctctagcc ttaactcaca ccatagactc cctttcttc ttaatatttt 112920 atgtgacatg gtgaactaaa tggacaaggc agtttgcatt cctctgtcta aaacactctt 112980 ctcccctaag aagccccacc tatatatccc catagtacac tgtgctaatg catttcagcc 113100 cttggcacct tgaatcaaaa aggcatgttt tcttatctgt aacctacaac taaaataaga 113160 gettetggag cacaggatet atattetgtt tatettttat caccaatgeg tageatagta 113220 cctagaaggt agtatgtggt aaacagatat ttgttgaatc aataaatata ttaatggtta 113280 tgacagcaaa tgagatgtga gagggttagt ttagagtcaa attattgaaa actttggagg 113340 acatgttaag atgtttgact ttttttttct gcaggcaatg gggagccatt gaagattttt 113400 gagaaaggag agacattatc tgacattttt attttgggaa gatgagtctg ctaatttgtg 113460 gagattggag agagaattat gaaggcaaga agataattag gatattataa agataattag 113520 aaaattaaaa tatcagtcaa cttttgctgc ctaaaatact gccttcaaac tcagctgcat 113580 acactgcagg ttggctactt cagccgatgg gtctgtaggt caattgcata ggctctgctt 113640 tagactgcag gtgcgtgggt tggctgatct agactgatct gggcggtttt attatcgaat 113700 tgaaggttca gttctatctt tttgatttgt cccttattct tctgggatat ttaggggaaa 113760 ctggacattc aggggaagct cttcacctag cattgtcacc agtacaagag gacaagccca 113820 actacacaag tatatatcaa gcccctgctt gtgtcttatc attgaccaaa gcaggtacaa 113880 aaggaagccc aacatcaacg aggcaggaaa aaaaagactc ttcccatgga agttaaaggg 113940 aaaggagtga ctgtttgatg aacaataatc accacagatg ctattgatat agtacagatc 114000 agtagttgtc aactggggag tacaaaggca tgctccacct tgaaaggtga aacaaaattt 114060 tagggaaggg gtaaccacgt atgtgtcttt taaatcgtac cttcacccct gcctttcaga 114120 atcgtttcta gtatgatttt tactaattag agtatcaaat ccatgaaatc tggtgggatg 114180 gaataaaagt ttggaaaata ttactgcaga ggataactga aacaggccta gaagatgaga 114240 ggagaaacac ataaaaaggc aaataattgg attcagcgga tagggaacaa gaaaagtcag 114300 tgacgacctg aagtgttaga gaccaagtga tcagtaacat agagatggtt tgaatgaaga 114360

tagtgaggga gaaaggcgtt tattaattga agaatcagga tgcattgatt atgtacaagc 114420 cccttattca cagacgtgga taagatgtgg tacctgtcca cacgtcttac agtccagtga 114480 acacaagact tgtgcaagta agacatatac acaggtaaat attagatgtt cttgaaagag 114540 gtgaatgcca tagggagaag aagaaattgc gagagcttaa ttccacctgt agaaatcagt 114600 agtggggaag atgacaataa atcttagtgc taatgtatag gtgaatttgg aaaagtagca 114660 gagaaggtca gggagatagc ctaagcaaag gtacagagaa acaagtgtct gggatgcatg 114720 caaggcagta tatatgaagg gatggtgaga aatggtgcta ggcatgttgg cattcttcag 114780 gcctcttgtg atggcaagag aaaaaaagtc caaactggat taggttagac aaaaagggaa 114840 ttttctagga agtgctaaag aatctcagga acccatgtga aggacagtgt attagtcaga 114900 gttcagtaga ggaacagaac atatacatat atattcatta agtattagct cacacgatca 114960 caagatccca caataggccg tccgctagct gaggagcaag gagagtcaga ccgagtccct 115020 aaactgaaga acttggagtc tgatgtttga gggcaggaag catccagcac aggagcaaga 115080 tgtaggctgg gaagctaggc cagtgtagtc ttttcatgtt tttctgcctg ctttatattc 115140 tagccacact ggcagctgat tagatggtgc ccacccagat aaatggtggg tctgcctttc 115200 ccagcccact gactcaaatg ttaatctcct ttggcaacaa cctcacagac acacatagga 115260 tcaacacttt gcatccttca atccaatcaa gttgacactc actcagcatt aaacaccaca 115320 gacagggaaa gtgtaaagtt ggctatgatg taatgacagg aagctactga gtatttctct 115380 tcagctgaca tctctacttg tctctatttt tttccttttc tgccactctt ttgtgccaaa 115440 ccaactgtct tagttcattt tttgcagcta taacagaata ccacaaactg ggtaatttat 115500 aaaccatata aatatatttg gttcatcatt ctggaggctg agaagtccaa gcgcatggtg 115560 cccacatcgg gtgagggtca tgccatgatg gaagacatcg catgatgaaa tctgtgtgca 115620 agacagagag aggaattggg ctgatcacat cctcattatg aggaacccat tcctttgata 115680 aactaaccaa ttcccaagat aaagacatta gtcctttcat gagggtgaag ctcttataac 115740 ctaatcacct cttaaagatc ttactcctta acaccactat aatagcaatt aaatttcagc 115800 atttgtttca gaggggatat tcaaactata gcaccaatcc atccacaaat tctgttaatt 115860 ataacttgaa catgtatcca gaaacttccc acttcccact attccacagc tagcacctag 115920 gtcaaaaagct tcattttctg tttcctgtat aatgcactgg ccttcacact ggtctccctg 115980 cctctaccct tgtatttctt cagtctgttc ttaacatggt aggcaaaggg atattttaaa 116040 atgatgtaaa atgatatttt aaaatgaggt catgtcacct ctctcttcta aaccccattt 116100 tccactactg ttctgacctt accacctctt actttttcct cattcacttt gttctagcca 116220

tgctgttctt tgaaaatgcc atacagattt tcattttctg atctttataa gtttcctctt 116280 catggaacac tcttcctcca ggaagcctaa taattcactc cttcatttcc ttcattgagt 116340 ctttgttcaa aggttacctt ctcaacagaa cctaccatga ctgcttaatt taaaactggg 116400 ccaggtgcag tggctgacat ctgtaatccc agcactttgg aaggccgagg tgggcggatc 116460 acgaggtcag aagattgaga ccatcctggc caacatggtg aaaccccatc tctactaaaa 116520 atacaaaaat tagctgggag tggtggtggg cacctgtagt cccagctact cgggaggctg 116580 acgcaggaga atcgctcgaa cctgggaggt ggaggttgca ctgagccgag gtcgcaccac 116640 agtaaaatta caacccgacc cccacactcc aaatcctatc tttacccttc tctatagtgt 116760 tatatgatta acttactatg ctttttattc tccatctctt tttctctaaa atataaagtc 116820 cacaagagct ggaatgttca catgttttct gtactttata ttcctagtac ctagactgat 116880 gtctggccag aagtaggggc ttaataattt tgttgaatga gttaatgaaa ttgcaaagtg 116940 atagttctaa cttttacatc atagttagag gatacattgg tgaaggtcat agggtagggg 117000 atagacaaac agctagaaga aaggtggtgt ggtcctggca aagaaaacga ttattccact 117060 aggcccagct acaatgtgaa tttcctgtga cacctacctg accctcagtt aggggtgctc 117120 ccctgtttac tctcaaaggt ctttgaacaa tcctgcacaa gagcacggat ttgcatgctt 117180 gcttaattgg tgatttacaa gtcttttccc ttaacagtgc tgaactttac ctgagccctg 117240 tgctcttgga aacgaatgac agttaagaaa tatttctcct acccttttgt attccctaaa 117300 atgttttact gtcataaacc actctcccca tatgactaag actctggtga atgtaccctt 117360 gaatacctat gacaaggcca gataaagacc ctccacagtt ccaccttttg tcccataagt 117420 gattagctga aatgtttgtc tccactgaca aatcaaaaca aaatgcccac taacttgacc 117480 aaatgttgtc aggcttttgt tttttccatg ggctgctgat ctttcaccct cagcctgagc 117540 cagccgtcct taaaggcttc cattgagaat aggctggatt cagagcaaaa ccttatatcc 117600 agtcgtgtca ccctgactca ctgattcatc ccactttttt ttttttttt tttttttt 117660 ttgagacgcg gtcttgctct gccacccagg ctggagtgcg gtggcgtgat ctcagctcac 117720 tgcaacctcc acctcctgag ttcaagctat tcttctgcct cagcctcccg agtagctggg 117780 actacaggcg tgcaccccca tgcccagcta atttttgtat ttttagtaga gatggggttt 117840 caccatactg gccagggtgg tettgaacte etgacettgt gatetgeetg ceteageete 117900 ccaaagtgct gggattacgg gcgtgagcca ctgtgactgg ccctcatccc acttctctac 117960 aaccagacct ttctaggtgt gtttatttct ccatgtaaaa gaaaaatctt tcggccaggc 118020 agggtggctc acgcctgtaa tcccagcact ttgggaggct aaggcgggtg gatcacctat 118080

ggtcaagagt ttgagagcag cctggcccac atggcgaaat ctcgcctcta ctaaaaatac 118140 aaaaaaaaa aaaaaaatag ctggatgtgg tggcacgcgc ctgtagtccc agctacccag 118200 gaggctgaga caggagaatc gcttgaaccc aggaggcgaa ggttgcagtg agctgaggtc 118260 acgccactgc actccagcct gggtgataga gcaagactcc atctaaaaaa aagaaaaaag 118320 aaagaaagaa aaaaaagaaa agaaaagtct ttccaggcct gaccattgag acactagcag 118380 atgtcatgct tggagccttc tccctattac aacaggcctc cctctccact gcagttttct 118440 cttttccctc tcttccggca gttctttcaa gtaaattatc tccttaccta agctcagatt 118500 tttgttttta ttggacatgc ttggcttgat tattttgttt ttcttaagga cagttgccat 118560 gtaggattca gcacaggatc tcagaacttc gcaccaggcc tgccagtata gtacttgtta 118620 tatattagct gaatgaactc acccacaca atatatgaat gaataaatac tgtgtcagta 118680 gcttggaaag acaaaagaaa aaactgggcc tcttcccctc cttcaaagat tctgtacctc 118740 agttcatttc agtagctttt ctcttaacac agatatttag cattgtttag acaaaaatct 118800 cactatgcag ctatgctaca gaattagcct aaatcatgca tctgcctgta tttttggcaa 118860 ttaattccca atcttaatta ggaataaagt taaagtgttt tctcaatcta gtgcaaaagc 118920 ttgtatttcc ttctacttca gcaagaccct ggagtgagtt tgaggttact gtttttaaaa 118980 ctttgaaagc tgggatggtg gtgcattact cctacttcta ttggtgggtg tacttcacta 119040 agetcaagtt aageatttgt tgeaggtatt tgtgttgtte taattetttg caggeatete 119100 tgtgatgaaa aacctgagca ttgcagactt ttttaacagc tctgaacaat tccattcaag 119160 gcaaagtccc tgcaccttcc tctgtgaatt ctatatattg tctgtatgtg tattagtcca 119220 ttttcacact actataaaga acttccttga gactgggtaa tctataaagg aaaaaggttt 119280 aattgactaa cagttctgcg tggctgggga ggcctcagga aacttagaat aatggtggaa 119340 gggaaagcag ctacatctta catggcagca ggtaagagag agcgtgttgg aggaactgtc 119400 aaacacttat aaaacaatca gatcttgtga aaactcacta ccatgagaac aacgtgggga 119460 aatctgcccc catgatccaa tcacctccca ctagatccgt ctcctgacat gtggggatta 119520 tggagattac aattcaagat aagatttggg tgcaggcaaa gagccaaacc gtatcattcc 119580 accccggccc ctcccaaatt tcacatcctt tttacatttc aaaactagtc gtgccttccc 119640 aacagtcccc caaagtctta actcgtttca gcattaactc aaaagtccat ggtccaaatc 119700 tcatctgaga caaggcaaga cccttccact tatgaacctg taaaatcaaa aataagttcg 119760 cttcttccaa gatacaatga gggtacggta aatacatcca tttcaaatgg gagagattgg 119820 ccaaaacaca ggggctacag gccccatgca agtccaaaac ccagtgggac agtcattaaa 119880 tcttaaaagt ccaaaatgat ctcctttgac tccacatctc acatccaggg cacgctgatg 119940

caaggggttg gctcccacag cttttggcag ttcctccatt ggctgacgtt tagtgcctgt 120000 tgctcttcaa agtgcacaat gcaagctgtc aatggatcta ccaatctagg gtgtgatgat 120060 ggtttccctc ttctcacagc tccactaacc agtgccccag tggggactct gtgtggggc 120120 tccaacccca catttttctt ccgcactgcc ctagcagagg ttctgcatga agtttccact 120180 tctgcagcaa gcttcttcct ggacatccag acatttccac atatcctctg aaatctaggt 120240 ggaggttccc aaacttcaat tttttacttc tgtgcaccct caaacccagc actacatgga 120300 accepactgg gettgggget tgeaccetet gaagcaacag eccaagetge aacttgggee 120360 cttgtagcac taatggagct ggagaagctg ggacacatgg caccatgtcc caaggctgca 120420 cagagcaggg ggaccettgg cccagcccag gaaaccattt ttccctccta ggcctctggg 120480 cttataatgg caggggctgc catgaagatc tctgacatgg tgctgagacg ttttccccat 120540 tgtcttggct attaccatgt gctcctcatt acttatgcag atttcttcag ctggcttcaa 120600 tttctcccca gaaaatgggt ttttctttc aactacatag taaggctgcc aattttccaa 120660 acttttatgc tgttcttctc ttttaattgt aagttccaat ttcaaatatt ctctttgtga 120720 atgcatataa ctgaacactt tcagaataat ccaggtcatg tcttgaatac atcgcttttt 120780 agaaatttct tccaccagaa acccataatc atctctctca agtttaaagt tccacagatc 120840 tctagggcaa gggcaaaatg cctccaatct ttttgctaaa ctgtagcgag agtgaccttt 120900 gcttcagttg ccaagaagtt cctcatctcc atctgagacc acctcatcct ggacttcatt 120960 atccgtatca ctctcagcat tttggtcaaa accattcgac aactgtctag gaagttccaa 121020 actttcccac atcttcctgt cttccaagcc ttccaaagtg ttccaacttc tgcccattac 121080 ccagttccaa agtaccttcc acattctcag gtatctcata gcaatgcccc actaccctca 121140 gtaccagttt tttgaattag tccgttttca cactgctata aagaacttcc ctgagactgg 121200 gtaacttata aaggaaagag gtttaattga cttatagttc tgcatggctg gggaagcctc 121260 aggaatetta cagteatggt gtgageggaa geaggaatge ettacatgge ageagtegag 121320 agagagtgtg tgaaggagga actgtcaaac acataaaccc atcagatctc atgagatctc 121380 actcactatc atgagaacag catgggggac actgccccca tgattcaatc aactcccact 121440 aggtccctcc ctctacatgt ggggattatg gggattacaa ttccagatga gattttggtg 121500 gggacacaga accaaaccat atcagtatgt ttaccagttt gccctagcct ctggcttcag 121560 aaaatagaaa gggcatcttt tcatttgttt tttgccttca ctttctgttt ttcctcttac 121620 tctgtaagaa agagtctgtt tttgttttct tttctgtgct atctgctcta ctgtttgagg 121680 aaggagggtc ttgatgagtt gtcacctttc tgtgaacaga gcttatattt tgagtgtggc 121740 ttcacttttt atcttagaaa taaagcagca agcagggtgt tctaatcagt cgcacttcgg 121800

tctcaaatac tacgtccatg taagtcaaat attaatagtg aagagaatga gccaactttc 121860 taaatcgagg ctgtatttcc atctctatgg ggtccaaaat aaaactggtt aaaaaaatgc 121920 catcttcact atgaaagact cactgtctac accatccctc ttcccatgga gtttctgttg 121980 acagagatgg agtcagtcat gtctcatggg aagcggactt gggcagaagg ttcccctgca 122040 aatgatgctc gatccccaca aagatgcagc agagaaaggc agaaaaccca gtcttcagtg 122100 caaaatggtg aggaggagcc tggcttagaa tctcagcctg aaatgacaag tgaaaaaaag 122160 tetetgaata cattigtiga ggetagatgg tgttacecae cettgetgtt teacteetet 122220 gaagtgttct ctctatattt tgctattttg caagggaggg gaagaaataa tatgtatgct 122280 tttctgtgtg gattttaaac aagttgctga attatcaata aagttttaaa gtgctctatc 122340 atttgtcatg ttatggtcag caatggttgt tettttette ttactteett gtgtatgtag 122400 atttacctgt cactactggc aggactgaaa attgttttat agtcatggtc ttctatgtgg 122460 cagcccagga taggggtaaa cttttgggga tagaaagaaa gaaaaatgat aatagcattt 122520 tttggcatta aatatcatta cccactttat acagcaaaaa atgagaaatt tcaaggggcc 122580 aaattaattt ggaaagaaac tgactataaa tgacttgaat aaacaaattc aaatgactca 122640 ttataataga ataatagaat attagaaaaa aattatcttt ttattagaag atggaactgg 122700 atttettttt etettteae etteettaea tetaceetea aettetagat aaatteaeaa 122760 ataaacactt cagacatttt tctgtgactt aatgtgttca gacactgttg cttgcttgtt 122820 tgcattttct ttcagatttt actgttgtac atgctgcacg cagtctggct acatcttgag 122880 ctctgtcatt tatccaacag agacatcccc tatatggatc taaaagatat cataacactt 122940 gaaaggtcat gtgtggctaa tgcctttctc catctggtga tagatctttt tcttcctttt 123000 tgttgtctgt ccataagact gctgataaaa aaccaagagt gattaaatat actaaattgt 123060 ccaacttaag gaaattccag catatcaaag agctaataac ttcttggaaa atttatatgc 123120 ctcagcaaaa tgcacaattt tatctggttt gagagtttga gctggaaaaa aatttcagca 123180 actitagaaa atctaatcta ctggaatact ttacaaacgc tctatagctc cggcaccaag 123240 gattetatat atgeagtgge actagtagee aagttgattg gttggtttte tgeagattaa 123300 acaactgatt gattcaggta gtccccttct tgtctaccac ctaactcctg tctaataatg 123360 atccaagttt tggcagttac tgagtcctac tatggactag ttcctggaca aataagttca 123420 ttagcatgat ctcaattaga cattttacct agaattttcg gaatggcttt ttctagagtt 123480 tgtatcctca tatgatgagt attataatac caaaatttta cttcactttt tatataactg 123540 aacaagtaaa taaaggacaa agcactatca tacctcatgc attactatta gactgtaatg 123600 attgtcattg ggactacttg ttacaatact ccccatcagg tctcaattgt acagactggg 123660

cctcctgtga tatttgtatc ctggaagata acaacatccc atttgctccc agaacaaatt 123720 attttttcaa ttattattat gaaagttttg ttttattgtc ttaagaacac ttaacatgag 123780 atgtatcccc taaacagatt tttatagcaa tggaatgaaa tttatttttc attataaact 123840 ctattgtact gtttgaattt attttgccat ttgcttgcat tacctgctag agaggcagag 123900 agaaagagaa acagagaaaa actatgagtg agttttcacc taattttcca acttaacctc 123960 ctactgaatc tcattttaca catgacaact cattgcttct caaagacact aagtatattc 124020 atattgagtg tgtgtttgtg tgtgtgtgtc taacattcca tcatccttga ctcacatgtt 124080 ttctgcctgt aaaaatccca tccctcaaaa gttcttctaa aacagatttt ttgcatttac 124140 atttcactat tcttaagtac agaaacaatt ctggacatca gatctctaga acttattcat 124200 gcgacaaaac tgaaaccact tgaatagaaa ctccccattt tcctctacct tcagcccctg 124260 acagctacca ttctactctg cttctataaa tttgactatt ttagatactt catataagtg 124320 gaatcatgca gtattagttt ttctgtgact gatttatttc acttagcata atgtcctcca 124380 ggttcattca tgttgttgca tatggcaaaa tttccatatt tttgaaacca aataatactc 124440 ccttgtatgt atatattaaa atttatttat ccattcatct gttgatagac atttaggttg 124500 tttctacatt ttggctactg tgaataaggc tgcagtgaac atggaagtgc aaatatctct 124560 ttgaaatcat gattttaatt cttttgtaca aataaacaga ggtgagatta caggatcaca 124620 tagtggttct atttttaatt ttttaaagga atctccaaac tgtttttaat agcagctgca 124680 ccattgtgca ttaccacaac ggtgtacaag ggtcccagtt cctcaccatc ctttccagcg 124740 ctttttgtct ttttcctttt ttcttaataa tagccatcct aacagttgcg aggtggtatc 124800 tccttctggt tttgatttgc attgttatga ttattagtga cattgagcat cttttaatgt 124860 acctgttggt catttgtatg tcttctttgg ggaaatgtct attcaagtct ttagaccata 124920 ttttaattgg gctatcagtt ttagctgttg tgttatgtga gtttctaata tattttggat 124980 attaacetet tttcaactat atggtttgca aatattttte ceatteatag gttgeetett 125040 caactatatt gtttcctttg ctttgtagca ggtttttggt gtgatgtagt cctacttgtc 125100 cattttttct tttgttgcct gtgcttttaa tgtcatgtct cttaaatcat tgccgagact 125160 actgtcacaa agctttccct catgtcgtct tctgggagtt tacagtttca agtcttggat 125220 ttaagtottt agtocatttt gagttttttt gtgtgtgtat ggtgtaagat aagggtctga 125280 tttcattctt ttgcatgtgg atatccagtt tttccaacac cattttttaa agagattatc 125340 ctttccctat aatttattat ttgtaccttt atcaaaaatc agttgacttc tctcttgact 125400 ggagcagtga aacaaacgaa cataaataag ttgactatat atgtgggggt ttatttccag 125460 actttctatt ttgctccatt ggtcttgtat atctgtcttt attatgccag caccatattg 125520

ttttgattac agcagctttg taatatattt gcaaatcaga aagtgtgatg ctttcagctt 125580 ttttctgctt tctcaagact gttttggcta ttcagatttc tttgcatatg tgcatgaatt 125640 ttagaattgt ttttttttct atttctgtaa atattgccat tgggattttc atagggatta 125700 aattgaatct gtagatcact ttaggtagta tggtcaattt gacaatatta agtcttctaa 125760 accgtgaaca cagaatattt tcccttttga ttgtgtcttc tttaatttca ttcaccaatg 125820 ttttgtagtg ttcagtgtac aagtcttttt acttctttag tttattccta agtatcgtat 125880 tcttaagtat cttatttttt gacactatag taaatagagt tgtcttccta attttctttt 125940 cagattattt gcttttaata tataagaaca gaactttttt ttgttcattg tgtatcctgc 126000 aacttcactg agattttaag tcagtattaa gagatttggg gtggggtctt taggatttct 126060 atgtataaga acacgtcatc tgcaaacaga gataatttca cttcttcctt tctgatttgg 126120 atgcattttt tttctcttac ctaattgctc tagctaggac ttctactact attttcttag 126180 tccatttcat attgctatac cagaatatca cagattgggt aatttacaaa gaacaaaagt 126240 ttatttggct cacagttctg gaggctgtga agacatcagg taaggaactt cattccacat 126300 tatcccatgg cagaagatat taaggcaaga gagggtgaga gggagagcaa gaattaaagg 126360 gagtggaatt tatcctgttt atcaggaaac tactcccaag ttaactaacc agttcctgta 126420 atagtaccat taatctattc acagggcaga gccttcatga cccagtcatc tcttaaaagt 126480 cccacttctt aacactgttg cattggggat aaagtttcca acacatgaac tttagagaaa 126540 cacatttaaa ccatagggac tatgttgaat agaagtggca agagtgggca tctttgtctt 126600 gttactgatc ttagagaaaa gcttttagtt tttcatcatc gataatgaag tgacctgtgg 126660 gcttgtcgta tatgaccttt tttgtgttca ggtacgttcc ttcttatacc taatttgttg 126720 agagttttat cataaaggga tgtagaattt tgtcagatgc ttttcttgca tttattgaaa 126780 tgaccatatg gttttcatat ttcattgtgt taatgtggta tatcacattt atagatttgc 126840 atatattgac cccttcttga ataccaggag ttaattcctc ttggtcatgg tgtataattc 126900 ttttactgtg ctgttgaatt ttttctgcta atgttataat ggaattttaa acatagtatt 126960 totttaatta aaatatgtta ttgttataaa aaaataaaat aataacagtg aaactgaagt 127020 ctttctctta tctgtgacaa gaagagtccc tgagggtcaa agacaagtgg gataagaaag 127080 ctgaaagaaa actcaaacag ataagggtga tggttcttac tcaacaatta attatctcct 127140 tgaactcagt gtgtcccttc atttctccag gcctcagtcc cctgaatgtg ggtattattt 127200 tattttattc ttcccttaaa aagctagatg cctttgtagt tattatttgg tcaaaagtaa 127260 tacaggtgag aaataaagac aaaacaaaac aaacaaaaac aaagatatat cacccatatt 127320 aagtetteet eteacecaca gtettateee tgeteectae tgacaaceae tgeteteggt 127380

ttcttggata tctttccagg acttttgtag tcatatccag gcatttgtac atattttcat 127440 tagtagttaa tatagtgcag tcttggaagc cagactcccc ggggttatat ctcctagttc 127560 ttttgctgtt tgaatttggc cttgtcactg aaacttttat ctcaaattcc tcatatgtga 127620 tatgggggtg ataatacagc ctgcctcata agtattgata taaagagtaa gggaattaat 127680 aaataattaa tagcacattc actcagtaag tgatcattaa atatgaatta atctacacct 127740 tetttattte titttatgta aggtatatet accteggtte titgtaatgg etitatatit 127800 ttacagggta gcataattta tataaccagt ctcctactga aaaacactga agctttcagt 127860 cttttgttat tagaagcatt actgtaaaga aaatcctttc ccaaactgca tttgcccaca 127920 cttatgaaca tattgatata ataatttttg acaagcagaa ttcctgtgtt aaaaggacta 127980 tgtactcaaa tatcgatcag tactgccaaa tttacctcca ataagttata ccattttatt 128040 cttccattag cgttatatgg gagtcccagt ttacccacac ccacacaaac tttatattcc 128100 aataattttg ttttatatgt ttaccatttc aatgtgtaaa aaaaatatct ccttgctata 128160 ttaactttta tattttaaac tataattaaa gctaataatc ttttcctggg ggtaccagct 128220 attttaacta cctatttatg ttatttgaca attttgtgat tttaaaaata aatgatcatt 128280 tcaaaactat ttaaactaat cccattgttt ggaagccttc agaattttga ctcaaagata 128340 ataaaaaaca aataacaaaa caaaataata ggaaaaaaaa cctcacctgc aatacccatt 128400 tcatggagaa gaaaaccaat tctcaaagaa tgtaaacacc tcataaggtt agagctaact 128460 agtgacagag cttgcatttt aaaactccct tgcttttgtt ctgttttgtt ttcttttatg 128520 ggagcagctg cactgctttt tggacaacat gttctagctt ggctttgcta atatatagat 128580 atcaccataa tcacctctct accacccttt atttcactgt atagcagcca tatgttttag 128640 atgtggaatg gcctattaac ttggctttcg tgtaaaagtg tagagtgcta atgagtcagt 128700 aatcttacca gcagtttcta tttactaaag tcgccactga ctatttcctc ttgggaaata 128760 gtcaccattt cccaaggaat gtcttttcac atagcataca agttcttata atagtgtctt 128820 caacatctat ggctaactcc acaaagttta ttttgcttta gtgcttcttc atttgtcatg 128880 tcttcttgag agattagtgt ccttacattg tattgtatta tttattgttc caaaataaca 128940 tactagggaa taatagggtc aatagatttg tttttattaa aatgaaactt gtcagaatgt 129000 gaatttcaga ccaacatgga tttgtataag tcagacatga atctggcggg atagcactgg 129060 ggaaaggggg aagtttgtat atgggggtgg gctgcaatgt ggtgagtgca agacaggatt 129120 tccttcattc tttattgaaa ataagcattt tgcattctca tctgtgaatg aaacgaatac 129180 tgccattatt tgagtgttac ctttctgggc actgtgctaa gcttttcaca tgtattatct 129240

tacttctcaa tactccttgt aagaagagtg ttattatatt aattttgtat atatagaaag 129300 aatgatgttc aggaagccta aataatgtct aaggtaatat agttaatagc tggtagagcc 129360 cctctatgta taaattatat gatctgaact aaggtgatac aagagacaga acaagatatg 129480 ctgatgcata tatgaacaga ggtggcaaaa atggaattat tagcctccaa ctctagtaag 129540 ttcttgccag aaaactggat aaggtattca tacatcagat gaacaatgcc caagatcatt 129600 gtttcccaaa attattccag agaacactaa ttgtttaggc taatgggtga tatttttgaa 129660 gggttctgtg ctctaataat ttttttaggt agatccattt attttttaaa tacaagtata 129720 cttctggaag ggctatttga caaattcagc attgactgcc aactttgtag acatttttaa 129780 caacaacaaa aaacaaggca tttactcttg gcccttttag tacaggccaa gggtcctatt 129840 gcatcacaag tgctagggat gcagtaacag acccaagcgc ataatattaa agatttttt 129900 tccaactgcg attcagttga aaaataatat agtacaaaca tatattaatg gtaatcgaga 129960 ccactagcga tctgcagaat acctagaagc ctacctactt agaaggctga aactggtaaa 130020 agcatattaa aatcataatt tttaaaagtg ttaattttag taaaattaaa ctggtttatc 130080 tatgtaggac ttctcaaagt agtcattgtg caaatgtgca ggttaataca ccaagatata 130140 tgatataata ttccacgttt cccaatctaa tttaacttag taattccatt tttaagagtc 130200 ttgtgtggca gggaaatggg tcctagcctg ggtccttggg aaagcttgga gtcctggccc 130260 acgaacttga tccctgccca ggtgttttcc gggggggggc acttgaggcc caatctttgc 130320 tcgaggcagg tgtaagacac ctcagaggga gaacggcact gcctcctctt tcccacctgc 130380 ctctcatctc aatccttgac tggcgagttt aaagttgttc tgcaaccatg caaacctgtc 130440 cttctcatgc aactccaagg agcttgctgg ctctgcagcc acccttgggc ccccgccagc 130500 ctgccatgaa tcagatctct ttcccagaat ctgggccttt ctgaagtttt ggggagagcc 130560 gttgggactc atccagtgct ccagaaggtg gacttgcttc tcgtgggttt taaaggagac 130620 tccaggagat atgcttaacc aaccatgatg gattttgccc caactggact cggcagcttc 130680 acgtggaatc caggtgcagc ctccagtctg ggaaagtcac ccaacctagc agttgtcatg 130740 tgggtaacct caagcacctc taagcctgac ctggaagaat gaccagcagc ccctccagaa 130800 ctctgctcag gacagcagga gcctcctggc tctgggtttg gaagctgggg tgggtagcgg 130860 gtggtaagta ctatatgtgg ctctggaaaa acagccgcta cttccaaatc tattgtccat 130920 aatggtttct ttctgaggtt gtttcttggc ctcaaagggc cccaggggat gtttggaaat 130980 agcettecta eccettetgga geatggetta caaaagecag etgaettetg gaactgeetg 131040 tggaggatag tttgggtgta ggttactgat gtctcacctg agttttataa gctgctgttg 131100

agtagtatgc tgggaggaat cttcttttt atatattgta tttttgtatg cctttcggga 131160 agtggtgtta actgcttttg tacaagaaaa aactcatggg caattctcct gttgcaaggg 131220 tctgatttat tttgagaggc aagttcacct gaaattttgt atttagctgt gattactgat 131280 tgcctgattt taaaatattg ccttctggga catcttctaa taaaagattt ctcaaacaaa 131340 caaacaaaaa aacaaaaaga gtcttgtgtg ccatagatca tactgtggga aatgctgact 131400 aattggaatc tcaagtccct tctaacactg aacgcttaca attccatgat tctgttacag 131460 gccatgaaga tataggagaa tacagatata tacatatata tatatatgta tatatatctc 131520 ctgtgttctt ggattaatct gtgattggtc cactgtgtaa gtgcctaatt aacctcagtg 131580 tgatattttc tataaaatgt cttggcaaga ttgttgatag gtccaagcat tcaatagaag 131640 attgaactgg acctagctgc acatttgacc catctaaagt atttgttgta agtacagatt 131700 tctgagacaa attcccagga tttctgattc tataatttga gggaaagctc tagaaacaat 131760 ttttaatggt cattccaggg gttctgcacc atatttggtc catatgtcaa tatttggaac 131820 aagtetaaga tataaagtea agaaageeta tgaggatget acagagttet teteaateet 131880 gtccatgcac cagttcctgg agctctaccc aagaccttgg aaacttgacc cagtagatcc 131940 aatggtgctg ggagtgggac ctgtggatgt ctccttaaga aaaaaaatc tacaagtgaa 132000 tcttatgttg ctgggtcaca gatatataat taggaccact ggcttaaatg acttccaatt 132060 tetteettee aaccatatat tittetacat tetgagtata atatgaette eetaaatgta 132120 cttagtgtga tggttaatac tgaatgtcaa ctcgattgga tagaaggata caaagtattg 132180 atcctatgtg tgtctgtgag gttgttgcca aaggagatta acatttgagt cagtgggctg 132240 ggaaaggcag acccatcctt aacctgagtg ggcacaatat aatcagctgc cagtgtggct 132300 agaatataaa tgggcagaaa aatgtgaaaa gagagactgg actagccttc cagcctacat 132360 ctttetectg tgetggatge tteeggeeet egaacattgg acteeaagtt etteegtttt 132420 ggaacttggg ctggctctcc ttgctcctta gcctgcagat ggcctatggt gggaccttgt 132480 gatcatgtaa gttaatactt aataaagtca tatatatata ttccattaat tctgtccctc 132540 tagagaacct aatacactta ttatgtgaag agaaacatga cgtgaggctg tttgtttata 132600 gtcccaactg taacctatgc tgatgaggct agaattgaga gcctgtgctc agatatgatt 132660 atcactctaa aaagaagcag cgacaaaccc gaataaaggt cagaggggag ggacgaaaat 132720 gataagggta ttcaaacaca tggcatatga ggaatcattg aaggaactgg ggtgtttagc 132780 ttggagaaga gaagaattgt gtgcagatag gaatattatc tttaaatatt caaaaggttg 132840 tcctgtggag gacctattag gctggctgtt taggatgcta taaaaaaagaa gacacctcta 132900 acagacagag gggaaagtgt tatgcttgag cacctgttag gccagggata gttctggata 132960

ttttaagcat gttattttat ttaacagtca tgcaaaatat gcaaaagagg tatagctgac 133020 ccattttaga aattaggaaa taggcccaga aatggtaaat tattccatgt tcctatgaat 133080 atatggataa tatggtagtc attaaagcta ctcacaaata ttccatttcc tcttcttcca 133140 gaaacatggt aggattgtac ttcccaacct tgtttgaagc taagggtagg cttgtggaat 133200 ccatatgcca agataaagca gaggttcccg gccaatatgg attggacata tagcaaaagt 133320 gagaaacaaa cttttttctc ttgtcatgaa aatccaagag aagcctgcta actatatgca 133380 ttcttagtct atgttcttgg tctaagtcat aggttgtata catttctgtt tgtcactggg 133440 aatttggagt tatttgttac tgtaggataa ttcagccctc ctggctgata atggcagaag 133500 tagaagagtc agagttaaac ctagcttatt ctgcttccca aatctgtgct cttcccattg 133560 taatacaaga cctcacagat aaccagtgtt aagctctata gcaatgaaag agagtattac 133620 agttcattca tgcaaatatt tgataaaaac ttgttgggac tgataaatct aatggctgaa 133680 ttgtaaccac ccagtgagtt tacctagccg actgcctaga cagagctgat ttatcaagac 133740 aagggaatta caatagagga agtttaattc acacagagct ggctacacgg gagactggag 133800 ttttattgtt gctcaaatca gtctccctaa gaattcaggg atcagagttt ttaagaatat 133860 tttggtgggt gtggaggcca gtgagtttgg agtgttgatt ggttgggtgg cagttgaaat 133920 catagggagt tgaagctgtc ctcatacact gagtcccttc atgggtggaa gccacaagac 133980 tagacaagcc agtttatcca tetgggtggt gecagetgac ceateaggtg cagggtetge 134040 aacatateta aageactgat etegttgeag tacatageta gteagacatg ageacageag 134100 gagagtgacg ccccacccc atcaagaaag tcaggcaacc attagggtat ggtcaagcag 134160 ttgttaaacc atctctctaa aataatattt ggtcacagcc agtgacagag aaaggcagtc 134220 ctccaataga tagaaaacat ctgaaactta taatcagcag cttcccagta ggatctcagg 134280 agttgggcca gtgggcttaa gcttgcgcat taagaggcaa aatggcagag tttaactggt 134340 atatgacctt ctagggacat tggactggta agagaagaaa acctctagtg ggcacgtgta 134400 caactccagt aaacacactg tgcatgcagc catttccaag tgctggcagg ccactgagca 134460 tgcagacagc ccactccaag agaagaatca ggggagaagg gatgcaggac cctggaagta 134520 caccaacata taaaacccta agtcaaaggt caaacatggc acttgatctc tcaggtcacc 134580 tgcctggccc tcttgcaagt atactttact tcctttcatt cctgatctaa agctttttaa 134640 tacgetttea etectgetet aaaatttace teggtetete ettetacett atgeetetea 134700 gttgaattct ttcttctgag aaggcaagaa ttgaggttgc tgcagacatg tacaaattca 134760 ccatcagtaa cataccttag tgcaagtttt aaagcagggg tgaaaattta ttaaaaagct 134820

and the Manager

. . . . .

gtaaagcaga aatgaaagga agtagagtac acttggaaga gggccaaata ggtgacttaa 134880 gagatcaagt gcacgccttg acttttgact tggggtttta ttagttggga ttcttctggc 134940 atctgaattt teteteecet gattetteee ttgggatggg etgeetgeat geacagtgge 135000 ctgctagcac ttgggagtgg ccccatgtac agtgtgttta atggagttgt atacatgctt 135060 acttgaggca ttcttccctt accagtcaaa tgtccccaga aagtcataca ccagttaaac 135120 tggcattttg cctcttaatg agcatgcttg agccaactcg cccagctcct gagatcttat 135180 taggaagetg etgateacea getteaggtt ttttetatgt attgggggae caeettteec 135240 tggcactggc tgggactatc aactgcctga ccatcacttg atggtcccct gacactcctg 135300 ttttggtggg gctctcctgc actgctcatg tctgactagc tacctactgt aacaatctta 135360 gggtttacca atagtgaggt tatccccagg aacaatttgg tgagggtcag aatattgtag 135420 cttccagctg cgtgacacct aaaccatggt ttctaatctt gtggctaatt tgttagtctt 135480 acaaaggcat cctagtccct aggcaagtag ggggcttgtt ttggaaaagg gatattattg 135540 tetttgttte aaagttaaae tataaaetaa gtteetteea aagttagttt ggeetaeaee 135600 caggaatgaa caatgacagc ttggaggtta gaagcaagat agagtcagtt aggtcatatc 135660 tctttcactg taataatttt ctctgttgta attttcaatg gcagtttcag aatggtctct 135720 tccaactcta atattctatg atttcctgat tctgtgacag gttgtagaac ccaaatacaa 135780 tttttaggcc taaggcatat tcactttatg tggacctttc ccagccccat ctcaattggt 135900 tggcaccaag tcacaatgac cttttattcc taatgacttc cctgaggcgg ggggcggggg 136020 ggaaagcatt tgcatttcag ctcattcttt cctggagcat aatacattct tagatttatt 136080 tataattttg agggtttgcc tctccctgct ggttctcaaa gtttaatgct atcccaaaat 136140 atgtttatcc atttcatgtc acaatgggga catggggatg atttccggtt tgagaccttc 136200 ccatcactat aatcattttc atgtcatctt tgaagcagat atgctcttag gggtgacctc 136260 attagagcca aaatatgatg gcaatgaaga aacatattta tcacattctt atcctcttat 136320 actttaaata etettaette ttatattgge tettaettat gtaactcate caattgcaga 136380 gacacttgaa aagactgtat ttcaacacac tttacaaaaa acagaagcca caaaattata 136440 acatacatta ttggcggcat ccttgaagat gactttcagt gcataggaca gggaatgtct 136500 acaaagactt acccctacgt ctttggaaca aaatctgaaa atatctctct aaaactgaac 136560 gaattettet tgggcaatat gagacatett caaaataaac taccatgatg aatggcatga 136620 aaatctggta ttactgagga aagcctacac cctacatctc taccatgaag atcagagtat 136680

ttctttattg aatacacaaa tcagagtgcc tttcaatcta attaatgtca ccagagtatg 136740 tgtgagctta ggaatgtaga tatacagtta gccaaagtat gtttggtgct cttgctggta 136800 aggcagtctg agaaaaacaa gtcccatggc caagttgcta aaacatacct cccactcaaa 136860 acttcaaaag gcatattagc atatcaaagg taataaaaag acccatagaa aagacacctc 136920 tttagctttg ttcaacccag ctttagccaa atgtatttgc taataaacct tttaaaaaat 136980 aatgctcatc gaaacagacc aagaaacata ttttggcaaa taccaaatta aggaaaaagc 137040 aagccataaa taaattgtct ttcataagtg taaaaagagt aataaatagg cttggcatga 137100 aaattetget teacaettga attatettta agagettatt gattttttee tgtgageete 137160 aatateetet tetataaaat ggaaateaaa atgetgagtg acgtaacgag aggtaaagee 137220 agctgggctc ctgggttgag tggggacttg gagaactttt ctgtctagct agaggattgt 137280 aaatgcacca atcagcgctc tgtgcctagc tagaggattg taaatgcacc aatcaacatt 137340 ctgtaaaaat ggaccaatca gcactctgta aaatggacca gtcagcagga catgggcggg 137400 gccaaataag ggaataaaag ctggccaccc acgccagcag cagcaacccg attgggtccc 137460 ctttcacgtt atgggagett tgttctttcg ctcttcatca taaatcttgc tgctgctcac 137520 tetttgggtc tgcgccacct ttaagagctg taacactcac caccggggtc tgtggcttcc 137580 ttcctgaagt cagcaagaca acgaacccac tgggaggaac gaataactct ggatgtgcca 137640 cttttaagag ctgtaacact cactatgagg tccgtggctt cattcttaaa gtcagcgaga 137700 ccaagaaccc accagaagga agaaactcca gacacggtaa gttattcaga cttaggaggg 137760 cagtagcaca tagtggttaa gcccaaagat tctggtgcca cacctactgg gtgtgaaatc 137820 tggcttcacc tctgcttact tatgtgatgt taggcaagtt attgcagctt acttttactt 137880 tgtttttttc acatttaaaa tggaaaaaaa tagtacctgc catcaaagaa aatgaccaag 137940 gcaagtctca atcattttag gaggtttatt tgccaaggtt aaggacatgc acctgggaga 138000 cagttctatg cctttctcca acgatgcttt tgagggtttc agtatttaaa ggggaaaggc 138060 tgagatattg agaaatacac aattttaatt tgagagggtg gtataggaaa ataatcttac 138120 atgccattgt ctggctcaga gtatccataa ttgtacataa tgtagaaagt agaaaagttc 138180 ctcttcaaag ctcatcttgg tttaaaaata aaataacaga cactagaaat aatagcttct 138240 tactctaaag cctcctatca actattagtt cttacacttt agcccagtta gtggctttgg 138300 cttactccgg tatgtctgga caggcccagg caagtcttag ctcatagctt atgccccttt 138360 cttatttgga aatgttattg cttccttgaa cctttcataa gcaacttcct ctccttctt 138420 gttcttcctt gcacttacct atttaggaaa gttttaggtt attagcaaat tggttattag 138480 tttaagactg tgaggtccag ctctagccaa tggatgcagg acacagcagt aaggacgacc 138540

caaatgcata aaggataaat atgtctgctt ttcctttgtt caagtgtgct ctcgccattg 138600 ttccatctgt gtgtagcacc ctttctgcag aaagtaaaga tggccttgct gagataatta 138660 aatttatatt caagtgctat ttctttgtgg cactggggaa caagcatttc taacacataa 138720 gataatgtag acaatacggc aaaggaaaca atcagatatg tatttgtctc aggtaggcag 138780 agtcataact ttgagttctg tcctgtttct caacagctgt gaagataagc tatcattctg 138840 ttaaagttta cattgccatg gtaaacttta acagaaacac actttagggt aaagatgttg 138900 gggcccacaa caaatttccc tgtgggaaaa aatataaggg aggtatgtcg cctttcatct 138960 ttgtagccat cttatttagg aacaaaaatg ggaggcaggt ttgcatgacc cagattccag 139020 cttgaatttt ccctttggct tagtgagttt ggggtcccag atttattttc ctttcacact 139080 gccaaagagg ttttctctga atattaaata gtattaaagt actttgagtg agcattccac 139140 tcaacataag ctgaggacta agctctgatt ctttttttt atttctatct tttttatctt 139200 geceaaatte etgtetaagg ggtetgggga gteataceet aceaatgatt aactateate 139260 agatgggttt tatttaaccc tatatatcat gacttacttt ccaatctgac tctggcataa 139320 cattatttga caaagaagaa aatcaaaata ttttacccaa aacatgtttc tttgccgtgt 139380 tttgaaatgg gcctgcaaga ccatccattg tgggggaaaa tttgcaactg tagaaattct 139440 ctattgatat agctagatct ttttcttcca ggctctccca atcctgaaga cattaattga 139500 gagtttagca ccttttaaag gtctgaatag aaaaaacatt tgtcatctat tgtctctaag 139560 ggcaaccact atgagacttc aaaagaacct tggtctccac aatcttttat cttaacctga 139620 acatttcctt tccattaatt ccaggcaaac tcaaccattt ataaaccaga aaatgtttaa 139680 atttacctat tgcctggaac cccctcccca ccactccgct cgaattgtcc cacctttctg 139740 gaccaaaccc atgtattttt caaatgtatt tgattgatgt ctcagaatca ctttagggaa 139800 tgatgtttca tgcctcccta aaatgtgtaa aaccaagctg caccccaatt cctttgagca 139860 gatattettg ggaceteetg tgggetgtgt cacaggeeat ggteacteat atttggeeta 139920 ggataaatct cttcaaatat tttacagagt ttgactcctg ttgttgacaa gctattgttt 139980 tagetttate aaatacetgg gteattgtaa ttgeteatgt attgtagtea aaceteagte 140040 aaagagaaac atgttgatag aagggaagga gtctgtaaga aatttagggg aaaatgtaga 140100 gagaaaaccc aagagaagaa tagttcatat ttattcagca gcctggtata tggctgcttt 140160 gateactgcc cacagagatt ttettaccet tgacaggeta getegtaggg cateagtetg 140220 tctcagttga aggacactgt taaaattctc agttttttac ctcctggcca gcttcaccct 140280 tatcaaacgc tcctctataa aacaccccaa gaatcattct tataaggtag agacacaagt 140340 tagggtaatt teetetacaa tatttetgea teaatactag etettaaggt geatttaaat 140400

attatttgta gttgcctatt tcccacagac tgactgtgag gaagctcaca gtaaaaatac 140460 attgatagag tggcttaaat atcaagaagg cctcaaaaac caaagagaga tggggaagat 140520 aattgtacca ggaaaaggga aagatataat tattgtaatt aagcactaat tttagctccg 140580 aagacattaa ggtctgaatt gcacttactt ttcaaactca gtcactattc tacgttttaa 140640 tcctttatac aattttgtac ctttatacaa gttagaatta tattggtaat ttattcaaat 140700 cttcttttat cagcattctc agttccctta agcccaatat ttaaatgttt aaaatgtcac 140760 tccctgctag tgatttttta aaggaactat tatcatttta tgttcagtac acacacaca 140820 acagacacac acacacacac acacacgagt ttcctcttta gtatatgtcc tagatcaatg 140880 tgtctggtta ctattactct tggatcttct caactctcct caccccacta caatatcaca 140940 tettteeett ceateacatt gaaacatetg aaacagetet cataaggaaa atcacageat 141000 acattttgcc aagcctatct tcatcctgct tgaattcaaa gcaccatttg acatcgctga 141060 ccattcgctt ctctcctgtc ctggcttctg cttgcatgtt ttcttatttt tctttctacc 141120 tcattaaaag catcttactc actctctgtc atcttttcca ggcctctaaa tatgggagtt 141180 tctcagcatt ctgttccaga attatgattc cttatatctc taagagtaaa acacaaaggc 141240 ctgcaagact ctatgcgatc tgcaccccac tccctttctg accaggtaga tacatttcta 141300 ggtacatcag tactctcctg gatatcaata ctcagaaata cttgtctcca cttaccatct 141360 ccattttctt tctttccatt ttctctagaa cccaccatga tcatgttttc atctgaagca 141420 cgccacacca ctgaacagct gttgtcaagg tcacaagtta ctacctagtt gccaatataa 141480 agettgatet teggteetee teteateega eetgtetgga geatttgaaa agttgateae 141540 tctcttcttt gtaaaatact gattcacgtg gttctaggac accactcatt cttttttctt 141600 ttcttacctt actggtctct ctcgttctgt atcttttgct tacaccttcc ccatcttcca 141660 gaccactaaa cattgaaatt cctaagatta gtcctggatc tattttcttc tctatttata 141720 ctcatttcct gggtgatctt atccagtcac atggctataa atatcatcta tatgctgaag 141780 acttccagat ttttatctcc tctctggact tcttaccaga aatacaaatt catatattta 141840 actgccaact acacatatgc actaataggc atttcaaatg tagtatgtcc ataccaaact 141900 gctaatactt tactcaaaaa ctcgctccat ctacattctt ctccatttta gcaaatggct 141960 gctcctttat ttttgttcag ttgttcaagc caaatgcttg ggagtcagct ttgcctccct 142020 ttttattcca caccacatac caatacttca gtaattcctg tcagtttcta cctttaagaa 142080 ataaaaatca aatcaaaata acaagaaaac tacagcagaa tctaatctgg ccacttctca 142140 ccgtaccatc tccattgctt ccaccttggt gcaatcatga cctcttgctt ggatgacttc 142200 cagagtette taactggett ctaactagtg taactagtet getaactgge ttetaetett 142260

, i. '

gcctttctac aaactactct ctatatagca aagtgattct gttaaaaagt aagtcagact 142320 atgtcactcc tctgttccaa accatccaag ggaaccgccc tcattcagag aaagaaaca 142380 aagtetttat accagetttt aaagatttae etaateeagt eetttgttte tetgaeetea 142440 tettetatae eteettetet tgetetettt etteaagtea eacteacete ettgttatte 142500 gttgaacttg aaggtattag gcatgctact accttacgat attgttattt ttgctatttt 142560 ctctacctgg aatattgttc ccacaaatag tcacatgtcc cactcccttt ctttcaggtc 142620 tttattcaaa tatcaccttc tcagagagac cttcgctgat gactttatat taaaagcatc 142680 ctgtcacttt ctaaccctat tatgctgctt tatattcttc gtagcattta tcatcaactg 142740 aaatattaca tgtttatttg tttattgtct ttcccgccta actagaatat aagtttatgg 142800 agataggatt gccactgttt tgcttactga tatatcctca atacctagaa ttctccctgg 142860 catataggag atgctcacta agtactaggt caatgcatga aatggacttt cttttcagtc 142920 tacagetetg tteatagatt caaatacett egaeggeact ttgaaaacaa tteattttte 142980 tcgttaaacc attttagtat ttgttgagct aggcgctgaa gctgcaataa gaaaaaataa 143040 ggtatttctt gctctcatag agttagatca gtttctcact ttcttcttcc cggtttcctc 143100 cccttgccac cactcacact gaaatgcagt ccttctgtgt tatacacgtt aatacaatgc 143160 tattactcat tatgtggcca gccaagttaa aaccagagtg ggtaatttta tctccttttt 143220 ccctatacct tcaaatccag tcacttaccc tgtccaatca gttctaccta gtatatctct 143280 aagatttatc atttccattt cacttctact ggcaaataga ttccactttc tccagtctca 143340 ccacgacett cttaggetet cataataate ttetaettaa aaactagtte aataaatttt 143400 cctgccttct tgcctgttcc ccttccctcc aatctatttt ctacattcca gccagggtgc 143460 tettteteaa atgeaaatae gaceagtete teetetgeta aetaceettt gatggttete 143520 cattgctcac aggacaaaat tcaaatatct taaaatggtg tttaagacct taaatgatta 143580 ggcacctact tacttctcta gcactatatt ttattagttt ttaagtccag ctcacatatg 143640 actgtcttta agcatcttcc cagatcttct tctattccat ttacaccact ggcacaacct 143700 gatcacacta cattagaatg agtagtgtgc ccaggagact ggcagtcttt tcaactggag 143760 tgtcagctct agatactcac tatgcaattt caaatacctc ctctgctgaa attgtgttct 143820 ctcccttccc tgacctcatt ctgtgttttc cctcctttct cttaacacct tttattccag 143880 ctagtgctgt actgctctcc ccactacaga ctgaaagctc ctggagggca ggactgtgtg 143940 cctcctgcca tagtcaggtt tccaacctgt gtaccactgg tcctggtggt ttgctcagag 144000 tagtaggtac tcagtcagta cttgtcaaat gggcagattg tgcctataaa tatttgtact 144060 catattgcat ttctgtcttt tccttttgat gatatagttt catcatttac aagatgctgt 144120

tatgatattt atgtctatta gcctttctgc taaataattg cttggcgctc cctgtttttc 144180 taaatttggt aaaaatatca taaaaaagca tttggtaaat ttctcacaga aagccaaaca 144240 cttttatgat gtgagagact tgatttgttg tatttatatc aagtcaatat tggtttaatc 144300 ttaaattcac cattcaccat cttttttgtt tctcgttatc aaaactcatt ttttatgact 144360 aatttaatca ttgactgaac tcactcaaca gttgcccata gttactaaaa gatacaaaat 144420 gatactgttt ataagcattt aggtcaaaaa tgttcaaaag aaaaatcaac taaactgata 144480 cttttaatta gtattttgag ggttgaggat ttttaaaaat ttgtttttca ctgaaactgc 144540 tttggtaaaa atcagtacaa aaacaattga ttttttaatt gtctggtttg aagagacatg 144600 ttggagtaac agaaacagtc acaaccaaat gcagcttctt ctggtggtac acttcgttcc 144660 atgatgtgga tcagttctaa atatcattcc aactattctt agattcaagt tatgatacta 144720 ttttgttctt tatatttggc tctgtttgta actcaacaag tgtcttgggt aagtcccatg 144780 agtaatagaa actgagagta agctagatca gaaatactgg atatggacga tcattataaa 144840 atgcacatgt tgacttctca aattatgtca agtgacaagg ctctttttga cacattaaag 144900 tgatctgctc tcttcaatac ttaatttatt actaatgagg gactgcaatt gcttcaaatt 144960 aagtagccta cacttatcat aagatctggc acatttctac ttctgttttt aaaagaatat 145020 ttgaaattaa aaatgtagaa aattagatgc ataaaaatgc attgtctaat caataaccat 145080 aatcattacc agctgtcaaa atatatctta aaatgttatg agctaaatta tgctgtaaag 145140 acatgcataa ttttttatag agatttagct gtatttgttg acccattgat ctcactccag 145200 tacagcatga accaaggaaa taaaagggga acagaacata atggaagaaa gaacacttat 145260 ccaggaggca agaaactcag cttaaccatt tattggctgt ctgaatttgg gcaagtcact 145320 ctccactgta tgtttccatt ttcccacctg taacatgaga tggttggacc tgagcaaagg 145380 tttctgactg cctggtagcc catgctgatt ccatgattca gcccatgctg aaaattcaat 145440 tcagttccgt tcaagtcagt tcaatccaac aatcttgagg gacagctatt gaagcagaag 145500 ttaaaaagag aaaaacaagt tttcctatac ttggctgact cactccaagg ccagcaatag 145560 gcagggccct ggcaaagtct caataacact atctggaaag ccagagccca aaggaatgag 145620 ctccagagac tctcccaaca aaccttccc ctccttggag caaggataag aaaaacaaat 145680 teetttacta teteetette eeeettacea ttacteagtg teteaagttt tgtaagttee 145740 tgttttccct tccatgcagc tgtaaggtca caagctatgc ttaggttaca aaacctgtca 145800 cagtttgatt aactgccttt gttctgcttc tgtaagcctg cctgcccgcc tcacaggttt 145860 tgtgccctca gtttcctgcc actgcattaa aactagccaa ttccctttca gaagtgtata 145920 taaaagtcaa gccctgtgtt tgttcagggc tcagcctttg gatgtgaatc tgctgtgcca 145980

gtagccacct aaataaaatc ctcctgttcc acccattggt ctctctggtc ttctgattcc 146040 cacaacacta cagcaccata ttataacata atactgccaa atgtaatata atataatatg 146100 aacatgataa aagtttttaa aatcagataa gaatttgact caacttacaa tctatatgat 146160 cataaagaag ccaattcaag ggaggtagag gaatatggtg gaatagaaag cttcactgat 146220 agttccccca gcaaggacat cagattaaca gctatctact cagaaaacac acctttataa 146280 gaaccaaaaa taaggtgagc actcagtacc tggttttagc ttcatatcac tgaaagaggc 146340 accaaaaagg tagaaaaaac agccttgaat tgctgatgcc acccctcctc aatctctggc 146400 agtggaatcc tggtacagag agtatctctg ggcactgggg gagggagaac acagcaattg 146460 tgaagcattg aactcagtgc tgctctgtta gagcagaaaa gaaaaaccag accaaactca 146520 gctgatgcct gcccacagag ggagcattca aatcagcctt agccagaggg gaatttccaa 146580 tcccagtggt tcaaacttga gtgcctgcaa accttgccac ccagggccaa agtgctctta 146640 gtctctaact aaacttgaaa ggcattctag cccataagca ctgcaactct taggtgagtt 146700 caagggctta actaggccta gagataatgg attagaaggc cacatgacat actgtgacac 146760 cagetttggc aggeaaaatg tgetggeate acceetecee taateecagg etgeacaget 146820 cacageteca aaaaagaeee ttttetteet ettgaggaga gtagagagaa gagtggggag 146880 gatcgtttct tgcacctgaa ataccagctt agccacagca ggatatggca ccagtcagag 146940 tcaagaggcc cccattccag gccctatcag ccagatgata tttatagata taccctgggc 147000 cagaagagaa cctatttgaa gaaagggatc cagtcctgct agcatgggct ctgaataacc 147060 agcagtaata tccaggtgct atgctacatc aagggttttg gtgagcctct gagacttgct 147120 ggcttcaagt accaacatca ccacaggggt gtagagcagc aagtcaagac tgtttactct 147180 tgaatgacat ttctggacct gccctgtgac agaggggagc gcactgccct gaaggatgag 147240 teccaggaca gacageacte accaeaaget gacttaagag acettgagae ttaagggaaa 147300 atcagtggta gtctggcagt actccttgtg gccaggggtg gctcctctgc ctttggaaaa 147360 gggagggaag agtgggaagg accaaagcaa atatggacaa atgggatcac gtcaagttaa 147420 aaagettetg cacaaaagtt acaatcaaca aagtgaagag acaacccaca gaatggaaga 147480 aaatattggc aactaccctt ctgacaagga attaataacg agaatatata aggagattaa 147540 acagcactat agaaaaaaat ctaataatct gatcaaaaga tggacaaaat atttgaatag 147600 atatttctca aaagaagtca tacaaatggc aaacagacat atgaaaatgt gctcaacatt 147660 agcatcagag aaatgcaaat ataaactaca atgagatatc atttcacccc aaatgtcttg 147720 gatatggctt atatccataa aacaggcaat aataaatgct agcaagtatg tggagaaaag 147780 ggaactcttg gacactgtag gtggtaatgt aaattagtat aacaactatg aagaacgttt 147840

tgtacgtttc taaaccaagt gatttgagaa tcacaatgac caagagagaa atttcaactt 147900 ggagactcag aggaagacac atatattctt tcagtgatca tttactgaac tgcattgtgc 147960 taagcagggg taaagtgatg gataagaaga aacacttgcc tttcttcaca aaaccaatga 148020 ttctatccct aaaaatatgg qcacatgatt ttgcatttaa gtgtaaagag ttcaagaact 148140 ctttggaaat ttattcttac atcccccagg cacatggact ccagattcaa acctcctaat 148200 ttagttgggg gttttattta aaaaggtagc atttgaataa agtcctgaaa aatggttaga 148260 atttcagatg ggagcaaaga acagtgttct tggactttga acctgtgatg gttattatta 148320 aatgtcaact tgattgtatt aaaggatgca aagtattgtt cctgggtgtg tctgtgaggg 148380 tggtgccaaa ggagattaac atttgagtca gtgaactgct agaggtggac ccacctcaa 148440 tctgggtggg caccttctaa tcagttgcca acatggctag gataaaagca acaatacgtg 148500 gaaagactag actagctacg tettetggee tecatettte teetgtgetg gatgetteet 148560 gecetegaae attggaette caagttette aacttttgga etettggaee tataceagtg 148620 gtttgccagg ggctcttggg cctttggcca cagactgaat gctgcactgt cggcttccct 148680 acttttgagg tttggaactc agactggctt ccttgctcct cagcttgcag actacctatt 148740 gtgggacttc accttacgat cgcgtgagtc aatattcctt aataaactcc ctttcatata 148800 gccatctatc ttattagtcc tgtccctcta aagaaccctg actaatacag aactcatctt 148860 ttccagtctc ctggctcata ctgaccactt gcttttgcac gtttgttgcc ttgggacaaa 148920 gtgcctcatt tctttcttg acattatcca tgtgttcctt gaattccgcc tgcttgcctg 148980 tettetgaat ceagetettt ageaacetea ggeetetgtg etateetagt etgeeaceet 149040 ccatctatgc atcaatgccc tcatatctag ttcctacttt tcattgctaa caaagtcttt 149100 ggtctcccat tctaactcct atgttggctc tatgatgcac tgccaacaaa tggcccagtg 149160 gtacaagtga acatagaggg aagaggtatg tatgagcaga agacctctct cagatccaaa 149220 gcctattctt aaaaagccag cctgacctat cagttctgct tttgcactgc cccaggtgtt 149280 gatetettat gtetgtatag gaetttatgg etcaeggagt agtagaetaa etaeagteae 149340 aaataaatcc caaatctcag tgtgttaacc caataaagat tagcattttg ctcatgcttc 149400 cgtccgatgc aggtaggcag agagggggct cagctccaag catcatttgg gtgcaagtct 149460 gaccacgttc cacacatggc tcccaagact gctctgggaa ttgacattga gatggcaaac 149520 agggaagaga gtcagtagca aggaaagtct ggcaggaact aaaacacatc ccatttcact 149580 ggccagaaca caactatgtg gcctttctaa ttgcagtggg gaggctagga aaggcagcct 149640 agctgtgtgt tcaaggggaa agtgaaaaga tgttaacaca tatcaactct gccacgcatg 149700

gccactacca tgttttgtgt gtgtgtgtgt gtgtgtgtgt gtgtgttttg agacagagtc 149760 ttgctctgtc acccagactg gagttcagtg gtgggatctt ggctcactgc aacctccacc 149820 tccaggactc aagcgattct tctgcctcag tctcctgaat agctgggatt acaggcgtgc 149880 accaccatgc ccagctaagt tttgtatttt tagtagagat ggggtttcac catgtttccc 149940 aggetagtet tgaacteetg accteaagtg atetgeecae ettggeetee caaagtgttg 150000 ggattacagg cgtgagccat ggcacctggc cgcctctctt attttatcct cctaagaact 150060 ctgggaggta catggcaata atttatatcc tctgttaata gatgaggcac taggatcata 150120 ttggtgaagt catttgccca aagccacaca gctggcaaat ggcagaatct atggtcaaac 150180 tcagtctgtc tgctctagta ctcaaactcc tcttatacaa catgacctat aggttatact 150240 aaaatataat gcctgcatgt cagaggaatt atatcaaagt gaaatttggg gatgacttac 150300 atcagaaata ttttaaggtg ttgtaagaat gcagattccc tcgttccaat ttatacctaa 150360 teactgatte ageatetaga agggtegget ggagaatetg cagatgatte ttatataett 150420 gatacagttt gagacctcgc tgccttaaga ctttatatga tttttcacct gtatatttaa 150480 aagagaacaa attcatatgg aaccaaaaaa gagcctgcat tgcccagtca atcctaagcc 150540 aaaagaacaa agctggaggc atcacgctac ctgacttcaa actatactac aaggctacag 150600 agccctcaga aataatgcca catatgtaca actatctqat ctttgacaaa cctgaaaaaa 150720 acaagaaatg gggaaacaat teettattta ataaatggtg etgggaaaac tggetageca 150780 tatgtagaaa gctgaaactg gatcccttcc ttacacctta cacaaaaatt aattcaagat 150840 ggattaaaga cttaaatgtt cgacctaaaa ccataaaaac cctagaagaa aacctaggca 150900 ataccattca ggacataggc atgggcaagg acttcatgtc taaaacacca aaagcattgg 150960 caacagaagc caaaattgac aaatgggatc taattaaact aaagagcttc tgcacagcaa 151020 aagaaactac catcagagtg aacatgcaac ctacagaatg ggagaaaatt tttgcaacct 151080 actcatctga caaagggcta atatccagaa tctacaaaga actcaaacaa atttacaaga 151140 aaaaaacaaa caaccccatc aaaaagtggg caaaggatat gaacagacac ttctccaaag 151200 aagacattta tgcagccaaa aaacacatga aaaaatgctc atcatcactg gccatcagag 151260 aaatgcaaat caaaaccaca atgagatacc atctcacacc agttagaatg gcgatcatta 151320 aaaagtcagg aaacaacagg tgctggagag gatgtggaga aataggaaca cttttacact 151380 gttggtggga ctgtaaacta gttcaaccat tgtggaagtc agtgtggtga ttcctcaggg 151440 atctagaact agaaatacca tttgacccag ccatcccatt actgggtata tacccaaagg 151500 aatataaaac atgctgctat aaagacacat gcacacgtat gtttattgtg gcactattca 151560

Sec. 35

caatagcaaa gacttggaag caacccaaat gtccaacaat gatagactgg attaagaaaa 151620 tgtggcacat atacaccatg gaatactatg cagccataaa aaaagatgag ttcatgtcct 151680 ttgtagggac atggatgaag ctggaaacca tcattctcag caaactatcg caaggacaaa 151740 aaaccaaaca ctgcatgttc tcactcatag gtgggaattg aacaatgaga acacatggac 151800 acaggaaggg gaaaatcaca caccagggcc tgttgtgggg tggggagaag ggggagggat 151860 agtattagga gatataccta atgttaaatc atgagttgat gtgtgcagca caccaacatg 151920 gcacatgtat acatatgtaa caaacctgca tgttgtgcaa atgtacccta aaacttaaac 151980 tataataaaa aaagacacta aaataaataa ataaattaat taattaatta aaagagaaca 152040 aattaaaggt ggttatagac agaagcattt tcactacttt ttaatttggt ctctgatgga 152100 agacctctaa atctgacatt gatgataaaa tattcatttg tatttcgatg tttaaaaaca 152160 aaaggatttc tttctaaaaa tagtcatgta ggggtagggg agagcaaggg tctatagcaa 152220 aatcatcatt caggtggaga gaagtttaat aaaactagct atctctattg gcaaagtgac 152280 tagagacgtg aatcacattc tttggcaatt caagtaaaaa aatatttctt tcttttgaat 152340 ttagagcttt atgtgtaatt ctgagataat gctttaaatt aaagataatt ttagaatcaa 152400 tttagggaat aggttettte ecceteacat tgeceaaata ttgaatacag attttactte 152460 acacatagca taaatattgt acggtctgtg acatcaggag tataaatatt tcataattca 152520 gaaacagata cagtaatcac tcatccagtt taataagctt ctcaatttgt agctttgcat 152580 tccatcccca aaatgtgaga ctgctgataa gcctcttaat tatattttat aatatttcat 152640 tttagtgtaa aaattatcca taatatttca ctttcattca gaaatcacta ttaatttaag 152700 gactgttaag taagctatct aagagcttta taaattactt ggataatcaa aatatttgct 152760 tttcacactt caaggtggtt ttacacatta attgtattaa ttctaacttt aggcttaaaa 152820 tatccttcta gtaattataa tttagcgtga attatttagt ctttagaaga atcacacata 152880 gagaaatgct aagtcatcaa atggtactca tgacttctta tggtagtgac aatcattaac 152940 aagttacctc gaatggttct attttctgcc ttagtagata caggtggttt gttggtacaa 153000 ccgaggccac attgggggtg tggaggggcc actcttcatc ttttctgaag agggtgaatg 153060 attgggcatc ctgatttgca gaagactgag gccagagttt atttgtagca caagctaaaa 153120 ccccagtttt ctgcctggtc ctgcttctta caaattgagg ccttagcatt tccacttggc 153180 ttctaacagc ctgataattt tgaaggggtt ttgggatggc ctgattattt ccgagtcagc 153240 atttgaggct atcaggtctg tttgcccatt tccactcttg caaagataca cctgaataca 153300 aatgtaaata tttcagtaaa ttttatagct gagttccatt tggttctagt ttatttgaat 153360 cttacgtgaa gttggagagg gcactatcta ggaactgcac tgtagtaaaa tgtaataatc 153420

aagagcaaat acttttaaat taaaaaggct tgggctcaag tcatggttct gtcatttacg 153480 aacgaggtaa ccttgaaaaa tttacttaat ctctctgagc ctccttttct ttgtgtaaat 153540 ataagtgatg atagaatcat aatatctatc taataaagct attactgcaa ttaaggatct 153600 gtettetete ttaaggaate tatecatetg tecatataca catataacae acacacatat 153660 agtgcttcac atagtacttg gcacgctata agcactgaag aatgaactat ggcctggtgt 153720 ggtggctcac gcctgtaatc ccaacacttt gggaggccga ggtgggcata ttacatqagg 153780 ctgggaggtc aacacctgcc tggccgacat ggtgaaaccc catctctact aaaaatacaa 153840 aaaatgagct gggtgcagtg acatgtgcct gtaatcccag ctactctgga ggctgaggca 153900 ggagaatcac ttgaatccag gaggtggaag ttgcagtgag ctgagatcac accactgcac 153960 tecegtetgg getacagage aagaetttgt caaaaaaaaa aaaaaaagaa tgaactgtga 154020 ctacataggc taagtgtaat cttgtggacc agaagaagga aggtccagga cagtaacttg 154080 aagcgtaacc ttgactcagc ttatcactca ctagctctgt gacctatggt aaaaataatt 154140 aaattatctg agcctctttc tcctagctgt aaaatggggc taagaacagt attgattaca 154200 caggtacata cgatacttaa cgtaatgtac ttagaatagc accggacaca tacttaggac 154260 ttattagatg ttagtacaga gccaagagaa tgtgctttag aaggaaaaaa tgggccgtgg 154320 cgtcaagagg cccagttgaa tatgaactgt gaagtatcca ttagctttag catcaaggat 154380 gatgttgatg actttggagg aaactttttc agtgaagggg caggcacagc ggggagaatg 154440 aatgagttgg cagaaaggaa gtgcaaaccg taagtatagc aacaacaaca acgactacta 154500 ccactaccat atatgaggtc ttactatgag tcagacttcc ttaagcattc ctcaggaatg 154560 atgccattca cactatttct acatcttaca gatgagaaaa ctgaggctca ggaggcttaa 154620 gtaacatggg cagtgttgca gttagcaggt gccataactg gattacaaac acaacttctt 154680 ttcacacctc catgctagca tagtgaaatg ctagaaagct ttgagacatt tatttaacag 154740 cttccacaga ttaggagaaa ctgtgtattt tagttttctt agcaccaggg caaggagaaa 154800 acacataaaa aagtaacctt ctaactcaaa tagctgcatt tcaaggctgg ggctttgaac 154860 ccagggttct acacatttgc tgggatgact aaaacttttc agattccctc taatgatgtg 154920 attgaaagac agtgctactt tagttatggt gccccaaact gacaatgttt gaaacactgc 154980 actcatagta aagattttgc aaaaatgagg cacagagtca ggaaacagct gtgttttacc 155100 catttatatg cactcctgct tccttaatgt ggatggatct ttctatttga acttcctcat 155160 gcagttcctt cccagtttac tccagtcact gtctccattg ggtacccagt cacagccttc 155220 tagtggcaaa ggtctacaag gatgcaatca caatgacaag cagaaagtca ctgggaagct 155280

gcagaaggag agggcagaag agctgtggtg aactgggtac agacttcatt ccactttatc 155340 cacccactat catgccacac cctaaacctc ataatcgtcc gcaattgcca acttgaaata 155400 ataactgcaa accetectet atggeetgtg teagaaagta gagagaagea gagactgaaa 155460 tcagactgat cacagctgtg ccactgctca gctctttgac cttgcacaca caatttgacc 155520 attgagtatc ttagtttcat cccatataaa atataaaaaa taacaatata tactcttagg 155580 gttattttta gatgtttgca tagaacagtg gctggattat agtgagtact agctcttgct 155640 actattgttc tctctcct tcaacacctg ctttttataa cccatttgat acctcccaac 155700 tttagacttt ttcattttct cccaaaccat cagttttctt cagatttcac cccatcttct 155760 attttaatct aggtactaga tttatcttct caattagtta ctgtctaaac ccttcaccgc 155820 cttggatcct tcactgtcct gcgtatcata cggcaaaatt ataaccctgg atcaatccag 155880 ctgttcacaa ttgtctggcc tcctgttcca tgcccttcct tcctcaatca tagtcaaaga 155940 ggtcttcact ctgaggcaga tcccagttct tatccctctt caaataattt aattcacaag 156000 tgatcccacc ttctgtatct tcaacttgtt tactaatttt ctatttcttt ctcatcagaa 156060 tttacaatgg cttagtttct cctgctatgg aacaaagtgc aaaacaccct ccccactacc 156120 atgtgtctct ctctagctac caacctagga cagcaatact tctagatttc acatttctag 156180 aatctaaaaa gagcaagtta cacaatgttg tattcacatt ctcattagca ttagttcctc 156240 agttaacagt ggtgtgcatt ttgcctttcg ttttttctga cgttgtcatg gcaaagtcac 156300 ctgtgcctta tgatggtatc aagggtagat cgatatggaa aaatgtttaa tctcccccat 156360 agggtacagt ataacaacac ctggcatgaa gtagaagctc agtaaatgct tcttagtagg 156420 aaagaagatg cacagtccaa cttattaaaa caaaaatgac ttgcaatgtt atttgtcttg 156480 ggcccgagtt ggcatatgaa attcaggaag aaaaaaacct ctcactggaa aaaatgggga 156540 ggctggagct gacttttatt aggtagcaac aacaaatggt ggcagttggc tttttaacgt 156600 tattttcatt atatattcgc gagtaaaatg ctaatttctt tagaaacaga agtatagaga 156660 gtggcttgta atcaagttga atgcattaag agggatgccc aggaaacttt gtgaaccaca 156720 gctgaagaca cactccttga aagctctaaa attttgtggg ggatgcgcca tcccctttca 156780 ccaattattc ctatcttctc tcccttgccc ccttctcaga tttgcttgct tcctttttac 156840 tcattgacat tcgtgagtgt tcatccatct attcatggag aggataccta ggctcagatc 156900 ccctgtgccg gtgccacccc agctcctggg aattttggct gctggcagct cccagatgct 156960 tttctcagct ggaaattgcc ataggcctcc cagacatgtt ttgccctggg atacttcctt 157020 tttagggact ggatgacgga ctacatctga gatacaaagg ccggtcagcc tgatacaaag 157080 gatgggtatt tttgcttcaa tttggaacaa ctttaaaggg ccatctcagc cctagatctc 157140

ccagtgaatc agatgaggca ctatttgcaa cctgattgca ggtcagaatc tctcactgct 157200 aaccetgeet ttetcaccet ttacaggeet gtettttgte agtgacataa tgcactegge 157260 aattaagaag atgcctttgt tcaggctatt aaaatagtaa atgttaaaag acaaaattac 157320 aaaaaaaagc atagttttgc agaccttaat tggctttaat tgtgagtgca taatcagact 157380 ctactgaaaa tggttcaaaa tcctccaccc taccacacgt gcaggtcata tttatactca 157440 gagtaaatga agtgacatac aaaaataacc tgattggctg ccctctgcag ttgccttata 157500 tggtcatatt ctggcagctc tcagcctcat tggctggcca ttcagctgct atgattgact 157560 gagacttggc tacttgttgc aagagggtac agattaggct acaatctgtt tacacatcaa 157620 gttaggttac atttcactat acattgtaaa acttttagat caaacttaaa atacgatgga 157680 ggcagctttt aggcaaatct tagttcaagt taacaaggga ctgtgtatta ataaaaaagt 157740 tctcaaagcc aaagaaggag gactggtgtt ttatggaggt aggagacaag ggaatcatct 157800 acatcattga ggagtcctgt aggggcaagt gaaagataga ggtgggtctt gtcttccaat 157860 acgtaaacat gtgagggtgg ggtggtccta agtggttagc catttccaga acagaaaagg 157920 gtggtgatcg tgtcagtggt agaggtggtg ggtgatggtg gctgtggttg tggtggttgt 157980 ggtagacttt ctatcttcca tcgccatctg aaactcatgg ctcaggtgca gttccacact 158040 gccactctca agagetttee ctaatcaace teetgcaage aactetegae eccagagtet 158100 gttttcaggt aacccactct gagaactctc tgccatccgg cagtatgaac caggtttgaa 158160 cttctctgtt tagaggcctg agcaccagaa atctacagaa ccgtacgctt atgagacaat 158220 ccgtgagatc ctgggtagag gttgagattc tagcccaaag ccttcgcatt tctttgggtg 158280 caatgagact ctggctgtga gctgggctgc ttcacagcca agctgggact ctgaattgga 158340 atctttaacc cagcaatgcc ctagcactct gaagatgata aagcatctag atgtaatacc 158400 cttggttctt ggtttttggt ttggacctag ggccttgtaa gatgggccat tgatgacagt 158460 gaaacctctt gcctctggct tcgagggtgg caacctgggg aagataaaac tgggaagaat 158520 gtagtggacc ttgcttgaag cctacaacta aaagttttgt ggggagcact agaaaagcgc 158580 cccaagatat acaaagagga cattttggaa attgtagctt aattgccagc agtcaggctg 158640 atagaggttt gagcttccat gctttggtca tgaatagtaa atgtaatctt tcaggctggt 158700 gaagtctggg atatcggtgt tacaatggta tctttaaata ggactcatta aaataatagt 158760 gttgtttctt ggcaagtgtg gtcacactta aataatatca aagatgagaa gactgttata 158820 gcaggatatg caggtttgtt acataggcaa atgtgtgcca tggtggtttg ctgcaactat 158940 cagoctatca cotagatatt aagoctagoa tgoatcagtt attiticota atgoottoto 159000

tecetecaca eccecacece caacaggeee cagtgtgtat tgtteeeete actgetgtgt 159060 ccatgtattc tcattgttca gctcccgctt ataagtgaga acatgaggtg tttggtttgc 159120 attagtttgc tgaggataat ggcttccagc tccatccacg tccctgcaaa gcacatgatc 159180 taattccttt ttatggatgc atagtattcc atggtgtata tgtaccacat tttctttatc 159240 ttgtgtatca ttgatgggca tttggattga ttccatgtct ttgctattgt gaatagtgct 159300 gcaataaaca tacatgtgca tatatcatta taatagaatg atttatatcc ttttgggtat 159360 atacctagta atgggattgc tgggtcaaat ggcatttctt gttctaggtg tttgaggaat 159420 tgccacactg tcttccacaa tggttgaact aatttacgtt cccaacaaca gtggaaaagt 159480 gtttctattt ctctaccacc ttgccagcat ctgttgtttc ctgacttttg agaagtgtct 159540 ggtcatgtct tttgcccact ttttaatgga tgatatggta tggctgtgtc cccacccaaa 159600 teteatette agttgtagtt eccataatee ecatgtgaea tggaaggaat ecagtgggag 159660 gtaattgaat catggggatg gtttccccta tgctattctt gtgatagtga atcagttctc 159720 atgaaatcta atgatattac aagtggcttt acccatcgct cagctctcat tcttctctt 159780 cgtgccgcca tgtgaagaag gatgtgttta cttcccccgt tctgccctga ttgtatgttt 159840 cctgtggcct ctcagccatg caaaagtgtg agtcagttaa acctcttttc tttataaatc 159900 atccaatttc agatatttca gatatgtctt tattagcaac acgagaatgg actaacacga 159960 tggggttttt cctgtaaatt tgtttaagtt ccttgtagat tctgaatatt agactttgtt 160020 agatgcataa attgcgaaag ttttctccca ctctctaggt tgcctgttgg ctctgatgat 160080 agtttatttt actgtgcaga actcttcatt taattagatc gtatttgtta atttttgctt 160140 ttgttgcaat tgcttttggc aattttgtca tgaaatcttt gcctgtgtct atgccctgaa 160200 tggtatcgcc tagattttct tttacggttt tcatagtgtt gagttttata ttgaagtctt 160260 taaccaacct tgagtttatt tttgtataag gtgtaaggaa ggagtccggt ttcaattttc 160320 tgcatatggc tatccaattc tcccagcacc atttatcaaa taggaaatta ttttcccatt 160380 gcttgttttt tgtcaggctt gccaaagatc agatggttgt aagtgcacaa ttttatttct 160440 gagtttttct attctgttcc attaatctat gtgtctgttt ttataccagt accatgctgt 160500 tttgattatt gtagccttgt agtattgtat caagtcgggt agtgagatgc ctgcctccag 160560 ctttgttcct tttgtttagg attgtcttgg gtatacaagt tattttttgg tttcacatga 160620 attttaaaat agtttcttct catgctatga aaaatgtcaa tggtagttta atggcaataa 160680 cattgactct ataaattact tcaggcagta tggccatttt catgatattg attctttcta 160740 tccatgagca tggaatgttt ttccacttgt ttgtgtcctc tctgatttcc tttagtagtg 160800 gtttgcagtt ctcctggaag aggtccttca ctttccttgt tagctgtatt cctaggtatt 160860

ctattctctt tgcagcaatt gtgaatgagt tcattcatta tttgctctct gattgtctgt 160920 tgttgtgtat agaaatgctt gtgatttttg cacattgatt ttgtatcctg atactgtcct 160980 gcagtagett atcagettaa gaagettttg ggetgagttg atggggtttt ctagacatag 161040 gatatgtcat ctgcaaaaat ggacaatttc acttcctctg ttcctatatg aataccattt 161100 atttctttct cttgcctgat agccctggac agaacttcca atactaggtt taataggagt 161160 ggtaagagag ggcacccttg tttcgtgcca gttatcatgg ggaatgtttc cagctattgc 161220 ccatttagta tgatatttgc tgtgggtttg tcataaatgg ctcataattt tgaggttcct 161280 cttcaatacc taatttatca agagttttta acatgaagtg atattgaatt tgattaaagg 161340 ccttttctgc atctattgag ataatcatgt gttttttgta tttagttctg tttatgtgat 161400 gaattatgct tattgatttg tatatgtgaa accagcctta cattccaagg atgaagctga 161460 cttaatcatg gtggattagc tttttgatgg gctgctggat tcagtttgcc agtattttat 161520 tgagaatttt tgcattgatg ttcacaagaa atattggcct gaagttttct tttactattc 161580 tatetecaca aggitetaat gieaggataa igetggeete ataaaatgag itagagagaa 161640 gtccttcctt ttcaattttt tttgaatatt ttcagaagaa atggaaccag ctcatctttg 161700 tacctctggt agaattcagc tgtaaatcca tctggtcctg ggcttttttt gtttttttt 161760 ttttggttga caggctattt attactacct caatttcaga acttgttact agtctattca 161820 ggggtttaac ttcctcctgg ttcagttttg ggagggttta tgtgtccaga aatttatcaa 161880 tttcttctgg attttctagt ttatttgcat ggaggtgttt atagtattct ctggtggttt 161940 tattttttgg gggggtcaat ggtgatattc cctttatcat tatatattgt gtctatttga 162000 tttacctctc ttttcttctt tattagtcta gctagtgttt ttttttttt tttttttt 162060 tttttttttt ccagaaaacc agctcctgat tcattgattt ttttaaagaa tttttttgtt 162120 tetetateae ettaagttet getetgaget tggatatttt ttgtettetg etagetttag 162180 ggtttgtttg cttttggttc tgtagttctt ttagatgtaa tgttaggacg atgatttaag 162240 atttttatag ctttttgatg tgggcatttt gtgctataaa ttttcctctt aacactgctt 162300 tagetgeate ceagagatee ttgeacattg tetetttgtt etegttagtt teaaagaact 162360 tettgattte tgeettaatt teattattta eecaggagee atteaaaate aggetgttea 162420 atttccatat agttgtgtgg ctttgagtga gtttattaat tttacgttct aatttgattg 162480 aactgtggtc tgagagactg ttatgatttc agttcttttg catttgctga ggcgtgtttt 162540 actttcaatt atgtgatcaa tgttagagta agtgccatgt ggcactgagg agaatgtata 162600 ttctgttatt tcagggggaa gagttctata gatatctatc aggtccactt gattcagagc 162660 tgagttcaat tcctaaacat ctatgttcat tttctgtcat ctaatattga taatctgtct 162720

aatattgaca gtggggtgtt aaagtctccc actattattg tgtggcagtt taagtccctt 162780 tgtagtttcc tgtgaacttg ctttatgaat ctgggtactc ctgtattggg tgcatatata 162840 tttaggatag ttagctcttc ttgttgaatc gaacccttta ccattatgta atgcccttct 162900 tegtettttt tgatettggt tggtttaaag tetgttttat cagaaactag gattatgace 162960 cctgcttttt tctatttttc atttgcttgg taaattttcc ttcattcctt tattttgagt 163020 ctatttgtgt cttggcacat aagatgggtc tcttgaatac agcacaccaa taggtcttga 163080 ctctttatcc agcttgttat tctatgtctt ttaattgggc catttatcat atttacattt 163140 aaggttaatg ttgttatgtg tgaatttgat tctgtcatca tgatactggc tggttatttt 163200 gcagactcgt ttatgtagtt actttatagt gtccttggcc cgtgtacttc agtatgtttt 163260 tgtaatggcc ggtagcagtt tttttctttc tatatttagt gcttccttca ggagctcttg 163320 caaggcaggc caggtggtga tgaattccct cagcatttgc ttgtctgcaa aggattttat 163380 ttcaccttct cctataaaac ttagtttgtc cagatatgaa attctgtgtt ggaaattctt 163440 ttcattaaga atgctgaata ttggccccca atctcttgtg gcttgtaagg tttacactga 163500 gaggtecact gttagtetga tgagettece tttgeaggtg acetggeett tetetetgge 163560 tgcccttaac attgtttctt tcatttcaac cttggagaat gtgatgatta tgtgtcttgg 163620 ggtttatctt ctcagggagt atcttactgg ggttctctgg atttcctgaa tttgaatgtt 163680 agectgtett gecaggetgg ggatgttett etggatgata teetgaagtg tgtttteeaa 163740 cttggttcca ttctccctgt ctctttcagg taccccaatt agtagtaggt ttggtatttt 163800 tacataatca catagttctc agaggttttt ttcattcctt tttattctgt tttttttttc 163860 ctctaatttt gtctgactgc cttgtttcag caagatagtc atcaagctct gatatttttc 163920 cttccgcttg gtcacttcag ccattgatac ttgtgtttgc attgtgaagt tctcttgtgt 163980 ttttcagctc catcaggtca cttatgttcc tctctaaact gtttattctg gttaacagct 164040 cctataatgt tttatcatgg ttcttagctt ctttgcattg ggttagaaca tatcccttta 164100 gctcagtgaa gtttgttatt acccacattc tgaagtctcc ttctctcaat tcatccatct 164160 cagectcage ceagtteteg geeettgeag aageagtgtt gtgateattt ggaggagaag 164220 aggeactetg getttttgag tttttggeat ttttgegttg attettete atettttagg 164280 atttatctac cttcaatctt tgaggctgct gacctttgga tggggatttt atgggggttt 164340 tttcattgat gttgctgttg ttgctttctg tttgttcttc acgtagcaat cccaccactc 164400 ttccccaggg ctgctgaggt ttgctggtgg gtccacttca gattctattc atctgggtcc 164460 ctcccacaac ttgaggtatc accactgaag gctgcaaaac agcaaaggtg gctgcatact 164520 ccttcctcta tgagctctgt cccagaggtg cactgacctg atgctgacaa gaactctcct 164580

gtatgaggta tetagaggee cetgttggga ggteteacee agteaggagg aatgggatea 164640 gggacccact taaataagca gtctggttgt cccttggcag ggtgggtgtg ctgtgcgggg 164700 tgaatctccc tcttttgggc tgtctttact ctccatagct ggcaggcaga gtaatataaa 164760 attttaagac aattattatt gttcctgtaa aggctactgg gagttcaact ttgtggtcag 164820 gcatttttat tttggagtct ggcagatctg tgtaacttca gactagattt taaccagtgg 164880 ggaagccagg gagaagagaa caatttctag ggacttcagt cccccacat atgatgtctc 164940 aatagcccta tggtccacaa tccaacccat acttaagaat taatgaaaac taattgcttg 165000 atatgtgaat ggaacctcaa ggcaggtttt ctaatccaga gaaaatttta ttaaaaatgt 165060 aaaggatggc cagtgacgtt tacatatgta actaacctgc acattgtgca catgtaccct 165120 aaaacttaaa gtataataat aataataaaa gaggaaaaaa aacaacaaaa acatatgtaa 165180 ctaacctgca cattgtgcac atgtacccta aaacttaaag tataataata ataataataa 165240 aaagaaagag gaaaaaaaaa aacaaaaaac aaaacaaaac aaaacaaaaa tgtaaaggaa 165300 tatacatgcg tacactcaca caggcaaccc aaaattaaaa cacaaacaaa caaacaaaca 165360 aaaatcactg agtaaaaaca gtagattttc agacaaattt agcttcaaaa taagaaagtc 165420 ctttagccag cttctaccca cacagcttac tcacttttgt gtttcttctc tactcctcta 165480 ccccaaacac atttttgcac aggggagtaa aggtctaaac ccttctgtat acagatgtgg 165540 tctccttaac tagctatatg taacttctct atgcctcaat tttccaatct gtgaagtgga 165600 aaaaataaga aacatttaat gagatettee acatatggtg ettaaagtgg gtgacccatt 165660 gtcagcatgc atgtatatgg aaaaatacag tattagaatt agatttttta taggttttat 165720 aaaatacctg gtaatgtatg tcatttatac taaaacattt gttgcatttt ttatatactt 165780 aaaggtagag tgagaggaaa atatttetet etgtetette etetgagtet ggaatteett 165840 ctacccatct gaatctggaa tcacttgatt gcaaggaaca aaaacagaaa tacttcagaa 165900 gagctcaaaa gagaagaatg gatttattaa taaggaaatc tcctggaacc caatttagga 165960 tgcacatatt ttacctggat tacttaattt aatgccctaa cataattagt caatattgtt 166020 tccattttaa agataagtaa aatgaaacac agagaggtaa tatagcttac tctttaaaaa 166080 taatcatttc cttattgttg gaattttcag ttgttttcat atgtttgtta ttattctaaa 166140 aacttcagga aatatttatg tgtgtattga ttttttattt ttaagtaatt ttgtcagaat 166200 aaatcctgaa gatatatatt atttagacaa agggtatgag cttttcaaca actcagtatg 166260 tgttctgttt tttgtttcat gaggtatttc cattaactaa gaaatagcct attattttgc 166320 caaagtagag atgctattgg cagcacttac taattgttta acactcgaat atattggatg 166380 ataaacattg gtattgaatt gtctgtgggc ttttcatcta gtgtatctat ttactcttcc 166440

tgattatett geatacetee tgagtacagg tettgteett geatgattea tacggteage 166500 ccctaagtca ggcatctcca atctctggag tcagagatct gcccctcat tgtggtagat 166560 tatcttctga agttttccca cagacacttt taggaaagaa atttgactgg aaaaatggaa 166620 acgttccact tgctttccca gctggttttg attaattata aggtagaata attataagtg 166680 taattaggtt attttgtctc tttggaataa aggttcagta ggaagaggag tgcagtaaga 166740 agagagaaat gatagcagtg ataacaatga taaagttggt gactgctgga ctggaagtga 166800 ggggtgatta catttettte atttetetag etgagettea ttetggaate agaatatgaa 166860 catttggatt aatcattaca catgagaagc aaccactgag aatatactaa tttgccatta 166920 attcaacaaa tatttattaa gtaactctgt tgtgctagga gcgggttgtg gggagggagg 166980 agagactgct ctagcacaca cagtatgtcc agaatgaaaa cgaagaaaat aatatttcac 167100 tgcatgtagc agtctctatt aggaggataa cattaaggaa tagcaaggta agatgacatg 167160 cctaaggtca gactcctaaa aggtattaga gttggggttt taaatgaaat ctatctgact 167220 cccccttttc ccctaaagga cagtaactcc tagtgtcatg agaaaaataa tatacaatta 167280 aagggctatg agagtttagc agaggaattg attaattctt ttccaggagt caggaagggc 167340 ttagtgggaa cgtttaaatg ggacccctga tggatgagta gggtttgatt ggcaaggggt 167400 aacatgtagg tggggggggg gggtgaaaag gctgatgata aaggttgaac agcagtatga 167460 gcaaaagtaa tggagtatta ttaatgtgtc tgaggttttc aaagcaagag cagtgtatgg 167520 cccttgtggg tggtccacag tttggatggg gcataggggg gtggtgatag acagcttgca 167580 tctccaaatg tagagagcct tggaatgcca tgccagaaag ttcagatttc attttatctg 167640 tagtaccaaa tgattgcaag gacaaatgtg agttgtaaga gcctgaaaca ttggttgcag 167700 caatgaaaac aaaaatgatt ggcaagattc caaagatagt ttaatggcag aattggctga 167760 ctttcattac cttttttag agagagaag agattgaaga tgctgaggtt tcagttttgg 167820 taaagagatt caccaaattc agttttattc agtttataca ccatttgctg ggtattcctg 167880 agttgtggca gcagacgaca gggaagtttg tttttgcaaa gacatttcta gaactggaag 167940 gctcaaagta aatgttttga tagtgtacta cctctaatca atataactcc atagtttaat 168000 aaagcactcc acagtttatc ttaccagatt ttctgacctt aaaaaaaagaa tttcttattt 168060 cttatactcc atgaaatcaa ggattctttc aatggatgtt gcccccctc acacacaca 168120 atttcacact ttgacacctc cattaatctg aagaaatgat tgataccaat tcaaaacctt 168180 aggctggctg tacctgcctt ttaaaatatt ttttttttgt agtacatatt caaagtatgt 168240 tgttgggttt tttaatctct gaaaaccgtg aagcaaaaaa actcgggctc aggagaagag 168300

ttggaggaag cgaggctact gcaatggagt ggaagtttgc tgagcatttt cacaaggccc 168360 ttgttcagca attacctttg tctgtaccat ttatatatgc ttagaataag ctctattgta 168420 tcactcttgt tgcccaggct ggagtgcaat ggtgcgatct cacctcacca caacctccgc 168540 ctcccgggtt caagcgattc tcctgcctca gactccaagt agctgagatc acaggcatgt 168600 gccaccatgc ccggctaatt ttgtattttt aatagagacg gggtttctcc atgttggtcc 168660 ggctggtctc aaactcctga cctcaggtga tctgcccgcc ttcaggtgat ctgcctgcct 168720 tggcctccca aagtgctggg attacaggca tgagccaccg tgctcagcct aagaaagccc 168780 tctgtgacac ttggaatcat cagcgggaaa ctatcttaac acattagaaa tcggtaatgg 168840 aagtggacta acattttggt cttcagagaa tgctaaatga agtaaatggt gaccatctgg 168900 ttatcatttg taaatttagt gaaccttgta ggatgaaagc ttacctcgta cctggccatg 168960 gattacatac ttttaacatt tattgactgc ttactatatt tcaggcacca tgatgcaaag 169020 ttttgtttca catcttattc aatcctcaga acagctcagc gtggcagtat ggttattctt 169080 atctccgttt tactgaggag aaactggggc taaagacatg aagtgacttg cacaaggtca 169140 geetgactet actettteta tgeetggetg tggetteetg tgagetgate tattaggeag 169200 tagttgaggt cttcacttac cctgaatttc ttctggttct ccactactgg taaacgacta 169260 gctctgtgaa ttgagtaatg gatgaagtca ggaatgagtc tattgcatgc gtgcatttat 169320 agaagagget geagtgeeaa gacteettta gttttgtgtt tgeacattgt gtatggatga 169380 ggctatgcca gtgttctcta tctttatttc acataaaatg cagaggattt caggcctggg 169440 tgtagaccat catcactcat gtgttgttgt tgccatgttt ataggcaaca aagataggtt 169500 tagacaaagc ttgtccaacc cgtagcccat gggccacatg tggcccaaca caaactcgta 169560 aactttctta aaacattatg agattttcct tcgattattt ttttaaagct catcagctgt 169620 cattagtgtt agtgtatttt gtgtgtggcc caagacaatt cttctttcaa tgtggttcag 169680 ggaagccaaa agattgggca gccctggttt agacagtgtt atgggttgaa ttgtgtctac 169740 taaaattett atgttgaagt tttaactgee ggtaceteaa aatatgtett tatttaggea 169800 tacagcagcg gttcccaacc tttttgacac cagggcctgg tttcatgcag acagtatttc 169860 caccgatggg tggggggatg gtttcaggat gaaactgttt gacttcagat catcaggcat 169920 tagctggagt ctcataaaga cagcacagtc tagattcctc acatgtgcag ttcacagtac 169980 agtttgtgct cctgtgacaa tctaatgcca ctggtaagct cactcgccaa acactcacct 170040 cctgctgtgc ggcctagttt ccaacaggcc acgaaccggt ctggtccatg gcctggaggt 170100 tggggggcccc tgctttacac agtcaatcat gttaatcatg ttaagtgaga tccattgtga 170160

tggatgtctt tataaaaaaa ggaaatttgg gtagagagga atgcatagaa ggaagatgat 170220 gtgaagacac acggtgagaa gacagacatt tccaagccat ggagagagac ctgatataca 170280 tecttatete aaageeaatt tatagtettg tgtgeacttg tacaaacaca atagatgaat 170340 aacatgggcg tggcgattat tattaatttg tgaggaagta gtagggagga ggtccaggga 170400 agattgtctg gaaataatga cacctgaggt gcagatgcat ggaggaacgg acgctaacct 170460 ggtggttggg atgcagtgtg ggagaagggt atcccaggca gaggagataa cttgagcaaa 170520 gtcagaggtg ggtaagagag gatggtatgc tcacgggact cettcetgct etgacetttg 170580 gcctgacact tcatgttcct ggttctccat cgcctctcct gagcatcatt ttctctccca 170640 ttactcatgc taagcactgt gtaaagttcg gttcctggcc cagtgatatt ctccttttac 170700 tacttttgaa aaatttaaaa aatgccatta tataaaacag catccctccc aggacccccg 170760 ccgtatgaaa ctccagctga gtggcagttc ttgcctccag catttacatt tgcatagccc 170820 agetteaget caggeetgag atgecaaaat gacaccette acettteett ccaaattgtt 170880 gtctagattc tgtattttaa aaaatattct catcatcaat aagtgacctg gtcctaaaac 170940 ctggagtgat ctctgacttc tcctgctacc aaacaccttg tcaggattca gggccagaca 171000 aacagtgtta ctgtatacat cctcaattgt ttctttttct tgaaattcta agcaaccttc 171060 gtctctcccc attctgtgag catctctctc cagttttaca agccacgtca aaaattactg 171120 acagtgactg aaattatacc tgtaagatct tttcacactg ggaatttcat taggctggat 171180 ccaagagett geatttttgg taaatagtea gataatetee tgetatettt ttgttgatet 171240 gggtcgggaa ttgccctctt aaactgtctg ttctattctt tctaatttga agaacattac 171300 ctttcctgaa taaaataggc acacaataga aaattaatag ttggaacttt ttccgataat 171360 cagtgaacat cacgccttct ttttttatt atactttaag ttctggggta catgtgcaga 171420 acgtgcagtt atgttacata ggtacacatg tgccacggtg gtttgctgta cccatcaacc 171480 tgtcatctac attaggtatt tctcctaatg ttatccctcc gctagcttcc cacccccga 171540 caggccccgg gaacatcaca tettettttg teeteattet etetgtetae agacattttt 171600 gcagtcattg acactgtgac taccctgttc ttgatacgac ttcgttcttg tttatgtgac 171660 atcattgtct cttggttttc tgtttctctc tgaggtcaat tctatttcaa actctgctac 171720 agaatctact ttctctgcta acattttaaa agtttaagtt tcctagtcat ttgccctgaa 171780 tccacttgtc atttttactc ttcagatttt atcttgtaat ttattggcag atctctactg 171840 ccaccaaacc cacacatctg aatctacaga tcagatctct cttctagaga ttcagctgcc 171900 acttcaacac ccctgctcgg attgtctaat agattcctta gcctcaatct accaaacact 171960 gatetattea cetatteett ettttaagag ggaettatat tgttgttaga attgggaaaa 172020

cgtatagcaa actttgtttc ctgagaggtt aaagtgattt atatctgttc caatttggtt 172080 tctggccact atatttgagg taggttaaat aatattacct aaaaagcttc agaataggca 172140 gggaaggaat aaaagtggcc acagcagact tcagtactta ttcattcagt ctacaaatgt 172200 gtagtaagca ccaactttgc tccagggatg acagtcatca ctagtggtac atggctttaa 172260 ggtatggtcc cttccctcat ggagcttcga ctgtgagata ttgtgtagac tttccttaag 172320 aagcatcaca ttctttcaca taccgagata tcctcaactt gagtcttacc tgtgtgatta 172380 tctataatta acatactgta caattaacat ttgtgcatgg acagttttat gaattataac 172440 acatgtttag atttatgtaa ctacaacaca atctggatac acaacagttc catcaccccc 172500 tcacattgta agggggtaaa gagtcttgag aaactcttta ctgttaaact ctccgcacac 172560 ccagaacccg tggcagccac agatgtgttc tccttcctat agtttttgct tttaaaatgt 172620 tatataaatg gaatcctaca gtagatggtt ttttttgaga ctgtcttttt tcactcatca 172680 tetttetetg ataateatte aagttgettg tattagtatt ttttaaaata tttaatgetg 172740 agtattattc cattatatag atgtatcaca ttgtggttat caattctcca attgagggca 172800 tttatgttgt ttacagttta tggtgatttt gaataaatat gctactaaac actcatgaac 172860 agttattttg tgaatataat tcacttaggt aaattcctag ggtaaatata atagggatag 172920 gattgctggt ctatagagtg aatataactt aacttctaga aactgcaaaa ctgttatcaa 172980 gagggtgtac cattttgcat ccccatgagc aatgcatgag gaacccagct gttctgcctc 173040 cttgccagca cctggtgttc tctggttgtt gttattttttg ttctttgttc atcataacag 173100 aagtgttggg gtatcacttc gaggatttca tttgcatttt cttaatgact tacttttata 173160 tgttcatttg ccatccacat atcttctttg ttcgtgtctg ttcacatatt tgctatttga 173220 atgttttaat tgatttctaa aaagtcttta tatgtatatg tcacataaaa tttttctgtc 173280 agattggcaa atattttctt tcagctcatt gcttgtcatt cagcttttaa atggtagatt 173340 tctcagagaa aacatttctt ttttcttctt tttgataaag ttattgtatt agtttgttct 173400 cactctgcta tagagacata cctgagactg ggtaatttat gaagaaaaga ggctgaattg 173460 actcactgtt ttgcagtcta tacaggaagc atggctggag aggccttagg aaacttataa 173520 tcatggtgga aggtgaaggg gaagcaagca cttcttacca tggtggagca ggagagagaa 173580 agagagagag agagcaaacg ggaagtgcta cacacttttc aaacaaccag atcttgtgag 173640 aactctacta tgagacagca ctaggggaat gatgctaaac cattagatac aacccccatg 173700 atccactcac ctccaaccag gcccctcctc caacactaga aattacaatt tgacatgaga 173760 tttggatggg gatgcagaat caaaccattt cattttctcc ctggaccctc ccaaatctca 173820 tgtctttctc acattgtaaa atacaatcat cccatatcaa tagtccccca aagtcttaac 173880

tcattacagc attaactcta aagtccaagt tcaaagtctc atctgagaga agggaaatcc 173940 cttccaccta tgagcctgtg aaataaaaaa caagttagtt acattaaaga tacaatagag 174000 gtaaaggcat tgggtaaatg ctcccattcc aaaaggaata aatttgtcaa gcaaagctgc 174060 tacaggcccc atgcaaatcc aaaacccagc agggcagtca ttaaatctta aaccttggaa 174120 ataatctcct ttgacttcat gtctcacatc tagggaacac tgatgcaaaa ggtgggctcc 174180 caaggetttg ggcagettca eccetgtgae tttgcagggt acagececca tgactgettt 174240 cacaggctgg cattgtgtgc ctgtggcttt tccaggttca cagtgcatgc tatcagtgga 174300 tctaatattc tggaggctgg aggacattgg cccttttctc acagctccac taggcagtga 174360 ctcagtgggg ctccacccc acatttcccc ttcacattgc cctagtagag gttctgcatg 174420 agggatccat ccctgcagct tatttctgcc tgaatgtcca ggcatttccg tacatctttt 174480 gaaatctagg cagggcctcc tgagcctcaa ctcttgccct ctgtacatat acaggcttaa 174540 caccatatgg aagccaccaa ggcttgcagc ttttactttc tggagcagca gcctgagaca 174600 catgtggggc ccttttagcc atggctggag ctggagcagc taggacacaa tgagtagtgt 174660 cctgaggtta ggcagggcaa cagggccctg ggcctggccc acgaaaccat tcttccctcc 174720 taggcctctg ggcctgtaat gggaggggct gctgtgaagg tctctgaaat gccctggagg 174780 .catttgccca attgtcttca ctattaacac tctgctcctc tttacttatg caaatctctg 174840 gagttggctt gaatttctcc tcaaaagtga gtttttcttt tctcttgcat ggtcaggctg 174900 caaatttttc aagcttttat actctgcttt ccttttaaat atatgttcca atttcagacc 174960 atctttttgg aagtgcatat gagcataagc tgttagaggc agccaggcca tttcttgaac 175020 attttgctgc ttagaaattt ttttttggta aacaccacag atcatetete tcaaattcaa 175080 agttccacaa atccgtagag cagaggcgca atgccaccag tcactttgcc aaagcatagc 175140 aagagtgacc tttactccag tttccaataa gtttcccatc tccatctgag actacctcag 175200 cctgaccttt attgtgcata tcactatcag tattttagtc acaatcattc aacaagtctc 175260 taggaaattc caaacttttc ctcatcttcc tgtcttcttc tgagccctcg aaagtctttc 175320 agcetetgte categeecag taccaaaget gettteacat ttteagtatt tttatageaa 175380 tgcctcactt ctctggtacc aattatctgt attagtttgt tgtcacactg ctataaagac 175440 atagctgaga ctgggtactt tataaagaaa agaggttaaa ttgactcact gttctgaagg 175500 ctgtgcagaa agcatggctg gggtgacctt aggaaactta caatcatggt ggaaggtgaa 175560 agggaagcaa gcacatccta ccatggtgga gcaggagaga gagagagaaa agtggaggtg 175620 ttacacactt ttcaaacaat caaatatcat gagaactgta tcataagaca atactgggga 175680 catggtgcta aaccatcaca aaccatcccc atgatccaaa cacctcctat caggctcctc 175740

ctctaacact aggaattaca attcaacatg agatttgggt ggggacacag agtcaaacca 175800 catcagtttt gtttacccat tctttcttta caggtcatac tttggtgtca tatctaagaa 175860 ctcttcacca agtcttaggt tacaaacatt tcctcctatg gtttctccta aaaaccttta 175920 tagttttatg ctatacatat tagtccaggt acaattttta attaatttta taaaacgtac 175980 aaggtttagg ttaagacagg ttttttccac ttatgaatat ccaatcattc caaccaaatt 176040 tettgaaaaa agttageett tetteattga tttgeetttg cacetttgte aaaaateeat 176100 tgtccatata tgtgtatcca tttccggact ctctgttgtc ctgtgtgata tttaacttgg 176160 ctagtaatag cagctggtgt tggggtccta ctgaccactt agaagtgagc tgcccctatt 176220 tgaccagagg gctacttaaa ggatggagct gattctcatt ggttggacag ttctctcttc 176280 agacaggggt ataggaatct gaactaaaga aggatttagg aggagaagtt ttgttggaac 176340 tgctggtagt aagccatgag gaattgaata tacactaaca tcacagtgta taaattgctt 176400 gggtttttt ttttttttg agcatataga tctgtcaggg aaaattgact tcctaaattt 176460 ctttatgcag agaggtactt tcaaatgagt tgattaactt catttatcaa aaataactct 176520 ttctgcctcc ctctattcca tatgcccctg cttactttcc actgaacaaa tgccttgttc 176580 cctccatctc agcagcatct ccctctacct cctggctcct catggaggac tagtgttccc 176640 tcccagctcc tcatggagga ctagtgttcc ctccccaaca tctcacagtg ccttaggggg 176700 ctccttccag caggattcag tctgctccat ccctgaagca cctggccctc tgtagttact 176760 ctgtgtttgt tatacttgaa tttcttcctg attattttgg aagaaaataa gcaggatgaa 176820 atgtttagaa aacatttccc agaaagaaag gaagactgaa tgatgctgca agggagctaa 176880 actagaagtt gggcacccga gttcaaatcc cacctaccag aaagcagctg tgtaatggtg 176940 agtgattttt tttcatctcc atctcagctg ccatgttctt atctggaaaa ggaagaaact 177000 ggatgaaaac agcagttaga ataccaaggc ctatacagat cagacaggca acctaaatta 177060 gtgcaatatg acgtgtataa gaacaagtag acatagaagc acattgatga atggcaatta 177120 gtgttctgcc tctctgaggg atggaaggaa gtggtaggac tgggggtaac tcagactcaa 177180 ggccacctaa agtgatcaca atcatgtggc tgcagctgaa ttttgacctg aaagctcagt 177240 gttgacgtgt catctgattt ttctgaaaaa gccagaaatt tagctttcca tatgaaatcc 177300 cattttaaaa aagatgtgcc tcatgtttta aaagatcgtc atgcaggcaa aagaaaatcc 177360 caagaaaacc catctggggg ccagatctca gatacatcac ctctggagta aataaactcc 177420 atggctccca tgctgcaaag ttctggggct cctaggttct gctaagaaag taggaagttg 177480 gaataaataa tcaacttcta ctatagtctg aaaatttctg tctctccaaa attcaagtga 177540 atacttaatc cccaatgcaa atgttttaag aggtgtggcc tttaggaaat gattaagcca 177600

tgatgactgc cctcctaaat agaataagta ccctaataaa agggctctag ggaaccaggc 177660 agececteae ectettteae eatgtgggaa eteagtgaca agatgteate tttecageaa 177720 agagecetca acaaacacaa aatetgetga teetttgate ttggaettee etgeeteeag 177780 aaatgtgaga aataaatttc tgttatttat aaataattga aatacatttc tgtttcttat 177840 ttccactgta aggtatttta ttatagcacc tggaattgtg taagacaaca tcttagctga 177900 gggtacactt aatgtgcttt ttatgtcagc ccctttgaaa gttaaatatt ttattaaaat 177960 aaaaatagca gttttgtgtg ctattaaaat aacataatat ttacattcag gaggctgtat 178020 aaaagtcatt tgttcaaaca tttgttgcaa taataagatc ataaaagtat ttgttaccag 178080 aagtgettta tteatetttt agttgettat tteaetgeag aacetateta tagettggtg 178140 getegtagee aagtgtaaga accetgegtg atacteetea ettgaaagtg etceaaatgg 178200 gacactacat gaatggatta ggcactgacc ctgttgttcc tttcactatt ccctactttt 178260 gtgactacaa ggggaaacac caactcttga atcagcattt acctggaagc tgcaggtagc 178320 cccgttaact gctcagcccc agggctgcct ctcagcctaa atgggcatcc tgttccctcc 178380 tetttettt etgeagatea taaggaetet eeteteetge agagetgeee atgteeacte 178440 cetettecag gegeetette etgecaagae tggeetetga attggatgta geettteece 178500 tecegettee ttaaaageee aaaatacaag cacacagage ceatgtgtgt acttggtttt 178560 tetgttaate aetttggcaa aagacaaggg teataaettt caccaaceca gtgtaacagg 178620 gtgtcctgat ttcctgattc tttagcatca ttgtcccaag actctgattt cctactgtct 178680 ttacctagtg tgttttgacc ctcagcctta ctgtaaagaa atatttttt ttcagtcagg 178740 catagtggct cacacctgta atcccagcac tttgggaggc caaggcgggc agatcacgag 178800 gtcaagagat cgagaacatc ctggccaata tggtgaaacc ctgtctctac tataaataca 178860 aaaattaget gageatggtg gtgeaeteet geagteaeag etaeteagga agttgagaea 178920 ggagaatcgc ttgaacccag gaggcagagg ttgcagtgag ctgagattgc gccactgcac 178980 agcaagaaag aaagaaagga attttttcaa tagcttttgg ggtacaagtg gtttctcatt 179100 acatggatga attatatagt ggtgaattct gagattttag tataccaatc acccgagtag 179160 tgtacaatgt acttaatgta gttaatttta tcccttgccc tcctctgacc ttcccccttc 179220 tgagtctcta aagtccataa tatcaatctg tatgcctttg catacttata gcttagctcc 179280 cattlataag tgagaatata cagttcttgg ttttccactc ctgagttact tcacttagaa 179340 taatggccta cagctatatc caagttgctg caaaagatat tatttcattt tttatggctg 179400 agtagtattc catggtgtac atataccaca ttttctttat tcacacatta gtcaatggga 179460

aattaggttg attccacacc tttgcaattg agaattgtgc tgctataaac atacaagtgc 179520 aggtgtcttt tttatataat gacttctttt cctttgggta gatatccagt agtgggcctg 179580 tgttgaatgc tgtgttgaac gttagatgta tttttagttc tttaaggaat ctccatactg 179640 gattccatag acgttgcaca aatttacatt cccaccagca gcgtataagc gtttcctata 179700 cettgtatec acaccaccat etettgtttt ttgactttta aatactgeec attettggag 179760 aagtaaggca gtacctcgtt gtggttttac tttgcatttc cttgctgatt agtgatatgg 179820 tttggtctgt gtccctgccc aaatctcatg tcaaatttta atccccaatg ttaaaggtgg 179880 ggcctggtgg gaggtgattt gatcatgctg gtggatttcc catttggtgc agttcttgtg 179940 atagtgagtg agttaccatg agatctggtt gtttaaacgt ttgtaacact ttcaccctct 180000 gtagcactta ctcctgctct ggccgtgtaa gatcaacctg cttctctttt gccttctgcc 180060 atgattgaaa gtttcctgac ccctccccca ccacccccag ctatgcttct ttcacagcct 180120 gtggaactgg aagccaatta aactttttt ctatacaaat tacccagtct cagatatttc 180180 tttacagcag tgcaagaaca gactaatata gaaaattggt accaggagta gggtactgct 180240 ataaaggtac ctgaaaatgt gactttggaa ttgaataaca ggcgtaggtt ggaagagtgt 180300 agagggetta gaaaaaggea ggaagatgag ggaatgtetg gaaetteeca gagaettgtt 180360 aaattgttgt gaccaaaatg ctgatagcga tattaacaat aaagtgtagg ctgaggtggt 180420 ctcagatgaa gatgagaaac ttattgggaa ctggagcagg ggccactttt gttatgcatt 180480 agcaaagagt ttggaggcat tgtgcccctg ccctaggaat ctttggaact ttgagcttga 180540 gagtaatgat ttagggtatt tggtagaaaa aaattctaag cagcaagtgt tcaagaattg 180600 gccaggctgc ttctaacagc gtatgctcat attcattctc agagtgacgg tctgaaattg 180660 aaacttatat ttaaaaggga agagagtctg gaagtttgga aaatttgcag cctggccatg 180720 tgaaagaaaa gaaacatcca ttttctgggg aggaattcaa gctgcctgca gaaatttgca 180780 tgtgtaaaga tcagccaaat gttgatagcc aagatcgtgg ggaaaatgcc tcaaatgcct 180840 ttcagagact ttcccagcag ctcctcccat cacaggcctg gaggcctaag agagaagaat 180900 gattttgtgg gccaggccca gggcactgct gccttgtgca gccttggaac atggtgccct 180960 gcatcccagc tgcaccagct ccagccttga ctaaaaggga ctatggtaca gttcacgcta 181020 ttgctttaga tagtgcaagc cccaagcctt ggtggcttct gcatggtgtt gggcctgtga 181080 cagtgcagaa ggcaaaaatt gaggcttagg agcctctgcc tagattccag cacagcagta 181140 gaaaggggtc aggtgggatt ggattcccca cacagagtcc ccacaggggc actgcctagt 181200 ggagctttga gaagacgacc actgtcctct ggcccacaga atggtagatc cactgacagc 181260 ttgcactgtg cactcagaaa agccacagga actcaacacc aatccatgaa agcagtcatt 181320

ggacctgtac cctgcagagc catagaggtg gagctttcca aggccttggg agcctacccc 181380 ttgagtcagt gtggcctgga tgtgagacat ggagtcaaag gaattatttt ggagctttaa 181440 gatttaatga ctgccttgct gggtttcaaa ctttcatggg gcctgtagcc cctttgtttt 181500 ggctgattta tcccttttga agcaggtgta tttacccaat gcctgtaccc tcattgtatc 181560 ttggaagtaa ttatcttgcc cttaatttta caggctcata ggcagaaggg acttgccttg 181620 tcttatctca gatgagattt tggacttgga catttgagtt aatgctggaa tgagttaaaa 181680 ctttgggtga ctgttgggat agcatgattg ttttgaaatg tgagaaagac atgcgatttg 181740 ggaggggcag gaggtgaaat gatacgtttt ggctttgtct ccatccaaat tttatgtcaa 181800 attgtaattc ctggtgttga aggagggcc tggtgggagt ggattggatc atgggggcag 181860 atttcctttt tggtactttt cttgtgatac tgagtgagtt actgtgagat atggttgttt 181920 aaaagtgtgt agcacttccc ctctctctgt cttgctcctg ctttggccat gtaagatgtg 181980 cctgcttccc cttcaccttc cgccatgact gtaagtttcc tgaggcctcc ccagccacac 182040 cgtttgtaag gcctgtgaaa ccaggagcca agtaagcctc ttttctgtat acatttccta 182100 gtctcaggta tttctttata gcagtgcaag aatggactaa tacaattagt gaggttgaac 182160 attttttgat atgtttgttg gccatttcta tatatgtatt ttttgacata aagtcttgct 182220 ctgccaccta ggctggcgtg cagtgtcata atctcggggg tttactgcag cctctaattc 182280 ctaggctcaa gtgatcctcc actgtcagcc ttccaagtag ttgggactac aggtacagat 182340 attttaatta taacattcac agctacagaa ctaattatat tttatatccc ctttgaagca 182400 actaccatac ctgaataact ttcatatttt ttgtaaagat aggttttcac tgtgttgccc 182460 aggraggtat caaactcctg ggctcaagcc atctgcctgc ctggacctcc caaagtgcta 182520 agattacagg catgagccat catgactggt atttatattt cttcttctgg gaaatgtcca 182580 ttcctgtcat ttttccactt tttgatggaa ttgtttattt cttgctgatt tgtttgagtt 182640 ccttatagat tacatggata ctagtcctat gtcagatgca gatgcatagt ttgcaaatat 182700 tttcttctat tctgtgggtt ggctatttac tctgattatt atttcttttg ctgtacaaac 182760 ctttttagtt taattaggtt ccatttattt atttttgttt ttattccatt tgctttttgg 182820 gtcttagtca taaattctct tctacactga tgtctagaat agttttttcc atgatatatt 182880 ctagaatttt tatggtctca aatcttatat ttaaggtttt gaaacatttt gagttgattt 182940 ttatataagg tgagaggtac ggatccagtt tcatccttct acatgcggct tgccagcttt 183000 cccagcacca tttattaaat aggttttcca ttccccaact tatatttttg aatgcattgt 183060 cagagatcag ttggctgtat gtatttggct ttatttctgt ttcttattct gtttcaaaac 183120 taggtctatg tgcctacttt tatatcagta ccatgcaata tgggtaactc tagccttgta 183180

gtataatttg aagtotggta atgtgatgto tocagatttg ctctttttgc ttaggattgc 183240 tctgactaat caggctcttt tttggttcca tgtgaatttt agaatttgtt tttctaattt 183300 ggtgaaaaat gatgttggta ttttgatggg aattgcattg aatctgtaga ttgctttggg 183360 tagtatgatt atttttgcaa tattgatttt ttcaatccat gagcatagga tgggtttcta 183420 tttgcttgtg tcatatatga tttctttctg cagtgtcttt tagttctctt gtaggaatct 183480 ttcacctcct tggctaagta tatttctagg tatttcattt atttccagct cttattaaag 183540 gaattaagtg tttgatttga ttctcagcat ggtaattgtt tgagcatagc agtgctactg 183600 atttgtgtac actaattttg taatctgaaa tgtactgact ttttttatca aacataacaa 183660 ttttttggag gcatctttaa aattttctag acatatttaa aattttctaa attgtgccat 183720 attatctgta gatgatatga tacaatgata tcatctacaa gcagtgataa tttgacttca 183780 tetttttee aatttgtatg ecegttatte ttttetettg cetgattact etggetagga 183840 cctccagaac tatgttgaat aggagtagga aaatgggcat acttgtcttg tttcagttct 183900 tagggggaat gctttcaact cttccccatt cattatgatg ttggccgtgg gattgtcata 183960 tatggettte attattttga ggttagteec ttetatgett agttttttga gagtgtetgt 184020 cataacagga tgctggattt tttcaaatgc tttctctgca tctattgaga tgatcatatg 184080 cettttgett ttaatgetgt ttatttaata tatcacattt attgatttgc atatgttata 184140 ctatctctga atccctggga taaaatgcac ttgatcatgt tgtgttatct ttctgatgtg 184200 ctattagatt cagttagcta gttttctgct caggtttttt gaatctatgt tcatcagagt 184260 tattgggctg tagttttttt ggtggtgttg taatgtcctt tactggattt ggtaacaggg 184320 tgatactggc ttcactgaat tttttaggga ggattccctc tttctcattt ttttttcccg 184380 tgggattggt accaattete etttgaatgt etggtagaat eagetgtgaa teeatetggt 184440 tgtaggctat tttttgtttg ttggcaattt taaaattact gattcaatat tgctgcatgt 184500 catttgtctg ttcagggttt ctatttcttc ctgatttaat ctaggaggct tttatgtttc 184560 ctgaaattaa tccatttcct ctaagttttc tagtttgtgc acataaaggt gttcatagta 184620 gtotoaaatg atottttgta tttotgtggt gttgtaatat ottoagotto atttotaatt 184680 gaacttattt gaagcttctc tgttcttttc ttggttaatc tagctaatgg tgtatcagtt 184740 ttgtttatct tttctaagaa ccagctgttt gtttcattgt tcttttgtat ttttgtttga 184800 atttaattct cctctaattt ttgttatttc ttttcttctg ctatctttgg gtttagtttg 184860 ttcttgtttc tctagtttct tcaggtatat aattagactg tcaagttgtg ctctttcaga 184920 ctttttttt ttctttgaga cagagtctca ttctgttgcc gaggctggag cacagtggtg 184980 tgatctccgc tcactgcaac ctccacctcc tgggttcaag cgattctcct gcctcagctg 185040

ctggagtagc tgggacaaca ggcgcatacc accacactgg caaatttttg tattttttgt 185100 agagacgggg tttcaccatg ttggccaggt ttgtctcaaa ctcctggcct taagtgatcc 185160 accageettg geeteecaaa atgttgggat taaaggaatg ageeaeggta eecageetet 185220 ttcagacttt ttgacgtagg catttagtac tataaaattt cctgttagca cagtttttgc 185280 ttcatcacag aggttttgat aactcgtatc attatcattc aataattaat ttccatcttg 185340 atttcatttt ttttttgttt tttgagatgg agtttcactc gtcactcagg ctggagtgca 185400 atggcacgat ctcagctcac tgcaacttcc acctcccagg ttcaagcaat tctcctgcct 185460 tagetteeca agtagetggg attatgggea eetgegacea tgeecaggta attettgtgt 185520 ttttagtaga gacggggttt caccatgttg gccaggctag tcttaaactt ctgacctcag 185580 gtggtccacc cacctcggcc tcccaaagtg ctgggattat aggtgtcagc caccgcacct 185640 gacctcaatc ttaatttctt cattaaccca taaatcattc aagaaaaaat tatttaattt 185700 ccatgtattt gtatagtttt gaggattcct tttggtgttg gtttctagtt ttactccatg 185760 gtggtctgag tagatagctg atataatttc acttttttct tgattgagat ttgttttggg 185820 gcctatcata tggtccgtct ttggagaatg ttccatgtgc tgatgagaag aatgtatatt 185880 ctacaatgct tgggtagaat ttctgtaaat atctgttaag tccatttttt ctactatgtc 185940 atttaagtcc atttttttgt tgacttcctg tcttgataat ctgtctagtg ctgtaagctg 186000 tgtattgaat tctcccgcta ttattgtgtt gctgtctatc tcattgaata ggtgtagtag 186060 tagttgtttt atgaatccgg ctattacagt gtttggtgca tataagttta gaattgtggt 186120 atcttcatgt tggattgatt atttaatcat tttataatta ccttctttgt cttttttaac 186180 tgttattgct ttgaaatctg ttttctctga tataagaata gttctgcttg cttttggttt 186240 tcatgtacat agaatatett tttccaecce tttacettga gtttatatga atcettgtgt 186300 tttaggtgag tttcttatag acagcatata tttggtttgt gatttttcat ccattctgcc 186360 attgtgtaca ttttaagtgg agcatttagg tcatttatat tcaacactaa tattgagata 186420 tgaggtaatg ctctcttcat catgttaact gttaacaaga tagtttttt ttcattatat 186480 tattgtttag taggccctgt gagttttaag ctttcaagca tttgtatttt ggcatatatt 186540 gaacttttgc ttcaatattt agaacttctt ttagcattat ttgtagtgct gatttgggag 186600 tgacaaattc cctaagcatt tgtttgtatg aaaatgattt tatttctctt tcatttatga 186660 aacagcttta ctggatacaa aacttttagc tgacaattat tctgtttaag aaggctgaaa 186720 attggacctc catttettet ggcttttaaa gtttetgeca agaagtetge tgttagtetg 186780 ataggttttc ctttacaggt tactttgtac ttttgtctta ttgctctttg aattatttcc 186840 ttcatgttga aattagatag cctgatgact gtgtgccttg tgaagatcta tttgtaatga 186900

tgaagttttc ctcaattatt ccctcaaata agatatccag acttttttt tttctcttct 187020 ctctcaggaa caccaattat tcttaggttt agccttttta cataatccga tatttcttgg 187080 acactttgtt cttttgattc ttttttcttt atttttctct gattatgtta atttaaaagc 187140 cttgtctttg aactctgaag tttttcttct agttcttcta gtctgttgta aaaatttccc 187200 actacatttt gtaattccct ttgtatttca cttccagaag ttttaattag ttttccttta 187260 tgatatctat ctctctagaa catcatttat tcatatgctg aactgtttgt aaagtcatct 187320 atgategett teacetttee tiggitatate etigaatage tiaataatga geetteigaa 187380 ttctttatct gatattttaa agatttcatc ttaatttgaa tccattactg gacagctggt 187440 gtgatctttt gaaggcattg tagaaccctg ttttgtcata ttaccagaat tacttttctg 187500 attttttttc tcatttgggt agtgtttctt ctaattatta ttgaatttat gttgatttga 187560 ctgtgtttat ttgtttttaa attttttct cttaagtatg ctactttaat gcttatagtg 187620 aaacatagcc taattcagtt actggttctt tcatgggtgg agactgtaag gttcctaggt 187680 tatatagagt ctttgtataa tagttttatc gtatgctggt tgtagtagca atgtgttcat 187740 tgtgtgagca aatttactgt ctcctataag gttggaatgg tagaggactc ttgaagctta 187800 tttcatttcc ccatggtgta cacttttttg catatttatt tttccccagt attttcttta 187860 agcettttee tgtttagaaa aaaatagtge agattgetge caccacattt tacataaaca 187920 cactetetga ggetgaagea aatetgaetg atttteagtg taaaaataaa atataaacte 187980 ttggagttat ttctaaacag aacaaacatc agaatcatct cagtcatcag attgtctatg 188040 tctgaaaaat cggattcatc aagtaagtct ctggccaaca actgttcatg gctgatgtta 188100 acatcatgca aaggaaagct atattttcta ggatttgaca ttttcagcaa ttgagaatta 188160 ctacattttt aagtggaaat accatttcta aaaacagaat gctatgaata gaatgatgta 188220 tttagtttcc aaagttcata tactagagtg atgtgaaaat aataataaaa gtgagatatt 188280 tcatagcaaa gttatctcat aataaatgct tcaaccacaa gcaccaccaa tgagtattct 188340 tggggcaaaa gggaaaaggg ttaatgattt gatagttcag ttttcaggcc agtaggggag 188400 gtttccctga gtaagaattg gttgtggcta aagctagtgg gtaaatgaaa tactcaatgg 188460 ttttttgaga cggagtctcg ctctgtcacc caggctggag tgcagtggca cgtgatctcg 188580 geteacteca agetetgeet eccaggitea egecatiete etgeeteage etecegagia 188640 gctgggacta caggtgccca ccaccacgcc cggctaattt tttgtatttt tagtagagac 188700 ggggtttcac catgttagcc aggatggtct tgatctcctg acctcgtgat ccacccgcct 188760

cggcctccca aagtgctggg attacaggcg tgagccactg cgcccggctg tgtccctgtc 188820 ttgacaaagg tggctggaga agctttcagt gaatcacact gaggtcttat cgggggaagg 188880 attagageca ecteggetee ectggeaggt cageagggaa getatecaet teteagaeat 188940 actectgtte cagtgeteca getattegga ecacacaggt acetettte atetgtagaa 189000 atgtagattt ttcaagttga gaggaattgt gactctatct tgaaagcctg aacctttagg 189060 atgtcctcct gcagggatgc tctcacccta aagtgttcca gaaaggttgt ctatagttgc 189120 acccatgcaa agctcccatg ggagaagccc caactgtgct catggtggtg aacaaagggg 189180 gaaagttgtt tccttctcca agacccttca cgtgcactaa ggctgcctga ctgttagatt 189240 agagetgeag aetttaettg etgageeeag eactgegaet gtgeetetge tgaaactgee 189300 caccagcaga aggatatggt actcaaggcc tgtcatctat attcttttgt ttcatgggcc 189360 gttcccttga tgtggtgcac tccctcttcc ccgaggagtc gaagtccctg ggagccagat 189420 gactgtgagt attgttgctc cactgggtct agctgcctag tgaaattgcc atactccagg 189480 ctggtgctag ggaatgagat caagggatcc agtgatgtga cctgttctca tgcctcccgg 189540 aagtgggtag cagcaccagc tetactgcta gtggcagggg agtgacctat actctgggat 189600 tccttgattt tagaaagcct tagtgtgttg gctttctcga atgccactta tcatagtaat 189660 aaactgatca tttggacaga atcaggacct cttgattagc cagagtggtg caggcagtgg 189720 tgatagetta ggecacacag aaattttete etteetagae teagtgttat tetaceagga 189780 gatgctgtaa tggactgtgt cggttggcct ccagccagga ggtggcactt gccaaagagc 189840 accagetgtg geagtageag tgagagtttt gettgeettg tgetgeecag agggggtaet 189900 ccagtttatc aggcaatggg tgaggccata cagttcccaa atgtttcttt cctttgtgtt 189960 aagctagcag ggcaggtggc agggcaaagc caggtgtggt ctaggtcagg cgggtttgtg 190020 aactgacttt ccacatgcag ggcaagcagc agttcctgtg ggtgtcaggg gaagggggtg 190080. gttctcaggc cactgggttt gtgctccaga ggggagtgtt gctgtctctg ctgcacagaa 190140 gagtttgagc agggagtgga gagtagcaga ctgcagtaag ccccacacgg atcccacaca 190200 tttggtgagg gagatctcac tcccactgtg ttccactagc agcagcgatc taagttccag 190260 gcagcctgca cttagaattt gcaactgccc caagtcatag gctttcccca gggagatagc 190320 aactgcatat ttcaggccac gcccctccgg gtccattcac aaagccaggc tcccagcccc 190380 tgtgcttgtg gctgtggccc atgtttcact tgaacaggct ggccttggtc aagagagttc 190440 atecceacce aaggtgacat catcaaacce agettgggge ttetttecae etgcgaccae 190500 tgcctgaact atttggctga cctccacagt gtcccctgtg aggatcaata gggagtggct 190560 ttccttgctt tgcactggag actggaggtg catacaaggg tcttcctgct gctgttccta 190620

ctattatgtt ccacaaccct ccccagtca gtttctgtgc tgggtaggct taaggctttc 190680 ccgatggcct ggtctttcag gctctctggt cacggtgtga atctgagaag cagtctctcc 190740 ccctcatatt tttggggact cacagccctt tgcctggctc agtgtaggct gcagcctgct 190800 getteetteg gaggetgtgt gggtteette aacttteetg tteagtteet geattgette 190860 ttgaaaaaaa aagtttgtgg tgtgaatctc tacacaatat tttccaagtg ggagaggtat 190920 gcgaacaatt cctctagtac accatcttgg gaaaaaaaat aaaaacctca gcctcacttt 190980 gateetttgt ttagatgeaa taaggeetgg agaageaate ageeeagatg getgttgete 191040 cctacccca gccataggaa caattggcat gttcatggaa gaactggagc gtgggaccag 191100 caagttcacc aggtaccttc cctgcccaga aatgagcttc ttttgcactt tttttactca 191160 cacgtttgtg gatgtgtagg agggtggggc tacttgccca gtggtagttg ggtaccccta 191220 gcaggtaccc ctctggatga tgggtaatcc caggaggatc tgtgggaagg actcaaagac 191280 tttgatctct ttaccttgtg agtctctttt atcatctgtg aaatgggaat gatcacagtg 191340 cttccttcac ttcgtggagc tgttgggaat ttcaaggaga ttcatgcctt tagagctcct 191400 ggcgcaaagg gagcctccat aagtcagccc gatttgttat catgatgact aggaagaact 191460 agcacagagt ctggctgtgg teettetgga gggctctgtg geettggtge teatggteat 191580 ctcccttcag ccatccccta cttcatgaat caagaaggtt ctttggaaac tcagtgccag 191640 tgtgtggtgc tccaggactc agccccatgc ttgtctgagt gcaggtgcac gtcctataag 191700 ctagggggat tgcaaaaata ttgaacatcg gcaatgacat gggccctgac aaattggaaa 191760 agtgtgtact gcagagaacc cacaccctac ctcacctaca acattcacat gcaaaatcca 191820 gtottatgac caaatootca otttoocagt ggcagtttoa ggcacatgot aaccotgatt 191880 gaatcaatat acagacccta caccatgtta agtettaaca aacaccaage tattggcgag 191940 tgtgcactcc ccattgcaac tcctgcctga ggagctccct tccactcctc tgccttgagt 192000 ttggttgggg gaggacgggc acatctgttt gagtaactgg acctgacatg gacaggacgt 192060 gtaggtcaca ggcacttctt cactggctct tgttattcac catggtgact cttcacagca 192120 taccgctggc attatttcct gaggaaacag gctgagagtt agtgaatgtg ccccaagtca 192180 cataggtagc aagtggcctt gctgggactc gagcctacct ctgtggactt caatgcatca 192240 tectgaette ecettigtta taggitattat gegeettaac ecaggicaatt getecatitig 192300 aaccgtgcag cacagatacg ggtggatgtg aacacttggc tgtctcagga tgcctcctgc 192360 ttccctcgta attaagacag cccctttctc caatcccaca ataaagcaaa cagtgagtga 192420 tgaccaggtg tgatgttcat gatttctatt ccacgtggtg ggaagagatg atgcttcata 192480

acttetetet eetagtattt getetgetee teaggggete teateacata gtgttttaaa 192540 tcccaggatt tggagttagt caaactttgg tctggtttcc agctcttcca cttcctaagt 192600 gtgcctggcc ttgggccact cactttcacc tatacatcca tcagttgaac aaatattgat 192660 gactctcttg attgtcaaat tgccacatgt tattttatgc tagaaatggg gctaaggaga 192720 tgagcacatg ctggattcta ctcacatgga ggtcacagtg ctgagacaga gtccgagcag 192780 tgagcacatg agggtagagg agtgacgtac gtgtgacatg ggcagggctg tgatggtgca 192840 gagaggagtc aacctgcccc acatcccctt cccccgtgct gttccttctt gaacagcttc 192900 cttcttcacc actaaagaag agctcctcca tccataaaac cccttccaga tacaacttcc 192960 tccatagatc caatctgcct tctgagatct atccttcttt gagcctcaag gacatcctat 193020 accttcctta aaatgcagtc ccttggtcat gccatatttc accttatttt ccacagggaa 193080 teegtgtetg acteatetet aggtttttat ggttttaggt etaactaate catteeteae 193140 agttcagtgg ctggcacaga aagaagttca gtagatgttt ataggtttca actgggaaca 193200 cactcaaata attctgcctt tcccaaatgc ttcctctggt atggaaatta aatgcagggc 193260 ctggaagaat gcattctggt taaaagtgca gctgaatgtc cattaatacg atacaggtgt 193320 gttcgtgact ctaattggtg accacatggg atggtattgc tgtttctaat cctagttatt 193380 cagaaatgca cccatatttt ttcatactga taagattcat ctaggcaaat gtaagcatat 193440 tcctgtgtaa tgacaaaatg aatttaactc caaacatttt ttgaaacaaa acattattag 193500 tgaaaatcat attttactct attattgcca gtggctaagt ttcatttccc tcgccaagct 193560 taacaaggtg gaaactttgt taattctagg ctatttttt gaaacctgga aacctctctg 193620 cetetatttt teteeteete etagagtgge eccageagag aatgeggtaa ecaegtteae 193680 ccctgtaatg tccttcaaga ttttgcaaat gttagctttt ggttcccatt taagtgaaag 193740 ggcttctgag ggaatgtgat gactcacaga tgagagatgg attgcgtcct ccatggtagg 193800 gacagaatgg ctgttagaag cgaagatctt tatatgttcc tgcaaatgta cccagcagca 193860 cattgttctg ctgaatgtac atgtcaaagg tatttccgtt ccctttccat cctatatttt 193920 cccaggttag aaatacctgc tttataaagc aggtattata aatgttctgt aaaatacaaa 193980 gcacaataca aaagaagaca gcagatgtag gagtaagtaa acagcaggaa aacgttgctt 194040 acaatgaaat gattaaaaag cccattctaa aacaaaattt tcaatgcatc ttaaatattt 194100 atgttactgt ggtaatgacc tcaacagtct ttgaccaagc taaatatgct ttagaaatat 194160 gttgatatct gcaaagtgtg aatattcaaa attgccatga tttgggaaaa ggaaagtaaa 194220 acacteteag tatgaggage tttteecatg gaatgtgaac tgcaaggtgg tgagaagggt 194280 taggtgtgat gtggtgagat catttttaga ccagtgtgtc tattattagc tttattacac 194340

tcccactggg cattataatt tcctgaaatt catcatttaa ttaaggctat gggttttgat 194400 taaatttttt taaatgtcaa acagcataat atttatagtg aaaaagaaaa ctgcttggtg 194460 gatacacatt ggttagcagg acgaggcatc ttagggattc agcatggagt cagctgtgga 194520 tggggtttta gtttctgtct ttgaattgac cttcacatag tgtctacctc ttgagagttc 194580 aggggatgtt ggagagataa ttaggtaaaa caggaagatc ttctcaggat acatgaggga 194640 gttaaataaa aatgcaggag caattacaat tttagttatt tgtaactgtt gtttgctaag 194700 tcgtaacatt gtcactgata acatgaaaaa ataaaatata ctaaatatca atagacaaaa 194760 accagttttc ttttctccat ccaaatacct aaatacctag cactaatatc cagaacaaaa 194820 tececcaaat accatetttg gaataaaaga atattettte aaettateaa ggeeacaagg 194880 taaaaacaac aacaacaaa aacaacaatg ctttttttct tacactttaa tatgtgcagt 194940 tgaaggtatt tctcattgca aactaagatt tccatccagc atgtgacatt aaagcactgt 195000 tcatattagg atagtaataa gggatcacac tggttagcct taggcgtttc agaggaaaaa 195060 aaattaaggt gagagaggtg gggcaagaaa agcagaatag aaggctgcac agatcagccc 195120 cctcgcaagg acacaaattt aacaactatc cacacagaac aaaacacctt tataagaacc 195180 aaaaatcggc cgggcgcggt ggttcacgcc tgtaatccca gcactttggg aggctgaggc 195240 gggcggatca cgaggtcagg aaatcgagac catcctggct aacacggtga aaccccgtct 195300 ctactaaaaa taaaaaaaa ttagccgggc gtggtggcgg gcgcctgtag tcccagctac 195360 tcgggaggct gaggtaggag aatcgcttga acccgggagg cagagcttgc agtgagccga 195420 gatecegeca ttgcaeteca geetgggega cagagtgaga eteegtetea gaaaaaaaa 195480 aaaaaaaaca aaattagggg aactctctta gtacctggtt gtatcactga aaaaggcact 195540 gaagagttag aaaaaacagt ctcaaatcgc tgaccccacc ccttccctac cctaggcagt 195600 ggcagtatgg tgtaaagagc atctccggaa gctggaagag caagagcaga gcagttgtga 195660 gcagagcagt ctcttacagg agaaaggaaa accagaccaa acttagctga ctcccatctg 195720 ggaagggagc attgaaacca cctctagcca gagggaaatt acccatccca ggaatcagaa 195780 cttgagtttc tgcaaacctt gccactaaag gctaaactgt tccgggtttc tcagaaaacc 195840 ttaaaggcag tctgggccat aaggactgca acgcttaggt gagttctagc attgaactga 195900 gcccagagac agtgttttgt ggcagggatg tggaggggtg cagatgacct accgagatac 195960 cagetggggc agccaaggga gtgetggege cacecetgee etageteeag actgeeceag 196020 ctagcggctc cataaaagag cacttccttc cacttgagga gaggagatgg aatggtgagg 196080 agcatttttt ttcttgcatc ttgaatacca gctcaaccgc agcaggacag ggcaccggtc 196140 agggttgtga agcccctgct ccaggcacta gctcctggat aacatttcta ggcacaccct 196200

gggccagaaa gcaacctgct gccttgaaag aaatgaccaa gccctggcag cattcatcac 196260 tggccacctg aatagccctt ggttcctgaa tagacagcag cgatacccag gtactgcatc 196320 aaggacettg ggtgaaccae tgagacatae tggetteagg taccagtatg gtaagagggg 196380 aatagcgtaa caagcgggct cttggggtcc ccaattccag gacttaactc ttggacagca 196440 tttctagacc tgcccgtgac cagacaggtg cccacagccc tgaagggtga gtcccagtcc 196500 aggcagcatt caccatgagc tgacttaaga acacttggga cttaagggag catcagtggt 196560 agtgttgcag tactctccat ggcctgcaat aggggtggct acaggttgag gctcccctgc 196620 ctttgaaaaa gggaggaggg aagtgtggga agaacggctt cttgtggttt gagttatggt 196680 ttgagtgtcg gctcagctgc agtacagtag aacaccaggt agatttctag gatctttaac 196740 tctaattcct gactccagga tggcatctct gaacccacct ggggggaactc actgccctga 196800 aaggaaagac acaggcctgg atagctttgc cacctgctga ttatagagcc tcaggggttt 196860 gagcaaataa aggcagcagc cagggagtgg ttacagaagg ccttgggcaa gacccagaac 196920 tatgcttgct tcaggcctga cccagcacag tcatagtgtt catagtgttg gtggccagag 196980 gagtgcctgt gttactccat ccccagcttt agatggctca gaacatggag agagagaga 197040 agaaagtaag gggagagaac aagagtetet geetgataac ceagagaett eteetggate 197160 atgtccaaga ccgtcaaggt gggacctcca cgagtatgta agaactgcag cattactggg 197220 cttgggtgcc cacaaaagca gatacagatt aaaatgaaac acccaagtat ttgtaaatat 197280 ctggaaaaca ttctcaatta gaatggctac aaacaagctc agacagtgaa gactacaata 197340 gatacctaaa tetteaatga eeagatgeea aagaatatet aetageatea aeaccateea 197400 ggaaaacata acctcaccaa atgaagtaaa taaaccacat ggaccaattc tggagaaaca 197460 gatatgtgac ctttcaaaca gaaaattcaa aatagctgtg ttgatcaaac tcaaagaaat 197520 tcagtataac acagaagaat tcagaattct atcagagaga ttaacaatga gtttgaaaca 197580 attgaatcaa gcagaaattc tggagctgaa aaatgcaagt gacaggttgc agcatctgtc 197640 aaattotott aatagoagaa toaatoaagg agaagaaaga attagtaago gtgaagacag 197700 gctatttaaa aatatacagt caggaaagac aaaattaaaa aatagtagaa agcaatgaag 197760 catgcatata ggatctaaaa aaaatagctt caaaaggaca aatctaagag ttattggcct 197820 taaagaggag gtagagaaaa acatatgggt agaaagtttc ttcaaatgga taataataga 197880 gaactttcca aacctagaga aaggtatcaa tatccaagta taagaatatt atagaatacc 197940 aagcagattt aactcaaaga agtctacctc aagtcattta ataatcaaac tcctgaaaat 198000 caaggataaa gaaaggttct taaagcagca agataagagc tccaatatgt ctggcagcag 198060

acttttcagt tgaaacctta caggccagga gaaaggcatg acatatttaa agtgctgaaa 198120 gataaaaatc ttttacctta gaaaatatat ctgaaaaaat atctttcaaa catgaaagag 198180 aaataaagat ggtcccagag aaacaagagc tgagggattt aatcaacacc agccctgtcc 198240 tacaagaaat gctaaaagga gtatttcagt cagaaataaa aggatgttaa ttaccaatat 198300 gcaatcatct aaaagcataa aactcaatgg taattgtaag tacacagaaa aaatagaata 198360 ttataacaat gtaactgtag tgtgtaaact gctgttattc taagtagaaa gactaaagac 198420 taaaccaaaa ataataacta caacttttca agacatagtc aatacaataa gatatgaata 198480 aaaacaacaa aaagtcaaaa agcagtgaga tgaagatgca gtttttatta gttttctttc 198540 tgcttacttc tttgtttata caaatagtct taagtagtta tcagattaaa ataatgggtt 198600 ataagatagt atttgcaagc ctcatggtaa cctcaaacca aaaaacatac aacggataca 198660 caaaaaatta aaggcaagaa actaaatcat atacccacag aaaaatcatc tttactaaag 198720 gaagacagga aggaaagaaa gaagaaggag aagatcacaa aaccatcaga aaataaataa 198780 caaaatgaca ggagtaagtt tttacttatc aataataaca ttgaatgtaa atgagctaaa 198840 ctctccaatt aaaatacata gagtggctga atgtatgaaa aaacaagaca cattgatctg 198900 ttgcctacca gaaacacact tcatctataa agaaacacat acactgaaaa taaagggatg 198960 gaaaaagata ctccatgcca atggaaacca aaaaagaagc aggattagct atactcatag 199020 cagacaaaat agatttcaag acaaaaagta taagaagaaa aaaaaggtca ctatataata 199080 ataaagaaat cagttcagca agaggatata acaattttac atatatatgc acccaacact 199140 ggagcaccaa gatatataaa ggaaatagta ttagaactaa tgagagagag aggtcccaac 199200 acaataatag ctggagactt caacacccca ctttcaggat tggacacatt ttccagacat 199260 aaaatcaaaa aagaaacatc agacttcatc tgcattatag accaagtgga tctaataaac 199320 atttacaaaa tgctttttcc aaagactgca gaatacacct tcttttactc agcacatgga 199380 tcattctcaa ggatagaata tacgttaggt catataccaa gtttgaaaac atgtaaacaa 199440 attgaaataa tatcaagcat cttctctgac caccaaaaaa tgaaaatgga aattaataac 199500 aaaaataatt ctggaaacta tacatataca tagaaattaa ataatatgct cctgaattac 199560 cagtgggtca atgaagaaat taagaggtaa attgaagttt cttaaatgat aatggaaaca 199620 caacatacta aaacccatgg gatacagcaa aagcagtatt aagtaggaag tttatagcta 199680 taagtgccta cattaaaaaa gaggaacaac tccaaataaa taattttatg gtgcatctta 199740 aaaaaactag aaaaatgaga tcaaactgaa cccaaaattc atagaagaaa ataaataata 199800 aagatcagag cagaaataaa tgaaactaaa atgaagaaaa tcaatacaga atatcaataa 199860 aacaaaaagt tggttttttg aaaagctaca caaaatgacg aaactttagc cagagtaagt 199920

aagaaaaagc agagaagatc caaataaata aaagcagaga ttaaaaaggag acattacaac 199980 agatacggca gaaattcaga ggatcgttag tggcgaccat gagaaactat atgtcaataa 200040 attggaaaat ctccaagaaa tgcataaatt cttacccata ccacctacca agtttgcatg 200100 aagatatcca aaacctgaat aaaccaaagg gatgtaacaa gataaaagct gtaataagca 200160 gtctctcagt aaaggaaagc ccaggacctg atggcttcac tgttgaattc taccaaacat 200220 ttaaagagga gctaatacca attttactca aactgttcca aaaaatagag gagaaggaaa 200280 tactttcaac atcattctaa aatgeetgtt ttaccctgat aaccaaaacc ggacaaagac 200340 acataaaaaa ggaaaaacaa aaactacagg ccaaaattct gatggatatt aatatgaaaa 200400 tecteaatga aatactagca aateatatta aacaatacat ttgaaagata atteateatg 200460 accaagtaga atttatcact gggatgcaaa aaggtctcaa catgcacaaa tcagtcaatg 200520 taatacatca tatcaacaga atgaaagcta aaaaccataa gatcatttca attgatgctg 200580 aaaagacatt tgataaaatt caatataatt tcatgttaag aaccctgaaa aaaaactgca 200640 tatagaatga acatatatca acataataaa agccatatgt gtcagaccca catctagtat 200700 catactgaat ggaaaaaaa gtgaaagtct ttatgatctg aaacacaaca aggatgccca 200760 ctttcaccat tgttatatag tgcttgaagt tctagctaga ataatcaagc aagagaaaga 200820 aagggcattt aaattggaat ggaagaagtg aaattatctg tgtttgcaga tgatacaatc 200880 ttctatttgg aaaaacctag agactctacc aaaaaactct cagaactcct aaacaaatta 200940 tttaaagttg caggatacga aatcaacaca caaaaatctg tagcatttat atatgccacc 201000 agtgaacaac ctgaaaaata aattttaaaa attattttat ttacattagc cacacgtaaa 201060 atgaaatacc taggaattaa cttcaccaaa gaagtgaaca atctgtataa tgaaaactaa 201120 aacactgatg aaagaaatta aagaggatgc caaaaaatgg aaatatattc cattttaatg 201180 gattgaaagg attaataatt ttaacatggc cctactaccc aaagcaatct acagattcaa 201240 ttccatctct atcaaagtac caatgagatt cttcacagga atagaaaaac caatcctaaa 201300 atttatatgg aaccacaata gatccagaat agctaacact atcctgtgca aaaagaacaa 201360 aactgaagga atcacattaa ctggcttcaa actatactac agagctgtag taaccaaaac 201420 agcatagtac tggtatcaaa acagactcat agaccaatgg aacaaaatag agaacatatt 201480 tacacatcta gggtgaacta attttcaaca aaagtaccaa gaacatacat tgggacatag 201540 acagtgtctt caataaatgg tgctggggaa actggatatc catatacaga agaatgaaac 201600 tagaccecta tttctctcca tatacataat tcaaatctaa atagaataaa aacttaaatc 201660 taagaccaca aacgtgaaat tgctacaaga aaacattgtg gaaaatttcc aggactttgg 201720 tctgcacaaa aattccttgg gcaatatctt atatcttaca agtgcaggca acctaggcaa 201780

acatggagaa atgagattat gtcaagttaa agagcttctg tgaacagtta ataaattgaa 201840 gagacaactc acaggatggg agaaaatatt tgcaaacaag ctgtggcaca agggattaat 201900 aaccagaata tacaaaaagc tcaaacaaca ctatgagata caaatataat aatctgatca 201960 aaaaatgggt aaaagatttg aatagacttt tctcaaagga agacatacaa atggcaaaca 202020 ggcatatgaa aaggtgctca acatcattga tcatcaggga aatgcaaata taactagaat 202080 gagatatcat ctcaccccag ttaaaatgac ttttatccaa aagacaggca attacaaatg 202140 ctggcgagga tacggagaaa agagaaccct tgtacactgt tggtgggaat ataaactaat 202200 acaaccatag ttcgaaggtt cctcaaaaac ctaaatagag ccaccatgtg atccaacaca 202260 cctactattg ggtatatacc caaaagtaag gaattcatta tattgaaaag acacctgcat 202320 tctcatgttt gttgcaggat tgttcacaat agctaagagt tggaagcaac ctaaatgtcc 202380 accaatagat aaatgaagaa aaaatggggt acatatacac agttgagtac tattcagcca 202440 tgaaaagaat gagatcccgt catttgcaac cacgtggatg ggactggaaa ccattatgct 202500 tagtgaaaca agccaggcac agaaagacaa gcatcacatg ttggcattta tttgggggat 202560 ctaaatatca aaacaattga actattcgac atattcgaaa tatcaaaaca attgaacatc 202620 ctctgaccag aggatgggat gtgtatttag gggttggggg aaatgtggga aaagttatgg 202680 ttataaaaaa tagaaagaat gagtaagacc tactatttga tagcacaaca gagtgacttc 202740 agccaatagt aacttaattg tacatttcaa aataaccaaa aggacattat tggattgttt 202800 gtaacatgaa gaataaattc ttgaagggat gagtacccca ttcttcatga tgtgattatt 202860 ctttattgta tgcatgtacc aaaacatctc atgtactcca taaatacatg cacctactat 202920 gtactcacaa gaattaaaaa taaaacaaaa ttaaaaaagaa aaaagttaaa atgttgagca 202980 ctgtagaaaa tttctgatga ctcagaatgt ttgattgtaa ggagtatgtt ttatttttc 203040 tcaggctgga cattacttca gtatatcttt tcaatatgcc atatatggaa tatacttttg 203100 ggatggcatg gagaacgatt ttcttcaaaa agtgcaggat gaggaccatg gtctttatat 203160 ccctatgact agtccagtgc ttgaaacaga atatgtgctc acttaagagt tgttgagaga 203220 cttgatggtc tttgatagct tacttctgtc taaagcatcc tagttttggg ctaatcctcc 203280 atattaaacc aacagcttta ttcttagggg ctagtattct cccagtggta atagaatcag 203340 aaggaagaac cacgatagtt caaggcagga tagccccacc acacatagtt ttacactgtg 203400 gagttgtaag tctggttggc tggattcata atataaccta aagtttaaag gaatcattaa 203460 gaaaacctag gcaataccat tcaggacata ggcatgggca aggacttcat gtctaaaaca 203520 ccaaacgcat tggcaacaaa agccaaaatt gacaaatggg atctaattaa actaaagagc 203580 ttctgcacag caaaagaaac taccatcaga gtgaacaggc aacctacaga atgggagaaa 203640

atttttgcaa cctactcatc tgacaaaggg ctaatatcca gaatctacaa agaactcaaa 203700 caaatttaca agaaaaaaac aaacaactcc atcaaaaagt gggcaaagga tatgaacaga 203760 cactteteca aagaagacat ttatgcagee aaaaaacaca tgaaaaaatg etcateatea 203820 ctggccatca gagaaatgca aatcaaaacc acaatgagat accatctcac accagttaga 203880 atggcgatca ttaaaaagtc aggaaacaac aggtgccgga gaggatgtgg agaaatagga 203940 acacttttac actgttgatg ggactgtaaa ctagttcaac catcgtggaa gtcagtgtgg 204000 caattcctca gggatctaga actagaaatc ccatttgacc cagccatccc attactgggt 204060 atatacccaa aggattagaa agcatgctgc tataaagaca catgcacacg tatgtttatt 204120 gcagcactat tcacaatagc aaagacttgg aaccaaccca aatgtccaac aacgatagac 204180 tggattaaga aaatgtggca catatacacc atggaatact atgcagccat aaaaaaatga 204240 tgacttcatg tcctttgtag ggacatggat gaaactggaa agcatcattc tcagcaaact 204300 atcacaagga caaaaaacca aacaccgcat gttctcactc ataggtggga attgaacaat 204360 gagaacacat ggacacagga aggggaacat cacacaccgg gggctgttgt ggggtcgggg 204420 gagacgggag ggatagcatt aggagatata cctaatacta aatgacgagt taatgggtgc 204480 agcacaccaa catggcacat gtatacatat gtaacaaacc tgcacgttgt gcacatgtac 204540 cctaaaactt aaagtataat aataataaaa tttttaaaaa gtgaggatta tagaatcata 204600 ccacceagge tggagtgcat tggccccatc tcagctcact gcaaccccca cctcctgggt 204720 tcaagcaatt ctcgttcttc agtttcctga gtagctggga ctctagggat gtgccaccat 204780 gcttgtctaa tttttggaat ttttagtaga gatggggttt tgccatattg cccaggctgg 204840 tetegaacte etaageteag geaatetget egeeteaget teecaaagtg etgggattac 204900 agctgtgagc cactgtgccc ggcctcatag catattttta aaaaatgaca ttggttgttc 204960 caattgactc atgctacagc tgagggatct gaagcctaca gaaggtacgc agtttaccca 205020 gagtaccaga aagaatatga gatgtagggc agcttgaact tggtttgaac actgtttcac 205080 aattactgtg ttattgagct tctctgagcc tcaatttcct tatcagtaaa tcagacccgc 205140 atgatgatat ctacctcctt ggactgctgt gagtattgca tctctgctga acatcttccc 205200 tetgeettte cagatecaet caccaccatt etteacetgt getgteetga gaggetattt 205260 aggaaggatt ctctcaatgg gctcctggac tctggtgtcc actgggtttg gctaatgaaa 205320 agccccaagg agagttggag gtgggaggga gaaaggaagg agagtgaggg ctgtggacct 205380 atteceetgg etceatecet gtgagteace ttgagetgga tgagtetett ggtggaggte 205440 actgtacttc tgaagacagc aattttctca tgattattga tttttccaga ttctagtaac 205500

cactteetee etgeteteat teetttgggt teggagttat ggeagetget actageacaa 205560 tetetgaegt tececetgea tetacetgtt tatagatggt ceetttgeag acaaatattt 205620 gtcaaatatc ccattttgga tgtatcatct gtttgaccta gatactatgt gcttagagca 205680 gagcctgaca tataataggt tcttggtgta tagaatctat ggctagtagt agtattaata 205740 . ttagtgtaga ggtagtggtg gttgcagtgg aggtaatcgt gctggtattt ttcaaagcca 205800 ctcattcagt cacacgtaaa gccagtagta ggatgtattt ctctttcata ctcaactctt 205860 teteaatgat tgetttteaa etgtetgtge teeagaggga aatataeggt tggettetaa 205920 caccttgctc tttgtggcca tggaatgctg cacatcccaa gcagatccta tcctgtgtct 205980 ggtactttgt gtggtgttta aacctacctt agataaaaat tgtaacaaaa atcattaaga 206040 atgcagttga gggttattat tataactaaa ctaatgtcag tctgtaatat cacttgtaca 206100 aaggetcaaa aacaagagt gaaaaggttt aaaggagtee etggttetga eeetgggtee 206160 atctctgact tacagcatga tatgggagag tcactttgag tagttcctca acctgatatg 206220 aaaaagaaga atattettaa aaactgaaca cataagaaat ttaaaaaaaa atcaatacaa 206280 tgaactcgtt gtacactgat gacctttaat tctttattat tcattttagt ggaaaatata 206340 acataatcac taagtttttc aataggagtt attttataaa gtaagttgta atctttcaat 206400 agaaatatgc cactgaatgt gttcctaaca ttttgatgaa ttttcactgg atagtgatat 206460 acccatcaaa atattttttg taaacaaatt tagaaaacaa tcataaaagg taataaggta 206520 attgaaagct gttattttca gcaattttaa tcaatttttg acctacccta tttgatacgg 206580 catggctgtt ggttcttgct tgttttgttt tgttttgttt tgttttttat gacacgacag 206640 tttgatgttc tcactgttaa ttgcaggcaa aagtccaaaa gaaataaata cttagatgtt 206700 agtttgtaag aatttactaa atggagttgt taatctgtag acaacatctg gaattcacta 206760 aggaaaaaaa atgtatacaa ggttcgcttg gtttgttagt gtttagatgg cagtcatggg 206820 agtgctataa attatttgtt tctggagggt cagcagcgta ttttgctagg cttttattga 206880 ttttatggtg tatgaagtaa agatatgtga gcttgacgaa caccggaaca aaaatccagg 206940 gtctacttca cttttgttct atttttaaat ttttttttc cgttattgcg ttttgtgact 207000 tcctatagag aatggacaag tgtcaaccta tgggaggaat ctagggccat gccttcttta 207060 tetttggece tetetettat tetettttaa aacattttta getttttatt ttgaaacaat 207120 tataagttca caagaagttt caaagatatg tacatggagg ccttatgtac ccttcaacca 207180 gcctctccca atggtaaaat cttcagtaca ctaccacatt acactatcaa aactagaaca 207240 ttgacagtga tgcaatccag agctttttaa gattcaacac ttttcttttg gctgttctag 207300 gcactttaca tttccatatg actattataa ttatcttgtc aatttctatt aaaaatcctt 207360

tttagaattt tgattagaat tgagttgaac ttacagatga atttggaata actgccactt 207420 tacaatattg aatcttccaa ccgaaaatca aagtatacat ctggattttt gatgtcatta 207480 acttatcatt gcaatttttt tgtagtttta agtgtacaag tcatttacat ctttggtcag 207540 atttatecet aagaetttaa tatttttagt gatattttaa attgeaetgt tettagttte 207600 aactttcatt tgttgaaatt aacttccagt ccaccctagg actaccatta gctgaaacac 207660 tgcctcttct aatatataaa catacaattg atttgtgtat tgatctctta ctctgcaatc 207720 ttgctaacct caattattgt agaagctttt ttatagattg acttttctac atatactttc 207780 atgtagtctt tgacaaaaga cacttttact tctccccttc caaactcaat gcatttttct 207840 ttttgcactg gacacaatct ccagtacaaa gtataactat gcccatactg gtgcacatgt 207900 gggtcttaga ttgtagcatc ctgcatgtaa acactgagaa caacttccag cacttgaata 207960 tccactcctt ccccaccca catactggga gaattcatgt tgggagacta catttactat 208020 gaacatacac ccctcatttg aaacaagact aggatacaca gtaaagaatg tttattcact 208080 aaaattttga cagactgaag gccattattg cagattggaa ataggaaatt taaaagaact 208140 acacggacat tgagtaaaat aacatgggtt gaaatttgcc tggcagtagc ctaaaagtaa 208200 atggtcttca aggtgcatat gaaggaactg taggagggaa atgggataat taattattaa 208260 ttattaaatg taactagtaa ttaataacta ataattaaat gtagccacac tagcttggag 208320 ggatttgagg tgagacatct aagatactaa gtcatggtga gggctggaag acaaaagaat 208380 gaatcacttc ataggaatga ctgcggggaa gggcttgaag gaatcatcct ctcgcttcca 208440 tgtgaaccgt gaacattaaa catggagaaa tgaggagtgg tggcagatca gtttgggatg 208500 catcttcagg ggatgctgaa acaacaacag catttggttt cctctacatc cctgtcaccc 208560 ctcccccaca agcccaggga gtggtcagca gtggtgcttt gtgatgtcaa agccacctta 208620 ggaccgccat tggctgggac actgcctgta tgatcaaaca aagctcaagg gtgtggcttt 208680 gccttgtcac caggagggta tatataggga gggcaagagc tctgggacat cccactggga 208740 agcttcaaca tagctgtgga agtctgcagt ctacaggagc ctactataga cattctacaa 208800 ccaaccagaa tcatggaaca gccaacttcc agcaccaatg gggagaagac gaagagcccc 208860 tgtgaatcca ataacaaaaa aaatgatgag gtaagattgt caggttttga agggaaggtg 208920 agggtgaaag aaagacacac agagaggggg tggctcaaac agcaacacag gaatactgca 208980 gacacetgtg gaagtggggg accegettaa tgecagagee cacegeeget tacaggetgg 209040 ggtgcttgta ggtaggggtg ggaggggcct gggcagtatg gcttgctgcc cggcaggata 209100 ttgataagat gtttttatga tcaggctgtt tggtcctttt tccagtggga tgtcattgtg 209160 gtgtatcttg gaactttgcc cagcaagata tgataggaaa gtttctttag ttggaccttt 209220

gtccgtcttg tgttacgacg attaggcaag atttttctca tggcccgaac ccccgtggaa 209280 tgtttcactt tgaccaaggt ctgaaaaata gcagggtgct tactaaatgg tggtttggac 209340 tcacattctt gccttctact ttagtataaa aggaagaggg gcattgttga ttatctggct 209400 getteetgee gaatagggga getgtaatca gggtttgggt tttgaageag tgggtgttgg 209460 acttcagagt tgttttcctg gaggcactgg tactggactt ggcagaggag aaggatggta 209520 tcaatgtgtt gctgggtggc cgcctggaca ggggagttta gccttcggga gataaagcgg 209580 gatatgaagg taaatataca tgggccaatt gtagtattag gaggaggaaa attaagggtc 209640 ctaagaaagg ggcccctgc tatctcagtg ctgactgcag cagagatgtt tacttctgct 209700 aacactagaa tgagatgtag agcctgctta gtgtgtgtgg aggaagatga gacagaagct 209760 actaaaggaa cctggatggt ctgcttgtta ggcaaaatgt taatgtttag gctgaaacac 209820 cagggtgtat gttcctgacc atttggccag taggcagaga taagagtttg tggcacaaaa 209880 gaagaagaca ctgggggtgg acagacaaaa gttgtaggtt atggtggcaa gccatgagaa 209940 ggtgggtgtt gaattctgca gaaattcttt gttttaactt ttatattttt ccaagttgaa 210000 tagetgecag caagggtage ecetetgacg geetgatagg aaatgttggt ggtggaggag 210060 atggaggctg tttggttttg gagagagaga gataaatggg tttttgtaac taatagccat 210120 tgtagccctg acagggcaga aggatatagg ttgcacttga gggaattgtt tgtgcatgtt 210180 tttctaaaag gtgttttatg gaatccgttt gtaacatatt cagttaagag gctatgaggc 210300 gagggagggt gacagccctg tatgtgatgg tgtgggtgga tttgatggat tggggggaaaa 210360 agagtttagc tgatcaagat tataaacagg tttgggaatg aactggtcaa gtaggtgaga 210420 tgcaggttta ttttggaccg agttcatgtg gccaggttga caggaagggc tgtgaattgc 210480 tggatttgtg tggacaaaca agtttaacag ttggaaggaa gaggggagtg tgactgattt 210540 aagaggaaag gtgtgaggct gatgaagggg gctcaactgt cagaggttgg gggtggggac 210600 ttagagtatc ccacagacaa agaggacaaa agaagaaaga ggagatttga gtaggagtga 210660 aattttggaa ggtgccctgc agtcatacct cctggattag tatgacgaat tggcatggac 210720 tattcaggga catggggaag ggtagccagg aaagatctga aataaagtag gagataaaag 210780 attggaaatt ggagacagag agtgttatgg actaaggtgt tctggattgg caacttctgg 210840 aattottgtt aagtacagtg aggttggtoc tgtoggggaa ggagaataat atgggggtga 210900 ggaaatttct agatgtgggt ctggtgctct ttttagtttg gaatggtgta ttcagtgtgg 210960 aaaggatgtt agctttgccc cagtcggagt agttaggata acctggtggg aacatttccg 211020 cttaggttgg agaggggagg aggaggagtc tgtgattcag acccagtccc ctggttgtag 211080

ggacagggag gagtgttttg aggatggact tttaggctgg gtcaagtaag catttgcgta 211140 ctgtcttatt agatgttggg tgaggtgtaa cgccggccaa gtattccata tagaatgggg 211200 ggaaaataca gggagattct ggaggataaa agggcatttg tacatgagtt taaatgggct 211260 taggctgagg agcttttggg aaatgactca taaatgcatg aggaacaatg ggagaagtga 211320 agtecaggee attttaacet ttagggaaga ttggtcagtt getgttttet aaaaaagttt 211380 ccctgaagat tcggggtggt aaggaatatg caaagccaat ttaatgttta cagcctttac 211440 cagctgttgg ttaaactgtg aaacaaattg gcccgttgtc tgactggatg caagagggga 211500 gtttaaaccg gtggataata tgggtgaaga gaatagaagc aatggtgtgt gccttttcgg 211560 tggtggtggg aaaagctttt atccatccag agaatgtatc tactattgtc agaaggtata 211620 ggaatcactt tctgggggac atgtgagtga cgttgatttg ctagtcctgc cctggtaagt 211680 gtcctcagac cttgtgtgtt ggaaaggagg tggtttgata gcttcctgag gggaagtttg 211740 agtgcaaagg gaacatgcct tagtaatata tttcagattg gcagccatgg cagaagaatg 211800 tatataattt tctaaaagct ggagtagggg cagtaagcag catggaaatg gttgtgcaca 211860 tatgaaagta cagaaggttt tttaaacttg gacaagacac tttatcactg agatcaaaca 211920 attttttcct gaatggcgcc agcccgggca agtggggttc attccttctg ggtatataca 211980 ggaaaaaatg agcaataacg atggggtttt aagggctgcc tgccaggctg ccaaatttgt 212040 tgaaaggttt ctctcggtta tggcatcttt agactttcgg caccccttgc aatggataat 212100 ggtggccttt ggtggtagtt tatccaccc cagcagctta tgtataagtt tgccatttct 212160 tatgggagtt ccttttgtag ttaggaaacc ctgttcctgc cagatgaagg catgagactg 212220 taggacatgg tatgcatatt tggaatgggt gtaaatgttg accetettte cetttgetag 212280 ggtgagggcc ctggttaggg caactagctt aggctgttga gaggtagcat ggggtggcag 212340 agcattggat tctaggagtt tattttcagc aatgatggaa tagccagctg ctggacatgg 212400 ctccctaaaa gagcttccat taactaaccg tgtatgtgtt ccctgcaaag gggcatgtga 212460 aatgtgttgg aaggaggagg agagggagtc taagaggtcc agacaggagt gagagagcct 212520 agaatcggaa gtgtttacag ggaggagggt ggctgggttg agagttttat atctctggaa 212580 ggggattaga tggctaccta ggaataaggc atgtacctgt tataagcagg atggtaggag 212640 ggatagaagg gattgatggt ttatgaggtc ctgtaggtaa tgggaagatg caatagtaat 212700 gtgttggtaa agagggagtt tccgtgcctc taaggccagc gatgtggcca cagccaagat 212760 ttttagtcag agtgaccagc cttggtcaca caaaacaaca gagtccagtt gttttgagag 212820 aagtgcagtg gcttgtgtgg cgttgccgta tgtttggcag agtagtccaa gggcaaggcc 212880 ctggtcagaa tgtacataca aagtaacggg cttggtgagg ttgggcagtc cctgtgccag 212940

ggccattaaa agggcatttt taagttttta agtgggagtt gatggggcaa gctgggttta 213000 ggggttttag gatgggccca tgtgaggccc tgtttagtgg cttggccagc aagtcaaaat 213060 tgggaactga cagccagaag taacccacaa ggccagagaa ggagagaagg tacttttttg 213120 tgtgaggaaa gggcatgtcc caaattagct cctttcattg ggttgggatg gctcgagaat 213180 taggggttag gacaaaccca aggtaagtaa ctttggtttg ggctacctga aatattgtgg 213240 gctaggccca aactttggtt tgggctacct gagatttcct ctattatgga ggaagtttaa 213300 aacctaagtg gtgtgttgga tggacaggtt aaggaagggg ctacagagaa ggagtttgac 213360 atgttgcagg agggtgctag cagcaaggga aagttcacct aggtccttga tgagggcaag 213420 tctgaatagg tgggggctat cctggaaccc ctgtaagagt acagtccact ctagttgggt 213480 gcacatgtga gtattaggac ttgaccaagt taaagcaaaa agacttctgt aagccggatt 213540 taagggaatg gtgaaatagg catctttcag ttccaataca gaggagtgtg tagtagattt 213600 aggaatatgg gagagtagag catattggtt gaggaccact agatgtattg gtaccactgc 213660 ctggtcaaca acttggagat cctggacaaa ggggtaagtc ccgtctgtct tttggaaagc 213720 cagaataggg gtgttctggg gagagttaac aggcttgaga atatgagctt gttaaagttt 213780 acaaataata ggtttgaggc ccctaagcac ggctggatta aggggatatt gagactgaaa 213840 gggtttagaa acattccaag ctttagaatt aacagaaggt aacagggtgg ataatgagga 213960 tgagtagggg gagagggaag cgtttgggtg tcggagtaaa ataaaagggg tagaattgta 214020 ggagccgcat tgcatggagg cctggaattt acttaatatg tcccaccca agataggggt 214080 aggggactga gggataacca ggaaacagtg ggtgaagggg gctgttgaat aggttgcata 214140 ataaaggacg agtctgtgcc tagaggggat tttattgatt ctcacaatag agatcgaaga 214200 acagaaaaag ggtctagaat attctggtaa aaccgagtaa ctagttgtcg tattgagtat 214260 ccaataggaa agacatggac ttactagaga ctgacagaat taccctgggt tccgaggtgg 214320 tgatggcagt aggggtggtg gactctaggc cccacctgtc ttcaggtaca ggtggtgaag 214380 ctagatgaag agtttcactg agcacagtct gacttccagt gttgcttgat atcacagatg 214440 gggcaagget tecagagtgt caegggatta ggccaggett ttgeteagtg tecetgttgg 214500 atgcacttat aacaggctcc tggagttgac tgttgccaag ttgaggaatt ctgtatgcct 214560 tgggaaccct gttgagtggc agctatcagc atttgatatt tagcctggcc cttttttagg 214620 tttgggtttt ttagttcttc ctctctaatc ttatagacct taaaggccac tttgattaag 214680 tctctttgga ggtttgaggg ccatcctcca ctttttaaag tttttttca aatgtctggg 214740 gctgactggg agataaagtg taaatggagg tcgattttgc ccttaatggt attagggctt 214800

aaggtggcat atttagttgt gacctttgaa aaggcgggag aggaaaagag caggggcgac 214860 tttatttatg ccagctagaa ggcatgatat catatggcct ggtttctgcc tgtctacaga 214920 agttgcctga taattccgat tgaggtcagt tctggggaca gctagggtcc ctactgggtt 214980 atgagcagca tettgttggt ggagggtgtt eteatgggee tgggeaceeg taaatatgtg 215040 ttccctgtcc tccagggtga gggtagagga gaggatgaca tatatgtcat gccaggtaag 215100 gtcataagat ttagggaagt acagacattc cttgaggaag gaggtaggat ccattgaaaa 215160 ggagcaaagt ctcttttcag tatgggagaa gtcagctagg gaacttgaat tcagattatg 215220 ccttcagtcc ttgcaacctc ctgcaaggga aagactttgg aaggcctttg ggcatgtgtc 215280 tggttttcgg caaaagaggg ttgggcgtga gacctggttt gaggtggaga aggaaggggg 215340 atggagggtg acagtgaggg ggtggaggag ccggatccga aggagaaggt ggagggaatg 215400 ggagagggca ggagccagac gaaggggttt gttggccagg ttgaaattca gaggaggaag 215460 gettgteeeg aggaggagge attttggggg gttteteett gaggaggaag atttgaaaag 215520 gcgaacaaga ttggcaggag agtgagtgag gcatgagcgg agataagcaa agcacttcag 215580 atcatttacc attgtgttgg agaaagattt ttagatgatg ttgaatttga aagttgaatg 215640 ttttgttttt tagaagaggg gagtgaatac tctggatggg agtgaatact ctgggggaaag 215700 tgagtacccc agaagggagt gaatacccca gaggggagtg agttctccag agggaagtga 215760 ataccccaga ggaaagtgag tactggattc cacctgggag aagggacctg gagagttggg 215820 gcagccccgt agctattcat gctccccaga ggacggagcg gccagaatgg caagtgttct 215880 gaggetgtee cetgagaagg gaggetgeag teacetggtg actggggaga ceteteacee 215940 agcactggaa tttttttgga gaacaagcag aaatagaaag gaatccagaa aggaagaata 216000 gggagactca cccacgaatt gaagcccagt gttggatgtg atgtccagca atgggggtga 216060 tcctggttgc agctgcttgg gaagggaag gaaggaaaaa taagatggag agtttgatca 216120 atatctggag gttagtccag ggctggagaa gatgagagaa taggggaaac aggactggga 216180 216215 acagacagtc cactcaggat ctggaagtag gcccc

<sup>&</sup>lt;210> 26

<sup>&</sup>lt;211> 4220

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Homo sapiens

<sup>&</sup>lt;400> 26
ctgatggatt tgcattcagg ttccagccct gcgtttccta tattgactcc ttatacacga 60
cctggcgctc cagtttagga ggagacgttg ttttgtaatc aaccacgaac gatgaaacct 120
tccatagctg agatgcttca cagaggaagg atgttgtgga taattcttct aagcacaatt 180

gctctaggat	ggactacccc	gattccccta	atagaggact	cagaggaaat	agatgagccc	240
tgttttgatc	catgctactg	tgaagttaaa	gaaagcctct	ttcatataca	ttgtgacagt	300
aaaggattta	caaatattag	tcagattacc	gagttctggt	caagaccttt	taaactgtat	360
ctgcagagga	attctatgag	gaaattatat	accaacagtt	ttcttcattt	gaataatgct	420
gtgtctatta	atcttgggaa	caatgcattg	caggacattc	agactggagc	tttcaatggt	480
cttaagattt	taaagagact	atatctacat	gaaaacaaac	tagatgtctt	cagaaatgac	540
accttccttg	gcttggaaag	tctagaatat	ctgcaggcag	attacaatgt	cattaaacgt	600
attgagagtg	gggcatttcg	gaacctaagt	aaattgaggg	ttctgatttt	aaatgataat	660
ctcatcccca	tgcttccaac	caatttattt	aaggctgtct	ctttaaccca	tttggaccta	720
cgtggaaata	ggttaaaggt	tctttttac	cgaggaatgc	tagatcacat	tggcagaagc	780
ctgatggagc	tccagctgga	agaaaaccct	tggaactgta	catgtgaaat	tgtacaactg	840
aagagttggc	tggaacgcat	tccttatact	gccctggtgg	gagacattac	ctgtgagacc	900
cctttccact	tccatggaaa	ggacctacga	gaaatcagga	agacagaact	ctgtcccttg	960
ttgtctgact	ctgaggtaga	ggctagtttg	ggaattccac	attcgtcatc	aagtaaggag	1020
aatgcatggc	: caactaagcc	ttcctcaatg	ctatcctctg	ttcattttac	tgcttcttct	1080
gtcgaataca	agtcctcaaa	taaacagcct	aagcccacca	aacagcctcg	aacaccaagg	1140
ccaccctcca	cctcccaage	tttatatcct	ggtccaaacc	agcctcccat	tgctccttat	1200
cagaccagac	caccaatccc	cattatatgc	cccactgggt	gtacctgtaa	tttgcacatc	1260
aatgaccttg	g gcttgactgt	caactgcaaa	gagcgaggat	ttaataacat	ttctgaactt	1320
cttccaagg	ccttgaatgo	caagaaactg	tatctgagta	gcaatctgat	: tcagaaaata	1380
taccgttctg	g atttttggaa	tttttcttcc	ttggatctct	tgcatctggg	gaacaatcgt	1440
atttcctate	g tccaagatgg	ggcctttatc	aacttgccca	acttaaagag	cetetteett	1500
aatggcaac	g atatagagaa	gctgacacca	ggcatgttcc	gaggcctaca	gagtttgcac	1560
tacttgtact	t ttgagttcaa	tgtcatccgg	gaaatccago	ctgcagcctt	cagcctcatg	1620
cccaacttg	a agctgctatt	cctcaataat	: aacttactga	ggactctgco	c aacagacgcc	1680
tttgctggc	a catecetgge	c ccggctcaac	ctgaggaaga	a actacttcct	ctatcttccc	1740
gtggctggt	g tcctggaac	a cttgaatgco	attgtccaga	a tagacctcaa	a tgagaatcct	1800
tgggactgc	a cctgtgacct	t ggtccccttt	aaacagtgga	a tcgaaacca	t cageteagte	1860
agtgtggtt	g gtgatgtgc	t ttgcaggago	c cctgagaaco	c tcacgcacc	g tgatgtgcgc	1920
actattgag	c tggaagttc	t ttgcccagag	g atgctgcac	g ttgcaccag	c tggagaatcc	1980
ccagcccag	c ctggagatt	c tcaccttati	t ggggcaccaa	a ccagtgcate	c accttatgag	2040

ttttctcctc	ctgggggccc	tgtgccactt	tctgtgttaa	ttctcagcct	gctggttctg	2100
tttttctcag	cagtctttgt	tgctgcaggc	ctctttgcct	acgtgctccg	aaggcgtcga	2160
aagaagctgc	ccttcagaag	caagcggcag	gaaggtgtgg	accttactgg	catccaaatg	2220
caatgccaca	ggctgtttga	ggatggtgga	ggtggtggtg	gcggaagtgg	gggtggtggt	2280
cgaccaactc	tttcctctcc	agagaaggcc	cctcccgtgg	gtcatgtgta	tgagtacatc	2340
ccccacccgg	ttacccaaat	gtgcaacaac	cccatctaca	agcctcgtga	ggaggaggag	2400
gtggctgttt	catcagccca	agaagcaggg	agtgcagaac	gtgggggtcc	agggacacaa	2460
ccaccgggaa	tgggtgaggc	tctcctagga	agtgagcagt	ttgctgagac	acccaaggag	2520
aaccatagta	actaccggac	cttgctggaa	aaagagaagg	agtgggccct	agcagtgtcc	2580
agctcccagc	ttaacaccat	agtgacggtg	aatcaccatc	accctcacca	cccagcagtt	2640
ggtggggttt	caggagtagt	tgggggaact	gggggagact	tggcagggtt	ccgccaccat	2700
gagaaaaatg	gtggggtggt	gctgtttcct	cctgggggag	gctgtggtag	tggcagtatg	2760
ctactagatc	gagagaggcc	acagcctgcc	ccctgcacag	tgggatttgt	ggactgtctc	2820
tatggaacag	tgcccaaatt	aaaggaactg	cacgtgcacc	ctcctggcat	gcaataccca	2880
gacttacago	aggatgccag	gctcaaagaa	accettetet	tctcggctga	aaagggcttc	2940
acagaccacc	aaacccaaaa	aagtgattac	ctcgagttaa	gggccaaact	tcaaaccaag	3000
ccggattacc	tcgaagtcct	ggagaagaca	acatacaggt	tctaacagag	agaagaaaat	3060
atattagtgo	ttttttt	tcaaaagaaa	aggaaaataa	aagaaatata	tcccttgctc	3120
cctttacact	tgtcccagta	actccatcct	cacgatcttt	cctaccctga	acaaaactaa	3180
aaccgcatga	taactagaga	atacagatgt	atgctctccc	ctctcagatg	cgatttggag	3240
gaagggccat	: actcagatca	ttaatcaatg	aaagtgcctt	cgcagacttt	tgccagcaaa	3300
tgttatcatt	attttttat	actgaaactt	gagactttga	ctgtgccatg	tataagatat	3360
actggggato	: attgtatgga	tcctaattaa	gtaaaattca	atgtgtcttt	ttattttcag	3420
taactattt	tttatagtt	gtagttttga	tttaaagggg	gggaaacaag	ttgacatttg	3480
tcatttgtgg	g ctttctttct	tatcatcatg	gcacagatto	tgtacatgta	ttaacaatgc	3540
agtttgctg	e atgeetggaa	actgcaagat	ggggagggag	ggggcgggtc	: ttgctcgaat	3600
gttctcacto	c actatcttgt	ctctcataca	catatccato	tgcagaccat	ggtccctaaa	3660
cctgcagtt	t cttcctgctg	gtgcaggtac	acacacacac	acacacaca	acacacacac	3720
acacacaca	c tecataceat	ttccattcaa	ctcaatctgo	: ttagttcggg	g tttgatccat	3780
ttttctcct	c tccatagtto	taccaccctt	cactgctagt	gtacagctca	a cagcatetet	3840
cctaccacc	c tgggaaaagt	cacattctag	gctggattct	actgaagtag	g aggcctggtg	3900

gtttaacagc	cgaagacaca	cgcctaggga	tgagcaccct	ctttgtgaca	cttcatcctg	3960
atgccaagat	tttttggaga	acatctgcac	tttcttatat	atatataa	tattaaaaaa	4020
agcaactggg	tatatatcac	taacagcttt	gtaggaagca	cttttaatgt	tttctctctc	4080
acacacaaag	attcaaaaga	aatgtgcata	tatttattct	gtaatttcag	tgattataaa	4140
ttgtaaaggt	aatgtttaat	cattgtatag	tgattatgcc	tctggtatag	ctttcctaat	4200
aaaaagtttt	tgaaaaacat					4220

<210> 27

<211> 3122

<212> DNA

<213> Homo sapiens

<400> 27

egetgeggee getateeect eeggaecatg geegaegaeg aegtgetgtt egaggatgtg 60 tacgagetgt gegaggtgat eggaaagggt ceetteagtg ttgtacgaeg atgtateaac 120 agagaaactg ggcaacaatt tgctgtaaaa attgttgatg tagccaagtt cacatcaagt 180 ccagggttaa gtacagaaga tctaaagcgg gaagccagta tctgtcatat gctgaaacat 240 ccacacatty tagagttatt ggagacatat agctcagatg gaatgcttta catggttttc 300 gaatttatgg atggagcaga tctgtgtttt gaaatcgtaa agcgagctga cgctggtttt 360 gtgtacagtg aagctgtagc cagccattat atgagacaga tactggaagc tctacgctac 420 tgccatgata ataacataat tcacagggat gtgaagcccc actgtgttct ccttgcctca 480 aaagaaaact cggcacctgt taaacttgga ggctttgggg tagctattca attaggggag 540 totggacttg tagotggagg acgtgttgga acacctcatt ttatggcacc agaagtggtc 600 aaaagagagc cttacggaaa gcctgtagac gtctgggggt gcggtgtgat cctttttatc 660 ctgctcagtg gttgtttgcc tttttacgga accaaggaaa gattgtttga aggcattatt 720 aaaggaaaat ataagatgaa tccaaggcag tggagccata tctctgaaag tgccaaagac 780 ctagtacgtc gcatgctgat gctggatcca gctgaaagga tcactgttta tgaagcactg 840 aatcacccat ggcttaagga gcgggatcgt tacgcctaca agattcatct tccagaaaca 900 gtagagcagc tgaggaaatt caatgcaagg aggaaactaa agggtgcagt actagccgct 960 gtgtcaagtc acaaattcaa ctcattctat ggggatcccc ctgaagagtt accagatttc 1020 tecgaagace ctaceteete agggetteta geageagaaa gageagtete acaggtgetg 1080 gacagcctgg aagagattca tgcgcttaca gactgcagtg aaaaggacct agattttcta 1140 cacagtgttt tccaggatca gcatcttcac acactactag atctgtatga caaaattaac 1200 acaaagtett caccacaaat caggaateet ccaagegatg cagtacagag agecaaagag 1260 gtattggaag aaatttcatg ttaccctgag aataacgacg caaaggaact aaagcgtatt 1320

ttaacacaac	ctcatttcat	ggccttactt	cagactcacg	acgtagtggc	acatgaagtt	1380
tacagtgatg	aagcattgag	ggtcacacct	cctcccacct	ctccctattt	aaacggcgat	1440
tctccagaaa	gtgctaacgg	aggcatggat	atggagaatg	tgaccagagt	teggetggta	1500
cagtttcaaa	agaacacaga	tgaaccaatg	ggaatcactt	taaaaatgaa	tgaactaaat	1560
cattgtattg	ttgcaagaat	tatgcatggg	ggcatgattc	acaggcaagg	tacacttcat	1620
gttggtgatg	aaattcgaga	aatcaatggc	atcagtgtgg	ctaaccaaac	agtggaacaa	1680
ctgcaaaaaa	tgcttaggga	aatgcggggg	agtattacct	tcaagattgt	gccaagttac	1740
cgcactcagt	cttcgtcctg	tgagagagat	tccccttcca	cttccagaca	gtccccagct	1800
aatggtcata	gcagcactaa	caattctgtt	tcggacttgc	catcaactac	ccaaccaaaa	1860
ggacgacaga	tctatgtaag	agcacaattt	gaatatgatc	cagccaagga	tgacctcatc	1920
ccctgtaaag	aagctggcat	tcgattcaga	gttggtgaca	tcatccagat	tattagtaag	1980
gatgatcata	attggtggca	gggtaaactg	gaaaactcca	aaaatggaac	tgcaggtctc	2040
attccttctt	ctgaacttca	ggaatggcga	gtagcttgca	ttgccatgga	gaagaccaaa	2100
caggagcagc	aggccagctg	tacttggttt	ggcaagaaaa	agaagcagta	caaagataaa	2160
tatttggcaa	agcacaatgc	agatcttgtc	acatatgaag	aagtagtaaa	actgccagca	2220
ttcaagagga	aaacactagt	cttattaggc	gcacatggtg	ttgggagaag	acacataaaa	2280
aacactctca	tcacaaagca	cccagaccgg	tttgcgtacc	ctattccaca	tacaaccaga	2340
cctccaaaga	gagacgaaga	aaatggaaag	aattattact	ttgtatctca	tgaccaaatg	2400
atgcaagaca	tctctaataa	cgagtacttg	gagtacggca	gccacgagga	tgcgatgtat	2460
gggacaaaac	: tggagaccat	ccggaagatc	cacgagcagg	ggctgattgc	aatactggac	2520
gtggagcctc	: aggcactgaa	. ggtcctgaga	actgcagagt	ttgctccttt	tgttgttttc	2580
attgctgcac	caactattac	tccaggttta	aatgaggatg	aatctcttca	gcgtctgcag	2640
aaggagtctg	g acatcttaca	gagaacatat	gcacactact	tegateteac	: aattatcaac	2700
aatgaaattg	g atgagacaat	cagacatctg	gaggaagctg	ttgagctcgt	gtgcacagcc	2760
ccacagtggg	g tecetgtete	ctgggtctat	taggcctctc	cccagatato	: tgagcataac	2820
tgggagcaco	tcatttgtgg	g aaaagcctct	ttgttatcgg	ccttgtgtca	a gcaggtcatg	2880
gtccctagag	g actacctagt	tgtagtgtga	cctacattta	taattattgt	catgtccgaa	2940
tagataggag	g gagaaaaaca	attacacact	: aatttaaaga	gacagtatct	tttttaatca	3000
gttctcctaa	a actttaataa	a aatgtatctt	: taaatgtatg	tattattca	a tcctttggaa	3060
tgttatatt	t ttggaaatc	a tagcttttta	tttccaaggo	ccctaaaact	gcacaaaata	3120
ga						3122

<210> 28 <211> 3753 <212> DNA <213> Homo sapiens

<400> 28 60 ggcttggcac cagcgctgtc actagcgccg cctgctcccg cgggcccgcg gacccagctg 120 tcaggcaagc ccagtggagc aaaatgagag cgcagtgagc cgggcccagc ttctctccta 180 gccgttccga ctcccaccat gaaccacttg gaggggtctg cggaggtgga ggtgaccgac 240 gaggcggcag gtggggaggt gaacgagtcg gtggaggccg acctggagca ccccgaggtg 300 gaagaggaac agcagcagcc gccgcagcag cagcactatg tgggccgcca ccagcgcggg 360 cgageceteg aggacetecg egeceagete ggeeaggagg aagaggageg eggggaatge 420 ctggcgcgct cagccagcac ggagagcggc ttccacaacc acacggacac cgccgagggc 480 gacgtgatcg ccgcggcccg cgacggctac gatgcggagc gcgcgcagga ccccgaggac 540 gagagegeet atgetgtgea gtaceggeee gaggeegagg agtacaegga geaggeagag 600 geogageacg ecgaggeeac geacegeege gegetgeeca accacetgea ettecacteg 660 A top of the second ctggagcacg aggaagccat gaatgcggcc tactcaggct acgtctacac gcaccggctc 720 ttccaccgcg gtgaggacga gccctactcc gagccctatg ccgactacgg cggcctccag 780 gagcacgtgt acgaggagat aggggacgcg cccgagctgc acgcacgcga cggtctgcgg 840 ctctacgagc aggagcgcga cgaggcggcc gcgtaccgcc aggaggccct gggcgcgcgg 900 ctgcaccatt acgacgagcg ctccgacggc gagtccgaca gccccgagaa ggaggccgag 960 ttcgcgccct acccgcgcat ggacagctac gagcaggagg aggacatcga ccagatagtg 1020 gccgaggtga agcagagcat gagctcgcag agcctcgaca aggcagccga ggacatgcct 1080 gaggccgagc aggacctgga gcgtccccct accccggccg ggggtcgccc cgacagcccc 1140 gggctgcagg cgccggcggg gcagcagcgg gcggtgggcc ccgcggggcgg cggcgaggcg 1200 gggcagcggt acagcaagga gaagcgcgat gccatctcgc tggccatcaa ggacatcaag 1260 gaggccatcg aggaggtgaa aaccaggacc atccgttcgc cttacacccc cgacgagccc 1320 aaagagccca tctgggtcat gcgccaggac attagcccca ccagggactg tgacgaccag 1380 aggecgatgg acggagatte teegteteet ggeageteet ecceettggg tgeagagtea 1440 1500 tcaagcacat ctcttcaccc cagtgaccct gtggaagtgc ccattaataa agagtcaaga aaaagcttgg cttcattccc aacctacgtt gaagttccgg gaccctgcga ccccgaagac 1560 ttgatcgatg gaatcatttt tgccgccaat taccttggct ccactcagct gctctcagac 1620

aaaactcctt	ccaaaaacgt	gcgcatgatg	caggcccagg	aagccgtaag	caggatcaag	1680
atggcccaga	aattagccaa	aagcaggaag	aaggctcctg	aaggcgaatc	tcagccaatg	1740
				tgctgaacgc		1800
gagacaatga	tggaccaccc	tctgaggacc	atttcctaca	ttgcggacat	tgggaacatc	1860
				cccaggagaa		1920
tcccacccat	cccaggatgg	gaaaaggcag	tacaagatga	tctgccacgt	cttcgagtct	1980
gaggatgctc	agctgattgc	acagtccatc	ggacaggcat	ttagcgtggc	ataccaggaa	2040
ttcctcaggg	ccaatgggat	taaccccgaa	gateteagee	agaaggagta	tagtgacctg	2100
ctcaataccc	aggacatgta	caacgatgac	ctgatccact	tctccaagtc	ggaaaactgt	2160
aaagatgttt	tcatagagaa	gcagaaagga	gaaatcctag	gtgtggtgat	tgtggagtct	2220
ggctggggat	ccatcctccc	caccgtgatc	attgccaaca	tgatgcatgg	tggccctgcg	2280
gagaaatctg	ggaagctgaa	tatcggtgac	cagatcatgt	ccattaatgg	caccagcctg	2340
gtgggcctgc	: ctctgtccac	ctgccagagc	attattaagg	gcttagagaa	tcagtcccga	2400
gtcaagctga	atatcgtgag	atgtcctccg	gtgaccaccg	tgttaatcag	aagaccagac	2460
cttcgctacc	agctcggttt	cagcgtccag	aatggaatta	tctgcagcct	catgcgaggg	2520
ggaatagcto	g agagaggagg	cgtccgtgtg	gggcaccgga	tcattgaaat	caatggacag	2580
agcgtcgtgg	g ccaccccca	cgagaagato	gtccacattc	tctccaatgc	tgttggggag	2640
attcatatga	a agacaatgco	agccgcgatg	, tacaggetge	tgacggccca	ggagcagcct	2700
gtttacatc	t gaccgcggc	: acacgcggtg	g gcatgcatgg	aggactctcc	tcttcgtggt	2760
tgtgtttct	c gtgctgcato	c cctgtgtcca	a ctgagacttt	ccctctcgc	gcccagcatt	2820
tggttttac	a caggaagaga	a agaatccaca	a aggacctctt	tactctctcc	gatttgcttt	2880
ttttttt	t ttttttcaat	c accagggaaq	g tttcgtatgo	: actcccttga	ggatggagag	2940
cagccagca	c ccacctggta	a ctgacccag	g accatcctgg	g agggetttet	gggtgtgtcc	3000
agggggtgg	g ctgtcactg	c ttgagggag	a atcctccctt	cccaggaggt	gcagacttct	3060
taaaaggag	c tcgcggggc	a gcaaagcag	c tgattcagca	a gtgcctaaaa	cccagttgct	3120
gatccctgc	t ctctgagtt	t atctgtggg	a atgtggtagt	acccagggco	: agcccacgtc	3180
attaaggtt	a tgcactgcc	t gccatgtag	t tggggcacca	a tacattattt	cttcccagaa	3240
tetetgage	c aaccttaaa	c ctcttctat	t gctagttcta	a atttcaacgt	atgtgtgttt	3300
tctaatacg	a gccttctca	c cccaggata	a aaggggaaa	t aactgccttg	g ggcaaggaca	3360
ccatagtgt	c acagagagc	t tggcaattc	a tggggcatc	t gaagctttad	c caggttgtcc	3420
tcaagttat	c aaccattag	a taaacacag	g caggtactg	t ctgcttctc	t ctctctcaca	3480

cacacaca	cacacacagt	cccattcgga	tatcaccctt	ccctgctccc	accaccagtg	3540
agacaagctg	aagattaggc	acacagatcc	cctggaaacc	cacctctctg	gaaggtccct	3600
tccctggcag	gtggtcaggc	aggcgggggc	tgttcagcct	catcctgaga	gacctgtcct	3660
ctctgtgctg	aggtccagcc	cctccagcac	cactttggct	tatcgtatcc	tcctcctgga	3720
cttaccctct	ctgccgaaca	cacatcccag	gcg			3753

<210> 29

<211> 2372

<212> DNA <213> Homo sapiens <400> 29 gtctgtaggt taagggagaa gatggcggcg ctaggggaac ccgtgcggct ggagagagat 60 atttgtagag caattgaatt attggaaaaa ctacaaagga gtggagaagt accaccacag 120 aaacttcagg ctttgcaaag agtccttcaa agtgaattct gcaatgctgt gagagaggta 180 tatgaacatg tctatgagac tgtggacatc agtagcagtc ctgaagtgag agcgaacgct 240 actgcaaagg ctactgttgc tgcatttgct gccagtgaag gacattctca tcctcgagtt 300 gttgagctac caaaaacaga agagggcctt ggattcaata ttatgggagg caaagaacaa 360 aactetecaa tetatatate eegaataatt eeaggtggaa ttgetgatag acatggggge 420 ctcaaacgtg gagatcaact cctctctgtt aatggagtga gtgttgaagg agaacatcat 480 gaaaaagctg tagaactgct gaaagccgca caaggaaagg ttaaattagt ggtacgatac 540 acacccaaag tottagaaga aatggagtog ogotttgaaa aaatgagato agcaaaacgo 600 aggcaacaga cctaatacat ttcaaaactt gatatttcat tttgcgtttt agctagagaa 660 720 gttttccttg tgacttacta atggctgcaa tgccaatgat tgtaagaaaa caaacaaatt tatcatgaaa ttctccttgt cattttataa atgcctattt taacatcatt tatggttcca 780 gagatgcata cacttttttc tgacaagaaa aagtaaaagg tgatgagggc aattctgtcc 840 tactgttttt acaggccttt ttcaaatgca gattttgtca taaagttgtt atagattttt 900 taaaatgctt ttttaatatt aaaatgtact tttacattct taatcttttt ttagaaagga 960 aaagttttct tcatttagct gctgatttaa aagtaaagtt ctccaattct ttttttttgc 1020 ttactctatt ttttttaacc tgtgaaattt ctttacagtt ttccaagaaa ttaagcataa 1080 cagteteate tacggeagtt cattacactg teaatgttaa cateattget geattttgta 1140 ctttgaacac acacataata tatataacca gtggtaaatc atgactcagt acagtgcaag 1200 ttttttcact tttacttaaa cataatatat aatggatatt catttatact gatttatgaa 1260 agtaagtttt taaacactga aacaatcatt gctaaaatac atattcttaa tatttgagca 1320 ttgaggcaag aggatgtaat tgatagcatt acttattaca tccctattta tgttcaaccg 1380

tacatcaaat	tataaatgca	aaacaggttc	agatttcatc	ttttgtgatt	tcttttaaat	1440
actattcatt	tttatttaaa	tgcacagtat	ttcccctata	ttttagtcct	tccattccta	1500
gagacaaacc	agttatttgg	tggtgggaag	tagctgaagc	aaagaaggaa	aagtaatacc	1560
tttaacctca	ctagcttcaa	gagtagacat	tcttactagc	tcaatttaaa	taattgattt	1620
taaataggaa	gaaaagagga	tatatttaag	atacatagaa	attatgatgc	gaagtattca	1680
tgagaatctg	tagattccat	caaaataagt	aggaactcat	actaaaattg	ttggatttaa	1740
agaggcaact	tttgtttatg	attcaaatat	gggaatttga	gaaatatttc	atttgtccac	1800
tggatgtcac	tattttacta	aaaggcagct	attagtgtgg	gactgtgact	gaggtcttaa	1860
agactgaaag	agttggggtt	cattttctgt	tacaacttac	aggaacattt	gtactttaag	1920
aaaaatttaa	gtgacaaatg	ttagaagatg	atggattgaa	aaatataagt	aatttggcat	1980
attgacccta	tataaaaaag	tgggcatttt	gtaacattcc	ttcaggaaga	atagaattgt	2040
atgcttttt	ctgcatgttt	gtgatcactg	tgagtctcag	atgattattc	cagttttcaa	2100
tgatttttca	aaataaaagt	caatcagcat	tgttatttat	cattaaggta	ttgaacactg	2160
gattgcatgg	ttgaatgtgt	ctttaattca	ctacaaaatg	tgcttgttat	tgataggatc	2220
atgttgttaa	attgtaaatt	ttcaaaatta	attgatgttt	taaaaatgtt	gagaccaaag	2280
tagtatagaa	gtatggactt	aatttaattg	taaaattatt	agaggtattt	gttgtagagc	2340
tttatatatt	. aaagagaggt	attggtgcat	at			2372

<210> 30

<211> 2260

<212> DNA

<213> Homo sapiens

<400> 30 atggcaaaga gggaggacag ccctggccca gaggtccagc caatggacaa gcagttcctg 60 gtatgcagca tetgeetgga teggtaccag tgccccaagg ttetteettg cetgcacacc 120 ttctgtgaga gatgtctcca aaactatatc cctgcccaga gcctgacgct atcctgtcca 180 gtatgccggc agacgtccat cctcccagag cagggcgtct cggcactgca gaacaacttc 240 ttcatcagca gcctcatgga ggcaatgcag caggcacctg atggggccca cgacccggag 300 gaccccacc ccctcagtgt agtggctggc cgccctctct cctgccccaa ccatgaaggc 360 aagacgatgg agttttactg tgaggcctgt gagacggcca tgtgtggtga gtgccgcgcc 420 ggggagcatc gtgagcatgg cacagtgctg ctgagggatg tggtggagca gcacaaggcg 480 gecetgeage gecagetega ggetgtgegt ggecgattge cacagetgte egcageaatt 540 gccttagtcg ggggcatcag ccagcagctg caggagcgca aggcagaggc cctggcccag 600

atcagtgcag	cgttcgagga	cctggagcaa	gcactgcagc	agcgcaagca	ggctctggtc .	660
agcgacctgg	agaccatttg	tggggccaaa	cagaaggtgt	tgcaaagcca	gctggacaca	720
ctgcgccagg	gtcaggaaca	catcggcagt	agctgcagct	ttgcagagca	ggcactgcgc	780
ctgggctcgg	ccccggaggt	gttgctggtg	cgcaagcaca	tgcgagagcg	gctggctgca	840
ttggcggcac	aggccttccc	ggagcggcca	catgagaatg	cacagctgga	actggtcctt	900
gaggtggacg	gtctgcggcg	atcggtgctc	aatctgggcg	cactgctcac	cacgagcgcc	960
actgcacacg	aaacggtggc	cacgggagag	ggcctgcgcc	aggcgctagt	gggccagcct	1020
gcctcgctca	ctgtcactac	caaagacaag	gacgggcggt	tggtgcgcac	aggcagcgct	1080
gagctgcgtg	cagagatcac	cggcccggac	ggcacgcgcc	ttccggtgcc	agtggtggac	1140
cacaagaatg	gcacatatga	gctagtgtac	acagcgcgca	cggaaggcga	getgeteete	1200
teggtgetge	tctacggaca	gccagtgcgc	ggcagcccct	teegegtgeg	tgccctgcgt	1260
ccgggggacc	tgccaccttc	cccggacgat	gtgaagcgcc	gtgtcaagtc	ccctggcggc	1320
cccggcagcc	atgtgcgcca	gaaggcagtg	cgtaggccca	gctccatgta	cagcacaggc	1380
ggcaaacgaa	aggacaaccc	aattgaggat	gagctcgtct	tccgtgttgg	cagtcgtgga	1440
agggagaaag	gtgaattcac	caatttacaa	ggtgtgtccg	cagccagcag	cggccgcatc	1500
gtggtagcag	acagcaacaa	ccagtgtatt	caggttttct	ccaatgaggg	ccagttcaag	1560
ttccgttttg	gggtccgagg	acgctcacct	gggcagctgc	agcgccccac	aggtgtggca	1620
gtggacacca	atggagacat	aattgtggca	gactatgaca	accgttgggt	cagcatcttc	1680
tcccctgagg	gcaagttcaa	gaccaagatt	ggagctggcc	gcctcatggg	ccccaaggga	1740
gtggccgtag	g accggaatgg	acatatcatt	gtggtcgaca	acaagtettg	ctgcgtcttt	1800
accttccago	ccaatggcaa	actggttgg	cgttttgggg	gccgtgggg	cactgaccgc	1860
cactttgcag	g ggccccattt	tgtggctgtg	g aacaacaaga	atgaaattgt	: agtaacggac	1920
ttccataaco	c attcagtgaa	ggtgtacag	gccgatggag	agttcctctt	caagtttggc	1980
tcccatggcg	g agggcaatgg	g gcagttcaa	c gccccacag	gagtagctgt	ggactccaat	2040
ggaaacatca	a ttgtggctga	a ctggggcaa	c agccgcatco	: aggtattcga	a cagctctggc	2100
teetteetg	t cctatatca	a cacatctgc	a gaaccactgt	: atggtccaca	a gggcctggca	2160
ctgacctcg	g atggccatg	ggtggtggc	t gatgctggca	accactgct	t taaagcctat	2220
cgctacctc	c agtagctgta	a cagaggccc	t gcctggcttg	ı		2260

<sup>&</sup>lt;210> 31 <211> 2250 <212> DNA <213> Homo sapiens

<400> 31 ccgccgctcc ggacccgcag ccgccgccgc cgcctcctcc ccccggatcg ggtgtactgt 60 cctaacccga aagtccagtt ctgcggcccg gcagcggcga gcgggcgcga tgacacagga 120 gtacgacaac aaacggccag tgttggctct tcagaatgaa gcactttatc cacagcggcg 180 gtcctacact agtgaggatg aggcctggaa atccttcctg gaaaaccctc tcactgcagc 240 gaccaaagcg atgatgagca tcaatggaga tgaagacagc gccgctgcgc tgggcctgct 300 ctatgactac tacaaggttc caagagagag aaggtcatca acagcaaagc cagaggtgga 360 gcaccctgag ccagatcaca gcaaaagaaa cagcatacca attgtgacag agcagcccct 420 catctctgct ggagaaaaca gagtgcaagt actgaaaaat gtgccattta acattgtcct 480 tccccatggc aaccagctgg gcattgataa gagaggccat ctgacagctc cagatacgac 540 600 agtcactgtc tccatagcaa cgatgcctac ccactccatc aagacagaaa cccagcctca tggcttcgct gtgggaatcc ccccagcagt gtatcatcct gagcccactg agcgggtggt 660 ggttttcgat cggaatctca atactgacca gttcagctct ggtgctcaag ccccaaatgc 720 tcaaaggcga actccagact cgaccttctc agagaccttc aaggaaggcg ttcaggaggt 780 tttcttcccc tcggatctca gtctgcggat gcctggcatg aattcagagg actatgtttt 840 tgacagtgtt tctgggaaca actttgaata taccctagaa gcttcaaaat cacttcgaca 900 960 gaagccagga gacagtacca tgacgtacct gaacaaaggc cagttctatc ccatcacctt gaaggaggtg agcagcagtg aaggaatcca tcatcccatc agcaaagttc gaagtgtgat 1020 catggtggtt tttgctgaag acaaaagcag agaagatcag ttaaggcatt ggaagtactg 1080 gcactcccgg cagcacaccg ctaaacaaag atgcattgac atagctgact ataaagaaag 1140 cttcaacact atcagtaaca tcgaggagat tgcgtataac gccatttcct tcacatggga 1200 1260 catcaacgat gaagcaaagg ttttcatctc tgtgaactgc ttaagcacag atttctcttc ccagaaggga gtgaaggggt tgcctcttaa cattcaagtt gatacctata gttacaacaa 1320 ccgcagcaac aagcctgtgc accgggccta ctgccagatc aaggtcttct gtgacaaggg 1380 1440 1500 taaagtgcca ctgcttccct ctcacaagcg aatggatatc acagttttca aacccttcat tgatctcgat actcagcctg tcctcttcat tcctgacgtg cactttgcca acttgcagcg 1560 gggcactcat gtccttccca ttgcctctga agaattggag ggtgaaggct ctgtcttgaa 1620 aagggggccg tacggcacag aagatgactt tgctgtccct ccttctacca agctggcccg 1680 1740 gatagaagaa ccaaagagag tgctgctcta cgttcgaaag gagtcagaag aagtctttga tgccctgatg ctcaaaaccc catctttgaa gggcttgatg gaagctatct cagacaaata 1800 cgatgttccc catgacaaga ttgggaaaat attcaagaag tgtaaaaagg ggatcctggt 1860

gaacatggac ga	caacattg t	gaagcatta	ctccaatgag	gacaccttcc	agctgcagat	1920
tgaagaagcc gg	ggggtett a	caagctcac	cctgacggag	atctaaaggc	ctgcgggcca	1980
cagctcccca gg	gagttcagt g	gcaggtgttt	ctagatctta	cggtttggca	actgcaggta	2040
accccagtca go	catgtcgc c	agcacaggt	ctatgtcgag	ggaatgggtt	ccttgcaggt	2100
tggaggcggg gc	tgcatctg g	gettggtggt	agcatttaat	ctattgcatt	ggtgtttttc	2160
agatgaaaga ga	aatccata t	accattatg	tttgaatttc	ctgatatata	caggatttaa	2220
agtgaaaact tt	tattccaag a	agttaacaga				2250
	sapiens					
<400> 32 cagccgccat to	ttctcgccg (	cttgtgtggc	tegetggetg	cgtggctcgg	ttcttgtgag	60
cgaagctttg t	ccggttcgg	caatggacgg	aatcgtcact	gaggttgcag	ttggcgtgaa	120
gagaggatct g	acgaactac	tctcaggcag	tgttctcagt	agtccgaact	ctaatatgag	180
cagcatggta g	ttacagcca	atggtaatga	tagtaaaaaa	tttaaaggag	aagataaaat	240
ggatggtgct c	cttctcgtg	tacttcatat	tcgaaaatta	cctggggaag	taacagaaac	300
tgaagttatt g	ctttaggct	taccttttgg	taaggtgacc	aacatcctta	tgctgaaagg	360
aaaaaatcag g	catttttgg	aactagcaac	cgaggaagca	gctattacta	tggttaatta	420
ctattctgct g	tgacacete	atcttcgtaa	ccaaccaata	tatatccagt	actcgaatca	480
caaagaacta a	agacagata	atacattaaa	ccaacgtgct	caggcagtto	: ttcaagctgt	540
gacagctgtc c	agacagcaa	atactcctct	tagtggcacc	acagttagcg	g agagtgcagt	600
gactccagcc c	agagtccag	tacttagaat	aattattgac	aacatgtact	accctgtaac	660
acttgatgtt c	ttcaccaaa	tattttctaa	gtttggtgct	gtattgaaga	a taatcacatt	720
tacaaaaaat a	accagtttc	aagctttgct	ccagtatggt	gatccagtaa	a atgctcaaca	780
agcaaaacta g	gccctagatg	gtcagaatat	ttataatgcc	tgctgtacco	taaggattga	840
tttttccaaa c	cttgtgaatt	tgaatgtaaa	atacaacaat	gataaaagta	a gggattatac	900
tcgacctgat (	cttccatctg	gggatggaca	acctgcattg	gacccagcta	a ttgctgcagc	960
atttgccaag (	gagacatccc	tcttagctgt	tccaggagct	ctgagtcct	t tggccattcc	1020
aaatgctgct (	gcagcagctg	ctgcagctgo	tgctggccga	gtgggtatg	c ctggagtctc	1080
agctggtggc a	aatacagtcc	tgttggttag	g caatttaaat	gaagagatg	g ttacgcccca	1140
aagtctgttt a	accctcttcg	gtgtttatgg	g agatgtgcag	cgtgtgaag	a ttttatacaa	1200

taagaaagac agcgctctaa tacagatggc tgatggaaac caatcacaac ttgccatgaa 1260 tcatcttaat ggacagaaaa tgtatggaaa aattattcgt gttactctgt ctaaacatca 1320 gactgtacag ctacctcgag agggacttga tgatcaaggg ctaacaaaag attttggtaa 1380 ttccccattg catcgtttta agaaacctgg atccaaaaat tttcaaaaca tttttcctcc 1440 ttctgccacc cttcacctat ctaatatccc tccatcagta gcagaagagg atctacgaac 1500 actgttcgct aacactgggg gcactgtgaa agcatttaag ttttttcaag atcacaaaat 1560 ggctcttctt cagatggcaa cagtggaaga agctattcag gccttgattg atcttcataa 1620 ttataacctt ggagaaaacc atcatctgag agtgtctttc tccaagtcaa caatttaaaa 1680 atgggaagat gaagattggg ggtgaatcac attgttcaat gtcatcacct atttgactgt 1740 tcagaaaagt ggggaccaga gtttgatttt ttttgttttt gttttttgg ggtttctttt 1800 ttttttccat gctgttatca ttccttggtt ataaaatgaa atggcatatg taaaggcaga 1860 gttgttaact gctatatttc atctgttcta tagggaagcc attttgtctg tttaaaattt 1920 cagtttaatt ttgcttttt tttttttt tttttccttt caacttagtt gacatacgtg 1980 ccttaaaaag gaaaactagt gttgctattg tgcatttact agaaaaaagg aattggttgt 2040 ttagggcaca ctgttatatg ggaattaaaa tatgtttagg caggggtgtg taaaaaggtt 2100 aagtttttgt ttctcctgct tggaacttat tttgaattac tggcttgtca cctttttttc 2160 tatttaatca aataagatac atgatattga aagaataaag cagcattttt agtttttact 2220 accttaggct ttattgcttt gaaaacaaca ttggcctttt gtatctcaca attctggtct 2280 agattcagtt atgaatgtag gcattagtta aaattaacaa gatgcagagt attaatttct 2340 taagacaaca aagtgatttc tgtaagtttg agccctatgt ggaaagcatt gtggaatctt 2400 aaccttttcg tacacactct tgtgggacgt atcatataaa tgtcagcact aagtaatgtc 2460 ttgtttgtgg ctgaatattt ttcgtagatg tttttgaagt tgacatgact tacgtgcatt 2520 taaatatata ttgccatcct tagtttgtaa ttaagatttg gaatatggtt gtggatttct 2580 gagcatgtgc agactggtct agctagttca ggaactggtg catgtatttt tcaaagataa 2640 agaaagtgta ctgcgaaaat atgcaggaag attaattttg tggcagtttt ctaaaactga 2700 caaccaggtg ggaccaaagt ttatgtgcct ttagtcttaa tttaccttgc attgtaatat 2760 tcagttttaa taaatcttca aaatattttg tatttaggaa tagatctgac tttaataaaa 2820 acatggctca gaatctacag gtcaaattaa tttgaacagt tcttgtcaat ccgaattgtt 2880 gattctgttt aaatgaccaa tactttttga aattgatgta cttagtttca agattcatag 2940 attctgttat ctatgtagac agaatggtca tgtatatttt ctattagttg agtttttaca 3000 tctttagaaa tgtaaaattc agtatagttt gaaagcggca caattaaaaa ttaattttct 3060

3063 aac

<210> 33 <211> 1680 <212> DNA

<213> Homo sapiens

<400> 33 atctgatgag cttctttctt ctggcatcat taacggacct tttaccatga atagttctac 60 tccttctaca gctaatggga atgacagcaa gaaatttaaa cgagatagac ctccctgttc 120 geetteeegt gtteteeate ttegaaaaat teeatgtgat gteacegaag cagagateat 180 240 atcattaggt ctaccatttg gcaaagtaac taatcttttg atgttgaaag gaaaaagcca ggctttctta gaaatggctt ctgaggaagc tgccgttact atggtgaatt attacactcc 300 tattactcct caccttcgaa gccagcctgt ttatattcag tattccaatc acagagaact 360 taagactgac aatctaccta atcaagctcg agcccaagct gcactgcagg ctgtcagtgc 420 cgtccaatca ggaagcctgg ccctttctgg aggtccttcc aatgaaggca cagtcctacc 480 tgggcagagc cctgtgcttc gaataattat tgaaaacctc ttttaccctg ttaccctgga 540 600 agttottoat cagatatttt otaaatttgg cacagtottg aagattatca ootttacaaa gaataatcag tttcaagcct tgcttcagta tgctgaccca gtaaatgcac attatgccaa 660 720 aatggctctg gatggccaga atatctataa tgcatgctgc actctgcgca ttgacttctc 780 caageteace ageettaatg tgaaatataa taatgacaaa ageagagaet teaetegett agaccttcct actggtgatg gccagccatc ccttgaaccc cctatggctg ctgcttttgg 840 900 tgcaccgggt ataatttctt caccatatgc aggggctgct ggatttgccc cagccattgg 960 atttcctcaa gctacaggtc tatcagttcc agctgttcct ggagctcttg gtcctctcac aatcacctct tctgctgtca ctggaaggat ggccattcct ggggctagtg gtataccagg 1020 aaattctgtt ctactcgtca caaatctcaa tcctgatctt atcacaccac atgggctttt 1080 tatcctattt ggagtctatg gtgatgtaca tcgagtgaag attatgttta ataagaaaga 1140 1200 aaatgccttg gttcagatgg cggatgcaaa tcaagctcag ctagcaatga accatctaag tggtcagaga ctttatggga aagtgcttcg tgctacactg tccaaacatc aagcagtaca 1260 1320 gcttcctcga gagggacaag aagaccaagg tctgactaag gatttcagca atagtccttt gcatcgcttt aaaaagccgg gctctaaaaa cttccagaat atctttccac catcagccac 1380 1440 tctgcatctt tccaacattc ccccttctgt tacagtggat gatctgaaga accttttcat agaagctgga tgttcagtga aggcttttaa attctttcag aaagatcgca aaatggcgct 1500 cattcaattg ggatctgtgg aagaagcaat tcaggccctc attgagcttc ataaccatga 1560 1620 ccttggagaa aatcaccacc tcagagtttc cttctcaaaa tctacaatct gacttttctg

1680

tgattttctc ctaaactgga ccataatttc aaaaccttca gacatagact gaaaaaaaaa <210> 34 <211> 3322 <212> DNA <213> Homo sapiens <400> 34 cttgtgagtc tataactcgg agccgttggg tcggttcctg ctattccggc gcctccactc 60 cgtcccccgc gggtctgctc tgtgtgccat ggacggcatt gtcccagata tagccgttgg 120 tacaaagcgg ggatctgacg agcttttctc tacttgtgtc actaacggac cgtttatcat 180 gagcagcaac tcggcttctg cagcaaacgg aaatgacagc aagaagttca aaggtgacag 240 ccgaagtgca ggcgtcccct ctagagtgat ccacatccgg aagctcccca tcgacgtcac 300 ggagggggaa gtcatctccc tggggctgcc ctttgggaag gtcaccaacc tcctgatgct 360 420 gaaggggaaa aaccaggcct tcatcgagat gaacacggag gaggctgcca acaccatggt gaactactac acctcggtga cccctgtgct gcgcggccag cccatctaca tccagttctc 480 caaccacaag gagctgaaga ccgacagctc tcccaaccag gcgcgggccc aggcggccct 540 gcaggcggtg aactcggtcc agtcggggaa cctggccttg gctgcctcgg cggcggccgt 600 ggacgcaggg atggcgatgg ccgggcagag ccccgtgctc aggatcatcg tggagaacct 660 cttctaccct gtgaccctgg atgtgctgca ccagattttc tccaagttcg gcacagtgtt 720 gaagatcatc accttcacca agaacaacca gttccaggcc ctgctgcagt atgcggaccc 780 cgtgagcgcc cagcacgcca agctgtcgct ggacgggcag aacatctaca acgcctgctg 840 cacgctgcgc atcgactttt ccaagctcac cagcctcaac gtcaagtaca acaatgacaa 900 gagccgtgac tacacacgcc cagacctgcc ttccggggac agccagccct cgctggacca 960 gaccatggcc gcggccttcg gtgcacctgg tataatctca gcctctccgt atgcaggagc 1020 tggtttccct cccacctttg ccattcctca agctgcaggc ctttccgttc cgaacgtcca 1080 cggcgccctg gcccccctgg ccatcccctc ggcggcggcg gcagctgcgg cggcaggtcg 1140 1200 gatcgccatc ccgggcctgg cgggggcagg aaattctgta ttgctggtca gcaacctcaa cccagagaga gtcacacccc aaagcctctt tattcttttc ggcgtctacg gtgacgtgca 1260 1320 gcgcgtgaag atcctgttca ataagaagga gaacgcccta gtgcagatgg cggacggcaa 1380 ccaggcccag ctggccatga gccacctgaa cgggcacaag ctgcacggga agcccatccg 1440 catcacgete tegaageace agaaegtgea getgeeeege gagggeeagg aggaceaggg 1500 cctgaccaag gactacggca actcacccct gcaccgcttc aagaagccgg gctccaagaa 1560 cttccagaac atattcccgc cctcggccac gctgcacctc tccaacatcc cgccctcagt

c	tccgaggag	gatctcaagg	tcctgttttc	cagcaatggg	ggcgtcgtca	aaggattcaa	1620
ç	ttcttccag	aaggaccgca	agatggcact	gatccagatg	ggctccgtgg	aggaggcggt	1680
C	caggccctc	attgacctgc	acaaccacga	cctcggggag	aaccaccacc	tgcgggtctc	1740
Ç	ttctccaag	tccaccatct	aggggcacag	gccccacgg	ccgggccccc	tggcgacaac	1800
ţ	tccatcatt	ccagagaaaa	gccactttaa	aaacagctga	agtgacctta	gcagaccaga	1860
ç	gattttattt	ttttaaagag	aaatcagttt	acctgttttt	aaaaaaatta	aatctagttc	1920
ć	accttgctca	ccctgcggtg	acagggacag	ctcaggctct	tggtgactgt	ggcagcggga	1980
9	gttcccggcc	ctccacaccc	ggggccagac	cctcggggcc	atgccttggt	ggggcctgtg	2040
1	tcgggcgtgg	ggcctgcagg	tgggcgcccc	gaccacgact	tggcttcctt	gtgccttaaa	2100
•	aaacctgcct	tcctgcagcc	acacacccac	ccggggtgtc	ctggggaccc	aaggggtggg	2160
•	ggggtcacac	cagagagagg	cagggggcct	ggccggctcc	tgcaggatca	tgcagctggg	2220
,	gcgcggcggc	cgcggctgcg	acaccccaac	cccagccctc	taatcaagtc	acgtgattct	2280
	cccttcaccc	cgccccagg	gccttccctt	ctgcccccag	gegggeteee	cgctgctcca	2340
	gctgcggagc	tggtcgacat	aatctctgta	ttatatactt	tgcagttgca	gacgtctgtg	2400
	cctagcaata	tttccagttg	accaaatatt	ctaatctttt	ttcatttata	tgcaaaagaa	2460
	atagttttaa	gtaacttttt	atagcaagat	gatacaatgg	tatgagtgta	atctaaactt	2520
	ccttgtggta	ttaccttgta	tgctgttact	tttattttat	tccttgtaat	taagtcacag	2580
	gcaggaccca	gtttccagag	agcaggcggg	gccgcccagt	gggtcaggca	cagggagccc	2640
	cggtcctatc	ttagagcccc	tgagcttcag	ggaaggggcg	ggcgtgtcgc	cgcctctggc	2700
	atcgcctccg	gttgccttac	accacgcctt	cacctgcagt	cgcctagaaa	acttgctctc	2760
	aaacttcagg	gtttttctt	ccttcaaatt	ttggaccaaa	gtctcatttc	tgtgttttgc	2820
	ctgcctctga	tgctgggacc	cggaaggcgg	gegeteetee	tgtcttctct	gtgctctttc	2880
	taccgccccc	gegteetgte	ccgggggctc	tcctaggatc	ccctttccgt	aaaagcgtgt	2940
	aacaagggtg	, taaatattta	taattttta	a tacctgttgt	gagacccgag	gggcggcggc	3000
	gcggttttt	atggtgacac	aaatgtatat	tttgctaaca	gcaattccag	gctcagtatt	3060
	gtgaccgcgg	g agccacaggg	gaccccacgo	acattccgtt	gccttacccg	atggcttgtg	3120
	acgcggagag	g aaccgattaa	aaccgtttg	a gaaactcctc	ccttgtctag	ccctgtgttc	3180
	gctgtggac	g ctgtagaggo	: aggttggcca	a gtctgtacct	ggacttcgaa	taaatcttct	3240
	gtatectego	c teegtteege	cttaaaaaa	a aaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3300
	aaaaaaaaa	a aaaaaaaaa	ı aa				3322

<211> 2722

<212> DNA

<213> Homo sapiens

<400> 35 gagcgggctg agggtaggaa gtagccgctc cgagtggagg cgactggggg ctgaagagcg 60 cgccgccctc tcgtcccact ttccaggtgt gtgatcctgt aaaattaaat cttccaagat 120 gatctggtat atattaatta taggaattct gcttccccag tctttggctc atccaggctt 180 ttttacttca attggtcaga tgactgattt gatccatact gagaaagatc tggtgacttc 240 300 tctgaaagat tatattaagg cagaagagga caagttagaa caaataaaaa aatgggcaga gaagttagat cggctaacta gtacagcgac aaaagatcca gaaggatttg ttgggcatcc 360 agtaaatgca ttcaaattaa tgaaacgtct gaatactgag tggagtgagt tggagaatct 420 ggtccttaag gatatgtcag atggctttat ctctaaccta accattcaga gaccagtact 480 ttctaatgat gaagatcagg ttggggcagc caaagctctg ttacgtctcc aggataccta 540 caatttggat acagatacca tctcaaaggg taatcttcca ggagtgaaac acaaatcttt 600 tctaacggct gaggactgct ttgagttggg caaagtggcc tatacagaag cagattatta 660 ccatacggaa ctgtggatgg aacaagccct aaggcaactg gatgaaggcg agatttctac 720 catagataaa gtctctgttc tagattattt gagctatgcg gtatatcagc agggagacct 780 ggataaggca cttttgctca caaagaagct tcttgaacta gatcctgaac atcagagagc 840 taatggtaac ttaaaatatt ttgagtatat aatggctaaa gaaaaagatg tcaataagtc 900 tgcttcagat gaccaatctg atcagaaaac tacaccaaag aaaaaagggg ttgctgtgga 960 ttacctgcca gagagacaga agtacgaaat gctgtgccgt ggggagggta tcaaaatgac 1020 1080 ccctcggaga cagaaaaaac tcttttgccg ctaccatgat ggaaaccgta atcctaaatt tattctggct ccagctaaac aggaggatga atgggacaag cctcgtatta ttcgcttcca 1140 tgatattatt tctgatgcag aaattgaaat cgtcaaagac ctagcaaaac caaggctgag 1200 ccgagctaca gtacatgacc ctgagactgg aaaattgacc acagcacagt acagagtatc 1260 taagagtgcc tggctctctg gctatgaaaa tcctgtggtg tctcgaatta atatgagaat 1320 1380 acaagatcta acaggactag atgtttccac agcagaggaa ttacaggtag caaattatgg agttggagga cagtatgaac cccattttga ctttgcacgg aaagatgagc cagatgcttt 1440 1500 caaagagctg gggacaggaa atagaattgc tacatggctg ttttatatga gtgatgtgtc 1560 tgcaggagga gccactgttt ttcctgaagt tggagctagt gtttggccca aaaaaggaac 1620 tgctgttttc tggtataatc tgtttgccag tggagaagga gattatagta cacggcatgc agcctgtcca gtgctagttg gcaacaaatg ggtatccaat aaatggctcc atgaacgtgg 1680 1740 acaagaattt cgaagacctt gtacgttgtc agaattggaa tgacaaacag gcttcccttt

ttctcctatt gttgtactct tatgtgtctg atatacacat ttccatagtc ttaactttca	1800
ggagtttaca attgactaac actccatgat tgattcagtc atgaacctca tcccatgttt	1860
catctgtgga caattgctta ctttgtgggt tcttttaaaa gtaacacgaa atcatcatat	1920
tgcataaaac cttaaagttc tgttggtatc acagaagaca aggcagagtt taaagtgagg	1980
aattttatat ttaaagaact ttttggttgg ataaaaacat aatttgagca tccagtttta	2040
gtatttcact acatctcagt tggtgggtgt taagctagaa tgggctgtgt gataggaaac	2100
aaatgcctta cagatgtgcc taggtgttct gtttacctag tgtcttactc tgttttctgg	2160
atctgaagac tagtaataaa ctaggacact aactgggttc catgtgattg ccctttcata	2220
tgatcttcta agttgatttt tttcctccca agtctttttt aaagaaagta tactgtattt	2280
taccaacccc ctctctttc ttttagctcc tctgtggtga attaaacgta cttgagttaa	2340
aatatttcga ttttttttt ttttttaatg gaaagtcctg cataacaaca ctgggccttc	2400
ttaactaaaa tgctcaccac ttagcctgtt tttttatccc ttttttaaaa tgacagatga	2460
ttttgttcag gaattttgct gtttttctta gtgctaatac cttgcctctt attcctgcta	2520
cagcagggtg gtaatattgg cattctgatt aaatactgtg ccttaggaga ctggaagttt	2580
aaaaatgtac aagtcctttc agtgatgagg gaattgattt tttttaaaag tctttttctt	2640
agaaagccaa aatgtttgtt tttttaagat tctgaaatgt gttgtgacaa caatgaccta	2700
tttatgatct taaatctttt tt	2722
<210> 36 <211> 2194	
<212> DNA <213> Homo sapiens	
<400> 36 ggggaaggaa cactgtaggg gatagctgtc cacggacgct gtctacaaga ccctggagtg	60
	120
agataacgtg cctggtactg tgccctgcat gtgtaagatg cccagttgac cttcgcagca	180
ggagcetgga teaggeactt cetgeeteag gtattgetgg acageceaga caetteeete	240
tgtgaccatg aaactctggg tgtctgcatt gctgatggcc tggtttggtg tcctgagctg	300
tgtgcaggcc gaattettca cetetattgg gcacatgact gacetgattt atgcagagaa	360
agagetggtg cagtetetga aagagtacat cettgtggag gaagecaage tttecaagat	
taagagctgg gccaacaaaa tggaagcctt gactagcaag tcagctgctg atgctgaggg	420
ctacctggct caccctgtga atgcctacaa actggtgaag cggctaaaca cagactggcc	480

540

600

tgcgctggag gaccttgtcc tgcaggactc agctgcaggt tttatcgcca acctctctgt

gcagcggcag ttcttcccca ctgatgagga cgagatagga gctgccaaag ccctgatgag

PCT/US03/06025 WO 03/083047

acttcaggac	acatacaggc	tggacccagg	cacaatttcc	agaggggaac	ttccaggaac	660
caagtaccag	gcaatgctga	gtgtggatga	ctgctttggg	atgggccgct	cggcctacaa	720
tgaaggggac	tattatcata	cggtgttgtg	gatggagcag	gtgctaaagc	agcttgatgc	780
cggggaggag	gccaccacaa	ccaagtcaca	ggtgctggac	tacctcagct	atgctgtctt	840
ccagttgggt	gatctgcacc	gtgccctgga	gctcacccgc	cgcctgctct	cccttgaccc	900
aagccacgaa	cgagctggag	ggaatctgcg	gtactttgag	cagttattgg	aggaagagag	960
agaaaaaacg	ttaacaaatc	agacagaagc	tgagctagca	accccagaag	gcatctatga	1020
gaggcctgtg	gactacctgc	ctgagaggga	tgtttacgag	agcctctgtc	gtggggaggg	1080
tgtcaaactg	acaccccgta	gacagaagag	gcttttctgt	aggtaccacc	atggcaacag	1140
ggccccacag	ctgctcattg	ccccttcaa	agaggaggac	gagtgggaca	gcccgcacat	1200
cgtcaggtac	tacgatgtca	tgtctgatga	ggaaatcgag	aggatcaagg	agatcgcaaa	1260
acctaaactt	gcacgagcca	ccgttcgtga	tcccaagaca	ggagtcctca	ctgtcgccag	1320
ctaccgggtt	tccaaaagct	cctggctaga	ggaagatgat	gaccctgttg	tggcccgagt	1380
aaatcgtcgg	atgcagcata	tcacagggtt	aacagtaaag	actgcagaat	tgttacaggt	1440
tgcaaattat	ggagtgggag	gacagtatga	accgcacttc	gacttctcta	ggaatgatga	1500
gcgagatact	ttcaagcatt	tagggacggg	gaatcgtgtg	gctactttct	taaactacat	1560
gagtgatgta	gaagctggtg	gtgccaccgt	cttccctgat	ctgggggctg	caatttggcc	1620
taagaagggt	acagctgtgt	tctggtacaa	cctcttgcgg	agcggggaag	gtgactaccg	1680
aacaagacat	getgeetgee	ctgtgcttgt	gggctgcaag	tgggtctcca	ataagtggtt	1740
ccatgaacga	a ggacaggagt	tcttgagacc	ttgtggatca	acagaagttg	actgacatcc	1800
ttttctgtc	ttccccttcc	tggtccttca	gcccatgtca	acgtgacaga	cacctttgta	1860
tgttccttgt	atgttcctat	caggctgatt	: tttggagaaa	tgaatgtttg	tctggagcag	1920
agggagacca	a tactagggcg	actcctgtgt	gactgaagtc	ccagcccttc	cattcagcct	1980
gtgccatcco	tggccccaag	gctaggatca	aagtggctgo	: agcagagtta	gctgtctagc	2040
gcctagcaa	g gtgcctttgt	acctcaggtg	g ttttaggtgt	gagatgttt	agtgaaccaa	2100
agttctgata	a ccttgtttac	: atgtttgttt	ttatggcatt	tctatctatt	gtggctttac	2160
caaaaaata	a aatgtcccta	ccagaagcct	taaa			2194

<sup>&</sup>lt;210> 37 <211> 4932

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Homo sapiens

<sup>&</sup>lt;400> 37

tgcgagcaac agatccggac gccgcgagct gacccgctct gctgttgggc gatttttttt

taattgcaga aaaatttatt aaattggaaa atcttgcgtt tttcaatggc gctggccccg 120 ggtcagcggg cgattttctc tgcatcaaga tgggctttgc cgtttccgta gtgggcacca 180 gtggtggcct gattgtcagt cttctcccgg catttttaag gccaggagcc gagcgctgct 240 tgtaggcgaa taccctacag agcggtttgg ctttttaaat tactgttatt attttgggca 300 gagaacagtc ggtctggtgc accccgtcct cgctgcagaa gaggctgcga gtccgaggtg 360 ggtctctcgg aaggtgaaat tccttctggg gtgagcgagc cccggccccg cgcgcagtcc 420 ageggeeeeg egtgtgtgee etegeeetge eggageeggg aaaatggagg etgtgattga 480 gaaggaatgc agcgcgctcg gaggcctctt ccagaccatc atcagcgaca tgaaggggag 540 ctatccagtt tgggaagatt tcataaacaa agcaggaaag ctgcagtccc agcttcggac 600 aacagtagta gcagcagctg ccttcttgga cgcctttcag aaagtggctg acatggccac 660 caacacacgt ggtgggacca gggagattgg atctgctctc accaggatgt gcatgaggca 720 780 cagaagcatt gaagccaagc tgaggcagtt ttcgagcgct ttaattgatt gtctgataaa cccacttcaa gaacagatgg aagaatggaa gaaagtggcc aaccagctgg ataaagacca 840 900 cgcaaaagaa tataagaaag cccgccaaga gataaaaaag aagtcctcgg atacgctgaa actgcagaag aaagcaaaaa aagggagagg tgatatccag cctcagttgg acagtgctct 960 1020 ccaagatgtc aatgataagt atctcttatt ggaagaaaca gaaaagcagg ctgtccggaa ggctttgatt gaagaacgtg gccgattctg taccttcatc tctatgctgc ggccagtgat 1080 tgaagaagaa atctcaatgc taggggaaat aacccacctt cagaccatct cggaagatct 1140 aaaaagcctg accatggacc ctcacaaact gccctcctca agtgaacagg tgattctgga 1200 1260 cttgaaaggt tctgattaca gctggtcgta tcagacgcca ccctcttccc ccagcaccac catgtccaga aagtccagtg tctgcagcag cctgaacagt gtcaacagca gtgactcccg 1320 gtccageggc teccaetege attececeag etcaeattae egetaeegea getecaacet 1380 ggcccagcag gctcctgtga ggctgtccag cgtgtcctcc catgactcag gattcatatc 1440 ccaggatgcc ttccagtcca agtcaccatc ccccatgccg ccagaggccc ccaaccagtt 1500 1560 gtctaacggg ttttctcact atagtttatc aagtgagtcc cacgtggggc ccacgggtgc aggeetttte ceteattgee tgeetgeete eegeetgete eetegggtea eetetgteea 1620 1680 cettecagae taegeteatt attacaccat tgggeeegge atgtteeegt cateteagat ccctagctgg aaggactggg ctaagcctgg gccctatgac cagcctctgg tgaacaccct 1740 gcagcgccgc aaagagaagc gagaaccgga ccccaacggg ggaggaccca ctaccgccag 1800 cggcccacct gcagcagctg aggaggctca gagaccacgg agcatgactg tatcggctgc 1860 1920 caccaggect ggtgaggaga tggaggettg tgaggagetg geeetggeee tgtetegggg

cctgcagctg gacacccaga ggagcagccg ggactcgctt cagtgctcca gcggctacag 1980 cacccagaca accacccct gctgctctga ggacaccatc ccttcccaag tttcagatta 2040 tgattatttc tctgtaagtg gtgaccagga ggcagatcag caggagttcg acaagtcctc 2100 caccattcca agaaacagcg acatcagcca gtcctaccga cggatgttcc aagccaagcg 2160 tecageetea actgetggee tecceaceae cetgggaeet getatggtea etccaggggt 2220 tgcaactatc cgacggaccc cttccaccaa gccttctgtc cgccggggaa ccattggagc 2280 tggtcccatc cccatcaaga cacccgtgat ccctgtcaag accccaaccg tcccagacct 2340 cccaggggtg atgccagccc ctccagatgg gccagaagag cggggggagc acagccctga 2400 gtcgccatct gtgggtgagg gcccccaagg tgtcaccagc atgccctcct caatgtggag 2460 cggccaaget tecgttaace etecaettee aggecegaag eccagtatee etgaggagea 2520 2580 cagacaggca attccagaaa gtgaagctga agaccaggaa cgggaacccc caagtgccac tgtctcccca ggccagattc cagagagtga ccctgcagac ctgagcccaa gggatactcc 2640 acaaggagaa gacatgctga acgccatccg aaggggcgtg aaactgaaga agaccacgac 2700 aaacgatcgc tcagcccctc gcttttctta ggttcacaag aaatgcgccg gtggggaatg 2760 aactgtttca ttaataaaac ctaatttgtc ttgatccatt ccactctata ataaaacaaa 2820 2880 agattttgta ggcaactcgg aatatagctc ttttgaaagt actcgacacc tttagataag aattaaaacc aacctatgta actgacataa tcttgatctt ttaatttgta aatattgaca 2940 attttctttc tgcacatttt aatcttagtt tcccttttga tttttctgaa ggtgccaaat 3000 tccatttaac ttttttacaa gtctttgtaa aattttaaat gcataaaggg ggttggggca 3060 ggggaaccac gaagtagtta attttagaaa aggatttact atacttcact cttcttttt 3120 3180 tttccccaca agcttttgta gatgcattgt agtagtctag cttagaagca aatgcaagtt attttaatgt acaaactaaa tgggtaagag gtaaaatctt catttaaata tactatgttc 3240 tggatgaaaa gagcaggagt aacaattgat gagcaatatt cagagtgaag taaatctgga 3300 aatggtagac tgtgttggga ttggggggag ggccatggga ggggtacatc gtcaacatag 3360 3420 ccgatcctgt tacatttaag agtagcctcg taggttgaat ttcttctggt agcttcatgg taaatgcatc cgaataagcc atactggatt gcagtgtttg tttctgtagg gtgtttaagg 3480 3540 acttgacttc ctttctccca tgattcctct ggactgcaca cagcacccac aaccagcccc atgcatgctg ctgcctctgg gcagtcgtag aatctcccac ttcagtttct cgttgattgt 3600 3660 actcaccttt atggaatcca aatacatcca aaagggtaag gcagttttaa aaatgtgaaa acatttaaaa atgataatag cagggaattc ttagattata gtaaatgcct tttacttaac 3720 3780 tgtgcccagc aggctgggtg cgttaaaaaag cccaagtatt ttgaaaaaac tcgaacagat

ttgacaaggg tagccagctt ggagtctagc aacttgccaa tgtgtttacc aatctggggg	3840
cttgtttttc ttttcttctt tcaaataaat ggcagttaac tggctttaca gtaaacattg	3900
aagagaggag gatttgttta ttgtcactgg gaatctgacc actatactgt cctttttttg	3960
tattctgggt aatgtttttt ggaaaagatt tgtcttttct aagtggaagt taaatttgtt	4020
atactgccca tcccctaaag ccaacagaga tttgtagatt taaagggatc acatttgaag	4080
acaatagtgt ttaagaaagc aagcaagtcc cttagcagtc aggtcataac agggcacatt	4140
tctgaccgaa ccctctcaag gcagaggagg agtttggtgg gtttcataca ccctgcagat	4200
tcctgttggc tctaaccctc aattacctaa tcttatgctt taacacataa ctgcattgga	4260
tgtgagagta acgtaccgta tggtcattgt tctatatatt aacattgaac actgctgcga	4320
ttgctcaagg acattttatg ttacggcttt aaagcaaagg catgattatt agaaactatt	4380
taagcttttt tctttgaaaa acaagcttct tttacagaat ataaacaaca gtagtgcctg	4440
tggtttagcc caccaatctt gatgactaaa agtagctgat gcattgtgca tatgatgctt	4500
gagatggttt ttgcaaaagc agaaatcgct gcaaggtaat cacaatagat aaaagtggta	4560
ttttaaacct ttgaaataaa tggatgtaac tgtaccttgg tacagctttt cacttgttta	4620
gtttttaaac gttagtataa tctgaataaa taaaatgttg ccaaattcaa tgtagaaaga	4680
atgtgacaac acaccttggg tagttctgct tgtgtttttg catattgtaa aagcagtgtc	4740
acagctaaaa agaaagaaat cgtttctaac agtaaattat tgtgctttag ttgctagttt	4800
gtactgagag ttgacctctc cctgtgcagt tttttgttct aaacttgtat aaataacaat	4860
tgtgtaatgt gtctccctcc tacattgtaa caattgcttc agcctacgtt ataaataaag	4920
aaccactaga tt	4932
<210> 38 <211> 879	
<211> 073 <211> DNA <213> Homo sapiens	
<400> 38	
agagetecta ecctatetgg gaggaettea actecaagge caegaagetg catteceage	60
tgaggaccac cgtgctggct gctgtggcct tcctggatgc cttccagaaa gtggctgaca	120
tggctaccaa cacccgaggg gccacgaggg acatcggctc ggcgctcaca cgcatgtgca	180
tgcgccaccg cagcattgag accaagctgc ggcagttcac caacgcactg ctggagagcc	240
tcatcaaccc gctgcaggag cgcatcgagg actggaagaa ggcggccaac cagctggaca	300
aggaccacgc gaaagagtac aaacgagccc ggcatgagat caaaaagaag tcgtcggaca	360
cgctgaagct gcagaagaag gcgcgcaaag ggaaaggaga cctgcagccc cagctggaca	420

gtgccctgca ggacgtcaac gacatgtacc tgctgctgga ggagacggag aagcaggccg	480
tgcgccgggc gctgatcgag gagcggggcc gcttctgcac cttcatcacc ttcctgcagc	540
ctgtggtgaa tggagagctg accatgctgg gagagatcac ccacctgcag ggcatcatcg	600
acgacttggt ggtgctgaca gcagaacccc acaaactgcc tcccgccagc gagcaggtaa	660
tcaaagacct aaagggctcg gactacagct ggtcctacca gaccccaccc ctccgtccca	720
tetgaaccat ttgtttcttt tettteegte agattttgga aaaattetee teteeteece	780
gececeteca caccatecte ecegatitaa atatagicae igetacaagi aacagaigea	840
ctgtgaagat tccagtatta ataaaggtgt actgtaatt	879
<210> 39 <211> 354 <212> DNA <213> Homo sapiens	
<400> 39 atgaggctgc ggcaggcacc agagtccaga aaggtgttca ttcagcgaga ctacagcagt	60
ggcacaggct gccagttcca gaccatgttc tccatggagc tggagaacca gattgatagg	120
cagcagtttg aagaaatagt tcaaactcta aataaccttt atgcagaagc agagaagctt	180
ggtggccaat catatctcga aggttgtttg gcttgtttaa cagcatatac catcttccta	240
	300
tgcttggaaa ctcattacca gaagcttctg aagaaagtct ccaaatgcat tcaagagcag	354
aatgagaaga tetatgttee acaaggeett eteetgacag actecattga gtaa	
<210> 40 <211> 1898 <212> DNA <213> Homo sapiens	
<400> 40 agctggaggg cagaggaggc ggcgcggggt gtcctgtcct	60
cgccggtgtc cggaaaggtg ttcattcagc gagactacag cagtggcaca cgctgccagt	120
tccagaccaa gttccctgcg gatggagaac cggattgata ggcagcagtt tgaagaaaca	180
gttcgaactc taaataacct ttatgcagaa gcagagaagc tcggcggcca gtcatatctc	240
gaaggttgtt tggcttgttt aacagcatat accatcttcc tatgcatgga aactcattat	300
gagaaggttc tgaagaaagt ctccaaatac attcaagagc agaatgagaa gatctatgct	360
ccacaaggcc tcctcctgac agaccctatt gagcgaggac tgcgagttat tgaaattacc	420
. atttatgaag acagaggcat gagcagtgga agataaaccg aagaattaaa gatcccactt	480
ccagccgggc ccctcatgta tccactggcc gaccgcagag tgtccctacc tcctctccag	540
agcatcattc ctttctatct gctgccagag ccacggtgcc atttactcca aggactcact	600

ttctaaaatt	ccacacctgg	agtgacctct	agtcgctcag	catccacttt	gtgtctccaa	660
attgtgtagg	actctgtaat	cttttgatta	gtttctgaga	aaacacaatg	aagcacttca	720
cttttttta	ttcaaagcca	tttaataaaa	cacagttggt	cagcccagtg	caaagcttgt	780
tatctgccac	cagtacatac	cattggttct	cttcattcct	tgggccagct	tctcaggtgg	840
ctttagacct	caacaagccg	tatcttcacc	agtgttctat	cttgttcccc	taaattaata	900
aaatgtttt	ctccaggatt	ttggtgaggg	ttggctgtgg	ctgtcgtttt	gcacctccca	960
gatttcaaag	aattactggt	tttaccatga	ctcaaatctt	aagatctgtt	tctactattc	1020
agttcctcaa	actgaagctt	attgaaaaaa	aaatgtataa	tgttatttgt	tttattatag	1080
caattattco	: taattaaagc	agtatttaat	gcaatttcca	gttatttctt	tggagaattt	1140
tatgtcattg	ttccattacc	ttgaatgttg	gaaagatatg	atacgtgctg	cttgttcatc	1200
acaaaaatca	a gtaagcacaa	taaagtggat	gccaaaccat	cagacacata	aatgttcccg	1260
ctgtgtccct	ggatatggaa	taagcaggta	taaaaaatat	tttaattata	gttttgttat	1320
aaatataaci	tatgagaaaa	aaatttgata	ggaataatac	tgtatattac	taatttttaa	1380
ctatcccta	a ggcaaacctt	atgacccaca	gaattttctc	atatacagta	ttcagtgcac	1440
agaaatctt	a tgattggctc	aagtacagta	agttacttct	cagtaaaact	ctcaagtctg	1500
agtccatat	t tgtagctctg	cttttggctg	tacgttccta	ggatcggggc	tgcttatgcc	1560
tttcgttta	t cettggggtt	tgagagcgct	gtatttggga	gagagtttaa	aaatacatta	1620
ggagagaga	a accattaaaa	gtttcactgt	cagagatatt	gtaggtgcta	atactggatt	1680
tcgtctcag	a tttaatttct	: tttatgggtc	tgttagtcat	tcaacaaatc	ccataagtat	1740
gtgttaata	t tttaattgtg	, taaaactcat	ttgttacttt	acageetgta	atagtgtgtc	1800
tgcattttc	a acctgttgca	ataactttgc	tgaaatatta	acacattaat	aaaacttttc	1860
ttaaacaaa	a aaaaaaaaa	aaaaaaaaaa	aaaaaaaa			1898

<210> 41

<211> 3640

<212> DNA

<213> Homo sapiens

<400> 41
gtgcagaagg ccgcgctagc cggctcttca gcagcgagtg cagattgctc ccccgcggcc 60
gcagatctcc cgtttgcgcc gcgttcagct gctcccgaac aacttttctg ccggcccaga 120
ggccccaggg cgtcgcagcg ccgcgtgcgg cccactcacg ggccggcagg atggactcca 180
acactgctcc gctgggcccc tcctgcccac agcccccgcc agcaccgcag ccccaggcgc 240
gttcccgact caatgccaca gcctcgttg agcaggagag gagcgaaagg ccccgagcac 300
ccggacccca ggctggccct ggccctggtg ttagagacgc agcggcccc gctgaacccc 360

aggcccagca taccaggagc cgggaaagag cagacggcac cgggcctaca aagggagaca 420 tggaaatccc ctttgaagaa gtcctggaga gggccaaggc cggggacccc aaggcacaga 480 ctgaggtggg gaagcactac ctgcagttgg ccggcgacac ggatgaagaa ctcaacagct 540 gcaccgctgt ggactggctg gtcctcgccg cgaagcaggg ccgtcgcgag gctgtgaagc 600 tgcttcgccg gtgcttggcg gacagaagag gcatcacgtc cgagaacgaa cgggaggtga 660 ggcagctctc ctccgagacc gacctggaga gggccgtgcg caaggcagcc ctggtcatgt 720 actggaagct caaccccaag aagaagaagc aggtggccgt ggcggagctg ctggagaatg 780 840 teggecaggt caacgageac gatggagggg cgcagecagg cecegtgeec aagteeetge agaagcagag gcggatgctg gagcgcctgg tcagcagcga gtccaagaac tacatcgcgc 900 960 tggatgactt tgtggagatc actaagaagt acgccaaggg cgtcatcccc agcagcctgt tcctgcagga cgacgaagat gatgacgagc tggcggggaa gagccctgag gacctgccac 1020 1080 tgcgtctgaa ggtggtcaag taccccctgc acgccatcat ggagatcaag gagtacctga 1140 ttgacatggc ctccagggca ggcatgcact ggctgtccac catcatcccc acgcaccaca tcaacgcgct catcttcttc ttcatcatca gcaacctcac catcgacttc ttcgccttct 1200 tcatcccgct ggtcatcttc tacctgtcct tcatctccat ggtgatctgc accctcaagg 1260 tgttccagga cagcaaggcc tgggagaact tccgcaccct caccgacctg ctgctgcgct 1320 1380 tcgagcccaa cctggatgtg gagcaggccg aggttaactt cggctggaac cacctggagc cctatgccca tttcctgctc tctgtcttct tcgtcatctt ctccttcccc atcgccagca 1440 1500 aggactgcat cccctgctcg gagctggctg tcatcaccgg cttctttacc gtgaccagct acctgageet gageaceeat geagageeet acaegegeag ggeeetggee acegaggtea 1560 1620 ccgccggcct gctatcgctg ctgccctcca tgcccttgaa ttggccctac ctgaaggtcc ttggccagac ettcatcacc gtgcctgtcg gccacctggt cgtcctcaat gtcagcgtcc 1680 1740 cgtgcctgct ctatgtctac ctgctctatc tcttcttccg catggcacag ctgaggaatt 1800 tcaagggcac ctactgctac cttgtgccct acctggtgtg cttcatgtgg tgtgagctct 1860 ccgtggtcat cctgctggag tccaccggcc tggggctgct ccgcgcctcc atcggctact 1920 tectetteet etttgeeete eccateetgg tggeeggeet ggeeetggtg ggegtgetge 1980 agttegeceg gtggtteaeg tetetggage teaccaagat egeagteaec gtggeggtet 2040 gtagtgtgcc cctgctgttg cgctggtgga ccaaggccag cttctctgtg gtggggatgg 2100 tgaagtccct gacgcggagc tccatggtca agctcatcct ggtgtggctc acggccatcg 2160 tgctgttctg ctggttctat gtgtaccgct cagagggcat gaaggtctac aactccacac 2220 tgacctggca gcagtatggt gcgctgtgcg ggccacgcgc ctggaaggag accaacatgg

				aataacataa	accaaccact	2280
	gatectetge					
	ccgcgtgact					2340
cgttcttcat	cggcgactgg	atgcgctgcc	tctacggcga	ggcctaccct	gcctgcagcc	2400
ctggcaacac	ctccacggcc	gaggaggagc	tctgtcgcct	taagctgctg	gccaagcacc	2460
cctgccacat	caagaagttc	gaccgctaca	agtttgagat	taccgtgggc	atgccattca	2520
gcagcggcgc	tgacggctcg	cgcagccgcg	aggaggacga	cgtcaccaag	gacatcgtgc	2580
tgcgggccag	cagcgagttc	aagagcgtgc	tgctcagcct	gcgccagggc	agcctcatcg	2640
agttcagcac	catcctggag	ggccgcctgg	gcagcaagtg	gcctgtcttc	gagctcaagg	2700
ccatcagctg	cctcaactgc	atggcccagc	tctcacccac	caggcggcac	gtgaagatcg	2760
agcacgactg	gcgcagcacc	gtgcatggcg	ccgtgaagtt	cgccttcgac	ttctttttct	2820
tcccattcct	gtcggcggcc	tgaggatggt	ccgccacgag	gagcttccag	tgcatgttgc	2880
catgaggcct	ttccccagtg	tggccccagc	ccgacaggca	tgcaccagtg	ccgcctgtgc	2940
ccacgtgtgc	agactgtggc	tgcagagacc	ttgcgaccat	gtgtagattg	cgtggacccc	3000
gacaaaggga	aggctgctgt	gtagctctgt	ccactctgaa	taccaagtgt	gttgggaatt	3060
gcatgccatc	tccaccctga	gcctgacctt	tctgagtgac	atgggtgtgc	caggctagac	-3120
taggaggtto	cggtgtctgg	aaaagcactt	tacagatgag	attccctctc	ctccccacc	3180
ttcaagcaco	: ctgttccctc	tttctttctt	ttgtgttgga	tttgtttaaa	aaccaaataa	3240
gcatctgtgt	: aacctccaca	gtagcatttc	ttatttgttt	ggtcactgct	acaccttagc	3300
agctcttccc	ctttcctggg	ggatgtgcac	ggcagcttga	gcctgtcacg	tggtcaaggc	3360
ccggccccat	: cagaggctgg	gggaggcggc	acattggcag	tgtgtcacac	tgagctgggc	3420
accacaggct	gcctcatgac	cctcctgtcc	agcaggtagt	gggtgaatgt	gtgaaggtct	3480
tgcctgaato	catcaggact	tgggaaacag	gagaccctgt	gggggcggct	gtgggggagg	3540
tccctgccag	g tgtttagaag	g agcctgactg	tgttcagtgc	cttggagcag	aaagccaggg	3600
tcctgagtg	g ctgaaataaa	a agcctctggt	ggaacctgca			3640
<210> 42 <211> 19 <212> DN <213> Hor						
<400> 42	a adototodo	a aggggatge	cccgagggtq	ccagtccago	: tagctgcccc	60
					g cagccctgtg	120
acccctcag	g cocageoug	, coccaage	_ coccactory	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	

180

ggcaagcage cgccgccatg gccgagcacc tggagctgct ggcagagatg cccatggtgg

gcaggatgag	cacacaggag	cggctgaagc	atgcccagaa	gcggcgcgcc	cagcaggtga	240
agatgtgggc	ccaggctgag	aaggaggccc	agggcaagaa	gggtcctggg	gagcgtcccc	300
ggaaggaggc	agccagccaa	gggctcctga	agcaggtcct	cttccctccc	agtgttgtcc	360
ttctggaggc	cgctgcccga	aatgacctgg	aagaagtccg	ccagttcctt	gggagtgggg	420
tcagccctga	cttggccaac	gaggacggcc	tgacggccct	gcaccagtgc	tgcattgatg	480
atttccgaga	gatggtgcag	cagctcctgg	aggctggggc	caacatcaat	gcctgtgaca	540
gtgagtgctg	gacgcctctg	catgctgcgg	ccacctgcgg	ccacctgcac	ctggtggagc	600
tgctcatcgc	cagtggcgcc	aatctcctgg	cggtcaacac	cgacgggaac	atgccctatg	660
acctgtgtga	tgatgagcag	acgctggact	gcctggagac	tgccatggcc	gaccgtggca	720
tcacccagga	cagcatcgag	gccgcccggg	ccgtgccaga	actgcgcatg	ctggacgaca	780
tccggagccg	gctgcaggcc	ggggcagacc	tccatgcccc	cctggaccac	ggggccacgc	840
tgctgcacgt	cgcagccgcc	aacgggttca	gcgaggcggc	tgccctgctg	ctggaacacc	900
gagccagcct	gagegetaag	gaccaagacg	gctgggagcc	gctgcacgcc	gcggcctact	960
ggggccaggt	gcccctggtg	gagctgctcg	tggcgcacgg	ggccgacctg	aacgcaaagt	1020
ccctgatgga	cgagacgccc	cttgatgtgt	gcggggacga	ggaggtgcgg	gccaagctgc	1080
tggagctgaa	gcacaagcac	gacgccctcc	tgcgcgccca	gagccgccag	cgctccttgc	1140
tgcgccgccg	cacctccagc	gccggcagcc	gcgggaaggt	ggtgaggcgg	gtgagcctaa	1200
cccagcgcac	cgacctgtac	cgcaagcagc	acgcccagga	ggccatcgtg	tggcaacagc	1260
cgccgcccac	cagcccggag	ccgcccgagg	acaacgatga	ccgccagaca	ggcgcagagc	1320
tcaggccgcc	gccccggag	gaggacaacc	ccgaagtggt	caggccgcac	aatggccgag	1380
tagggggctc	cccagtgcgg	catctatact	ccaagcgact	agaccggagt	gtctcctacc	1440
agctgagccc	cctggacagc	accacccccc	acaccctggt	ccacgacaag	gcccaccaca	1500
ccctggctga	cctgaagcgc	cagcgagctg	ctgccaagct	gcagcgaccc	ccacctgagg	1560
ggcccgagag	ccctgagaca	gctgagcctg	gcctgcctgg	tgacacggtg	acccccagc	1620
ctgactgtgg	cttcagggca	ggeggggaee	cacccctgct	caagetcaca	gcccggcgg	1680
tggaggctco	cgtggagagg	aggccgtgct	gcctgctcat	gtgaggctgt	tgctcagcat	1740
gcaggggcc	tgtcgcgggc	acagcccaag	getgeeteee	cacggtgcgt	gccctggtgc	1800
tgcgggtgca	gcacggaaac	cccggcttct	actgtacagg	acactggccc	: ctctcaggtc	1860
agaagacato	g cctggaggga	tgtctggctg	caaagactat	tttatcctg	g caactcttga	1920
taaagggctg	g ttttgccatg	gaaaaaaaa	aaaaaaaaaa	aaaaaaaaa	aaaaaa	1976

<211> 6162 <212> DNA

<213> Homo sapiens

gccacaccat gaggccccag ccccaccaga ggccccgcgc tgccctggcc cccggtgcac 60 cgtgctagcc cccagccagg gcgttgggga gggcggtggc catggccagt cacgtggacc 120 tgctgacgga gctgcagctg ctggagaagg tgcccacgct ggagcggctg cgggctgccc 180 agaagegeeg ggeecageag etgaagaaat gggeacagta egageaggae ttgeageace 240 gcaagcgaaa gcatgagcgg aagcgcagca cgggcggccg ccgcaagaaa gtgtccttcg 300 360 aggccagcgt ggccctgctg gaggcctcgc tgaggaacga cgccgaggaa gtacgctact tcctgaagaa taaggtcagc cctgatttgt gcaatgagga cggactcaca gccctacacc 420 agtgctgcat cgacaacttt gaggaaattg tgaagctgct cctctcccat ggtgccaatg . 480 540 tgaacgccaa ggacaacgag ctgtggacac ctctccatgc tgcagccacc tgcggccaca 600 tcaacctggt gaagatcctc gttcagtatg gggccgactt gcttgctgtc aactcggatg ggaacatgcc atatgacctc tgcgaggatg aacccaccct ggatgtcatc gagacctgca 660 tggcatacca gggcatcacc caagagaaaa tcaacgagat gcgggtggct cctgagcagc 720 agatgattgc ggacatccac tgcatgatcg cagcgggcca ggacctggac tggatagatg 780 cccagggtgc cacactgctg cacatagctg gagccaatgg atacctgcgg gcagctgagc 840 tcctcctgga ccatggagtg cgtgtggatg tgaaggactg ggatggctgg gagcccctgc 900 960 atgcagctgc cttctgggga cagatgcaga tggcagagct attggtgtcc catggagcta 1020 gtctcagtgc aaggacatcc atggatgaga tgccaataga cctgtgcgag gaggaagagt tcaaggtcct gctgctggag ctaaaacaca agcatgatgt gatcatgaag tcacagctga 1080 ggcacaagtc atccttgagc cggaggacct ccagcgcagg cagccgtggg aaggtggtgc 1140 ggcgagccag cctgtcggac aggaccaacc tgtataggaa ggagtatgag ggagaggcca 1200 tcctgtggca gcggagtgca gctgaggatc agcggacctc cacctacaac ggggacatca 1260 1320 gggagaccag gacagaccaa gagaataagg accctaaccc caggctggag aagcccgtgc tactctccga atttcctacc aagatcccac gaggtgaact ggacatgcct gttgagaatg 1380 gcctccgggc tccggtcagt gcctaccagt atgcgctggc caacggggat gtctggaagg 1440 tgcatgaggt gcctgactac agcatggcct atggcaaccc tggcgtggcc gacgccaccc 1500 1560 cgccctggag cagctacaag gaacagagcc ctcagacgct tctggagctg aagcggcagc gggctgcagc caagctgctc agccacccct tccttagcac acacctgggc agcagcatgg 1620 1680 ccaggacggg cgagagtagc agtgaaggca aggccccctt gatcggaggc agaacttcac 1740 cgtacagcag caatgggacc tcggtatatt acacggtcac cagcggagat cccccactct

					taccatatat	1800
			aggagaaggt			
cctagtctcc	gtgtgatgga	ggagggagat	gcctggggag	gggctcctgg	aatccaggcc	1860
agcccaacag	ccctggctgg	ggaggtgtca	gggcagctgg	ggagaggtgg	gctctgcttt	1920
tcagaggaac	tcagacccca	gccctcagct	ggctgcccat	agcatcccat	gtcccacgtc	1980
ccgtggttct	gcttcctgct	gcatcgtctg	ccatctgaca	caaggcctgt	cgtggcctcc	2040
tggttcactc	tgctgtctga	tcttgggagg	gtgggcttga	gatcccagct	ctattcttgg	2100
tataaaggct	tctccggatc	agtacatgca	tgtcacatta	acacacacac	acacacacat	2160
atacacacac	acacaagctc	gatcagtgtg	tgtaggaatg	acatacctgg	gctcagggga	2220
agcaaggggg	cttagaattt	gtggggtatt	cccaaaagga	tggaagttaa	gactcagagt	2280
ctcattacca	ctgccaatgt	ggttttagca	ggggagggga	cctgctaagc	tgagacccat	2340
agtectgete	agagttatcc	caaagtctga	gccaccagcc	acacctgaca	ggggtgagaa	2400
gtcctcgctg	tgttcagagg	gagccaggaa	tctacatggg	tagatgagat	agacacagac	2460
ctgctccccg	cagccttgtt	gagagccaca	cttctgccca	tgccaggagc	cagctgtgtg	2520
accatccagg	ggtggagggg	gaaaaccagg	caatttcgtt	cctggaatca	accaaatcat	2580
gttttcctct	tggatggaag	tgtcaaaggc	agaagggtgt	gggaggggga	caaggtcagt	2640
atttaccaaa	gtgtatctga	ttttaaaaat	tcctttagtc	tgtaaaactc	ctagagggag	2700
ggaggtaact	gaattcactt	ctttttgtgg	atcgtatcaa	ggtcactggg	ttttactggc	2760
tggtgctggg	aaaatgaagc	taagtgagga	gcttccattg	gaatgctttt	ccagggagag	2820
aggccagtta	atttaaaaaa	aacagtcgct	agttaacagc	gacagagccc	agcaccctgg	2880
ggtctttgtg	aatatccaga	ctgtttcago	ccagcccatc	tcagccaacc	ctccttagac	2940
tgagctgtca	gagcaagcaa	ttaggggcca	geetgeetee	acctcccacc	cccttccacc	3000
tccatcagto	: atgtgtgcag	g agtcagtgct	cgggatcccg	ggcccagctt	ttgccttttt	3060
ggggatgctt	ggtgagacag	g atttgccagt	cagccctttt	gagttcccgc	ctcacccagg	3120
ggctcccago	ctgcacttgo	aggagtggtg	g atgccccaag	tctgcgaatc	cagggtgcac	3180
gtggtcaata	tcccctcctg	g cattcaggag	g agccatggta	gggctagagt	tgggtcttgc	3240
ccagccctgo	c agtttcatag	g teccageett	cctggtgctg	gggagggagg	actgtgaatg	3300
gctgttctcc	c cctcactgc	t gagtetecca	a ggaccccctt	tggagatgcc	: catggcatgg	3360
gcactgccca	a caggeteage	c cagaacctc	t tggtgtaccc	gataagctgc	: aggttatccc	3420
ttgctctgtg	g cgcctttta	t ttgtcctta	a actacctcct	tagagetetg	aaggggtctc	3480
ctagttccag	g attttaatt	t ggggaacag	a tctgggttct	tttaaccct	: cttctttctc	3540
agtctatga	g aaacttgcc	c tgaggggca	c ctgggctagg	ggcttgggad	: tggaagacca	3600

teccegeett gtgecacaae tttggteatg ggatetgete tttgteatte ttageceeet 3660 actgtggccc ccatagcccc ataacccaga gagggagctg gacttcaggg agcctgagtg 3720 atgettteee aggageaggg cagetggetg gaccagaaag tagagggeee atgggagtga 3780 3840 ctgcaccctt ggtggctgct ggaaggggag aggttctcag catcaggcca cctccacccc aatgccagga tagatgtatt ctagagtagg ggtggaggcg gcccaggagg ctgaagacag 3900 gtgcacagat gcttcccacg accttgccat ttggggtggg ctcttcaaca tctcaggctg 3960 tggctggaac aggacaggat gatctaaaac acacgtacca ttggctgtaa aacagtatga 4020 4080 gcccagactg acgctgaaat ccctcatgag ccaaccttag ctacaaggta gggagttctg agggaagccg cgtgctcctc aggagagagc tgtttaggtt ttccgatctt tttgctcagg 4140 ggccaaacac tgaaggcacg tactgcccaa cccactgagc gcctgaggcc attccctcct 4200 tttccgcatg cctcctgcct cctgggctat tcctctccac ccagaaggct gggaatccca 4260 4320 gctgattccc tgacaggagc cgacttcaca cacaggtgac tctcaggcat tggctcatgt tttcagccag ggataaacca tcccttcttg gggctttaag tccctgggga gctttccctg 4380 taggtetect gggtgttgag agacaagttg gagaccaacc tecaatgaat gageegeggt 4440 cattcattaa ttcactcacg taatttactg agtagctgca acatgccagc ctctacgtta 4500 4560 ggttctgcgg ataaaggagg aataagacag agtcaggaga actgttcctt gtggtttccg tcccttgggg accacaggca tcagcagtcc cattcaagtc acctgaggca aagtgtctgc 4620 atcttcgtcc agcgaccctt tgcttttcgg ctcctagaat ccttagagtc tgaattcctt 4680 4740 tagctgggaa cagctgtcat ggtcacccct ggataacatt tgccaccaag tatagatgct 4800 ggatcttggg ttccaggcag acatcatcca ggtccatctg gaactttcag tgatagctgc 4860 cttcagccag catctttggg ggactctata atagcagctt gagatcagtg tctagaagac tgttctgcaa tttgctgcca aatgcatctc aggtttttaa agtcattgtt tcttgctcat 4920 ggtggctcat ttattacata gtcccctcac cccactaatg gataatggga ggaaaagttg 4980 ctgcttcctt cagcatcaaa gcctttcctt gggaatctgc ctccctccat ggcaggggtg 5040 5100 gattcgggag ctgggagtaa ccaggcaaag tcaaccagat gcctagctcc tgctgagacc caggtcctat ggcagctcct cattagatta aaggagacca cttccaaagc aggtgctgca 5160 5220 tggctcacca tcatatgccc caaacaactg aaagttggcg gttatcacca gactgtgagt ttctggcaag tagcttgggg aagctgaata aactctaggc ccagggctac taaagacttc 5280 aggatagaat totocatcaa atatacagca taagtaaaac tgototgcac tgtttaatco 5340 atttccaagg ggcttagaaa agctaacaag ggtgtgtccc ctgtcctgcc ccaccggttt 5400 getggetttg taataacata agaccattgt ggttgttggt gtcagatacc ttcccatcct 5460

gagctctctc	acctacctgc	teteteteet	agagcaggat	actggggtac	ttttaagaag	5520
ggtgctcctt	ttaagatgcc	cagaaaagct	gtatttaact	cttgctattt	gtaacttggg	5580
gatggtctcc	cctgccccag	ggcacataag	agcaaaggct	ccaatggtca	gtggatgact	5640
ctgcaaaagt	gaccccctgt	gccagaagct	atagccctct	ccccaacagg	tctctcttgt	5700
tggccagagg	gcctgcttcc	catgggcatt	gcaagtgcca	ccgtgcgggg	cctggctctg	5760
cacacccagg	aaaagtctgc	agacccccag	ccctccgcaa	taattcacca	gaccagaagc	5820
cactggtgta	cagagaacac	ttaaaaaaat	gtattttatg	tgaaaaaaaa	ttaaaactct	5880
gtatactgta	tcagcagctt	tgtgtaaaaa	tggcaatcaa	gagagtctaa	tatatttaaa	5940
acttttttaa	aaaaaatctt	cgcagatctt	tgatatcgta	ctgaggtaac	ttccacgtag	6000
ccccttgcca	cgcggcaccg	gtgggccttg	ggtccaaaac	tgtggctcag	ccacatccca	6060
aagggggcac	atgtccctgg	agttgcttcc	agctgccaag	gcctgtgaca	gaattcgctg	6120
ttaagagttt	ttaattaaaa	ttattaaatt	ccttttaata	ac		6162
<210> 44 <211> 161	9			:		

<212> DNA

<213> Homo sapiens

<400> 44 gctcggttca tgccgtgccc ccgggcagtt ctggtgaggc taagcaagag gcctctgcat 60 cttgacacct aggagagcag ggacggagtc tcccagggtg gaggaccatg ctgcgccgca 120 180 agccctccaa tgccagtgag aaggagccca ctcagaagaa aaagctctcc cttcagcgct ccagcagctt caaggatttt gccaaatcca aacccagctc ccccgtggtg agcgagaagg 240 300 agtttaatct ggatgataac attccagaag atgactcagg tgtccccacc ccagaagatg ctgggaagag tggcaaaaag ctggggaaga agtggagggc agtgatttcc cgaaccatga 360 acaggaagat gggcaagatg atggtgaagg ccctgtcaga agagatggca gacactctgg 420 aggagggete tgeeteeceg acateteeag actaeageet ggaeageeet ggeeetgaga 480 540 agatggcgct ggccttttct gagcaagagg agcatgaact tccggtgctc agccgccagg catcaacagg cagtgagctc tgcagcccca gcccaggttc tggcagcttc ggggaggaac 600 660 cacctgcccc ccagtacaca gggcctttct gtggccgggc acgagtccac accgacttca ctcccagccc ctatgaccac gactcgctga aactgcagaa aggagatgtg atccagatca 720 780 ttgaaaagcc acctgtgggc acgtggctgg gcctactcaa tggcaaggtg ggctctttca aattcatcta tgtggatgtg ctgcccgagg aggccgtggg gcatgcccgc cccagccgcc 840 900 gacagagcaa gggcaagagg cccaagccta agaccctgca tgagctgctg gagcgcatcg

gcctggagga	gcacacatcc	accctcctgc	tcaatggcta	ccagacactg	gaagacttca	960
aagagctgcg	agaaacacac	ctcaatgagc	tgaacatcat	ggatccacag	caccgggcca	1020
agctgctcac	ggccgccgag	ctgctgctgg	actatgacac	tggcagtgag	gaggctgaag	1080
agggcgccga	gagcagccag	gagccagtgg	cacacacagt	gtcggaaccc	aaggtggaca	1140
tcccgcgcga	ctcaggctgc	tttgagggct	cggagagcgg	gcgcgatgac	gcagagctgg	1200
caggcactga	ggagcagctg	caaggcctct	ccctggccgg	ggcaccttga	ggtggcggtg	1260
gcaataggcc	aaggctggga	cccagctgca	aaggctgtag	gagtgggccc	agcctcccgt	1320
ggtggcccag	gtcctgagga	ctggcactga	gcctggccct	gcttccccag	ggacacttag	1380
ggccacagag	gccaggccag	ggccctacag	gttccaggct	cagctggagt	ggttggggag	1440
tcgcccaagg	gcacatccca	cctgcctgag	cccgccctc	caccagcgac	tgacagcgca	1500
gcccctcctg	gcaccaactg	ctcccctgcc	atggccacgg	ccacagcaag	tggggcactg	1560
ggaaaccctg	cccatgtccc	tcaccaacaa	ggcctccaaa	tcctcctcac	cccacacc	1619

<210> 45

<211> 4726

<212> DNA

<213> Homo sapiens

<400> 45 attttgaaga gaggggtccc ggggagctcc ctccaagatc tagaggctcc gcggccaccc 60 ctgccgggtc ctgccaagac ttgctagaag gaacgagtcg cgtgccttag ttagttggtt 120 cccgtcacag gaagaaacgc ctttgcagtg ggtttaattg cttctgggcc gagcgaattc 180 cccgccgtac aactcagtgg tgcggacttt gcctcctgct accctgttgc tgcgccgagc 240 ggggtgggaa agtttctgga gttgtcagtc gcgcagcccg tggccaccta gacccgaggt 300 360 gcgggcgcct gcgaagggcc cccgcggggt ggccggggcc gccggggcat gcagcgcggg 420 ggcgcggctc ggtgacgccg cgggcgggga cccggcatcc gggcaggctg cgcgcgggtg cggggcgagg gcgccgcggg gactgggacg cacggcccgc gcgcgggaca cggccatgga 480 540 ggacgcggga gcagctggcc cggggccgga gcctgagccc gagcccgagc cggagcccga gecegegeeg gageeggaae eggageecaa geegggtget ggeaeateeg aggegttete 600 ccgactctgg accgacgtga tgggtatcct ggacggttca ctgggaaaca tcgatgacct 660 ggcgcagcag tatgcagatt attacaacac ctgtttctcc gacgtgtgcg agaggatgga 720 780 ggagctgcgg aaacggcggg tttcccagga cctggaagtg gagaaacccg atgctagccc 840 cacgtcactt cagctgcggt cccagatcga agagtcgctt ggcttctgta gcgccgtgtc 900 aaccccagaa gtggaaagaa agaaccctct tcataaatca aactcagaag acagctctgt aggaaaagga gactggaaga agaaaaataa gtatttctgg cagaacttcc gaaagaacca 960

gaaaggaata atgagacaga cttcaaaagg agaagacgtt ggttatgttg ccagtgaaat 1020 aacgatgagc gatgaggagc ggattcagct aatgatgatg gtcaaagaaa agatgatcac 1080 aattgaggaa gcacttgcta ggctcaagga atacgaggcc cagcaccggc agtcggctgc 1140 cctggaccct gctgactggc cagatggttc ttacccaacg tttgatggct catcaaactg 1200 caattcaaga gaacaatcgg atgatgagac tgaggagtcg gtgaagttta agaggttaca 1260 caagctggta aactccactc gcagagtcag aaagaaacta attagggtgg aagaaatgaa 1320 1380 aaaacccagc actgaaggtg gggaggagca cgtgtttgag aattcgccgg tcctggatga acggtccgcc ctctactctg gcgtgcacaa gaagcccctt ttctttgatg gctctcctga 1440 gaaacctccc gaagatgact cagactctct caccacgtct ccatcctcca gcagcctgga 1500 cacctggggg gctggccgga agttggtcaa aaccttcagc aaaggagaga gccggggcct 1560 gattaagccc cccaagaaga tggggacatt cttctcctac ccagaagaag aaaaggccca 1620 1680 gaaagtgtcc cgctccctca ccgaggggga gatgaagaag ggtctcgggt ccctaagcca cgggagaacc tgcagttttg gaggatttga cttgacgaat cgctctctgc acgttggcag 1740 taataattot gacccaatgg gtaaagaagg agactttgtg tacaaagaag tcatcaaatc 1800 acctactgcc tctcgcatct ctcttgggaa aaaggtgaaa tcagtgaaag agacgatgag 1860 aaagagaatg tctaaaaaat acagcagctc tgtctctgag caggactcgg gccttgatgg 1920 aatgeetgge teeceteege etteacagee egaceeegaa caettggaca ageeeaaget 1980 caaggeeggg ggttetgtag aaagtetteg cagttetete agtgggeaga getecatgag 2040 cggtcaaaca gtgagcacca ctgattcctc aaccagcaac cgggaaagcg tcaagtcgga 2100 2160 agatggggat gacgaagagc cgccttaccg aggcccgttc tgcgggcgtg ccagggtgca caccgacttc acccccagtc cctatgacac agactcactc aagctcaaga aaggagatat 2220 catcgatata atcagcaagc cacccatggg gacctggatg ggcctgctga acaacaaagt 2280 cggcacgttc aagttcatct acgtggacgt gctcagtgaa gacgaggaga aacccaaacg 2340 2400 ccccaccagg aggcgtcgga aaggacgacc accccagccc aagtctgtgg aggatctcct ggatcggatt aacctaaaag agcacatgcc cactttcctg ttcaatggat atgaagattt 2460 2520 ggacaccttt aagctgctgg aggaggaaga cttggatgag ttaaatatca gggacccgga acacagaget gttetettga cagcagtgga getgttacaa gagtatgaca gtaacagega 2580 2640 ccagtcagga tcccaggaga agctgctcgt tgacagccag ggcctgagtg gatgctcacc 2700 ccgagactca ggatgctacg aaagcagtga gaacctggaa aacggcaaga ctcggaaagc 2760 tagcctccta tctgccaagt catccaccga gcccagcttg aagtctttta gcagaaacca 2820 gttgggcaat tacccaacat tgcctttaat gaaatcaggg gatgcactga agcagggaca

ggaggagggc	aggctgggtg	gtggccttgc	cccagacacg	tccaagagct	gtgacccacc	2880
tggtgtgact	ggtttgaata	aaaaccgaag	aagcctccca	gtttccatct	gccggagctg	2940
tgagaccctg	gagggccccc	agactgtgga	cacttggccc	cgatcccatt	ccctggatga	3000
ccttcaagtg	gagcctggtg	ctgagcaaga	cgtgcctacc	gaggtgacag	aaccgccccc	3060
tcagattgta	cctgaagtgc	cacagaagac	gaccgcctct	tccacgaagg	cccagcccct	3120
ggagcaagac	tctgctgtcg	acaatgcatt	gctactgacc	caaagcaaga	gattttctga	3180
acctcagaaa	ttgacaacta	agaaactgga	gggctcaatc	gcagcctctg	gtegeggeet	3240
gtcaccccct	cagtgtttgc	ccagaaacta	tgatgctcag	cctcctggag	ctaaacacgg	3300
tttagcaagg	acgcctctgg	agggccacag	aaaaggacac	gagtttgaag	gaacacacca	3360
tcccctgggc	accaaagaag	gggtagatgc	tgagcagaga	atgcagccca	aaattccatc	3420
acagcctcca	cctgttcctg	ccaaaaagag	cagagaacgc	cttgctaacg	gactccaccc	3480
tgttcccatg	ggccccagtg	gggccctccc	cagtcccgat	gcgccatgcc	tgccagtgaa	3540
aaggggcagc	cccgccagcc	ccaccagccc	tagcgactgt	ccccagcac	tggctcccag	3600
gcctctctca	gggcaggcgc	ctggcagccc	accaagcaca	aggccgcccc	cctggctctc	3660
agagetecce	gagaacacaa	gcctccagga	gcacggtgtg	aagctgggcc	cggctttgac	3720
caggaaggtc	tcctgtgccc	ggggagtgga	tctagaaacg	ctcactgaaa	acaagctgca	3780
cgctgaaggc	atcgatctca	cggaggagcc	gtattctgat	aagcatggcc	gctgtgggat	3840
tcctgaagcc	ctggtgcaga	gatacgcaga	ggacttggat	cagcccgagc	gggacgtcgc	3900
cgccaacatg	gaccagatcc	gggtgaagca	gcttcggaag	cagcaccgca	tggcgattcc	3960
aagtggtgga	ctcacggaaa	tctgccgaaa	gcccgtctct	cctgggtgca	tttcgtctgt	4020
gtcagattgg	ctcatttcca	teggtetgee	catgtacgcc	ggcaccctct	ccaccgcggg	4080
cttcagcaca	ctgagccaag	tgccttctct	gtctcacact	tgccttcagg	aggccggcat	4140
cacagaggag	agacacataa	gaaagctcct	atctgcagco	agactcttca	aactgccgcc	4200
aggccctgag	gccatgtagc	caggcccgga	atgggcctct	ctggacaaga	gccacccttt	4260
cactgtgcat	atgatgctga	tgcaattcct	ccatcatctc	: tggacgtgca	gaccagatcc	4320
agaagaaagg	cctggcgtgt	ggccaaacag	cgtgaaacct	tggcacagga	ctgaggatcc	4380
tctcctccag	aaaagcccc	: tcgaggaaat	: aaattagtgo	ggttctcttt	gacccccaaa	4440
gacaagacaa	gcacttattt	ttattttcag	g aagacaaaa	g aaccaagat	g ccaactggct	4500
gcgaatgcto	: tatctccagt	ctgtctctgt	gtactggtag	g aggctgggag	g gagtaggggg	4560
cagcctgttc	catttctgat	agtgcccttq	g ctcttctgto	tgtcatctt	g caggatgccc	4620
gagggccaga	tgggcttago	: taggccaaaq	g taacagacto	aagagttat	t gtacattact	4680

gaccacgctc atttgttcaa aagttagaac atctggctgc accagg	726
<210> 46 <211> 2216 <212> DNA <213> Homo sapiens	
<400> 46 ggaagctcag cagtgtccac tgtcgccatt ccttggccat agaaaacaat gtatttgaat	60
tttgatgtaa gcatagcaaa ttgaagatga agatgacacg ttgatttctt gtttgaaatt	120
aaccaagtcc cgagaaaaga aagtgaatag tgttagcacg aggaggaagg aagaaatgga	180
gattagattg gatactcttt ctgcatcact gggtagatcc agcactttaa atgactgcaa	240
cttggaagat aaattagctt ggtatgaagg tgaagcttac atgtggcatc actggaagcc	300
ttttcctgaa aaccetetet ggacatgtet tgatttecaa atageacaag ttggaccetg	360
ggactactgc tcctcttgta ttcgccacac acgtctcaag tcttcctgct cagatatgga	420
totoctacat toatggogaa goagoagttt tgggaattto gatogtttto ggaataatto	480
tttatcaaaa ccagatgatt caactgaggc acatgaagga gatcccacaa atggaagtgg	540
agaacaaagt aaaacttcaa ataatggagg cggtttgggt aaaaaaatga gagctatttc	600
atggacaatg aagaaaaaag tgggtaaaaa gtacatcaaa gccctttctg aggaaaagga	660
tgaggaagat ggagagaatg cccacccata tagaaacagt gaccctgtga ttgggaccca	720
cacagagaag gtgtccctca aagccagtga ctccatggat agtctctaca gtggacagag	780
ctcatcaagt ggcataacaa gctgttcaga tggtacaagt aaccgggaca gctttcgact	840
ggatgacgat ggcccctatt caggaccatt ctgtggccgt gccagagtgc atacggattt	900
cacgccaagt ccctatgaca ctgactccct caaaatcaag aaaggagaca tcatagacat	960
tatttgcaaa acaccaatgg ggatgtggac aggaatgttg aacaataaag tgggaaactt	1020
caaattcatt tatgtggatg tcatctcaga agaggaagca gcccccaaga aaataaaggc	1080
aaaccgaagg agtaacagca aaaaatccaa gactctgcag gagttcctag agaggattca	1140
tctgcaggaa tacacctcaa cacttttgct caatggttat gagactctag aagatttaaa	1200
agatataaaa gagagtcacc tcattgaatt aaatattgaa aacccagatg acagaagaag	1260
gttactatca gctgctgaaa acttccttga agaagaaatt attcaagagc aagaaaatga	1320
acctgagccc ctatccttga gctcagacat ctccttaaat aagtcacagt tagatgactg	1380
cccaagggac tctggttgct atatctcatc aggaaattca gataatggca aagaggatct	1440
ggagtctgaa aatctgtctg acatggtaca taagattatt atcacagagc caagtgactg	1500
aacacgcatt cccaactata tatctacaga tgcattccat tttaactctt cttgagctaa	1560

aacgtcaaat	aggagaggaa	gataagataa	atatttgtaa	ataaaaccta	aagtttaaat	1620
gttttaatct	gaataattgt	acataaaatt	ttgtatctct	aacattccaa	attactgtca	1680
ataaaatata	tatttattat	tttaaatgct	atgtgttaat	atttcacttg	cttgtattag	1740
aaaggcaaaa	tgtaagactt	tggtatgtgt	gacatatgct	ttatttggct	ttattttaca	1800
agtacagtat	ctgcaaaaaa	caaagtaacc	ttttttcata	cctgccagtt	ttgaatttat	1860
atatgttatt	gaacaaatag	taatagagga	ttcgctgttg	aaacaagttg	tccaagcaat	1920
gttatattca	tttttatact	tattgggaaa	gtgtgagtta	atattggaca	cattttatcc	1980
tgatccacag	tggagtttta	gtaattatat	tttgttgatt	tcttcatttt	gttttctggt	2040
ataaaagtag	agataatgtg	tagtcacttc	tgatttagtg	aaaccaattg	taataattgt	2100
ggaaatgttt	tgtctttaag	tgtaaatatt	ttaaaatttg	acatacccta	atgttaataa	2160
taaaaagaac	tatttgcata	aaaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaa	2216

<210> 47

<211> 2018

<212> DNA

<213> Homo sapiens

<400> 47 gccccacgcc acgcgtcgct ggtcccaggc agcgagtcgc tcgcgcgccc cgccgcccgc 60 ctggcgacag ctccgccgcg cacgcacatg gaggggagcg cgagccccc ggaaaagccc 120 180 cgcgcccgcc ctgcggctgc cgtgctgtgc cggggcccgg tagagccgct ggtcttcctg gccaactttg ccttggtcct gcagggcccg ctcaccacgc agtatctgtg gcaccgcttc 240 agcgccgacc tcggctacaa tggcacccgc caaagggggg gctgcagcaa ccgcagcgcg 300 gaccccacca tgcaggaagt ggagaccctt acctcccact ggaccctcta catgaacgtg 360 ggcggcttcc tggtggggct cttctcgtcc accctgctgg gagcttggag cgacagtgtg 420 ggccgccgcc cgctgctagt gctggcctcg ctgggcctgc tgctccaggc cctagtgtcc 480 540 gtttttgtgg tgcagctgca gctccacgtc ggctacttcg tgctgggtcg catcctttgt 600 gccctcctcg gcgacttcgg tggccttctg gctgctagct ttgcgtccgt ggcagatgtc agctccagtc gcagccgcac cttccggatg gccctgctgg aagccagcat cggggtggct 660 720 gggatgctgg caagcctcct cgggggccac tggctccggg cccagggtta tgccaacccc 780 ttctggctgg ccttggcctt gctgatagcc atgactctct atgcagcttt ctgctttggt 840 gagacettaa aggageeaaa gteeaecegg etetteaegt teegteaeca eegateeatt 900 gtccagctct atgtggctcc cgccccagag aagtccagga aacatttagc cctctactca 960 ctggccatct tcgtggtgat cactgtgcac tttggggccc aggacatctt aaccetttat

1020

gaactaagca cacccctctg ctgggactcc aaactaatcg gctatggttc tgcagctcag

catctcccct	acctcaccag	cctgctggcc	ctgaagctcc	tgcagtactg	cctggccgat	1080
gcctgggtag	ctgagatcgg	cctggccttc	aacatcctgg	ggatggtggt	ctttgccttt	1140
gccactatca	cgcctctcat	gttcacaggt	gctctctttt	ctgctgtggc	ctgtgtgaat	1200
agcctggcca	tgctgacggc	ctccggcatc	ttcaactcac	tctacccagc	cactctgaac	1260
tttatgaagg	ggttcccctt	cctcctggga	gctggcctcc	tgctcatccc	ggctgttctg	1320
attgggatgc	tggaaaaggc	tgatcctcac	ctcgagttcc	agcagtttcc	ccagagcccc	1380
tgatctgcct	ggaccagaag	acagagggca	agaggagcaa	agtgaacacc	aagcaactgg	1440
aggtctgcag	ctggaagccc	agcccacagc	aggacaagca	actcttgtct	aagggcagtg	1500
ctctctttgg	acgaggtagt	caagagagac	caaggcacca	ccccatccac	agctgaccca	1560
gcctctgtct	aggatctaga	atcataaccc	acacaggccc	actgcaggac	aggtggcaga	1620
ggagctattt	gggacaggag	tcagttctcc	ctttctgcta	tccatcactt	ataaccccac .	1680
aggccagagg	agaggtcctg	agagaggtga	cacttcaggg	accagaggca	gcacgagggc	1740
tggcatctct	ccttccagcc	caaactgcac	agccccaacc	aggttcccaa	cacgtgtagc	1800
agtcatcagc	cattccttaa	caatgaatgt	ggtacctggt	tagtgccagc	cttgggaagg	1860
agggagggag	gtaagagggg	cttggtgatc	tctggaggaa	gagtgttgcc	tttgctgtgg	1920
ttggggaatc	gatccttggc	tatggcctac	ccactcccct	ggctgaagag	tgccaatcat	1980
tacaaatcag	cttcagcaaa	ctgaaaaaaa	aaaaaaaa			2018

<210> 48 <211> 1748

<212> DNA <213> Homo sapiens

<400> 48 tgcccttgaa cccgggcgcg cacgagcgca gggcatccga ggcgacagcc cctggcacgg 60 cccgacctgt acccagcctg gcaggaagac tgtaatcgtg ggaatacagc tacctaccca 120 ggcaatatga agattttatt tgtagaacct gccattttcc ttagtgcatt tgctatgact 180 ttgaccggtc cactgacaac gcaatatgtt tatcggagaa tatgggaaga aactggcaac 240 tacacttttt catctgatag caatatttct gagtgtgaaa aaaacaaaag cagcccaatt 300 tttgcattcc aggaggaagt tcagaaaaaa gtgtcacgtt ttaatctgca gatggacata 360 agtggattaa ttcctgggct agtgtctaca ttcatacttt tgtctattag tgatcactac 420 ggacgaaaat tccctatgat tttgtcttcc gttggtgctc ttgcaaccag cgtttggctc 480 tgtttgcttt gctattttgc ccttccattc cagcttttga ttgcatctac cttcattggt 540 gcaatttgtg gcaattatac cacattttgg ggagcttgct ttgcctatat agttgatcag 600

tgtaaagaac	acaaacaaaa	aacaattcga	atagctatca	ttgactttct	acttggactt	660
gttactggac	taacaggact	gtcatctggc	tattttatta	gagagctagg	ttttgagtgg	720
tcgtttctaa	ttattgctgt	gtctcttgct	gttaatttga	tctatatttt	attttttctc	780
ggagatccag	tgaaagagtg	ttcatctcag	aatgttacta	tgtcatgtag	tgaaggcttc	840
aaaaacctat	tttaccgaac	ttacatgctt	tttaagaatg	cttctggtaa	gagacgattt	900
ttgctctgtt	tgttactttt	tacagtaatc	acttatttt	ttgtggtaat	tggcattgcc	960
ccaatttta	tcctttatga	attggattca	ccactctgct	ggaatgaagt	ttttataggt	1020
tatggatcag	ctttgggtag	tgcctctttt	ttgactagtt	tcctaggaat	atggcttttt	1080
tcttattgta	tggaagatat	tcatatggcc	ttcattggga	tttttaccac	gatgacagga	1140
atggctatga	ccgcgtttgc	cagtacaaca	ctgatgatgt	ttttagccag	ggtgccgttc	1200
cttttcacta	ttgtgccatt	ctctgttcta	cggtccatgt	tgtcaaaagt	ggttcgttcg	1260
actgaacaag	gtaccctgtt	tgcttgtatt	gctttcttag	aaacacttgg	aggagtcact	1320
gcagtttcta	cttttaatgg	aatttactca	gccactgttg	cttggtaccc	tggcttcact	1380
ttcctgctgt	ctgctggtct	gttactactt	ccagccatca	gtctatgtgt	tgtcaagtgt	1440
accagctgga	atgagggaag	ctatgaactt	cttatacaag	aagaatccag	tgaagatgct	1500
tcagacagag	g cctgttaagc	tgctattgat	agtcggagct	tatatactgt	gacttctgaa	1560
gactatacat	gaattcccca	atcagtgctt	tgttgataca	aaatccttaa	aagggaggca	1620
ctttaaagaa	a tatgtatttt	tcacttttct	: taatatgttt	catcggtgac	aggcatgata	1680
atatttctat	atgtaatggg	; taattgggaa	aaaatagatg	ataaataaaa	ttgctctaaa	1740
gaagttaa				•		1748

<210> 49

<211> 2605

<212> DNA

<213> Homo sapiens

<400> 49 60 geggagetee geatecaace cegggeegeg gecaacttet etggaetgga ceagaagttt ctagccggcc agttgctacc tccctttatc tcctccttcc cctctggcag cgaggaggct 120 atttccagac acttccaccc ctctctggcc acgtcacccc cgcctttaat tcataaaggt 180 240 geceggegee ggetteeegg acaegtegge ggeggagagg ggeceaegge ggeggeeegg 300 ccagagactc ggcgcccgga gccagcgccc cgcacccgcg ccccagcggg cagaccccaa cccagcatga gcgccgccac ccactcgccc atgatgcagg tggcgtccgg caacggtgac 360 cgcgaccctt tgcccccgg atgggagatc aagatcgacc cgcagaccgg ctggcccttc 420 ttcgtggacc acaacagccg caccactacg tggaacgacc cgcgcgtgcc ctctgagggc 480

cccaaggaga ctccatcctc tgccaatggc ccttcccggg agggctctag gctgccgcct 540 gctagggaag gccaccctgt gtacccccag ctccgaccag gctacattcc cattcctgtg 600 ctccatgaag gcgctgagaa ccggcaggtg caccetttee atgtetatee ecageetggg 660 atgcagcgat tecgaactga ggeggeagea geggeteete agaggteeca gteacetetg 720 cggggcatgc cagaaaccac tcagccagat aaacagtgtg gacaggtggc agcggcggcg 780 840 gcageccage ecceagecte ecaeggaeet gageggteee agtetecage tgeetetgae 900 tgctcatcct catcctcctc ggccagcctg ccttcctccg gcaggagcag cctgggcagt 960 caccagetee egegggggta catetecatt eeggtgatae aegageagaa egttaeeegg ccagcagccc agccctcctt ccaccaagcc cagaagacgc actacccagc gcagcagggg 1020 1080 gagtaccaga cccaccagcc tgtgtaccac aagatccagg gggatgactg ggagccccgg cccctgcggg cggcatcccc gttcaggtca tctgtccagg gtgcatcgag ccgggagggc 1140 teaccageca ggageageae gccactecae tececetege ceateegtgt geacacegtg 1200 gtcgacaggc ctcagcagcc catgacccat cgagaaactg cacctgtttc ccagcctgaa 1260 aacaaaccag aaagtaagcc aggcccagtt ggaccagaac tccctcctgg acacatccca 1320 attcaagtga teegcaaaga ggtggattet aaacetgttt eecagaagee eecaceteee 1380 tetgagaagg tagaggtgaa agtteeceet geteeagtte ettgteetee teecageeet 1440 ggcccttctg ctgtcccctc ttcccccaag agtgtggcta cagaagagag ggcagcccc 1500 agcactgccc ctgcagaagc tacacctcca aaaccaggag aagccgaggc tcccccaaaa 1560 catccaggag tgctgaaagt ggaagccatc ctggagaagg tgcaggggct ggagcaggct 1620 1680 gtagacaact ttgaaggcaa gaagactgac aaaaagtacc tgatgatcga agagtatttg 1740 accaaagagc tgctggccct ggattcagtg gaccccgagg gacgagccga tgtgcgtcag 1800 gccaggagag acggtgtcag gaaggttcag accatcttgg aaaaacttga acagaaagcc attgatgtcc caggtcaagt ccaggtctat gaactccagc ccagcaacct tgaagcagat 1860 1920 cagccactgc aggcaatcat ggagatgggt gccgtggcag cagacaaggg caagaaaaat gctggaaatg cagaagatcc ccacacagaa acccagcagc cagaagccac agcagcagcg 1980 2040 acttcaaacc ccagcagcat gacagacacc cctggtaacc cagcagcacc gtagcctctg ccctgtaaaa atcagactcg gaaccgatgt gtgctttagg gaattttaag ttgcatgcat 2100 2160 ttcagagact ttaagtcagt tggtttttat tagctgcttg gtatgcagta acttgggtgg aggcaaaaca ctaataaaag ggctaaaaag gaaaatgatg cttttcttct atattcttac 2220 2280 totgtacaaa taaagaagtt gottgttgtt tgagaagttt aaccccgttg cttgttctgc 2340 agccctgtct acttgggcac ccccaccacc tgttagctgt ggttgtgcac tgtcttttgt

agctctggac	tggaggggta	gatggggagt	caattaccca	tcacataaat	atgaaacatt	2400
tatcagaaat	gttgccattt	taatgagatg	attttcttca	tctcataatt	aaaatacctg	2460
actttagaga	gagtaaaatg	tgccaggagc	cataggaata	tctgtatgtt	ggatgacttt	2520
aatgctacat	tttaaaaaaa	gaaaataaag	taataatata	actcaaaaaa	aaaaaaaaa	2580
aaaaaaaaaa	aaaaaaaaaa	aaaaa				2605

<210> 50

<211> 2182

<212> DNA

<213> Homo sapiens

<400> 50 aggtaagagg aaactccatt ggataaatgg cgaggaaacg tatactccct cttaaggaac 60 acggtgtett cettegtete egggtteeeg agaccecaga gteaetgace teegteeete 120 agettteggg gtteggeage agaaggggeg ggeeegggee tgggattgge tggegtegte 180 240 egacecett egetgetete cattegeaat egecegeggg egeetgegeg atgggtegge cgtggggagc ggggcgggaa gcgcttcagg gcagcggatc ccatgtcggc cctgaggcgc 300 tegggetacg geceeagtga eggteegtee taeggeeget actaegggee tgggggtgga 360 gatgtgccgg tacacccacc tccaccctta tatcctcttc gccctgaacc tccccagcct 420 480 cccatttcct ggcgggtgcg cgggggggcggc ccggcggaga ccacctggct gggagaaggc ggaggaggcg atggctacta tccctcggga ggcgcctggc cagagcctgg tcgagccgga 540 ggaagccacc aggagcagcc accatatcct agctacaatt ctaactattg gaattctact 600 gcgagatcta gggctcctta cccaagtaca tatcctgtaa gaccagaatt gcaaggccag 660 720 agtttgaatt cttatacaaa tggagcgtat ggtccaacat accccccagg ccctggggca aatactgeet catactcagg ggettattat geacetggtt atactcagae cagttactee 780 acagaagttc caagtactta ccgttcatct ggcaacagcc caactccagt ctctcgttgg 840 atctatecee ageaggactg teagactgaa geaceeete ttagggggea ggtteeagga 900 tatecgeett cacagaacce tggaatgace etgeceeatt atcettatgg agatggtaat 960 1020 cgtagtgttc cacaatcagg accgactgta cgaccacaag aagatgcgtg ggcttctcct ggtgcttatg gaatgggtgg ccgttatccc tggccttcat cagcgccctc agcaccaccc 1080 ggcaatetet acatgactga aagtacttca ccatggccta gcagtggctc tccccagtca 1140 1200 ccccttcac ccccagtcca gcagcccaag gattcttcat acccctatag ccaatcagat 1260 caaagcatga accggcacaa ctttccttgc agtgtccatc agtacgaatc ctcggggaca gtgaacaatg atgattcaga tcttttggat tcccaagtcc agtatagtgc tgagcctcag 1320

atgccaccag	tgaccatccc	aacaatcaag	atcaaagtag	cagtcttcct	1380
taccttcaga	tgaaagtact	cctccgagta	ttaaaaaaaat	catacatgtg	1440
tccagtatct	tgaacaagaa	gtagaagaat	ttgtaggaaa	aaagacagac	1500
ggcttctgga	agaaatgcta	accaaggaac	ttttggaact	ggattcagtt	1560
gccaggactc	tgtacggcag	gccagaaaag	aggctgtttg	taagattcag	1620
aaaaattaga	aaaaaaagga	ttatgaaagg	atttagaaca	aagtggaagc	1680
cttgaccaaa	gaacacttga	tttggttaat	taccctcttt	ttgaaatgcc	1740
aagaagcaat	acattccagc	tttcctttga	ttttatactt	gaaaaactgg	1800
gaagaatatt	ttagtcatga	gttgttttca	gttttcagac	gaatgaatgt	1860
tatggagtta	ccaatattgc	caagtagact	cactccttaa	aaaatttatg	1920
agctgcttct	taccagcagg	agggaaacac	acttcacaca	acaggcttat	1980
ccagatgaaa	ctggatataa	tctgagacaa	acaggatgtg	ttttttaaa	2040
tcttgtcaca	tttttgtaca	ttgtgactgc	tttcaacata	tacttcatgt	2100
cttagacttt	agccttcttg	gacttctgtt	ttgttttgtt	atttgcagtt	2160
gtattattct	ct				2182
	taccttcaga tccagtatct ggcttctgga gccaggactc aaaaattaga cttgaccaaa aagaagcaat gaagaatatt tatggagtta agctgcttct ccagatgaaa tcttgtcaca cttagacttt	taccttcaga tgaaagtact tccagtatct tgaacaagaa ggcttctgga agaaatgcta gccaggactc tgtacggcag aaaaattaga aaaaaaagga cttgaccaaa gaacacttga aagaagcaat acattccagc gaagaatatt ttagtcatga tatggagtta ccaatattgc agctgcttct taccagcagg ccagatgaaa ctggatataa tcttgtcaca tttttgtaca	taccttcaga tgaaagtact cctccgagta tccagtatct tgaacaagaa gtagaagaat ggcttctgga agaaatgcta accaaggaac gccaggactc tgtacggcag gccagaaaag aaaaattaga aaaaaaagga ttatgaaagg cttgaccaaa gaacacttga tttggttaat aagaagcaat acattccagc tttcctttga gaagaatatt ttagtcatga gttgtttca tatggagtta ccaatattgc caagtagact agctgcttct taccagcagg agggaaacac ccagatgaaa ctggatataa tctgagacaa tcttgtcaca tttttgtaca ttgtgactgc ccttagacttt agccttcttg gacttctgt	taccttcaga tgaaagtact cctccgagta ttaaaaaaat tccagtatct tgaacaagaa gtagaagaat ttgtaggaaa ggcttctgga agaaatgcta accaaggaac ttttggaact gccaggactc tgtacggcag gccagaaaag aggctgtttg aaaaattaga aaaaaaagga ttatgaaagg atttagaaca cttgaccaaa gaacacttga tttggttaat taccctctt aagaagaatatt ttagtcatga gttgtttca gttttcagac tatggagtta ccaatattgc caagtagact cactccttaa agctgcttct taccagcagg agggaaacac acttcacaca ccagatgaaa ctggatataa tctgagacaa acaggatgtg tcttgtcaca tttttgtaca ttgtgactgc tttcaacata ccttagacttt agccttcttg gacttcttt ttgttaca ttgtgactgc tttcaacata ccttagacttt agccttcttg gacttctttt ttgttaca ttgtgactgc tttcaacata cttagacttt agccttcttg gacttctgtt ttgttttgtt	atgccaccag tgaccatccc aacaatcaag atcaaagtag cagtcttcct taccttcaga tgaaagtact cetecgagta ttaaaaaaat catacatgtg tecagtatct tgaacaagaa gtagaagaat ttgtaggaaa aaagacagac ggettetgga agaaatgeta accaaggaac ttttggaact ggatteagtt gecaggacte tgtacggcag gecagaaaag aggetgtttg taagatteag aaaaattaga aaaaaaagga ttatgaaagg atttagaaca aagtggaage cttgaccaaa gaacaettga tttggttaat taccetettt ttgaaatgee aagaagcaat acattecage ttteettga ttttataett gaaaaaetgg gaagaatatt ttagteatga gttgtttea gtttteagae gaatgaatgt tatggagtta ceaatattge caagtagaet cacteettaa aaaatttatg agetgettet taccageagg agggaaacae actteacaca acaggettat ccagatgaaa etggatataa tetgagacaa acaggatgtg ttttttaaa tettgtcaca tttttgtaca ttgtgactge ttteaacata tactteatgt gtattattet et

<210> 51

<211> 2899

<212> DNA

<213> Homo sapiens

<400> 51 ccgacccgcc ctggggtgct gcgtgcgctg cctgctcccg cctgaggaaa acactgccca 60 tggcgcaagg ccgggagcgc gacgaaggcc cccactccgc cggcggcgcg tccttgtccg 120 tgagatgggt gcaaggattc cctaagcaga atgttcattt gtcaacgaca acaccatttg 180 ctacccttgt gggaattatg taatatttat taatattgaa accaagaaaa agactgtact 240 gcagtgtagt aatggaattg tgggcgtcat ggcaactaac atcccctgtg aagttgtggc 300 tttttctgac cggaagctaa aacctctcat ctacgtatac agctttccag gattgaccag 360 aaggaccaaa ttgaaaggca acatteteet ggactacaet ttaettteat teagttaetg 420 tggcacctac ctggctagtt actcctctct cccagaattt gaactggccc tttggaactg 480 ggaatcgagt atcattttgt gtaagaaatc acagcctgga atggatgtga accaaatgtc 540 600 ttttaacccc atgaactggc gccagctgtg cttatcaagt ccaagtacag tgagcgtgtg gaccattgaa agaagtaacc aggagcattg tttcagagca aggtcggtga aattacctct 660 720 agaagatggg tcattttta atgaaacgga tgtcgttttc ccccagtcgt tgccgaaaga 780 tctcatctat ggtcccgtgc tgccactgtc agccattgcc gggctggtag gcaaagaggc

agagactttc	cggccgaaag	atgatctata	tcctttgctt	cacccgacta	tgcattgctg	840
gactccaaca	agtgacttgt	acattggctg	tgaagagggt	catcttttaa	tgattaatgg	900
agacaccttg	caagtgactg	tacttaataa	gatagaagag	gaatcgccat	tggaagacag	960
aagaaatttt	atcagtccag	taaccttggt	atatcagaag	gagggcgtgc	tggcttctgg	1020
aattgatggc	tttgtgtatt	cttttattat	taaagataga	agttacatga	tcgaggattt	1080
tcttgagatt	gaaagacctg	tagaacatat	gacattttct	cccaattata	cagtgttgct	1140
gattcaaaca	gacaagggat	ctgtttatat	ctacactttt	ggtaaggagc	caaccttaaa	1200
taaagtccta	gatgcttgtg	atgggaaatt	tcaggcaatt	gactttatca	cacctggaac	1260
ccaatacttc	atgacactta	catattcagg	ggaaatttgt	gtttggtggc	tggaggattg	1320
tgcttgtgta	agcaagattt	atctgaatac	cctagcaacg	gttctggctt	gctgtccatc	1380
ctccctctct	gcagccgtgg	gcacggagga	tggctcggtc	tacttcatca	gcgtatatġa	1440
taaggaatcc	cctcaggtcg	tgcacaaggc	ctttctctcg	gaatcgtccg	tgcagcacgt	1500
cgtgtaagtc	ctttctgcct	ccaggagcgg	ctccgtgtca	cacccgtctg	ttgaaaattc	1560
tagtgaagcc	atcctttctt	ttaattttaa	gttttacgtg	tttcatttgt	tttgaatgtt	1620
aatatattca	cacagttcaa	cactcaaaag	gtacagaggg	ctgtgtagta	aagtaccccc	1680
catacccagg	tctgtccttg	caggcagcct	ggtaccaatt	tctcatgtct	ctcctgagat	1740
gttttatcca	tgaacaagca	aaacataata	agcacttctt	tttacttgta	tcaatggcca	1800
tcatgtgtgt	atagtgtgcc	aggcacttct	gctgtattaa	ctccatgagg	taaacactct	1860
tgttgtctct	atttgacagg	tgaggaagat	aaggcacaag	gattttaaat	aacttgctca	1920
atagtacaca	gatagtgaat	ggcaaatgtt	gggatttgaa	cccaggtagt	tgggctgcag	1980
agtcactgcc	tttgctctta	aaaggagaaa	actatgtaca	atgcctcatt	tctttttca	2040
cttaatcgta	tatcttggag	aatgttttat	atccacacat	aaagaccagc	ctgattattt	2100
gtatagccac	: atagtattcc	attatatgaa	tatactatca	tttttaaaa	acggtatatt	2160
aatgaacatt	: tagagtattt	caaaactttt	gaagcaatac	: ttttaagatg	ataatataga	2220
gacattagat	: ttggacttgt	aggtgctatc	attattactg	, tttcttttta	atttattata	2280
ttattaggta	ı ttaataagaa	cagacatttg	tattctgctt	tacagettga	gatcactgta	2340
gcttgtggca	tgtgatcctc	: aaaacaccag	tcagaaaggt	gttattctta	tecetattag	2400
acaaattagg	g gaattcaggg	, ttagagaggt	gaggaaaagc	e attgtccaag	attacacatt	2460
acacagctag	g cacactgagg	g agctggccct	gccactgtgg	g actgcccago	tecaccaccc	2520
tagctcagt	g gggaaggatg	g gataacctcc	: ttccatttac	cccctgcctt	tetgeactgt	2580
catttttt	g tgcctttcct	ttctcagato	ctcttattct	aatttacato	ttcccacttt	2640

ttctaatttg	ataaagttgt	agacatgttt	cactacattc	ttcctcccac	tgccaggtac	2700
cagacacagg	gtaatgaaat	gtcacaccca	ccactaattt	gagaattgct	tatttgcgct	2760
tgaaacatca	agaaagctct	accgacagac	atgtttcatt	cacttatgat	gaaccaactg	2820
cccatcttta	ctgaatcttc	ttgactgtat	ttattaaagt	tgcaatttgg	aaataaaaaa	2880
aaaaaaaaaa	aaaaaaagg					2899

<210> 52 <211> 2218

<212> DNA

<213> Homo sapiens

tcgatgcaga actccgtctc cttagacatc agaaactaaa actagatact cagatgaaat 60 tatctgacct gcaccatgtc accttatttc aagaaatact tctcctgaag aattttgaaa 120 aacaggagaa catacttcaa gaacgtgtta attccttaga caaagaggaa cagtacatgc 180 aatggaaaat aaatgaaact cttaaagaga tggaagagaa aaagaatgaa atcaccaaac 240 tccaggagca agaaaaggca ctctatgctg gttttcaagc agccattgga gaaaacaata 300 aatttgcaaa cttcctcatg aaggtcctaa agaagaggat taaacgggta aagaaaaaag 360 420 aagttgaagg agatgctgat gaagatgagg agagtgagga atcaagtgaa gaagaatcta gcttggagag tgatgaagat gagtctgaat cagaagatga ggtttttgat gattctattt 480 geccaacaaa ttgtgatgtg getetttttg agetggeeet teacettega gagaaaagge 540 600 tggacattga ggaggcttta gttgaagaaa agaaaattgt tgataacctc aaaaaggaat atgatacatt gtcaaaaaaa gtgaaaattg tggcaactaa tctgaatgca gcagaggagg 660 ccctggaggc ttatcagcga gagaagcagc agcggctgaa tgaactgcta gttgtgattc 720 780 cgctcaagct ccaccagata gagtatgtgg tatttggaga aatacctagc gatctttctg gtactttggt cttctctaac catgccttga gacggctgca agaacgaatc cgtgagctcc 840 900 aggaggaaaa ttccaagcag caaaaactta acaaagaatg gagagagaga cgtaaacagc 960 tcatccgaga aaagagagaa atgacaaaaa ccatacacaa aatggaggaa acagtccggc agctcatgat cagcaagttt ggccgtgtgg taaatctaga agcccttcaa acgctttctg 1020 ttaatacaac acttgaagaa ctgaagatca gaaaacttcg aaaggagcta gcaaatgcga 1080 1140 aagagatgaa gatgtgggag gaaaagattg ctcaaatgcg atgggaactg atgatgaaga caaaagaaca caccagaaag ctttatcaga tgaatgattt gtgtattgaa aagaagaaac 1200 1260 1320 tgttccaaca gtttggtcct ctgaagaaga gcatcagcat cacctgggaa cttgtttaaa

atggcaatgc cttccagggc cctcgggaag cagatgttgt ggcaagagag gaggtcactg 1380 aattgatcca actccaggcg gaaaggattt cggccttaaa ggaggagatt gctcttttgc 1440 gtaggaaagg cggtcttatc ctcccaccca ttcagtctcc acgagagaaa gagatacagc 1500 1560 ccgcagacct ttgagtttgc tattttctca aacccataca aaatttctga cataactcac tggaagttct gtctcctcat cacctccaac aatcttatta ctttaaactg aacttgcctg 1620 aaagtgtaaa accagatcca gtcacgttaa gtcactttaa gaatctctct acaatttggt 1680 tatcttagaa ctgactgcag cacccaacct ctgttatgaa actgaatcat tttagatgtt 1740 togaacotac tagattgaat atgaagtoto ggaaggotgt gtttcatgat tgcagcaaat 1800 cacctgtaat atattttgtt ttaggaaaat ttgatttggg ggtatcctga atttttagcc 1860 cttggcaaga aaaactatca ttcagcaatt catgagaaaa ctttgttttc ttgatcctta 1920 gaaaataaac ttagatgtta ttaagtgttc tctgagagga tgcaggagaa aaggacattt 1980 tgtcagctat atcttagaat agaaatgcaa atttcagttt tggcattgtt gacttcataa 2040 agcagtgttt tgagggctca ggattcagga aatacaaaca gacatggcag agcagtttgc 2100 2160 tttgggttgg cagaaagcag gaaaataacc agcettettg gattgcccac agtttttgta gactcctcag ttctgagtgg agcagagggg catgcttaat aaaacagtca ataaagag 2218

<220>

<400> 53 cttttcccat cgtgtagtca agagtctgtg ccagacttga aggctttact ttgttagcca 60 tgtgtttatg aacccccagc gctttcccta gatcttttgg ctgataatct caaacatgga 120 ggatgcttct gaatcttcac gaggggttgc tccattaatt aataatgtag ttctcccagg 180 240 ctctccgctg tctcttcctg tatcagtgac aggctgtaaa agtcatcgag tagccaataa 300 aaaggtagaa gcgaggagtg aaaagctcct cccaacagct cttcctcctt cagagccgaa 360 agtagatcag aaacttccca ggagctccga gaggcgggga agtggcggtg ggacgcaatt ccccgcgcgg agtcgggcag tggcagcggg agaagcggca gccaggggcg cggcggggcc 420 480 ggagagaggc agtcccctgg gaagacgggt ctcccctcgt tgcctttgta gtggagaagg tggacaagtg gcagtcggcg tgatcgcagg gaagcggggc cggcgcgggc gcgacgggtc 540 600 caggegagee cegggeggae gggagatgee getgetaeae egaaageegt ttgtgagaea

<sup>&</sup>lt;210> 53 .

<sup>&</sup>lt;211> 5925

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Homo sapiens

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (5402)..(5402)

<sup>&</sup>lt;223> n is a, c, g, or t

gaagccgccc	geggaeetge	ggcccgacga	ggaagttttc	tactgtaaag	tcaccaacga	660
gatcttccgc	cactacgatg	acttttttga	acgaaccatt	ctgtgcaaca	gccttgtgtg	720
gagttgtgct	gtgacgggta	gacctggact	gacgtatcag	gaagcacttg	agtcagaaaa	780
aaaagcaaga	cagaatcttc	agagttttcc	agaaccacta	attattccag	ttttatactt	840
gaccagcctt	acccatcgtt	cgcgcttaca	tgaaatttgt	gatgatatct	ttgcatatgt	900
caaggatcga	tattttgtcg	aagaaactgt	ggaagtcatt	aggaacaatg	gtgcaaggtt	960
gcagtgtacg	attttggaag	tectecetee	atcacatcaa	aatggttttg	ctaatggaca	1020
tgttaacagt	gtggatggag	aaactattat	catcagtgat	agtgatgatt	cagaaacaca	1080
aagctgttct	tttcaaaatg	ggaagaaaaa	agatgcaatt	gatcccttac	tattcaagta	1140
taaagtgcaa	cccactaaaa	aagaattaca	tgagtctgct	attgttaaag	caacacaaat	1200
cagccggaga	aaacacctat	tttctcgtga	taaactaaag	ctttttctga	agcaacactg	1260
tgaaccacaa	gaaggagtca	ttaaaataaa	ggcatcatct	ctttcaacgt	ataaaatagc	1320
agaacaagat	ttttcttatt	tetteeetga	tgatccaccc	acatttatct	tcagtcctgc	1380
taacagacga	agagggagac	ctcccaaacg	aatacatatt	agtcaagagg	acaatgttgc	1440
taataaacag	actcttgcaa	gttataggag	caaagctact	aaagaaagag	ataaactttt	1500
gaaacaagaa	gaaatgaagt	cactggcttt	tgaaaaggct	aaattaaaaa	gagaaaaagc	1560
agatgcccta	gaagcgaaga	aaaaagaaaa	agaagataaa	gagaaaaaga	gggaagaatt	1620
gaaaaaaatt	gttgaagaag	agagactaaa	gaaaaaagaa	gaaaaagaga	ggcttaaagt	1680
agaaagagaa	aaggaaagag	agaagttacg	tgaagaaaag	cgaaagtatg	, tggaatactt	1740
aaaacagtgg	agtaaaccta	gagaagatat	ggaatgtgat	gaccttaagg	aacttccaga	1800
accaacacca	gtgaaaacta	gactacctcc	tgaaatcttt	ggtgatgcto	tgatggtttt	1860
ggagttcctt	aatgcatttg	gggaactttt	tgatcttcaa	gatgagttto	ctgatggagt	1920
aaccctagaa	gtattagagg	aagctcttgt	tggaaatgac	agtgaaggc	c cactgtgtga	1980
attgcttttt	ttcttcctga	ctgcaatctt	ccaggcaata	gctgaagaaq	g aagaggaagt	2040
agccaaagag	caactaactg	atgctgacac	: caaaggctgc	: agtttgaaaa	a gtttggatct	2100
tgatagctgc	actetttcag	aaatcctcag	actgcacato	ttagcttcag	g gtgctgatgt	2160
aacatcagca	aatgcaaagt	atagatatca	aaaacgagga	a ggatttgat	g ctacagatga	2220
tgcttgtatg	gagcttcgtt	tgagcaatco	cagtctagts	g aagaaactg	t caagcacctc	2280
agtgtatgat	ttgacaccag	gagaaaaaat	gaagatacto	catgetete	t gtggaaagct	2340
actgacccta	gtttcaacta	gggattttat	tgaagattat	gttgatata	t tacgacaggc	2400
aaagcaggag	ttccgggaat	: taaaagcaga	a acaacatcga	a aaagagagg	g aagaagcagc	2460

tgccagaatt cgtaaaagga aggaagaaaa acttaaggag caagaacaa	aa aaatgaaaga 2520
gaaacaagaa aaactgaaag aagatgagca aagaaattca acggcagat	a tatctattgg 2580
ggaggaagaa agggaagatt ttgatactag cattgagagc aaagacaca	ag agcaaaagga 2640
attagatcaa gatatgttca ctgaagatga agatgaccca ggatcacat	a aaagaggcag 2700
aagggggaaa agaggacaaa atggatttaa agaatttaca aggcaagaa	ac agatcaactg 2760
tgtaacaaga gagcttctta ctgctgatga ggaagaagca ttaaaacag	gg aacaccaacg 2820
aaaagagaaa gagctcttag aaaaaatcca aagtgccata gcctgtac	ca atatctttcc 2880
cttgggtcgc gaccgcatgt atagacgata ctggattttc ccttctat	tc ctggactctt 2940
tattgaagag gattattctg gtcttactga agacatgctg ttgcctaga	ac cttcatcatt 3000
tcagaataat gtacagtctc aagatcctca ggtatccact aaaactgg	ag agcctttgat 3060
gtctgaatct acctccaaca ttgaccaagg tccacgtgac cattctgt	gc agctgccaaa 3120
accagtgcat aagccaaatc ggtggtgctt ttacagttct tgtgaaca	gc tagaccagct 3180
tattgaagct cttaattcta gaggacatag agaaagtgcc ttaaaaga	aa ctttgttaca 3240
agagaaaagc agaatatgtg cacagctagc ccgtttttct gaagagaa	at ttcatttttc 3300
agacaaacct cagcctgata gcaaaccaac atatagtcgg ggaagatc	tt ccaatgcata 3360
tgatccatct cagatgtgtg cagaaaagca acttgaacta aggctgag	ag attttctttt 3420
agatattgaa gatagaatct accaaggaac attaggagcc atcaaggt	ta cagatcgaca 3480
tatctggaga tcagcattag aaagtggacg gtatgagctg ttaagtga	gg aaaacaagga 3540
aaatgggata attaaaactg tgaatgaaga cgtagaagag atggaaat	tg atgaacaaac 3600
aaaggtcata gtaaaagaca gacttttggg gataaaaaca gaaactcc	aa gtactgtatc 3660
aacaaatgca agtacaccac aatcagtgag cagtgtggtt cattatct	gg caatggcact 3720
ctttcaaata gagcagggca ttgagcggcg ttttctgaaa gctccact	tg atgccagtga 3780
cagtgggcgt tcttataaaa cagttctgga ccgttggaga gagtctct	cc tttcttctgc 3840
tagtctatcc caagtttttc ttcacctatc caccttggat cgtagcgt	ga tatggtctaa 3900
atctatactg aatgcgcgtt gcaagatatg tcgaaagaaa ggcgatgc	tg aaaacatggt 3960
tctttgtgat ggctgtgata ggggtcatca tacctactgt gttcgacc	caa agctcaagac 4020
tgtgcctgaa ggagactggt tttgtccaga atgtcgacca aagcaacg	gtt gtagaagact 4080
gtcctttaga cagagaccat ccttggaaag tgatgaagat gtggaaga	aca gtatgggagg 4140
tgaggatgat gaagttgatg gcgatgaaga agaaggtcaa agtgagga	agg aagagtatga 4200
ggtagaacaa gatgaagatg actctcaaga agaggaagaa gtcagcct	cac ccaaacgagg 4260
aagaccacaa gttagattgc cagttaaaac aagagggaaa cttagcto	ctt ctttctcaag 4320

tcgtggccaa	caacaagaac	ctggaagata	cccttccagg	agtcagcaga	gcacacccaa	4380
aacaactgtt	tcttctaaaa	ctggtagaag	cctaagaaag	ataaactctg	ctcctcctac	4440
agaaacaaaa	tctttaagaa	ttgccagtcg	ttctactcgc	cacagtcatg	gcccactgca	4500
agcagatgta	tttgtggaat	tgcttagtcc	tcgtagaaaa	cgcagaggca	ggaaaagtgc	4560
taataataca	ccagaaaata	gtcccaactt	ccctaacttc	agagtcattg	ccacaaagtc	4620
aagtgaacag	tcaagatctg	taaatattgc	ttcaaaactt	tctctccaag	agagtgaatc	4680
caaaagaaga	tgcagaaaaa	gacaatctcc	agagccatcg	cctgtgacac	tgggtcgaag	4740
gagttctggc	cgacagggag	gagttcatga	attgtctgct	tttgaacaac	ttgttgtaga	4800
attggtacga	catgatgaca	gctggccttt	tttgaaactt	gtttctaaaa	tccaggtccc	4860
agactactat	gacatcatca	aaaagcccat	tgccttaaat	ataattcgtg	aaaaagtgaa	4920
taagtgtgaa	tataaattag	catctgagtt	tattgatgac	attgagttaa	tgttttcgaa	4980
ctgctttgaa	tacaaccctc	gtaacacaag	tgaagcaaaa	gctggaacta	ggcttcaagc	5040
attttttcat	attcaggctc	aaaagcttgg	actccacgtc	acacccagta	atgtggacca	5100
agttagcaca	ccaccggctg	cgaaaaagtc	acgaatctga	ctttgtcctt	ctaaaggata	5160
tatttgaaga	aaaacaaatt	gttcatgaaa	atggaacatt	aaatcatgct	gtataaagca	5220
ataacaaaca	attgattgac	cacatgaaag	tgtggcctgc	actatattct	caattttaat	5280
attaagcact	caggagaatg	taggaaagat	atcctttgct	acagttttgt	tcagtatcta	5340
ataagtttga	tagatgtatt	ggatacagta	ctggtttaca	gaggtttttg	tacatttttg	5400
anatcattca	tgtgtccaga	gatcttggaa	aatattttt	cacccacgat	ttattttgtt	5460
attgatgatt	tatttttaaa	gtggtggtat	taagggagag	ttatctacat	ggatgagtct	5520
tccgctatag	cacagtttag	aaaaggtgtt	tatgtcttaa	ttaattgttt	gagtacattc	5580
tttcaacact	acacatgaat	gaatccaatc	ttataacctt	gaagtgctgt	accagtgctg	5640
gctgcaggta	ttaagtccaa	gtttattaac	tagatattta	tttagtattg	agagtaattt	5700
gtgaatttgt	tttgtattta	taaaatttat	acctggaaaa	tgttccttaa	tgttttaaac	5760
cttttactgt	gtttttattc	ctctaacttc	cttaatgatc	aatcaaaaaa	agtaacaccc	5820
tccctttttc	ctgacagttc	tttcagcttt	acagaactgt	attataagtt	ctatgtataa	5880
ttttaactgt	tcaaataaaa	tacatttttc	caataaaaaa	aaaaa		5925

<sup>&</sup>lt;210> 54 <211> 6079 <212> DNA <213> Homo sapiens

<sup>&</sup>lt;400> 54

cgttggccgg	gcccggggga	ggaggggaat	ctcccgccat	ttttcaataa	tttcctccgg	60
tgctgctgag	gagagtcgtg	actgccggcc	gccgggaccc	gaagcggagg	tcggcggggg	120
gctgctggga	ggcgcggcgg	tgtgcgcggg	agctctgcgc	cggtggcgtt	ccgctccatg	180
actgtcgcgc	ggccgcgccg	gcggtgaggg	agccggagtt	cgcgccgccc	tctcacccct	240
cccttcaccc	accccacccc	egggegeetg	gcgctcgctc	cgggccgcgg	ggcctagtgc	300
tgcgccgcgg	ggccggcccc	agcagccgcc	agtccccacc	gccgccgccg	cgatggcgcc	360
gctcctgggc	cgcaagccct	tecegetggt	gaagccgttg	cccggagagg	agccgctctt	420
caccatcccg	cacactcagg	aggccttccg	cacccgggaa	gagtatgaag	cccgcttgga	480
aaggtacagt	gagcgcattt	ggacgtgcaa	gagtactgga	agcagtcagc	taacacacaa	540
ggaagcctgg	gaggaagaac	aggaagttgc	tgagcttttg	aaggaggagt	ttcctgcctg	600
gtatgagaag	cttgttctgg	aaatggttca	ccataacaca	gcctccttag	agaagttagt	660
agatactgct	tggttggaga	tcatgaccaa	atatgctgtg	ggagaagagt	gtgacttcga	720
ggttgggaag	gagaaaatgc	tcaaggtgaa	gattgtgaag	attcatcctt	tggagaaagt	780
ggatgaagag	gccactgaga	agaaatctga	tggtgcctgt	gattctccat	caagtgacaa	840
agagaactcc	agtcagattg	ctcaggacca	tcagaagaag	gagacagttg	tgaaagagga	900
tgaaggaagg	agagagagta	ttaatgacag	agcacgtaga	tcgccacgaa	aacttcctac	960
ttcattaaaa	aaaggagaaa	ggaaatgggc	tcctccaaaa	tttctgcctc	acaaatatga	1020
tgtgaaacta	caaaatgaag	ataagatcat	cagtaacgtg	ccagcagaca	gcttgattcg	1080
tacagagcgc	ccaccaaata	aggagatagt	tcgatacttt	atacggcata	atgcattacg	1140
agctggtact	ggtgaaaatg	caccttgggt	cgtagaagat	gaattggtga	agaaatactc	1200
tctgcccagc	aagttcagtg	actttttact	tgatccatac	aagtatatga	ctctcaaccc	1260
ttctactaag	aggaagaata	ctggatcccc	agacaggaag	ccctcaaaga	aatccaagac	1320
agacaactct	tctcttagtt	caccactaaa	, tcctaagtta	tggtgtcacg	tacacttgaa	1380
gaagtcattg	agtggctcgc	cactcaaagt	gaagaactca	aagaattcca	aatctcctga	1440
agaacatcta	gaagaaatga	tgaagatgat	gtcgcccaat	aagctgcaca	ctaactttca	1500
cattcctaaa	aaaggcccac	ctgccaagaa	accagggaag	cacagtgaca	agcctttgaa	1560
ggcaaagggc	agaagcaaag	gcatectgaa	tggacagaaa	tccacaggga	attccaaatc	1620
tcccaaaaaa	ggactgaaga	ctcctaaaac	caaaatgaag	cagatgactt	tgttggatat	1680
ggccaaaggc	: acgcagaaga	tgacacgago	cccacggaat	tctgggggta	cacctaggac	1740
ctctagtaaa	cctcataaac	atctgcctco	tgcagcccta	cacctcatto	r catactacaa	1800
agaaaacaaa	gacagggagg	g acaagaggag	g cgccctgtcc	tgtgttatct	ccaaaacagc	1860

togtottete totagtgaag atagageteg teteccagaa gaattgegaa gtettgttea 1920 aaaacgctat gaacttctag agcacaaaaa gaggtgggct tctatgtctg aagaacaacg 1980 2040 gaaagaatat ttgaaaaaga aacgggagga gctgaaaaag aagttgaagg aaaaagccaa agaacgaaga gagaaagaaa tgcttgagag attagaaaaa cagaagcggt atgaggacca 2100 agagttaact ggcaaaaacc ttccagcatt cagattggtg gatacccctg aagggctgcc 2160 caacacgctg tttggggatg tggccatggt ggtggaattc ttgagctgtt attctgggct 2220 acttttacca gatgctcagt atcctattac tgctgtgtcc cttatggaag ccttgagtgc 2280 2340 agataagggt ggctttttat accttaacag ggtgttggtc atcctcttac agaccctcct 2400 acaagatgag atagcagaag actatggtga attgggaatg aagctgtcgg aaatcccctt gactctgcat tctgtttcag agctggtgcg gctctgcttg cgcagatctg atgttcagga 2460 2520 ggaaagcgag ggctcagaca cagatgacaa taaagattca gctgcatttg aggataatga 2580 ggtacaagat gagttcctag aaaagctgga gacctctgaa ttttttgagc tgacgtcaga 2640 ggagaagcta cagatettga cagcactgtg ccaceggate etcatgacat acteagtgca 2700 agaccacatg gagaccagac agcagatgtc tgcagagttg tggaaggaac ggcttgctgt 2760 gttgaaggaa gaaaatgata agaagagagc agagaaacag aaacggaaag aaatggaagc 2820 caaaaataaa gaaaatggaa aagttgagaa tgggttaggc aaaactgata ggaaaaaaga 2880 aattgtgaag tttgagcccc aagtagatac agaagctgaa gacatgatta gtgctgtgaa 2940 gagcagaagg ttgcttgcca ttcaagctaa gaaggaacgg gaaatccagg aaagagaaat 3000 gaaagtgaaa ctggaacgcc aagctgaaga agaacgaata cggaagcaca aagcagctgc 3060 tgagaaagct ttccaggaag ggattgccaa ggccaaacta gtcatgcgca ggactcctat 3120 tggcacagat cgaaaccata atagatactg gctcttctca gatgaagttc caggattatt 3180 cattgaaaaa ggctgggtac atgacagcat tgactaccga ttcaaccatc actgcaaaga 3240 ccacacagtc tctggtgatg aggattactg tcctcgcagt aagaaagcaa acttaggtaa 3300 aaatgcaagc.atgaacacac aacatggaac agcaacagaa gttgctgtag agacaaccac 3360 acccaaacaa ggacagaacc tatggttttt atgtgatagt caaaaggagc tggatgagtt 3420 gctaaactgt cttcaccctc agggaataag agaaagtcaa cttaaagaga gactagagaa 3480 gaggtaccag gacattattc actctattca tctagcacgg aagccaaatt tgggtctaaa 3540 atcttgtgat ggcaaccagg agcttttaaa cttccttcgt agtgatctca ttgaagttgc 3600 aacaaggtta caaaaaggag gacttggata tgtggaagaa acatcagaat ttgaagcccg 3660 ggtcatttca ttagagaaat tgaaggattt tggtgagtgt gtgattgccc ttcaggccag 3720 tgtcataaag aaatttctcc aaggcttcat ggctcccaag caaaagagaa gaaaactcca

aagtgaagat	tcagcaaaaa	ctgaggaagt	ggatgaagag	aagaaaatgg	tagaggaagc	3780
			gacagcaatc			3840
			tgcctgtatc			3900
			aggtgaggat			3960
			tctgaggccg			4020
			cgctactgcc			4080
			cagtgaagat			4140
			agattatgag			4200
			cgtcatcccc			4260
			gaggtctcag			4320
			gaccaagcgg			4380
ggagctgcag	aagtgtgaag	agatcctcca	catgatcgtg	aagtaccgct	tcagctggcc	4440
cttcagggag	cctgtgacca	gagatgaggc	cgaggactac	tatgatgtga	tcacgcaccc	4500
catggacttt	cagacagtgc	agaacaaatg	ttcctgtggg	agctaccgct	ctgtgcagga	4560
gtttcttact	gacatgaagc	aagtgtttac	caatgctgag	gtttacaact	gccgtggcag	4620
ccatgtgcta	agctgcatgg	tgaagacaga	acagtgtcta	gtggctctgt	tgcataaaca	4680
ccttcctggc	cacccatatg	tccgcaggaa	gcgcaagaag	tttcctgata	ggcttgctga	4740
agatgaaggg	gacagtgagc	cagaggccgt	tggacagtcc	aggggacgaa	gacagaagaa	4800
gtagagaggc	agggccgtgg	tgacagtato	agtgagtgcc	atacagaatt	gtgtattcac	4860
cagcatcatg	aaacagttgt	ggtcttttga	gttgatcttg	gcagagtaaa	gggacgtgtc	4920
ctggagccat	tcctgaatct	ccccttcttt	gtgacagctc	ctcccacccc	cccaaaaaat	4980
aaaaaaacca	. caaaaaacaa	aaaaacaaa	ctaaggcact	tcacttagag	g actggagtcc	5040
tgcttataat	catgcatata	acctttactt	tgatggatct	ggccagaggg	g gtgttggagc	5100
ccagcccacc	: cacataccag	tcaagctctt	aggggagcag	g aagaaaagca	a ggaagaattt	5160
aaatgtttaa	ttttttt	aaattgactt	ttctagttat	: taaaagttg	ttgtttcagc	5220
agtgatattg	tataaagaac	atcttgtaag	g atactcctga	a catcttgct	tagcacatgt	5280
acagtacagt	: ttctatgata	atgtgtttgd	tctaacttc	c ctggcttctc	c cttcagccca	5340
tccactctcc	tctagagcaç	; ttgggttgga	a ggctcattga	a ggcaagcag	c aacattggag	5400
ggggagcagg	g gcagtgctgt	gtetgetge	tcccatgcc	gttctgacc	t cagccttgga	5460
actcctcaag	g aacctgaaga	ttgagagcgg	g cagagaagc	t ctgagagcc	c cttcccccac	5520
aacaaatcta	a gctctagttg	g ttatatttag	g gcaaaactt	t gtagtcttc	t ttccctttta	5580

tgatggattt	tgataaaagt	acaaaacagg	gtttttcttt	tttatcacct	ttgaatttgg	5640
aaattttgag	cacccaagct	cttctgtacc	tatttaaagt	ccaccaaggg	gactgcagct	5700
cctagaacat	gagaatcaag	cctcttaatt	ttaaactgcg	gaatgtggcc	tetgetteet	5760
ccgtcctcct	gcccaaggac	gacgaggatt	gctccagggc	tgctgggtag	tttaccgtcc	5820
cttctatagg	catggagttg	gcactgacat	cacagcttca	taaccccacc	accgccagct	5880
tcccctgcct	cctacatcca	gtctgttctt	gttcatagtg	agaatcctgt	gttcccactt	5940
cagtgacacc	tgaattgttt	gttgttgttt	tttttttta	ttgtcttcaa	agaggaaggg	6000
cccattaaa	gggtgaactt	gtaataaatt	ggaatttcaa	ataaacctca	tgtacttgtg	6060
tttataaaga	agaaaccaa					6079

<210> 55

<211> 1839

<212> DNA

<213> Homo sapiens

<400> 55 60 atacgcatgc gtgcacgctg ccggtcgggc tgggctgaga ggggaggggg cggcggcggc 120 cgaggcggcg tcgttatttc cgtggtccgg acagtgcgtg gcggcgcggg tgaccacggg agaagtaggc ataatggtta tgaaagcttc tgtagatgat gacgattcag gatgggagct 180 240 cagtatgcca gaaaaaatgg agaaaagcaa tacaaactgg gtggacatta cccaagattt tgaagaagct tgtcgagaat taaagttggg agaactactt catgataagc tatttggtct 300 360 ttttgaagcc atgtctgcta ttgaaatgat ggatcccaag atggatgctg gcatgattgg 420 aaaccaagtt aatcgaaaag ttctcaattt tgaacaagct atcaaggatg gcactattaa 480 aattaaagat ctcaccttgc ctgaactgat agggattatg gatacatgtt tttgctgttt 540 gataacgtgg ttagaaggcc attcactggc acagacagta tttacgtgcc tttacattca 600 taatccagac tttatagaag atcctgctat gaaggctttt gctctgggaa tcttgaaaat 660 ctgtgacatt gcaagggaaa aagtaaataa agctgctgtt tttgaagagg aagattttca 720 gtcaatgact tatggattta aaatggctaa cagtgtgaca gatcttcgag ttacaggcat 780 gctaaaagat gtggaggatg acatgcaaag aagagtaaag agtactcgaa gtcgacaagg 840 agaagaaaga gatccagaag ttgaactaga acaccaacga tgtttagcag tattcagcag 900 agtgaaattt actcgtgtgt tactgacagt gcttatagcc tttactaaga aagagaccag 960 tgctgttgca gaagctcaaa aattgatggt tcaagcagca gatcttcttt ctgccattca 1020 taattcattg catcatggca tccaggccca gaatgatact acaaaaggag atcatccaat 1080 tatgatgggt tttgaacccc ttgtgaacca gaggctactt ccacctacct tccctcgata tgcaaaaata attaaaaggg aagaaatggt gaactatttt gcaagattaa tagatagaat 1140

aaaaactgtc	tgtgaggttg	tgaatttaac	aaatttacat	tgtatcctgg	attttttctg	1200
tgaatttagt	gaacagtcac	catgtgttct	ttcaagatct	ctgttacaaa	ccactttcct	1260
ggtggataac	aaaaaggtct	ttggaactca	tctcatgcaa	gacatggtga	aagatgcact	1320
tcggtctttt	gtcagtcctc	cggtgctttc	ccccaagtgc	tacctatata	ataatcacca	1380
ggctaaggac	tgtatcgact	cctttgttac	tcactgtgtt	cggccattct	gtagtcttat	1440
tcagatccat	ggacataaca	gggctcgaca	gagagataag	cttggtcata	ttcttgagga	1500
atttgccacc	ttgcaggatg	aggcagagaa	ggttgatgca	gcgcttcaca	ccatgctgtt	1560
gaaacaggaa	ccccaaaggc	aacatttggc	ctggttaggt	acctgggtcc	tttaccataa	1620
ccttcgcatt	atgatacagt	accttctaag	tggctttgaa	ttggaactct	acagtatgca	1680
cgagatacta	ttacatatat	tggtatctct	ctgaattcct	ttacgcatgg	ttgatgtcaa	1740
cattgagtcg	tgccgatggc	tctcaaatgg	cagaggaaag	gataatggaa	gagcagcaga	1800
aaggccgtag	tagtaaaaaa	acaaaaaaaa	aaaaaaaa			1839

<210> 56

<211> 2923

<212> DNA

<213> Homo sapiens

<400> 56 aaggaatcaa gcccccaaga tggcggcagc ggcggaggag cggatggcag aggaaggagg 60 120 cggcggccaa ggcgacggcg gttcctcttt ggcctccggc tctacccagc gacagcctcc accgcccgcg ccacagcacc cgcagccggg gtcccaggcg ctcccagccc ccgcgctggc 180 240 tccggaccag ctgcctcaaa acaacacgct tgtggcgctg cccatcgtag ccatcgagaa 300 catectcage tttatgtect acgacgaaat tagccagete egeetggttt gtaaaagaat ggacttggtc tgccagagaa tgttgaatca gggatttctg aaagtggaga ggtaccataa 360 420 tctatgtcag aaacaagtta aagcacaact cccaaggaga gagtcagaaa ggagaaacca 480 ttcattagct cgtcatgcag acattcttgc tgctgttgaa acaaggctgt cactattaaa 540 tatgactttc atgaaatatg tggattccaa tctctgttgc ttcatcccag gaaaggtgat 600 tgatgagatt tatcgtgtgt tgagatatgt caattctacc agagcccctc aacgagctca 660 tgaagtactt caagaattaa gggatatatc ctctatggca atggagtact ttgatgaaaa 720 gattgttcca attttaaaga ggaaattacc aggatcagat gtttctggaa gactcatggg 780 ctctcctcca gttccaggac cgtctgcagc cctaacaaca atgcagctct tctccaagca 840 aaatccttca agacaagagg ttaccaaact ccagcagcag gttaaaacaa atggtgctgg 900 cgtgactgtt ctcaggcgtg aaatttctga gcttcgcacc aaagtgcaag aacagcaaaa

acagcttcaa	gaccaggacc	agaaactgct	agagcagacc	cagatcatag	gtgaacaaaa	960
tgcacggttg	gcagagctag	aacgcaaact	acgagaagta	atggaaagtg	ctgtaggaaa	1020
ttcctcaggg	tccgggcaga	atgaggagtc	tcctcggaaa	cgaaaaaagg	ccacggaagc	1080
catagactct	cttaggaaat	ctaaacgtct	tcggaataga	aagtaaattg	gaatgtggtt	1140
ctagttccag	aggaagacac	agcttagtag	cttaagcagt	tatgcatatc	aggatactgt	1200
gagcaacatg	gtgtccctta	agcttctagg	ctttcagaac	acaacttaaa	cttgaactct	1260
tatggttggg	acattctttt	cctgcttctc	ctgattgaac	tgatgcacag	aatcttttta	1320
ctttgcaata	gatttgtact	aaccagacct	gttctatcat	gttttgagga	gttaactttt	1380
ttctgtgcag	ataatgttga	aagtaagtta	atttgtttct	gcatatatgc	acatacatac	1440
gtaaggatct	taaacccagt	cttgacagac	tagaagttaa	gtttaataca	gaaaatgtcc	1500
tgttcacttg	aaagaaaaga	cctacttttt	aaatggacac	tatcttggtt	ctttttttt	1560
aagtcatctt	tttgttataa	gtgacctttg	tctggaatgt	ctgaaaagta	gttaatgctt	1620
tttggtattg	aagtaatggg	taactaaaat	ggacttccat	agtattgact	gtagaaggag	1680
cctctacaat	attgactata	tatttttata	aactactggc	aaggaactta	cccagctgtt	1740
atacatgttt	tcagttctct	ttgggggcca	tgtcctacat	ttgcatggat	ggatgcatgc	1800
attgcctagt	caactcactt	aaaaagctct	tgcactggta	ttgatcttga	acctctatac	1860
ttctccactt	tttagagcgg	cgtcttagtt	tatttaaacg	cttaacatct	tecacegeaa	1920
cagcttgcct	ctagaggggg	aattgttcat	ccatttgtcc	tccagtttta	taggaacaag	1980
agactattaa	agcccattgc	tttatctgct	ctctgtaggg	ttcaggtaca	ctggctaagg	2040
cagaacccca	aatttcaagg	ctctttctat	caatattgga	cctctgggag	ctaatactcc	2100
tctttgctca	ccaccatgtg	atcattgatc	agatgtggtg	agtgagtagg	ggactcgact	2160
tgcgggatgc	agttttgcca	ttgcagcaaa	gttcattgag	gaaaattgta	ccatgaaaaa	2220
gcattttgat	tatttcattt	ctggaggatg	accttgaggg	aagctttta	atattagttt	2280
caagctttcc	ttaccctaca	actttaaaca	aaagctttaa	ttttgtttgc	actcctattt	2340
tgagcttgta	actggaaaag	catgtcttgc	actgttcaac	ctcctgagtg	gtcgctttaa	2400
caacctccaa	attgtgtaca	gtggttattt	tccccagttg	tatagttttg	agacattcaa	2460
ttatcactgt	cttagttgta	ttttaattta	ctaaattatg	tagctatctg	actgttaagt	2520
tcttttaaac	aactgtttcc	ttgggcttca	gttatttaaa	gtaaatttag	gtgtaatata	2580
gaaaactgtc	cctttccagg	tgggagctta	acacctgtat	aaaacctaag	gttttagtaa	2640
gtaccttagt	tgaataaaag	cacaaggtta	tcaccttttt	tatccgtcca	ccgtgacatg	2700
gttatgcatc	ctttagatta	acctcaccaa	atgaagcttt	ttctatccat	tttaatatt	2760

gtccttacat aatattgtcc ttagattttg atcaattcta tgtctgactt tgaaatacca 2820
tttacaatgt agtatgtttt caatgaaaaa ccataaagta acatccaagt gtttcatggt 2880
ttgttgggaa ggtaatttta aaataaaaca atttccaaaa aac 2923

<210> 57

<211> 316

<212> PRT

<213> Homo sapiens

<400> 57

Met Gly Asn Arg His Ala Lys Ala Ser Ser Pro Gln Gly Phe Asp Val 1 5 10

Asp Arg Asp Ala Lys Lys Leu Asn Lys Ala Cys Lys Gly Met Gly Thr 20 25 30

Asn Glu Ala Ala Ile Ile Glu Ile Leu Ser Gly Arg Thr Ser Asp Glu 35 40 45

Arg Gln Gln Ile Lys Gln Lys Tyr Lys Ala Thr Tyr Gly Lys Glu Leu 50 55 60

Glu Glu Val Leu Lys Ser Glu Leu Ser Gly Asn Phe Glu Lys Thr Ala 65 70 75 80

Leu Ala Leu Leu Asp Arg Pro Ser Glu Tyr Ala Ala Arg Gln Leu Gln 85 90 95

Lys Ala Met Lys Gly Leu Gly Thr Asp Glu Ser Val Leu Ile Glu Phe 100 105 110

Leu Cys Thr Arg Thr Asn Lys Glu Ile Ile Ala Ile Lys Glu Ala Tyr 115 120 125

Gln Arg Leu Phe Asp Arg Ser Leu Glu Ser Asp Val Lys Gly Asp Thr 130 135 140

Ser Gly Asn Leu Lys Lys Ile Leu Val Ser Leu Leu Gln Ala Asn Arg 145 150 155 160

Asn Glu Gly Asp Asp Val Asp Lys Asp Leu Ala Gly Gln Asp Ala Lys 165 170 175

Asp Leu Tyr Asp Ala Gly Glu Gly Arg Trp Gly Thr Asp Glu Leu Ala 180 185 190

Phe Asn Glu Val Leu Ala Lys Arg Ser Tyr Lys Gln Leu Arg Ala Thr 195 200 205

Phe Gln Ala Tyr Gln Ile Leu Ile Gly Lys Asp Ile Glu Glu Ala Ile 210 215 220

Glu Glu Glu Thr Ser Gly Asp Leu Gln Lys Ala Tyr Leu Thr Leu Val 225 230 235 240

Arg Cys Ala Gln Asp Cys Glu Asp Tyr Phe Ala Glu Arg Leu Tyr Lys 245 250 255

Ser Met Lys Gly Ala Gly Thr Asp Glu Glu Thr Leu Ile Arg Ile Val 260 265 270

Val Thr Arg Ala Glu Val Asp Leu Gln Gly Ile Lys Ala Lys Phe Gln 275 280 285

Glu Lys Tyr Gln Lys Ser Leu Ser Asp Met Val Arg Ser Asp Thr Ser 290 295 300

Gly Asp Phe Arg Lys Leu Leu Val Ala Leu Leu His 305 310 315

<210> 58

<211> 321

<212> PRT

<213> Homo sapiens

<400> 58

Met Ala Met Ala Thr Lys Gly Gly Thr Val Lys Ala Ala Ser Gly Phe 1 5 10 15

Asn Ala Met Glu Asp Ala Gln Thr Leu Arg Lys Ala Met Lys Gly Leu 20 25 30

Gly Thr Asp Glu Asp Ala Ile Ile Ser Val Leu Ala Tyr Arg Asn Thr 35 40 45

Ala Gln Arg Gln Glu Ile Arg Thr Ala Tyr Lys Ser Thr Ile Gly Arg
50 55 60

Asp Leu Ile Asp Asp Leu Lys Ser Glu Leu Ser Gly Asn Phe Glu Gln 65 70 75 80

Val Ile Val Gly Met Met Thr Pro Thr Val Leu Tyr Asp Val Gln Glu 85 90 95

Leu Arg Arg Ala Met Lys Gly Ala Gly Thr Asp Glu Gly Cys Leu Ile 100 105 110

Glu Ile Leu Ala Ser Arg Thr Pro Glu Glu Ile Arg Arg Ile Ser Gln 115 120 125

Thr Tyr Gln Gln Tyr Gly Arg Ser Leu Glu Asp Asp Ile Arg Ser 130 135

Asp Thr Ser Phe Met Phe Gln Arg Val Leu Val Ser Leu Ser Ala Gly 145 150 155 160

Gly Arg Asp Glu Gly Asn Tyr Leu Asp Asp Ala Leu Val Arg Gln Asp 165 170 175

Ala Gln Asp Leu Tyr Glu Ala Gly Glu Lys Lys Trp Gly Thr Asp Glu 180 185 190

Val Lys Phe Leu Thr Val Leu Cys Ser Arg Asn Arg Asn His Leu Leu 195 200 205

His Val Phe Asp Glu Tyr Lys Arg Ile Ser Gln Lys Asp Ile Glu Gln 210 215 220

Ser Ile Lys Ser Glu Thr Ser Gly Ser Phe Glu Asp Ala Leu Leu Ala 225 235 240

Ile Val Lys Cys Met Arg Asn Lys Ser Ala Tyr Phe Ala Glu Lys Leu 245 250 255

Tyr Lys Ser Met Lys Gly Leu Gly Thr Asp Asp Asn Thr Leu Ile Arg 260 265 270

Val Met Val Ser Arg Ala Glu Ile Asp Met Leu Asp Ile Arg Ala His 275 280 285

Phe Lys Arg Leu Tyr Gly Lys Ser Leu Tyr Ser Phe Ile Lys Gly Asp 290 295 300

Thr Ser Gly Asp Tyr Arg Lys Val Leu Leu Val Leu Cys Gly Gly Asp 305 310 315

Asp

<210> 59

<211> 704

<212> PRT

<213> Homo sapiens

<400> 59

Met Glu Ser Lys Pro Ser Arg Ile Pro Arg Arg Ile Ser Val Gln Pro 1 5 10 15

Ser Ser Ser Leu Ser Ala Arg Met Met Ser Gly Ser Arg Gly Ser Ser 20 25 30

Leu Asn Asp Thr Tyr His Ser Arg Asp Ser Ser Phe Arg Leu Asp Ser 35 40 45

Glu Tyr Gln Ser Thr Ser Ala Ser Ala Ser Ala Ser Pro Phe Gln Ser 50 55 60

Ala Trp Tyr Ser Glu Ser Glu Ile Thr Gln Gly Ala Arg Ser Arg Ser 65 70 75 80

Gln Asn Gln Gln Arg Asp His Asp Ser Lys Arg Pro Lys Leu Ser Cys 85 90 95

Thr Asn Cys Thr Thr Ser Ala Gly Arg Asn Val Gly Asn Gly Leu Asn 100 105 110

Thr Leu Ser Asp Ser Ser Trp Arg His Ser Gln Val Pro Arg Ser Ser 115 120 125

Ser Met Val Leu Gly Ser Phe Gly Thr Asp Leu Met Arg Glu Arg Arg 130 135 140

Asp Leu Glu Arg Arg Thr Asp Ser Ser Ile Ser Asn Leu Met Asp Tyr 145 150 155 160

Ser His Arg Ser Gly Asp Phe Thr Thr Ser Ser Tyr Val Gln Asp Arg 165 170 175

Val Pro Ser Tyr Ser Gln Gly Ala Arg Pro Lys Glu Asn Ser Met Ser 180 185 190

Thr Leu Gln Leu Asn Thr Ser Ser Thr Asn His Gln Leu Pro Ser Glu 195 200 205

His Gln Thr Ile Leu Ser Ser Arg Asp Ser Arg Asn Ser Leu Arg Ser 210 215 220

Asn Phe Ser Ser Arg Glu Ser Glu Ser Ser Arg Ser Asn Thr Gln Pro 225 230 235 240

- Gly Phe Ser Tyr Ser Ser Ser Arg Asp Glu Ala Pro Ile Ile Ser Asn 245 250 255
- Ser Glu Arg Val Val Ser Ser Gln Arg Pro Phe Gln Glu Ser Ser Asp 260 265 270
- Asn Glu Gly Arg Arg Thr Thr Arg Arg Leu Leu Ser Arg Ile Ala Ser 275 280 285
- Ser Met Ser Ser Thr Phe Phe Ser Arg Arg Ser Ser Gln Asp Ser Leu 290 295 300
- Asn Thr Arg Ser Leu Asn Ser Glu Asn Ser Tyr Val Ser Pro Arg Ile 305 310 315 320
- Leu Thr Ala Ser Gln Ser Arg Ser Asn Val Pro Ser Ala Ser Glu Val 325 330 335
- Pro Asp Asn Arg Ala Ser Glu Ala Ser Gln Gly Phe Arg Phe Leu Arg 340 345 350
- Arg Arg Trp Gly Leu Ser Ser Leu Ser His Asn His Ser Ser Glu Ser 355 360 365
- Asp Ser Glu Asn Phe Asn Gln Glu Ser Glu Gly Arg Asn Thr Gly Pro 370 375 380
- Trp Leu Ser Ser Ser Leu Arg Asn Arg Cys Thr Pro Leu Phe Ser Arg 385 390 395 400
- Arg Arg Arg Glu Gly Arg Asp Glu Ser Ser Arg Ile Pro Thr Ser Asp 405 410 415
- Thr Ser Ser Arg Ser His Ile Phe Arg Arg Glu Ser Asn Glu Val Val 420 425 430
- His Leu Glu Ala Gln Asn Asp Pro Leu Gly Ala Ala Ala Asn Arg Pro 435 440 445
- Gln Ala Ser Ala Ala Ser Ser Ser Ala Thr Thr Gly Gly Ser Thr Ser 450 455 460
- Asp Ser Ala Gln Gly Gly Arg Asn Thr Gly Ile Ser Gly Ile Leu Pro 465 470 475 480

Gly Ser Leu Phe Arg Phe Ala Val Pro Pro Ala Leu Gly Ser Asn Leu 485 490 495

Thr Asp Asn Val Met Ile Thr Val Asp Ile Ile Pro Ser Gly Trp Asn 500 505 510

Ser Ala Asp Gly Lys Ser Asp Lys Thr Lys Ser Ala Pro Ser Arg Asp 515 520 525

Pro Glu Arg Leu Gln Lys Ile Lys Glu Ser Leu Leu Glu Asp Ser 530 535 540

Glu Glu Glu Glu Gly Asp Leu Cys Arg Ile Cys Gln Met Ala Ala Ala 545 550 560

Ser Ser Ser Asn Leu Leu Ile Glu Pro Cys Lys Cys Thr Gly Ser Leu 565 570 575

Gln Tyr Val His Gln Asp Cys Met Lys Lys Trp Leu Gln Ala Lys Ile 580 585 590

Asn Ser Gly Ser Ser Leu Glu Ala Val Thr Thr Cys Glu Leu Cys Lys 595 600 605

Glu Lys Leu Glu Leu Asn Leu Glu Asp Phe Asp Ile His Glu Leu His 610 615 620

Arg Ala His Ala Asn Glu Gln Ala Glu Tyr Glu Phe Ile Ser Ser Gly 625 630 635 640

Leu Tyr Leu Val Val Leu Leu His Leu Cys Glu Gln Ser Phe Ser Asp 645 650 655

Met Met Gly Asn Thr Asn Glu Pro Ser Thr Arg Val Arg Phe Ile Asn 660 665 670

Leu Ala Arg Thr Leu Gln Ala His Met Glu Asp Leu Glu Thr Ser Glu 675 680 685

Asp Asp Ser Glu Glu Asp Gly Asp His Asn Arg Thr Phe Asp Ile Ala 690 695 700

<210> 60

<211> 490

<212> PRT

<213> Homo sapiens

<400> 60

Met Ile Lys Gln Leu Lys Glu Glu Leu Arg Leu Glu Glu Ala Lys Leu 1 5 10 15

Val Leu Leu Lys Lys Leu Arg Gln Ser Gln Ile Gln Lys Glu Ala Thr 20 25 30

Ala Gln Lys Pro Thr Gly Ser Val Gly Ser Thr Val Thr Thr Pro Pro 35 40 45

Pro Leu Val Arg Gly Thr Gln Asn Ile Pro Ala Gly Lys Pro Ser Leu 50 55 60

Gln Thr Ser Ser Ala Arg Met Pro Gly Ser Val Ile Pro Pro Pro Leu 65 70 75 80

Val Arg Gly Gly Gln Gln Ala Ser Ser Lys Leu Gly Pro Gln Ala Ser 85 90 95

Ser Gln Val Val Met Pro Pro Leu Val Arg Gly Ala Gln Gln Ile His 100 105 110

Ser Ile Arg Gln His Ser Ser Thr Gly Pro Pro Pro Leu Leu Leu Ala 115 120 125

Pro Arg Ala Ser Val Pro Ser Val Gln Ile Gln Gly Gln Arg Ile Ile 130 135 140

Gln Gln Gly Leu Ile Arg Val Ala Asn Val Pro Asn Thr Ser Leu Leu 145 150 155 160

Val Asn Ile Pro Gln Pro Thr Pro Ala Ser Leu Lys Gly Thr Thr Ala 165 170 175

Thr Ser Ala Gln Ala Asn Ser Thr Pro Thr Ser Val Ala Ser Val Val 180 185 190

Thr Ser Ala Glu Ser Pro Ala Ser Arg Gln Ala Ala Ala Lys Leu Ala 195 200 205

Leu Arg Lys Gln Leu Glu Lys Thr Leu Leu Glu Ile Pro Pro Pro Lys 210 215 220

Pro Pro Ala Pro Glu Met Asn Phe Leu Pro Ser Ala Ala Asn Asn Glu 225 230 230 235 240

Phe Ile Tyr Leu Val Gly Leu Glu Glu Val Val Gln Asn Leu Leu Glu 245 250 255

Thr Gln Gly Arg Met Ser Ala Ala Thr Val Leu Ser Arg Glu Pro Tyr 260 265 270

Met Cys Ala Gln Cys Lys Thr Asp Phe Thr Cys Arg Trp Arg Glu Glu 275 280 285

Lys Ser Gly Ala Ile Met Cys Glu Asn Cys Met Thr Thr Asn Gln Lys 290 295 300

Lys Ala Leu Lys Val Glu His Thr Ser Arg Leu Lys Ala Ala Phe Val 305 310 315 320

Lys Ala Leu Gln Gln Glu Gln Glu Ile Glu Gln Arg Leu Leu Gln Gln 325 330 335

Gly Thr Ala Pro Ala Gln Ala Lys Ala Glu Pro Thr Ala Ala Pro His 340 345 350

Pro Val Leu Lys Gln Val Ile Lys Pro Arg Arg Lys Leu Ala Phe Arg 355 360 365

Ser Gly Glu Ala Arg Asp Trp Ser Asn Gly Ala Val Leu Gln Ala Ser 370 375 380

Ser Gln Leu Ser Arg Gly Ser Ala Thr Thr Pro Arg Gly Val Leu His 385 390 395 400

Thr Phe Ser Pro Ser Pro Lys Leu Gln Asn Ser Ala Ser Ala Thr Ala 405 410 415

Leu Val Ser Arg Thr Gly Arg His Ser Glu Arg Thr Val Ser Ala Gly 420 425 430

Lys Gly Ser Ala Thr Ser Asn Trp Lys Lys Thr Pro Leu Ser Thr Gly 435 440 445

Gly Thr Leu Ala Phe Val Ser Pro Ser Leu Ala Val His Lys Ser Ser 450 455 460

Ser Ala Val Asp Arg Gln Arg Glu Tyr Leu Leu Asp Met Ile Pro Pro 465 470 475 480

Arg Ser Ile Pro Gln Ser Ala Thr Trp Lys

485 490

<210> 61

<211> 495

<212> PRT

<213> Homo sapiens

<400> 61

Met Ser Ser Glu Ile Pro Gln Gly Leu Gln Thr Thr Asn Pro Gln Gly
1 5 10 15

His Ile Leu Val Phe Pro Asp Gln Thr Glu Ala Val Val Leu Gly Leu 20 25 30

Pro Ser Ala Trp Ala Val Gly Ala Cys Ala Arg Ala Cys Pro Ala Ala 35 40 45

Cys Ala Cys Ser Thr Val Glu Arg Gly Cys Ser Val Arg Cys Asp Arg 50 55 60

Ala Gly Leu Leu Arg Val Pro Ala Glu Leu Pro Cys Glu Ala Val Ser 65 70 75 80

Ile Asp Leu Asp Arg Asn Gly Leu Arg Phe Leu Gly Glu Arg Ala Phe
85 90 95

Gly Thr Leu Pro Ser Leu Arg Arg Leu Ser Leu Arg His Asn Asn Leu 100 105 110

Ser Phe Ile Thr Pro Gly Ala Phe Lys Gly Leu Pro Arg Leu Ala Glu 115 120 125

Leu Arg Leu Ala His Asn Gly Asp Leu Arg Tyr Leu His Ala Arg Thr 130 135 140

Phe Ala Ala Leu Ser Arg Leu Arg Leu Asp Leu Ala Ala Cys Arg 145 150 155 160

Leu Phe Ser Val Pro Glu Arg Leu Leu Ala Glu Leu Pro Ala Leu Arg 165 170 175

Glu Leu Ala Ala Phe Asp Asn Leu Phe Arg Arg Val Pro Gly Ala Leu 180 185 190

Arg Gly Leu Ala Asn Leu Thr His Ala His Leu Glu Arg Gly Arg Ile 195 200 205

Glu Ala Val Ala Ser Ser Ser Leu Gln Gly Leu Arg Arg Leu Arg Ser 210 215 220

- Leu Ser Leu Gln Ala Asn Arg Val Arg Ala Val His Ala Gly Ala Phe 225 230 235 240
- Gly Asp Cys Gly Val Leu Glu His Leu Leu Leu Asn Asp Asn Leu Leu 245 250 255
- Ala Glu Leu Pro Ala Asp Ala Phe Arg Gly Leu Arg Arg Leu Arg Thr 260 265 270
- Leu Asn Leu Gly Gly Asn Ala Leu Asp Arg Val Ala Arg Ala Trp Phe 275 280 285
- Ala Asp Leu Ala Glu Leu Glu Leu Leu Tyr Leu Asp Arg Asn Ser Ile 290 295 300
- Ala Phe Val Glu Glu Gly Ala Phe Gln Asn Leu Ser Gly Leu Leu Ala 305 310 315 320
- Leu His Leu Asn Gly Asn Arg Leu Thr Val Leu Ala Trp Val Ala Phe 325 330 335
- Gln Pro Gly Phe Phe Leu Gly Arg Leu Phe Leu Phe Arg Asn Pro Trp
  340 345 350
- Cys Cys Asp Cys Arg Leu Glu Trp Leu Arg Asp Trp Met Glu Gly Ser 355 360 365
- Gly Arg Val Thr Asp Val Pro Cys Ala Ser Pro Gly Ser Val Ala Gly 370 375 380
- Leu Asp Leu Ser Gln Val Thr Phe Gly Arg Ser Ser Asp Gly Leu Cys 385 395 400
- Val Asp Pro Glu Glu Leu Asn Leu Thr Thr Ser Ser Pro Gly Pro Ser 405 410 415
- Pro Glu Pro Ala Ala Thr Thr Val Ser Arg Phe Ser Ser Leu Leu Ser 420 425 430
- Lys Leu Leu Ala Pro Arg Val Pro Val Glu Glu Ala Ala Asn Thr Thr 435 440 445
- Gly Gly Leu Ala Asn Ala Ser Leu Ser Asp Ser Leu Ser Ser Arg Gly 450 455 460

Val Gly Gly Ala Gly Arg Gln Pro Trp Phe Leu Leu Ala Ser Cys Leu 465 470 475 480

Leu Pro Ser Val Ala Gln His Val Val Phe Gly Leu Gln Met Asp 485 490 495

<210> 62

<211> 370

<212> PRT

<213> Homo sapiens

<400> 62

Met Lys Val Thr Gly Ile Thr Ile Leu Phe Trp Pro Leu Ser Met Ile 1 5 10 15

Leu Leu Ser Asp Lys Ile Gln Ser Ser Lys Arg Glu Val Gln Cys Asn 20 25 30

Phe Thr Glu Lys Asn Tyr Thr Leu Ile Pro Ala Asp Ile Lys Lys Asp 35 40 45

Val Thr Ile Leu Asp Leu Ser Tyr Asn Gln Ile Thr Leu Asn Gly Thr 50 55 60

Asp Thr Arg Val Leu Gln Thr Tyr Phe Leu Leu Thr Glu Leu Tyr Leu 65 70 75 80

Ile Glu Asn Lys Val Thr Ile Leu His Asn Asn Gly Phe Gly Asn Leu 85 90 95

Ser Ser Leu Glu Ile Leu Asn Ile Cys Arg Asn Ser Ile Tyr Val Ile 100 105 110

Gln Gln Gly Ala Phe Leu Gly Leu Asn Lys Leu Lys Gln Leu Tyr Leu 115 120 125

Cys Gln Asn Lys Ile Glu Gln Leu Asn Ala Asp Val Phe Val Pro Leu 130 135 140

Arg Ser Leu Lys Leu Leu Asn Leu Gln Gly Asn Leu Ile Ser Tyr Leu 145 150 155 160

Asp Val Pro Pro Leu Phe His Leu Glu Leu Ile Thr Leu Tyr Gly Asn 165 170 175

Leu Trp Asn Cys Ser Cys Ser Leu Phe Asn Leu Gln Asn Trp Leu Asn

180 185 190

Thr Ser Asn Val Thr Leu Glu Asn Glu Asn Ile Thr Met Cys Ser Tyr 195 200 205

Pro Asn Ser Leu Gln Ser Tyr Asn Ile Lys Thr Val Pro His Lys Ala 210 215 220

Glu Cys His Ser Lys Phe Pro Ser Ser Val Thr Glu Asp Leu Tyr Ile 225 230 235 240

His Phe Gln Pro Ile Ser Asn Ser Ile Phe Asn Ser Ser Ser Asn Asn 245 250 255

Leu Thr Arg Asn Ser Glu His Glu Pro Leu Gly Lys Ser Trp Ala Phe 260 265 270

Leu Val Gly Val Val Val Thr Val Leu Thr Thr Ser Leu Leu Ile Phe 275 280 285

Ile Ala Ile Lys Cys Pro Ile Trp Tyr Asn Ile Leu Leu Ser Tyr Asn 290 295 300

His His Arg Leu Glu Glu His Glu Ala Glu Thr Tyr Glu Asp Gly Phe 305 310 315 320

Thr Gly Asn Pro Ser Ser Leu Ser Gln Ile Pro Glu Thr Asn Ser Glu 325 330 335

Glu Thr Thr Val Ile Phe Glu Gln Leu His Ser Phe Val Val Asp Asp 340 345 350

Asp Gly Phe Ile Glu Asp Lys Tyr Ile Asp Ile His Glu Leu Cys Glu 355 360 365

Glu Asn 370

<210> 63

<211> 662

<212> PRT

<213> Homo sapiens

<400> 63

Met Arg Pro Gln Ile Leu Leu Leu Leu Ala Leu Leu Thr Leu Gly Leu 1 5 10 15

Ala Ala Gln His Gln Asp Lys Val Pro Cys Lys Met Val Asp Lys Lys 20 25 30

- Val Ser Cys Gln Val Leu Gly Leu Leu Gln Val Pro Ser Val Leu Pro 35 40 45
- Pro Asp Thr Glu Thr Leu Asp Leu Ser Gly Asn Gln Leu Arg Ser Ile 50 55 60
- Leu Ala Ser Pro Leu Gly Phe Tyr Thr Ala Leu Arg His Leu Asp Leu 65 70 75 80
- Ser Thr Asn Glu Ile Ser Phe Leu Gln Pro Gly Ala Phe Gln Ala Leu 85 90 95
- Thr His Leu Glu His Leu Ser Leu Ala His Asn Arg Leu Ala Met Ala 100 105 110
- Thr Ala Leu Ser Ala Gly Gly Leu Gly Pro Leu Pro Arg Val Thr Ser 115 120 125
- Leu Asp Leu Ser Gly Asn Ser Leu Tyr Ser Gly Leu Leu Glu Arg Leu 130 135 140
- Leu Gly Glu Ala Pro Ser Leu His Thr Leu Ser Leu Ala Glu Asn Ser 145 150 155 160
- Leu Thr Arg Leu Thr Arg His Thr Phe Arg Asp Met Pro Ala Leu Glu 165 170 175
- Gln Leu Asp Leu His Ser Asn Val Leu Met Asp Ile Glu Asp Gly Ala 180 185 190
- Phe Glu Gly Leu Pro Arg Leu Thr His Leu Asn Leu Ser Arg Asn Ser 195 200 205
- Leu Thr Cys Ile Ser Asp Phe Ser Leu Gln Gln Leu Arg Val Leu Asp 210 215 220
- Leu Ser Cys Asn Ser Ile Glu Ala Phe Gln Thr Ala Ser Gln Pro Gln 225 230 235 240
- Ala Glu Phe Gln Leu Thr Trp Leu Asp Leu Arg Glu Asn Lys Leu Leu 255
- His Phe Pro Asp Leu Ala Ala Leu Pro Arg Leu Ile Tyr Leu Asn Leu 260 265 270

Ser Asn Asn Leu Ile Arg Leu Pro Thr Gly Pro Pro Gln Asp Ser Lys 275 280 285

- Gly Ile His Ala Pro Ser Glu Gly Trp Ser Ala Leu Pro Leu Ser Ala 290 295 300
- Pro Ser Gly Asn Ala Ser Gly Arg Pro Leu Ser Gln Leu Leu Asn Leu 305 310 315 320
- Asp Leu Ser Tyr Asn Glu Ile Glu Leu Ile Pro Asp Ser Phe Leu Glu 325 330 335
- His Leu Thr Ser Leu Cys Phe Leu Asn Leu Ser Arg Asn Cys Leu Arg 340 345 350
- Thr Phe Glu Ala Arg Arg Leu Gly Ser Leu Pro Cys Leu Met Leu Leu 355 360 365
- Asp Leu Ser His Asn Ala Leu Glu Thr Leu Glu Leu Gly Ala Arg Ala 370 375 380
- Leu Gly Ser Leu Arg Thr Leu Leu Leu Gln Gly Asn Ala Leu Arg Asp 385 390 395 400
- Leu Pro Pro Tyr Thr Phe Ala Asn Leu Ala Ser Leu Gln Arg Leu Asn 405 410 415
- Leu Gln Gly Asn Arg Val Ser Pro Cys Gly Gly Pro Asp Glu Pro Gly 420 425 430
- Pro Ser Gly Cys Val Ala Phe Ser Gly Ile Thr Ser Leu Arg Ser Leu 435 440 445
- Ser Leu Val Asp Asn Glu Ile Glu Leu Leu Arg Ala Gly Ala Phe Leu 450 455 460
- His Thr Pro Leu Thr Glu Leu Asp Leu Ser Ser Asn Pro Gly Leu Glu 465 470 475 480
- Val Ala Thr Gly Ala Leu Gly Gly Leu Glu Ala Ser Leu Glu Val Leu 485 490 495
- Ala Leu Gln Gly Asn Gly Leu Met Val Leu Gln Val Asp Leu Pro Cys 500 505 510

Phe Ile Cys Leu Lys Arg Leu Asn Leu Ala Glu Asn Arg Leu Ser His 515 520 525

Leu Pro Ala Trp Thr Gln Ala Val Ser Leu Glu Val Leu Asp Leu Arg 530 535 . 540

Asn Asn Ser Phe Ser Leu Leu Pro Gly Ser Ala Met Gly Gly Leu Glu 545 550 555 560

Thr Ser Leu Arg Arg Leu Tyr Leu Gln Gly Asn Pro Leu Ser Cys Cys 565 570 575

Gly Asn Gly Trp Leu Ala Ala Gln Leu His Gln Gly Arg Val Asp Val 580 585 590

Asp Ala Thr Gln Asp Leu Ile Cys Arg Phe Ser Ser Gln Glu Glu Val 595 600 605

Ser Leu Ser His Val Arg Pro Glu Asp Cys Glu Lys Gly Gly Leu Lys 610 615 620

Asn Ile Asn Leu Ile Ile Ile Leu Thr Phe Ile Leu Val Ser Ala Ile 625 630 635 640

Leu Leu Thr Thr Leu Ala Ala Cys Cys Cys Val Arg Arg Gln Lys Phe 645 650 655

Asn Gln Gln Tyr Lys Ala 660

<210> 64

<211> 626

<212> PRT

<213> Homo sapiens

<400> 64

Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro 1 5 10 15

His Pro Ile Cys Glu Val Ser Lys Val Ala Ser His Leu Glu Val Asn 20 25 30

Cys Asp Lys Arg Asn Leu Thr Ala Leu Pro Pro Asp Leu Pro Lys Asp 35 40 45

Thr Thr Ile Leu His Leu Ser Glu Asn Leu Leu Tyr Thr Phe Ser Leu 50 55 60

Ala Thr Leu Met Pro Tyr Thr Arg Leu Thr Gln Leu Asn Leu Asp Arg 65 70 75 80

- Cys Glu Leu Thr Lys Leu Gln Val Asp Gly Thr Leu Pro Val Leu Gly 85 90 95
- Thr Leu Asp Leu Ser His Asn Gln Leu Gln Ser Leu Pro Leu Gly 100 105 110
- Gln Thr Leu Pro Ala Leu Thr Val Leu Asp Val Ser Phe Asn Arg Leu
  115 120 125
- Thr Ser Leu Pro Leu Gly Ala Leu Arg Gly Leu Gly Glu Leu Gln Glu 130 135 140
- Leu Tyr Leu Lys Gly Asn Glu Leu Lys Thr Leu Pro Pro Gly Leu Leu 145 150 155 160
- Thr Pro Thr Pro Lys Leu Glu Lys Leu Ser Leu Ala Asn Asn Asn Leu 165 170 175
- Thr Glu Leu Pro Ala Gly Leu Leu Asn Gly Leu Glu Asn Leu Asp Thr 180 185 190
- Leu Leu Gln Glu Asn Ser Leu Tyr Thr Ile Pro Lys Gly Phe Phe 195 200 205
- Gly Ser His Leu Leu Pro Phe Ala Phe Leu His Gly Asn Pro Trp Leu 210 215 220
- Cys Asn Cys Glu Ile Leu Tyr Phe Arg Arg Trp Leu Gln Asp Asn Ala 225 235 240
- Glu Asn Val Tyr Val Trp Lys Gln Gly Val Asp Val Lys Ala Met Thr 245 250 255
- Ser Asn Val Ala Ser Val Gln Cys Asp Asn Ser Asp Lys Phe Pro Val 260 265 270
- Tyr Lys Tyr Pro Gly Lys Gly Cys Pro Thr Leu Gly Asp Glu Gly Asp 275 280 285
- Thr Asp Leu Tyr Asp Tyr Tyr Pro Glu Glu Asp Thr Glu Gly Asp Lys 290 295 300
- Val Arg Ala Thr Arg Thr Val Val Lys Phe Pro Thr Lys Ala His Thr

305 310 315 320

Thr Pro Trp Gly Leu Phe Tyr Ser Trp Ser Thr Ala Ser Leu Asp Ser 325 330 335

Gln Met Pro Ser Ser Leu His Pro Thr Gln Glu Ser Thr Lys Glu Gln 340 345 350

Thr Thr Phe Pro Pro Arg Trp Thr Pro Asn Phe Thr Leu His Met Glu 355 360 365

Ser Ile Thr Phe Ser Lys Thr Pro Lys Ser Thr Thr Glu Pro Thr Pro 370 375 380

Ser Pro Thr Thr Ser Glu Pro Val Pro Glu Pro Ala Pro Asn Met Thr 385 390 395 400

Thr Leu Glu Pro Thr Pro Ser Pro Thr Thr Pro Glu Pro Thr Ser Glu 405 410 415

Pro Ala Pro Ser Pro Thr Thr Pro Glu Pro Thr Pro Ile Pro Thr Ile 420 425 430

Ala Thr Ser Pro Thr Ile Leu Val Ser Ala Thr Ser Leu Ile Thr Pro 435 440 445

Lys Ser Thr Phe Leu Thr Thr Lys Pro Val Ser Leu Leu Glu Ser 450 455 460

Thr Lys Lys Thr Ile Pro Glu Leu Asp Gln Pro Pro Lys Leu Arg Gly 465 470 475 480

Val Leu Gln Gly His Leu Glu Ser Ser Arg Asn Asp Pro Phe Leu His 485 490 495

Pro Asp Phe Cys Cys Leu Leu Pro Leu Gly Phe Tyr Val Leu Gly Leu
500 505 510

Phe Trp Leu Leu Phe Ala Ser Val Val Leu Ile Leu Leu Ser Trp 515 520 525

Val Gly His Val Lys Pro Gln Ala Leu Asp Ser Gly Gln Gly Ala Ala 530 535 540

Leu Thr Thr Ala Thr Gln Thr Thr His Leu Glu Leu Gln Arg Gly Arg 545 550 555

Gln Val Thr Val Pro Arg Ala Trp Leu Leu Phe Leu Arg Gly Ser Leu 565 570 575

Pro Thr Phe Arg Ser Ser Leu Phe Leu Trp Val Arg Pro Asn Gly Arg 580 585 585

Val Gly Pro Leu Val Ala Gly Arg Arg Pro Ser Ala Leu Ser Gln Gly 595 600 605

Arg Gly Gln Asp Leu Leu Ser Thr Val Ser Ile Arg Tyr Ser Gly His 610 615 620

Ser Leu 625

<210> 65

<211> 560

<212> PRT

<213> Homo sapiens

<400> 65

Met Leu Arg Gly Thr Leu Leu Cys Ala Val Leu Gly Leu Leu Arg Ala 1 5 10 15

Gln Pro Phe Pro Cys Pro Pro Ala Cys Lys Cys Val Phe Arg Asp Ala 20 25 30

Ala Gln Cys Ser Gly Gly Asp Val Ala Arg Ile Ser Ala Leu Gly Leu 35 . 40 45

Pro Thr Asn Leu Thr His Ile Leu Leu Phe Gly Met Gly Arg Gly Val 50 55 60

Leu Gln Ser Gln Ser Phe Ser Gly Met Thr Val Leu Gln Arg Leu Met 65 70 75 80

Ile Ser Asp Ser His Ile Ser Ala Val Ala Pro Gly Thr Phe Ser Asp 85 90 95

Leu Ile Lys Leu Lys Thr Leu Arg Leu Ser Arg Asn Lys Ile Thr His 100 105 110

Leu Pro Gly Ala Leu Leu Asp Lys Met Val Leu Leu Glu Gln Leu Phe 115 120 125

Leu Asp His Asn Ala Leu Arg Gly Ile Asp Gln Asn Met Phe Gln Lys 130 135 140

Leu Val Asn Leu Gln Glu Leu Ala Leu Asn Gln Asn Gln Leu Asp Phe 145 150 150 160

- Leu Pro Ala Ser Leu Phe Thr Asn Leu Glu Asn Leu Lys Leu Leu Asp 165 170 170
- Leu Ser Gly Asn Asn Leu Thr His Leu Pro Lys Gly Leu Leu Gly Ala 180 185 190
- Gln Ala Lys Leu Glu Arg Leu Leu Leu His Ser Asn Arg Leu Val Ser 195 200 205
- Leu Asp Ser Gly Leu Leu Asn Ser Leu Gly Ala Leu Thr Glu Leu Gln 210 215 220
- Phe His Arg Asn His Ile Arg Ser Ile Ala Pro Gly Ala Phe Asp Arg 225 230 235 240
- Leu Pro Asn Leu Ser Ser Leu Thr Leu Ser Arg Asn His Leu Ala Phe 245 255
- Leu Pro Ser Ala Leu Phe Leu His Ser His Asn Leu Thr Leu Leu Thr 260 265 27.0
- Leu Phe Glu Asn Pro Leu Ala Glu Leu Pro Gly Val Leu Phe Gly Glu 275 280 285
- Met Gly Gly Leu Gln Glu Leu Trp Leu Asn Arg Thr Gln Leu Arg Thr 290 295 300
- Leu Pro Ala Ala Ala Phe Arg Asn Leu Ser Arg Leu Arg Tyr Leu Gly 305 310 315
- Val Thr Leu Ser Pro Arg Leu Ser Ala Leu Pro Gln Gly Ala Phe Gln 325 330 335
- Gly Leu Gly Glu Leu Gln Val Leu Ala Leu His Ser Asn Gly Leu Thr 340 345 350
- Ala Leu Pro Asp Gly Leu Leu Arg Gly Leu Gly Lys Leu Arg Gln Val 355 360 365
- Ser Leu Arg Arg Asn Arg Leu Arg Ala Leu Pro Arg Ala Leu Phe Arg 370 375 380

Asn Leu Ser Ser Leu Glu Ser Val Gln Leu Asp His Asn Gln Leu Glu 385 390 395 400

Thr Leu Pro Gly Asp Val Phe Gly Ala Leu Pro Arg Leu Thr Glu Val 405 410 415

Leu Leu Gly His Asn Ser Trp Arg Cys Asp Cys Gly Leu Gly Pro Phe 420 425 430

Leu Gly Trp Leu Arg Gln His Leu Gly Leu Val Gly Glu Glu Pro 435 440 445

Pro Arg Cys Ala Gly Pro Gly Ala His Ala Gly Leu Pro Leu Trp Ala 450 455 460

Leu Pro Gly Gly Asp Ala Glu Cys Pro Gly Pro Arg Gly Pro Pro 465 470 475 480

Arg Pro Ala Ala Asp Ser Ser Ser Glu Ala Pro Val His Pro Ala Leu 485 490 495

Ala Pro Asn Ser Ser Glu Pro Trp Val Trp Ala Gln Pro Val Thr Thr 500 505 510

Gly Lys Gly Gln Asp His Ser Pro Phe Trp Gly Phe Tyr Phe Leu Leu 515 520 525

Leu Ala Val Gln Ala Met Ile Thr Val Ile Ile Val Phe Ala Met Ile 530 535 540

Lys Ile Gly Gln Leu Phe Arg Lys Leu Ile Arg Glu Arg Ala Leu Gly 545 550 555 560

<210> 66

<211> 345

<212> PRT

<213> Homo sapiens

<400> 66

Met Lys Gly Glu Leu Leu Phe'Ser Ser Val Ile Val Leu Leu Gln 1 5 10

Val Val Cys Ser Cys Pro Asp Lys Cys Tyr Cys Gln Ser Ser Thr Asn 20 25 30

Phe Val Asp Cys Ser Gln Gln Gly Leu Ala Glu Ile Pro Ser His Leu 35 40 45

Pro Pro Gln Thr Arg Thr Leu His Leu Gln Asp Asn Gln Ile His His 50 55 60

- Leu Pro Ala Phe Ala Phe Arg Ser Val Pro Trp Leu Met Thr Leu Asn 65 70 75 80
- Leu Ser Asn Asn Ser Leu Ser Asn Leu Ala Pro Gly Ala Phe His Gly 85 90 95
- Leu Gln His Leu Gln Val Leu Asn Leu Thr Gln Asn Ser Leu Leu Ser 100 105 110
- Leu Glu Ser Arg Leu Phe His Ser Leu Pro Gln Leu Arg Glu Leu Asp 115 120 125
- Leu Ser Ser Asn Asn Ile Ser His Leu Pro Thr Ser Leu Gly Glu Thr 130 135 140
- Trp Glu Asn Leu Thr Ile Leu Ala Val Gln Gln Asn Gln Leu Gln Gln 145 150 155 160
- Leu Asp Arg Ala Leu Leu Glu Ser Met Pro Ser Val Arg Leu Leu Leu 165 170 175
- Leu Lys Asp Asn Leu Trp Lys Cys Asn Cys His Leu Leu Gly Leu Lys 180 185 190
- Leu Trp Leu Glu Lys Phe Val Tyr Lys Gly Gly Leu Thr Asp Gly Ile 195 200 205
- Ile Cys Glu Ser Pro Asp Thr Trp Lys Gly Lys Asp Leu Leu Arg Ile 210 215 220
- Pro His Glu Leu Tyr Gln Pro Cys Pro Leu Pro Ala Pro Asp Pro Val 225 235 240
- Ser Ser Gln Ala Gln Trp Pro Gly Ser Ala His Gly Val Val Leu Arg 245 250 255
- Pro Pro Glu Asn His Asn Ala Gly Glu Arg Glu Leu Leu Glu Cys Glu 260 265 270
- Leu Lys Pro Lys Pro Arg Pro Ala Asn Leu Arg His Ala Ile Ala Thr 275 280 285
- Val Ile Ile Thr Gly Val Val Cys Gly Ile Val Cys Leu Met Met Leu

290 295 300

Ala Ala Ala Ile Tyr Gly Cys Thr Tyr Ala Ala Ile Thr Ala Gln Tyr 305 310 315 320

His Gly Gly Pro Leu Ala Gln Thr Asn Asp Pro Gly Lys Val Glu Glu 325 330 335

Lys Glu Arg Phe Asp Ser Ser Pro Ala 340 345

<210> 67

<211> 516

<212> PRT

<213> Homo sapiens

<400> 67

Met Gly Leu His Phe Lys Trp Pro Leu Gly Ala Pro Met Leu Ala Ala 1 5 10 15

Ile Tyr Ala Met Ser Met Val Leu Lys Met Leu Pro Ala Leu Gly Met 20 25 30

Ala Cys Pro Pro Lys Cys Arg Cys Glu Lys Leu Leu Phe Tyr Cys Asp 35 40 45

Ser Gln Gly Phe His Ser Val Pro Asn Ala Thr Asp Lys Gly Ser Leu 50 55 60

Gly Leu Ser Leu Arg His Asn His Ile Thr Glu Leu Glu Arg Asp Gln 65 70 75 80

Phe Ala Ser Phe Ser Gln Leu Thr Trp Leu His Leu Asp His Asn Gln 85 90 95

Ile Ser Thr Val Lys Glu Asp Ala Phe Gln Gly Leu Tyr Lys Leu Lys
100 105 110

Glu Leu Ile Leu Ser Ser Asn Lys Ile Phe Tyr Leu Pro Asn Thr Thr 115 120 125

Phe Thr Gln Leu Ile Asn Leu Gln Asn Leu Asp Leu Ser Phe Asn Gln 130 135 140

Leu Ser Ser Leu His Pro Glu Leu Phe Tyr Gly Leu Arg Lys Leu Gln 145 150 155 160

Thr Leu His Leu Arg Ser Asn Ser Leu Arg Thr Ile Pro Val Arg Leu 165 170 175

- Phe Trp Asp Cys Arg Ser Leu Glu Phe Leu Asp Leu Ser Thr Asn Arg 180 185 190
- Leu Arg Ser Leu Ala Arg Asn Gly Phe Ala Gly Leu Ile Lys Leu Arg 195 200 205
- Glu Leu His Leu Glu His Asn Gln Leu Thr Lys Ile Asn Phe Ala His 210 215 220
- Phe Leu Arg Leu Ser Ser Leu His Thr Leu Phe Leu Gln Trp Asn Lys 225 230 235 240
- Ile Ser Asn Leu Thr Cys Gly Met Glu Trp Thr Trp Gly Thr Leu Glu 245 250 255
- Lys Leu Asp Leu Thr Gly Asn Glu Ile Lys Ala Ile Asp Leu Thr Val 260 265 270
- Phe Glu Thr Met Pro Asn Leu Lys Ile Leu Leu Met Asp Asn Asn Lys 275 280 285
- Leu Asn Ser Leu Asp Ser Lys Ile Leu Asn Ser Leu Arg Ser Leu Thr 290 295 300
- Thr Val Gly Leu Ser Gly Asn Leu Trp Glu Cys Ser Ala Arg Ile Cys 305 310 315 320
- Ala Leu Ala Ser Trp Leu Gly Ser Phe Gln Gly Arg Trp Glu His Ser 325 330 335
- Ile Leu Cys His Ser Pro Asp His Thr Gln Gly Glu Asp Ile Leu Asp 340 345 350
- Ala Val His Gly Phe Gln Leu Cys Trp Asn Leu Ser Thr Thr Val Thr 355 360 365
- Val Met Ala Thr Thr Tyr Arg Asp Pro Thr Thr Glu Tyr Thr Lys Arg 370 375 380
- Ile Ser Ser Ser Ser Tyr His Val Gly Asp Lys Glu Ile Pro Thr Thr 385 390 395 400
- Ala Gly Ile Ala Val Thr Thr Glu Glu His Phe Pro Glu Pro Asp Asn 405 410 415

Ala Ile Phe Thr Gln Arg Val Ile Thr Gly Thr Met Ala Leu Leu Phe 420 425 430

Ser Phe Phe Phe Ile Ile Phe Ile Val Phe Ile Ser Arg Lys Cys Cys 435 440 445

Pro Pro Thr Leu Arg Arg Ile Arg Gln Cys Ser Met Val Gln Asn His 450 455 460

Arg Gln Leu Arg Ser Gln Thr Arg Leu His Met Ser Asn Met Ser Asp 465 470 475 480

. Gln Gly Pro Tyr Asn Glu Tyr Glu Pro Thr His Glu Gly Pro Phe Ile 485 490 495

Ile Ile Asn Gly Tyr Gly Gln Cys Lys Cys Gln Gln Leu Pro Tyr Lys 500 505 510

Glu Cys Glu Val 515

<210> 68

<211> 661

<212> PRT

<213> Homo sapiens

<400> 68

Met Ala Phe Asp Val Ser Cys Phe Phe Trp Val Val Leu Phe Ser Ala 1 5 10 15

Gly Cys Lys Val Ile Thr Ser Trp Asp Gln Met Cys Ile Glu Lys Glu 20 25 30

Ala Asn Lys Thr Tyr Asn Cys Glu Asn Leu Gly Leu Ser Glu Ile Pro 35 40 45

Asp Thr Leu Pro Asn Thr Thr Glu Phe Leu Glu Phe Ser Phe Asn Phe 50 55 60

Leu Pro Thr Ile His Asn Arg Thr Phe Ser Arg Leu Met Asn Leu Thr 65 70 75 80

Phe Leu Asp Leu Thr Arg Cys Gln Ile Asn Trp Ile His Glu Asp Thr 85 90 95

Phe Gln Ser His His Gln Leu Ser Thr Leu Val Leu Thr Gly Asn Pro

100 105 110

Leu Ile Phe Met Ala Glu Thr Ser Leu Asn Gly Pro Lys Ser Leu Lys 115 120 125

- His Leu Phe Leu Ile Gln Thr Gly Ile Ser Asn Leu Glu Phe Ile Pro 130 135 140
- Val His Asn Leu Glu Asn Leu Glu Ser Leu Tyr Leu Gly Ser Asn His 145 150 155 160
- Ile Ser Ser Ile Lys Phe Pro Lys Asp Phe Pro Ala Arg Asn Leu Lys 165 170 175
- Val Leu Asp Phe Gln Asn Asn Ala Ile His Tyr Ile Ser Arg Glu Asp 180 185 190
- Met Arg Ser Leu Glu Gln Ala Ile Asn Leu Ser Leu Asn Phe Asn Gly
  195 . 200 205
- Asn Asn Val Lys Gly Ile Glu Leu Gly Ala Phe Asp Ser Thr Ile Phe 210 215 220
- Gln Ser Leu Asn Phe Gly Gly Thr Pro Asn Leu Ser Val Ile Phe Asn 225 235 240
- Gly Leu Gln Asn Ser Thr Thr Gln Ser Leu Trp Leu Gly Thr Phe Glu 245 250 255
- Asp Ile Asp Asp Glu Asp Ile Ser Ser Ala Met Leu Lys Gly Leu Cys 260 265 270
- Glu Met Ser Val Glu Ser Leu Asn Leu Gln Glu His Arg Phe Ser Asp 275 280 285
- Ile Ser Ser Thr Thr Phe Gln Cys Phe Thr Gln Leu Gln Glu Leu Asp 290 295 300
- Leu Thr Ala Thr His Leu Lys Gly Leu Pro Ser Gly Met Lys Gly Leu 305 310 315 320
- Asn Leu Leu Lys Lys Leu Val Leu Ser Val Asn His Phe Asp Gln Leu 325 330 335
- Cys Gln Ile Ser Ala Ala Asn Phe Pro Ser Leu Thr His Leu Tyr Ile 340 345 350

Arg Gly Asn Val Lys Lys Leu His Leu Gly Val Gly Cys Leu Glu Lys 355 360 365

- Leu Gly Asn Leu Gln Thr Leu Asp Leu Ser His Asn Asp Ile Glu Ala 370 375 380
- Ser Asp Cys Cys Ser Leu Gln Leu Lys Asn Leu Ser His Leu Gln Thr 385 390 395 400
- Leu Asn Leu Ser His Asn Glu Pro Leu Gly Leu Gln Ser Gln Ala Phe 405 410 415
- Lys Glu Cys Pro Gln Leu Glu Leu Leu Asp Leu Ala Phe Thr Arg Leu 420 425 430
- His Ile Asn Ala Pro Gln Ser Pro Phe Gln Asn Leu His Phe Leu Gln 435 440 445
- Val Leu Asn Leu Thr Tyr Cys Phe Leu Asp Thr Ser Asn Gln His Leu 450 455 460
- Leu Ala Gly Leu Pro Val Leu Arg His Leu Asn Leu Lys Gly Asn His 465 470 475 480
- Phe Gln Asp Gly Thr Ile Thr Lys Thr Asn Leu Leu Gln Thr Val Gly 485 490 495
- Ser Leu Glu Val Leu Ile Leu Ser Ser Cys Gly Leu Leu Ser Ile Asp 500 505 510
- Gln Gln Ala Phe His Ser Leu Gly Lys Met Ser His Val Asp Leu Ser 515 520 525
- His Asn Ser Leu Thr Cys Asp Ser Ile Asp Ser Leu Ser His Leu Lys 530 535 540
- Gly Ile Tyr Leu Asn Leu Ala Ala Asn Ser Ile Asn Ile Ile Ser Pro 545 550 555 560
- Arg Leu Leu Pro Ile Leu Ser Gln Gln Ser Thr Ile Asn Leu Ser His 565 570 575
- Asn Pro Leu Asp Cys Thr Cys Ser Asn Ile His Phe Leu Thr Trp Tyr 580 585 590
- Lys Glu Asn Leu His Lys Leu Glu Gly Ser Glu Glu Thr Thr Cys Ala

595 600 605

Asn Pro Pro Ser Leu Arg Gly Val Lys Leu Ser Asp Val Lys Leu Ser 610 615 620

Cys Gly Ile Thr Ala Ile Gly Ile Phe Phe Leu Ile Val Phe Leu Leu 625 630 635 640

Leu Leu Ala Ile Leu Leu Phe Phe Ala Val Lys Tyr Leu Leu Arg Trp 645 650 655

Lys Tyr Gln His Ile 660

<210> 69

<211> 614

<212> PRT

<213> Homo sapiens

<400> 69

Met Leu Ala Gly Gly Val Arg Ser Met Pro Ser Pro Leu Leu Ala Cys 1 5 10 15

Trp Gln Pro Ile Leu Leu Leu Val Leu Gly Ser Val Leu Ser Gly Ser 20 25 30

Ala Thr Gly Cys Pro Pro Arg Cys Glu Cys Ser Ala Gln Asp Arg Ala 35 40 45

Val Leu Cys His Arg Lys Arg Phe Val Ala Val Pro Glu Gly Ile Pro 50 55 60

Thr Glu Thr Arg Leu Leu Asp Leu Gly Lys Asn Arg Ile Lys Thr Leu 65 70 75 80

Asn Gln Asp Glu Phe Ala Ser Phe Pro His Leu Glu Glu Leu Glu Leu 85 90 95

Asn Glu Asn Ile Val Ser Ala Val Glu Pro Gly Ala Phe Asn Asn Leu 100 105 110

Phe Asn Leu Arg Thr Leu Gly Leu Arg Ser Asn Arg Leu Lys Leu Ile 115 120 125

Pro Leu Gly Val Phe Thr Gly Leu Ser Asn Leu Thr Lys Leu Asp Ile 130 135 140

Ser Glu Asn Lys Ile Val Ile Leu Leu Asp Tyr Met Phe Gln Asp Leu 145 150 155 160

- Tyr Asn Leu Lys Ser Leu Glu Val Gly Asp Asn Asp Leu Val Tyr Ile 165 170 175
- Ser His Arg Ala Phe Ser Gly Leu Asn Ser Leu Glu Gln Leu Thr Leu 180 185 190
- Glu Lys Cys Asn Leu Thr Ser Ile Pro Thr Glu Ala Leu Ser His Leu 195 200 205
- His Gly Leu Ile Val Leu Arg Leu Arg His Leu Asn Ile Asn Ala Ile 210 215 220
- Arg Asp Tyr Ser Phe Lys Arg Leu Tyr Arg Leu Lys Val Leu Glu Ile 225 230 235 240
- Ser His Trp Pro Tyr Leu Asp Thr Met Thr Pro Asn Cys Leu Tyr Gly 245 250 255
- Leu Asn Leu Thr Ser Leu Ser Ile Thr His Cys Asn Leu Thr Ala Val 260 265 270
- Pro Tyr Leu Ala Val Arg His Leu Val Tyr Leu Arg Phe Leu Asn Leu 275 280 285
- Ser Tyr Asn Pro Ile Ser Thr Ile Glu Gly Ser Met Leu His Glu Leu 290 295 300
- Leu Arg Leu Gln Glu Ile Gln Leu Val Gly Gly Gln Leu Ala Val 305 310 315 320
- Glu Pro Tyr Ala Phe Arg Gly Leu Asn Tyr Leu Arg Val Leu Asn Val 325 330 335
- Ser Gly Asn Gln Leu Thr Thr Leu Glu Glu Ser Val Phe His Ser Val 340 345 350
- Gly Asn Leu Glu Thr Leu Ile Leu Asp Ser Asn Pro Leu Ala Cys Asp 355 360 365
- Cys Arg Leu Leu Trp Val Phe Arg Arg Trp Arg Leu Asn Phe Asn 370 375 380
- Arg Gln Gln Pro Thr Cys Ala Thr Pro Glu Phe Val Gln Gly Lys Glu 385 390 395 400

Phe Lys Asp Phe Pro Asp Val Leu Leu Pro Asn Tyr Phe Thr Cys Arg 405 410 415

Arg Ala Arg Ile Arg Asp Arg Lys Ala Gln Gln Val Phe Val Asp Glu 420 425 430

Gly His Thr Val Gln Phe Val Cys Arg Ala Asp Gly Asp Pro Pro Pro 435 440 445

Ala Ile Leu Trp Leu Ser Pro Arg Lys His Leu Val Ser Ala Lys Ser 450 455 460

Asn Gly Arg Leu Thr Val Phe Pro Asp Gly Thr Leu Glu Val Arg Tyr 465 470 475 480

Ala Gln Val Gln Asp Asn Gly Thr Tyr Leu Cys Ile Ala Ala Asn Ala 485 490 495

Gly Gly Asn Asp Ser Met Pro Ala His Leu His Val Arg Ser Tyr Ser 500 505

Pro Asp Trp Pro His Gln Pro Asn Lys Thr Phe Ala Phe Ile Ser Asn 515 520 525

Gln Pro Gly Glu Gly Glu Ala Asn Ser Thr Arg Ala Thr Val Pro Phe 530 535 540

Pro Phe Asp Ile Lys Thr Leu Ile Ile Ala Thr Thr Met Gly Phe Ile 545 550 555 560

Ser Phe Leu Gly Val Val Leu Phe Cys Leu Val Leu Leu Phe Leu Trp 565 570 575

Ser Arg Gly Lys Gly Asn Thr Lys His Asn Ile Glu Ile Glu Tyr Val 580 585 590

Pro Arg Lys Ser Asp Ala Gly Ile Ser Ser Ala Asp Ala Pro Arg Lys 595 600 605

Phe Asn Met Lys Met Ile 610

<210> 70

<211> 428

<212> PRT

<213> Homo sapiens

<400> 70

Met Gln Glu Leu His Leu Leu Trp Trp Ala Leu Leu Gly Leu Ala 1 5 10 15

Gln Ala Cys Pro Glu Pro Cys Asp Cys Gly Glu Lys Tyr Gly Phe Gln 20 25 30

Ile Ala Asp Cys Ala Tyr Arg Asp Leu Glu Ser Val Pro Pro Gly Phe 35 40 45

Pro Ala Asn Val Thr Thr Leu Ser Leu Ser Ala Asn Arg Leu Pro Gly 50 55 60

Leu Pro Glu Gly Ala Phe Arg Glu Val Pro Leu Leu Gln Ser Leu Trp 65 70 75 80

Leu Ala His Asn Glu Ile Arg Thr Val Ala Ala Gly Ala Leu Ala Ser 85 90 95

Leu Ser His Leu Lys Ser Leu Asp Leu Ser His Asn Leu Ile Ser Asp 100 105 110

Phe Ala Trp Ser Asp Leu His Asn Leu Ser Ala Leu Gln Leu Leu Lys 115 120 125

Met Asp Ser Asn Glu Leu Thr Phe Ile Pro Arg Asp Ala Phe Arg Ser 130 135 140

Leu Arg Ala Leu Arg Ser Leu Gln Leu Asn His Asn Arg Leu His Thr 145 150 155 160

Leu Ala Glu Gly Thr Phe Thr Pro Leu Thr Ala Leu Ser His Leu Gln 165 170 175

Ile Asn Glu Asn Pro Phe Asp Cys Thr Cys Gly Ile Val Trp Leu Lys 180 185 190

Thr Trp Ala Leu Thr Thr Ala Val Ser Ile Pro Glu Gln Asp Asn Ile 195 200 205

Ala Cys Thr Ser Pro His Val Leu Lys Gly Thr Pro Leu Ser Arg Leu 210 215 220

Pro Pro Leu Pro Cys Ser Ala Pro Ser Val Gln Leu Ser Tyr Gln Pro 225 230 235 240

Ser Gln Asp Gly Ala Glu Leu Arg Pro Gly Phe Val Leu Ala Leu His 245 250

Cys Asp Val Asp Gly Gln Pro Ala Pro Gln Leu His Trp His Ile Gln 265

Ile Pro Ser Gly Ile Val Glu Ile Thr Ser Pro Asn Val Gly Thr Asp 280

Gly Arg Ala Leu Pro Gly Thr Pro Val Ala Ser Ser Gln Pro Arg Phe 295

Gln Ala Phe Ala Asn Gly Ser Leu Leu Ile Pro Asp Phe Gly Lys Leu 315 310

Glu Glu Gly Thr Tyr Ser Cys Leu Ala Thr Asn Glu Leu Gly Ser Ala

Glu Ser Ser Val Asp Val Ala Leu Ala Thr Pro Gly Glu Gly Glu 345

Asp Thr Leu Gly Arg Arg Phe His Gly Lys Ala Val Glu Gly Lys Gly 360

Cys Tyr Thr Val Asp Asn Glu Val Gln Pro Ser Gly Pro Glu Asp Asn 375 370

Val Val Ile Ile Tyr Leu Ser Arg Ala Gly Asn Pro Glu Ala Ala Val 390 395

Ala Glu Gly Val Pro Gly Gln Leu Pro Pro Gly Leu Leu Leu Gly

Gln Ser Leu Leu Phe Phe Phe Leu Thr Ser Phe

<210> 71 <211> 612

<212> PRT

<213> Homo sapiens

<400> 71

Met Asp Val Ser Leu Cys Pro Ala Lys Cys Ser Phe Trp Arg Ile Phe 10

Leu Leu Gly Ser Val Trp Leu Asp Tyr Val Gly Ser Val Leu Ala Cys 20 25

Pro Ala Asn Cys Val Cys Ser Lys Thr Glu Ile Asn Cys Arg Arg Pro 35 40 45

- Asp Asp Gly Asn Leu Phe Pro Leu Leu Glu Gly Gln Asp Ser Gly Asn 50 55 60
- Ser Asn Gly Asn Ala Ser Ile Asn Ile Thr Asp Ile Ser Arg Asn Ile 65 70 75 80
- Thr Ser Ile His Ile Glu Asn Trp Arg Ser Leu His Thr Leu Asn Ala 85 90 95
- Val Asp Met Glu Leu Tyr Thr Gly Leu Gln Lys Leu Thr Ile Lys Asn 100 105 110
- Ser Gly Leu Arg Ser Ile Gln Pro Arg Ala Phe Ala Lys Asn Pro His 115 120 125
- Leu Arg Tyr Ile Asn Leu Ser Ser Asn Arg Leu Thr Thr Leu Ser Trp 130 135 140
- Gln Leu Phe Gln Thr Leu Ser Leu Arg Glu Leu Gln Leu Glu Gln Asn 145 150 155 160
- Phe Phe Asn Cys Ser Cys Asp Ile Arg Trp Met Gln Leu Trp Gln Glu 165 170 175
- Gln Gly Glu Ala Lys Leu Asn Ser Gln Asn Leu Tyr Cys Ile Asn Ala 180 185 190
- Asp Gly Ser Gln Leu Pro Leu Phe Arg Met Asn Ile Ser Gln Cys Asp 195 200 205
- Leu Pro Glu Ile Ser Val Ser His Val Asn Leu Thr Val Arg Glu Gly 210 215 220
- Asp Asn Ala Val Ile Thr Cys Asn Gly Ser Gly Ser Pro Leu Pro Asp 225 230 235 240
- Val Asp Trp Ile Val Thr Gly Leu Gln Ser Ile Asn Thr His Gln Thr 245 250 255
- Asn Leu Asn Trp Thr Asn Val His Ala Ile Asn Leu Thr Leu Val Asn 260 265 270

Val Thr Ser Glu Asp Asn Gly Phe Thr Leu Thr Cys Ile Ala Glu Asn 275 280 285

- Val Val Gly Met Ser Asn Ala Ser Val Ala Leu Thr Val Tyr Tyr Pro 290 295 300 .
- Pro Arg Val Val Ser Leu Glu Glu Pro Glu Leu Arg Leu Glu His Cys 305 310 315 320
- Ile Glu Phe Val Val Arg Gly Asn Pro Pro Pro Thr Leu His Trp Leu 325 330 335
- His Asn Gly Gln Pro Leu Arg Glu Ser Lys Ile Ile His Val Glu Tyr 340 345 350
- Tyr Gln Glu Gly Glu Ile Ser Glu Gly Cys Leu Leu Phe Asn Lys Pro 355 360 365
- Thr His Tyr Asn Asn Gly Asn Tyr Thr Leu Ile Ala Lys Asn Pro Leu 370 375 380
- Gly Thr Ala Asn Gln Thr Ile Asn Gly His Phe Leu Lys Glu Pro Phe 385 390 395 400
- Pro Glu Ser Thr Asp Asn Phe Ile Leu Phe Asp Glu Val Ser Pro Thr 405 410 415
- Pro Pro Ile Thr Val Thr His Lys Pro Glu Glu Asp Thr Phe Gly Val 420 425 430
- Ser Ile Ala Val Gly Leu Ala Ala Phe Ala Cys Val Leu Leu Val Val 435 440 445
- Leu Phe Val Met Ile Asn Lys Tyr Gly Arg Arg Ser Lys Phe Gly Met 450 455 460
- Lys Gly Pro Val Ala Val Ile Ser Gly Glu Glu Asp Ser Ala Ser Pro 465 470 475 480
- Leu His His Ile Asn His Gly Ile Thr Thr Pro Ser Ser Leu Asp Ala 485 490 495
- Gly Pro Asp Thr Val Val Ile Gly Met Thr Arg Ile Pro Val Ile Glu 500 505 510
- Asn Pro Gln Tyr Phe Arg Gln Gly His Asn Cys His Lys Pro Asp Thr 515 520 525

Trp Val Phe Ser Asn Ile Asp Asn His Gly Ile Leu Asn Leu Lys Asp 530 535 540

Asn Arg Asp His Leu Val Pro Ser Thr His Tyr Ile Tyr Glu Glu Pro 545 550 560

Glu Val Gln Ser Gly Glu Val Ser Tyr Pro Arg Ser His Gly Phe Arg 565 570 575

Glu Ile Met Leu Asn Pro Ile Ser Leu Pro Gly His Ser Lys Pro Leu 580 585 590

Asn His Gly Ile Tyr Val Glu Asp Val Asn Val Tyr Phe Ser Lys Gly 595 600 605

Arg His Gly Phe 610

<210> 72

<211> 493

<212> PRT

<213> Homo sapiens

<400> 72

Met His Pro His Arg Asp Pro Arg Gly Leu Trp Leu Leu Pro Ser 1 5 10 15

Leu Ser Leu Leu Leu Phe Glu Val Ala Arg Ala Gly Arg Ala Val Val 20 25 30

Ser Cys Pro Ala Ala Cys Leu Cys Ala Ser Asn Ile Leu Ser Cys Ser 35 40 45

Lys Gln Gln Leu Pro Asn Val Pro His Ser Leu Pro Ser Tyr Thr Ala 50 55 60

Leu Leu Asp Leu Ser His Asn Asn Leu Ser Arg Leu Arg Ala Glu Trp 65 70 75 80

Thr Pro Thr Arg Leu Thr Gln Leu His Ser Leu Leu Leu Ser His Asn 85 90 95

His Leu Asn Phe Ile Ser Ser Glu Ala Phe Ser Pro Val Pro Asn Leu 100 105 110

Arg Tyr Leu Asp Leu Ser Ser Asn Gln Leu Arg Thr Leu Asp Glu Phe

115 120 125

Leu Phe Ser Asp Leu Gln Val Leu Glu Val Leu Leu Leu Tyr Asn Asn 130 135 140

His Ile Met Ala Val Asp Arg Cys Ala Phe Asp Asp Met Ala Gln Leu 145 150 155 160

Gln Lys Leu Tyr Leu Ser Gln Asn Gln Ile Ser Arg Phe Pro Leu Glu 165 170 175

Leu Val Lys Glu Gly Ala Lys Leu Pro Lys Leu Thr Leu Leu Asp Leu 180 185 190

Ser Ser Asn Lys Leu Lys Asn Leu Pro Leu Pro Asp Leu Gln Lys Leu 195 200 205

Pro Ala Trp Ile Lys Asn Gly Leu Tyr Leu His Asn Asn Pro Leu Asn 210 215 220

Cys Asp Cys Glu Leu Tyr Gln Leu Phe Ser His Trp Gln Tyr Arg Gln 225 230 235 240

Leu Ser Ser Val Met Asp Phe Gln Glu Asp Leu Tyr Cys Met Asn Ser 245 250 255

Lys Lys Leu His Asn Val Phe Asn Leu Ser Phe Leu Asn Cys Gly Glu 260 265 270

Tyr Lys Glu Arg Ala Trp Glu Ala His Leu Gly Asp Thr Leu Ile Ile 275 280 285

Lys Cys Asp Thr Lys Gln Gln Gly Met Thr Lys Val Trp Val Thr Pro 290 295 , 300

Ser Asn Glu Arg Val Leu Asp Glu Val Thr Asn Gly Thr Val Ser Val 305 310 315 320

Ser Lys Asp Gly Ser Leu Leu Phe Gln Gln Val Gln Val Glu Asp Gly 325 330 335

Gly Val Tyr Thr Cys Tyr Ala Met Gly Glu Thr Phe Asn Glu Thr Leu 340 345 350

Ser Val Glu Leu Lys Val His Asn Phe Thr Leu His Gly His His Asp 355 360 365

Thr Leu Asn Thr Ala Tyr Thr Thr Leu Val Gly Cys Ile Leu Ser Val 375

Val Leu Val Leu Ile Tyr Leu Tyr Leu Thr Pro Cys Arg Cys Trp Cys 390 395

Arg Gly Val Glu Lys Pro Ser Ser His Gln Gly Asp Ser Leu Ser Ser 410

Ser Met Leu Ser Thr Thr Pro Asn His Asp Pro Met Ala Gly Gly Asp 425 420

Lys Asp Asp Gly Phe Asp Arg Arg Val Ala Phe Leu Glu Pro Ala Gly 435

Pro Gly Gln Gly Gln Asn Gly Lys Leu Lys Pro Gly Asn Thr Leu Pro

Val Pro Glu Ala Thr Gly Lys Gly Gln Arg Arg Met Ser Asp Pro Glu

Ser Val Ser Ser Val Phe Ser Asp Thr Pro Ile Val Val 490 485

<210> 73

<211> 616 <212> PRT

<213> Homo sapiens

<400> 73

Met Asn His Asn Arg Leu Gly Ser Leu Pro Arg Asp Ala Leu Gly Ala

Leu Pro Asp Leu Arg Ser Leu Arg Ile Asn Asn Asn Arg Leu Arg Thr 25

Leu Ala Pro Gly Thr Phe Asp Ala Leu Ser Ala Leu Ser His Leu Gln 35 40

Leu Tyr His Asn Pro Phe His Cys Gly Cys Gly Leu Val Trp Leu Gln 60 50

Ala Trp Ala Ala Ser Thr Arg Val Ser Leu Pro Glu Pro Asp Ser Ile 75 65 70

Ala Cys Ala Ser Pro Pro Ala Leu Gln Gly Val Pro Val Tyr Arg Leu 85 90

Pro Ala Leu Pro Cys Ala Pro Pro Ser Val His Leu Ser Ala Glu Pro 100 105 110

- Pro Leu Glu Ala Pro Gly Thr Pro Leu Arg Ala Gly Leu Ala Phe Val 115 120 125
- Leu His Cys Ile Ala Asp Gly His Pro Thr Pro Arg Leu Gln Trp Gln 130 135 140
- Leu Gln Ile Pro Gly Gly Thr Val Val Leu Glu Pro Pro Val Leu Ser 145 150 155 160
- Gly Glu Asp Asp Gly Val Gly Ala Glu Glu Gly Glu Gly Glu Gly Asp 165 170 175
- Gly Asp Leu Leu Thr Gln Thr Gln Ala Gln Thr Pro Thr Pro Ala Pro 180 185 190
- Ala Trp Pro Ala Pro Pro Ala Thr Pro Arg Phe Leu Ala Leu Ala Asn 195 200 205
- Gly Ser Leu Leu Val Pro Leu Leu Ser Ala Lys Glu Ala Gly Val Tyr 210 215 220
- Thr Cys Arg Ala His Asn Glu Leu Gly Ala Asn Ser Thr Ser Ile Arg 225 230 235 240
- Val Ala Val Ala Ala Thr Gly Pro Pro Lys His Ala Pro Gly Ala Gly
  245 250 255
- Gly Glu Pro Asp Gly Gln Ala Pro Thr Ser Glu Arg Lys Ser Thr Ala 260 265 270
- Lys Gly Arg Gly Asn Ser Val Leu Pro Ser Lys Pro Glu Gly Lys Ile 275 280 285
- Lys Gly Gln Gly Leu Ala Lys Val Ser Ile Leu Gly Glu Thr Glu Thr 290 295 300
- Glu Pro Glu Glu Asp Thr Ser Glu Gly Glu Glu Ala Glu Asp Gln Ile 305 310 315 320
- Leu Ala Asp Pro Ala Glu Glu Gln Arg Cys Gly Asn Gly Asp Pro Ser 325 330 335

Arg Tyr Val Ser Asn His Ala Phe Asn Gln Ser Ala Glu Leu Lys Pro 340 345 350

- His Val Phe Glu Leu Gly Val Ile Ala Leu Asp Val Ala Glu Arg Glu 355 360 365
- Ala Arg Val Gln Leu Thr Pro Leu Ala Ala Arg Trp Gly Pro Gly Pro 370 375 . 380
- Gly Gly Ala Gly Gly Ala Pro Arg Pro Gly Arg Arg Pro Leu Arg Leu 385 390 395 400
- Leu Tyr Leu Cys Pro Ala Gly Gly Gly Ala Ala Val Gln Trp Ser Arg 405 410 415
- Val Glu Glu Gly Val Asn Ala Tyr Trp Phe Arg Gly Leu Arg Pro Gly 420 425 430
- Thr Asn Tyr Ser Val Cys Leu Ala Leu Ala Gly Glu Ala Cys His Val 435 440 445
- Gln Val Val Phe Ser Thr Lys Lys Glu Leu Pro Ser Leu Leu Val Ile 450 455 460
- Val Ala Val Ser Val Phe Leu Leu Val Leu Ala Thr Val Pro Leu Leu 465 470 475 480
- Gly Ala Ala Cys Cys His Leu Leu Ala Lys His Pro Gly Lys Pro Tyr 485 490 495
- Arg Leu Ile Leu Arg Pro Gln Ala Pro Asp Pro Met Glu Lys Arg Ile 500 505 510
- Ala Ala Asp Phe Asp Pro Arg Ala Ser Tyr Leu Glu Ser Glu Lys Ser 515 520 525
- Tyr Pro Ala Gly Gly Glu Ala Gly Gly Glu Glu Pro Glu Asp Val Gln 530 · 535 540
- Gly Glu Gly Leu Asp Glu Asp Ala Glu Gln Gly Asp Pro Ser Gly Asp 545 550 555 560
- Leu Gln Arg Glu Glu Ser Leu Ala Ala Cys Ser Leu Val Glu Ser Gln 565 570 575
- Ser Lys Ala Asn Gln Glu Glu Phe Glu Ala Gly Ser Glu Tyr Ser Asp 580 585 590

Arg Leu Pro Leu Gly Ala Glu Ala Val Asn Ile Ala Gln Glu Ile Asn 595 . 600 605

Gly Asn Tyr Arg Gln Thr Ala Gly 610 615

<210> 74

<211> 504

<212> PRT

<213> Homo sapiens

<400> 74

Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg Val 1 5 10 15

Gly Leu Gly Thr Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His 20 25 30

Asn Cys Pro Tyr Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr 35 40 45

Gly Leu Gly Leu Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala 50 55 60

Asp Leu Asp Leu Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp 65 70 75 80

Leu Ala Pro Leu Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu 85 90 95

Leu Asp Ala Leu Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg 100 105 110

Leu Leu Asp Leu Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp 115 120 125

Leu Asp Gly Leu Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg 130 135 140

Leu Val His Leu Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser 145 150 155 160

His Leu Tyr Leu Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His 165 170 175

Leu His Gly Leu Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser

180 185 190

Asn Arg Leu Gly His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala 195 200 205

Phe Leu Lys Asn Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp 210 215 220

Cys Arg Leu Tyr His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser 225 230 235 240

Ala Val Arg Asp Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val 245 250 255

Pro Ala Ser Arg Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn 260 265 270

Cys Ser Ser Ala Pro Ala Leu Gly Leu Glu Arg Pro Glu Glu His Leu 275 280 285

Tyr Ala Leu Val Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val 290 295 300

Pro Ala Met Arg Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg 305 310 315 320

Ala Pro Gly Ser Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser 325 330 335

Leu Ala Ile Gly Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys 340 345 350

Leu Ala Thr Gly Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn 355 360 365

Val Ser Val His Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr Gly 370 375 380

Phe Thr Thr Leu Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu 400

Tyr Leu Phe Ala Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Arg Cys 405 410 415

Arg Arg Trp Pro Gln Thr Pro Ser Pro Leu Gln Glu Leu Ser Ala Gln 420 425 430

Ser Ser Val Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Arg Lys Ala 435 440 445

Ser Val His Lys His Val Val Phe Leu Glu Pro Gly Arg Arg Gly Leu 450 455 460

Asn Gly Arg Val Gln Leu Ala Val Ala Glu Glu Phe Asp Leu Tyr Asn 465 470 475 480

Pro Gly Gly Leu Gln Leu Lys Ala Gly Ser Glu Ser Ala Ser Ser Ile 485 490 495

Gly Ser Glu Gly Pro Met Thr Thr 500

<210> 75

<211> 623

<212> PRT

<213> Homo sapiens

<400> 75

Met Arg Val Ala Leu Gly Met Leu Trp Leu Leu Ala Leu Ala Trp Pro 1 5 10 15

Pro Gln Ala Arg Gly Phe Cys Pro Ser Gln Cys Ser Cys Ser Leu His 20 25 30

Ile Met Gly Asp Gly Ser Lys Ala Arg Thr Val Val Cys Asn Asp Pro 35 40 45

Asp Met Thr Leu Pro Pro Ala Ser Ile Pro Pro Asp Thr Ser Arg Leu 50 55 60

Arg Leu Glu Arg Thr Ala Ile Arg Arg Val Pro Gly Glu Ala Phe Arg 65 70 75 80

Pro Leu Gly Arg Leu Glu Gln Leu Trp Leu Pro Tyr Asn Ala Leu Ser 85 90 95

Glu Leu Asn Ala Leu Met Leu Arg Gly Leu Arg Arg Leu Arg Glu Leu 100 105 110

Arg Leu Pro Gly Asn Arg Leu Ala Ala Phe Pro Trp Ala Ala Leu Arg 115 120 125

Asp Ala Pro Lys Leu Arg Leu Leu Asp Leu Gln Ala Asn Arg Leu Ser 130 135 140

Ala Val Pro Ala Glu Ala Ala Arg Phe Leu Glu Asn Leu Thr Phe Leu 145 150 155 160

- Asp Leu Ser Ser Asn Gln Leu Met Arg Leu Pro Gln Glu Leu Ile Val 165 170 175
- Ser Trp Ala His Leu Glu Thr Gly Ile Phe Pro Pro Gly His His Pro 180 185 190
- Arg Arg Val Leu Gly Leu Gln Asp Asn Pro Trp Ala Cys Asp Cys Arg 195 200 205
- Leu Tyr Asp Leu Val His Leu Leu Asp Gly Trp Ala Pro Asn Leu Ala 210 215 220
- Phe Ile Glu Thr Glu Leu Arg Cys Ala Ser Pro Arg Ser Leu Ala Gly 225 230 235 240
- Val Ala Phe Ser Gln Leu Glu Leu Arg Lys Cys Gln Gly Pro Glu Leu 245 250 255
- His Pro Gly Val Ala Ser Ile Arg Ser Leu Leu Gly Gly Thr Ala Leu 260 265 270
- Leu Arg Cys Gly Ala Thr Gly Val Pro Gly Pro Glu Met Ser Trp Arg 275 280 285
- Arg Ala Asn Gly Arg Pro Leu Asn Gly Thr Val His Gln Glu Val Ser 290 295 300
- Ser Asp Gly Thr Ser Trp Thr Leu Leu Gly Leu Pro Ala Val Ser His 305 310 315
- Leu Asp Ser Gly Asp Tyr Ile Cys Gln Ala Lys Asn Phe Leu Gly Ala 325 330 335
- Ser Glu Thr Val Ile Ser Leu Ile Val Thr Glu Pro Pro Thr Ser Thr 340 345 350
- Glu His Ser Gly Ser Pro Gly Ala Leu Trp Ala Arg Thr Gly Gly Gly 355 360 365
- Gly Glu Ala Ala Ala Tyr Asn Asn Lys Leu Val Ala Arg His Val Pro 370 375 380

Gln Ile Pro Lys Pro Ala Val Leu Ala Thr Gly Pro Ser Val Pro Ser 385 390 395 400

Thr Lys Glu Glu Leu Thr Leu Glu His Phe Gln Met Asp Ala Leu Gly
405 410 415

Glu Leu Ser Asp Gly Arg Ala Gly Pro Ser Glu Ala Arg Met Val Arg 420 425 430

Ser Val Lys Val Val Gly Asp Thr Tyr His Ser Val Ser Leu Val Trp 435 440 445

Lys Ala Pro Gln Ala Lys Asn Thr Thr Ala Phe Ser Val Leu Tyr Ala 450 455 460

Val Phe Gly Gln His Ser Met Arg Arg Val Ile Val Gln Pro Gly Lys 465 470 475 480

Thr Arg Val Thr Ile Thr Gly Leu Leu Pro Lys Thr Lys Tyr Val Ala 485 490 495

Cys Val Cys Val Gln Gly Leu Val Pro Arg Lys Glu Gln Cys Val Ile 500 505 510

Phe Ser Thr Asn Glu Val Val Asp Ala Glu Asn Thr Gln Gln Leu Ile 515 520 . 525

Asn Val Val Val Ile Ser Val Ala Ile Val Ile Ala Leu Pro Leu Thr 530 535 540

Leu Leu Val Cys Cys Ser Ala Leu Gln Lys Arg Cys Arg Lys Cys Phe 545 550 555 560

Asn Lys Asp Ser Thr Glu Ala Thr Val Thr Tyr Val Asn Leu Glu Arg 565 570 575

Leu Gly Tyr Ser Glu Asp Gly Leu Glu Glu Leu Ser Arg His Ser Val 580 585 590

Ser Glu Ala Asp Arg Leu Leu Ser Ala Arg Ser Ser Val Asp Phe Gln 595 600 605

Ala Phe Gly Val Lys Gly Gly Arg Arg Ile Asn Glu Tyr Phe Cys 610 615 620

<210> 76 <211> 789

<212> PRT

<213> Homo sapiens

<400> 76

Met Glu Thr Leu Leu Gly Gly Leu Leu Ala Phe Gly Met Ala Phe Ala 1 5 10 15

Val Val Asp Ala Cys Pro Lys Tyr Cys Val Cys Gln Asn Leu Ser Glu 20 25 30

Ser Leu Gly Thr Leu Cys Pro Ser Lys Gly Leu Leu Phe Val Pro Pro 35 40 45

Asp Ile Asp Arg Arg Thr Val Glu Leu Arg Leu Gly Gly Asn Phe Ile 50 55 60

Ile His Ile Ser Arg Gln Asp Phe Ala Asn Met Thr Gly Leu Val Asp 65 70 75 80

Leu Thr Leu Ser Arg Asn Thr Ile Ser His Ile Gln Pro Phe Ser Phe 85 90 95

Leu Asp Leu Glu Ser Leu Arg Ser Leu His Leu Asp Ser Asn Arg Leu 100 105 110

Pro Ser Leu Gly Glu Asp Thr Leu Arg Gly Leu Val Asn Leu Gln His 115 120 125

Leu Ile Val Asn Asn Asn Gln Leu Gly Gly Ile Ala Asp Glu Ala Phe 130 135 140

Glu Asp Phe Leu Leu Thr Leu Glu Asp Leu Asp Leu Ser Tyr Asn Asn 145 150 155 160

Leu His Gly Leu Pro Trp Asp Ser Val Arg Arg Met Val Asn Leu His 165 170 175

Gln Leu Ser Leu Asp His Asn Leu Leu Asp His Ile Ala Glu Gly Thr 180 185 190

Phe Ala Asp Leu Gln Lys Leu Ala Arg Leu Asp Leu Thr Ser Asn Arg 195 200 205

Leu Gln Lys Leu Pro Pro Asp Pro Ile Phe Ala Arg Ser Gln Ala Ser 210 215 220

Ala Leu Thr Ala Thr Pro Phe Ala Pro Pro Leu Ser Phe Ser Phe Gly

225 230 235 240

Gly Asn Pro Leu His Cys Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu 245 250 255

Glu Arg Asp Asp Leu Glu Thr Cys Gly Ser Pro Gly Gly Leu Lys 260 265 270

Gly Arg Tyr Phe Trp His Val Arg Glu Glu Glu Phe Val Cys Glu Pro 275 280 285

Pro Leu Ile Thr Gln His Thr His Lys Leu Leu Val Leu Glu Gly Gln 290 295 300

Ala Ala Thr Leu Lys Cys Lys Ala Ile Gly Asp Pro Ser Pro Leu Ile 305 310 315 320

His Trp Val Ala Pro Asp Asp Arg Leu Val Gly Asn Ser Ser Arg Thr 325 330 335

Ala Val Tyr Asp Asn Gly Thr Leu Asp Ile Phe Ile Thr Thr Ser Gln 340 345 350

Asp Ser Gly Ala Phe Thr Cys Ile Ala Ala Asn Ala Ala Gly Glu Ala 355 360 365

Thr Ala Met Val Glu Val Ser Ile Val Gln Leu Pro His Leu Ser Asn 370 375 380

Ser Thr Ser Arg Thr Ala Pro Pro Lys Ser Arg Leu Ser Asp Ile Thr 385 390 395 400

Gly Ser Ser Lys Thr Ser Arg Gly Gly Gly Gly Ser Gly Gly Glu 405 410 415

Pro Pro Lys Ser Pro Pro Glu Arg Ala Val Leu Val Ser Glu Val Thr 420 425 430

Thr Thr Ser Ala Leu Val Lys Trp Ser Val Ser Lys Ser Ala Pro Arg 435 440 445

Val Lys Met Tyr Gln Leu Gln Tyr Asn Cys Ser Asp Asp Glu Val Leu 450 455 460

Ile Tyr Arg Met Ile Pro Ala Ser Asn Lys Ala Phe Val Val Asn Asn 465 470 475 480

Leu Val Ser Gly Thr Gly Tyr Asp Leu Cys Val Leu Ala Met Trp Asp 485 490 495

- Asp Thr Ala Thr Thr Leu Thr Ala Thr Asn Ile Val Gly Cys Ala Gln 500 505 510
- Phe Phe Thr Lys Ala Asp Tyr Pro Gln Cys Gln Ser Met His Ser Gln 515 520 525
- Ile Leu Gly Gly Thr Met Ile Leu Val Ile Gly Gly Ile Ile Val Ala 530 540
- Thr Leu Leu Val Phe Ile Val Ile Leu Met Val Arg Tyr Lys Val Cys 545 550 555 560
- Asn His Glu Ala Pro Ser Lys Met Ala Ala Ala Val Ser Asn Val Tyr 565 570 575
- Ser Gln Thr Asn Gly Ala Gln Pro Pro Pro Pro Ser Ser Ala Pro Ala 580 585 590
- Gly Ala Pro Pro Gln Gly Pro Pro Lys Val Val Val Arg Asn Glu Leu
  595 600 605
- Leu Asp Phe Thr Ala Ser Leu Ala Arg Ala Ser Asp Ser Ser Ser Ser 610 615 620
- Ser Ser Leu Gly Ser Gly Glu Ala Ala Gly Leu Gly Arg Ala Pro Trp 625 630 635 640
- Arg Ile Pro Pro Ser Ala Pro Arg Pro Lys Pro Ser Leu Asp Arg Leu 645 650 655
- Met Gly Ala Phe Ala Ser Leu Asp Leu Lys Ser Gln Arg Lys Glu Glu 660 665 670
- Leu Leu Asp Ser Arg Thr Pro Ala Gly Arg Gly Ala Gly Thr Ser Ala 675 680 685
- Arg Gly His His Ser Asp Arg Glu Pro Leu Leu Gly Pro Pro Ala Ala 690 695 700
- Arg Ala Arg Ser Leu Leu Pro Leu Pro Leu Glu Gly Lys Ala Lys Arg 705 710 715 720
- Ser His Ser Phe Asp Met Gly Asp Phe Ala Ala Ala Ala Gly Gly

725 730 735

Val Val Pro Gly Gly Tyr Ser Pro Pro Arg Lys Val Ser Asn Ile Trp 740 745 750

Thr Lys Arg Ser Leu Ser Val Asn Gly Met Leu Leu Pro Phe Glu Glu
755 760 765

Ser Asp Leu Val Gly Ala Arg Gly Thr Phe Gly Ser Ser Glu Trp Val 770 775 780

Met Glu Ser Thr Val 785

<210> 77

<211> 628

<212> PRT

<213> Homo sapiens

<400> 77

Met Ala Ile Leu Pro Leu Leu Leu Cys Leu Leu Pro Leu Ala Pro Ala 1 5 10 15

Ser Ser Pro Pro Gln Ser Ala Thr Pro Ser Pro Cys Pro Arg Arg Cys 20 25 30

Arg Cys Gln Thr Gln Ser Leu Pro Leu Ser Val Leu Cys Pro Gly Ala 35 40 45

Gly Leu Leu Phe Val Pro Pro Ser Leu Asp Arg Arg Ala Ala Glu Leu 50 55 60

Arg Leu Ala Asp Asn Phe Ile Ala Ser Val Arg Arg Arg Asp Leu Ala 65 70 75 80

Asn Met Thr Gly Leu Leu His Leu Ser Leu Ser Arg Asn Thr Ile Arg 85 90 95

His Val Ala Ala Gly Ala Phe Ala Asp Leu Arg Ala Leu Arg Ala Leu 100 105 110

His Leu Asp Gly Asn Arg Leu Thr Ser Leu Gly Glu Gly Gln Leu Arg 115 120 125

Gly Leu Val Asn Leu Arg His Leu Ile Leu Ser Asn Asn Gln Leu Ala 130 135 140

Ala Leu Ala Ala Gly Ala Leu Asp Asp Cys Ala Glu Thr Leu Glu Asp 145 150 155 160

- Leu Asp Leu Ser Tyr Asn Asn Leu Glu Gln Leu Pro Trp Glu Ala Leu 165 170 175
- Gly Arg Leu Gly Asn Val Asn Thr Leu Gly Leu Asp His Asn Leu Leu 180 185 190
- Ala Ser Val Pro Ala Gly Ala Phe Ser Arg Leu His Lys Leu Ala Arg 195 200 . 205
- Leu Asp Met Thr Ser Asn Arg Leu Thr Thr Ile Pro Pro Asp Pro Leu 210 215 220
- Phe Ser Arg Leu Pro Leu Leu Ala Arg Pro Arg Gly Ser Pro Ala Ser 225 230 235 240
- Ala Leu Val Leu Ala Phe Gly Gly Asn Pro Leu His Cys Asn Cys Glu 245 250 255
- Leu Val Trp Leu Arg Arg Leu Ala Arg Glu Asp Asp Leu Glu Ala Cys 260 265 270
- Ala Ser Pro Pro Ala Leu Gly Gly Arg Tyr Phe Trp Ala Val Gly Glu 275 280 285
- Glu Glu Phe Val Cys Glu Pro Pro Val Val Thr His Arg Ser Pro Pro 290 295 300
- Leu Ala Val Pro Ala Gly Arg Pro Ala Ala Leu Arg Cys Arg Ala Val 305 310 315 320
- Gly Asp Pro Glu Pro Arg Val Arg Trp Val Ser Pro Gln Gly Arg Leu 325 330 335
- Leu Gly Asn Ser Ser Arg Ala Arg Ala Phe Pro Asn Gly Thr Leu Glu 340 345 350
- Leu Leu Val Thr Glu Pro Gly Asp Gly Gly Ile Phe Thr Cys Ile Ala 355 360 365
- Ala Asn Ala Ala Gly Glu Ala Thr Ala Ala Val Glu Leu Thr Val Gly 370 375 380
- Pro Pro Pro Pro Pro Gln Leu Ala Asn Ser Thr Ser Cys Asp Pro Pro 385 390 395 400

Arg Asp Gly Asp Pro Asp Ala Leu Thr Pro Pro Ser Ala Ala Ser Ala 405 410 415

Ser Ala Lys Val Ala Asp Thr Gly Pro Pro Thr Asp Arg Gly Val Gln 420 425 430

Val Thr Glu His Gly Ala Thr Ala Ala Leu Val Gln Trp Pro Asp Gln 435 440 445

Arg Pro Ile Pro Gly Ile Arg Met Tyr Gln Ile Gln Tyr Asn Ser Ser 450 455 460

Ala Asp Asp Ile Leu Val Tyr Arg Met Ile Pro Ala Glu Ser Arg Ser 465 470 475 480

Phe Leu Leu Thr Asp Leu Ala Ser Gly Arg Thr Tyr Asp Leu Cys Val

Leu Ala Val Tyr Glu Asp Ser Ala Thr Gly Leu Thr Ala Thr Arg Pro 500 505 510

Val Gly Cys Ala Arg Phe Ser Thr Glu Pro Ala Leu Arg Pro Cys Gly 515 520 525

Ala Pro His Ala Pro Phe Leu Gly Gly Thr Met Ile Ile Ala Leu Gly 530 535 540

Gly Val Ile Val Ala Ser Val Leu Val Phe Ile Phe Val Leu Leu Met 545 550 555 560

Arg Tyr Lys Val His Gly Gly Gln Pro Pro Gly Lys Ala Lys Ile Pro 565 570 575

Ala Pro Val Ser Ser Val Cys Ser Gln Thr Asn Gly Ala Leu Gly Pro 580 585 590

Thr Pro Thr Pro Ala Pro Pro Ala Pro Glu Pro Ala Ala Leu Arg Ala 595 600 605

His Thr Val Val Gln Leu Asp Cys Glu Pro Trp Gly Pro Gly His Glu 610 615 620

Pro Val Gly Pro 625

<210> 78 <211> 673 <212> PRT <213> Homo sapiens

<400> 78

Met Cys Ser Arg Val Pro Leu Leu Leu Pro Leu Leu Leu Leu Ala

Leu Gly Pro Gly Val Gln Gly Cys Pro Ser Gly Cys Gln Cys Ser Gln . 25

Pro Gln Thr Val Phe Cys Thr Ala Arg Gln Gly Thr Thr Val Pro Arg 40

Asp Val Pro Pro Asp Thr Val Gly Leu Tyr Val Phe Glu Asn Gly Ile

Thr Met Leu Asp Ala Gly Ser Phe Ala Gly Leu Pro Gly Leu Gln Leu 70

Leu Asp Leu Ser Gln Asn Gln Ile Ala Ser Leu Pro Ser Gly Val Phe 85

Gln Pro Leu Ala Asn Leu Ser Asn Leu Asp Leu Thr Ala Asn Arg Leu 105

His Glu Ile Thr Asn Glu Thr Phe Arg Gly Leu Arg Arg Leu Glu Arg 120

Leu Tyr Leu Gly Lys Asn Arg Ile Arg His Ile Gln Pro Gly Ala Phe 135

Asp Thr Leu Asp Arg Leu Leu Glu Leu Lys Leu Gln Asp Asn Glu Leu 155 145

Arg Ala Leu Pro Pro Leu Arg Leu Pro Arg Leu Leu Leu Asp Leu 170 165

Ser His Asn Ser Leu Leu Ala Leu Glu Pro Gly Ile Leu Asp Thr Ala 180 185

Asn Val Glu Ala Leu Arg Leu Ala Gly Leu Gly Leu Gln Gln Leu Asp 195 200

Glu Gly Leu Phe Ser Arg Leu Arg Asn Leu His Asp Leu Asp Val Ser 220 ' 210 215

Asp Asn Gln Leu Glu Arg Val Pro Pro Val Ile Arg Gly Leu Arg Gly 225 230 235 240

- Leu Thr Arg Leu Arg Leu Ala Gly Asn Thr Arg Ile Ala Gln Leu Arg 245 250 255
- Pro Glu Asp Leu Ala Gly Leu Ala Ala Leu Gln Glu Leu Asp Val Ser 260 265 270
- Asn Leu Ser Leu Gln Ala Leu Pro Gly Asp Leu Ser Gly Leu Phe Pro 275 280 285
- Arg Leu Arg Leu Leu Ala Ala Ala Arg Asn Pro Phe Asn Cys Val Cys 290 295 300
- Pro Leu Ser Trp Phe Gly Pro Trp Val Arg Glu Ser His Val Thr Leu 305 310 315 320
- Ala Ser Pro Glu Glu Thr Arg Cys His Phe Pro Pro Lys Asn Ala Gly 325 330 335
- Arg Leu Leu Glu Leu Asp Tyr Ala Asp Phe Gly Cys Pro Ala Thr 340 345 345
- Thr Thr Thr Ala Thr Val Pro Thr Thr Arg Pro Val Val Arg Glu Pro
  355 360 365
- Thr Ala Leu Ser Ser Ser Leu Ala Pro Thr Trp Leu Ser Pro Thr Glu 370 375 380
- Pro Ala Thr Glu Ala Pro Ser Pro Pro Ser Thr Ala Pro Pro Thr Val 385 390 395 400
- Gly Pro Val Pro Gln Pro Gln Asp Cys Pro Pro Ser Thr Cys Leu Asn 405 410 415
- Gly Gly Thr Cys His Leu Gly Thr Arg His His Leu Ala Cys Leu Cys 420 425 430
- Pro Glu Gly Phe Thr Gly Leu Tyr Cys Glu Ser Gln Met Gly Gln Gly 435 440 445
- Thr Arg Pro Ser Pro Thr Pro Val Thr Pro Arg Pro Pro Arg Ser Leu 450 455 460
- Thr Leu Gly Ile Glu Pro Val Ser Pro Thr Ser Leu Arg Val Gly Leu

465 470 475 480

Gln Arg Tyr Leu Gln Gly Ser Ser Val Gln Leu Arg Ser Leu Arg Leu 485 490 495

Thr Tyr Arg Asn Leu Ser Gly Pro Asp Lys Arg Leu Val Thr Leu Arg 500 505 510

Leu Pro Ala Ser Leu Ala Glu Tyr Thr Val Thr Gln Leu Arg Pro Asn 515 520 525

Ala Thr Tyr Ser Val Cys Val Met Pro Leu Gly Pro Gly Arg Val Pro 530 535 540

Glu Gly Glu Glu Ala Cys Gly Glu Ala His Thr Pro Pro Ala Val His 545 550 555 560

Ser Asn His Ala Pro Val Thr Gln Ala Arg Glu Gly Asn Leu Pro Leu 565 570 575

Leu Ile Ala Pro Ala Leu Ala Ala Val Leu Leu Ala Ala Leu Ala Ala 580 585 590

Val Gly Ala Ala Tyr Cys Val Arg Arg Gly Arg Ala Met Ala Ala Ala 595 600 605

Ala Gln Asp Lys Gly Gln Val Gly Pro Gly Ala Gly Pro Leu Glu Leu 610 615 620

Glu Gly Val Lys Val Pro Leu Glu Pro Gly Pro Lys Ala Thr Glu Gly 625 630 635 640

Gly Gly Glu Ala Leu Pro Ser Gly Ser Glu Cys Glu Val Pro Leu Met 645 650 655

Gly Phe Pro Gly Pro Gly Leu Gln Ser Pro Leu His Ala Lys Pro Tyr 660 665 670

Ile

<210> 79

<211> 696

<212> PRT

<213> Homo sapiens

<400> 79

Met Leu Leu Trp Ile Leu Leu Glu Thr Ser Leu Cys Phe Ala Ala 1 5 10 15

- Gly Asn Val Thr Gly Asp Val Cys Lys Glu Lys Ile Cys Ser Cys Asn 20 25 30
- Glu Ile Glu Gly Asp Leu His Val Asp Cys Glu Lys Lys Gly Phe Thr 35 40 45
- Ser Leu Gln Arg Phe Thr Ala Pro Thr Ser Gln Phe Tyr His Leu Phe 50 55 60
- Leu His Gly Asn Ser Leu Thr Arg Leu Phe Pro Asn Glu Phe Ala Asn 65 70 75 80
- Phe Tyr Asn Ala Val Ser Leu His Met Glu Asn Asn Gly Leu His Glu 85 90 95
- Ile Val Pro Gly Ala Phe Leu Gly Leu Gln Leu Val Lys Arg Leu His
  100 105 110
- Ile Asn Asn Lys Ile Lys Ser Phe Arg Lys Gln Thr Phe Leu Gly 115 120 125
- Leu Asp Asp Leu Glu Tyr Leu Gln Ala Asp Phe Asn Leu Leu Arg Asp 130 135 140
- Ile Asp Pro Gly Ala Phe Gln Asp Leu Asn Lys Leu Glu Val Leu Ile 145 150 155 160
- Leu Asn Asp Asn Leu Ile Ser Thr Leu Pro Ala Asn Val Phe Gln Tyr 165 170 175
- Val Pro Ile Thr His Leu Asp Leu Arg Gly Asn Arg Leu Lys Thr Leu 180 185 190
- Pro Tyr Glu Glu Val Leu Glu Gln Ile Pro Gly Ile Ala Glu Ile Leu 195 200 205
- Leu Glu Asp Asn Pro Trp Asp Cys Thr Cys Asp Leu Leu Ser Leu Lys 210 215 220
- Glu Trp Leu Glu Asn Ile Pro Lys Asn Ala Leu Ile Gly Arg Val Val 225 230 235 240
- Cys Glu Ala Pro Thr Arg Leu Gln Gly Lys Asp Leu Asn Glu Thr Thr 245 250 . 255

Glu Gln Asp Leu Cys Pro Leu Lys Asn Arg Val Asp Ser Ser Leu Pro 260 265 270

- Ala Pro Pro Ala Gln Glu Glu Thr Phe Ala Pro Gly Pro Leu Pro Thr 275 280 285
- Pro Phe Lys Thr Asn Gly Gln Glu Asp His Ala Thr Pro Gly Ser Ala 290 295 300
- Pro Asn Gly Gly Thr Lys Ile Pro Gly Asn Trp Gln Ile Lys Ile Arg 305 310 315 320
- Pro Thr Ala Ala Ile Ala Thr Gly Ser Ser Arg Asn Lys Pro Leu Ala 325 330 335
- Asn Ser Leu Pro Cys Pro Gly Gly Cys Ser Cys Asp His Ile Pro Gly 340 345 350
- Ser Gly Leu Lys Met Asn Cys Asn Asn Arg Asn Val Ser Ser Leu Ala 355 360 365
- Asp Leu Lys Pro Lys Leu Ser Asn Val Gln Glu Leu Phe Leu Arg Asp 370 375 380
- Asn Lys Ile His Ser Ile Arg Lys Ser His Phe Val Asp Tyr Lys Asn 385 390 395 400
- Leu Ile Leu Leu Asp Leu Gly Asn Asn Ile Ala Thr Val Glu Asn 405 410 415
- Asn Thr Phe Lys Asn Leu Leu Asp Leu Arg Trp Leu Tyr Met Asp Ser 420 425 430
- Asn Tyr Leu Asp Thr Leu Ser Arg Glu Lys Phe Ala Gly Leu Gln Asn 435 440 445
- Leu Glu Tyr Leu Asn Val Glu Tyr Asn Ala Ile Gln Leu Ile Leu Pro 450 455 460
- Gly Thr Phe Asn Ala Met Pro Lys Leu Arg Ile Leu Ile Leu Asn Asn 465 470 475 480
- Asn Leu Leu Arg Ser Leu Pro Val Asp Val Phe Ala Gly Val Ser Leu 485 490 495

Ser Lys Leu Ser Leu His Asn Asn Tyr Phe Met Tyr Leu Pro Val Ala 500 505 510

- Gly Val Leu Asp Gln Leu Thr Ser Ile Ile Gln Ile Asp Leu His Gly 515 520 525
- Asn Pro Trp Glu Cys Ser Cys Thr Ile Val Pro Phe Lys Gln Trp Ala 530 535 540
- Glu Arg Leu Gly Ser Glu Val Leu Met Ser Asp Leu Lys Cys Glu Thr 545 550 560
- Pro Val Asn Phe Phe Arg Lys Asp Phe Met Leu Leu Ser Asn Asp Glu 565 570 575
- Ile Cys Pro Gln Leu Tyr Ala Arg Ile Ser Pro Thr Leu Thr Ser His 580 585 590
- Ser Lys Asn Ser Thr Gly Leu Ala Glu Thr Gly Thr His Ser Asn Ser 595 600 605
- Tyr Leu Asp Thr Ser Arg Val Ser Ile Ser Val Leu Val Pro Gly Leu 610 615 620
- Leu Leu Val Phe Val Thr Ser Ala Phe Thr Val Val Gly Met Leu Val 625 630 635 640
- Phe Ile Leu Arg Asn Arg Lys Arg Ser Lys Arg Arg Asp Ala Asn Ser 645 650 655
- Ser Ala Ser Glu Ile Asn Ser Leu Gln Thr Val Cys Asp Ser Ser Tyr 660 665 670
- Trp His Asn Gly Pro Tyr Asn Ala Asp Gly Ala His Arg Val Tyr Asp 675 680 685
- Cys Gly Ser His Ser Leu Ser Asp 690 695
- <210> 80
- <211> 834
- <212> PRT
- <213> Homo sapiens
- <220>
- <221> misc\_feature
- <222> (734)..(767)
- <223> Xaa can be any naturally occurring amino acid

<400> 80

Met His Thr Cys Cys Pro Pro Val Thr Leu Glu Gln Asp Leu His Arg
1 5 10 15

Lys Met His Ser Trp Met Leu Gln Thr Leu Ala Phe Ala Val Thr Ser 20 25 30

Leu Val Leu Ser Cys Ala Glu Thr Ile Asp Tyr Tyr Gly Glu Ile Cys 35 40 45

Asp Asn Ala Cys Pro Cys Glu Glu Lys Asp Gly Ile Leu Thr Val Ser 50 55 60

Cys Glu Asn Arg Gly Ile Ile Ser Leu Ser Glu Ile Ser Pro Pro Arg 65 70 75 80

Phe Pro Ile Tyr His Leu Leu Leu Ser Gly Asn Leu Leu Asn Arg Leu 85 90 95

Tyr Pro Asn Glu Phe Val Asn Tyr Thr Gly Ala Ser Ile Leu His Leu 100 105 110

Gly Ser Asn Val Ile Gln Asp Ile Glu Thr Gly Ala Phe His Gly Leu 115 120 125

Arg Gly Leu Arg Arg Leu His Leu Asn Asn Asn Lys Leu Glu Leu Leu 130 135 140

Arg Asp Asp Thr Phe Leu Gly Leu Glu Asn Leu Glu Tyr Leu Gln Val 145 150 155 160

Asp Tyr Asn Tyr Ile Ser Val Ile Glu Pro Asn Ala Phe Gly Lys Leu 165 170 175

His Leu Leu Gln Val Leu Ile Leu Asn Asp Asn Leu Leu Ser Ser Leu 180 185 190

Pro Asn Asn Leu Phe Arg Phe Val Pro Leu Thr His Leu Asp Leu Arg 195 200 205

Gly Asn Arg Leu Lys Leu Leu Pro Tyr Val Gly Leu Leu Gln His Met 210 215 220

Asp Lys Val Val Glu Leu Gln Leu Glu Glu Asn Pro Trp Asn Cys Ser 225 230 235 240

Cys Glu Leu Ile Ser Leu Lys Asp Trp Leu Asp Ser Ile Ser Tyr Ser 245 250 255

- Ala Leu Val Gly Asp Val Val Cys Glu Thr Pro Phe Arg Leu His Gly 260 265 270
- Arg Asp Leu Asp Glu Val Ser Lys Gln Glu Leu Cys Pro Arg Arg Leu 275 280 285
- Ile Ser Asp Tyr Glu Met Arg Pro Gln Thr Pro Leu Ser Thr Thr Gly 290 295 300
- Tyr Leu His Thr Thr Pro Ala Ser Val Asn Ser Val Ala Thr Ser Ser 305 310 315 320
- Ser Ala Val Tyr Lys Pro Pro Leu Lys Pro Pro Lys Gly Thr Arg Gln 325 330 335
- Pro Asn Lys Pro Arg Val Arg Pro Thr Ser Arg Gln Pro Ser Lys Asp 340 345 350
- Leu Gly Tyr Ser Asn Tyr Gly Pro Ser Ile Ala Tyr Gln Thr Lys Ser 355 360 365
- Pro Val Pro Leu Glu Cys Pro Thr Ala Cys Ser Cys Asn Leu Gln Ile 370 375 380
- Ser Asp Leu Gly Leu Asn Val Asn Cys Gln Glu Arg Lys Ile Glu Ser 385 390 395 400
- Ile Ala Glu Leu Gln Pro Lys Pro Tyr Asn Pro Lys Lys Met Tyr Leu
  405 410 415
- Thr Glu Asn Tyr Ile Ala Val Val Arg Arg Thr Asp Phe Leu Glu Ala 420 425 430
- Thr Gly Leu Asp Leu Leu His Leu Gly Asn Asn Arg Ile Ser Met Ile 435 440 445
- Gln Asp Arg Ala Phe Gly Asp Leu Thr Asn Leu Arg Arg Leu Tyr Leu 450 455 460
- Asn Gly Asn Arg Ile Glu Arg Leu Ser Pro Glu Leu Phe Tyr Gly Leu 465 470 475 480
- Gln Ser Leu Gln Tyr Leu Phe Leu Gln Tyr Asn Leu Ile Arg Glu Ile

485 490 495

Gln Ser Gly Thr Phe Asp Pro Val Pro Asn Leu Gln Leu Phe Leu 500 505 510

Asn Asn Asn Leu Leu Gln Ala Met Pro Ser Gly Val Phe Ser Gly Leu 515 520 525

Thr Leu Leu Arg Leu Asn Leu Arg Ser Asn His Phe Thr Ser Leu Pro 530 535 540

Val Ser Gly Val Leu Asp Gln Leu Lys Ser Leu Ile Gln Ile Asp Leu 545 550 555 560

His Asp Asn Pro Trp Asp Cys Thr Cys Asp Ile Val Gly Met Lys Leu 565 570 575

Trp Val Glu Gln Leu Lys Val Gly Val Leu Val Asp Glu Val Ile Cys 580 585 590

Lys Ala Pro Lys Lys Phe Ala Glu Thr Asp Met Arg Ser Ile Lys Ser 595 600 605

Glu Leu Leu Cys Pro Asp Tyr Ser Asp Val Val Ser Thr Pro Thr 610 615 620

Pro Ser Ser Ile Gln Val Pro Ala Arg Thr Ser Ala Val Thr Pro Ala 625 630 635 640

Val Arg Leu Asn Ser Thr Gly Ala Pro Ala Ser Leu Gly Ala Gly Gly 645 650 655

Gly Ala Ser Ser Val Pro Leu Ser Val Leu Ile Leu Ser Leu Leu 660 665 670

Val Phe Ile Met Ser Val Phe Val Ala Ala Gly Leu Phe Val Leu Val 675 680 685

Met Lys Arg Arg Lys Lys Asn Gln Ser Asp His Thr Ser Thr Asn Asn 690 695 700

Ser Asp Val Ser Ser Phe Asn Met Gln Tyr Ser Val Tyr Gly Gly 705 710 715 720

Gly Gly Thr Gly Gly His Pro His Ala His Val His Tyr Xaa Xaa Xaa 725 730 735

Ala Ala Ala Pro Ala Ala Ala Ala Ala Ala Arg Gly Gly Glu
770 780

Ala Gly Lys Pro Pro Leu Ala Glu Pro Arg Leu Gln Arg Gln His His 785 790 795 800

Arg Ala Pro Gly Gly Pro Ala Val Ala Gly Ala Gly Arg Arg Pro Leu 805 810 815

Leu Gln Gly His Phe Arg Thr Arg Gln Thr Leu Leu His His Pro Arg 820 825 830

Arg Gln

<210> 81

<211> 853

<212> PRT

<213> Homo sapiens

<400> 81

Tyr Phe Ser Leu Phe Arg Ser Ile Gln Leu Phe Ala Asp Cys Lys Lys 1 5 10 15

Met Phe Leu Trp Leu Phe Leu Ile Leu Ser Ala Leu Ile Ser Ser Thr 20 25 30

Asn Ala Asp Ser Asp Ile Ser Val Glu Ile Cys Asn Val Cys Ser Cys 35 40 45

Val Ser Val Glu Asn Val Leu Tyr Val Asn Cys Glu Lys Val Ser Val 50 55 60

Tyr Arg Pro Asn Gln Leu Lys Pro Pro Trp Ser Asn Phe Tyr His Leu 65 70 75 80

Asn Phe Gln Asn Asn Phe Leu Asn Ile Leu Tyr Pro Asn Thr Phe Leu 85 90 95

Asn Phe Ser His Ala Val Ser Leu His Leu Gly Asn Asn Lys Leu Gln 100 105 110

Asn Ile Glu Gly Gly Ala Phe Leu Gly Leu Ser Ala Leu Lys Gln Leu 115 120 125

- His Leu Asn Asn Asn Glu Leu Lys Ile Leu Arg Ala Asp Thr Phe Leu 130 135 140
- Gly Ile Glu Asn Leu Glu Tyr Leu Gln Ala Asp Tyr Asn Leu Ile Lys 145 150 155 160
- Tyr Ile Glu Arg Gly Ala Phe Asn Lys Leu His Lys Leu Lys Val Leu 165 170 175
- Ile Leu Asn Asp Asn Leu Ile Ser Phe Leu Pro Asp Asn Ile Phe Arg 180 185 190
- Phe Ala Ser Leu Thr His Leu Asp Ile Arg Gly Asn Arg Ile Gln Lys 195 200 205
- Leu Pro Tyr Ile Gly Val Leu Glu His Ile Gly Arg Val Val Glu Leu 210 215 220
- Gln Leu Glu Asp Asn Pro Trp Asn Cys Ser Cys Asp Leu Leu Pro Leu 225 230 235 240
  - Lys Ala Trp Leu Glu Asn Met Pro Tyr Asn Ile Tyr Ile Gly Glu Ala 245 250 255
  - Ile Cys Glu Thr Pro Ser Asp Leu Tyr Gly Arg Leu Leu Lys Glu Thr 260 265 270
  - Asn Lys Gln Glu Leu Cys Pro Met Gly Thr Gly Ser Asp Phe Asp Val 275 280 285
  - Arg Ile Leu Pro Pro Ser Gln Leu Glu Asn Gly Tyr Thr Thr Pro Asn 290 295 300
  - Gly His Thr Thr Gln Thr Ser Leu His Arg Leu Val Thr Lys Pro Pro 305 310 315 320
  - Lys Thr Thr Asn Pro Ser Lys Ile Ser Gly Ile Val Ala Gly Lys Ala 325 330 335
  - Leu Ser Asn Arg Asn Leu Ser Gln Ile Val Ser Tyr Gln Thr Arg Val 340 345 350

Pro Pro Leu Thr Pro Cys Pro Ala Pro Cys Phe Cys Lys Thr His Pro 355 360 365

- Ser Asp Leu Gly Leu Ser Val Asn Cys Gln Glu Lys Asn Ile Gln Ser 370 375 380
- Met Ser Glu Leu Ile Pro Lys Pro Leu Asn Ala Lys Lys Leu His Val 385 390 395 400
- Asn Gly Asn Ser Ile Lys Asp Val Asp Val Ser Asp Phe Thr Asp Phe 405 410 415
- Glu Gly Leu Asp Leu Leu His Leu Gly Ser Asn Gln Ile Thr Val Ile 420 425 430
- Lys Gly Asp Val Phe His Asn Leu Thr Asn Leu Arg Arg Leu Tyr Leu 435 440 445
- Asn Gly Asn Gln Ile Glu Arg Leu Tyr Pro Glu Ile Phe Ser Gly Leu 450 455 460
- His Asn Leu Gln Tyr Leu Tyr Leu Glu Tyr Asn Leu Ile Lys Glu Ile 465 470 475 480
- Ser Ala Gly Thr Phe Asp Ser Met Pro Asn Leu Gln Leu Leu Tyr Leu 485 490 495
- Asn Asn Asn Leu Leu Lys Ser Leu Pro Val Tyr Ile Phe Ser Gly Ala 500 505 505
- Pro Leu Ala Arg Leu Asn Leu Arg Asn Asn Lys Phe Met Tyr Leu Pro 515 520 525
- Val Ser Gly Val Leu Asp Gln Leu Gln Ser Leu Thr Gln Ile Asp Leu 530 535 540
- Glu Gly Asn Pro Trp Asp Cys Thr Cys Asp Leu Val Ala Leu Lys Leu 545 550 555 560
- Trp Val Glu Lys Leu Ser Asp Gly Ile Val Val Lys Glu Leu Lys Cys 565 570 575
- Glu Thr Pro Val Gln Phe Ala Asn Ile Glu Leu Lys Ser Leu Lys Asn 580 585 590
- Glu Ile Leu Cys Pro Lys Leu Leu Asn Lys Pro Ser Ala Pro Phe Thr 595 600 605

Ser Pro Ala Pro Ala Ile Thr Phe Thr Thr Pro Leu Gly Pro Ile Arg 610 615 620

- Ser Pro Pro Gly Gly Pro Val Pro Leu Ser Ile Leu Ile Leu Ser Ile 625 630 635 640
- Leu Val Val Leu Ile Leu Thr Val Phe Val Ala Phe Cys Leu Val 645 650 655
- Phe Val Leu Arg Arg Asn Lys Lys Pro Thr Val Lys His Glu Gly Leu 660 665 670
- Gly Asn Pro Asp Cys Gly Ser Met Gln Leu Gln Leu Arg Lys His Asp 675 680 685
- His Lys Thr Asn Lys Lys Asp Gly Leu Ser Thr Glu Ala Phe Ile Pro 690 695 700
- Gln Thr Ile Glu Gln Met Ser Lys Ser His Thr Cys Gly Leu Lys Glu 705 710 715 720
- Ser Glu Thr Gly Phe Met Phe Ser Asp Pro Pro Gly Gln Lys Val Val 725 730 735
- Met Arg Asn Val Ala Asp Lys Glu Lys Asp Leu Leu His Val Asp Thr 740 745 750
- Arg Lys Arg Leu Ser Thr Ile Asp Glu Leu Asp Glu Leu Phe Pro Ser 755 760 765
- Arg Asp Ser Asn Val Phe Ile Gln Asn Phe Leu Glu Ser Lys Lys Glu 770 780
- Tyr Asn Ser Ile Gly Val Ser Gly Phe Glu Ile Arg Tyr Pro Glu Lys 785 790 795 800
- Gln Pro Asp Lys Lys Ser Lys Lys Ser Leu Ile Gly Gly Asn His Ser 805 810 815
- Lys Ile Val Val Glu Gln Arg Lys Ser Glu Tyr Phe Glu Leu Lys Ala 820 825 830
- Lys Leu Gln Ser Ser Pro Asp Tyr Leu Gln Val Leu Glu Glu Gln Thr 835 840 845

Ala Leu Asn Lys Ile 850

<210> 82 <211> 977 <212> PRT <213> Homo sapiens

<400> 82

Met Lys Pro Ser Ile Ala Glu Met Leu His Arg Gly Arg Met Leu Trp

Ile Ile Leu Leu Ser Thr Ile Ala Leu Gly Trp Thr Thr Pro Ile Pro 25

Leu Ile Glu Asp Ser Glu Glu Ile Asp Glu Pro Cys Phe Asp Pro Cys 40

Tyr Cys Glu Val Lys Glu Ser Leu Phe His Ile His Cys Asp Ser Lys

Gly Phe Thr Asn Ile Ser Gln Ile Thr Glu Phe Trp Ser Arg Pro Phe 70

Lys Leu Tyr Leu Gln Arg Asn Ser Met Arg Lys Leu Tyr Thr Asn Ser

Phe Leu His Leu Asn Asn Ala Val Ser Ile Asn Leu Gly Asn Asn Ala 105

Leu Gln Asp Ile Gln Thr Gly Ala Phe Asn Gly Leu Lys Ile Leu Lys 120

Arg Leu Tyr Leu His Glu Asn Lys Leu Asp Val Phe Arg Asn Asp Thr 140 135

Phe Leu Gly Leu Glu Ser Leu Glu Tyr Leu Gln Ala Asp Tyr Asn Val 155 150

Ile Lys Arg Ile Glu Ser Gly Ala Phe Arg Asn Leu Ser Lys Leu Arg 170 165

Val Leu Ile Leu Asn Asp Asn Leu Ile Pro Met Leu Pro Thr Asn Leu 180 185

Phe Lys Ala Val Ser Leu Thr His Leu Asp Leu Arg Gly Asn Arg Leu 205 195 200

Lys Val Leu Phe Tyr Arg Gly Met Leu Asp His Ile Gly Arg Ser Leu 210 215 220

- Met Glu Leu Gln Leu Glu Glu Asn Pro Trp Asn Cys Thr Cys Glu Ile 225 230 235 240
- Val Gln Leu Lys Ser Trp Leu Glu Arg Ile Pro Tyr Thr Ala Leu Val 245 250 255
- Gly Asp Ile Thr Cys Glu Thr Pro Phe His Phe His Gly Lys Asp Leu 260 265 270
- Arg Glu Ile Arg Lys Thr Glu Leu Cys Pro Leu Leu Ser Asp Ser Glu 275 280 285
- Val Glu Ala Ser Leu Gly Ile Pro His Ser Ser Ser Ser Lys Glu Asn 290 295 300
- Ala Trp Pro Thr Lys Pro Ser Ser Met Leu Ser Ser Val His Phe Thr 305 310 315 320
- Ala Ser Ser Val Glu Tyr Lys Ser Ser Asn Lys Gln Pro Lys Pro Thr 325 330 335
- Lys Gln Pro Arg Thr Pro Arg Pro Pro Ser Thr Ser Gln Ala Leu Tyr 340 345 350
- Pro Gly Pro Asn Gln Pro Pro Ile Ala Pro Tyr Gln Thr Arg Pro Pro 355 360 365
- Ile Pro Ile Ile Cys Pro Thr Gly Cys Thr Cys Asn Leu His Ile Asn 370 375 380
- Asp Leu Gly Leu Thr Val Asn Cys Lys Glu Arg Gly Phe Asn Asn Ile 385 390 395 400
- Ser Glu Leu Leu Pro Arg Pro Leu Asn Ala Lys Lys Leu Tyr Leu Ser 405 410 415
- Ser Asn Leu Ile Gln Lys Ile Tyr Arg Ser Asp Phe Trp Asn Phe Ser 420 425 430
- Ser Leu Asp Leu Leu His Leu Gly Asn Asn Arg Ile Ser Tyr Val Gln 435 440 445
- Asp Gly Ala Phe Ile Asn Leu Pro Asn Leu Lys Ser Leu Phe Leu Asn

450 455 460

Gly Asn Asp Ile Glu Lys Leu Thr Pro Gly Met Phe Arg Gly Leu Gln 465 470 475 480

Ser Leu His Tyr Leu Tyr Phe Glu Phe Asn Val Ile Arg Glu Ile Gln 485 490 495

Pro Ala Ala Phe Ser Leu Met Pro Asn Leu Lys Leu Leu Phe Leu Asn 500 505.

Asn Asn Leu Leu Arg Thr Leu Pro Thr Asp Ala Phe Ala Gly Thr Ser 515 520 525

Leu Ala Arg Leu Asn Leu Arg Lys Asn Tyr Phe Leu Tyr Leu Pro Val 530 535 540

Ala Gly Val Leu Glu His Leu Asn Ala Ile Val Gln Ile Asp Leu Asn 545 550 560

Glu Asn Pro Trp Asp Cys Thr Cys Asp Leu Val Pro Phe Lys Gln Trp 565 570 575

Ile Glu Thr Ile Ser Ser Val Ser Val Val Gly Asp Val Leu Cys Arg
580 585 590

Ser Pro Glu Asn Leu Thr His Arg Asp Val Arg Thr Ile Glu Leu Glu 595 600 605

Val Leu Cys Pro Glu Met Leu His Val Ala Pro Ala Gly Glu Ser Pro 610 615 620

Ala Gln Pro Gly Asp Ser His Leu Ile Gly Ala Pro Thr Ser Ala Ser 625 630 635 640

Pro Tyr Glu Phe Ser Pro Pro Gly Gly Pro Val Pro Leu Ser Val Leu 645 650 655

Ile Leu Ser Leu Leu Val Leu Phe Phe Ser Ala Val Phe Val Ala Ala 660 665 670

Gly Leu Phe Ala Tyr Val Leu Arg Arg Arg Lys Lys Leu Pro Phe 675 680 685

Arg Ser Lys Arg Gln Glu Gly Val Asp Leu Thr Gly Ile Gln Met Gln 690 695 700

Cys His Arg Leu Phe Glu Asp Gly Gly Gly Gly Gly Gly Gly Ser Gly 705 710 715 720

- Gly Gly Gly Arg Pro Thr Leu Ser Ser Pro Glu Lys Ala Pro Pro Val 725 730 735
- Gly His Val Tyr Glu Tyr Ile Pro His Pro Val Thr Gln Met Cys Asn 740 745 750
- Asn Pro Ile Tyr Lys Pro Arg Glu Glu Glu Glu Val Ala Val Ser Ser 755 760 765
- Ala Gln Glu Ala Gly Ser Ala Glu Arg Gly Gly Pro Gly Thr Gln Pro
  770 775 780
- Pro Gly Met Gly Glu Ala Leu Leu Gly Ser Glu Gln Phe Ala Glu Thr 785 790 795 800
- Pro Lys Glu Asn His Ser Asn Tyr Arg Thr Leu Leu Glu Lys Glu Lys 805 810 815
- Glu Trp Ala Leu Ala Val Ser Ser Ser Gln Leu Asn Thr Ile Val Thr 820 825 830
- Val Asn His His Pro His His Pro Ala Val Gly Gly Val Ser Gly 835 840 845
- Val Val Gly Gly Thr Gly Gly Asp Leu Ala Gly Phe Arg His His Glu 850 855 860
- Lys Asn Gly Gly Val Val Leu Phe Pro Pro Gly Gly Cys Gly Ser 865 870 875 880
- Gly Ser Met Leu Leu Asp Arg Glu Arg Pro Gln Pro Ala Pro Cys Thr 885 890 895
- Val Gly Phe Val Asp Cys Leu Tyr Gly Thr Val Pro Lys Leu Lys Glu 900 905 910
- Leu His Val His Pro Pro Gly Met Gln Tyr Pro Asp Leu Gln Gln Asp 915 920 925
- Ala Arg Leu Lys Glu Thr Leu Leu Phe Ser Ala Glu Lys Gly Phe Thr 930 935 940
- Asp His Gln Thr Gln Lys Ser Asp Tyr Leu Glu Leu Arg Ala Lys Leu

945 950 955 960

Gln Thr Lys Pro Asp Tyr Leu Glu Val Leu Glu Lys Thr Thr Tyr Arg 965 970 975

Phe

<210> 83

<211> 921

<212> PRT

<213> Homo sapiens

<400> 83

Met Ala Asp Asp Asp Val Leu Phe Glu Asp Val Tyr Glu Leu Cys Glu 1 5 10 15

Val Ile Gly Lys Gly Pro Phe Ser Val Val Arg Arg Cys Ile Asn Arg 20 25 30

Glu Thr Gly Gln Gln Phe Ala Val Lys Ile Val Asp Val Ala Lys Phe 35 40 45

Thr Ser Ser Pro Gly Leu Ser Thr Glu Asp Leu Lys Arg Glu Ala Ser 50 55 60

Ile Cys His Met Leu Lys His Pro His Ile Val Glu Leu Leu Glu Thr 65 75 80

Tyr Ser Ser Asp Gly Met Leu Tyr Met Val Phe Glu Phe Met Asp Gly 85 90 95

Ala Asp Leu Cys Phe Glu Ile Val Lys Arg Ala Asp Ala Gly Phe Val

Tyr Ser Glu Ala Val Ala Ser His Tyr Met Arg Gln Ile Leu Glu Ala 115 120 125

Leu Arg Tyr Cys His Asp Asn Asn Ile Ile His Arg Asp Val Lys Pro 130 135 140

His Cys Val Leu Leu Ala Ser Lys Glu Asn Ser Ala Pro Val Lys Leu 145 150 155 160

Gly Gly Phe Gly Val Ala Ile Gln Leu Gly Glu Ser Gly Leu Val Ala 165 170 175

Gly Gly Arg Val Gly Thr Pro His Phe Met Ala Pro Glu Val Val Lys 180 185 190

- Arg Glu Pro Tyr Gly Lys Pro Val Asp Val Trp Gly Cys Gly Val Ile 195 200 205
- Leu Phe Ile Leu Leu Ser Gly Cys Leu Pro Phe Tyr Gly Thr Lys Glu 210 215 220
- Arg Leu Phe Glu Gly Ile Ile Lys Gly Lys Tyr Lys Met Asn Pro Arg 225 230 235 240
- Gln Trp Ser His Ile Ser Glu Ser Ala Lys Asp Leu Val Arg Arg Met 245 250 255
- Leu Met Leu Asp Pro Ala Glu Arg Ile Thr Val Tyr Glu Ala Leu Asn 260 265 270
- His Pro Trp Leu Lys Glu Arg Asp Arg Tyr Ala Tyr Lys Ile His Leu 275 280 285
- Pro Glu Thr Val Glu Gln Leu Arg Lys Phe Asn Ala Arg Arg Lys Leu 290 295 300
- Lys Gly Ala Val Leu Ala Ala Val Ser Ser His Lys Phe Asn Ser Phe 305 310 315 320
- Tyr Gly Asp Pro Pro Glu Glu Leu Pro Asp Phe Ser Glu Asp Pro Thr 325 330 335
- Ser Ser Gly Leu Leu Ala Ala Glu Arg Ala Val Ser Gln Val Leu Asp 340 345 350
- Ser Leu Glu Glu Ile His Ala Leu Thr Asp Cys Ser Glu Lys Asp Leu 355 360 365
- Asp Phe Leu His Ser Val Phe Gln Asp Gln His Leu His Thr Leu Leu 370 375 380
- Asp Leu Tyr Asp Lys Ile Asn Thr Lys Ser Ser Pro Gln Ile Arg Asn 385 390 395 400
- Pro Pro Ser Asp Ala Val Gln Arg Ala Lys Glu Val Leu Glu Glu Ile 405 410 415
- Ser Cys Tyr Pro Glu Asn Asn Asp Ala Lys Glu Leu Lys Arg Ile Leu 420 425 430

Thr Gln Pro His Phe Met Ala Leu Leu Gln Thr His Asp Val Val Ala 435 440 445

- His Glu Val Tyr Ser Asp Glu Ala Leu Arg Val Thr Pro Pro Pro Thr 450 455 460
- Ser Pro Tyr Leu Asn Gly Asp Ser Pro Glu Ser Ala Asn Gly Gly Met 465 470 475 480
- Asp Met Glu Asn Val Thr Arg Val Arg Leu Val Gln Phe Gln Lys Asn 485 . 490 495
- Thr Asp Glu Pro Met Gly Ile Thr Leu Lys Met Asn Glu Leu Asn His 500 505 510
- Cys Ile Val Ala Arg Ile Met His Gly Gly Met Ile His Arg Gln Gly 515 520 525
- Thr Leu His Val Gly Asp Glu Ile Arg Glu Ile Asn Gly Ile Ser Val 530 535 540
- Ala Asn Gln Thr Val Glu Gln Leu Gln Lys Met Leu Arg Glu Met Arg 545 550 555 560
- Gly Ser Ile Thr Phe Lys Ile Val Pro Ser Tyr Arg Thr Gln Ser Ser 565 570 575
- Ser Cys Glu Arg Asp Ser Pro Ser Thr Ser Arg Gln Ser Pro Ala Asn 580 585 590
- Gly His Ser Ser Thr Asn Asn Ser Val Ser Asp Leu Pro Ser Thr Thr 595 600 605
- Gln Pro Lys Gly Arg Gln Ile Tyr Val Arg Ala Gln Phe Glu Tyr Asp 610 615 620
- Pro Ala Lys Asp Asp Leu Ile Pro Cys Lys Glu Ala Gly Ile Arg Phe 625 630 635 640
- Arg Val Gly Asp Ile Ile Gln Ile Ile Ser Lys Asp Asp His Asn Trp 645 650 655
- Trp Gln Gly Lys Leu Glu Asn Ser Lys Asn Gly Thr Ala Gly Leu Ile 660 665 670

Pro Ser Ser Glu Leu Gln Glu Trp Arg Val Ala Cys Ile Ala Met Glu 675 680 685

Lys Thr Lys Gln Glu Gln Gln Ala Ser Cys Thr Trp Phe Gly Lys Lys 690 695 700

Lys Lys Gln Tyr Lys Asp Lys Tyr Leu Ala Lys His Asn Ala Asp Leu 705 710 715 720

Val Thr Tyr Glu Glu Val Val Lys Leu Pro Ala Phe Lys Arg Lys Thr 725 730 735

Leu Val Leu Leu Gly Ala His Gly Val Gly Arg Arg His Ile Lys Asn 740 745 750

Thr Leu Ile Thr Lys His Pro Asp Arg Phe Ala Tyr Pro Ile Pro His 755 760 765

Thr Thr Arg Pro Pro Lys Arg Asp Glu Glu Asn Gly Lys Asn Tyr Tyr 770 775 780

Phe Val Ser His Asp Gln Met Met Gln Asp Ile Ser Asn Asn Glu Tyr 785 790 795 800

Leu Glu Tyr Gly Ser His Glu Asp Ala Met Tyr Gly Thr Lys Leu Glu 805 810 815

Thr Ile Arg Lys Ile His Glu Gln Gly Leu Ile Ala Ile Leu Asp Val 820 825 830

Glu Pro Gln Ala Leu Lys Val Leu Arg Thr Ala Glu Phe Ala Pro Phe 835 840 845

Val Val Phe Ile Ala Ala Pro Thr Ile Thr Pro Gly Leu Asn Glu Asp 850 855 860

Glu Ser Leu Gln Arg Leu Gln Lys Glu Ser Asp Ile Leu Gln Arg Thr 865 870 875 880

Tyr Ala His Tyr Phe Asp Leu Thr Ile Ile Asn Asn Glu Ile Asp Glu 885 890 895

Thr Ile Arg His Leu Glu Glu Ala Val Glu Leu Val Cys Thr Ala Pro 900 905 910

Gln Trp Val Pro Val Ser Trp Val Tyr 915 920

<210> 84 <211> 837 <212> PRT <213> Homo sapiens

<400> 84

Met Asn His Leu Glu Gly Ser Ala Glu Val Glu Val Thr Asp Glu Ala

Ala Gly Gly Glu Val Asn Glu Ser Val Glu Ala Asp Leu Glu His Pro 25

Glu Val Glu Glu Glu Gln Gln Pro Pro Gln Gln Gln His Tyr Val

Gly Arg His Gln Arg Gly Arg Ala Leu Glu Asp Leu Arg Ala Gln Leu

Gly Gln Glu Glu Glu Arg Gly Glu Cys Leu Ala Arg Ser Ala Ser . 70

Thr Glu Ser Gly Phe His Asn His Thr Asp Thr Ala Glu Gly Asp Val . 85 . 90

Ile Ala Ala Ala Arg Asp Gly Tyr Asp Ala Glu Arg Ala Gln Asp Pro 105

Glu Asp Glu Ser Ala Tyr Ala Val Gln Tyr Arg Pro Glu Ala Glu Glu 120

Tyr Thr Glu Gln Ala Glu Ala Glu His Ala Glu Ala Thr His Arg Arg 135

Ala Leu Pro Asn His Leu His Phe His Ser Leu Glu His Glu Glu Ala 150 155

Met Asn Ala Ala Tyr Ser Gly Tyr Val Tyr Thr His Arg Leu Phe His 165 170

Arg Gly Glu Asp Glu Pro Tyr Ser Glu Pro Tyr Ala Asp Tyr Gly Gly 180

Leu Gln Glu His Val Tyr Glu Glu Ile Gly Asp Ala Pro Glu Leu His 205 195 200

Ala Arg Asp Gly Leu Arg Leu Tyr Glu Gln Glu Arg Asp Glu Ala Ala

210 215 220

Ala Tyr Arg Gln Glu Ala Leu Gly Ala Arg Leu His His Tyr Asp Glu 225 230 235 240

- Arg Ser Asp Gly Glu Ser Asp Ser Pro Glu Lys Glu Ala Glu Phe Ala 245 250 255
- Pro Tyr Pro Arg Met Asp Ser Tyr Glu Glu Glu Glu Asp Ile Asp Glu 260 265 270
- Ile Val Ala Glu Val Lys Gln Ser Met Ser Ser Gln Ser Leu Asp Lys 275 280 285
- Ala Ala Glu Asp Met Pro Glu Ala Glu Gln Asp Leu Glu Arg Pro Pro 290 295 300
- Thr Pro Ala Gly Gly Arg Pro Asp Ser Pro Gly Leu Gln Ala Pro Ala 305 310 315 320
- Gly Gln Gln Arg Ala Val Gly Pro Ala Gly Gly Gly Glu Ala Gly Gln 325 330 335
- Arg Tyr Ser Lys Glu Lys Arg Asp Ala Ile Ser Leu Ala Ile Lys Asp 340 345 350
- Ile Lys Glu Ala Ile Glu Glu Val Lys Thr Arg Thr Ile Arg Ser Pro 355 360 365
- Tyr Thr Pro Asp Glu Pro Lys Glu Pro Ile Trp Val Met Arg Gln Asp 370 375 380
- Ile Ser Pro Thr Arg Asp Cys Asp Asp Gln Arg Pro Met Asp Gly Asp 385 390 395 400
- Ser Pro Ser Pro Gly Ser Ser Ser Pro Leu Gly Ala Glu Ser Ser Ser 405 410 415
- Thr Ser Leu His Pro Ser Asp Pro Val Glu Val Pro Ile Asn Lys Glu 420 425 430
- Ser Arg Lys Ser Leu Ala Ser Phe Pro Thr Tyr Val Glu Val Pro Gly 435 440 445
- Pro Cys Asp Pro Glu Asp Leu Ile Asp Gly Ile Ile Phe Ala Ala Asn 450 455 460

Tyr Leu Gly Ser Thr Gln Leu Leu Ser Asp Lys Thr Pro Ser Lys Asn 465 470 475 480

- Val Arg Met Met Gln Ala Gln Glu Ala Val Ser Arg Ile Lys Met Ala 485 490 495
- Gln Lys Leu Ala Lys Ser Arg Lys Lys Ala Pro Glu Gly Glu Ser Gln 500 505 510
- Pro Met Thr Glu Val Asp Leu Phe Ile Leu Thr Gln Arg Ile Lys Val 515 520 525
- Leu Asn Ala Asp Thr Gln Glu Thr Met Met Asp His Pro Leu Arg Thr 530 540
- Ile Ser Tyr Ile Ala Asp Ile Gly Asn Ile Val Val Leu Met Ala Arg 545 550 555 560
- Arg Arg Ile Pro Arg Ser Asn Ser Gln Glu Asn Val Glu Ala Ser His 565 570 575
- Pro Ser Gln Asp Gly Lys Arg Gln Tyr Lys Met Ile Cys His Val Phe 580 585 . 590
- Glu Ser Glu Asp Ala Gln Leu Ile Ala Gln Ser Ile Gly Gln Ala Phe 595 600 605
- Ser Val Ala Tyr Gln Glu Phe Leu Arg Ala Asn Gly Ile Asn Pro Glu 610 615 620
- Asp Leu Ser Gln Lys Glu Tyr Ser Asp Leu Leu Asn Thr Gln Asp Met 625 630 635 640
- Tyr Asn Asp Asp Leu Ile His Phe Ser Lys Ser Glu Asn Cys Lys Asp 645 650 655
- Val Phe Ile Glu Lys Gln Lys Gly Glu Ile Leu Gly Val Val Ile Val 660 665 670
- Glu Ser Gly Trp Gly Ser Ile Leu Pro Thr Val Ile Ile Ala Asn Met 675 680 685
- Met His Gly Gly Pro Ala Glu Lys Ser Gly Lys Leu Asn Ile Gly Asp 690 695 700
- Gln Ile Met Ser Ile Asn Gly Thr Ser Leu Val Gly Leu Pro Leu Ser

705 · 710 715 720

Thr Cys Gln Ser Ile Ile Lys Gly Leu Glu Asn Gln Ser Arg Val Lys 725 730 735

Leu Asn Ile Val Arg Cys Pro Pro Val Thr Thr Val Leu Ile Arg Arg 740 745 750

Pro Asp Leu Arg Tyr Gln Leu Gly Phe Ser Val Gln Asn Gly Ile Ile 755 760 765

Cys Ser Leu Met Arg Gly Gly Ile Ala Glu Arg Gly Gly Val Arg Val 770 780

Gly His Arg Ile Ile Glu Ile Asn Gly Gln Ser Val Val Ala Thr Pro 785 790 795 800

His Glu Lys Ile Val His Ile Leu Ser Asn Ala Val Gly Glu Ile His 805 810 815

Met Lys Thr Met Pro Ala Ala Met Tyr Arg Leu Leu Thr Ala Gln Glu 820 825 830

Gln Pro Val Tyr Ile 835

<210> 85

<211> 197

<212> PRT

<213> Homo sapiens

<400> 85

Met Ala Ala Leu Gly Glu Pro Val Arg Leu Glu Arg Asp Ile Cys Arg 1 5 10 15

Ala Ile Glu Leu Leu Glu Lys Leu Gln Arg Ser Gly Glu Val Pro Pro 20 25 30

Gln Lys Leu Gln Ala Leu Gln Arg Val Leu Gln Ser Glu Phe Cys Asn 35 40 45

Ala Val Arg Glu Val Tyr Glu His Val Tyr Glu Thr Val Asp Ile Ser 50 55 60

Ser Ser Pro Glu Val Arg Ala Asn Ala Thr Ala Lys Ala Thr Val Ala 65 70 75 80

Ala Phe Ala Ala Ser Glu Gly His Ser His Pro Arg Val Val Glu Leu 85 90 95

Pro Lys Thr Glu Glu Gly Leu Gly Phe Asn Ile Met Gly Gly Lys Glu 100 105 110

Gln Asn Ser Pro Ile Tyr Ile Ser Arg Ile Ile Pro Gly Gly Ile Ala 115 120 125

Asp Arg His Gly Gly Leu Lys Arg Gly Asp Gln Leu Leu Ser Val Asn 130 135 140

Gly Val Ser Val Glu Gly Glu His His Glu Lys Ala Val Glu Leu Leu 145 150 155 160

Lys Ala Ala Gln Gly Lys Val Lys Leu Val Val Arg Tyr Thr Pro Lys 165 170 175

Val Leu Glu Glu Met Glu Ser Arg Phe Glu Lys Met Arg Ser Ala Lys 180 185 190

Arg Arg Gln Gln Thr 195

<210> 86

<211> 744

<212> PRT

<213> Homo sapiens

<400> 86

Met Ala Lys Arg Glu Asp Ser Pro Gly Pro Glu Val Gln Pro Met Asp 1 5 10 15

Lys Gln Phe Leu Val Cys Ser Ile Cys Leu Asp Arg Tyr Gln Cys Pro 20 25 30

Lys Val Leu Pro Cys Leu His Thr Phe Cys Glu Arg Cys Leu Gln Asn 35 40 45

Tyr Ile Pro Ala Gln Ser Leu Thr Leu Ser Cys Pro Val Cys Arg Gln 50 55 60

Thr Ser Ile Leu Pro Glu Gln Gly Val Ser Ala Leu Gln Asn Asn Phe 65 70 75 80

Phe Ile Ser Ser Leu Met Glu Ala Met Gln Gln Ala Pro Asp Gly Ala 85 90 95

His Asp Pro Glu Asp Pro His Pro Leu Ser Val Val Ala Gly Arg Pro 100 105 110

- Phe Ser Cys Pro Asn His Glu Gly Lys Thr Met Glu Phe Tyr Cys Glu 115 120 125
- Ala Cys Glu Thr Ala Met Cys Gly Glu Cys Arg Ala Gly Glu His Arg 130 135 140
- Glu His Gly Thr Val Leu Leu Arg Asp Val Val Glu Gln His Lys Ala 145 150 155 160
- Ala Leu Gln Arg Gln Leu Glu Ala Val Arg Gly Arg Leu Pro Gln Leu 165 170 175
- Ser Ala Ala Ile Ala Leu Val Gly Gly Ile Ser Gln Gln Leu Gln Glu 180 185 190
- Arg Lys Ala Glu Ala Leu Ala Gln Ile Ser Ala Ala Phe Glu Asp Leu 195 200 205
- Glu Gln Ala Leu Gln Gln Arg Lys Gln Ala Leu Val Ser Asp Leu Glu 210 215 220
- Thr Ile Cys Gly Ala Lys Gln Lys Val Leu Gln Thr Gln Leu Asp Thr 225 230 235 240
- Leu Arg Gln Gly Gln Glu His Ile Gly Ser Ser Cys Ser Phe Ala Glu 245 250 255
- Gln Ala Leu Arg Leu Gly Ser Ala Pro Glu Val Leu Leu Val Arg Lys 260 265 270
- His Met Arg Glu Arg Leu Ala Ala Leu Ala Ala Gln Ala Phe Pro Glu 275 280 285
- Arg Pro His Glu Asn Ala Gln Leu Glu Leu Val Leu Glu Val Asp Gly 290 295 300
- Leu Arg Arg Ser Val Leu Asn Leu Gly Ala Leu Leu Thr Thr Ser Ala 305 310 315 320
- Thr Ala His Glu Thr Val Ala Thr Gly Glu Gly Leu Arg Gln Ala Leu 325 330 335
- Val Gly Gln Pro Ala Ser Leu Thr Val Thr Ala Lys Asp Lys Asp Gly

340 345 350

Arg Leu Val Arg Thr Gly Ser Ala Glu Leu Arg Ala Glu Ile Thr Gly 355 360 365

Pro Asp Gly Thr Arg Leu Pro Val Pro Val Val Asp His Lys Asn Gly . 370 380

Thr Tyr Glu Leu Val Tyr Thr Ala Arg Thr Glu Gly Glu Leu Leu Leu 385 390 395 400

Ser Val Leu Leu Tyr Gly Gln Pro Val Arg Gly Ser Pro Phe Arg Val 405 410 415

Arg Ala Leu Arg Pro Gly Asp Leu Pro Pro Ser Pro Asp Asp Val Lys
420 425 430

Arg Arg Val Lys Ser Pro Gly Gly Pro Gly Ser His Val Arg Gln Lys
435 440 445

Ala Val Arg Arg Pro Ser Ser Met Tyr Ser Thr Gly Gly Lys Arg Lys 450 455 460

Asp Asn Pro Ile Glu Asp Glu Leu Val Phe Arg Val Gly Ser Arg Gly 465 470 475 480

Arg Glu Lys Gly Glu Phe Thr Asn Leu Gln Gly Val Ser Ala Ala Ser 485 490 495

Ser Gly Arg Ile Val Val Ala Asp Ser Asn Asn Gln Cys Ile Gln Val 500 505 510

Phe Ser Asn Glu Gly Gln Phe Lys Phe Arg Phe Gly Val Arg Gly Arg 515 520 525

Ser Pro Gly Gln Leu Gln Arg Pro Thr Gly Val Ala Val Asp Thr Asn 530 535 540

Gly Asp Ile Ile Val Ala Asp Tyr Asp Asn Arg Trp Val Ser Ile Phe . 545 550 560

Ser Pro Glu Gly Lys Phe Lys Thr Lys Ile Gly Ala Gly Arg Leu Met 565 570 575

Gly Pro Lys Gly Val Ala Val Asp Arg Asn Gly His Ile Ile Val Val 580 585 590

Asp Asn Lys Ser Cys Cys Val Phe Thr Phe Gln Pro Asn Gly Lys Leu 595 600 605

Val Gly Arg Phe Gly Gly Arg Gly Ala Thr Asp Arg His Phe Ala Gly 610 615 620

Pro His Phe Val Ala Val Ser Asn Lys Asn Glu Val Val Thr Asp 625 630 635 640

Phe His Asn His Ser Glu Lys Val Tyr Ser Ala Asp Gly Glu Phe Leu 645 650 655

Phe Lys Phe Gly Ser His Gly Glu Gly Asn Gly Gln Phe Asn Ala Pro 660 665 670

Thr Gly Val Ala Val Asp Ser Asn Gly Asn Ile Ile Val Ala Asp Trp
675 680 685

Gly Asn Ser Arg Ile Gln Val Phe Asp Ser Ser Gly Ser Phe Leu Ser 690 695 700

Tyr Ile Asn Thr Ser Ala Glu Pro Leu Tyr Gly Pro Gln Gly Leu Ala 705 710 715 720

Leu Thr Ser Asp Gly His Val Val Val Ala Asp Ala Gly Asn His Cys 725 730 735

Phe Lys Ala Tyr Arg Tyr Leu Gln 740

<210> 87

<211> 618

<212> PRT

<213> Homo sapiens

<400> 87

Met Thr Gln Glu Tyr Asp Asn Lys Arg Pro Val Leu Ala Leu Gln Asn 1 5 10 15

Glu Ala Leu Tyr Pro Gln Arg Arg Ser Tyr Thr Ser Glu Asp Glu Ala 20 25 30

Trp Lys Ser Phe Leu Glu Asn Pro Leu Thr Ala Ala Thr Lys Ala Met 35 40 45

Met Ser Ile Asn Gly Asp Glu Asp Ser Ala Ala Ala Leu Gly Leu Leu 50 55 60

Tyr Asp Tyr Tyr Lys Val Pro Arg Glu Arg Arg Ser Ser Thr Ala Lys 65 70 75 80

- Pro Glu Val Glu His Pro Glu Pro Asp His Ser Lys Arg Asn Ser Ile 85 90 95
- Pro Ile Val Thr Glu Gln Pro Leu Ile Ser Ala Gly Glu Asn Arg Val 100 105 110
- Gln Val Leu Lys Asn Val Pro Phe Asn Ile Val Leu Pro His Gly Asn 115 120 125
- Gln Leu Gly Ile Asp Lys Arg Gly His Leu Thr Ala Pro Asp Thr Thr 130 135 140
- Val Thr Val Ser Ile Ala Thr Met Pro Thr His Ser Ile Lys Thr Glu 145 150 155 160
- Thr Gln Pro His Gly Phe Ala Val Gly Ile Pro Pro Ala Val Tyr His 165 170 175
- Pro Glu Pro Thr Glu Arg Val Val Phe Asp Arg Asn Leu Asn Thr 180 185 190
- Asp Gln Phe Ser Ser Gly Ala Gln Ala Pro Asn Ala Gln Arg Arg Thr 195 200 205
- Pro Asp Ser Thr Phe Ser Glu Thr Phe Lys Glu Gly Val Gln Glu Val 210 215 220
- Phe Phe Pro Ser Asp Leu Ser Leu Arg Met Pro Gly Met Asn Ser Glu 225 230 235 240
- Asp Tyr Val Phe Asp Ser Val Ser Gly Asn Asn Phe Glu Tyr Thr Leu 245 250 250
- Glu Ala Ser Lys Ser Leu Arg Gln Lys Pro Gly Asp Ser Thr Met Thr 260 265 270
- Tyr Leu Asn Lys Gly Gln Phe Tyr Pro Ile Thr Leu Lys Glu Val Ser 275 280 285
- Ser Ser Glu Gly Ile His His Pro Ile Ser Lys Val Arg Ser Val Ile 290 295 300

Met Val Val Phe Ala Glu Asp Lys Ser Arg Glu Asp Gln Leu Arg His 305 310 315 320

- Trp Lys Tyr Trp His Ser Arg Gln His Thr Ala Lys Gln Arg Cys Ile 325 330 335
- Asp Ile Ala Asp Tyr Lys Glu Ser Phe Asn Thr Ile Ser Asn Ile Glu 340 345 350
- Glu Ile Ala Tyr Asn Ala Ile Ser Phe Thr Trp Asp Ile Asn Asp Glu 355 360 365
- Ala Lys Val Phe Ile Ser Val Asn Cys Leu Ser Thr Asp Phe Ser Ser 370 380
- Gln Lys Gly Val Lys Gly Leu Pro Leu Asn Ile Gln Val Asp Thr Tyr 385 390 395 400
- Ser Tyr Asn Asn Arg Ser Asn Lys Pro Val His Arg Ala Tyr Cys Gln 405 410 415
- Ile Lys Val Phe Cys Asp Lys Gly Ala Glu Arg Lys Ile Arg Asp Glu 420 425 430
- Glu Arg Lys Gln Ser Lys Arg Lys Val Ser Asp Val Lys Val Pro Leu 435 440 445
- Leu Pro Ser His Lys Arg Met Asp Ile Thr Val Phe Lys Pro Phe Ile 450 455 460
- Asp Leu Asp Thr Gln Pro Val Leu Phe Ile Pro Asp Val His Phe Ala 465 470 475 480
- Asn Leu Gln Arg Gly Thr His Val Leu Pro Ile Ala Ser Glu Glu Leu 485 490 495
- Glu Gly Glu Gly Ser Val Leu Lys Arg Gly Pro Tyr Gly Thr Glu Asp 500 505 510
- Asp Phe Ala Val Pro Pro Ser Thr Lys Leu Ala Arg Ile Glu Glu Pro 515 520 525
- Lys Arg Val Leu Leu Tyr Val Arg Lys Glu Ser Glu Glu Val Phe Asp 530 535 540
- Ala Leu Met Leu Lys Thr Pro Ser Leu Lys Gly Leu Met Glu Ala Ile 545 550 555 560

Ser Asp Lys Tyr Asp Val Pro His Asp Lys Ile Gly Lys Ile Phe Lys 565 570 575

Lys Cys Lys Lys Gly Ile Leu Val Asn Met Asp Asp Asn Ile Val Lys 580 585 590

His Tyr Ser Asn Glu Asp Thr Phe Gln Leu Gln Ile Glu Glu Ala Gly 595 600 605

Gly Ser Tyr Lys Leu Thr Leu Thr Glu Ile 610 615

<210> 88

<211> 531

<212> PRT

<213> Homo sapiens

<400> 88

Met Asp Gly Ile Val Thr Glu Val Ala Val Gly Val Lys Arg Gly Ser 1 5 10 15

Asp Glu Leu Leu Ser Gly Ser Val Leu Ser Ser Pro Asn Ser Asn Met 20 25 30

Ser Ser Met Val Val Thr Ala Asn Gly Asn Asp Ser Lys Lys Phe Lys 35 40 45

Gly Glu Asp Lys Met Asp Gly Ala Pro Ser Arg Val Leu His Ile Arg 50 55 60

Lys Leu Pro Gly Glu Val Thr Glu Thr Glu Val Ile Ala Leu Gly Leu 65 70 75 80

Pro Phe Gly Lys Val Thr Asn Ile Leu Met Leu Lys Gly Lys Asn Gln 85 90 95

Ala Phe Leu Glu Leu Ala Thr Glu Glu Ala Ala Ile Thr Met Val Asn 100 105 110

Tyr Tyr Ser Ala Val Thr Pro His Leu Arg Asn Gln Pro Ile Tyr Ile 115 120 125

Gln Tyr Ser Asn His Lys Glu Leu Lys Thr Asp Asn Thr Leu Asn Gln 130 135 140

Arg Ala Gln Ala Val Leu Gln Ala Val Thr Ala Val Gln Thr Ala Asn

Thr Pro Leu Ser Gly Thr Thr Val Ser Glu Ser Ala Val Thr Pro Ala Gln Ser Pro Val Leu Arg Ile Ile Ile Asp Asn Met Tyr Tyr Pro Val Thr Leu Asp Val Leu His Gln Ile Phe Ser Lys Phe Gly Ala Val Leu Lys Ile Ile Thr Phe Thr Lys Asn Asn Gln Phe Gln Ala Leu Leu Gln Tyr Gly Asp Pro Val Asn Ala Gln Gln Ala Lys Leu Ala Leu Asp Gly Gln Asn Ile Tyr Asn Ala Cys Cys Thr Leu Arg Ile Asp Phe Ser Lys Leu Val Asn Leu Asn Val Lys Tyr Asn Asn Asp Lys Ser Arg Asp Tyr Thr Arg Pro Asp Leu Pro Ser Gly Asp Gly Gln Pro Ala Leu Asp Pro Ala Ile Ala Ala Ala Phe Ala Lys Glu Thr Ser Leu Leu Ala Val Pro Gly Ala Leu Ser Pro Leu Ala Ile Pro Asn Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Gly Arg Val Gly Met Pro Gly Val Ser Ala Gly Gly Asn Thr Val Leu Leu Val Ser Asn Leu Asn Glu Glu Met Val Thr Pro Gln Ser Leu Phe Thr Leu Phe Gly Val Tyr Gly Asp Val Gln Arg Val Lys Ile Leu Tyr Asn Lys Lys Asp Ser Ala Leu Ile Gln Met Ala Asp

Gly Asn Gln Ser Gln Leu Ala Met Asn His Leu Asn Gly Gln Lys Met 385 390 395 400

Tyr Gly Lys Ile Ile Arg Val Thr Leu Ser Lys His Gln Thr Val Gln 405 410 415

Leu Pro Arg Glu Gly Leu Asp Asp Gln Gly Leu Thr Lys Asp Phe Gly 420 425 430

Asn Ser Pro Leu His Arg Phe Lys Lys Pro Gly Ser Lys Asn Phe Gln 435 440 445

Asn Ile Phe Pro Pro Ser Ala Thr Leu His Leu Ser Asn Ile Pro Pro 450 455 460

Ser Val Ala Glu Glu Asp Leu Arg Thr Leu Phe Ala Asn Thr Gly Gly 465 470 475 480

Thr Val Lys Ala Phe Lys Phe Phe Gln Asp His Lys Met Ala Leu Leu 485 490 495

Gln Met Ala Thr Val Glu Glu Ala Ile Gln Ala Leu Ile Asp Leu His 500 505 510

Asn Tyr Asn Leu Gly Glu Asn His His Leu Arg Val Ser Phe Ser Lys 515 520 525

Ser Thr Ile 530

<210> 89

<211> 521

<212> PRT

<213> Homo sapiens

<400> 89

Met Asn Ser Ser Thr Pro Ser Thr Ala Asn Gly Asn Asp Ser Lys Lys 1 5 10 15

Phe Lys Arg Asp Arg Pro Pro Cys Ser Pro Ser Arg Val Leu His Leu 20 25 30

Arg Lys Ile Pro Cys Asp Val Thr Glu Ala Glu Ile Ile Ser Leu Gly 35 40

Leu Pro Phe Gly Lys Val Thr Asn Leu Leu Met Leu Lys Gly Lys Ser 50 55 60

Gln Ala Phe Leu Glu Met Ala Ser Glu Glu Ala Ala Val Thr Met Val 65 70 75 80

Asn Tyr Tyr Thr Pro Ile Thr Pro His Leu Arg Ser Gln Pro Val Tyr 85 90 95

- Ile Gln Tyr Ser Asn His Arg Glu Leu Lys Thr Asp Asn Leu Pro Asn 100 105 110
- Gln Ala Arg Ala Gln Ala Ala Leu Gln Ala Val Ser Ala Val Gln Ser 115 120 125
- Gly Ser Leu Ala Leu Ser Gly Gly Pro Ser Asn Glu Gly Thr Val Leu 130 135 140
- Pro Gly Gln Ser Pro Val Leu Arg Ile Ile Ile Glu Asn Leu Phe Tyr 145 150 155 160
- Pro Val Thr Leu Glu Val Leu His Gln Ile Phe Ser Lys Phe Gly Thr 165 170 175
- Val Leu Lys Ile Ile Thr Phe Thr Lys Asn Asn Gln Phe Gln Ala Leu 180 185 190
- Leu Gln Tyr Ala Asp Pro Val Asn Ala His Tyr Ala Lys Met Ala Leu 195 200 205
- Asp Gly Gln Asn Ile Tyr Asn Ala Cys Cys Thr Leu Arg Ile Asp Phe 210 215 220
- Ser Lys Leu Thr Ser Leu Asn Val Lys Tyr Asn Asn Asp Lys Ser Arg 225 230 235 240
- Asp Phe Thr Arg Leu Asp Leu Pro Thr Gly Asp Gly Gln Pro Ser Leu 245 250 255
- Glu Pro Pro Met Ala Ala Ala Phe Gly Ala Pro Gly Ile Ile Ser Ser 260 265 270
- Pro Tyr Ala Gly Ala Ala Gly Phe Ala Pro Ala Ile Gly Phe Pro Gln 275 280 285
- Ala Thr Gly Leu Ser Val Pro Ala Val Pro Gly Ala Leu Gly Pro Leu 290 295 300
- Thr Ile Thr Ser Ser Ala Val Thr Gly Arg Met Ala Ile Pro Gly Ala 305 310 315 320

Ser Gly Ile Pro Gly Asn Ser Val Leu Leu Val Thr Asn Leu Asn Pro 325 330 335

Asp Leu Ile Thr Pro His Gly Leu Phe Ile Leu Phe Gly Val Tyr Gly 340 345 350

Asp Val His Arg Val Lys Ile Met Phe Asn Lys Lys Glu Asn Ala Leu 355 360 365

Val Gln Met Ala Asp Ala Asn Gln Ala Gln Leu Ala Met Asn His Leu 370 375 380

Ser Gly Gln Arg Leu Tyr Gly Lys Val Leu Arg Ala Thr Leu Ser Lys 385 390 395 400

His Gln Ala Val Gln Leu Pro Arg Glu Gly Gln Glu Asp Gln Gly Leu 405 410 415

Thr Lys Asp Phe Ser Asn Ser Pro Leu His Arg Phe Lys Lys Pro Gly 420 425 430

Ser Lys Asn Phe Gln Asn Ile Phe Pro Pro Ser Ala Thr Leu His Leu 435 440 445

Ser Asn Ile Pro Pro Ser Val Thr Val Asp Asp Leu Lys Asn Leu Phe 450 455 460

Ile Glu Ala Gly Cys Ser Val Lys Ala Phe Lys Phe Phe Gln Lys Asp 465 470 475 480

Arg Lys Met Ala Leu Ile Gln Leu Gly Ser Val Glu Glu Ala Ile Gln 485 490 495

Ala Leu Ile Glu Leu His Asn His Asp Leu Gly Glu Asn His His Leu 500 505 510

Arg Val Ser Phe Ser Lys Ser Thr Ile 515 520

<210> 90

<211> 557

<212> PRT

<213> Homo sapiens

<400> 90

Met Asp Gly Ile Val Pro Asp Ile Ala Val Gly Thr Lys Arg Gly Ser 1 5 10 15

Asp Glu Leu Phe Ser Thr Cys Val Thr Asn Gly Pro Phe Ile Met Ser 20 25 30

- Ser Asn Ser Ala Ser Ala Ala Asn Gly Asn Asp Ser Lys Lys Phe Lys 35 40 45
- Gly Asp Ser Arg Ser Ala Gly Val Pro Ser Arg Val Ile His Ile Arg 50 55 60
- Lys Leu Pro Ile Asp Val Thr Glu Gly Glu Val Ile Ser Leu Gly Leu 65 70 75 80
- Pro Phe Gly Lys Val Thr Asn Leu Leu Met Leu Lys Gly Lys Asn Gln 85 90 95
- Ala Phe Ile Glu Met Asn Thr Glu Glu Ala Ala Asn Thr Met Val Asn 100 105 110
- Tyr Tyr Thr Ser Val Thr Pro Val Leu Arg Gly Gln Pro Ile Tyr Ile 115 120 125
- Gln Phe Ser Asn His Lys Glu Leu Lys Thr Asp Ser Ser Pro Asn Gln 130 135 140
- Ala Arg Ala Gln Ala Ala Leu Gln Ala Val Asn Ser Val Gln Ser Gly
  145 150 155 160
- Asn Leu Ala Leu Ala Ala Ser Ala Ala Ala Val Asp Ala Gly Met Ala 165 170 175
- Met Ala Gly Gln Ser Pro Val Leu Arg Ile Ile Val Glu Asn Leu Phe 180 185 190
- Tyr Pro Val Thr Leu Asp Val Leu His Gln Ile Phe Ser Lys Phe Gly
  195 200 205
- Thr Val Leu Lys Ile Ile Thr Phe Thr Lys Asn Asn Gln Phe Gln Ala 210 215 220
- Leu Leu Gln Tyr Ala Asp Pro Val Ser Ala Gln His Ala Lys Leu Ser 225 230 235 240
- Leu Asp Gly Gln Asn Ile Tyr Asn Ala Cys Cys Thr Leu Arg Ile Asp 245 250 255
- Phe Ser Lys Leu Thr Ser Leu Asn Val Lys Tyr Asn Asn Asp Lys Ser

260 265 270

Arg Asp Tyr Thr Arg Pro Asp Leu Pro Ser Gly Asp Ser Gln Pro Ser 275 280 285

Leu Asp Gln Thr Met Ala Ala Ala Phe Gly Ala Pro Gly Ile Ile Ser 290 295 300

Ala Ser Pro Tyr Ala Gly Ala Gly Phe Pro Pro Thr Phe Ala Ile Pro 305 310 315 320

Gln Ala Ala Gly Leu Ser Val Pro Asn Val His Gly Ala Leu Ala Pro 325 330 335

Leu Ala Ile Pro Ser Ala Ala Ala Ala Ala Ala Ala Ala Ala Gly Arg Ile 340 350

Ala Ile Pro Gly Leu Ala Gly Ala Gly Asn Ser Val Leu Leu Val Ser 355 360 365

Asn Leu Asn Pro Glu Arg Val Thr Pro Gln Ser Leu Phe Ile Leu Phe 370 375 380

Gly Val Tyr Gly Asp Val Gln Arg Val Lys Ile Leu Phe Asn Lys Lys 385 390 395 400

Glu Asn Ala Leu Val Gln Met Ala Asp Gly Asn Gln Ala Gln Leu Ala 405 410 415

Met Ser His Leu Asn Gly His Lys Leu His Gly Lys Pro Ile Arg Ile 420 425 430

Thr Leu Ser Lys His Gln Asn Val Gln Leu Pro Arg Glu Gly Gln Glu 435 440 445

Asp Gln Gly Leu Thr Lys Asp Tyr Gly Asn Ser Pro Leu His Arg Phe 450 455 460

Lys Lys Pro Gly Ser Lys Asn Phe Gln Asn Ile Phe Pro Pro Ser Ala 465 470 475 480

Thr Leu His Leu Ser Asn Ile Pro Pro Ser Val Ser Glu Glu Asp Leu 485 490 495

Lys Val Leu Phe Ser Ser Asn Gly Gly Val Val Lys Gly Phe Lys Phe 500 505 510

Phe Gln Lys Asp Arg Lys Met Ala Leu Ile Gln Met Gly Ser Val Glu 515 520 525

Glu Ala Val Gln Ala Leu Ile Asp Leu His Asn His Asp Leu Gly Glu 530 535 540

Asn His His Leu Arg Val Ser Phe Ser Lys Ser Thr Ile 545 550 555

<210> 91

<211> 534

<212> PRT

<213> Homo sapiens

<400> 91

Met Ile Trp Tyr Ile Leu Ile Ile Gly Ile Leu Leu Pro Gln Ser Leu 1 5 10 15

Ala His Pro Gly Phe Phe Thr Ser Ile Gly Gln Met Thr Asp Leu Ile 20 25 30

His Thr Glu Lys Asp Leu Val Thr Ser Leu Lys Asp Tyr Ile Lys Ala 35 40 45

Glu Glu Asp Lys Leu Glu Gln Ile Lys Lys Trp Ala Glu Lys Leu Asp
50 60

Arg Leu Thr Ser Thr Ala Thr Lys Asp Pro Glu Gly Phe Val Gly His 65 70 75 80

Pro Val Asn Ala Phe Lys Leu Met Lys Arg Leu Asn Thr Glu Trp Ser 85 90 95

Glu Leu Glu Asn Leu Val Leu Lys Asp Met Ser Asp Gly Phe Ile Ser 100 105 110

Asn Leu Thr Ile Gln Arg Pro Val Leu Ser Asn Asp Glu Asp Gln Val 115 120 125

Gly Ala Ala Lys Ala Leu Leu Arg Leu Gln Asp Thr Tyr Asn Leu Asp 130 135 140

Thr Asp Thr Ile Ser Lys Gly Asn Leu Pro Gly Val Lys His Lys Ser 145 150 155 160

Phe Leu Thr Ala Glu Asp Cys Phe Glu Leu Gly Lys Val Ala Tyr Thr 165 170 175

Glu Ala Asp Tyr Tyr His Thr Glu Leu Trp Met Glu Gln Ala Leu Arg 180 185 190

- Gln Leu Asp Glu Gly Glu Ile Ser Thr Ile Asp Lys Val Ser Val Leu 195 200 205
- Asp Tyr Leu Ser Tyr Ala Val Tyr Gln Gln Gly Asp Leu Asp Lys Ala 210 215 220
- Leu Leu Thr Lys Lys Leu Leu Glu Leu Asp Pro Glu His Gln Arg 225 230 235 235
- Ala Asn Gly Asn Leu Lys Tyr Phe Glu Tyr Ile Met Ala Lys Glu Lys 245 250 255
- Asp Val Asn Lys Ser Ala Ser Asp Gln Ser Asp Gln Lys Thr Thr 260 265 270
- Pro Lys Lys Gly Val Ala Val Asp Tyr Leu Pro Glu Arg Gln Lys 275 280 285
- Tyr Glu Met Leu Cys Arg Gly Glu Gly Ile Lys Met Thr Pro Arg Arg 290 295 300
- Gln Lys Lys Leu Phe Cys Arg Tyr His Asp Gly Asn Arg Asn Pro Lys 305 310 315 320
- Phe Ile Leu Ala Pro Ala Lys Gln Glu Asp Glu Trp Asp Lys Pro Arg 325 330 335
- Ile Ile Arg Phe His Asp Ile Ile Ser Asp Ala Glu Ile Glu Ile Val 340 345 350
- Lys Asp Leu Ala Lys Pro Arg Leu Ser Arg Ala Thr Val His Asp Pro 355 360 365
- Glu Thr Gly Lys Leu Thr Thr Ala Gln Tyr Arg Val Ser Lys Ser Ala 370 375 380
- Trp Leu Ser Gly Tyr Glu Asn Pro Val Val Ser Arg Ile Asn Met Arg 385 390 395 400
- Ile Gln Asp Leu Thr Gly Leu Asp Val Ser Thr Ala Glu Glu Leu Gln 405 410 415

1

Val Ala Asn Tyr Gly Val Gly Gly Gln Tyr Glu Pro His Phe Asp Phe 420 425 430

Ala Arg Lys Asp Glu Pro Asp Ala Phe Lys Glu Leu Gly Thr Gly Asn 435 440 445

Arg Ile Ala Thr Trp Leu Phe Tyr Met Ser Asp Val Ser Ala Gly Gly
450 455 460

Ala Thr Val Phe Pro Glu Val Gly Ala Ser Val Trp Pro Lys Lys Gly 465 470 475 480

Thr Ala Val Phe Trp Tyr Asn Leu Phe Ala Ser Gly Glu Gly Asp Tyr 485 490 495

Ser Thr Arg His Ala Ala Cys Pro Val Leu Val Gly Asn Lys Trp Val 500 505 510

Ser Asn Lys Trp Leu His Glu Arg Gly Gln Glu Phe Arg Arg Pro Cys 515 520 525

Thr Leu Ser Glu Leu Glu 530

<210> 92

<211> 535

<212> PRT

<213> Homo sapiens

<400> 92

Met Lys Leu Trp Val Ser Ala Leu Leu Met Ala Trp Phe Gly Val Leu 1 5 10 15

Ser Cys Val Gln Ala Glu Phe Phe Thr Ser Ile Gly His Met Thr Asp 20 25 30

Leu Ile Tyr Ala Glu Lys Glu Leu Val Gln Ser Leu Lys Glu Tyr Ile 35 40 45

Leu Val Glu Glu Ala Lys Leu Ser Lys Ile Lys Ser Trp Ala Asn Lys 50 55 60

Met Glu Ala Leu Thr Ser Lys Ser Ala Ala Asp Ala Glu Gly Tyr Leu 65 70 75 80

Ala His Pro Val Asn Ala Tyr Lys Leu Val Lys Arg Leu Asn Thr Asp 85 90 95

Trp Pro Ala Leu Glu Asp Leu Val Leu Gln Asp Ser Ala Ala Gly Phe 100 105 110

- Ile Ala Asn Leu Ser Val Gln Arg Gln Phe Phe Pro Thr Asp Glu Asp 115 120 125
- Glu Ile Gly Ala Ala Lys Ala Leu Met Arg Leu Gln Asp Thr Tyr Arg 130 135 140
- Leu Asp Pro Gly Thr Ile Ser Arg Gly Glu Leu Pro Gly Thr Lys Tyr 145 150 150 160
- Gln Ala Met Leu Ser Val Asp Asp Cys Phe Gly Met Gly Arg Ser Ala 165 170 175
- Tyr Asn Glu Gly Asp Tyr Tyr His Thr Val Leu Trp Met Glu Gln Val 180 185 190
- Leu Lys Gln Leu Asp Ala Gly Glu Glu Ala Thr Thr Thr Lys Ser Gln .195 200 205
- Val Leu Asp Tyr Leu Ser Tyr Ala Val Phe Gln Leu Gly Asp Leu His 210 215 220
- Arg Ala Leu Glu Leu Thr Arg Arg Leu Leu Ser Leu Asp Pro Ser His 225 230 235 240
- Glu Arg Ala Gly Gly Asn Leu Arg Tyr Phe Glu Gln Leu Leu Glu Glu 245 250 255
- Glu Arg Glu Lys Thr Leu Thr Asn Gln Thr Glu Ala Glu Leu Ala Thr 260 265 270
- Pro Glu Gly Ile Tyr Glu Arg Pro Val Asp Tyr Leu Pro Glu Arg Asp 275 280 285
- Val Tyr Glu Ser Leu Cys Arg Gly Glu Gly Val Lys Leu Thr Pro Arg 290 295 300
- Arg Gln Lys Arg Leu Phe Cys Arg Tyr His His Gly Asn Arg Ala Pro 305 310 315 320
- Gln Leu Leu Ile Ala Pro Phe Lys Glu Glu Asp Glu Trp Asp Ser Pro 325 330 335
- His Ile Val Arg Tyr Tyr Asp Val Met Ser Asp Glu Glu Ile Glu Arg

340 345 350

Ile Lys Glu Ile Ala Lys Pro Lys Leu Ala Arg Ala Thr Val Arg Asp 355 360 365

Pro Lys Thr Gly Val Leu Thr Val Ala Ser Tyr Arg Val Ser Lys Ser 370 375 380

Ser Trp Leu Glu Glu Asp Asp Asp Pro Val Val Ala Arg Val Asn Arg 385 390 395 400

Arg Met Gln His Ile Thr Gly Leu Thr Val Lys Thr Ala Glu Leu Leu 405 410 415

Gln Val Ala Asn Tyr Gly Val Gly Gly Gln Tyr Glu Pro His Phe Asp 420 425 430

Phe Ser Arg Asn Asp Glu Arg Asp Thr Phe Lys His Leu Gly Thr Gly
435 440 445

Asn Arg Val Ala Thr Phe Leu Asn Tyr Met Ser Asp Val Glu Ala Gly 450 455 460

Gly Ala Thr Val Phe Pro Asp Leu Gly Ala Ala Ile Trp Pro Lys Lys 465 470 475 480

Gly Thr Ala Val Phe Trp Tyr Asn Leu Leu Arg Ser Gly Glu Gly Asp 485 490 495

Tyr Arg Thr Arg His Ala Ala Cys Pro Val Leu Val Gly Cys Lys Trp 500 505 510

Val Ser Asn Lys Trp Phe His Glu Arg Gly Gln Glu Phe Leu Arg Pro 515 520 525

Cys Gly Ser Thr Glu Val Asp 530 535

<210> 93

<211> 755

<212> PRT

<213> Homo sapiens

<400> 93

Met Glu Ala Val Ile Glu Lys Glu Cys Ser Ala Leu Gly Gly Leu Phe 1 5 10 15

Gln Thr Ile Ile Ser Asp Met Lys Gly Ser Tyr Pro Val Trp Glu Asp 20 25 30

- Phe Ile Asn Lys Ala Gly Lys Leu Gln Ser Gln Leu Arg Thr Thr Val 35 40 45
- Val Ala Ala Ala Phe Leu Asp Ala Phe Gln Lys Val Ala Asp Met 50 55 60
- Ala Thr Asn Thr Arg Gly Gly Thr Arg Glu Ile Gly Ser Ala Leu Thr 65 70 75 80
- Arg Met Cys Met Arg His Arg Ser Ile Glu Ala Lys Leu Arg Gln Phe 85 90 95
- Ser Ser Ala Leu Ile Asp Cys Leu Ile Asn Pro Leu Gln Glu Gln Met 100 105 110
- Glu Glu Trp Lys Lys Val Ala Asn Gln Leu Asp Lys Asp His Ala Lys 115 120 125
- Glu Tyr Lys Lys Ala Arg Gln Glu Ile Lys Lys Lys Ser Ser Asp Thr 130 135 140
- Leu Lys Leu Gln Lys Lys Ala Lys Lys Gly Arg Gly Asp Ile Gln Pro 145 150 155 160
- Gln Leu Asp Ser Ala Leu Gln Asp Val Asn Asp Lys Tyr Leu Leu Leu 165 170 175
- Glu Glu Thr Glu Lys Gln Ala Val Arg Lys Ala Leu Ile Glu Glu Arg 180 185 190
- Gly Arg Phe Cys Thr Phe Ile Ser Met Leu Arg Pro Val Ile Glu Glu 195 200 205
- Glu Ile Ser Met Leu Gly Glu Ile Thr His Leu Gln Thr Ile Ser Glu 210 215 220
- Asp Leu Lys Ser Leu Thr Met Asp Pro His Lys Leu Pro Ser Ser Ser 225 230 235 240
- Glu Gln Val Ile Leu Asp Leu Lys Gly Ser Asp Tyr Ser Trp Ser Tyr 245 250 255
- Gln Thr Pro Pro Ser Ser Pro Ser Thr Thr Met Ser Arg Lys Ser Ser 260 265 270

Val Cys Ser Ser Leu Asn Ser Val Asn Ser Ser Asp Ser Arg Ser Ser 275 280 285

- Gly Ser His Ser His Ser Pro Ser Ser His Tyr Arg Tyr Arg Ser Ser 290 295 300
- Asn Leu Ala Gln Gln Ala Pro Val Arg Leu Ser Ser Val Ser Ser His 305 310 315 320
- Asp Ser Gly Phe Ile Ser Gln Asp Ala Phe Gln Ser Lys Ser Pro Ser 325 330 335
- Pro Met Pro Pro Glu Ala Pro Asn Gln Leu Ser Asn Gly Phe Ser His 340 345 350
- Tyr Ser Leu Ser Ser Glu Ser His Val Gly Pro Thr Gly Ala Gly Leu 355 360 365
- Phe Pro His Cys Leu Pro Ala Ser Arg Leu Leu Pro Arg Val Thr Ser 370 375 380
- Val His Leu Pro Asp Tyr Ala His Tyr Tyr Thr Ile Gly Pro Gly Met 385 390 395 400
- Phe Pro Ser Ser Gln Ile Pro Ser Trp Lys Asp Trp Ala Lys Pro Gly 405 410 415
- Pro Tyr Asp Gln Pro Leu Val Asn Thr Leu Gln Arg Arg Lys Glu Lys
  420 425 430
- Arg Glu Pro Asp Pro Asn Gly Gly Gly Pro Thr Thr Ala Ser Gly Pro 435 440 445
- Pro Ala Ala Ala Glu Glu Ala Gln Arg Pro Arg Ser Met Thr Val Ser 450 455 460
- Ala Ala Thr Arg Pro Gly Glu Glu Met Glu Ala Cys Glu Glu Leu Ala 465 470 475 480
- Leu Ala Leu Ser Arg Gly Leu Gln Leu Asp Thr Gln Arg Ser Ser Arg 485 490 495
- Asp Ser Leu Gln Cys Ser Ser Gly Tyr Ser Thr Gln Thr Thr Pro
  500 505 510

Cys Cys Ser Glu Asp Thr Ile Pro Ser Gln Val Ser Asp Tyr Asp Tyr 515 520 525

Phe Ser Val Ser Gly Asp Gln Glu Ala Asp Gln Glu Phe Asp Lys 530 535 540

Ser Ser Thr Ile Pro Arg Asn Ser Asp Ile Ser Gln Ser Tyr Arg Arg 545 550 555 560

Met Phe Gln Ala Lys Arg Pro Ala Ser Thr Ala Gly Leu Pro Thr Thr 565 570 575

Leu Gly Pro Ala Met Val Thr Pro Gly Val Ala Thr Ile Arg Arg Thr 580 585 589

Pro Ser Thr Lys Pro Ser Val Arg Arg Gly Thr Ile Gly Ala Gly Pro 595 600 605

Ile Pro Ile Lys Thr Pro Val Ile Pro Val Lys Thr Pro Thr Val Pro 610 615 620

Asp Leu Pro Gly Val Met Pro Ala Pro Pro Asp Gly Pro Glu Glu Arg 625 630 635 640

Gly Glu His Ser Pro Glu Ser Pro Ser Val Gly Glu Gly Pro Gln Gly 645 650 655

Val Thr Ser Met Pro Ser Ser Met Trp Ser Gly Gln Ala Ser Val Asn 660 665 670

Pro Pro Leu Pro Gly Pro Lys Pro Ser Ile Pro Glu Glu His Arg Gln 675 680 685

Ala Ile Pro Glu Ser Glu Ala Glu Asp Gln Glu Arg Glu Pro Pro Ser 690 695 700

Ala Thr Val Ser Pro Gly Gln Ile Pro Glu Ser Asp Pro Ala Asp Leu 705 710 715 720

Ser Pro Arg Asp Thr Pro Gln Gly Glu Asp Met Leu Asn Ala Ile Arg 725 730 735

Arg Gly Val Lys Leu Lys Lys Thr Thr Thr Asn Asp Arg Ser Ala Pro 740 745 750

Arg Phe Ser 755

<210> 94 <211> 211 <212> PRT <213> Homo sapiens

<400> 94

Met Cys Met Arg His Arg Ser Ile Glu Thr Lys Leu Arg Gln Phe Thr

Asn Ala Leu Leu Glu Ser Leu Ile Asn Pro Leu Gln Glu Arg Ile Glu 25

Asp Trp Lys Lys Ala Ala Asn Gln Leu Asp Lys Asp His Ala Lys Glu 40

Tyr Lys Arg Ala Arg His Glu Ile Lys Lys Lys Ser Ser Asp Thr Leu

Lys Leu Gln Lys Lys Ala Arg Lys Gly Lys Gly Asp Leu Gln Pro Gln 75

Leu Asp Ser Ala Leu Gln Asp Val Asn Asp Met Tyr Leu Leu Leu Glu 90 85

Glu Thr Glu Lys Gln Ala Val Arg Arg Ala Leu Ile Glu Glu Arg Gly 105 100

Arg Phe Cys Thr Phe Ile Thr Phe Leu Gln Pro Val Val Asn Gly Glu

Leu Thr Met Leu Gly Glu Ile Thr His Leu Gln Gly Ile Ile Asp Asp 135

Leu Val Val Leu Thr Ala Glu Pro His Lys Leu Pro Pro Ala Ser Glu 160 150 155

Gln Val Ile Lys Asp Leu Lys Gly Ser Asp Tyr Ser Trp Ser Tyr Gln 175 170

Thr Pro Pro Ser Val Pro Ser Glu Pro Phe Val Ser Phe Leu Ser Val 180 185

Arg Phe Trp Lys Asn Ser Pro Leu Leu Pro Ala Pro Ser Thr Pro Ser 205 195 200

Ser Pro Ile

210

<210> 95

<211> 117

<212> PRT

<213> Homo sapiens

<400> 95

Met Arg Leu Arg Gln Ala Pro Glu Ser Arg Lys Val Phe Ile Gln Arg 1 5 10 15

Asp Tyr Ser Ser Gly Thr Gly Cys Gln Phe Gln Thr Met Phe Ser Met 20 25 30

Glu Leu Glu Asn Gln Ile Asp Arg Gln Gln Phe Glu Glu Ile Val Gln 35 40 45

Thr Leu Asn Asn Leu Tyr Ala Glu Ala Glu Lys Leu Gly Gly Gln Ser 50 60

Tyr Leu Glu Gly Cys Leu Ala Cys Leu Thr Ala Tyr Thr Ile Phe Leu 65 70 75 80

Cys Leu Glu Thr His Tyr Gln Lys Leu Leu Lys Lys Val Ser Lys Cys 85 90 95

Ile Gln Glu Gln Asn Glu Lys Ile Tyr Val Pro Gln Gly Leu Leu Leu 100 105 110

Thr Asp Ser Ile Glu 115

<210> 96

<211> 104

<212> PRT

<213> Homo sapiens

<400> 96

Met Glu Asn Arg Ile Asp Arg Gln Gln Phe Glu Glu Thr Val Arg Thr 1 5 10 15

Leu Asn Asn Leu Tyr Ala Glu Ala Glu Lys Leu Gly Gly Gln Ser Tyr 20 25 30

Leu Glu Gly Cys Leu Ala Cys Leu Thr Ala Tyr Thr Ile Phe Leu Cys 35 40 45

Met Glu Thr His Tyr Glu Lys Val Leu Lys Lys Val Ser Lys Tyr Ile

50 55 60

Gln Glu Gln Asn Glu Lys Ile Tyr Ala Pro Gln Gly Leu Leu Leu Thr 65 70 75 80

Asp Pro Ile Glu Arg Gly Leu Arg Val Ile Glu Ile Thr Ile Tyr Glu 85 90 95

Asp Arg Gly Met Ser Ser Gly Arg 100

<210> 97

<211> 890

<212> PRT

<213> Homo sapiens

<400> 97

Met Asp Ser Asn Thr Ala Pro Leu Gly Pro Ser Cys Pro Gln Pro Pro 1 5 10 15

Pro Ala Pro Gln Pro Gln Ala Arg Ser Arg Leu Asn Ala Thr Ala Ser 20 25 30

Leu Glu Gln Glu Arg Ser Glu Arg Pro Arg Ala Pro Gly Pro Gln Ala 35 40 45

Gly Pro Gly Pro Gly Val Arg Asp Ala Ala Pro Ala Glu Pro Gln
50 55 60

Ala Gln His Thr Arg Ser Arg Glu Arg Ala Asp Gly Thr Gly Pro Thr 65 70 75 80

Lys Gly Asp Met Glu Ile Pro Phe Glu Glu Val Leu Glu Arg Ala Lys 85 90 95

Ala Gly Asp Pro Lys Ala Gln Thr Glu Val Gly Lys His Tyr Leu Gln 100 105 110

Leu Ala Gly Asp Thr Asp Glu Glu Leu Asn Ser Cys Thr Ala Val Asp 115 120 125

Trp Leu Val Leu Ala Ala Lys Gln Gly Arg Arg Glu Ala Val Lys Leu 130 135 140

Leu Arg Arg Cys Leu Ala Asp Arg Gly Ile Thr Ser Glu Asn Glu 145 150 155 160

Arg Glu Val Arg Gln Leu Ser Ser Glu Thr Asp Leu Glu Arg Ala Val 165 170 175

- Arg Lys Ala Ala Leu Val Met Tyr Trp Lys Leu Asn Pro Lys Lys Lys 180 185 190
- Lys Gln Val Ala Val Ala Glu Leu Leu Glu Asn Val Gly Gln Val Asn 195 200 205
- Glu His Asp Gly Gly Ala Gln Pro Gly Pro Val Pro Lys Ser Leu Gln 210 215 220
- Lys Gln Arg Arg Met Leu Glu Arg Leu Val Ser Ser Glu Ser Lys Asn 225 230 235 240
- Tyr Ile Ala Leu Asp Asp Phe Val Glu Ile Thr Lys Lys Tyr Ala Lys 245 250 255
- Gly Val Ile Pro Ser Ser Leu Phe Leu Gln Asp Asp Glu Asp Asp Asp 260 265 270
- Glu Leu Ala Gly Lys Ser Pro Glu Asp Leu Pro Leu Arg Leu Lys Val 275 280 285
- Val Lys Tyr Pro Leu His Ala Ile Met Glu Ile Lys Glu Tyr Leu Ile 290 295 300
- Asp Met Ala Ser Arg Ala Gly Met His Trp Leu Ser Thr Ile Ile Pro 305 310 315 320
- Thr His His Ile Asn Ala Leu Ile Phe Phe Phe Ile Ile Ser Asn Leu 325 330 335
- Thr Ile Asp Phe Phe Ala Phe Phe Ile Pro Leu Val Ile Phe Tyr Leu 340 345 350
- Ser Phe Ile Ser Met Val Ile Cys Thr Leu Lys Val Phe Gln Asp Ser 355 360 365
- Lys Ala Trp Glu Asn Phe Arg Thr Leu Thr Asp Leu Leu Leu Arg Phe 370 375 380
- Glu Pro Asn Leu Asp Val Glu Gln Ala Glu Val Asn Phe Gly Trp Asn 385 390 395 400
- His Leu Glu Pro Tyr Ala His Phe Leu Leu Ser Val Phe Phe Val Ile 405 410 415

Phe Ser Phe Pro Ile Ala Ser Lys Asp Cys Ile Pro Cys Ser Glu Leu 420 425 430

- Ala Val Ile Thr Gly Phe Phe Thr Val Thr Ser Tyr Leu Ser Leu Ser 435 440 445
- Thr His Ala Glu Pro Tyr Thr Arg Arg Ala Leu Ala Thr Glu Val Thr 450 455 460
- Ala Gly Leu Leu Ser Leu Leu Pro Ser Met Pro Leu Asn Trp Pro Tyr 465 470 475 480
- Leu Lys Val Leu Gly Gln Thr Phe Ile Thr Val Pro Val Gly His Leu 485 490 495
- Val Val Leu Asn Val Ser Val Pro Cys Leu Leu Tyr Val Tyr Leu Leu 500 505 510
- Tyr Leu Phe Phe Arg Met Ala Gln Leu Arg Asn Phe Lys Gly Thr Tyr 515 520 525
- Cys Tyr Leu Val Pro Tyr Leu Val Cys Phe Met Trp Cys Glu Leu Ser 530 535 540
- Val Val Ile Leu Leu Glu Ser Thr Gly Leu Gly Leu Leu Arg Ala Ser 545 550 555 560
- Ile Gly Tyr Phe Leu Phe Leu Phe Ala Leu Pro Ile Leu Val Ala Gly 565 570 575
- Leu Ala Leu Val Gly Val Leu Gln Phe Ala Arg Trp Phe Thr Ser Leu 580 585 585
- Glu Leu Thr Lys Ile Ala Val Thr Val Ala Val Cys Ser Val Pro Leu 595 600 605
- Leu Leu Arg Trp Trp Thr Lys Ala Ser Phe Ser Val Val Gly Met Val 610 615 620
- Lys Ser Leu Thr Arg Ser Ser Met Val Lys Leu Ile Leu Val Trp Leu 625 630 635 640
- Thr Ala Ile Val Leu Phe Cys Trp Phe Tyr Val Tyr Arg Ser Glu Gly 645 650 655

Met Lys Val Tyr Asn Ser Thr Leu Thr Trp Gln Gln Tyr Gly Ala Leu 660 665 670

Cys Gly Pro Arg Ala Trp Lys Glu Thr Asn Met Ala Arg Thr Gln Ile 675 680 685

Leu Cys Ser His Leu Glu Gly His Arg Val Thr Trp Thr Gly Arg Phe 690 695 700

Lys Tyr Val Arg Val Thr Asp Ile Asp Asn Ser Ala Glu Ser Ala Ile 705 710 715 720

Asn Met Leu Pro Phe Phe Ile Gly Asp Trp Met Arg Cys Leu Tyr Gly 725 730 735

Glu Ala Tyr Pro Ala Cys Ser Pro Gly Asn Thr Ser Thr Ala Glu Glu
740 745 750

Glu Leu Cys Arg Leu Lys Leu Leu Ala Lys His Pro Cys His Ile Lys 755 760 765

Lys Phe Asp Arg Tyr Lys Phe Glu Ile Thr Val Gly Met Pro Phe Ser 770 780

Ser Gly Ala Asp Gly Ser Arg Ser Arg Glu Glu Asp Asp Val Thr Lys 785 790 795 800

Asp Ile Val Leu Arg Ala Ser Ser Glu Phe Lys Ser Val Leu Leu Ser 805 810 815

Leu Arg Gln Gly Ser Leu Ile Glu Phe Ser Thr Ile Leu Glu Gly Arg 820 825 830

Leu Gly Ser Lys Trp Pro Val Phe Glu Leu Lys Ala Ile Ser Cys Leu 835 840 845

Asn Cys Met Ala Gln Leu Ser Pro Thr Arg Arg His Val Lys Ile Glu 850 855 860

His Asp Trp Arg Ser Thr Val His Gly Ala Val Lys Phe Ala Phe Asp 865 870 875 880

Phe Phe Phe Pro Phe Leu Ser Ala Ala 885 890

<210> 98 <211> 528

<212> PRT

<213> Homo sapiens

<400> 98

Met Ala Glu His Leu Glu Leu Leu Ala Glu Met Pro Met Val Gly Arg
1 5 10 15

Met Ser Thr Gln Glu Arg Leu Lys His Ala Gln Lys Arg Arg Ala Gln 20 25 30

Gln Val Lys Met Trp Ala Gln Ala Glu Lys Glu Ala Gln Gly Lys Lys 35 40 45

Gly Pro Gly Glu Arg Pro Arg Lys Glu Ala Ala Ser Gln Gly Leu Leu 50 55 60

Lys Gln Val Leu Phe Pro Pro Ser Val Val Leu Leu Glu Ala Ala Ala 65 70 75 80

Arg Asn Asp Leu Glu Glu Val Arg Gln Phe Leu Gly Ser Gly Val Ser 85 90 95

Pro Asp Leu Ala Asn Glu Asp Gly Leu Thr Ala Leu His Gln Cys Cys
100 105 110

Ile Asp Asp Phe Arg Glu Met Val Gln Gln Leu Leu Glu Ala Gly Ala 115 120 125

Asn Ile Asn Ala Cys Asp Ser Glu Cys Trp Thr Pro Leu His Ala Ala 130 135 140

Ala Thr Cys Gly His Leu His Leu Val Glu Leu Leu Ile Ala Ser Gly 145 150 155 160

Ala Asn Leu Leu Ala Val Asn Thr Asp Gly Asn Met Pro Tyr Asp Leu 165 170 175

Cys Asp Asp Glu Gln Thr Leu Asp Cys Leu Glu Thr Ala Met Ala Asp 180 185 190

Arg Gly Ile Thr Gln Asp Ser Ile Glu Ala Ala Arg Ala Val Pro Glu 195 200 205

Leu Arg Met Leu Asp Asp Ile Arg Ser Arg Leu Gln Ala Gly Ala Asp 210 215 220

Leu His Ala Pro Leu Asp His Gly Ala Thr Leu Leu His Val Ala Ala

225 230 235 240

Ala Asn Gly Phe Ser Glu Ala Ala Ala Leu Leu Leu Glu His Arg Ala 245 250 255

Ser Leu Ser Ala Lys Asp Gln Asp Gly Trp Glu Pro Leu His Ala Ala 260 265 270

Ala Tyr Trp Gly Gln Val Pro Leu Val Glu Leu Leu Val Ala His Gly 275 280 285

Ala Asp Leu Asn Ala Lys Ser Leu Met Asp Glu Thr Pro Leu Asp Val 290 295 300

Cys Gly Asp Glu Glu Val Arg Ala Lys Leu Leu Glu Leu Lys His Lys 305 310 315 320

His Asp Ala Leu Leu Arg Ala Gln Ser Arg Gln Arg Ser Leu Leu Arg 325 330 335

Arg Arg Thr Ser Ser Ala Gly Ser Arg Gly Lys Val Val Arg Arg Val 340 345 350

Ser Leu Thr Gln Arg Thr Asp Leu Tyr Arg Lys Gln His Ala Gln Glu 355 360 365

Ala Ile Val Trp Gln Gln Pro Pro Pro Thr Ser Pro Glu Pro Pro Glu 370 380

Asp Asn Asp Asp Arg Gln Thr Gly Ala Glu Leu Arg Pro Pro Pro 870 385 390 395 400

Glu Glu Asp Asn Pro Glu Val Val Arg Pro His Asn Gly Arg Val Gly
405 410 415

Gly Ser Pro Val Arg His Leu Tyr Ser Lys Arg Leu Asp Arg Ser Val 420 425 430

Ser Tyr Gln Leu Ser Pro Leu Asp Ser Thr Thr Pro His Thr Leu Val 435 440 445

His Asp Lys Ala His His Thr Leu Ala Asp Leu Lys Arg Gln Arg Ala 450 455 460

Ala Ala Lys Leu Gln Arg Pro Pro Pro Glu Gly Pro Glu Ser Pro Glu 465 470 475 480

Thr Ala Glu Pro Gly Leu Pro Gly Asp Thr Val Thr Pro Gln Pro Asp 490 485

Cys Gly Phe Arg Ala Gly Gly Asp Pro Pro Leu Leu Lys Leu Thr Ala 505 500

Pro Ala Val Glu Ala Pro Val Glu Arg Arg Pro Cys Cys Leu Leu Met 520 525

<210> 99 <211> 567 <212> PRT <213> Homo sapiens

<400> 99

Met Ala Ser His Val Asp Leu Leu Thr Glu Leu Gln Leu Leu Glu Lys 5

Val Pro Thr Leu Glu Arg Leu Arg Ala Ala Gln Lys Arg Arg Ala Gln 25 .

Gln Leu Lys Lys Trp Ala Gln Tyr Glu Gln Asp Leu Gln His Arg Lys . 40

Arg Lys His Glu Arg Lys Arg Ser Thr Gly Gly Arg Arg Lys Lys Val

Ser Phe Glu Ala Ser Val Ala Leu Leu Glu Ala Ser Leu Arg Asn Asp 75 70

Ala Glu Glu Val Arg Tyr Phe Leu Lys Asn Lys Val Ser Pro Asp Leu 90 85

Cys Asn Glu Asp Gly Leu Thr Ala Leu His Gln Cys Cys Ile Asp Asn 100

Phe Glu Glu Ile Val Lys Leu Leu Ser His Gly Ala Asn Val Asn 120 115

Ala Lys Asp Asn Glu Leu Trp Thr Pro Leu His Ala Ala Ala Thr Cys 135

Gly His Ile Asn Leu Val Lys Ile Leu Val Gln Tyr Gly Ala Asp Leu 155 145

Leu Ala Val Asn Ser Asp Gly Asn Met Pro Tyr Asp Leu Cys Glu Asp 165 170

Glu Pro Thr Leu Asp Val Ile Glu Thr Cys Met Ala Tyr Gln Gly Ile 180 185 190

- Thr Gln Glu Lys Ile Asn Glu Met Arg Val Ala Pro Glu Gln Gln Met 195 200 205
- Ile Ala Asp Ile His Cys Met Ile Ala Ala Gly Gln Asp Leu Asp Trp 210 215 220
- Ile Asp Ala Gln Gly Ala Thr Leu Leu His Ile Ala Gly Ala Asn Gly 225 230 235 240
- Tyr Leu Arg Ala Ala Glu Leu Leu Leu Asp His Gly Val Arg Val Asp 245 250 255
- Val Lys Asp Trp Asp Gly Trp Glu Pro Leu His Ala Ala Ala Phe Trp 260 265 270
- Gly Gln Met Gln Met Ala Glu Leu Leu Val Ser His Gly Ala Ser Leu 275 280 285
- Ser Ala Arg Thr Ser Met Asp Glu Met Pro Ile Asp Leu Cys Glu Glu 290 295 300
- Glu Glu Phe Lys Val Leu Leu Leu Glu Leu Lys His Lys His Asp Val 305 310 315 320
- Ile Met Lys Ser Gln Leu Arg His Lys Ser Ser Leu Ser Arg Arg Thr 325 330 335
- Ser Ser Ala Gly Ser Arg Gly Lys Val Val Arg Arg Ala Ser Leu Ser 340 345 350
- Asp Arg Thr Asn Leu Tyr Arg Lys Glu Tyr Glu Gly Glu Ala Ile Leu 355 360 365
- Trp Gln Arg Ser Ala Ala Glu Asp Gln Arg Thr Ser Thr Tyr Asn Gly 370 375 380
- Asp Ile Arg Glu Thr Arg Thr Asp Gln Glu Asn Lys Asp Pro Asn Pro 385 390 395 400
- Arg Leu Glu Lys Pro Val Leu Leu Ser Glu Phe Pro Thr Lys Ile Pro 405 410 415

Arg Gly Glu Leu Asp Met Pro Val Glu Asn Gly Leu Arg Ala Pro Val
420 425 430

Ser Ala Tyr Gln Tyr Ala Leu Ala Asn Gly Asp Val Trp Lys Val His 435 440 445

Glu Val Pro Asp Tyr Ser Met Ala Tyr Gly Asn Pro Gly Val Ala Asp 450 455 460

Ala Thr Pro Pro Trp Ser Ser Tyr Lys Glu Gln Ser Pro Gln Thr Leu 465 470 475 480

Leu Glu Leu Lys Arg Gln Arg Ala Ala Ala Lys Leu Leu Ser His Pro 485 490 495

Phe Leu Ser Thr His Leu Gly Ser Ser Met Ala Arg Thr Gly Glu Ser 500 505 510

Ser Ser Glu Gly Lys Ala Pro Leu Ile Gly Gly Arg Thr Ser Pro Tyr 515 520 525

Ser Ser Asn Gly Thr Ser Val Tyr Tyr Thr Val Thr Ser Gly Asp Pro 530 535 540

Pro Leu Leu Lys Phe Lys Ala Pro Ile Glu Glu Met Glu Glu Lys Val 545 550 555 560

His Gly Cys Cys Arg Ile Ser 565

<210> 100

<211> 380

<212> PRT

<213> Homo sapiens

<400> 100

Met Leu Arg Arg Lys Pro Ser Asn Ala Ser Glu Lys Glu Pro Thr Gln 1 5 10 15

Lys Lys Leu Ser Leu Gln Arg Ser Ser Ser Phe Lys Asp Phe Ala 20 25 30

Lys Ser Lys Pro Ser Ser Pro Val Val Ser Glu Lys Glu Phe Asn Leu 35 40 45

Asp Asp Asn Ile Pro Glu Asp Asp Ser Gly Val Pro Thr Pro Glu Asp 50 55 60

Ala Gly Lys Ser Gly Lys Lys Leu Gly Lys Lys Trp Arg Ala Val Ile 65 70 75 80

- Ser Arg Thr Met Asn Arg Lys Met Gly Lys Met Met Val Lys Ala Leu 85 90 95
- Ser Glu Glu Met Ala Asp Thr Leu Glu Glu Gly Ser Ala Ser Pro Thr 100 105 110
- Ser Pro Asp Tyr Ser Leu Asp Ser Pro Gly Pro Glu Lys Met Ala Leu 115 120 125
- Ala Phe Ser Glu Glu Glu Glu His Glu Leu Pro Val Leu Ser Arg Gln 130 135 140
- Ala Ser Thr Gly Ser Glu Leu Cys Ser Pro Ser Pro Gly Ser Gly Ser 145 150 155 160
- Phe Gly Glu Glu Pro Pro Ala Pro Gln Tyr Thr Gly Pro Phe Cys Gly 165 170 175
- Arg Ala Arg Val His Thr Asp Phe Thr Pro Ser Pro Tyr Asp His Asp 180 185 190
- Ser Leu Lys Leu Gln Lys Gly Asp Val Ile Gln Ile Ile Glu Lys Pro 195 200 205
- Pro Val Gly Thr Trp Leu Gly Leu Leu Asn Gly Lys Val Gly Ser Phe 210 215 220
- Lys Phe Ile Tyr Val Asp Val Leu Pro Glu Glu Ala Val Gly His Ala 225 230 235 240
- Arg Pro Ser Arg Gln Ser Lys Gly Lys Arg Pro Lys Pro Lys Thr 245 250 255
- Leu His Glu Leu Leu Glu Arg Ile Gly Leu Glu Glu His Thr Ser Thr 260 265 270
- Leu Leu Asn Gly Tyr Gln Thr Leu Glu Asp Phe Lys Glu Leu Arg 275 280 285
- Glu Thr His Leu Asn Glu Leu Asn Ile Met Asp Pro Gln His Arg Ala 290 295 300
- Lys Leu Leu Thr Ala Ala Glu Leu Leu Leu Asp Tyr Asp Thr Gly Ser

305 310 315 320

Glu Glu Ala Glu Glu Gly Ala Glu Ser Ser Gln Glu Pro Val Ala His 325 330 335

Thr Val Ser Glu Pro Lys Val Asp Ile Pro Arg Asp Ser Gly Cys Phe 340 345 350

Glu Gly Ser Glu Ser Gly Arg Asp Asp Ala Glu Leu Ala Gly Thr Glu 355 360 365

Glu Gln Leu Gln Gly Leu Ser Leu Ala Gly Ala Pro 370 375 380

<210> 101

<211> 1247

<212> PRT

<213> Homo sapiens

<400> 101

Met Glu Asp Ala Gly Ala Ala Gly Pro Gly Pro Glu Pro Glu Pro Glu 15

Pro Glu Pro Glu Pro Glu Pro Ala Pro Glu Pro Glu Pro Glu Pro Lys
20 25 30

Met Gly Ile Leu Asp Gly Ser Leu Gly Asn Ile Asp Asp Leu Ala Gln 50 55 60

Gln Tyr Ala Asp Tyr Tyr Asn Thr Cys Phe Ser Asp Val Cys Glu Arg 65 70 75 80

Met Glu Glu Leu Arg Lys Arg Arg Val Ser Gln Asp Leu Glu Val Glu 85 90 95

Lys Pro Asp Ala Ser Pro Thr Ser Leu Gln Leu Arg Ser Gln Ile Glu 100 105 110

Glu Ser Leu Gly Phe Cys Ser Ala Val Ser Thr Pro Glu Val Glu Arg 115 . 120 125

Lys Asn Pro Leu His Lys Ser Asn Ser Glu Asp Ser Ser Val Gly Lys 130 135 140

Gly Asp Trp Lys Lys Lys Asn Lys Tyr Phe Trp Gln Asn Phe Arg Lys 145 150 155 160

- Asn Gln Lys Gly Ile Met Arg Gln Thr Ser Lys Gly Glu Asp Val Gly 165 170 175
- Tyr Val Ala Ser Glu Ile Thr Met Ser Asp Glu Glu Arg Ile Gln Leu 180 185 190
- Met Met Met Val Lys Glu Lys Met Ile Thr Ile Glu Glu Ala Leu Ala 195 200 205
- Arg Leu Lys Glu Tyr Glu Ala Gln His Arg Gln Ser Ala Ala Leu Asp 210 215 220
- Pro Ala Asp Trp Pro Asp Gly Ser Tyr Pro Thr Phe Asp Gly Ser Ser 225 230 235 240
- Asn Cys Asn Ser Arg Glu Gln Ser Asp Asp Glu Thr Glu Glu Ser Val 245 250 255
- Lys Phe Lys Arg Leu His Lys Leu Val Asn Ser Thr Arg Arg Val Arg 260 265 270
- Lys Lys Leu Ile Arg Val Glu Glu Met Lys Lys Pro Ser Thr Glu Gly 275 280 285
- Gly Glu Glu His Val Phe Glu Asn Ser Pro Val Leu Asp Glu Arg Ser 290 295 300
- Ala Leu Tyr Ser Gly Val His Lys Lys Pro Leu Phe Phe Asp Gly Ser 305 310 315 320
- Pro Glu Lys Pro Pro Glu Asp Asp Ser Asp Ser Leu Thr Thr Ser Pro 325 330 335
- Ser Ser Ser Leu Asp Thr Trp Gly Ala Gly Arg Lys Leu Val Lys 340 345 350
- Thr Phe Ser Lys Gly Glu Ser Arg Gly Leu Ile Lys Pro Pro Lys Lys 355 360 365
- Met Gly Thr Phe Phe Ser Tyr Pro Glu Glu Glu Lys Ala Gln Lys Val 370 375 380
- Ser Arg Ser Leu Thr Glu Gly Glu Met Lys Lys Gly Leu Gly Ser Leu 385 390 395 400

Ser His Gly Arg Thr Cys Ser Phe Gly Gly Phe Asp Leu Thr Asn Arg 405 410 415

- Ser Leu His Val Gly Ser Asn Asn Ser Asp Pro Met Gly Lys Glu Gly 420 425 430
- Asp Phe Val Tyr Lys Glu Val Ile Lys Ser Pro Thr Ala Ser Arg Ile 435 440 445
- Ser Leu Gly Lys Lys Val Lys Ser Val Lys Glu Thr Met Arg Lys Arg 450 455 460
- Met Ser Lys Lys Tyr Ser Ser Ser Val Ser Glu Gln Asp Ser Gly Leu 465 470 475 480
- Asp Gly Met Pro Gly Ser Pro Pro Pro Ser Gln Pro Asp Pro Glu His
  485 490 495
- Leu Asp Lys Pro Lys Leu Lys Ala Gly Gly Ser Val Glu Ser Leu Arg 500 505 510
- Ser Ser Leu Ser Gly Gln Ser Ser Met Ser Gly Gln Thr Val Ser Thr 515 520 525
- Thr Asp Ser Ser Thr Ser Asn Arg Glu Ser Val Lys Ser Glu Asp Gly 530 535 540
- Asp Asp Glu Glu Pro Pro Tyr Arg Gly Pro Phe Cys Gly Arg Ala Arg 545 550 555 560
- Val His Thr Asp Phe Thr Pro Ser Pro Tyr Asp Thr Asp Ser Leu Lys 565 570 575
- Leu Lys Lys Gly Asp Ile Ile Asp Ile Ile Ser Lys Pro Pro Met Gly 580 585 590
- Thr Trp Met Gly Leu Leu Asn Asn Lys Val Gly Thr Phe Lys Phe Ile 595 600 605
- Tyr Val Asp Val Leu Ser Glu Asp Glu Glu Lys Pro Lys Arg Pro Thr 610 615 620
- Arg Arg Arg Lys Gly Arg Pro Pro Gln Pro Lys Ser Val Glu Asp 625 630 635 640

Leu Leu Asp Arg Ile Asn Leu Lys Glu His Met Pro Thr Phe Leu Phe 645 650 655

- Asn Gly Tyr Glu Asp Leu Asp Thr Phe Lys Leu Leu Glu Glu Glu Asp 660 665 670
- Leu Asp Glu Leu Asn Ile Arg Asp Pro Glu His Arg Ala Val Leu Leu 675 680 685
- Thr Ala Val Glu Leu Leu Gln Glu Tyr Asp Ser Asn Ser Asp Gln Ser 690 695 700
- Gly Ser Gln Glu Lys Leu Leu Val Asp Ser Gln Gly Leu Ser Gly Cys 705 710 715 720
- Ser Pro Arg Asp Ser Gly Cys Tyr Glu Ser Ser Glu Asn Leu Glu Asn 725 730 735
- Gly Lys Thr Arg Lys Ala Ser Leu Leu Ser Ala Lys Ser Ser Thr Glu
  740 745 750
- Pro Ser Leu Lys Ser Phe Ser Arg Asn Gln Leu Gly Asn Tyr Pro Thr .755 760 765
- Leu Pro Leu Met Lys Ser Gly Asp Ala Leu Lys Gln Gly Gln Glu Glu 770 775 780
- Gly Arg Leu Gly Gly Leu Ala Pro Asp Thr Ser Lys Ser Cys Asp 785 790 795 800
- Pro Pro Gly Val Thr Gly Leu Asn Lys Asn Arg Arg Ser Leu Pro Val 805 810 815
- Ser Ile Cys Arg Ser Cys Glu Thr Leu Glu Gly Pro Gln Thr Val Asp 820 825 830
- Thr Trp Pro Arg Ser His Ser Leu Asp Asp Leu Gln Val Glu Pro Gly 835 840 845
- Ala Glu Gln Asp Val Pro Thr Glu Val Thr Glu Pro Pro Pro Gln Ile 850 855 860
- Val Pro Glu Val Pro Gln Lys Thr Thr Ala Ser Ser Thr Lys Ala Gln 865 870 875 880
- Pro Leu Glu Gln Asp Ser Ala Val Asp Asn Ala Leu Leu Leu Thr Gln 885 890 895

Ser Lys Arg Phe Ser Glu Pro Gln Lys Leu Thr Thr Lys Lys Leu Glu 900 905 910

- Gly Ser Ile Ala Ala Ser Gly Arg Gly Leu Ser Pro Pro Gln Cys Leu 915 920 925
- Pro Arg Asn Tyr Asp Ala Gln Pro Pro Gly Ala Lys His Gly Leu Ala 930 935 940
- Arg Thr Pro Leu Glu Gly His Arg Lys Gly His Glu Phe Glu Gly Thr 945 950 955 960
- His His Pro Leu Gly Thr Lys Glu Gly Val Asp Ala Glu Gln Arg Met 965 970 975
- Gln Pro Lys Ile Pro Ser Gln Pro Pro Pro Val Pro Ala Lys Lys Ser 980 985 990
- Arg Glu Arg Leu Ala Asn Gly Leu His Pro Val Pro Met Gly Pro Ser 995 1000 1005
- Gly Ala Leu Pro Ser Pro Asp Ala Pro Cys Leu Pro Val Lys Arg 1010 1015 1020
- Gly Ser Pro Ala Ser Pro Thr Ser Pro Ser Asp Cys Pro Pro Ala 1025 1030 1035
- Leu Ala Pro Arg Pro Leu Ser Gly Gln Ala Pro Gly Ser Pro Pro 1040 1045 1050
- Ser Thr Arg Pro Pro Pro Trp Leu Ser Glu Leu Pro Glu Asn Thr 1055 1060 1065
- Ser Leu Gln Glu His Gly Val Lys Leu Gly Pro Ala Leu Thr Arg 1070 1075 1080
- Lys Val Ser Cys Ala Arg Gly Val Asp Leu Glu Thr Leu Thr Glu 1085 1090 1095
- Asn Lys Leu His Ala Glu Gly Ile Asp Leu Thr Glu Glu Pro Tyr 1100 1105 1110
- Ser Asp Lys His Gly Arg Cys Gly Ile Pro Glu Ala Leu Val Gln 1115 1120 1125

Arg Tyr Ala Glu Asp Leu Asp Gln Pro Glu Arg Asp Val Ala Ala 1130 1135 1140

- Asn Met Asp Gln Ile Arg Val Lys Gln Leu Arg Lys Gln His Arg 1145 1150 1155
- Met Ala Ile Pro Ser Gly Gly Leu Thr Glu Ile Cys Arg Lys Pro 1160 1165 1170
- Val Ser Pro Gly Cys Ile Ser Ser Val Ser Asp Trp Leu Ile Ser 1175 1180 1185
- Ile Gly Leu Pro Met Tyr Ala Gly Thr Leu Ser Thr Ala Gly Phe 1190 1195 1200
- Ser Thr Leu Ser Gln Val Pro Ser Leu Ser His Thr Cys Leu Gln 1205 1210 1215
- Glu Ala Gly Ile Thr Glu Glu Arg His Ile Arg Lys Leu Leu Ser 1220 1225 1230
- Ala Ala Arg Leu Phe Lys Leu Pro Pro Gly Pro Glu Ala Met 1235 1240 1245

<210> 102 ·

<211> 373

<212> PRT

<213> Homo sapiens

<400> 102

- Met Leu Lys Arg Lys Pro Ser Asn Val Ser Glu Lys Glu Lys His Gln 1 5 10 15
- Lys Pro Lys Arg Ser Ser Ser Phe Gly Asn Phe Asp Arg Phe Arg Asn 20 25 30
- Asn Ser Leu Ser Lys Pro Asp Asp Ser Thr Glu Ala His Glu Gly Asp 35 40 45
- Pro Thr Asn Gly Ser Gly Glu Gln Ser Lys Thr Ser Asn Asn Gly Gly 50 55 60
- Gly Leu Gly Lys Lys Met Arg Ala Ile Ser Trp Thr Met Lys Lys Lys 65 70 75 80
- Val Gly Lys Lys Tyr Ile Lys Ala Leu Ser Glu Glu Lys Asp Glu Glu 85 90 95

Asp Gly Glu Asn Ala His Pro Tyr Arg Asn Ser Asp Pro Val Ile Gly 100 105 110

- Thr His Thr Glu Lys Val Ser Leu Lys Ala Ser Asp Ser Met Asp Ser 115 120 125
- Leu Tyr Ser Gly Gln Ser Ser Ser Ser Gly Ile Thr Ser Cys Ser Asp 130 135 140
- Gly Thr Ser Asn Arg Asp Ser Phe Arg Leu Asp Asp Asp Gly Pro Tyr 145 150 155 160
- Ser Gly Pro Phe Cys Gly Arg Ala Arg Val His Thr Asp Phe Thr Pro 165 170 175
- Ser Pro Tyr Asp Thr Asp Ser Leu Lys Ile Lys Lys Gly Asp Ile Ile 180 185 190
- Asp Ile Ile Cys Lys Thr Pro Met Gly Met Trp Thr Gly Met Leu Asn 195 200 205
- Asn Lys Val Gly Asn Phe Lys Phe Ile Tyr Val Asp Val Ile Ser Glu 210 215 220
- Glu Glu Ala Ala Pro Lys Lys Ile Lys Ala Asn Arg Arg Ser Asn Ser 225 230 235 240
- Lys Lys Ser Lys Thr Leu Gln Glu Phe Leu Glu Arg Ile His Leu Gln 245 250 255
- Glu Tyr Thr Ser Thr Leu Leu Leu Asn Gly Tyr Glu Thr Leu Glu Asp 260 265 270
- Leu Lys Asp Ile Lys Glu Ser His Leu Ile Glu Leu Asn Ile Glu Asn 275 280 285
- Pro Asp Asp Arg Arg Leu Leu Ser Ala Ala Glu Asn Phe Leu Glu 290 295 300
- Glu Glu Ile Ile Gln Glu Gln Glu Asn Glu Pro Glu Pro Leu Ser Leu 305 310 315 320
- Ser Ser Asp Ile Ser Leu Asn Lys Ser Gln Leu Asp Asp Cys Pro Arg 325 330 335
- Asp Ser Gly Cys Tyr Ile Ser Ser Gly Asn Ser Asp Asn Gly Lys Glu

340 345 350

Asp Leu Glu Ser Glu Asn Leu Ser Asp Met Val His Lys Ile Ile Ile 355 360 365

Thr Glu Pro Ser Asp 370

<210> 103

<211> 431

<212> PRT

<213> Homo sapiens

<400> 103

Met Glu Gly Ser Ala Ser Pro Pro Glu Lys Pro Arg Ala Arg Pro Ala 1 5 10 15

Ala Ala Val Leu Cys Arg Gly Pro Val Glu Pro Leu Val Phe Leu Ala 20 25 30

Asn Phe Ala Leu Val Leu Gln Gly Pro Leu Thr Thr Gln Tyr Leu Trp 35 40 45

His Arg Phe Ser Ala Asp Leu Gly Tyr Asn Gly Thr Arg Gln Arg Gly 50 55 60

Gly Cys Ser Asn Arg Ser Ala Asp Pro Thr Met Gln Glu Val Glu Thr 65 70 75 80

Leu Thr Ser His Trp Thr Leu Tyr Met Asn Val Gly Gly Phe Leu Val 85 90 95

Gly Leu Phe Ser Ser Thr Leu Leu Gly Ala Trp Ser Asp Ser Val Gly 100 105 110

Arg Arg Pro Leu Leu Val Leu Ala Ser Leu Gly Leu Leu Gln Ala 115 120 125

Leu Val Ser Val Phe Val Val Gln Leu Gln Leu His Val Gly Tyr Phe 130 135 140

Val Leu Gly Arg Ile Leu Cys Ala Leu Leu Gly Asp Phe Gly Gly Leu 145 150 155 160

Leu Ala Ala Ser Phe Ala Ser Val Ala Asp Val Ser Ser Ser Arg Ser 165 170 175

Arg Thr Phe Arg Met Ala Leu Leu Glu Ala Ser Ile Gly Val Ala Gly 180 185 190

- Met Leu Ala Ser Leu Leu Gly Gly His Trp Leu Arg Ala Gln Gly Tyr 195 200 205
- Ala Asn Pro Phe Trp Leu Ala Leu Ala Leu Leu Ile Ala Met Thr Leu 210 215 220
- Tyr Ala Ala Phe Cys Phe Gly Glu Thr Leu Lys Glu Pro Lys Ser Thr 225 230 235 240
- Arg Leu Phe Thr Phe Arg His His Arg Ser Ile Val Gln Leu Tyr Val 245 250 255
- Ala Pro Ala Pro Glu Lys Ser Arg Lys His Leu Ala Leu Tyr Ser Leu 260 265 270
- Ala Ile Phe Val Val Ile Thr Val His Phe Gly Ala Gln Asp Ile Leu 275 280 285
- Thr Leu Tyr Glu Leu Ser Thr Pro Leu Cys Trp Asp Ser Lys Leu Ile 290 295 300
- Gly Tyr Gly Ser Ala Ala Gln His Leu Pro Tyr Leu Thr Ser Leu Leu 305 310 315
- Ala Leu Lys Leu Gln Tyr Cys Leu Ala Asp Ala Trp Val Ala Glu 325 330 335
- Ile Gly Leu Ala Phe Asn Ile Leu Gly Met Val Val Phe Ala Phe Ala 340 345 350
- Thr Ile Thr Pro Leu Met Phe Thr Gly Ala Leu Phe Ser Ala Val Ala 355 360 365
- Cys Val Asn Ser Leu Ala Met Leu Thr Ala Ser Gly Ile Phe Asn Ser 370 380
- Leu Tyr Pro Ala Thr Leu Asn Phe Met Lys Gly Phe Pro Phe Leu Leu 385 390 395 400
- Gly Ala Gly Leu Leu Leu Ile Pro Ala Val Leu Ile Gly Met Leu Glu 405 410 415
- Lys Ala Asp Pro His Leu Glu Phe Gln Gln Phe Pro Gln Ser Pro 420 425 430

PCT/US03/06025 WO 03/083047

<210> 104 <211> 463 <212> PRT <213> Homo sapiens

<400> 104

Met Lys Ile Leu Phe Val Glu Pro Ala Ile Phe Leu Ser Ala Phe Ala

Met Thr Leu Thr Gly Pro Leu Thr Thr Gln Tyr Val Tyr Arg Arg Ile 25

Trp Glu Glu Thr Gly Asn Tyr Thr Phe Ser Ser Asp Ser Asn Ile Ser

Glu Cys Glu Lys Asn Lys Ser Ser Pro Ile Phe Ala Phe Gln Glu Glu 55

Val Gln Lys Lys Val Ser Arg Phe Asn Leu Gln Met Asp Ile Ser Gly 70

Leu Ile Pro Gly Leu Val Ser Thr Phe Ile Leu Leu Ser Ile Ser Asp 85

His Tyr Gly Arg Lys Phe Pro Met Ile Leu Ser Ser Val Gly Ala Leu 105

Ala Thr Ser Val Trp Leu Cys Leu Leu Cys Tyr Phe Ala Leu Pro Phe 120

Gln Leu Leu Ile Ala Ser Thr Phe Ile Gly Ala Ile Cys Gly Asn Tyr 135

Thr Thr Phe Trp Gly Ala Cys Phe Ala Tyr Ile Val Asp Gln Cys Lys 145 150 155

Glu His Lys Gln Lys Thr Ile Arg Ile Ala Ile Ile Asp Phe Leu Leu 170 165

Gly Leu Val Thr Gly Leu Thr Gly Leu Ser Ser Gly Tyr Phe Ile Arg 180 185

Glu Leu Gly Phe Glu Trp Ser Phe Leu Ile Ile Ala Val Ser Leu Ala 205 195 200

Val Asn Leu Ile Tyr Ile Leu Phe Phe Leu Gly Asp Pro Val Lys Glu

210 215 220

Cys Ser Ser Gln Asn Val Thr Met Ser Cys Ser Glu Gly Phe Lys Asn 225 230 235 240

Leu Phe Tyr Arg Thr Tyr Met Leu Phe Lys Asn Ala Ser Gly Lys Arg 245 250 255

Arg Phe Leu Leu Cys Leu Leu Leu Phe Thr Val Ile Thr Tyr Phe Phe 260 265 270

Val Val Ile Gly Ile Ala Pro Ile Phe Ile Leu Tyr Glu Leu Asp Ser 275 280 285

Pro Leu Cys Trp Asn Glu Val Phe Ile Gly Tyr Gly Ser Ala Leu Gly 290 295 300

Ser Ala Ser Phe Leu Thr Ser Phe Leu Gly Ile Trp Leu Phe Ser Tyr 305 310 315 320

Cys Met Glu Asp Ile His Met Ala Phe Ile Gly Ile Phe Thr Thr Met 325 330 335

Thr Gly Met Ala Met Thr Ala Phe Ala Ser Thr Thr Leu Met Met Phe 340 345 350

Leu Ala Arg Val Pro Phe Leu Phe Thr Ile Val Pro Phe Ser Val Leu 355 360 365

Arg Ser Met Leu Ser Lys Val Val Arg Ser Thr Glu Gln Gly Thr Leu 370 375 380

Phe Ala Cys Ile Ala Phe Leu Glu Thr Leu Gly Gly Val Thr Ala Val 385 390 395 400

Ser Thr Phe Asn Gly Ile Tyr Ser Ala Thr Val Ala Trp Tyr Pro Gly 405 410 415

Phe Thr Phe Leu Leu Ser Ala Gly Leu Leu Leu Leu Pro Ala Ile Ser 420 425 430

Leu Cys Val Val Lys Cys Thr Ser Trp Asn Glu Gly Ser Tyr Glu Leu 435 440 445

Leu Ile Gln Glu Glu Ser Ser Glu Asp Ala Ser Asp Arg Ala Cys 450 455 460

<210> 105

<211> 575 <212> PRT <213> Homo sapiens

<400> 105

Met Ser Ala Ala Thr His Ser Pro Met Met Gln Val Ala Ser Gly Asn 5

Gly Asp Arg Asp Pro Leu Pro Pro Gly Trp Glu Ile Lys Ile Asp Pro 25

Gln Thr Gly Trp Pro Phe Phe Val Asp His Asn Ser Arg Thr Thr 40 35

Trp Asn Asp Pro Arg Val Pro Ser Glu Gly Pro Lys Glu Thr Pro Ser 50

Ser Ala Asn Gly Pro Ser Arg Glu Gly Ser Arg Leu Pro Pro Ala Arg 70

Glu Gly His Pro Val Tyr Pro Gln Leu Arg Pro Gly Tyr Ile Pro Ile 85

Pro Val Leu His Glu Gly Ala Glu Asn Arg Gln Val His Pro Phe His 100

Val Tyr Pro Gln Pro Gly Met Gln Arg Phe Arg Thr Glu Ala Ala Ala 120 115

Ala Ala Pro Gln Arg Ser Gln Ser Pro Leu Arg Gly Met Pro Glu Thr 130

Thr Gln Pro Asp Lys Gln Cys Gly Gln Val Ala Ala Ala Ala Ala Ala 155 145

Gln Pro Pro Ala Ser His Gly Pro Glu Arg Ser Gln Ser Pro Ala Ala 170 165

Ser Asp Cys Ser Ser Ser Ser Ser Ser Ala Ser Leu Pro Ser Ser Gly 185 180

Arg Ser Ser Leu Gly Ser His Gln Leu Pro Arg Gly Tyr Ile Ser Ile 205 200

Pro Val Ile His Glu Gln Asn Val Thr Arg Pro Ala Ala Gln Pro Ser 220 215

Phe His Gln Ala Gln Lys Thr His Tyr Pro Ala Gln Gln Gly Glu Tyr 225 230 235 240

- Gln Thr His Gln Pro Val Tyr His Lys Ile Gln Gly Asp Asp Trp Glu 245 250 255
- Pro Arg Pro Leu Arg Ala Ala Ser Pro Phe Arg Ser Ser Val Gln Gly 260 265 270
- Ala Ser Ser Arg Glu Gly Ser Pro Ala Arg Ser Ser Thr Pro Leu His 275 280 285
- Ser Pro Ser Pro Ile Arg Val His Thr Val Val Asp Arg Pro Gln Gln 290 295 300
- Pro Met Thr His Arg Glu Thr Ala Pro Val Ser Gln Pro Glu Asn Lys 305 310 315 320
- Pro Glu Ser Lys Pro Gly Pro Val Gly Pro Glu Leu Pro Pro Gly His 325 330 335
- Ile Pro Ile Gln Val Ile Arg Lys Glu Val Asp Ser Lys Pro Val Ser 340 345 350
- Gln Lys Pro Pro Pro Pro Ser Glu Lys Val Glu Val Lys Val Pro Pro 355 360 365
- Ala Pro Val Pro Cys Pro Pro Pro Ser Pro Gly Pro Ser Ala Val Pro 370 375 380
- Ser Ser Pro Lys Ser Val Ala Thr Glu Glu Arg Ala Ala Pro Ser Thr 385 390 395 400
- Ala Pro Ala Glu Ala Thr Pro Pro Lys Pro Gly Glu Ala Glu Ala Pro 405 410 415
- Pro Lys His Pro Gly Val Leu Lys Val Glu Ala Ile Leu Glu Lys Val 420 425 430
- Gln Gly Leu Glu Gln Ala Val Asp Asn Phe Glu Gly Lys Lys Thr Asp 435 440 445
- Lys Lys Tyr Leu Met Ile Glu Glu Tyr Leu Thr Lys Glu Leu Leu Ala 450 455 460

Leu Asp Ser Val Asp Pro Glu Gly Arg Ala Asp Val Arg Gln Ala Arg 465 470 475 480

Arg Asp Gly Val Arg Lys Val Gln Thr Ile Leu Glu Lys Leu Glu Gln 485 490 495

Lys Ala Ile Asp Val Pro Gly Gln Val Gln Val Tyr Glu Leu Gln Pro 500 505 510

Ser Asn Leu Glu Ala Asp Gln Pro Leu Gln Ala Ile Met Glu Met Gly 515 520 525

Ala Val Ala Ala Asp Lys Gly Lys Lys Asn Ala Gly Asn Ala Glu Asp 530 535 540

Pro His Thr Glu Thr Gln Gln Pro Glu Ala Thr Ala Ala Ala Thr Ser 545 550 555 560

Asn Pro Ser Ser Met Thr Asp Thr Pro Gly Asn Pro Ala Ala Pro 565 570 575

<210> 106

<211> 457

<212> PRT

<213> Homo sapiens

<400> 106

Met Ser Ala Leu Arg Arg Ser Gly Tyr Gly Pro Ser Asp Gly Pro Ser 1 5 10 15

Tyr Gly Arg Tyr Tyr Gly Pro Gly Gly Gly Asp Val Pro Val His Pro 20 25 30

Pro Pro Pro Leu Tyr Pro Leu Arg Pro Glu Pro Pro Gln Pro Pro Ile 35 40 45

Ser Trp Arg Val Arg Gly Gly Gly Pro Ala Glu Thr Thr Trp Leu Gly 50 55 60

Glu Gly Gly Gly Gly Asp Gly Tyr Tyr Pro Ser Gly Gly Ala Trp Pro 65 70 75 80

Glu Pro Gly Arg Ala Gly Gly Ser His Gln Glu Gln Pro Pro Tyr Pro 85 90 95

Ser Tyr Asn Ser Asn Tyr Trp Asn Ser Thr Ala Arg Ser Arg Ala Pro 100 105 110

Tyr Pro Ser Thr Tyr Pro Val Arg Pro Glu Leu Gln Gly Gln Ser Leu 115 120 125

- Asn Ser Tyr Thr Asn Gly Ala Tyr Gly Pro Thr Tyr Pro Pro Gly Pro 130 135 140
- Gly Ala Asn Thr Ala Ser Tyr Ser Gly Ala Tyr Tyr Ala Pro Gly Tyr 145 150 155 160
- Thr Gln Thr Ser Tyr Ser Thr Glu Val Pro Ser Thr Tyr Arg Ser Ser 165 170 175
- Gly Asn Ser Pro Thr Pro Val Ser Arg Trp Ile Tyr Pro Gln Gln Asp 180 185 190
- Cys Gln Thr Glu Ala Pro Pro Leu Arg Gly Gln Val Pro Gly Tyr Pro 195 200 205
- Pro Ser Gln Asn Pro Gly Met Thr Leu Pro His Tyr Pro Tyr Gly Asp 210 215 220
- Gly Asn Arg Ser Val Pro Gln Ser Gly Pro Thr Val Arg Pro Gln Glu 225 230 235 240
- Asp Ala Trp Ala Ser Pro Gly Ala Tyr Gly Met Gly Gly Arg Tyr Pro 245 250 255
- Trp Pro Ser Ser Ala Pro Ser Ala Pro Pro Gly Asn Leu Tyr Met Thr
  260 265 270
- Glu Ser Thr Ser Pro Trp Pro Ser Ser Gly Ser Pro Gln Ser Pro Pro 275 280 285
- Ser Pro Pro Val Gln Gln Pro Lys Asp Ser Ser Tyr Pro Tyr Ser Gln 290 295 300
- Ser Asp Gln Ser Met Asn Arg His Asn Phe Pro Cys Ser Val His Gln 305 310 315 320
- Tyr Glu Ser Ser Gly Thr Val Asn Asn Asp Asp Ser Asp Leu Leu Asp 325 330 335
- Ser Gln Val Gln Tyr Ser Ala Glu Pro Gln Leu Tyr Gly Asn Ala Thr 340 345 350
- Ser Asp His Pro Asn Asn Gln Asp Gln Ser Ser Ser Leu Pro Glu Glu

> 360 365 355

Cys Val Pro Ser Asp Glu Ser Thr Pro Pro Ser Ile Lys Lys Ile Ile 375

His Val Leu Glu Lys Val Gln Tyr Leu Glu Gln Glu Val Glu Glu Phe 390

Val Gly Lys Lys Thr Asp Lys Ala Tyr Trp Leu Leu Glu Glu Met Leu 410

Thr Lys Glu Leu Leu Glu Leu Asp Ser Val Glu Thr Gly Gly Gln Asp 425

Ser Val Arg Gln Ala Arg Lys Glu Ala Val Cys Lys Ile Gln Ala Ile

Leu Glu Lys Leu Glu Lys Lys Gly Leu 455

<210> 107 <211> 373 <212> PRT

<213> Homo sapiens

1

<400> 107

Met Ala Gln Gly Arg Glu Arg Asp Glu Gly Pro His Ser Ala Gly Gly

Ala Ser Leu Ser Val Arg Trp Val Gln Gly Phe Pro Lys Gln Asn Val

His Phe Val Asn Asp Asn Thr Ile Cys Tyr Pro Cys Gly Asn Tyr Val

Ile Phe Ile Asn Ile Glu Thr Lys Lys Lys Thr Val Leu Gln Cys Ser 55

Asn Gly Ile Val Gly Val Met Ala Thr Asn Ile Pro Cys Glu Val Val 70

Ala Phe Ser Asp Arg Lys Leu Lys Pro Leu Ile Tyr Val Tyr Ser Phe 85

Pro Gly Leu Thr Arg Arg Thr Lys Leu Lys Gly Asn Ile Leu Leu Asp 100 105

Tyr Thr Leu Leu Ser Phe Ser Tyr Cys Gly Thr Tyr Leu Ala Ser Tyr 115 120 125

- Ser Ser Leu Pro Glu Phe Glu Leu Ala Leu Trp Asn Trp Glu Ser Ser 130 135 140
- Ile Ile Leu Cys Lys Lys Ser Gln Pro Gly Met Asp Val Asn Glu Met 145 150 150 160
- Ser Phe Asn Pro Met Asn Trp Arg Gln Leu Cys Leu Ser Ser Pro Ser 165 170 175
- Thr Val Ser Val Trp Thr Ile Glu Arg Ser Asn Gln Glu His Cys Phe 180 185 190
- Arg Ala Arg Ser Val Lys Leu Pro Leu Glu Asp Gly Ser Phe Phe Asn 195 200 205
- Glu Thr Asp Val Val Phe Pro Gln Ser Leu Pro Lys Asp Leu Ile Tyr 210 215 220
- Gly Pro Val Leu Pro Leu Ser Ala Ile Ala Gly Leu Val Gly Lys Glu 225 230 235 240
- Ala Glu Thr Phe Arg Pro Lys Asp Asp Leu Tyr Pro Leu Leu His Pro 245 250 255
- Thr Met His Cys Trp Thr Pro Thr Ser Asp Leu Tyr Ile Gly Cys Glu 260 265 270
- Glu Gly His Leu Leu Met Ile Asn Gly Asp Thr Leu Gln Val Thr Val 275 280 285
- Leu Asn Lys Ile Glu Glu Glu Ser Pro Leu Glu Asp Arg Arg Asn Phe 290 295 300
- Ile Ser Pro Val Thr Leu Val Tyr Gln Lys Glu Gly Val Leu Ala Ser 305 310 315 320
- Gly Ile Asp Gly Phe Val Tyr Ser Phe Ile Ile Lys Asp Arg Ser Tyr 325 330 335
- Met Ile Glu Asp Phe Leu Glu Ile Glu Arg Pro Val Glu His Met Thr 340 345 350
- Phe Ser Pro Asn Tyr Thr Val Leu Leu Ile Gln Thr Asp Lys Val Cys 355 360 365

Trp Met Val Ile Ser 370

<210> 108

<211> 401

<212> PRT

<213> Homo sapiens

<400> 108

Met Lys Leu Ser Asp Leu His His Val Thr Leu Phe Gln Glu Ile Leu 1 5 10 15

Leu Leu Lys Asn Phe Glu Lys Gln Glu Asn Ile Leu Gln Glu Arg Val 20 25 30

Asn Ser Leu Asp Lys Glu Glu Gln Tyr Met Gln Trp Lys Ile Asn Glu 35 40 45

Thr Leu Lys Glu Met Glu Glu Lys Lys Asn Glu Ile Thr Lys Leu Gln 50 55 60

Glu Gln Glu Lys Ala Leu Tyr Ala Gly Phe Gln Ala Ala Ile Gly Glu 65 70 75 80

Asn Asn Lys Phe Ala Asn Phe Leu Met Lys Val Leu Lys Lys Arg Ile 85 90 95

Lys Arg Val Lys Lys Lys Glu Val Glu Gly Asp Ala Asp Glu Asp Glu
100 105 110

Glu Ser Glu Glu Ser Ser Glu Glu Glu Ser Ser Leu Glu Ser Asp Glu 115 120 125

Asp Glu Ser Glu Ser Glu Asp Glu Val Phe Asp Asp Ser Ile Cys Pro 130 135 140

Thr Asn Cys Asp Val Ala Leu Phe Glu Leu Ala Leu His Leu Arg Glu 145 150 155 160

Lys Arg Leu Asp Ile Glu Glu Ala Leu Val Glu Glu Lys Lys Ile Val 165 170 175

Asp Asn Leu Lys Lys Glu Tyr Asp Thr Leu Ser Lys Lys Val Lys Ile 180 185 190

Val Ala Thr Asn Leu Asn Ala Ala Glu Glu Ala Leu Glu Ala Tyr Gln

195 200 205

Arg Glu Lys Gln Gln Arg Leu Asn Glu Leu Leu Val Val Ile Pro Leu 210 215 220

Lys Leu His Gln Ile Glu Tyr Val Val Phe Gly Glu Ile Pro Ser Asp 225 230 235 240

Leu Ser Gly Thr Leu Val Phe Ser Asn His Ala Leu Arg Arg Leu Gln 245 250 255

Glu Arg Ile Arg Glu Leu Gln Glu Glu Asn Ser Lys Gln Gln Lys Leu 260 265 270

Asn Lys Glu Trp Arg Glu Arg Arg Lys Gln Leu Ile Arg Glu Lys Arg 275 280 285

Glu Met Thr Lys Thr Ile His Lys Met Glu Glu Thr Val Arg Gln Leu 290 295 300

Met Ile Ser Lys Phe Gly Arg Val Val Asn Leu Glu Ala Leu Gln Thr 305 310 315 320

Leu Ser Val Asn Thr Thr Leu Glu Glu Leu Lys Ile Arg Lys Leu Arg 325 330 335

Lys Glu Leu Ala Asn Ala Lys Glu Met Lys Met Trp Glu Glu Lys Ile 340 345 350

Ala Gln Met Arg Trp Glu Leu Met Met Lys Thr Lys Glu His Thr Arg 355 360 365

Lys Leu Tyr Gln Met Asn Asp Leu Cys Ile Glu Lys Lys Lys Leu Asp 370 375 380

Ser Arg Leu Asn Thr Leu Gln Asn Gln Gln Asn Pro Gly Asn Gly Leu 385 390 395 400

Ser

<210> 109

<211> 1674

<212> PRT

<213> Homo sapiens

<400> 109

Met Glu Asp Ala Ser Glu Ser Ser Arg Gly Val Ala Pro Leu Ile Asn 1 5 10 15

- Asn Val Val Leu Pro Gly Ser Pro Leu Ser Leu Pro Val Ser Val Thr 20 25 30
- Gly Cys Lys Ser His Arg Val Ala Asn Lys Lys Val Glu Ala Arg Ser 35 40 45
- Glu Lys Leu Leu Pro Thr Ala Leu Pro Pro Ser Glu Pro Lys Val Asp 50 55 60
- Gln Lys Leu Pro Arg Ser Ser Glu Arg Arg Gly Ser Gly Gly Gly Thr 65 70 75 80
- Gln Phe Pro Ala Arg Ser Arg Ala Val Ala Ala Gly Glu Ala Ala Ala 85 90 95
- Arg Gly Ala Ala Gly Pro Glu Arg Gly Ser Pro Leu Gly Arg Arg Val 100 105 110
- Ser Pro Arg Cys Leu Cys Ser Gly Glu Gly Gly Gln Val Ala Val Gly
  115 120 125
- Val Ile Ala Gly Lys Arg Gly Arg Arg Gly Arg Asp Gly Ser Arg Arg 130 135 140
- Ala Pro Gly Gly Arg Glu Met Pro Leu Leu His Arg Lys Pro Phe Val 145 150 155 160
- Arg Gln Lys Pro Pro Ala Asp Leu Arg Pro Asp Glu Glu Val Phe Tyr 165 170 175
- Cys Lys Val Thr Asn Glu Ile Phe Arg His Tyr Asp Asp Phe Phe Glu 180 185 190
- Arg Thr Ile Leu Cys Asn Ser Leu Val Trp Ser Cys Ala Val Thr Gly
  195 200 205
- Arg Pro Gly Leu Thr Tyr Gln Glu Ala Leu Glu Ser Glu Lys Lys Ala 210 215 220
- Arg Gln Asn Leu Gln Ser Phe Pro Glu Pro Leu Ile Ile Pro Val Leu 225 230 235 240
- Tyr Leu Thr Ser Leu Thr His Arg Ser Arg Leu His Glu Ile Cys Asp 245 250 255

Asp Ile Phe Ala Tyr Val Lys Asp Arg Tyr Phe Val Glu Glu Thr Val 260 265 270

- Glu Val Ile Arg Asn Asn Gly Ala Arg Leu Gln Cys Thr Ile Leu Glu 275 280 285
- Val Leu Pro Pro Ser His Gln Asn Gly Phe Ala Asn Gly His Val Asn 290 295 300
- Ser Val Asp Gly Glu Thr Ile Ile Ile Ser Asp Ser Asp Ser Glu 305 310 315 320
- Thr Gln Ser Cys Ser Phe Gln Asn Gly Lys Lys Lys Asp Ala Ile Asp 325 330 335
- Pro Leu Leu Phe Lys Tyr Lys Val Gln Pro Thr Lys Lys Glu Leu His 340 345 350
- Glu Ser Ala Ile Val Lys Ala Thr Gln Ile Ser Arg Arg Lys His Leu 355 360 365
- Phe Ser Arg Asp Lys Leu Lys Leu Phe Leu Lys Gln His Cys Glu Pro 370 375 380
- Gln Glu Gly Val Ile Lys Ile Lys Ala Ser Ser Leu Ser Thr Tyr Lys 385 390 395 400
- Ile Ala Glu Gln Asp Phe Ser Tyr Phe Phe Pro Asp Asp Pro Pro Thr 405 410 415
- Phe Ile Phe Ser Pro Ala Asn Arg Arg Gly Arg Pro Pro Lys Arg 420 425 430
- Ile His Ile Ser Gln Glu Asp Asn Val Ala Asn Lys Gln Thr Leu Ala 435 440 445
- Ser Tyr Arg Ser Lys Ala Thr Lys Glu Arg Asp Lys Leu Leu Lys Gln 450 455 460
- Glu Glu Met Lys Ser Leu Ala Phe Glu Lys Ala Lys Leu Lys Arg Glu 465 470 475 480
- Lys Ala Asp Ala Leu Glu Ala Lys Lys Glu Lys Glu Asp Lys Glu 485 490 495

Lys Lys Arg Glu Glu Leu Lys Lys Ile Val Glu Glu Glu Arg Leu Lys 500 505 510

- Lys Lys Glu Glu Lys Glu Arg Leu Lys Val Glu Arg Glu Lys Glu Arg 515 520 525
- Glu Lys Leu Arg Glu Glu Lys Arg Lys Tyr Val Glu Tyr Leu Lys Gln 530 540
- Trp Ser Lys Pro Arg Glu Asp Met Glu Cys Asp Asp Leu Lys Glu Leu 545 550 555 560
- Pro Glu Pro Thr Pro Val Lys Thr Arg Leu Pro Pro Glu Ile Phe Gly 565 570 575
- Asp Ala Leu Met Val Leu Glu Phe Leu Asn Ala Phe Gly Glu Leu Phe 580 585 590
- Asp Leu Gln Asp Glu Phe Pro Asp Gly Val Thr Leu Glu Val Leu Glu 595 600 605
- Glu Ala Leu Val Gly Asn Asp Ser Glu Gly Pro Leu Cys Glu Leu Leu 610 615 620
- Phe Phe Phe Leu Thr Ala Ile Phe Gln Ala Ile Ala Glu Glu Glu 625 635 640
- Glu Val Ala Lys Glu Gln Leu Thr Asp Ala Asp Thr Lys Gly Cys Ser 645 650 655
- Leu Lys Ser Leu Asp Leu Asp Ser Cys Thr Leu Ser Glu Ile Leu Arg 660 665 670
- Leu His Ile Leu Ala Ser Gly Ala Asp Val Thr Ser Ala Asn Ala Lys 675 680 685
- Tyr Arg Tyr Gln Lys Arg Gly Gly Phe Asp Ala Thr Asp Asp Ala Cys 690 695 700
- Met Glu Leu Arg Leu Ser Asn Pro Ser Leu Val Lys Lys Leu Ser Ser 705 710 715 720
- Thr Ser Val Tyr Asp Leu Thr Pro Gly Glu Lys Met Lys Ile Leu His 725 730 735
- Ala Leu Cys Gly Lys Leu Leu Thr Leu Val Ser Thr Arg Asp Phe Ile 740 745 750

Glu Asp Tyr Val Asp Ile Leu Arg Gln Ala Lys Gln Glu Phe Arg Glu 755 760 765

- Leu Lys Ala Glu Gln His Arg Lys Glu Arg Glu Glu Ala Ala Arg 770 775 780
- Ile Arg Lys Arg Lys Glu Glu Lys Leu Lys Glu Gln Glu Gln Lys Met 785 790 795 800
- Lys Glu Lys Gln Glu Lys Leu Lys Glu Asp Glu Gln Arg Asn Ser Thr 805 810 815
- Ala Asp Ile Ser Ile Gly Glu Glu Glu Arg Glu Asp Phe Asp Thr Ser 820 825 830
- Ile Glu Ser Lys Asp Thr Glu Gln Lys Glu Leu Asp Gln Asp Met Phe 835 840 845
- Thr Glu Asp Glu Asp Asp Pro Gly Ser His Lys Arg Gly Arg Arg Gly 850 855 860
- Lys Arg Gly Gln Asn Gly Phe Lys Glu Phe Thr Arg Gln Glu Gln Ile 865 870 875 880
- Asn Cys Val Thr Arg Glu Leu Leu Thr Ala Asp Glu Glu Glu Ala Leu 885 890 895
- Lys Gln Glu His Gln Arg Lys Glu Lys Glu Leu Leu Glu Lys Ile Gln 900 905 910
- Ser Ala Ile Ala Cys Thr Asn Ile Phe Pro Leu Gly Arg Asp Arg Met 915 920 925
- Tyr Arg Arg Tyr Trp Ile Phe Pro Ser Ile Pro Gly Leu Phe Ile Glu 930 935 940
- Glu Asp Tyr Ser Gly Leu Thr Glu Asp Met Leu Leu Pro Arg Pro Ser 945 950 955 960
- Ser Phe Gln Asn Val Gln Ser Gln Asp Pro Gln Val Ser Thr Lys 965 970 975
- Thr Gly Glu Pro Leu Met Ser Glu Ser Thr Ser Asn Ile Asp Gln Gly 980 985 990

Pro Arg Asp His Ser Val Gln Leu Pro Lys Pro Val His Lys Pro Asn 995 1000 1005

- Arg Trp Cys Phe Tyr Ser Ser Cys Glu Gln Leu Asp Gln Leu Ile 1010 1015 1020
- Glu Ala Leu Asn Ser Arg Gly His Arg Glu Ser Ala Leu Lys Glu 1025 1030 1035
- Thr Leu Leu Gln Glu Lys Ser Arg Ile Cys Ala Gln Leu Ala Arg 1040 1045 1050
- Phe Ser Glu Glu Lys Phe His Phe Ser Asp Lys Pro Gln Pro Asp 1055 1060 1065
- Ser Lys Pro Thr Tyr Ser Arg Gly Arg Ser Ser Asn Ala Tyr Asp 1070 1075 1080
- Pro Ser Gln Met Cys Ala Glu Lys Gln Leu Glu Leu Arg Leu Arg 1085 1090 1095
- Asp Phe Leu Leu Asp Ile Glu Asp Arg Ile Tyr Gln Gly Thr Leu 1100 1105 1110
- Gly Ala Ile Lys Val Thr Asp Arg His Ile Trp Arg Ser Ala Leu 1115 1120 1125
- Glu Ser Gly Arg Tyr Glu Leu Leu Ser Glu Glu Asn Lys Glu Asn 1130 1135 1140
- Gly Ile Ile Lys Thr Val Asn Glu Asp Val Glu Glu Met Glu Ile 1145 1150 1155
- Asp Glu Gln Thr Lys Val Ile Val Lys Asp Arg Leu Leu Gly Ile 1160 1165 1170
- Lys Thr Glu Thr Pro Ser Thr Val Ser Thr Asn Ala Ser Thr Pro 1175 1180 1185
- Gln Ser Val Ser Ser Val Val His Tyr Leu Ala Met Ala Leu Phe 1190 1195 1200
- Gln Ile Glu Gln Gly Ile Glu Arg Arg Phe Leu Lys Ala Pro Leu 1205 1210 1215
- Asp Ala Ser Asp Ser Gly Arg Ser Tyr Lys Thr Val Leu Asp Arg 1220 1225 1230

Trp	Arg 1235		Ser	Leu	Leu	Ser 1240		Ala	Ser	Leu	Ser 1245		Val	Phe
Leu	His 1250		Ser	Thr	Leu	Asp 1255		Ser	Val	Ile	Trp 1260		Lys	Ser
Ile	Leu 1265		Ala	Arg	Cys	Lys 1270		Cys	Arg	Lys ·	Lys 1275	_	Asp	Ala
Glu	Asn 1280		Val	Leu	Cys	Asp 1285		Суз	Asp	Arg	Gly 1290		His	Thr
Tyr	Cys 1295		Arg	Pro	Lys	Leu 1300		Thr	Val	Pro	Glu 1305	Gly	Asp	Trp
Phe	Cys 1310	Pro	Glu	Cys	Arg	Pro 1315		Gln	Arg	Cys	Arg 1320		Leu	Ser
Phe	Arg 1325	Gln	Arg	Pro	Ser	Leu 1330	Glu	Ser	Asp	Glu	Asp 1335	Val	Glu	Asp
Ser	Met 1340		Gly	Glu	Asp	Asp 1345	Glu	Val	Asp	Gly	Asp 1350	Glu	Glu	Glu
Gly	Gln 1355	Ser	Glu	Glu	Glu	Glu 1360	Tyr	Glu	Val	Glu	Gln 1365	Asp	Glu	Asp
Asp	Ser 1370	Gln	Glu	Glu	Glu	Glu 1375	Val	Ser	Leu	Pro	Lys 1380	Arg	Gly	Arg
Pro	Gln 1385	Val	Arg	Leu	Pro	Val 1390	Lys	Thr	Arg	Gly	Lys 1395	Leu	Ser	Ser
Ser	Phe 1400	Ser	Ser	Arg	Gly	Gln 1405	Gln	Gln	Glu	Pro	Gly 1410	Arg	Tyr	Pro
Ser	Arg 1415 <sub>,</sub>	Ser	Gln	Gln	Ser	Thr 1420	Pro	Lys	Thr	Thr	Val 1425	Ser	Ser	Lys
Thr	Gly 1430	Arg	Ser	Leu	Arg	Lys 1435	Ile	Asn	Ser	Ala	Pro 1440	Pro	Thr	Glu
Thr	Lys 1445	Ser	Leu	Arg	Ile	Ala 1450	Ser	Arg	Ser	Thr	Arg 1455	His	Ser	His

Gly Pro Leu Gln Ala Asp Val Phe Val Glu Leu Leu Ser Pro Arg 1460 1465 1470

- Arg Lys Arg Arg Gly Arg Lys Ser Ala Asn Asn Thr Pro Glu Asn 1475 1480 1485
- Ser Pro Asn Phe Pro Asn Phe Arg Val Ile Ala Thr Lys Ser Ser 1490 1495 1500
- Glu Gln Ser Arg Ser Val Asn Ile Ala Ser Lys Leu Ser Leu Gln 1505 1510 1515
- Glu Ser Glu Ser Lys Arg Arg Cys Arg Lys Arg Gln Ser Pro Glu 1520 1530
- Pro Ser Pro Val Thr Leu Gly Arg Arg Ser Ser Gly Arg Gln Gly 1535 1540 1545
- Gly Val His Glu Leu Ser Ala Phe Glu Gln Leu Val Val Glu Leu 1550 1560
- Val Arg His Asp Asp Ser Trp Pro Phe Leu Lys Leu Val Ser Lys 1565 1570 1575
- Ile Gln Val Pro Asp Tyr Tyr Asp Ile Ile Lys Lys Pro Ile Ala 1580 1585 1590
- Leu Asn Ile Ile Arg Glu Lys Val Asn Lys Cys Glu Tyr Lys Leu 1595 1600 1605
- Ala Ser Glu Phe Ile Asp Asp Ile Glu Leu Met Phe Ser Asn Cys 1610 1615 1620
- Phe Glu Tyr Asn Pro Arg Asn Thr Ser Glu Ala Lys Ala Gly Thr 1625 1630 1635
- Arg Leu Gln Ala Phe Phe His Ile Gln Ala Gln Lys Leu Gly Leu 1640 1650
- His Val Thr Pro Ser Asn Val Asp Gln Val Ser Thr Pro Pro Ala 1655 1660 1665
- Ala Lys Lys Ser Arg Ile 1670

<210> 110 <211> 1483

<212> PRT

<213> Homo sapiens

<400> 110

Met Ala Pro Leu Leu Gly Arg Lys Pro Phe Pro Leu Val Lys Pro Leu 1 5 10 15

Pro Gly Glu Glu Pro Leu Phe Thr Ile Pro His Thr Gln Glu Ala Phe 20 25 30

Arg Thr Arg Glu Glu Tyr Glu Ala Arg Leu Glu Arg Tyr Ser Glu Arg 35 40 45

Ile Trp Thr Cys Lys Ser Thr Gly Ser Ser Gln Leu Thr His Lys Glu 50 55 60

Ala Trp Glu Glu Glu Glu Val Ala Glu Leu Leu Lys Glu Glu Phe 65 70 75 80

Pro Ala Trp Tyr Glu Lys Leu Val Leu Glu Met Val His His Asn Thr 85 90 95

Ala Ser Leu Glu Lys Leu Val Asp Thr Ala Trp Leu Glu Ile Met Thr 100 105 110

Lys Tyr Ala Val Gly Glu Glu Cys Asp Phe Glu Val Gly Lys Glu Lys 115 120 125

Met Leu Lys Val Lys Ile Val Lys Ile His Pro Leu Glu Lys Val Asp 130 135 140

Glu Glu Ala Thr Glu Lys Lys Ser Asp Gly Ala Cys Asp Ser Pro Ser 145 150 155 160

Ser Asp Lys Glu Asn Ser Ser Gln Ile Ala Gln Asp His Gln Lys Lys 165 170 175

Glu Thr Val Val Lys Glu Asp Glu Gly Arg Arg Glu Ser Ile Asn Asp 180 185 190

Arg Ala Arg Arg Ser Pro Arg Lys Leu Pro Thr Ser Leu Lys Lys Gly 195 200 205

Glu Arg Lys Trp Ala Pro Pro Lys Phe Leu Pro His Lys Tyr Asp Val 210 215 220

Lys Leu Gln Asn Glu Asp Lys Ile Ile Ser Asn Val Pro Ala Asp Ser

225 230 235 240

Leu Ile Arg Thr Glu Arg Pro Pro Asn Lys Glu Ile Val Arg Tyr Phe 245 250. 255

Ile Arg His Asn Ala Leu Arg Ala Gly Thr Gly Glu Asn Ala Pro Trp 260 265 270

Val Val Glu Asp Glu Leu Val Lys Lys Tyr Ser Leu Pro Ser Lys Phe 275 280 285

Ser Asp Phe Leu Leu Asp Pro Tyr Lys Tyr Met Thr Leu Asn Pro Ser 290 295 300

Thr Lys Arg Lys Asn Thr Gly Ser Pro Asp Arg Lys Pro Ser Lys Lys 305 310 315 320

Ser Lys Thr Asp Asn Ser Ser Leu Ser Ser Pro Leu Asn Pro Lys Leu 325 330 335

Trp Cys His Val His Leu Lys Lys Ser Leu Ser Gly Ser Pro Leu Lys 340 345 350

Val Lys Asn Ser Lys Asn Ser Lys Ser Pro Glu Glu His Leu Glu Glu 355 360 365

Met Met Lys Met Met Ser Pro Asn Lys Leu His Thr Asn Phe His Ile 370  $\phantom{\bigg|}375\phantom{\bigg|}380\phantom{\bigg|}$ 

Pro Lys Lys Gly Pro Pro Ala Lys Lys Pro Gly Lys His Ser Asp Lys 385 390 395 400

Pro Leu Lys Ala Lys Gly Arg Ser Lys Gly Ile Leu Asn Gly Gln Lys 405 410 415

Ser Thr Gly Asn Ser Lys Ser Pro Lys Lys Gly Leu Lys Thr Pro Lys 420 425 430

Thr Lys Met Lys Gln Met Thr Leu Leu Asp Met Ala Lys Gly Thr Gln 435 440 445

Lys Met Thr Arg Ala Pro Arg Asn Ser Gly Gly Thr Pro Arg Thr Ser 450 455 460

Ser Lys Pro His Lys His Leu Pro Pro Ala Ala Leu His Leu Ile Ala 465 470 475 480

Tyr Tyr Lys Glu Asn Lys Asp Arg Glu Asp Lys Arg Ser Ala Leu Ser 485 490 495

- Cys Val Ile Ser Lys Thr Ala Arg Leu Leu Ser Ser Glu Asp Arg Ala 500 505 510
- Arg Leu Pro Glu Glu Leu Arg Ser Leu Val Gln Lys Arg Tyr Glu Leu 515 520 525
- Leu Glu His Lys Lys Arg Trp Ala Ser Met Ser Glu Glu Gln Arg Lys 530 540
- Glu Tyr Leu Lys Lys Lys Arg Glu Glu Leu Lys Lys Lys Leu Lys Glu 545 550 555 560
- Lys Ala Lys Glu Arg Arg Glu Lys Glu Met Leu Glu Arg Leu Glu Lys 565 570 575
- Gln Lys Arg Tyr Glu Asp Gln Glu Leu Thr Gly Lys Asn Leu Pro Ala 580 585 590
- Phe Arg Leu Val Asp Thr Pro Glu Gly Leu Pro Asn Thr Leu Phe Gly 595 600 605
- Asp Val Ala Met Val Val Glu Phe Leu Ser Cys Tyr Ser Gly Leu Leu 610 615 620
- Leu Pro Asp Ala Gln Tyr Pro Ile Thr Ala Val Ser Leu Met Glu Ala 625 630 635 640
- Leu Ser Ala Asp Lys Gly Gly Phe Leu Tyr Leu Asn Arg Val Leu Val 645 650 655
- Ile Leu Leu Gln Thr Leu Leu Gln Asp Glu Ile Ala Glu Asp Tyr Gly 660 665 670
- Glu Leu Gly Met Lys Leu Ser Glu Ile Pro Leu Thr Leu His Ser Val 675 680 685
- Ser Glu Leu Val Arg Leu Cys Leu Arg Arg Ser Asp Val Gln Glu Glu 690 695 700
- Ser Glu Gly Ser Asp Thr Asp Asp Asn Lys Asp Ser Ala Ala Phe Glu 705 710 715 720
- Asp Asn Glu Val Gln Asp Glu Phe Leu Glu Lys Leu Glu Thr Ser Glu

725 730 735

Phe Phe Glu Leu Thr Ser Glu Glu Lys Leu Gln Ile Leu Thr Ala Leu 740 745 750

Cys His Arg Ile Leu Met Thr Tyr Ser Val Gln Asp His Met Glu Thr 755 760 765

Arg Gln Gln Met Ser Ala Glu Leu Trp Lys Glu Arg Leu Ala Val Leu 770 780

Lys Glu Glu Asn Asp Lys Lys Arg Ala Glu Lys Gln Lys Arg Lys Glu 785 790 795 800

Met Glu Ala Lys Asn Lys Glu Asn Gly Lys Val Glu Asn Gly Leu Gly 805 810 815

Lys Thr Asp Arg Lys Lys Glu Ile Val Lys Phe Glu Pro Gln Val Asp 820 825 830

Thr Glu Ala Glu Asp Met Ile Ser Ala Val Lys Ser Arg Arg Leu Leu 835 840 845

Ala Ile Gln Ala Lys Lys Glu Arg Glu Ile Gln Glu Arg Glu Met Lys 850 855 860

Val Lys Leu Glu Arg Gln Ala Glu Glu Glu Arg Ile Arg Lys His Lys 865 870 875 886

Ala Ala Ala Glu Lys Ala Phe Gln Glu Gly Ile Ala Lys Ala Lys Leu 885 890 895

Val Met Arg Arg Thr Pro Ile Gly Thr Asp Arg Asn His Asn Arg Tyr 900 905 910

Trp Leu Phe Ser Asp Glu Val Pro Gly Leu Phe Ile Glu Lys Gly Trp 915 920 925

Val His Asp Ser Ile Asp Tyr Arg Phe Asn His His Cys Lys Asp His 930 935 940

Thr Val Ser Gly Asp Glu Asp Tyr Cys Pro Arg Ser Lys Lys Ala Asn 945 950 955 960

Leu Gly Lys Asn Ala Ser Met Asn Thr Gln His Gly Thr Ala Thr Glu 965 970 975

Val Ala Val Glu Thr Thr Thr Pro Lys Gln Gly Gln Asn Leu Trp Phe 980 985 990

- Leu Cys Asp Ser Gln Lys Glu Leu Asp Glu Leu Leu Asn Cys Leu His 995 1000 1005
- Pro Gln Gly Ile Arg Glu Ser Gln Leu Lys Glu Arg Leu Glu Lys 1010 1015 1020
- Arg Tyr Gln Asp Ile Ile His Ser Ile His Leu Ala Arg Lys Pro 1025 1030 1035
- Asn Leu Gly Leu Lys Ser Cys Asp Gly Asn Gln Glu Leu Leu Asn 1040 1045 1050
- Phe Leu Arg Ser Asp Leu Ile Glu Val Ala Thr Arg Leu Gln Lys 1055 1060 1065
- Gly Gly Leu Gly Tyr Val Glu Glu Thr Ser Glu Phe Glu Ala Arg 1070 1075 1080
- Val Ile Ser Leu Glu Lys Leu Lys Asp Phe Gly Glu Cys Val Ile 1085 1090 1095
- Ala Leu Gln Ala Ser Val Ile Lys Lys Phe Leu Gln Gly Phe Met 1100 1105 1110
- Ala Pro Lys Gln Lys Arg Arg Lys Leu Gln Ser Glu Asp Ser Ala 1115 1120 1125
- Lys Thr Glu Glu Val Asp Glu Glu Lys Lys Met Val Glu Glu Ala 1130 1135 1140
- Lys Val Ala Ser Ala Leu Glu Lys Trp Lys Thr Ala Ile Arg Glu 1145 1150 1155
- Ala Gln Thr Phe Ser Arg Met His Val Leu Leu Gly Met Leu Asp 1160 1165 1170
- Ala Cys Ile Lys Trp Asp Met Ser Ala Glu Asn Ala Arg Cys Lys 1175 1180 1185
- Val Cys Arg Lys Lys Gly Glu Asp Asp Lys Leu Ile Leu Cys Asp 1190 1195 1200
- Glu Cys Asn Lys Ala Phe His Leu Phe Cys Leu Arg Pro Ala Leu

1205 1210 1215

Tyr Glu Val Pro Asp Gly Glu Trp Gln Cys Pro Ala Cys Gln Pro 1220 1225 1230

- Ala Thr Ala Arg Arg Asn Ser Arg Gly Arg Asn Tyr Thr Glu Glu 1235 1240 1245
- Ser Ala Ser Glu Asp Ser Glu Asp Asp Glu Ser Asp Glu Glu Glu 1250 1260
- Gly Leu Arg Leu Arg Pro Arg Lys Thr Ile Arg Gly Lys His Ser 1280 1285 1290
- Val Ile Pro Pro Ala Ala Arg Ser Gly Arg Pro Gly Lys Lys 1295 1300 1305
- Pro His Ser Thr Arg Arg Ser Gln Pro Lys Ala Pro Pro Val Asp 1310 1315 1320
- Asp Ala Glu Val Asp Glu Leu Val Leu Gln Thr Lys Arg Ser Ser 1325 1330 1335
- Arg Arg Gln Ser Leu Glu Leu Gln Lys Cys Glu Glu Ile Leu His 1340 1345 1350
- Met Ile Val Lys Tyr Arg Phe Ser Trp Pro Phe Arg Glu Pro Val 1355 1360 1365
- Thr Arg Asp Glu Ala Glu Asp Tyr Tyr Asp Val Ile Thr His Pro 1370 1375 1380
- Met Asp Phe Gln Thr Val Gln Asn Lys Cys Ser Cys Gly Ser Tyr 1385 1390 1395
- Arg Ser Val Gln Glu Phe Leu Thr Asp Met Lys Gln Val Phe Thr 1400 1405 1410
- Asn Ala Glu Val Tyr Asn Cys Arg Gly Ser His Val Leu Ser Cys 1415 1420 1425
- Met Val Lys Thr Glu Gln Cys Leu Val Ala Leu Leu His Lys His 1430 1435 1440

Leu Pro Gly His Pro Tyr Val Arg Arg Lys Arg Lys Lys Phe Pro 1445 1450 1455

Asp Arg Leu Ala Glu Asp Glu Gly Asp Ser Glu Pro Glu Ala Val 1460 1465 1470

Gly Gln Ser Arg Gly Arg Arg Gln Lys Lys 1475 1480

<210> 111

<211> 526

<212> PRT

<213> Homo sapiens

<400> 111

Met Val Met Lys Ala Ser Val Asp Asp Asp Ser Gly Trp Glu Leu 1 5 10 15

Ser Met Pro Glu Lys Met Glu Lys Ser Asn Thr Asn Trp Val Asp Ile 20 25 30

Thr Gln Asp Phe Glu Glu Ala Cys Arg Glu Leu Lys Leu Gly Glu Leu 35 40 45

Leu His Asp Lys Leu Phe Gly Leu Phe Glu Ala Met Ser Ala Ile Glu50 55 60

Met Met Asp Pro Lys Met Asp Ala Gly Met Ile Gly Asn Gln Val Asn 65 70 80

Arg Lys Val Leu Asn Phe Glu Gln Ala Ile Lys Asp Gly Thr Ile Lys 85 90 95

Ile Lys Asp Leu Thr Leu Pro Glu Leu Ile Gly Ile Met Asp Thr Cys
100 105 110

Phe Cys Cys Leu Ile Thr Trp Leu Glu Gly His Ser Leu Ala Gln Thr 115 120 125

Val Phe Thr Cys Leu Tyr Ile His Asn Pro Asp Phe Ile Glu Asp Pro 130 135 140

Ala Met Lys Ala Phe Ala Leu Gly Ile Leu Lys Ile Cys Asp Ile Ala 145 150 155 160

Arg Glu Lys Val Asn Lys Ala Ala Val Phe Glu Glu Glu Asp Phe Gln 165 170 175

Ser Met Thr Tyr Gly Phe Lys Met Ala Asn Ser Val Thr Asp Leu Arg 180 185 190

- Val Thr Gly Met Leu Lys Asp Val Glu Asp Asp Met Gln Arg Arg Val 195 200 205
- Lys Ser Thr Arg Ser Arg Gln Gly Glu Glu Arg Asp Pro Glu Val Glu 210 215 220
- Leu Glu His Gln Arg Cys Leu Ala Val Phe Ser Arg Val Lys Phe Thr 225 230 235 240
- Arg Val Leu Leu Thr Val Leu Ile Ala Phe Thr Lys Lys Glu Thr Ser 245 250 255
- Ala Val Ala Glu Ala Gln Lys Leu Met Val Gln Ala Ala Asp Leu Leu 260 265 270
- Ser Ala Ile His Asn Ser Leu His His Gly Ile Gln Ala Gln Asn Asp 275 280 285
- Thr Thr Lys Gly Asp His Pro Ile Met Met Gly Phe Glu Pro Leu Val 290 295 300
- Asn Gln Arg Leu Leu Pro Pro Thr Phe Pro Arg Tyr Ala Lys Ile Ile 305 310 315 320
- Lys Arg Glu Glu Met Val Asn Tyr Phe Ala Arg Leu Ile Asp Arg Ile 325 330 335
- Lys Thr Val Cys Glu Val Val Asn Leu Thr Asn Leu His Cys Ile Leu 340 345 350
- Asp Phe Phe Cys Glu Phe Ser Glu Gln Ser Pro Cys Val Leu Ser Arg 355 360 365
- Ser Leu Leu Gln Thr Thr Phe Leu Val Asp Asn Lys Lys Val Phe Gly 370 375 380
- Thr His Leu Met Gln Asp Met Val Lys Asp Ala Leu Arg Ser Phe Val 385 390 . 395 400
- Ser Pro Pro Val Leu Ser Pro Lys Cys Tyr Leu Tyr Asn Asn His Gln 405 410 415

Ala Lys Asp Cys Ile Asp Ser Phe Val Thr His Cys Val Arg Pro Phe 420 425 430

Cys Ser Leu Ile Gln Ile His Gly His Asn Arg Ala Arg Gln Arg Asp 435 440 445

Lys Leu Gly His Ile Leu Glu Glu Phe Ala Thr Leu Gln Asp Glu Ala 450 455 460

Glu Lys Val Asp Ala Ala Leu His Thr Met Leu Leu Lys Gln Glu Pro 465 470 475 480

Gln Arg Gln His Leu Ala Trp Leu Gly Thr Trp Val Leu Tyr His Asn 485 490 495

Leu Arg Ile Met Ile Gln Tyr Leu Leu Ser Gly Phe Glu Leu Glu Leu 500 505 510

Tyr Ser Met His Glu Ile Leu Leu His Ile Leu Val Ser Leu 515 520 525

<210> 112

<211> 368

<212> PRT

<213> Homo sapiens .

<400> 112

Met Ala Ala Ala Glu Glu Arg Met Ala Glu Glu Gly Gly Gly 1 5 10 15

Gln Gly Asp Gly Gly Ser Ser Leu Ala Ser Gly Ser Thr Gln Arg Gln 20 25 30

Pro Pro Pro Pro Ala Pro Gln His Pro Gln Pro Gly Ser Gln Ala Leu 35 40 45

Pro Ala Pro Ala Leu Ala Pro Asp Gln Leu Pro Gln Asn Asn Thr Leu 50 55 60

Val Ala Leu Pro Ile Val Ala Ile Glu Asn Ile Leu Ser Phe Met Ser 65 70 75 80

Tyr Asp Glu Ile Ser Gln Leu Arg Leu Val Cys Lys Arg Met Asp Leu 85 90 95

Val Cys Gln Arg Met Leu Asn Gln Gly Phe Leu Lys Val Glu Arg Tyr 100 105 110

His Asn Leu Cys Gln Lys Gln Val Lys Ala Gln Leu Pro Arg Glu 115 120 125

- Ser Glu Arg Arg Asn His Ser Leu Ala Arg His Ala Asp Ile Leu Ala 130  $$135\$
- Ala Val Glu Thr Arg Leu Ser Leu Leu Asn Met Thr Phe Met Lys Tyr 145 150 155 160
- Val Asp Ser Asn Leu Cys Cys Phe Ile Pro Gly Lys Val Ile Asp Glu . 165 170 175
- Ile Tyr Arg Val Leu Arg Tyr Val Asn Ser Thr Arg Ala Pro Gln Arg 180 185 190
- Ala His Glu Val Leu Gln Glu Leu Arg Asp Ile Ser Ser Met Ala Met 195 200 205
- Glu Tyr Phe Asp Glu Lys Ile Val Pro Ile Leu Lys Arg Lys Leu Pro 210 215 220
- Gly Ser Asp Val Ser Gly Arg Leu Met Gly Ser Pro Pro Val Pro Gly 225 230 235 240
- Pro Ser Ala Ala Leu Thr Thr Met Gln Leu Phe Ser Lys Gln Asn Pro 245 250 255
- Ser Arg Gln Glu Val Thr Lys Leu Gln Gln Gln Val Lys Thr Asn Gly 260 265 270
- Ala Gly Val Thr Val Leu Arg Arg Glu Ile Ser Glu Leu Arg Thr Lys 275 280 285
- Val Gln Glu Gln Gln Lys Gln Leu Gln Asp Gln Asp Gln Lys Leu Leu 290 295 300
- Glu Gln Thr Gln Ile Ile Gly Glu Gln Asn Ala Arg Leu Ala Glu Leu 305 310 315 320
- Glu Arg Lys Leu Arg Glu Val Met Glu Ser Ala Val Gly Asn Ser Ser 325 330 335
- Gly Ser Gly Gln Asn Glu Glu Ser Pro Arg Lys Arg Lys Ala Thr 340 . 345 . 350
- Glu Ala Ile Asp Ser Leu Arg Lys Ser Lys Arg Leu Arg Asn Arg Lys

355 360 365

## (19) World Intellectual Property Organization

International Bureau



## 

(43) International Publication Date 9 October 2003 (09.10.2003)

### (10) International Publication Number WO 2003/083047 A3

(51) International Patent Classification7: C12P 21/06

G01N 33/53,

(21) International Application Number:

PCT/US2003/006025

- (22) International Filing Date: 28 February 2003 (28.02.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/361,196

1 March 2002 (01.03.2002)

- (71) Applicant (for all designated States except US): EX-ELIXIS, INC. [US/US]; P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BELVIN, Marcia [US/US]; 921 Santa Fe Avenue, Albany, CA 94706 (US). FRANCIS-LANG, Helen [GB/US]; 1782 Pacific Avenue #2, San Francisco, CA 94109 (US). FRIEDMAN, Lori [US/US]; 113 Arundel Road, San Carlos, CA 94070 (US). PLOWMAN, Gregory, D. [US/US]; 35 Winding Way, San Carlos, CA 94070 (US). HEUER, Timothy, S. [US/US]; 581A Paloma Avenue, Pacifica, CA 94044 (US). LI, Danxi [CN/US]; 90 Behr Avenue, #302, San Francisco, CA 94131 (US). FUNKE, Roel, P. [NL/US]; 668 Sierra Point Road, Brisbane, CA 95005 (US).

- (74) Agents: SHAYESTEH, Laleh et al.; Exelixis, Inc., P. O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of. amendments
- (88) Date of publication of the international search report: 19 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/06025

A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) : G01N 33/53; C12P 21/06					
US CL: 435/7.2, 69.1  According to International Patent Classification (IPC) or to both national classification and IPC					
	DS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/7.2, 69.1					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
	ata base consulted during the international search (nar continuation Sheet	ne of data base and, where practicable, so	earch terms used)		
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where ap		Relevant to claim No.		
Y	WANG, X. et al. Poly(ADP-rybosyl)ation is requir transduction induced by radiation. Oncogene, 1998, page 2820, and 2824.		1-7, 16-18		
Y	US 5,804,396 A (PLOWMAN) 08 September 1998 (8.9.1998) entire document, especially column 7, lines 60-67, column8, lines 1-60				
Y	US 5,885,961 A (SHOYAB et al) 23 March 1999 (23.3.1999) entire document.		1-7, 16-18		
Y	OLLMANN, M. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell, March 31, 2000, Vol. 101, pages 91-101.		1-7, 16-18		
	·				
Further	r documents are listed in the continuation of Box C.	See patent family annex.			
"A" document	pecial categories of cited documents: t defining the general state of the art which is not considered to be ular relevance	"I" later document published after the inte date and not in conflict with the applie principle or theory underlying the inve	ation but cited to understand the		
•	pplication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone			
	t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as )	"Y?" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is documents, such combination		
"O" documen	t referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	art		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent i			
Date of the actual completion of the international search 26 September 2003 (26.09.2003)		Date of mailing of the international sear	cn report		
	nailing address of the ISA/US	Authorized officer	100		
Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450		Suryaprabha Chunduru Jawa	re Ford		
Ale	xandria, Virginia 22313-1450 o. (703)305-3230	Telephone No. 703-308-0196	0 4		

Form PCT/ISA/210 (second sheet) (July 1998)

### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/06025

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)		
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
Claim Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:		
Claim Nos.:     because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet		
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.		
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.		
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, and 16-18		
Remark on Protest  The additional search fees were accompanied by the applicant's protest.		
No protest accompanied the payment of additional search fees.		

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

P	BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACK	ING	
Th in be	This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.		
po	Group I, claim(s) 1-7, 16-18, drawn to a method of identifying a candidate p53 path polypeptide.		
G: M	Group II, claim(s) 1, 8-10, 16-19, drawn to drawn to a method of identifying a cand MP53 nucleic acid.	lidate p53 pathway modulating agent comprising a	
G	Group III, claim(s) 11-12, 21, drawn to a method for administering the candidate p5 detecting a phenotypic change in the system.	53 pathway modulating agent into a model system	
po	Group I Group IV, claim(s) 13-15, 20, 22, drawn to a method for modulating a p53 polypeptide.	3 pathway of a cell comprising a MP53	
G	Group V, claim(s) 23-25, drawn to a method for diagnosing a disease in a patient.		
p:	The inventions listed as Groups I-V do not relate to a single general inventive conce 13.2, they lack the same or corresponding special technical features for the followin p53 pathway modulating agent requiring a MP53 polypeptide in Group I and other n special technical feature because each of the methods of Groups I-V are independent and hence lack special technical feature that binds all the groups together.	ng reasons: The method of identifying a candidate methods claims in Groups II-V, do not share same	
	·		
1	Continuation of B. FIELDS SEARCHED Item 3: Medline, Biosis, Embase, Lifesci, Caplus, EAST databases search terms: MP53, p53 modulator, modifier, p53 pathway		
- [			

INTERNATIONAL SEARCH REPORT

PCT/US03/06025

# (19) World Intellectual Property Organization International Bureau





## (43) International Publication Date 22 February 2001 (22.02.2001)

### PCT

# (10) International Publication Number WO 01/12662 A2

(51) International Patent Classification7: C07K 14/00

(21) International Application Number: PCT/US00/22315

(22) International Filing Date: 14 August 2000 (14.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/149,641 17 August 1999 (17.08.1999) US 60/164,203 9 November 1999 (09.11.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/149,641 (CIP)
Filed on 17 August 1999 (17.08.1999)
US 60/164,203 (CIP)
Filed on 9 November 1999 (09.11.1999)

- (71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). BURFORD, Neil [GB/US]; 1308 4th Avenue, San

Francisco, CA 94122 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).

- (74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

2662 A2

(54) Title: MEMBRANE ASSOCIATED PROTEINS

(57) Abstract: The invention provides human membrane associated proteins (MEMAP) and polynucleotides which identify and encode MEMAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MEMAP.

#### MEMBRANE ASSOCIATED PROTEINS

#### **TECHNICAL FIELD**

This invention relates to nucleic acid and amino acid sequences of membrane associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders.

#### BACKGROUND OF THE INVENTION

Eukaryotic cells are surrounded by plasma membranes which enclose the cell and maintain an environment inside the cell that is distinct from its surroundings. In addition, eukaryotic organisms are distinct from prokaryotes in possessing many intracellular organelle and vesicle structures. Many of the metabolic reactions which distinguish eukaryotic biochemistry from prokaryotic biochemistry take place within these structures. The plasma membrane and the membranes surrounding organelles and vesicles are composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. These components confer identity and functionality to the membranes with which they associate.

#### Integral Membrane Proteins

20

The majority of known integral membrane proteins are transmembrane proteins (TM) which are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α-helical conformation. TM proteins are classified as bitopic (Types I and II) and polytopic (Types III and IV) (Singer, S.J. (1990) Annu. Rev. Cell Biol. 6:247-96). Bitopic proteins span the membrane once while polytopic proteins contain multiple membrane-spanning segments. TM proteins that act as cell-surface receptor proteins involved in signal transduction include growth and differentiation factor receptors, and receptor-interacting proteins such as *Drosophila* pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins) and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins act as vesicle organelle-forming molecules, such as calveolins, or as cell recognition molecules, such as cluster of differentiation (CD) antigens, glycoproteins, and mucins.

Many membrane proteins (MPs) contain amino acid sequence motifs that target these proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing peptides have been used as drug delivery agents in cancer

1

treatments which target tumor vasculature (Arap, W. et al. (1998) Science, 279:377-380). Furthermore, MPs may also contain amino acid sequence motifs, such as the carbohydrate recognition domain (CRD), also known as the C-type lectin domain, that mediate interactions with extracellular or intracellular molecules.

5

15

20

35

Membrane proteins may also interact with and regulate the properties of the membrane lipids. Phospholipid scramblase, a type II plasma membrane protein, mediates calcium dependent movement of phospholipids (PL) between membrane leaflets. Calcium induced remodeling of plasma membrane PL plays a key role in expression of platelet anticoagulant activity and in clearance of injured or apoptotic cells (Zhou Q. et al. (1997) J. Biol. Chem. 272:18240-18244). Scott syndrome, a bleeding disorder, is caused by an inherited deficiency in plasma membrane PL scramblase function (Online Mendelian Inheritance in Man (OMIM) \*262890 Platelet Receptor for Factor X, Deficiency of).

Chemical modification of amino acid residue side chains alters the manner in which MPs interact with other molecules, such as phospholipid membranes. Examples of such chemical modifications to amino acid residue side chains are covalent bond formation with glycosaminoglycans, oligosaccharides, phospholipids, acetyl and palmitoyl moieties, ADP-ribose, phosphate, and sulphate groups.

One function of TM proteins is to facilitate cell-cell communication. The slit proteins are extracellular matrix proteins expressed by cells at the ventral midline of the nervous system. Slit proteins are ligands for the repulsive guidance receptor Robo and thus play a role in repulsive axon guidance (Brose, K. et al. (1999) Cell 96:795-806).

In some cases TM proteins serve as transporters or channels in the cell membrane. For example, the mouse transporter protein (MTP) has four transmembrane domains and resides in an intracellular membrane compartment. MTP can mediate transport of nucleosides in vitro. The role of MTP in the cell may therefore be to transfer nucleosides between the cytosol and the lumen of intracellular organelles (Hogue, D. L. (1996) J. Biol. Chem. 271:9801-9808). The human stomatin-like protein (hSLP-1), expressed primarily in the brain, contains an N-terminal domain similar to the erythrocyte internal membrane protein stomatin, as well as a non-specific lipid transfer protein domain at the C-terminus. hSLP-1 is the human homologue of the C. elegans behavioral gene unc-24, which is believed to be involved in lipid transfer between closely apposed membranes (Seidel, G. and Prohaska, R (1998) Gene 225:23-29).

The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene family encoding type III integral membrane proteins (Wright, M.D. and Tomlinson, M.G. (1994) Immunol. Today 15:588-594). TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins,

melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S.A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another.

A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated.

5

20

25

30

35

Tumor antigens are cell surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J. Cancer 61: 706-715; Liu, E. et al. (1992) Oncogene 7: 1027-1032). For example, the biliary glycoprotein-encoding gene is a member of the human carcinoembryonic antigen family, which are important tumor markers for colorectal carcinomas (Hammarstrom, S. (1999) Semin. Cancer Bio. 9:67-81). Another example is the neuron and testis specific protein Ma1, a marker for paraneoplastic neuronal disorders (Dalmau, J. et al. (1999) Brain 122:27-39).

Other types of cell surface antigens include those identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a "cluster of differentiation" or "CD" designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego, CA, pp. 17-20.)

The TM cell surface glycoprotein CD69 is an early activation antigen of T lymphocytes. CD69 is homologous to members of a supergene family of type II integral membrane proteins having C-type lectin domains. Although the precise functions of the CD-69 antigen is not known, evidence suggests that these proteins transmit mitogenic signals across the plasma membrane and are upregulated in response to lymphocyte activation (Hamann, J. et. al. (1993) J. Immunol. 150:4920-4927).

Macrophages are involved in functions including clearance of senescent or apoptotic cells, cytokine production, hemopoiesis, bone resorption, antigen transport, and neuroendocrine regulation. These diverse roles are influenced by specialized macrophage plasma membrane proteins. The murine macrophage restricted C-type lectin is a type II integral membrane protein expressed exclusively in macrophages. The strong expression of this protein in bone marrow suggests a hemopoeitic function, while the lectin domain suggests it may be involved in cell-cell recognition (Balch, S. G. et al. (1998) J. Biol. Chem. 273:18656-18664).

The surface of red blood cells is populated with characteristic glycoproteins, such as the major sialoglycoproteins glycophorin A and B. Red blood cells lacking either glycophorin A or B are resistant to infection with the malaria parasite Plasmodium falciparum (OMIM Entry 111300 Blood Group-MN Locus). White blood cells also possess characteristic surface glycoproteins, such as the plasma cell glycoprotein-1 (PC-1). PC-1 is expressed on the surface of plasma cells, which are terminally differentiated, antibody-secreting B-lymphocytes. The extracellular domain of PC-1 has nucleotide phosphodiesterase (pyrophosphatase) activity (Funakoshi, I. et al. (1992) Arch. Biochem. Biophys. 295:180-187). Phosphodiesterase activity is associated with the hydrolytic removal of nucleotide subunits from oligonucleotides. Although the precise physiological role of PC-1 is not clear, increased PC-1 phosphodiesterase activity has been correlated with insulin resistance in patients with noninsulin-dependent diabetes mellitus, with abnormalities of bone mineralization and calcification, and with defects in renal tubule function. In addition, it appears that hPC-1 and mPC-1 are members of a multigene family of transmembrane phosphodiesterases with extracellular active sites. These enzymes may play a role in regulating the concentration of pharmacologically active extracellular compounds such as adenosine or other nucleotide derivatives in a variety of tissues and cell types. (Reviewed in Goding, J. W. et al. (1998) Immunol. Rev. 161:11-26.)

### 25 Peripheral and Anchored Membrane Proteins

Some membrane proteins are not membrane-spanning but are attached to the plasma membrane via membrane anchors or interactions with integral membrane proteins. Membrane anchors are covalently joined to a protein post-translationally and include such moieties as prenyl, myristyl, and glycosylphosphatidyl inositol (GPI) groups. Membrane localization of peripheral and anchored proteins is important for their function in processes such as receptor-mediated signal transduction. For example, prenylation of Ras is required for its localization to the plasma membrane and for its normal and oncogenic functions in signal transduction.

The pancortins are a group of four glycoproteins which are predominantly expressed in the cerebral cortex of adult rodents. Immunological localization indicates that the pancortins are endoplasmic reticulum anchored proteins. The pancortins share a common sequence in the middle of

their structure, but have alternative sequences at both ends due to differential promoter usage and alternative splicing. Each pancortin appears to be differentially expressed and may perform different functions in the brain (Nagano, T. et al. (1998) Mol. Brain Res. 53:13-23).

The discovery of new membrane associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders.

#### SUMMARY OF THE INVENTION

10 The invention features purified polypeptides, membrane associated proteins, referred to collectively as "MEMAP" and individually as "MEMAP-1," "MEMAP-2," "MEMAP-3," "MEMAP-4," "MEMAP-5," "MEMAP-6," "MEMAP-7," "MEMAP-8," "MEMAP-9," "MEMAP-10," "MEMAP-11," "MEMAP-12," "MEMAP-13," "MEMAP-14," "MEMAP-15," "MEMAP-16," "MEMAP-17," "MEMAP-18," "MEMAP-19," "MEMAP-20," "MEMAP-21," "MEMAP-22," "MEMAP-23," "MEMAP-24," "MEMAP-25," "MEMAP-26," "MEMAP-27," "MEMAP-28," "MEMAP-29," "MEMAP-30," "MEMAP-31," "MEMAP-32," "MEMAP-33," "MEMAP-34," "MEMAP-35," "MEMAP-36," and "MEMAP-37." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-37.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-37. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:38-74.

25

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid

sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37.

20

25

35

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group

consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

10

20

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence

selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

10

15

20

25

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally

occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:38-74, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

15

20

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of the above polynucleotide sequence; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

1 3 HOLD 1

المالي جه مجعدا إليواله

#### **BRIEF DESCRIPTION OF THE TABLES**

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding MEMAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of MEMAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding MEMAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

#### **DESCRIPTION OF THE INVENTION**

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

20

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the

invention is not entitled to antedate such disclosure by virtue of prior invention.

#### **DEFINITIONS**

10

20

30

35

"MEMAP" refers to the amino acid sequences of substantially purified MEMAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of MEMAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MEMAP either by directly interacting with MEMAP or by acting on components of the biological pathway in which MEMAP participates.

An "allelic variant" is an alternative form of the gene encoding MEMAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding MEMAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MEMAP or a polypeptide with at least one functional characteristic of MEMAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MEMAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MEMAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MEMAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MEMAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring

protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of MEMAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MEMAP either by directly interacting with MEMAP or by acting on components of the biological pathway in which MEMAP participates.

10

20

25

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind MEMAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The second of the

. - -

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the

designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic MEMAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

10

15

20

25

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding MEMAP or fragments of MEMAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

30	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
35	Cys	Ala, Ser
;	Gln	Asn, Glu, His
	Glu	Asp, Gln, His

	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
5	Lys ·	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
10	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

20

30

The term "derivative" refers to a chemically modified polynucleotide or polypeptide.

Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of MEMAP or the polynucleotide encoding MEMAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the

present embodiments.

15

20

35

A fragment of SEQ ID NO:38-74 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:38-74, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:38-74 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:38-74 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:38-74 and the region of SEQ ID NO:38-74 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-37 is encoded by a fragment of SEQ ID NO:38-74. A fragment of SEQ ID NO:1-37 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-37. For example, a fragment of SEQ ID NO:1-37 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-37. The precise length of a fragment of SEQ ID NO:1-37 and the region of SEQ ID NO:1-37 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full-length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full-length" polynucleotide sequence encodes a "full-length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms

is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

15 Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

20 Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

. 아동 왕 - 사람 원년

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative

substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

10

15

20

30

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.

Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

10

30

35

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0$ t or  $R_0$ t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide

sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of MEMAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of MEMAP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

5

10

15

20

25

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of MEMAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MEMAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an MEMAP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of MEMAP.

"Probe" refers to nucleic acid sequences encoding MEMAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

10

15

35

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific

needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, <u>supra</u>. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

10

20

25

30

35

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding MEMAP, or fragments thereof, or MEMAP itself, may comprise a bodily fluid; an

extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

10

15

20

30

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with

a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook, J. et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

## THE INVENTION

10

15

25

30

35

The invention is based on the discovery of new human membrane associated proteins (MEMAP), the polynucleotides encoding MEMAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, neurological and

gastrointestinal disorders.

10

20

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding MEMAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each MEMAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each MEMAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs:

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding MEMAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:38-74 and to distinguish between SEQ ID NO:38-74 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express MEMAP as a fraction of total tissues expressing MEMAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing MEMAP as a fraction of total tissues expressing MEMAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:41, SEQ ID NO:48, and SEQ ID NO:56 in nervous tissues, of SEQ ID NO:52, SEQ ID NO:65, and SEQ ID NO:74 in gastrointestinal tissues, and of SEQ ID NO:55 in hematopoietic/immune tissues.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding MEMAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

SEQ ID NO:38 maps to chromosome 4 within the interval from 77.9 to 86.0 centiMorgans, to chromosome 6 within the interval from 132.7 to 144.4 centiMorgans, and to chromosome 14 within the interval from 89.4 to 103.7 centiMorgans. The interval on chromosome 4 from 77.9 to 86.0 centiMorgans also contains a gene associated with deoxycytidine kinase deficiency. The interval on chromosome 6 from 132.7 to 144.4 centiMorgans also contains genes associated with peroxisomal disorders and leukemia. The interval on chromosome 14 from 89.4 to 103.7 centiMorgans also contains genes associated with spinocerebellar ataxia and protease inhibitor deficiencies. SEQ ID NO:39 maps to chromosome 2 within the interval from 236.2 to 269.5 centiMorgans, and to the X chromosome within the interval from 94.4 to 97.4 centiMorgans. The interval on chromosome 2 from 236.2 to 269.5 centiMorgans also contains genes associated with Crigler-Najjar syndrome, Oguchi disease, and oxaolis I. The interval on the X chromosome from 94.4 to 97.4 centiMorgans also contains genes associated with Charcot-Marie tooth disease, X-linked severe combined immunodeficiency, alpha thalassemia/mental retardation syndrome, Menkes' syndrome, and choroideremia. SEQ ID NO:42 maps to chromosome 1 within the interval from 218.2 to 232.0 centiMorgans. This interval also contains genes associated with familial hypertrophic cardiomyopathy, malignant hyperthermia, and hypokalemic periodic paralysis. SEQ ID NO:44 maps to chromosome 7 within the interval from 136.4 to 145.8 centiMorgans, to chromosome 14 within the interval from 28.0 to 32.9 centiMorgans, and to chromosome 14 within the interval from 71.5 to 73.7 centiMorgans. The interval on chromosome 7 from 136.4 to 145.8 centiMorgans also contains genes associated with diphosphoglycerate mutase deficiency. SEQ ID NO:60 maps to chromosome 7 within the interval from 167.6 to 184.0 centiMorgans, and to chromosome 14 within the interval from 50.0 to 59.0 centiMorgans. SEQ ID NO:63 maps to chromosome 8 within the interval from 101.0 to 125.8 centiMorgans, and to chromosome 8 within the interval from 132.4 to 135.1 centiMorgans. SEQ ID NO:67 maps to chromosome 4 within the interval from 145.3 to 146.4 centiMorgans.

10

15

25

35

The invention also encompasses MEMAP variants. A preferred MEMAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the MEMAP amino acid sequence, and which contains at least one functional or structural characteristic of MEMAP.

The invention also encompasses polynucleotides which encode MEMAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:38-74, which encodes MEMAP. The polynucleotide sequences of SEQ ID NO:38-74, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding MEMAP.

In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding MEMAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:38-74 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:38-74. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of MEMAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding MEMAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring MEMAP, and all such variations are to be considered as being specifically disclosed.

15

20

Although nucleotide sequences which encode MEMAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring MEMAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding MEMAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding MEMAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode MEMAP and MEMAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding MEMAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:38-74 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.

152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

10

20

The nucleic acid sequences encoding MEMAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic, 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National

Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode MEMAP may be cloned in recombinant DNA molecules that direct expression of MEMAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express MEMAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter MEMAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MEMAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of

30

35

gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial"

5 breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding MEMAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.)

Alternatively, MEMAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of MEMAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

20

In order to express a biologically active MEMAP, the nucleotide sequences encoding MEMAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding MEMAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding MEMAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding MEMAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no

additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MEMAP and appropriate transcriptional and translational control elements. These methods include <u>in vitro</u> recombinant DNA techniques, synthetic techniques, and <u>in vivo</u> genetic recombination. (See, e.g., Sambrook, J. et al. (1989) <u>Molecular Cloning, A</u>

<u>Laboratory Manual</u>, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) <u>Current Protocols in Molecular Biology</u>, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

15

A variety of expression vector/host systems may be utilized to contain and express sequences encoding MEMAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding MEMAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding MEMAP can be achieved using a multifunctional <u>E. coli</u> vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding MEMAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of MEMAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of MEMAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of MEMAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast <u>Saccharomyces cerevisiae</u> or <u>Pichia pastoris</u>. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, <u>supra</u>; Bitter, <u>supra</u>; and Scorer, <u>supra</u>.)

Plant systems may also be used for expression of MEMAP. Transcription of sequences encoding MEMAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, supra; Broglie, supra; and Winter, supra.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

20

35

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding MEMAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses MEMAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of

DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

5

30

For long term production of recombinant proteins in mammalian systems, stable expression of MEMAP in cell lines is preferred. For example, sequences encoding MEMAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk and apr cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), ß glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding MEMAP is inserted within a marker gene sequence, transformed cells containing sequences encoding MEMAP can be identified by the absence of marker gene function.

Alternatively, a marker gene can be placed in tandem with a sequence encoding MEMAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding MEMAP and that express MEMAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

5

10

15

Immunological methods for detecting and measuring the expression of MEMAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on MEMAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding MEMAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.

Alternatively, the sequences encoding MEMAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia

Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding MEMAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode MEMAP may be designed to contain signal sequences which direct secretion of MEMAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of

the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding MEMAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric MEMAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of MEMAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the MEMAP encoding sequence and the heterologous protein sequence, so that MEMAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled MEMAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

25

35

MEMAP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to MEMAP. At least one and up to a plurality of test compounds may be screened for specific binding to MEMAP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of

MEMAP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J.E. et al. (1991) <u>Current Protocols in Immunology</u> 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which MEMAP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express MEMAP, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, <u>Drosophila</u>, or <u>E. coli</u>. Cells expressing MEMAP or cell membrane fractions which contain MEMAP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either MEMAP or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with MEMAP, either in solution or affixed to a solid support, and detecting the binding of MEMAP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

MEMAP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of MEMAP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for MEMAP activity, wherein MEMAP is combined with at least one test compound, and the activity of MEMAP in the presence of a test compound is compared with the activity of MEMAP in the absence of the test compound. A change in the activity of MEMAP in the presence of the test compound is indicative of a compound that modulates the activity of MEMAP. Alternatively, a test compound is combined with an in vitro or cell-free system comprising MEMAP under conditions suitable for MEMAP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of MEMAP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

20

30

In another embodiment, polynucleotides encoding MEMAP or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of

interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding MEMAP may also be manipulated <u>in vitro</u> in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding MEMAP can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding MEMAP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress MEMAP, e.g., by secreting MEMAP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

and the second

人名德特莱特人

## 25 THERAPEUTICS

10

15

20

35

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of MEMAP and membrane associated proteins. In addition, the expression of MEMAP is closely associated with neurological and gastrointestinal tissues, cancer, cell proliferation, and inflammation/trauma. Therefore, MEMAP appears to play a role in cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders. In the treatment of disorders associated with increased MEMAP expression or activity, it is desirable to decrease the expression or activity of MEMAP. In the treatment of disorders associated with decreased MEMAP expression or activity, it is desirable to increase the expression or activity of MEMAP.

Therefore, in one embodiment, MEMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or

activity of MEMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, 20 bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating 25 diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including

30

35

mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.

In another embodiment, a vector capable of expressing MEMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those described above.

20

25

30

35

In a further embodiment, a composition comprising a substantially purified MEMAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of MEMAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of MEMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MEMAP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders described above. In one aspect, an antibody which specifically binds MEMAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express MEMAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide

encoding MEMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MEMAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of MEMAP may be produced using methods which are generally known in the art. In particular, purified MEMAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind MEMAP. Antibodies to MEMAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

10

20

30

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with MEMAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

t vi java

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to MEMAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of MEMAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to MEMAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce MEMAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing <u>in vivo</u> production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

10

15

20

30

35

Antibody fragments which contain specific binding sites for MEMAP may also be generated. For example, such fragments include, but are not limited to,  $F(ab')_2$  fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

A the court

Burgas B.

1. 11. 11. 12. 19.

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between MEMAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering MEMAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for MEMAP. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of MEMAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple MEMAP epitopes, represents the average affinity, or avidity, of the antibodies for MEMAP. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular MEMAP epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in

which the MEMAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K<sub>a</sub> ranging from about 10<sup>6</sup> to 10<sup>7</sup> L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of MEMAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of MEMAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

In another embodiment of the invention, the polynucleotides encoding MEMAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding MEMAP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding MEMAP. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

15

20

35

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding MEMAP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency

(e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by Xlinked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in MEMAP expression or regulation causes disease, the expression of MEMAP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

MEMAP are treated by constructing mammalian expression vectors encoding MEMAP and introducing these vectors by mechanical means into MEMAP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Sugar Addition of the

Expression vectors that may be effective for the expression of MEMAP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). MEMAP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the

FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, <u>supra</u>)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MEMAP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID

5 TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to MEMAP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding MEMAP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ Tcells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding MEMAP to cells which have one or more genetic abnormalities with respect to the expression of MEMAP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have

proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544; and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding MEMAP to target cells which have one or more genetic abnormalities with respect to the expression of MEMAP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing MEMAP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is 15 hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. 20 (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

5 ...

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding MEMAP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for MEMAP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of MEMAP-coding RNAs and the synthesis of high levels of MEMAP in vector transduced cells. While

alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of MEMAP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10

20

25

30

35

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding MEMAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by <u>in vitro</u> and <u>in vivo</u> transcription of DNA sequences encoding MEMAP. Such DNA sequences may be incorporated into a wide variety of

vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding MEMAP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased MEMAP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding MEMAP may be therapeutically useful, and in the treament of disorders associated with decreased MEMAP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding MEMAP may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding MEMAP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an <u>in vitro</u> cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding MEMAP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence

25

30

35

complementary to the sequence of the polynucleotide encoding MEMAP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

15

20

30

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of MEMAP, antibodies to MEMAP, and mimetics, agonists, antagonists, or inhibitors of MEMAP.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form.

These compositions are generally aerosolized immediately prior to inhalation by the patient. In the

case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

10

25

35

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising MEMAP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, MEMAP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example MEMAP or fragments thereof, antibodies of MEMAP, and agonists, antagonists or inhibitors of MEMAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the

active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about  $0.1~\mu g$  to  $100,000~\mu g$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## **DIAGNOSTICS**

20

30

In another embodiment, antibodies which specifically bind MEMAP may be used for the diagnosis of disorders characterized by expression of MEMAP, or in assays to monitor patients being treated with MEMAP or agonists, antagonists, or inhibitors of MEMAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for MEMAP include methods which utilize the antibody and a label to detect MEMAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring MEMAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of MEMAP expression. Normal or standard values for MEMAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to MEMAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of MEMAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding MEMAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of MEMAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess

expression of MEMAP, and to monitor regulation of MEMAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding MEMAP or closely related molecules may be used to identify nucleic acid sequences which encode MEMAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding MEMAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the MEMAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:38-74 or from genomic sequences including promoters, enhancers, and introns of the MEMAP gene.

Means for producing specific hybridization probes for DNAs encoding MEMAP include the cloning of polynucleotide sequences encoding MEMAP or MEMAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

20

30

Polynucleotide sequences encoding MEMAP may be used for the diagnosis of disorders associated with expression of MEMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal noctumal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves'

disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, 15 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha, antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis,

peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas. The polynucleotide sequences encoding MEMAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered MEMAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding MEMAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding MEMAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding MEMAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

15

20

In order to provide a basis for the diagnosis of a disorder associated with expression of MEMAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding MEMAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals

to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding MEMAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced <u>in vitro</u>. Oligomers will preferably contain a fragment of a polynucleotide encoding MEMAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding MEMAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

10

20

35

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding MEMAP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding MEMAP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in highthroughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of MEMAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the

polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J.J. et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, antibodies specific for MEMAP, or MEMAP or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

20

30

35

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with <u>in vitro</u> model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and

toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

10

25

30

35

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The

optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for MEMAP to quantify
the levels of MEMAP expression. In one embodiment, the antibodies are used as elements on a
microarray, and protein expression levels are quantified by exposing the microarray to the sample and
detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem.
270:103-111; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed
by a variety of methods known in the art, for example, by reacting the proteins in the sample with a
thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at
each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

25

35

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of

protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

5

25

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in <u>DNA Microarrays: A Practical Approach</u>, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding MEMAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

2. 1 3. A. A.

. Sukri ku kijara Kiloni su bar ari

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding MEMAP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.

Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is

valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, MEMAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between MEMAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with MEMAP, or fragments thereof, and washed. Bound MEMAP is then detected by methods well known in the art. Purified MEMAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

15

20

25

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding MEMAP specifically compete with a test compound for binding MEMAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with MEMAP.

In additional embodiments, the nucleotide sequences which encode MEMAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/149,641 and U.S. Ser. No. 60/164,203 are hereby expressly incorporated by reference.

#### **EXAMPLES**

#### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies); a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., 25 PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5a, DH10B, or ElectroMAX DH10B from Life Technologies.

#### II. **Isolation of cDNA Clones**

15

30

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1

ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

30

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems), in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned

sequences.

15

25

30

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:38-74. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

1. Sec. 3 . Francis

#### 20 IV. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, <u>supra</u>, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

BLAST Score x Percent Identity

5 x minimum {length(Seq. 1), length(Seq. 2)}

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the

product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding MEMAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

### 0 V. Chromosomal Mapping of MEMAP Encoding Polynucleotides

10

30

The cDNA sequences which were used to assemble SEQ ID NO:38-74 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:38-74 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEO ID NO:, to that map location.

The genetic map locations of SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:60, SEQ ID NO:63, and SEQ ID NO:67 are described in The Invention as ranges, or intervals, of human chromosomes. More than one map location is reported for SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:60, and SEQ ID NO:63, indicating that previously mapped sequences having similarity, but not complete identity, to SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:60, and SEQ ID NO:63 were assembled into their respective

clusters. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Diseases associated with the public and Incyte sequences located within the indicated intervals are also reported in the Invention where applicable. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

# VI. Extension of MEMAP Encoding Polynucleotides

20

30

35

The full length nucleic acid sequences of SEQ ID NO:38-74 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length; to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg<sup>2+</sup>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing  $100 \,\mu l$  PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5  $\,\mu l$  of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar,

Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent <u>E. coli</u> cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

135 333

3 00 0 1 1 1 1 1 1 Tu

In like manner, the polynucleotide sequences of SEQ ID NO:38-74 are used to obtain 5' regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

# VII. Labeling and Use of Individual Hybridization Probes

15

20

25

30

35

Hybridization probes derived from SEQ ID NO:38-74 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of  $[\gamma^{-32}P]$  adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a

SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

#### VIII. Microarrays

5

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, <u>supra</u>), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), <u>supra</u>). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

#### Tissue or Cell Sample Preparation

35

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and

poly(A)\* RNA is purified using the oligo-(dT) cellulose method. Each poly(A)\* RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)\* RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)\* RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37 °C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85 °C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μl 5X SSC/0.2% SDS.

#### 15 Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 µg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 µl of the array element DNA, at an average concentration of 100 ng/µl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60 °C followed by washes in

0.2% SDS and distilled water as before.

#### **Hybridization**

Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65 °C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60 °C. The arrays are washed for 10 min at 45 °C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45 °C in a second wash buffer (0.1X SSC), and dried.

### **Detection**

15

20

35

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

م روز د

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital

(A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

#### IX. Complementary Polynucleotides

10

20

Sequences complementary to the MEMAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring MEMAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of MEMAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the MEMAP-encoding transcript.

#### X. Expression of MEMAP

Expression and purification of MEMAP is achieved using bacterial or virus-based expression systems. For expression of MEMAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MEMAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MEMAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MEMAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.

Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, MEMAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MEMAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified MEMAP obtained by these methods can be used directly in the assays shown in Examples XI and XV.

# XI. Demonstration of MEMAP Activity

35

MEMAP-specific activity assay as outlined below. As a general approach, cell lines or tissues transformed with a vector containing MEMAP coding sequences can be assayed for MEMAP activity by immunoblotting. Transformed cells are denatured in SDS in the presence of β-mercaptoethanol, nucleic acids are removed by ethanol precipitation, and proteins are purified by acetone precipitation. Pellets are resuspended in 20 mM tris buffer at pH 7.5 and incubated with Protein G-Sepharose precoated with an antibody specific for MEMAP. After washing, the Sepharose beads are boiled in electrophoresis sample buffer, and the eluted proteins subjected to SDS-PAGE. Proteins are transferred from the SDS-PAGE gel to a membrane for immunoblotting, and the MEMAP activity is assessed by visualizing and quantifying bands on the blot using antibody specific for MEMAP as the primary antibody and <sup>125</sup>I-labeled IgG specific for the primary antibody as the secondary antibody.

A specific assay for MEMAP activity measures the expression of MEMAP on the cell surface. cDNA encoding MEMAP is transfected into a mammalian (non-human) cell line. Cell surface proteins are labeled with biotin as described in de la Fuente, M.A.. et al. ((1997) Blood 90:2398-2405). Immunoprecipitations are performed using MEMAP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of MEMAP expressed on the cell surface.

In an alternative specific assay, MEMAP transport activity is assayed by measuring uptake of

labeled substrates into Xenopus laevis oocytes. Oocytes at stages V and VI are injected with MEMAP mRNA (10 ng per oocyte) and incubated for 3 days at 18 °C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 1mM Na<sub>2</sub>HPO<sub>4</sub>, 5 mM Hepes, 3.8 mM NaOH, 50µg/ml gentamycin, pH 7.8) to allow expression of MEMAP protein. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, and neurotransmitters) is initiated by adding a <sup>3</sup>H substrate to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na<sup>+</sup>-free medium, measuring the incorporated <sup>3</sup>H, and comparing with controls. MEMAP activity is proportional to the level of internalized <sup>3</sup>H substrate.

#### XII. Functional Assays

10

20

MEMAP function is assessed by expressing the sequences encoding MEMAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 µg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of MEMAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MEMAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions

of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MEMAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

# XIII. Production of MEMAP Specific Antibodies

10

15

20

25

30

35

MEMAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the MEMAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, <a href="mailto:supra">supra</a>.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-MEMAP activity by, for example, binding the peptide or MEMAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

# XIV. Purification of Naturally Occurring MEMAP Using Specific Antibodies

Naturally occurring or recombinant MEMAP is substantially purified by immunoaffinity chromatography using antibodies specific for MEMAP. An immunoaffinity column is constructed by covalently coupling anti-MEMAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing MEMAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MEMAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MEMAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MEMAP is collected.

## XV. Identification of Molecules Which Interact with MEMAP

MEMAP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate

molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MEMAP, washed, and any wells with labeled MEMAP complex are assayed. Data obtained using different concentrations of MEMAP are used to calculate values for the number, affinity, and association of MEMAP with the candidate molecules.

Alternatively, molecules interacting with MEMAP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

5

MEMAP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the

invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
н	38	112301	PITUNOT01	003382R1 (HMC1NOT01), 094523R1 (PITUNOT01), 112301H1 (PITUNOT01), 301778X11 (TESTNOT04), 320551X13 (EOSIHET02), 1368852R1 (SCORNON02), 1800784H1 (COLNNOT27), 2117174X17C1 (BRSTTUT02), 2526345F6 (BRAITUT21), 4333609H1 (KIDCTMT01)
2	39	997947	KIDNTUT01	997947H1 (KIDNTUT01), 997947T6 (KIDNTUT01), 1417936X306D1 (KIDNNOT09), 1672062X307V1 (BLADNOT05), 3738956T6 (MENTNOT01), SCCA01437V1, SCCA05013V1, SCCA01691V1, SCCA02873V1
3	40	1521513	BLADTUT04	1222062H1 (NEUTGMT01), 1521513H1 (BLADTUT04), 1521513T1 (BLADTUT04), 3558522F6 (LUNGNOT31), 3558522F6 (LUNGNOT31)
4i	17	1863994	PROSNOT19	265171R6 (HNT2AGT01), 1863994H1 (PROSNOT19), 3750444F6 (UTRSNOT18), 4177677F6 (BRAINOT22), 4697638F6 (BRALNOT01), 4774040F6 (BRAQNOT01), SCEA02960V1
χ.	75	2071941	ISLTNOT01	286350R1 (EOSIHETO2), 491305R1 (HNT2AGT01), 724168R1 (SYNOOAT01), 1466668F1 (PANCTUT02), 2071941H1 (ISLTNOT01), 2071941X11C1 (ISLTNOT01), 3579445H1 (293TF3T01)
9	43	2172512	ENDCNOT03	217251241 (ENDCNOT03), 2544419F6 (UTRSNOT11), 2798626H1 (NPOLNOT01), 3203359H1 (PENCNOT02), g1241299
7	<b>7</b> 7	2483172	SMCANOT01	217987F1 (STOMNOT01), 1289703F6 (BRAINOT11), 1289703T6 (BRAINOT11), 2211377F6 (SINTFET03), 2483172H1 (SMCANOT01), 2493236H1 (ADRETUT05), 3274006F6 (PROSBPT06)

Table

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
8	57	2656128	THYMNOT04	2654722T6 (THYMNOT04), 2656128H1 (THYMNOT04), 2837168F6 (TLYMNOT03)
6	95	5855841	FIBAUNT02	894553T1 (BRSTNOT05), 1296289F1 (PGANNOT03), 1466541T1 (PANCTUT02), 2046927F6 (THP1T7T01), 2058873R6 (OVARNOT03), 3800875F6 (SPLNNOT12), 5855841H1 (FIBAUNT02)
10	£4.	603462	BRSTTUT01	603462H1 (BRSTTUT01), 1487733H1 (UCMCL5T01), 1750451F6 (STOMTUT02), 5182853T6 (LUNGTMT03)
11	87	747681	BRAITUT01	747681H1 (BRAITUTO1), 752009R1 (BRAITUTO1), 1267874F1 (BRAINOTO9), 1833308R6 (BRAINONO1), 2673538X19F1 (KIDNNOT19), SBCA07003F3, SCDA07521V1, SCDA04982V1, SCDA07275V1
12	67	919469	RATRNOT02	153337R6 (THP1PLBO2), 1525415F6 (UCMCL5T01), 1527804F1 (UCMCL5T01), 1985565R6 (LUNGAST01), 2397811T6 (THP1AZT01), SARB01416F1, SARA03198F1
13	20	977658	BRSTNOT02	977658H1 (BRSTNOT02), 1873689F6 (LEUKNOT02), 2155095F6 (BRAINOT09), 2186432F6 (PROSNOT26), 2204117F6 (SPLNFET02), 3255048R6 (OVARTUN01), 3501520H1 (ADRENOT11), 3743427H1 (THYMNOT08)
14	15	1004703	BRSTNOT03	742178H1 (PANCNOT04), 1444583F6 (THYRNOT03), 2068902X15C1 (ISLTNOT01), 2616367F6 (GBLANOT01), SBVA02190V1
15	52	1334051	COLINIOT13	3222815T6 (COLNNON03), SXBC00794V1, SXBC00639V1
16	53	1336728	COLNNOT13	630458R6 (KIDNNOTO5), 1336728H1 (COLNNOT13), SXBC00758V1, SXBC01825V1, SXBC01531V1, SXBC01624V1, SXBC00128V1

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
17	54	1452856	PENITUT01	873008R1 (LUNGAST01), 1452856H1 (PENITUT01), 2433573H1 (BRAVUNT02), 2444932F6 (THP1NOT03), 2858295F6 (SININOT03)
18	55	1562471	SPLNNOT04	286237F1 (EOSIHETO2), 1562471H1 (SPLNNOTO4), 1880730F6 (LEUKNOTO3), 3420608F6 (UCMCNOTO4), SBWA00968V1, SXBC01387V1, SBWA02301V1
19	56	1618158	BRAITUT12	967563R1 (BRSTNOT05), 1618158H1 (BRAITUT12), 1785271F6 (BRAINOT10), 2074680F6 (ISLINOT01), 2822196H1 (ADRETUT06)
20	57	1656935	URETTUT01	1656935F6 (URETTUT01), 1656935H1 (URETTUT01), 2827605F6 (TLYMNOT03), 5272146H1 (OVARDIN02), 91482116
21	သိ	1859305	PROSNOT18	079372F1 (SYNORAB01), 639845R1 (BRSTNOT03), 1859305H1 (PROSNOT18), 3328091F6 (HEAONOT04), 3354812F6 (PROSNOT28), 5510642H1 (BRADDIR01)
22	65	1949083	PITUNOTO1	1287161H1 (BRAINOT11), 1949083H1 (PITUNOT01), 1949083R6 (PITUNOT01), 3814131F6 (TONSNOT03)
23	09	1996357	BRSTTUT03	260527R6 (HNT2RATO1), 260527T6 (HNT2RATO1), 1313441F1 (BLADTUTO2), 1442781R1 (THYRNOTO3), 1996357H1 (BRSTTUTO3), 4262451H1 (BSCNDITO2), SAZA00147F1
24	61	2061330	OVARNOT03	2061330H1 (OVARNOT03), 2724233T6 (LUNGTUT10), 5104031T6 (PROSTUS20)
25	62	2346947	TESTTUT02	2346947F6 (TESTTUT02), 2346947H1 (TESTTUT02), 4051345F6 (SINTNOT18)

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
26	63	2795577	NPOLNOT01	867213R6 (BRAITUTO3), 2381770H1 (ISLTNOTO1), 2795577CT1 (NPOLNOTO1), 2795577CT1
27	64	3255825	OVARTUN01	3255825CT1 (OVARTUN01), 3255825H1 (OVARTUN01)
28	65	3393430	LUNGNOT28	218716941 (PROSNOT26), 339325641 (LUNGNOT28), 339343041 (LUNGNOT28), 339577441 (LUNGNOT28), 468968841 (LIVRTUT12), 489599641 (LIVRTUT12), 4896461F6 (LIVRTUT12), 4984527F6 (LIVRTUT10), 499294641 (LIVRTUT11)
29	99	3490990	EPIGNOT01	1235428F1 (LUNGFET03), 1662973T6 (BRSTNOT09), 2362021H1 (LUNGFET05), 2362021R6 (LUNGFET05), 3490990H1 (EPIGNOT01)
30	29	3635154	LIVRNOT03	027592H1 (SPLNFET01), 3635154H1 (LIVRNOT03), g1012932
31	89	4374347	CONFNOT03	860875X11 (BRAITUTO3), 898143R6 (BRSTNOTO5), 4374347H1 (CONFNOTO3)
32	69	4596747	COLSTUT01	137213R1 (SYNORAB01), 54556RR6 (OVARNOTO2), 1235402F1 (LUNGFET03), 1268010F1 (BRAINOTO9), 1271078F1 (TESTTUTO2), 1301951F6 (BRSTNOTO7), 1994442R6 (BRSTTUTO3), 2343102H1 (TESTTUTO2), 3274538F6 (PROSBPT06), 4596747H1 (COLSTUTO1)
33	70	5052680	BRSTNOT33	1973688H1 (UCMCL5T01), 3926410F6 (KIDNNOT19), 4501839F6 (BRAVTXT02), 5052680F6 (BRSTNOT33), 5052680H1 (BRSTNOT33), 5186780F6 (LUNGTWT04)
34	71	5373575	BRAINOT22	262776T6 (HNT2AGT01), 1234057F1 (LUNGFET03), 1741526R6 (HIPONONO1), 1871204F6 (SKINBIT01), 2192479F6 (THYRTUT03), 2556849H1 (THYMNOT03), 2722451T6 (LUNGTUT10), 4114985H1 (UTRSTUT07), 5373575H1 (BRAINOT22)

Table

Polypeptide SEQ ID NO:	SEQ ID NO: SEQ ID NO:	Clone ID	Library	Fragments
35	72	5524468	LIVRDIR01	LIVRDIR01 4024068F6 (BRAXNOT02), 5524468H1 (LIVRDIR01), SXBC01952V1
36	73	5944279	COLADITOS	1662182H1 (BRSTNOT09), 1698677F6 (BLADTUT05), 1916639R6 (PROSNOT06), 2298565R6 (BRSTNOT05), 2298565R6 (BRSTNOT05), 2583019F6 (KIDNTUT13), 2870903F6 (THYRNOT10), 3970715H1 (PROSTUT10), 3971695H1 (PROSTUT10), 5944279H1 (COLADIT05)
37	74	6114480	SINITMT04	1579843F6 (DUODNOT01), 1579843T6 (DUODNOT01), 4181024T6 (SINITUT03), 6114480H1 (SINITMT04), SXBC00007V1, SXBC00504V1, SCSA05104V1

77

# Table 2

s Analytical Methods and Databases	astic BLAST-GenBank MOTIFS A1 SPSCAN	-3 BLAST-GenBank ulus] MOTIFS SPSCAN HMMER BLAST-PRODOM	BLAST-GenBank e C- MOTIFS in SPSCAN ulus] HWMER-PFAM BLIMPS-BLOCKS PROFILESCAN BLAST-DOMO	BLAST-GenBank MOTIFS HMMER
Homologous Sequences	Paraneoplastic neuronal antigen MA1 [Homo sapiens] g4104634	Pancortin-3 [Mus musculus] g3218528	Murine macrophage C- type lectin [Mus musculus] g5821286	
Signature Sequences, Motifs, and Domains	Signal peptide: M1-A33	Signal peptide: M1-T24 Glycoprotein signature: C199-L448	Signal peptide: M1-C42 Transmembrane domain: L32-F49 C-type lectin domain: C80-E206	Signal peptide: M1-G31 Transmembrane domain: I184-F201 Cell attachment sequence: R149-D151
Potential Glycosyla- tion Sites	N128	N75 N159 N279 N445	N2 N62 N107	
Potential Phosphorylation Sites	S31 T116 S169 T229 T2 S209 T306	T198 S27 S37 T87 S251 S257 S325 S373 S405 S422 T454 T210 S228 S401 Y93	T51 S120 S163 T175 T181 S3 T12 T45 S75 S104 S128	S213 S91 S113 S35 S70 S76 S147 T163 S206
Amino Acid Residues	351	458	219	276
Polypeptide SEQ ID NO:	1	2	٣	4

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
رح د	375	S18 S205 T286 S3 S120 S197 T260 Y85		Transmembrane domains: W139-R158; F173-H191 p232-Q254 Transmembrane protein signature: I95-C369	Transmembrane protein [S. pombe] g1065898	BLAST-GenBank MOTIFS HWMER BLAST-DOMO BLAST-PRODOM
9	249	T7 T135 T170 S204 Y154	N18 N92 N147		Phospholipid scramblase [Homo sapiens] g4092081	BLAST-GenBank MOTIFS
7	353	T162 T4 S97 T115 S165 S194 T225 S242 S17 S47 S205	N299	Signal peptide: M1-A33	Paraneoplastic neuronal antigen MA1 [Homo sapiens] g4104634	BLAST-GenBank MOTIFS SPSCAN
ω	194	T12 S115 S29 S99 S187	N95 N147	Signal peptide: M1-C50 Transmembrane domain: L38-L56 C-type lectin domain: C75-E194	Lectin-like NK cell receptor LLT1 [Homo sapiens] g6651065	BLAST-GenBank MOTIFS SPSCAN HMMER HMMER-PFAM BLIMPS-BLOCKS BLAST-DOMO
6	322	S304 S48 S146 S72 T133 S255 S280	N20 N60 N70	Signal peptide: M1-A50		BLAST-GenBank MOTIFS SPSCAN

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
	335	S125 S140 S183 S222 T252		Transmembrane domains: G71-L94; A255-I283 GufA transmembrane protein domain: L12-H101; G180-G335 Glycosaminoglycan attachment site: S310-G313	GufA protein [Thermotoga maritima] g4982315	BLAST-GenBank MOTIFS HWMER BLAST-PRODOM BLAST-DOMO
11	620	S49 S108 T146 S300 T348 T349 S607 S4 S128 S183 S234 T420 S460 S467 S543 Y597	N144 N202 N264 N274 N293 N341 N492 N505 N526 N542	Transmembrane domain: M563-W582 Immunoglobulin domain: G439-A499 Leucine-rich repeat signature: L337-L350 Glycoprotein hormone receptor domain: T40-L198	Slit2 [Rattus norvegicus] g4585574	BLAST-GenBank MOTIFS HWMER HWMER-PFAM BLIMPS-PRINTS BLAST-DOMO

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
12	491	T231 T232 S253 T482 S185 S276	N56 N220 N229	Transmembrane domains: 1115-1142; I184-V201 F422-F441 Transmembrane protein domain: L8-Y215; I396-F471	Selectively expressed in embryonic epithelia protein-1 [Mus musculus] g6715148 PB39 [Homo sapiens] g3462515	BLAST-GenBank MOTIFS HWMER BLAST-PRODOM
13	580	S557 S10 T34 S51 T92 T210 S343 T12 S217 T222 S268 S296 T417 T523 S550	N159 N179 N220 N230	Transmembrane domains: F297-F313; I356-I373 L496-I514 Lipases serine active site: L104-A113		MOTIFS HMMER
14	455	T53 T182 S239 S69 S135 S202 T280 S355 S372 Y38	N67 N180 N243	Transmembrane domains: V81-V99; I343-I361 S375-V392; W425-Y442 Glycosaminoglycan attachment site: S162-G165	putative G- protein coupled receptor [Homo sapiens] g6649579	BLAST-Genbank MOTIFS HMMER

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
15	277	S265 T66 T225 S268 S273 S30 S49 S61 S152 S193 Y242	N29 N38 N47 N48 N92 N160 N210	Transmembrane domain: K9-F27 Brush border protein domain: Y8-R277 RGD cell attachment sequence: R113-D115	AdRab-A brush border membrane protein [Oryctolagus cuniculus] g1762	BLAST-GenBank MOTIFS HMMER BLAST-PRODOM
16	647	8490 T50 S67 8105 T110 S121 T220 S249 S264 S272 S322 T389 S469 T501 S639 S132 T155 S242 S324 T381 T400 S522 S554	N261	Signal peptide: M1-A22 Transmembrane domains: L328-L347; M406-L424 L559-A578; W618-L638 GufA transmembrane protein domain: E485-L640 Glycosaminoglycan attachment site: S34-G37	LIV-1 protein [Homo sapiens] g1256001	BLAST-GenBank MOTIFS SPSCAN HMMER BLAST-PRODOM
17	406	S29 S215 S236 T69	N23	Transmembrane domains: Q76-V95; W286-S313 M367-I384		MOTIFS HMMER

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
18	290	T221 S44 S69 S71 S81 T94 T101 T113 T131 S216 Y284	N88	Signal peptide: M1-A19 Transmembrane domains: P160-M181 Immunoglubulin domain: R33-I110 Transmembrane glycoprotein domain: I22-D116	NK inhibitory receptor [Homo sapiens] g6707799 CMRF-35-H9 leukocyte antigen [Homo sapiens] g4103066	BLAST-GenBank MOTIFS SPSCAN HMMER HMMER-PFAM BLAST-PRODOM BLAST-DOMO
19	390	S7 T68 S153 T23 T166 T281 Y20 Y37	N5 N88 N330 N367	Immunoglobulins and MHC proteins signature: T90-P112; F242-V259 Glycoprotein antigen signature: L61-V72; V92-I113		MOTIFS BLIMPS-BLOCKS BLIMPS-PRODOM
20	427	S13 S41 S65 S66 S99 T150 S323 S324 S101 S275 S353 S367 T399 Y71	N106 N148 N171 N233. N312	Mucin glycoprotein precursor domain: V136-P142	Gastric mucin [Sus scrofa] g915208	BLAST-GenBank MOTIFS BLIMPS-PRODOM

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
. 21	459	T4 S60 S66 S116 T176 S16 T235	N14 N158 N323	Transmembrane domains: F202-V219; I246-L268 W343-L367; P417-P440	six transmembrane epithelial antigen of prostate [Homo sapiens] g6572948	BLAST-GenBank MOTIFS HWMER
22	229	S13 S118 T155 Y24		Transmembrane domains: 193-V111; V132-L150 F164-V182 Transmembrane protein domain: S156-V182		MOTIFS HMMER BLIMPS-PRODOM
23	311	S85 S234 S236 S269 S80 S119 S186 T294	N2.2	Transmembrane domains: W58-I76; P152-K177 A216-Y232		MOTIFS HMMER
24	92	S47 T54 T12 S70	N62		HERV-E envelope glycoprotein [Homo sapiens] g2587024	BLAST-GenBank MOTIFS
25	258	S34 T33 S148 S243		Transmembrane domains: I39-I57; F86-L106 V122-I140; L190-S210		MOTIFS HMMER

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
26	226	S56 S128 T196 T167 Y194	N54 N187 N198	Signal peptide: M1-P50 Transmembrane domains: T23-L43; M72-A89 I101-I124; I158-N178 Transmembrane 4 family signature: A70-I120 Lysosomal-associated transmembrane protein domain: C15-Y223	MTP (mouse transporter protein) [Mus musculus] g1276631	BLAST-GenBank MOTIFS SPSCAN HMMER PROFILESCAN BLAST-PRODOM
27	136	s3 s132		Signal peptide: M1-R53 Transmembrane domains: I10-L28; T26-I50 F70-L89 Transmembrane protein domain: D31-V104		MOTIFS SPSCAN HMMER BLAST-PRODOM

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
28	458	T408 T98 S126 S170 T334	N293 N332	Signal peptide: M1-A20 Transmembrane domain: L10-N30 Membrane glycoprotein signature: L9-V101; L64-Q457 Olfactory ligand binding domain: T67-S452	Potential ligand (odorant) binding protein [Rattus rattus] g57732	BLAST-GenBank MOTIFS SPSCAN HIMMER BLAST-PRODOM BLAST-DOMO
29	368	S24 T166 T302 S12 S134 Y307	N17		Fuzzy (TM protein involved in tissue polarity) [Drosophila melanogaster] g2564657	BLAST-GenBank MOTIFS
30	91	T44 S84		Signal peptide: M1-A19 Transmembrane domain: P58-S82 Glycophorin A proteins signature: T22-S32; I63-G91 Glycophorin domain: M1-R86	Preglycophorin B [Homo sapiens] g4803699	BLAST-GenBank MOTIFS SPSCAN HWMER BLIMPS-BLOCKS PROFILESCAN BLAST-PRODOM BLAST-DOMO

# Table 2

Analytical Methods and Databases	BLAST-GenBank MOTIFS SPSCAN HWMER HWMER-PFAM BLAST-PRODOM BLAST-DOMO	MOTIFS HMMER BLAST-DOMO
Homologous Sequences	Biliary glycoprotein [Mus musculus] g312590	·
Signature Sequences, Motifs, and Domains	Signal peptide: M1-G48 Transmembrane domain: L241-L259 Immunoglobulin domain: K159-V216 Carcinoembryonic antigen domain: I38-P147 Glycoprotein antigen domain: M1-V140; Y141-Y234 G239-S295	Transmembrane domain: 1611-F630 Membrane protein domain: T4-L209
Potential Glycosyla- tion Sites	N111 N169 N223	N279 N348
Potential Phosphorylation Sites	896 T113 S129 T155 T125 T157 T187 S222 T231 T263 Y212	T39 S47 T171 S205 T224 S225 T241 S285 S301 T323 S352 T353 S439 S509 S517 S537 T659 T707 S8 S18 S49 S72 T85 T159 S173 S271 S367 S560 S588 Y499
Amino Acid Residues	295	724
Polypeptide SEQ ID NO:	31	

# Table 2

Analytical Methods and Databases	BLAST-GenBank MOTIFS SPSCAN HWMER BLAST-PRODOM	BLAST-GenBank MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO	BLAST-GenBank MOTIFS SPSCAN HWMER HWMER-PFAM BLIMPS-PRINTS
Homologous A Sequences M	Putative Golgi B UDP-GlcNAc M transporter S [S. pombe] B g3738167	Stomatin-like B protein UNC24 M [Homo sapiens] H g5326747 B B B	Similar to Leucine-rich  transmembrane proteins Homo sapiens]  g2781386 B
Signature Sequences, Motifs, and Domains	Signal peptide: M1-S16 Transmembrane domains: A67-N87; I118-C134 W240-V269; L294-Y310 Transmembrane protein domain: A6-T311	Transmembrane domain: 159-L79  Band 7 family domain: F64-A231, A78-V90; R116-L154  Stomatin signature: T84-L106; L131-P152 T166-L183; I186-G209 L54-Q227	Signal peptide: M1-G19 Leucine rich repeats: A62-F85; Q86-S109 G110-G133; A134-R157 A158-S181; H184-P207
Potential Glycosyla- tion Sites	N222	÷	N107
Potential Phosphorylation Sites	S117 S147 S149 T320 S138 S174 T274 T319 S328 Y198	T42 T158 S271 S28 S285 T334 S375	S199 T120 S192
Amino Acid Residues	331	398	220
Polypeptide SEQ ID NO:	33	34	3.5

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosyla- tion Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
3 6	706	T564 T74 T113 S291 S452 S632 S14 T42 S66 T115 T142 S286 T551 T575 S701	N101	Transmembrane domains: F158-M178; L344-V368 L425-L442; M478-F498 A581-I604; L641-V665 Glycosaminoglycan attachment site: S223-G226	LAK-4p [Homo sapiens] g7209574	BLAST-GenBank MOTIFS HMMER
37	466	T326 S10 T46 T105 S187 S98 T164 T310 S321 Y388	N3 6 8	Signal peptide: M1-G23 Transmembrane domain: A236-1255 SPRY domain: A338-S464; E123-S136 E322-W343; V407-F420 Butyrophilin domain: W19-C114	Butyrophilin like receptor [Homo sapiens] g4587209	BLAST-GenBank MOTIFS SPSCAN HWMER HWMER-PFAM BLIMPS-PFAM BLAST-PRODOM BLAST-DOMO

Table ?

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
38	844-888	Nervous (0.377) Reproductive (0.180) Cardiovascular (0.115) Gastrointestinal (0.115)	Cancer (0.410) Inflammation/Trauma (0.296) Cell Proliferation (0.131)	PBLUESCRIPT
39	579-623	Developmental (0.400) Musculoskeletal (0.200) Nervous (0.200) Urologic (0.200)	Cancer (0.400) Cell Proliferation (0.400)	PSPORT1
40	336-380	Cardiovascular (0.267) Hematopoietic/Immune (0.200) Endocrine (0.133) Reproductive (0.133)	Cancer (0.400) Inflammation/Trauma (0.400) Cell Proliferation (0.133)	pINCY
41	596-640	Nervous (0.588) Gastrointestinal (0.118) Reproductive (0.118)	Inflammation/Trauma (0.470) Cancer (0.235) Cell Proliferation (0.176)	pINCY
42	1281-1325	Reproductive (0.237) Hematopoietic/Immune (0.145) Nervous (0.145)	Cancer (0.441) Inflammation/Trauma (0.323) Cell Proliferation (0.178)	pincy
43	227-271	Reproductive (0.444) Dermatologic (0.222) Endocrine (0.111) Gastrointestinal (0.111) Nervous (0.111)	Cancer (0.333) Cell Proliferation (0.222) Inflammation/Trauma (0.222)	pincy

Table 3

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
44	1368-1412	Nervous (0.339) Reproductive (0.278) Gastrointestinal (0.104)	Cancer (0.478) Inflammation/Trauma (0.278) Cell Proliferation (0.165)	pINCY
45	543-587	Hematopoietic/Immune (0.500) Gastrointestinal (0.188)	Inflammation/Trauma (0.500) Cancer (0.250) Cell Proliferation (0.188)	pINCY
46	280-324	Reproductive (0.267) Nervous (0.233) Gastrointestinal (0.112)	Cancer (0.483) Inflammation/Trauma (0.345) Cell Proliferation (0.155)	pINCY
47	380-424 875-919	Reproductive (0.412) Gastrointestinal (0.176) Cardiovascular (0.118)	Cancer (0.647) Inflammation/Trauma (0.178)	PSPORT1
48	272-316 1514-1558	Nervous (0.645) Developmental (0.129)	Cancer (0.355) Cell Proliferation (0.258) Neurological (0.194)	PSPORT1
49	282-326 768-812	Hematopoietic/Immune (0.238) Gastrointestinal (0.155) Reproductive (0.143)	Cancer (0.381) Inflammation/Trauma (0.381) Cell Proliferation (0.202)	PSPORT1
50	597-641 1074-1118	Reproductive (0.214) Nervous (0.196) Hematopoietic/Immune (0.143)	Cancer (0.464) Inflammation/Trauma (0.304) Cell Proliferation (0.196)	PSPORT1
51	973-1017	Reproductive (0.266) Nervous (0.234) Hematopoietic/Immune (0.125)	Cancer (0.516) Inflammation/Trauma (0.359) Cell Proliferation (0.109)	PSPORT1

Table 3

Vector	pINCY	pincy	pINCY	pINCY	pINCY	pincy	pincy
Disease or Condition (Fraction of Total)	Cancer (0.500) Inflammation/Trauma (0.500)	Cancer (0.578) Inflammation/Trauma (0.311) Cell Proliferation (0.178)	Cancer (0.449) Inflammation/Trauma (0.305) Cell Proliferation (0.144)	Inflammation/Trauma (0.625) Cancer (0.125)	Cancer (0.458) Inflammation/Trauma (0.250)	Cancer (0.571) Inflammation/Trauma (0.286) Cell Proliferation (0.143)	Cancer (0.500) Inflammation/Trauma (0.500)
Tissue Expression (Fraction of Total)	Gastrointestinal (1.000)	Gastrointestinal (0.289) Reproductive (0.244) Cardiovascular (0.111) Hematopoietic/Immune (0.111)	Nervous (0.195) Reproductive (0.186) Gastrointestinal (0.144)	Hematopoietic/Immune (0.750)	Nervous (0.583)	Reproductive (0.429) Hematopoietic/Immune (0.286) Musculoskeletal (0.143) Urologic (0.143)	Reproductive (0.350) Nervous (0.150) Cardiovascular (0.100) Gastrointestinal (0.100) Hematopoietic/Immune (0.100) Urologic (0.100)
Selected Fragments	299-343	380-424 1199-1243	1135-1179	325-369 820-864	487-531 1090-1134	569-613 1360-1405	272-472 551-595 812-1012 1523-1567
Nucleotide SEQ ID NO:	52	53	54	55	95	57	58

Table 3

ondition Vector Total)	Inflammation/Trauma (0.428) PBLUESCRIPT Cancer (0.357) Cell Proliferation (0.143)	Cancer (0.467) Inflammation/Trauma (0.359) Cell Proliferation (0.163)	Cancer (0.500) Inflammation/Trauma (0.321)	Cancer (0.750) Inflammation/Trauma (0.250)	Cancer (0.594) Cell Proliferation (0.231) Inflammation/Trauma (0.210)	Cancer (0.455) Inflammation/Trauma (0.367) Cell Proliferation (0.189)
Disease or Condition (Fraction of Total)	Inflammation/7 Cancer (0.357) Cell Prolifers	Cancer (0.467) Inflammation/T Cell Prolifera	Cancer (0.500 Inflammation/	Cancer (0.750) Inflammation/T	Cancer (0.594) Cell Prolifera Inflammation/7	Cancer (0.455) Inflammation/7 Cell Prolifers
Tissue Expression (Fraction of Total)	Nervous (0.286) Developmental (0.143) Gastrointestinal (0.143) Hematopoietic/Immune (0.143) Reproductive (0.143)	Nervous (0.207) Reproductive (0.207) Gastrointestinal (0.130) Hematopoietic/Immune (0.130)	Reproductive (0.464) Endocrine (0.143) Cardiovascular (0.107) Gastrointestinal (0.107)	Gastrointestinal (0.500) Hematopoietic/Immune (0.250) Reproductive (0.250)	Reproductive (0.315) Gastrointestinal (0.161) Cardiovascular (0.147)	Gastrointestinal (0.455) Cardiovascular (0.273) Reproductive (0.189)
Selected Fragments	217-261	444-488	643-687	146-344 390-434 506-704 786-830	163-207	201-506 525-569 606-912 975-1280
Nucleotide SEQ ID NO:	59	09	61	62	63	64

Table 3

Vector	pincy	pINCY	pincy	pincy	PINCY	PINCY
Disease or Condition (Fraction of Total)	Cancer (1.000)	Cancer (0.429) Cell Proliferation (0.171) Inflammation/Trauma (0.143)	Cell Proliferation (0.727) Cancer (0.273) Inflammation/Trauma (0.182)	Cancer (0.556) Inflammation/Trauma (0.333)	Cancer (0.429) Inflammation/Trauma (0.337) Cell Proliferation (0.255)	Cancer (0.467) Cell Proliferation (0.267) Inflammation/Trauma (0.267)
Tissue Expression (Fraction of Total)	Gastrointestinal (0.667) Cardiovascular (0.167) Reproductive (0.167)	Nervous (0.314) Reproductive (0.314) Developmental (0.114) Urologic (0.114)	Developmental (0.364) Hematopoietic/Immune (0.364) Gastrointestinal (0.182)	Reproductive (0.444) Nervous (0.222) Endocrine (0.111) Hematopoietic/Immune (0.111) Musculoskeletal (0.111)	Reproductive (0.255) Nervous (0.184) Developmental (0.122) Gastrointestinal (0.122)	Nervous (0.467) Hematopoietic/Immune (0.200) Reproductive (0.133) Urologic (0.133)
Selected Fragments	703-747	271-315 319-363	319–363	812-856	596-640 1577-1621	379-675 703-747 766-1062 1081-1347
Nucleotide SEQ ID NO:	65	99	29	89	69	70

Table 3

ondition Vector Total)	Cancer (0.500) DINCY Inflammation/Trauma (0.264) Cell Proliferation (0.147)	Inflammation/Trauma (0.667) pINCY Cancer (0.333)	Cancer (0.686) Inflammation/Trauma (0.294)	Cancer (0.462) Inflammation/Trauma (0.385)
Disease or Condition (Fraction of Total)	Cancer (0.500) Inflammation/T	Inflammation/T Cancer (0.333)	Cancer (0.686) Inflammation/T	Cancer (0.462) Inflammation/T
Tissue Expression (Fraction of Total)	Nervous (0.265) Reproductive (0.206) Musculoskeletal (0.147)	Gastrointestinal (0.333) Hematopoietic/Immune (0.333) Nervous (0.333)	Reproductive (0.392) Gastrointestinal (0.294) Cardiovascular (0.118)	Gastrointestinal (0.923)
Selected Fragments	18-62	290-488 507-704 759-803	649-693 1711-1755	704-748
Nucleotide SEQ ID NO:	71	72	73	74

Nucleotide SEQ ID NO:	Library	Library Description
38	PITUNOT01	This library was constructed using RNA obtained from Clontech (CLON 6584-2, lot 35278). The RNA was isolated from pituitary glands removed from a pool of 18 male and female Caucasian donors, 16 to 70 years old, who died from trauma.
3.9	KIDNTUT01	This library was constructed using RNA isolated from kidney tumor tissue removed from an 8-month-old female during nephroureterectomy. Pathology indicated Wilms' tumor (nephroblastoma), which involved 90 percent of the renal parenchyma. Prior to surgery, the patient was receiving heparin anticoagulant therapy.
40	BLADTUT04	This library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Carcinoma in-situ was identified in the dome and trigone. Patient history included tobacco use. Family history included type I diabetes, malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and acute myocardial infarction.
41	PROSNOT19	This library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+3). The patient presented with elevated prostate-specific antigen (PSA). Patient history included colon diverticuli, asbestosis, and thrombophlebitis. Family history included benign hypertension, multiple myeloma, hyperlipidemia and rheumatoid arthritis.
42	ISLTNOT01	This library was constructed using RNA isolated from a pooled collection of pancreatic islet cells.

Nucleotide SEQ ID NO:	Library	Library Description
43	ENDCNOT03	This library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male.
44	SMCANOT01	This library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male obtained during a heart transplant.
45	THYMNOT04	This library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from anoxia.
46	FIBAUNT02	This library was constructed using RNA isolated from untreated aortic adventitial fibroblasts removed from a 65-year-old Caucasian female.
47	BRSTTUT01	This library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign breast neoplasm. Family history included cardiovascular and cerebrovascular disease and depressive disorder.
48	BRAITUT01	This library was constructed using RNA isolated from brain tumor tissue removed from a 50-year-old Caucasian female during a frontal lobectomy. Pathology indicated recurrent grade 3 oligoastrocytoma with focal necrosis and extensive calcification. Patient history included a speech disturbance and epilepsy. The patient's brain had also been irradiated with a total dose of 5,082 cyg (Fraction 8). Family history included a brain tumor.
49	RATRNOT02	This library was constructed using RNA isolated from the right atrium tissue of a 39-year-old Caucasian male, who died from a gunshot wound.

Nucleotide SEQ ID NO:	Library	Library Description
20	BRSTNOT02	This library was constructed using RNA isolated from diseased breast tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated proliferative fibrocysytic changes characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Pathology for the associated tumor tissue indicated an invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign neoplasm. Family history included cardiovascular and cerebrovascular disease.
51	BRSTNOT03	This library was constructed using RNA isolated from diseased breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypertension, hyperlipidemia and a malignant neoplasm of the colon.
52	COLNNOT13	This library was constructed using RNA isolated from ascending colon tissue of a 28-year-old Caucasian male with moderate chronic ulcerative colitis.
53	COLINIOT13	This library was constructed using RNA isolated from ascending colon tissue of a 28-year-old Caucasian male with moderate chronic ulcerative colitis.
54	PENITUT01	This library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.

Nucleotide SEQ ID NO:	Library	Library Description .
55	SPLNNOT04	This library was constructed using RNA isolated from the spleen tissue of a 2-year-old Hispanic male, who died from cerebral anoxia.
95	BRAITUT12	This library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 40-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated grade 4 gemistocytic astrocytoma.
57	URETIUTO1	This library was constructed using RNA isolated from right ureter tumor tissue of a 69-year-old Caucasian male during ureterectomy and lymph node excision. Pathology indicated invasive grade 3 transitional cell carcinoma. Patient history included benign colon neoplasm, tobacco use, asthma, emphysema, acute duodenal ulcer, and hyperplasia of the prostate. Family history included atherosclerotic coronary artery disease, congestive heart failure, and malignant lung neoplasm.
58	PROSNOT18	This library was constructed using RNA isolated from diseased prostate tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated adenofibromatous hyperplasia; this tissue was associated with a grade 3 transitional cell carcinoma. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
59	PITUNOT01	This library was constructed using RNA obtained from Clontech (CLON 6584-2, lot 35278). The RNA was isolated from the pituitary glands removed from a pool of 18 male and female Caucasian donors, 16 to 70 years old, who died from trauma.

Nucleotide SEQ ID NO:	Library	Library Description
09	BRSTTUT03	This library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
61	OVARNOT03	This library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
62	TESTTUT02	This library was constructed using RNA isolated from testicular tumor tissue removed from a 31-year-old Caucasian male during unilateral orchiectomy. Pathology indicated embryonal carcinoma.
63	NPOLNOT01	This library was constructed using RNA isolated from nasal polyp tissue removed from a 78-year-old Caucasian male during a nasal polypectomy. Pathology indicated a nasal polyp and striking eosinophilia. Patient history included asthma and nasal polyps.

Nucleotide SEQ ID NO:	Library	Library Description
64	OVARTUN01	This normalized library was constructed from 5.36 million independent clones obtained from an ovarian tumor library. RNA was isolated from tumor tissue removed from the left ovary of a 58-year-old Caucasian female during a total abdominal hysterectomy, removal of a single ovary, and inguinal hernia repair. Pathology indicated a metastatic grade 3 adenocarcinoma of colonic origin, forming a partially cystic and necrotic tumor mass in the left ovary, and a nodule in the left mesovarium. A single intramural leiomyoma was identified in the myometrium. The cervix showed mild chronic cystic cervicitis. Patient history included benign hypertension, follicular ovarian cyst, colon cancer, benign colon neoplasm, and osteoarthritis. Family history included emphysema, myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, hyperlipidemia, and primary tuberculous complex. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228) and Bonaldo et al. (Genome Research (1996) 6:791).
65	LUNGNOT28	This library was constructed using RNA isolated from lung tissue removed from a 53-year-old male. Pathology for the associated tumor tissue indicated grade 4 adenocarcinoma.
99	EPIGNOT01	This library was constructed using RNA isolated from epiglottic tissue removed from a 71-year-old male during laryngectomy with right parathyroid biopsy. Pathology for the associated tumor tissue indicated recurrent grade 1 papillary thyroid carcinoma.
67	LIVRNOT03	This library was constructed using RNA isolated from liver tissue removed from a Caucasian male fetus, who died from Patau's syndrome (trisomy 13) at 20 weeks' gestation.

SEQ ID NO:	Library	uibrary Description
89	CONFNOT03	This library was constructed using RNA isolated from mesenteric fat tissue removed from a 71-year-old Caucasian male during a partial colectomy and permanent colostomy. Pathology indicated mesenteric fat tissue associated with diverticulosis and diverticulitis with abscess formation. Approximately 50 diverticula were noted, one of which was perforated and associated with abscess formation in adjacent mesenteric fat. The patient presented with atrial fibrillation. Patient history included viral hepatitis, a hemangioma, and diverticulitis of colon. Family history included extrinsic asthma, atherosclerotic coronary artery disease, and myocardial infarction.
69	COLSTUT01	This library was constructed using RNA isolated from colon tumor tissue removed from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma, with invasion through the muscularis. Patient history included hyperlipidemia, cataract disorder and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
70	BRSTNOT33	This library was constructed using RNA isolated from right breast tissue removed from a 46-year-old Caucasian female during a unilateral extended simple mastectomy with breast reconstruction. Pathology for the associated tumor tissue indicated invasive grade 3 adenocarcinoma, ductal type, with apocrine features, nuclear grade 3 forming a mass in the outer quadrant. There was greater than 50% intraductal component. Patient history included breast cancer.

Nucleotide SEQ ID NO:	Library	Library Description
71	BRAINOT22	This library was constructed using RNA isolated from right temporal lobe tissue removed from a 45-year-old Black male during a brain lobectomy. Pathology for the associated tumor tissue indicated dysembryoplastic neuroepithelial tumor of the right temporal lobe. The right temporal region dura was consistent with calcifying pseudotumor of the neuraxis. Patient history included obesity, meningitis, backache, unspecified sleep apnea, acute stress reaction, acquired knee deformity, and chronic sinusitis. Family history included obesity, benign hypertension, cirrhosis of the liver, obesity, hyperlipidemia, cerebrovascular disease, and type II diabetes.
72	LIVRDIR01	This library was constructed using RNA isolated from diseased liver tissue removed from a 63-year-old Caucasian female during a liver transplant. Patient history included primary biliary cirrhosis. Serology was positive for anti-mitochondrial antibody.
73	COLADIT05	This library was constructed using RNA isolated from diseased ascending colon tissue removed from a 32-year-old Caucasian male during a total intraabdominal colectomy, abdominal-perineal rectal resection, and temporary ileostomy. Pathology indicated chronic ulcerative colitis extending in a continuous fashion from the mid-portion of the ascending colon distally to the rectum. This was characterized microscopically by crypt abscess formation and inflammation confined to the mucosa and submucosa. The terminal ileum exhibited ileitis and the rectal mucosa showed crypt abscess formation. Patient history included tobacco use. Family history included ulcerative colitis, malignant neoplasm of the breast and acute myocardial infarction.

Nucleotide SEQ ID NO:	Library	Library Description
74	SINITMT04	Library was constructed using RNA isolated from ileum tissue removed from a 70-year-old Caucasian female during right hemicolectomy, open liver biopsy, flexible sigmoidoscopy, colonoscopy, and permanent colostomy. Pathology indicated a non-tumorous margin of ileum. Pathology for the associated tumor indicated invasive grade 2 adenocarcinoma forming an ulcerated mass, situated 2 cm distal to the ileocecal valve. The tumor invaded through the muscularis propria just into the serosal adipose tissue. One (of 16) regional lymph node was positive for a microfocus of metastatic adenocarcinoma. Patient history included a malignant breast neoplasm, type II diabetes, hyperlipidemia, viral hepatitis, an unspecified thyroid disorder, osteoarthritis, and a malignant skin neoplasm. Family history included breast cancer, atherosclerotic coronary artery disease, benign hypertension, cerebrovascular disease, ovarian cancer, and hyperlipidemia.

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	PE Biosystems, Foster City, CA.	
ABIPARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	PE Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences,	PE Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nuclcic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

# Table 5 (cont.)

Program	Description	Réference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score CCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed .	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

#### What is claimed is:

5

20

35

 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37,
- b) a naturally occurring amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37,
- c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and
- d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37.
  - 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1,

SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37.

- 3. An isolated polynucleotide encoding a polypeptide of claim 1.
- 4. An isolated polynucleotide encoding a polypeptide of claim 2.
- An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74.
- 20 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
  - 7. A cell transformed with a recombinant polynucleotide of claim 6.
  - 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
    - 9. A method for producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
    - b) recovering the polypeptide so expressed.
    - 10. An isolated antibody which specifically binds to a polypeptide of claim 1.

25

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEO ID NO:73, SEO ID NO:74,
- b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74,
  - c) a polynucleotide sequence complementary to a),
  - d) a polynucleotide sequence complementary to b), and
  - e) an RNA equivalent of a)-d).
- 12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.
- 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
  - 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

10

20

25

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5

10

25

30

35

- 16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
- 17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37.
- 18. A method for treating a disease or condition associated with decreased expression of
   functional MEMAP, comprising administering to a patient in need of such treatment the composition of claim 16.
  - 19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
    - a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
    - b) detecting agonist activity in the sample.

A Company of the Section Com-

- 20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.
- 21. A method for treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment a composition of claim 20.
  - 22. A method for screening a compound for effectiveness as an antagonist of a polypeptide

of claim 1, the method comprising:

5

10

15

20

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting antagonist activity in the sample.

----

- 23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.
- 24. A method for treating a disease or condition associated with overexpression of functional MEMAP, comprising administering to a patient in need of such treatment a composition of claim 23.
- 25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
  - 26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:
- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
- 27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
  - a) exposing a sample comprising the target polynucleotide to a compound, and
  - b) detecting altered expression of the target polynucleotide.
- 35 28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological
   5 sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
  - c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the
   amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

#### SEQUENCE LISTING

```
<110> INCYTE GENOMICS, INC.
     LAL, Preeti
     YUE, Henry
     TANG, Y. Tom
     BANDMAN, Olga
     BURFORD, Neil
AZIMZAI, Yalda
     BAUGHN, Mariah R.
     LU, Dyung Aina M.
      PATTERSON, Chandra
<120> MEMBRANE ASSOCIATED PROTEINS
<130> PF-0731 PCT
<140> To Be Assigned
<141> Herewith
<150> 60/149,641; 60/164,203
<151> 1999-08-17; 1999-11-09
<160> 74
<170> PERL Program
<210> 1
<211> 351
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 112301CD1
<400> 1
Met Thr Leu Arg Leu Leu Glu Asp Trp Cys Arg Gly Met Asp Met
                  5
                                      10
Asn Pro Arg Lys Ala Leu Leu Ile Ala Gly Ile Ser Gln Ser Cys
                 20
                                      25
Ser Val Ala Glu Ile Glu Glu Ala Leu Gln Ala Gly Leu Ala Pro
                 35
                                      40
Leu Gly Glu Tyr Arg Leu Leu Gly Arg Met Phe Arg Arg Asp Glu
                 50
                                      55
Asn Arg Lys Val Ala Leu Val Gly Leu Thr Ala Glu Thr Ser His
                 65
                                      70
Ala Leu Val Pro Lys Glu Ile Pro Gly Lys Gly Gly Ile Trp Arg
                 80
                                      85
Val Ile Phe Lys Pro Pro Asp Pro Asp Asn Thr Phe Leu Ser Arg
                 95
                                     100
Leu Asn Glu Phe Leu Ala Gly Glu Gly Met Thr Val Gly Glu Leu
                110
                                     115
Ser Arg Ala Leu Gly His Glu Asn Gly Ser Leu Asp Pro Glu Gln
                125
                                     130
                                                         135
Gly Met Ile Pro Glu Met Trp Ala Pro Met Leu Ala Gln Ala Leu
                140
                                     145
Glu Ala Leu Gln Pro Ala Leu Gln Cys Leu Lys Tyr Lys Lys Leu
                155
                                     160
Arg Val Phe Ser Gly Arg Glu Ser Pro Glu Pro Gly Glu Glu Glu
                170
                                     175
                                                          180
Phe Gly Arg Trp Met Phe His Thr Thr Gln Met Ile Lys Ala Trp
```

```
190
                185
                                                         195
Gln Val Pro Asp Val Glu Lys Arg Arg Arg Leu Leu Glu Ser Leu
                200
                                    205
Arg Gly Pro Ala Leu Asp Val Ile Arg Val Leu Lys Ile Asn Asn
                215
                                    220
                                                         225
Pro Leu Ile Thr Val Asp Glu Cys Leu Gln Ala Leu Glu Glu Val
                230
                                    235
Phe Gly Val Thr Asp Asn Pro Arg Glu Leu Gln Val Lys Tyr Leu
                245
                                    250
                                                         255
Thr Thr Tyr Gln Lys Asp Glu Glu Lys Leu Ser Ala Tyr Val Leu
                260
                                    265
Arg Leu Glu Pro Leu Leu Gln Lys Leu Val Gln Arg Gly Ala Ile
                275
                                    280
Glu Arg Asp Ala Val Asn Gln Ala Arg Leu Asp Gln Val Ile Ala
                290
                                    295
Gly Ala Val His Lys Thr Ile Arg Arg Glu Leu Asn Leu Pro Glu
                305
                                    310
Asp Gly Pro Ala Pro Gly Phe Leu Gln Leu Leu Val Leu Ile Lys
                320
                                    325
                                                         330
Asp Tyr Glu Ala Ala Glu Glu Glu Glu Ala Leu Leu Gln Ala Ile
                335
                                    340
Leu Glu Gly Asn Phe Thr
<210> 2
<211> 458
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 997947CD1
<400> 2
Met Gln Ala Thr Ser Asn Leu Leu Asn Leu Leu Leu Ser Leu
                                                         15
Phe Ala Gly Leu Asp Pro Ser Lys Thr Gln Ile Ser Pro Lys Glu
                 20
                                     25
Gly Trp Gln Val Tyr Ser Ser Ala Gln Asp Pro Asp Gly Arg Cys
                 35
                                     40
Ile Cys Thr Val Val Ala Pro Glu Gln Asn Leu Cys Ser Arg Asp
                 50
                                     55
Ala Lys Ser Arg Gln Leu Arg Gln Leu Leu Glu Lys Val Gln Asn
                                     70
                 65
Met Ser Gln Ser Ile Glu Val Leu Asn Leu Arg Thr Gln Arg Asp
                 80
                                     85
Phe Gln Tyr Val Leu Lys Met Glu Thr Gln Met Lys Gly Leu Lys
                                    100
                                                         105
Ala Lys Phe Arg Gln Ile Glu Asp Asp Arg Lys Thr Leu Met Thr
                110
                                    115
Lys His Phe Gln Glu Leu Lys Glu Lys Met Asp Glu Leu Leu Pro
                125
                                    130
Leu Ile Pro Val Leu Glu Gln Tyr Lys Thr Asp Ala Lys Leu Ile
                140
                                    145
                                                         150
Thr Gln Phe Lys Glu Glu Ile Arg Asn Leu Ser Ala Val Leu Thr
                155
                                    160
Gly Ile Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Glu Glu Leu His
                170
                                    175
                                                        180
Gln Arg Val Leu Ser Leu Glu Thr Arg Leu Arg Asp Cys Met Lys
                185
                                    190
Lys Leu Thr Cys Gly Lys Leu Met Lys Ile Thr Gly Pro Val Thr
                200
                                    205
                                                         210
Val Lys Thr Ser Gly Thr Arg Phe Gly Ala Trp Met Thr Asp Pro
                215
                                   . 220
                                                         225
```

```
Leu Ala Ser Glu Lys Asn Asn Arg Val Trp Tyr Met Asp Ser Tyr
                230
                                    235
Thr Asn Asn Lys Ile Val Arg Glu Tyr Lys Ser Ile Ala Asp Phe
                245
                                    250
Val Ser Gly Ala Glu Ser Arg Thr Tyr Asn Leu Pro Phe Lys Trp
                260
                                    265
                                                        270
Ala Gly Thr Asn His Val Val Tyr Asn Gly Ser Leu Tyr Phe Asn
                                    280
                275
Lys Tyr Gln Ser Asn Ile Ile Lys Tyr Ser Phe Asp Met Gly
                290
                                    295
Arg Val Leu Ala Gln Arg Ser Leu Glu Tyr Ala Gly Phe His Asn
                305
                                    310
Val Tyr Pro Tyr Thr Trp Gly Gly Phe Ser Asp Ile Asp Leu Met
                                    325
                320
Ala Asp Glu Ile Gly Leu Trp Ala Val Tyr Ala Thr Asn Gln Asn
                335
                                    340
Ala Gly Asn Ile Val Ile Ser Gln Leu Asn Gln Asp Thr Leu Glu
                                    355
                350
Val Met Lys Ser Trp Ser Thr Gly Tyr Pro Lys Arg Ser Ala Gly
                                    370
                                                        375
                365
Glu Ser Phe Met Ile Cys Gly Thr Leu Tyr Val Thr Asn Ser His
                380
                                    385
                                                        390
Leu Thr Gly Ala Lys Val Tyr Tyr Ser Tyr Ser Thr Lys Thr Ser
                395
                                    400
Thr Tyr Glu Tyr Thr Asp Ile Pro Phe His Asn Gln Tyr Phe His
                                    415
                410
Ile Ser Met Leu Asp Tyr Asn Ala Arg Asp Arg Ala Leu Tyr Ala
                425
                                    430
Trp Asn Asn Gly His Gln Val Leu Phe Asn Val Thr Leu Phe His
                440
                                    445
Ile Ile Lys Thr Glu Asp Asp Thr
                455
<210> 3
<211> 219
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1521513CD1
<400> 3
Met Asn Ser Ser Lys Ser Ser Glu Thr Gln Cys Thr Glu Arg Gly
                                     10
Cys Phe Ser Ser Gln Met Phe Leu Trp Thr Val Ala Gly Ile Pro
                                     25
Ile Leu Phe Leu Ser Ala Cys Phe Ile Thr Arg Cys Val Val Thr
                 35
                                     40
Phe Arg Ile Phe Gln Thr Cys Asp Glu Lys Lys Phe Gln Leu Pro
                 50
                                     55
Glu Asn Phe Thr Glu Leu Ser Cys Tyr Asn Tyr Gly Ser Gly Ser
                                     70
                 65
Val Lys Asn Cys Cys Pro Leu Asn Trp Glu Tyr Phe Gln Ser Ser
                 80
                                     85
Cys Tyr Phe Phe Ser Thr Asp Thr Ile Ser Trp Ala Leu Ser Leu
                 95
                                    100
Lys Asn Cys Ser Ala Met Gly Ala His Leu Val Val Ile Asn Ser
                110
                                    115
                                                        120
Gln Glu Glu Gln Glu Phe Leu Ser Tyr Lys Lys Pro Lys Met Arg
                125
                                    130
Glu Phe Phe Ile Gly Leu Ser Asp Gln Val Val Glu Gly Gln Trp
                140
                                    145
Gln Trp Val Asp Gly Thr Pro Leu Thr Lys Ser Leu Ser Phe Trp
```

PCT/US00/22315 WO 01/12662

```
155
                                     160
Asp Val Gly Glu Pro Asn Asn Ile Ala Thr Leu Glu Asp Cys Ala
                170
                                     175
                                                         180
Thr Met Arg Asp Ser Ser Asn Pro Arg Gln Asn Trp Asn Asp Val
                185
                                    190
                                                         195
Thr Cys Phe Leu Asn Tyr Phe Arg Ile Cys Glu Met Val Gly Ile
                200
                                     205
Asn Pro Leu Asn Lys Gly Lys Ser Leu
<210> 4
<211> 276
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1863994CD1
<400> 4
Met Glu Ser Arg Met Trp Pro Ala Leu Leu Leu Ser His Leu Leu
 1
                 - 5
                                     10
Pro Leu Trp Pro Leu Leu Leu Pro Leu Pro Pro Pro Ala Gln
                                     25
Gly Ser Ser Ser Pro Arg Thr Pro Pro Ala Pro Ala Arg Pro
                 35
                                     40
Pro Cys Ala Arg Gly Gly Pro Ser Ala Pro Arg His Val Cys Val
                 50
                                     55
Trp Glu Arg Ala Pro Pro Pro Ser Arg Ser Pro Arg Val Pro Arg
                 65
                                     70
Ser Arg Arg Gln Val Leu Pro Gly Thr Ala Pro Pro Ala Thr Pro
                 80
                                     85
                                                          90
Ser Gly Phe Glu Glu Gly Pro Pro Ser Ser Gln Tyr Pro Trp Ala
                 95
                                    100
Ile Val Trp Gly Pro Thr Val Ser Arg Glu Asp Gly Gly Asp Pro
                110
                                    115
                                                         120
Asn Ser Ala Asn Pro Gly Phe Leu Asp Tyr Gly Phe Ala Ala Pro
                125
                                    130
His Gly Leu Ala Thr Pro His Pro Asn Ser Asp Ser Met Arg Gly
                140
                                    145
Asp Gly Asp Gly Leu Ile Leu Gly Glu Ala Pro Ala Thr Leu Arg
                155
                                    160
Pro Phe Leu Phe Gly Gly Arg Gly Glu Gly Val Asp Pro Gln Leu
               170
                                    175
                                                         180
Tyr Val Thr Ile Thr Ile Ser Ile Ile Ile Val Leu Val Ala Thr
               185
                                    190
                                                         195
Gly Ile Ile Phe Lys Phe Cys Trp Asp Arg Ser Gln Lys Arg Arg
                200
                                    205
                                                        210
Arg Pro Ser Gly Gln Gln Gly Ala Leu Arg Gln Glu Glu Ser Gln
                215
                                    220
                                                        225
Gln Pro Leu Thr Asp Leu Ser Pro Ala Gly Val Thr Val Leu Gly
                230
                                    235
Ala Phe Gly Asp Ser Pro Thr Pro Thr Pro Asp His Glu Glu Pro
               245
                                    250
Arg Gly Gly Pro Arg Pro Gly Met Pro His Pro Lys Gly Ala Pro
               260
                                    265
Ala Phe Gln Leu Asn Arg
<210> 5
<211> 375
<212> PRT
<213> Homo sapiens
```

<220>

<221> misc\_feature <223> Incyte ID No: 2071941CD1 <400> 5 Met Ser Ser His Lys Gly Ser Val Val Ala Gln Gly Asn Gly Ala Pro Ala Ser Asn Arg Glu Ala Asp Thr Val Glu Leu Ala Glu Leu Gly Pro Leu Leu Glu Glu Lys Gly Lys Arg Val Ile Ala Asn Pro Pro Lys Ala Glu Glu Glu Gln Thr Cys Pro Val Pro Gln Glu Glu Glu Glu Glu Val Arg Val Leu Thr Leu Pro Leu Gln Ala His His Ala Met Glu Lys Met Glu Glu Phe Val Tyr Lys Val Trp Glu Gly Arg Trp Arg Val Ile Pro Tyr Asp Val Leu Pro Asp Trp Leu Lys Asp Asn Asp Tyr Leu Leu His Gly His Arg Pro Pro Met Pro Ser Phe Arg Ala Cys Phe Lys Ser Ile Phe Arg Ile His Thr Glu Thr Gly Asn Ile Trp Thr His Leu Leu Gly Phe Val Leu Phe Leu Phe Leu Gly Ile Leu Thr Met Leu Arg Pro Asn Met Tyr Phe Met Ala Pro Leu Gln Glu Lys Val Val Phe Gly Met Phe Phe Leu Gly Ala Val Leu Cys Leu Ser Phe Ser Trp Leu Phe His Thr Val Tyr Cys His Ser Glu Lys Val Ser Arg Thr Phe Ser Lys Leu Asp Tyr Ser Gly Ile Ala Leu Leu Ile Met Gly Ser Phe Val Pro Trp Leu Tyr Tyr Ser Phe Tyr Cys Ser Pro Gln Pro Arg Leu Ile Tyr Leu Ser Ile Val Cys Val Leu Gly Ile Ser Ala Ile Ile Val Ala Gln Trp Asp Arg Phe Ala Thr Pro Lys His Arg Gln Thr Arg Ala Gly Val Phe Leu Gly Leu Gly Leu Ser Gly Val Val Pro Thr Met His Phe Thr Ile Ala Glu Gly Phe Val Lys Ala Thr Thr Val Gly Gln Met Gly Trp Phe Phe Leu Met Ala Val Met Tyr Ile Thr Gly Ala Gly Leu Tyr Ala Ala Arg Ile Pro Glu Arg Phe Pro Gly Lys Phe Asp Ile Trp Phe Gln Ser His Gln Ile Phe His Val Leu Val Val Ala Ala Phe Val His Phe Tyr Gly Val Ser Asn Leu Gln Glu Phe Arg Tyr Gly Leu Glu Gly Gly Cys Thr Asp Asp Thr Leu Leu <210> 6 <211> 249 <212> PRT <213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 2172512CD1

<400> 6

```
Met Ser Gly Val Val Pro Thr Ala Pro Glu Gln Pro Ala Gly Glu
                                     10
Met Glu Asn Gln Thr Lys Pro Pro Asp Pro Arg Pro Asp Ala Pro
                 20
                                     25
Pro Glu Tyr Ser Ser His Phe Leu Pro Gly Pro Pro Gly Thr Ala
                 35
                                      40
Val Pro Pro Pro Thr Gly Tyr Pro Gly Gly Leu Pro Met Gly Tyr
                 50
                                     55
Tyr Ser Pro Gln Gln Pro Ser Thr Phe Pro Leu Tyr Gln Pro Val
                 65
                                     70
Gly Gly Ile His Pro Val Arg Tyr Gln Pro Gly Lys Tyr Pro Met
Pro Asn Gln Ser Val Pro Ile Thr Trp Met Pro Gly Pro Thr Pro
                 95
                                    100
Met Ala Asn Cys Pro Pro Gly Leu Glu Tyr Leu Val Gln Leu Asp
                110
                                    115
Asn Ile His Val Leu Gln His Phe Glu Pro Leu Glu Met Met Thr
                125
                                                         135
                                    130
Cys Phe Glu Thr Asn Asn Arg Tyr Asp Ile Lys Asn Asn Ser Asp
                                    145
                140
                                                         150
Gln Met Val Tyr Ile Val Thr Glu Asp Thr Asp Asp Phe Thr Arg
                155
                                    160
Asn Ala Tyr Arg Thr Leu Arg Pro Phe Val Leu Arg Val Thr Asp
                170
                                    175
                                                         180
Cys Met Gly Arg Glu Ile Met Thr Met Gln Arg Pro Phe Arg Cys
                185
                                    190
                                                         195
Thr Cys Cys Cys Phe Cys Cys Pro Ser Ala Arg Gln Glu Leu Glu
                200
                                    205
Val Gln Cys Pro Pro Gly Val Thr Ile Gly Phe Val Ala Glu His
                215
                                    220
                                                         225
Trp Asn Leu Cys Arg Ala Val Tyr Ser Ile Gln Lys Lys Lys
               230
                                    235
                                                         240
Lys Ile Ala Ala Gln Ala Tyr Ser Leu
               - 245
<210> 7
<211> 353
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2483172CD1
<400> 7
Met Ala Met Thr Leu Leu Glu Asp Trp Cys Arg Gly Met Asp Val
                                     10
Asn Ser Gln Arg Ala Leu Leu Val Trp Gly Ile Pro Val Asn Cys
Asp Glu Ala Glu Ile Glu Glu Thr Leu Gln Ala Ala Met Pro Gln
                                     40
Val Ser Tyr Arg Met Leu Gly Arg Met Phe Trp Arg Glu Glu Asn
                 50
                                     55
Ala Lys Ala Ala Leu Leu Glu Leu Thr Gly Ala Val Asp Tyr Ala
                 65
                                                          75
                                     70
Ala Ile Pro Arg Glu Met Pro Gly Lys Gly Gly Val Trp Lys Val
                 80
                                     85
                                                          90
Leu Phe Lys Pro Pro Thr Ser Asp Ala Glu Phe Leu Glu Arg Leu
                 95
                                    100
His Leu Phe Leu Ala Arg Glu Gly Trp Thr Val Gln Asp Val Ala
               110
                                    115
                                                         120
Arg Val Leu Gly Phe Gln Asn Pro Thr Pro Thr Pro Gly Pro Glu
                                    130
```

```
Met Pro Ala Glu Met Leu Asn Tyr Ile Leu Asp Asn Val Ile Gln
                140
                                    145
Pro Leu Val Glu Ser Ile Trp Tyr Lys Arg Leu Thr Leu Phe Ser
                                                         165
                155
                                    160
Gly Arg Asp Ile Pro Gly Pro Gly Glu Glu Thr Phe Asp Pro Trp
                170
                                    175
                                                         180
Leu Glu His Thr Asn Glu Val Leu Glu Glu Trp Gln Val Ser Asp
                                    190
                185
Val Glu Lys Arg Arg Arg Leu Met Glu Ser Leu Arg Gly Pro Ala
                200
                                    205
Ala Asp Val Ile Arg Ile Leu Lys Ser Asn Asn Pro Ala Ile Thr
                215
                                    220
                                                         225
Thr Ala Glu Cys Leu Lys Ala Leu Glu Gln Val Phe Gly Ser Val
                230
                                    235
Glu Ser Ser Arg Asp Ala Gln Ile Lys Phe Leu Asn Thr Tyr Gln
                245
                                    250
                                                         255
Asn Pro Gly Glu Lys Leu Ser Ala Tyr Val Ile Arg Leu Glu Pro
                260
                                    265
Leu Leu Gln Lys Val Val Glu Lys Gly Ala Ile Asp Lys Asp Asn
                275
                                    280
Val Asn Gln Ala Arg Leu Glu Gln Val Ile Ala Gly Ala Asn His
                290
                                    295
Ser Gly Ala Ile Arg Arg Gln Leu Trp Leu Thr Gly Ala Gly Glu
                305
                                    310
Gly Pro Ala Pro Asn Leu Phe Gln Leu Leu Val Gln Ile Arg Glu
                                                         330
                320
                                    325
Glu Glu Ala Lys Glu Glu Glu Glu Ala Glu Ala Thr Leu Leu
                335
                                    340
                                                         345
Gln Leu Gly Leu Glu Gly His Phe
                350
<210> 8
<211> 194
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2656128CD1
<400> 8
Met His Asp Ser Asn Asn Val Glu Lys Asp Ile Thr Pro Ser Glu
                                     10
Leu Pro Ala Asn Pro Gly Cys Leu His Ser Lys Glu His Ser Ile
                 20
                                     25
Lys Ala Thr Leu Ile Trp Arg Leu Phe Phe Leu Ile Met Phe Leu
                 35
                                     40
                                                          45
Thr Ile Ile Val Cys Gly Met Val Ala Ala Leu Ser Ala Ile Arg
                 50
                                     55
                                                          60
Ala Asn Cys His Gln Glu Pro Ser Val Cys Leu Gln Ala Ala Cys
                                     70
Pro Glu Ser Trp Ile Gly Phe Gln Arg Lys Cys Phe Tyr Phe Ser
                                     85
                 80
Asp Asp Thr Lys Asn Trp Thr Ser Ser Gln Arg Phe Cys Asp Ser
                 95
                                    100
Gln Asp Ala Asp Leu Ala Gln Val Glu Ser Phe Gln Glu Leu Asn
                110
                                    115
                                                         120
Phe Leu Leu Arg Tyr Lys Gly Pro Ser Asp His Trp Ile Gly Leu
                125
                                    130
Ser Arg Glu Gln Gly Gln Pro Trp Lys Trp Ile Asn Gly Thr Glu
                                                         150
                140
                                    145
Trp Thr Arg Gln Leu Val Met Lys Glu Asp Gly Ala Asn Leu Tyr
                                                         165
                155
                                    160
Val Ala Lys Val Ser Gln Val Pro Arg Met Asn Pro Arg Pro Val
```

```
175
Met Val Ser Tyr Pro Gly Ser Arg Arg Val Cys Leu Phe Glu
                185
                                    190
<210> 9
<211> 322
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5855841CD1
Met Ser Ser Leu Gly Gly Gly Ser Gln Asp Ala Gly Gly Ser Ser
                                     10
Ser Ser Ser Thr Asn Gly Ser Gly Gly Ser Gly Ser Ser Gly Pro
                 20
                                     25
Lys Ala Gly Ala Ala Asp Lys Ser Ala Val Val Ala Ala Ala Ala
                 35
                                     40
Pro Ala Ser Val Ala Asp Asp Thr Pro Pro Pro Glu Arg Arg Asn
                 50
                                     55
Lys Ser Gly Ile Ile Ser Glu Pro Leu Asn Lys Ser Leu Arg Arg
                                                          75
                 65
                                     70
Ser Arg Pro Leu Ser His Tyr Ser Ser Phe Gly Ser Ser Gly Gly
                                     85
Ser Gly Gly Gly Ser Met Met Gly Gly Glu Ser Ala Asp Lys Ala
                 95
                                    100
Thr Ala Ala Ala Ala Ala Ser Leu Leu Ala Asn Gly His Asp
                110
                                                         120
                                    115
Leu Ala Ala Met Ala Val Asp Lys Ser Asn Pro Thr Ser Lys
                125
                                    130
                                                         135
His Lys Ser Gly Ala Val Ala Ser Leu Leu Ser Lys Ala Glu Arg
                140
                                    145
Ala Thr Glu Leu Ala Ala Glu Gly Gln Leu Thr Leu Gln Gln Phe
                                                         165
                155
                                    160
Ala Gln Ser Thr Glu Met Leu Lys Arg Val Val Gln Glu His Leu
                                                         180
                170
                                    175
Pro Leu Met Ser Glu Ala Gly Ala Gly Leu Pro Asp Met Glu Ala
                185
                                    190
Val Ala Gly Ala Glu Ala Leu Asn Gly Gln Ser Asp Phe Pro Tyr
                200
                                                         210
                                    205
Leu Gly Ala Phe Pro Ile Asn Pro Gly Leu Phe Ile Met Thr Pro
                215
                                    220
                                                         225
Ala Gly Val Phe Leu Ala Glu Ser Ala Leu His Met Ala Gly Leu
                230
                                    235
                                                         240
Ala Glu Tyr Pro Met Gln Gly Glu Leu Ala Ser Ala Ile Ser Ser
                                                         255
                245
                                    250
Gly Lys Lys Arg Lys Arg Cys Gly Met Cys Ala Pro Cys Arg
                                                         270
                260
                                    265
Arg Arg Ile Asn Cys Glu Gln Cys Ser Ser Cys Arg Asn Arg Lys
                275
                                                         285
                                    280
Thr Gly His Gln Ile Cys Lys Phe Arg Lys Cys Glu Glu Leu Lys
                                                         300
                290
                                    295
Lys Lys Pro Ser Ala Ala Leu Glu Lys Val Met Leu Pro Thr Gly
                305
                                    310
                                                         315
Ala Ala Phe Arg Trp Phe Gln
               320
<210> 10
<211> 335
<212> PRT
<213> Homo sapiens
<220>
```

Ĭ. .

```
<221> misc_feature
<223> Incyte ID No: 603462CD1
<400> 10
Met Leu Gln Gly His Ser Ser Val Phe Gln Ala Leu Leu Gly Thr
                                     10
Phe Phe Thr Trp Gly Met Thr Ala Ala Gly Ala Ala Leu Val Phe
                 20
                                     25
Val Phe Ser Ser Gly Gln Arg Arg Ile Leu Asp Gly Ser Leu Gly
                                     40
                 35
Phe Ala Ala Gly Val Met Leu Ala Ala Ser Tyr Trp Ser Leu Leu
                 50
                                     55
Ala Pro Ala Val Glu Met Ala Thr Ser Ser Gly Gly Phe Gly Ala
                                     70
Phe Ala Phe Phe Pro Val Ala Val Gly Phe Thr Leu Gly Ala Ala
                                     85
Phe Val Tyr Leu Ala Asp Leu Leu Met Pro His Leu Gly Ala Ala
                 95
                                    100
Glu Asp Pro Gln Thr Ala Leu Ala Leu Asn Phe Gly Ser Thr Leu
                110
                                    115
Met Lys Lys Ser Asp Pro Glu Gly Pro Ala Leu Leu Phe Pro
                125
                                    130
Glu Ser Glu Leu Ser Ile Arg Ile Asp Lys Ser Glu Asn Gly Glu
                140
                                    145
                                                         150
Ala Tyr Gln Arg Lys Lys Ala Ala Ala Thr Gly Leu Pro Glu Gly
                155
                                    160
Pro Ala Val Pro Val Pro Ser Arg Gly Asn Leu Ala Gln Pro Gly
                170
                                    175
Gly Ser Ser Trp Arg Arg Ile Ala Leu Leu Ile Leu Ala Ile Thr
                185
                                    190
                                                         195
Ile His Asn Val Pro Glu Gly Leu Ala Val Gly Val Gly Phe Gly
                200
                                    205
                                                         210
Ala Ile Glu Lys Thr Ala Ser Ala Thr Phe Glu Ser Ala Arg Asn
                215
                                    220
                                                         225
Leu Ala Ile Gly Ile Gly Ile Gln Asn Phe Pro Glu Gly Leu Ala
                230
                                    235
Val Ser Leu Pro Leu Arg Gly Ala Gly Phe Ser Thr Trp Arg Ala
                                                         255
                                    250
Phe Trp Tyr Gly Gln Leu Ser Gly Met Val Glu Pro Leu Ala Gly
                260
                                    265
Val Phe Gly Ala Phe Ala Val Val Leu Ala Glu Pro Ile Leu Pro
                275
                                    280
Tyr Ala Leu Ala Phe Ala Ala Gly Ala Met Val Tyr Val Val Met
                290
                                    295
Asp Asp Ile Ile Pro Glu Ala Gln Ile Ser Gly Asn Gly Lys Leu
                305
                                    310
                                                         315
Ala Ser Trp Ala Ser Ile Leu Gly Phe Val Val Met Met Ser Leu
                320
                                    325
Asp Val Gly Leu Gly
                335
<210> 11
<211> 620
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 747681CD1
<400> 11
Met Gln Val Ser Lys Arg Met Leu Ala Gly Gly Val Arg Ser Met
                                     10
```

Pro Ser Pro Leu Leu Ala Cys Trp Gln Pro Ile Leu Leu Leu Val

Leu Gly Ser Val Leu Ser Gly Ser Ala Thr Gly Cys Pro Pro Arg Cys Glu Cys Ser Ala Gln Asp Arg Ala Val Leu Cys His Arg Lys Arg Phe Val Ala Val Pro Glu Gly Ile Pro Thr Glu Thr Arg Leu Leu Asp Leu Gly Lys Asn Arg Ile Lys Thr Leu Asn Gln Asp Glu Phe Ala Ser Phe Pro His Leu Glu Glu Leu Glu Leu Asn Glu Asn Ile Val Ser Ala Val Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn Leu Arg Thr Leu Gly Leu Arg Ser Asn Arg Leu Lys Leu Ile Pro Leu Gly Val Phe Thr Gly Leu Ser Asn Leu Thr Lys Leu Asp Ile Ser Glu Asn Lys Ile Val Ile Leu Leu Asp Tyr Met Phe Gln Asp Leu Tyr Asn Leu Lys Ser Leu Glu Val Gly Asp Asn Asp Leu Val Tyr Ile Ser His Arg Ala Phe Ser Gly Leu Asn Ser Leu Glu Gln Leu Thr Leu Glu Lys Cys Asn Leu Thr Ser Ile Pro Thr Glu Ala Leu Ser His Leu His Gly Leu Ile Val Leu Arg Leu Arg His Leu Asn Ile Asn Ala Ile Arg Asp Tyr Ser Phe Lys Arg Leu Tyr Arg Leu Lys Val Leu Glu Ile Ser His Trp Pro Tyr Leu Asp Thr Met Thr Pro Asn Cys Leu Tyr Gly Leu Asn Leu Thr Ser Leu Ser Ile Thr His Cys Asn Leu Thr Ala Val Pro Tyr Leu Ala Val Arg His Leu Val Tyr Leu Arg Phe Leu Asn Leu Ser Tyr Asn Pro Ile Ser Thr Ile Glu Gly Ser Met Leu His Glu Leu Leu Arg Leu Gln Glu Ile Gln Leu Val Gly Gly Gln Leu Ala Val Val Glu Pro Tyr Ala Phe Arg Gly Leu Asn Tyr Leu Arg Val Leu Asn Val Ser Gly Asn Gln Leu Thr Thr Leu Glu Glu Ser Val Phe His Ser Val Gly Asn Leu Glu Thr Leu Ile Leu Asp Ser Asn Pro Leu Ala Cys Asp Cys Arg Leu Leu Trp Val Phe Arg Arg Arg Trp Arg Leu Asn Phe Asn Arg Gln Gln Pro Thr Cys Ala Thr Pro Glu Phe Val Gln Gly Lys Glu Phe Lys Asp Phe Pro Asp Val Leu Leu Pro Asn Tyr Phe Thr Cys Arg Arg Ala Arg Ile Arg Asp Arg Lys Ala Gln Gln Val Phe Val Asp Glu Gly His Thr Val Gln Phe Val Cys Arg Ala Asp Gly Asp Pro Pro Pro Ala Ile Leu Trp Leu Ser Pro Arg Lys His Leu Val Ser Ala Lys Ser Asn Gly Arg Leu Thr Val Phe Pro Asp Gly Thr Leu Glu Val Arg Tyr Ala Gln Val Gln Asp Asn Gly Thr Tyr 

```
Leu Cys Ile Ala Ala Asn Ala Gly Gly Asn Asp Ser Met Pro Ala
                500
                                    505
His Leu His Val Arg Ser Tyr Ser Pro Asp Trp Pro His Gln Pro
                515
                                    520
                                                         525
Asn Lys Thr Phe Ala Phe Ile Ser Asn Gln Pro Gly Glu Gly Glu
                530
                                    535
                                                         540
Ala Asn Ser Thr Arg Ala Thr Val Pro Phe Pro Phe Asp Ile Lys
                545
                                    550
                                                         555
Thr Leu Ile Ile Ala Thr Thr Met Gly Phe Ile Ser Phe Leu Gly
                                    565
                                                         570
Val Val Leu Phe Cys Leu Val Leu Leu Phe Leu Trp Ser Arg Gly
                575
                                    580
                                                         585
Lys Gly Asn Thr Lys His Asn Ile Glu Ile Glu Tyr Val Pro Arg
                590
                                    595
Lys Ser Asp Ala Gly Ile Ser Ser Ala Asp Ala Pro Arg Lys Phe
                605
                                    610
Asn Met Lys Met Ile
                620
<210> 12
<211> 491
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 919469CD1
<400> 12
Met Ala Gly Gln Gly Leu Pro Leu His Val Ala Thr Leu Leu Thr
                                     10
Gly Leu Leu Glu Cys Leu Gly Phe Ala Gly Val Leu Phe Gly Trp
                                     25
Pro Ser Leu Val Phe Val Phe Lys Asn Glu Asp Tyr Phe Lys Asp
                35
                                     40
                                                          45
Leu Cys Gly Pro Asp Ala Gly Pro Ile Gly Asn Ala Thr Gly Gln
               50
Ala Asp Cys Lys Ala Gln Asp Glu Arg Phe Ser Leu Ile Phe Thr
                 65
                                     70
Leu Gly Ser Phe Met Asn Asn Phe Met Thr Phe Pro Thr Gly Tyr
                80
                                     85
Ile Phe Asp Arg Phe Lys Thr Thr Val Ala Arg Leu Ile Ala Ile
                95
                                    100
Phe Phe Tyr Thr Thr Ala Thr Leu Ile Ile Ala Phe Thr Ser Ala
                110
                                    115
                                                         120
Gly Ser Ala Val Leu Leu Phe Leu Ala Met Pro Met Leu Thr Ile
               125
                                    130
                                                         135
Gly Gly Ile Leu Phe Leu Ile Thr Asn Leu Gln Ile Gly Asn Leu
                140
                                    145
Phe Gly Gln His Arg Ser Thr Ile Ile Thr Leu Tyr Asn Gly Ala
               155
                                    160
Phe Asp Ser Ser Ser Ala Val Phe Leu Ile Ile Lys Leu Leu Tyr
               170
                                    175
Glu Lys Gly Ile Ser Leu Arg Ala Ser Phe Ile Phe Ile Ser Val
                185
                                    190 .
                                                         195
Cys Ser Thr Trp His Val Ala Arg Thr Phe Leu Leu Met Pro Arg
               200
                                    205
                                                         210
Gly His Ile Pro Tyr Pro Leu Pro Pro Asn Tyr Ser Tyr Gly Leu
               215
                                    220
Cys Pro Gly Asn Gly Thr Thr Lys Glu Glu Lys Glu Thr Ala Glu
               230
                                    235
His Glu Asn Arg Glu Leu Gln Ser Lys Glu Phe Leu Ser Ala Lys
               245
                                    250
                                                         255
Glu Glu Thr Pro Gly Ala Gly Gln Lys Gln Glu Leu Arg Ser Phe
```

```
265
 Trp Ser Tyr Ala Phe Ser Arg Arg Phe Ala Trp His Leu Val Trp
                 275
                                     280
 Leu Ser Val Ile Gln Leu Trp His Tyr Leu Phe Ile Gly Thr Leu
                 290
                                     295
                                                         300
 Asn Ser Leu Leu Thr Asn Met Ala Gly Gly Asp Met Ala Arg Val
                 305
                                     310
 Ser Thr Tyr Thr Asn Ala Phe Ala Phe Thr Gln Phe Gly Val Leu
                 320
                                     325
                                                         330
Cys Ala Pro Trp Asn Gly Leu Leu Met Asp Arg Leu Lys Gln Lys
                 335
                                     340
Tyr Gln Lys Glu Ala Arg Lys Thr Gly Ser Ser Thr Leu Ala Val
                 350
                                     355
Ala Leu Cys Ser Thr Val Pro Ser Leu Ala Leu Thr Ser Leu Leu
                 365
                                     370
                                                         375
Cys Leu Gly Phe Ala Leu Cys Ala Ser Val Pro Ile Leu Pro Leu
                380
                                     385
Gln Tyr Leu Thr Phe Ile Leu Gln Val Ile Ser Arg Ser Phe Leu
                395
                                     400
                                                         405
Tyr Gly Ser Asn Ala Ala Phe Leu Thr Leu Ala Phe Pro Ser Glu
                410
                                     415
                                                         420
His Phe Gly Lys Leu Phe Gly Leu Val Met Ala Leu Ser Ala Val
                425
                                     430
                                                         435
Val Ser Leu Leu Gln Phe Pro Ile Phe Thr Leu Ile Lys Gly Ser
                 440
                                     445
                                                         450
Leu Gln Asn Asp Pro Phe Tyr Val Asn Val Met Phe Met Leu Ala
                455
                                     460
                                                         465
Ile Leu Leu Thr Phe Phe His Pro Phe Leu Val Tyr Arg Glu Cys
                470
                                     475
Arg Thr Trp Lys Glu Ser Pro Ser Ala Ile Ala
                485
<210> 13
<211> 580
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 977658CD1
<400> 13
Met Thr Ala Pro Ala Gly Pro Arg Gly Ser Glu Thr Glu Arg Leu
                                     10
Leu Thr Pro Asn Pro Gly Tyr Gly Thr Gln Ala Gly Pro Ser Pro
                 20
                                     25
Ala Pro Pro Thr Pro Pro Glu Glu Asp Leu Arg Arg Arg Leu
                 35
                                      40
                                                          45
Lys Tyr Phe Phe Met Ser Pro Cys Asp Lys Phe Arg Ala Lys Gly
                                     55
                                                          60
Arg Lys Pro Cys Lys Leu Met Leu Gln Val Val Lys Ile Leu Val
                 65
                                     70
Val Thr Val Gln Leu Ile Leu Phe Gly Leu Ser Asn Gln Leu Ala
                 80
                                     85
Val Thr Phe Arg Glu Glu Asn Thr Ile Ala Phe Arg His Leu Phe
                 95
                                    100
Leu Leu Gly Tyr Ser Asp Gly Ala Asp Asp Thr Phe Ala Ala Tyr
                110
                                    115
                                                         120
Thr Arg Glu Gln Leu Tyr Gln Ala Ile Phe His Ala Val Asp Gln
                125
                                    130
                                                         135
Tyr Leu Ala Leu Pro Asp Val Ser Leu Gly Arg Tyr Ala Tyr Val
               140
                                   145
Arg Gly Gly Gly Asp Pro Trp Thr Asn Gly Ser Gly Leu Ala Leu
                155
                                    160
```

```
Cys Gln Arg Tyr Tyr His Arg Gly His Val Asp Pro Ala Asn Asp
                170
                                    175
Thr Phe Asp Ile Asp Pro Met Val Val Thr Asp Cys Ile Gln Val
                185
                                    190
Asp Pro Pro Glu Arg Pro Pro Pro Pro Pro Ser Asp Asp Leu Thr
                200
                                    205
Leu Leu Glu Ser Ser Ser Tyr Lys Asn Leu Thr Leu Lys Phe
                215
                                    220
His Lys Leu Val Asn Val Thr Ile His Phe Arg Leu Lys Thr Ile
                230
                                    235
Asn Leu Gln Ser Leu Ile Asn Asn Glu Ile Pro Asp Cys Tyr Thr
                245
                                    250
Phe Ser Val Leu Ile Thr Phe Asp Asn Lys Ala His Ser Gly Arg
                260
                                    265
Ile Pro Ile Ser Leu Glu Thr Gln Ala His Ile Gln Glu Cys Lys
                275
                                    280
His Pro Ser Val Phe Gln His Gly Asp Asn Ser Phe Arg Leu Leu
                290
                                    295
Phe Asp Val Val Ile Leu Thr Cys Ser Leu Ser Phe Leu Leu
                305
                                    310
Cys Ala Arg Ser Leu Leu Arg Gly Phe Leu Leu Gln Asn Glu Phe
                320
                                    325
Val Gly Phe Met Trp Arg Gln Arg Gly Arg Val Ile Ser Leu Trp
                335
                                    340
Glu Arg Leu Glu Phe Val Asn Gly Trp Tyr Ile Leu Leu Val Thr
                350
                                    355
Ser Asp Val Leu Thr Ile Ser Gly Thr Ile Met Lys Ile Gly Ile
                365
                                    370
Glu Ala Lys Asn Leu Ala Ser Tyr Asp Val Cys Ser Ile Leu Leu
                                    385
                -380
Gly Thr Ser Thr Leu Leu Val Trp Val Gly Val Ile Arg Tyr Leu
                395
                                    400
Thr Phe Phe His Asn Tyr Asn Ile Leu Ile Ala Thr Leu Arg Val
                410
                                    415
Ala Leu Pro Ser Val Met Arg Phe Cys Cys Cys Val Ala Val Ile
                425
                                    430
                                                         435
Tyr Leu Gly Tyr Cys Phe Cys Gly Trp Ile Val Leu Gly Pro Tyr
                440
                                    445
His Val Lys Phe Arg Ser Leu Ser Met Val Ser Glu Cys Leu Phe
                455
                                    460
Ser Leu Ile Asn Gly Asp Asp Met Phe Val Thr Phe Ala Ala Met
                                    475
                470
Gln Ala Gln Gln Gly Arg Ser Ser Leu Val Trp Leu Phe Ser Gln
                485
                                    490
Leu Tyr Leu Tyr Ser Phe Ile Ser Leu Phe Ile Tyr Met Val Leu
                500
                                    505
                                                         510
Ser Leu Phe Ile Ala Leu Ile Thr Gly Ala Tyr Asp Thr Ile Lys
                515
                                    520
                                                         525
His Pro Gly Gly Ala Gly Ala Glu Glu Ser Glu Leu Gln Ala Tyr
                530
                                    535
Ile Ala Gln Cys Gln Asp Ser Pro Thr Ser Gly Lys Phe Arg Arg
                545
                                    550
Gly Ser Gly Ser Ala Cys Ser Leu Leu Cys Cys Cys Gly Arg Asp
                560
                                    565
Pro Ser Glu Glu His Ser Leu Leu Val Asn
                575
<210> 14
<211> 455
<212> PRT
<213> Homo sapiens
<220>
```

<221> misc\_feature

<223> Incyte ID No: 1004703CD1

<400> 14 Met Ser Phe Leu Ile Asp Ser Ser Ile Met Ile Thr Ser Gln Ile Leu Phe Phe Gly Phe Gly Trp Leu Phe Phe Met Arg Gln Leu Phe Lys Asp Tyr Glu Ile Arg Gln Tyr Val Val Gln Val Ile Phe Ser Val Thr Phe Ala Phe Ser Cys Thr Met Phe Glu Leu Ile Ile Phe Glu Ile Leu Gly Val Leu Asn Ser Ser Ser Arg Tyr Phe His Trp Lys Met Asn Leu Cys Val Ile Leu Leu Ile Leu Val Phe Met Val Pro Phe Tyr Ile Gly Tyr Phe Ile Val Ser Asn Ile Arg Leu Leu His Lys Gln Arg Leu Leu Phe Ser Cys Leu Leu Trp Leu Thr Phe Met Tyr Phe Phe Trp Lys Leu Gly Asp Leu Phe Pro Ile Leu Ser Pro Lys His Gly Ile Leu Ser Ile Glu Gln Leu Ile Ser Arg Val Gly Val Ile Gly Val Thr Leu Met Ala Leu Leu Ser Gly Phe Gly Ala Val Asn Cys Pro Tyr Thr Tyr Met Ser Tyr Phe Leu Arg Asn Val Thr Asp Thr Asp Ile Leu Ala Leu Glu Arg Arg Leu Leu Gln Thr Met Asp Met Ile Ile Ser Lys Lys Arg Met Ala Met Ala Arg Arg Thr Met Phe Gln Lys Gly Glu Val His Asn Lys Pro Ser Gly Phe Trp Gly Met Ile Lys Ser Val Thr Thr Ser Ala Ser Gly Ser Glu Asn Leu Thr Leu Ile Gln Gln Glu Val Asp Ala Leu Glu Glu Leu Ser Arg Gln Leu Phe Leu Glu Thr Ala Asp Leu Tyr Ala Thr Lys Glu Arg Ile Glu Tyr Ser Lys Thr Phe Lys Gly Lys Tyr Phe Asn Phe Leu Gly Tyr Phe Phe Ser Ile Tyr Cys Val Trp Lys Ile Phe Met Ala Thr Ile Asn Ile Val Phe Asp Arg Val Gly Lys Thr Asp Pro Val Thr Arg Gly Ile Glu Ile Thr Val Asn Tyr Leu Gly Ile Gln Phe Asp Val Lys Phe Trp Ser Gln His Ile Ser Phe Ile Leu Val Gly Ile Ile Ile Val Thr Ser Ile Arg Gly Leu Leu Ile Thr Leu Thr Lys Phe Phe Tyr Ala Ile Ser Ser Ser Lys Ser Ser Asn Val Ile Val Leu Leu Leu Ala Gln Ile Met Gly Met Tyr Phe Val Ser Ser Val Leu Leu Ile Arg Met Ser Met Pro Leu Glu Tyr Arg Thr Ile Ile Thr Glu Val Leu Gly Glu Leu Gln Phe Asn Phe Tyr His Arg Trp Phe Asp Val Ile Phe Leu Val Ser Ala Leu Ser Ser Ile Leu Phe Leu Tyr Leu Ala His Lys Gln Ala Pro Glu 

```
Lys Gln Met Ala Pro
<210> 15
<211> 277
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1334051CD1
<400> 15
Met Lys Ile Ser Met Ile Asn Tyr Lys Ser Leu Leu Ala Leu Leu
 1
                                      10
Phe Ile Leu Ala Ser Trp Ile Ile Phe Thr Val Phe Gln Asn Ser
                 20
                                      25
Thr Lys Val Trp Ser Ala Leu Asn Leu Ser Ile Ser Leu His Tyr
                 35
                                      40
                                                           45
Trp Asn Asn Ser Thr Lys Ser Leu Phe Pro Lys Thr Pro Leu Ile
                 50
                                      55
Ser Leu Lys Pro Leu Thr Glu Thr Glu Leu Arg Ile Lys Glu Ile
                                      70
                 65
Ile Glu Lys Leu Asp Gln Gln Ile Pro Pro Arg Pro Phe Thr His
                 80
                                      85
Val Asn Thr Thr Thr Ser Ala Thr His Ser Thr Ala Thr Ile Leu
                 95
                                     100
Asn Pro Arg Asp Thr Tyr Cys Arg Gly Asp Gln Leu His Ile Leu
                110 .
                                     115
Leu Glu Val Arg Asp His Leu Gly Arg Arg Lys Gln Tyr Gly Gly
                125
                                    130
                                                         135
Asp Phe Leu Arg Ala Arg Met Ser Ser Pro Ala Leu Met Ala Gly
                140
                                     145
                                                         150
Ala Ser Gly Lys Val Thr Asp Phe Asn Asn Gly Thr Tyr Leu Val
                155
                                    :160
Ser Phe Thr Leu Phe Trp Glu Gly Gln Val Ser Leu Ser Leu Leu
                170
                                     175
                                                         180
Leu Ile His Pro Ser Glu Gly Val Ser Ala Leu Trp Ser Ala Arg
                185
                                     190
                                                         195
Asn Gln Gly Tyr Asp Arg Val Ile Phe Thr Gly Gln Phe Val Asn
                200
                                     205
Gly Thr Ser Gln Val His Ser Glu Cys Gly Leu Ile Leu Asn Thr
                215
                                    220
                                                         225
Asn Ala Glu Leu Cys Gln Tyr Leu Asp Asn Arg Asp Gln Glu Gly
                230
                                     235
                                                         240
Phe Tyr Cys Val Arg Pro Gln His Met Pro Cys Ala Ala Leu Thr
                245
                                     250
His Met Tyr Ser Lys Asn Lys Lys Val Ser Tyr Leu Ser Lys Gln
                260
                                    265
Glu Lys Ser Leu Phe Glu Arg
                275
<210> 16
<211> 647
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1336728CD1
<400> 16
Met Ala Ser Leu Val Ser Leu Glu Leu Gly Leu Leu Leu Ala Val
                 5
                                     10
Leu Val Val Thr Ala Thr Ala Ser Pro Pro Ala Gly Leu Leu Ser
```

```
30
                                     25
Leu Leu Thr Ser Gly Gln Gly Ala Leu Asp Gln Glu Ala Leu Gly
                                     40
Gly Leu Leu Asn Thr Leu Ala Asp Arg Val His Cys Thr Asn Gly
                                                          60
                                     55
                 50
Pro Cys Gly Lys Cys Leu Ser Val Glu Asp Ala Leu Gly Leu Gly
                                     70
                 65
Glu Pro Glu Gly Ser Gly Leu Pro Pro Gly Pro Val Leu Glu Ala
                                     85
                 80
Arg Tyr Val Ala Arg Leu Ser Ala Ala Ala Val Leu Tyr Leu Ser
                                    100
Asn Pro Glu Gly Thr Cys Glu Asp Thr Arg Ala Gly Leu Trp Ala
                                    115
                110
Ser His Ala Asp His Leu Leu Ala Leu Leu Glu Ser Pro Lys Ala
                                                         135
                                    130
                125
Leu Thr Pro Gly Leu Ser Trp Leu Leu Gln Arg Met Gln Ala Arg
                                    145
                140
Ala Ala Gly Gln Thr Pro Lys Thr Ala Cys Val Asp Ile Pro Gln
                                                         165
                                    160
                155
Leu Leu Glu Glu Ala Val Gly Ala Gly Ala Pro Gly Ser Ala Gly
                                                         180
                                    175
                170
Gly Val Leu Ala Ala Leu Leu Asp His Val Arg Ser Gly Ser Cys
                                     190
                185
Phe His Ala Leu Pro Ser Pro Gln Tyr Phe Val Asp Phe Val Phe
                                                         210
                                     205
                200
Gln Gln His Ser Ser Glu Val Pro Met Thr Leu Ala Glu Leu Ser
                                                         225
                                     220
                215
Ala Leu Met Gln Arg Leu Gly Val Gly Arg Glu Ala His Ser Asp
                                     235
                230
His Ser His Arg His Arg Gly Ala Ser Ser Arg Asp Pro Val Pro
                                     250
                                                         255
                245
Leu Ile Ser Ser Ser Asn Ser Ser Ser Val Trp Asp Thr Val Cys
                                                         270
                                    265
                260
Leu Ser Ala Arg Asp Val Met Ala Ala Tyr Gly Leu Ser Glu Gln
                                     280
                275
Ala Gly Val Thr Pro Glu Ala Trp Ala Gln Leu Ser Pro Ala Leu
                                     295
                                                         300
                290
Leu Gln Gln Leu Ser Gly Ala Cys Thr Ser Gln Ser Arg Pro
                                                          315
                                     310
                305
Pro Val Gln Asp Gln Leu Ser Gln Ser Glu Arg Tyr Leu Tyr Gly
                                                          330
                                     325
                320
Ser Leu Ala Thr Leu Leu Ile Cys Leu Cys Ala Val Phe Gly Leu
                                                          345
                                     340
                335
Leu Leu Leu Thr Cys Thr Gly Cys Arg Gly Val Thr His Tyr Ile
                                                          360
                 350
                                     355
Leu Gln Thr Phe Leu Ser Leu Ala Val Gly Ala Leu Thr Gly Asp
                                     370
                 365
Ala Val Leu His Leu Thr Pro Lys Val Leu Gly Leu His Thr His
                                                          390
                                     385
                 380
 Ser Glu Glu Gly Leu Ser Pro Gln Pro Thr Trp Arg Leu Leu Ala
                                     400
                 395
 Met Leu Ala Gly Leu Tyr Ala Phe Phe Leu Phe Glu Asn Leu Phe
                                                          420
                                     415
                 410
 Asn Leu Leu Pro Arg Asp Pro Glu Asp Leu Glu Asp Gly Pro
                                                          435
                                     430
                 425
 Cys Gly His Ser Ser His Ser His Gly Gly His Ser His Gly Val
                                     445
                 440
 Ser Leu Gln Leu Ala Pro Ser Glu Leu Arg Gln Pro Lys Pro Pro
                                     460
                 455
 His Glu Gly Ser Arg Ala Asp Leu Val Ala Glu Glu Ser Pro Glu
                                     475
                 470
 Leu Leu Asn Pro Glu Pro Arg Arg Leu Ser Pro Glu Leu Arg Leu
                 485
```

```
Leu Pro Tyr Met Ile Thr Leu Gly Asp Ala Val His Asn Phe Ala
                500
                                    505
Asp Gly Leu Ala Val Gly Ala Ala Phe Ala Ser Ser Trp Lys Thr
                515
                                    520
                                                         525
Gly Leu Ala Thr Ser Leu Ala Val Phe Cys His Glu Leu Pro His
                530
                                    535
Glu Leu Gly Asp Phe Ala Ala Leu Leu His Ala Gly Leu Ser Val
                545
                                    550
Arg Gln Ala Leu Leu Asn Leu Ala Ser Ala Leu Thr Ala Phe
                                    565
                                                         570
Ala Gly Leu Tyr Val Ala Leu Ala Val Gly Val Ser Glu Glu Ser
                575
                                    580
Glu Ala Trp Ile Leu Ala Val Ala Thr Gly Leu Phe Leu Tyr Val
                590
                                    595
Ala Leu Cys Asp Met Leu Pro Ala Met Leu Lys Val Arg Asp Pro
                605
                                    610
                                                         615
Arg Pro Trp Leu Leu Phe Leu Leu His Asn Val Gly Leu Leu Gly
                620
                                    625
                                                         630
Gly Trp Thr Val Leu Leu Leu Ser Leu Tyr Glu Asp Asp Ile
                635
                                    640
Thr Phe
<210> 17
<211> 406
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1452856CD1
<400> 17
Met Ala Glu Asn Gly Lys Asn Cys Asp Gln Arg Arg Val Ala Met
                                                         15
                                     10
Asn Lys Glu His His Asn Gly Asn Phe Thr Asp Pro Ser Ser Val
                                     25
                                                          30
Asn Glu Lys Lys Arg Arg Glu Arg Glu Glu Arg Gln Asn Ile Val
                 35
                                     40
Leu Trp Arg Gln Pro Leu Ile Thr Leu Gln Tyr Phe Ser Leu Glu
                 50
                                     55
Ile Leu Val Ile Leu Lys Glu Trp Thr Ser Lys Leu Trp His Arg
                 65
                                     70
Gln Ser Ile Val Val Ser Phe Leu Leu Leu Leu Ala Val Leu Ile
                 80
                                     85
Ala Thr Tyr Tyr Val Glu Gly Val His Gln Gln Tyr Val Gln Arg
                 95
                                    100
Ile Glu Lys Gln Phe Leu Leu Tyr Ala Tyr Trp Ile Gly Leu Gly
                                    115
Ile Leu Ser Ser Val Gly Leu Gly Thr Gly Leu His Thr Phe Leu
                125
                                    130
Leu Tyr Leu Gly Pro His Ile Ala Ser Val Thr Leu Ala Ala Tyr
                140
                                    145
                                                         150
Glu Cys Asn Ser Val Asn Phe Pro Glu Pro Pro Tyr Pro Asp Gln
                155
                                    160
Ile Ile Cys Pro Asp Glu Glu Gly Thr Glu Gly Thr Ile Ser Leu
                170
                                    175
                                                         180
Trp Ser Ile Ile Ser Lys Val Arg Ile Glu Ala Cys Met Trp Gly
                185
                                    190
Ile Gly Thr Ala Ile Gly Glu Leu Pro Pro Tyr Phe Met Ala Arg
                200
                                    205
                                                         210
Ala Ala Arg Leu Ser Gly Ala Glu Pro Asp Asp Glu Glu Tyr Gln
                215
                                    220
                                                         225
Glu Phe Glu Glu Met Leu Glu His Ala Glu Ser Ala Gln Asp Phe
```

```
230
                                    235
Ala Ser Arg Ala Lys Leu Ala Val Gln Lys Leu Val Gln Lys Val
                 245
                                     250
Gly Phe Phe Gly Ile Leu Ala Cys Ala Ser Ile Pro Asn Pro Leu
                260
                                    265
                                                         270
Phe Asp Leu Ala Gly Ile Thr Cys Gly His Phe Leu Val Pro Phe
                275
                                     280
Trp Thr Phe Phe Gly Ala Thr Leu Ile Gly Lys Ala Ile Ile Lys
                 290
                                     295
                                                         300
Met His Ile Gln Lys Ile Phe Val Ile Ile Thr Phe Ser Lys His
                305
                                     310
Ile Val Glu Gln Met Val Ala Phe Ile Gly Ala Val Pro Gly Ile
                320
                                     325
                                                         330
Gly Pro Ser Leu Gln Lys Pro Phe Gln Glu Tyr Leu Glu Ala Gln
                335
                                    340
Arg Gln Lys Leu His His Lys Ser Glu Met Gly Thr Pro Gln Gly
                350
                                     355
                                                         360
Glu Asn Trp Leu Ser Trp Met Phe Glu Lys Leu Val Val Met
                365
                                    370
                                                         375
Val Cys Tyr Phe Ile Leu Ser Ile Ile Asn Ser Met Ala Gln Ser
                380
                                    385
Tyr Ala Lys Arg Ile Gln Gln Arg Leu Asn Ser Glu Glu Lys Thr
                395
                                    400
Lys
<210> 18
<211> 290
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1562471CD1
Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly
                                     10
Tyr Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly
                 20
                                     25
Leu Glu Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly
                 35
                                     40
                                                         45
Trp Glu Thr Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg
                 50
                                     55
Asp Cys Lys Ile Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val
                 65
                                     70
Lys Arg Asp Arg Val Ser Ile Lys Asp Asn Gln Lys Asn Arg Thr
                                     85
                                                        90
Phe Thr Val Thr Met Glu Asp Leu Met Lys Thr Asp Ala Asp Thr
                 95
                                    100
Tyr Trp Cys Gly Ile Glu Lys Thr Gly Asn Asp Leu Gly Val Thr
                110
                                    115
Val Gln Val Thr Ile Asp Pro Ala Pro Val Thr Gln Glu Glu Thr
                125
                                    130
Ser Ser Ser Pro Thr Leu Thr Gly His His Leu Asp Asn Arg His
               140
                                    145
                                                        150
Lys Leu Leu Lys Leu Ser Val Leu Leu Pro Leu Ile Phe Thr Ile
               155
                                   160
                                                        165
Leu Leu Leu Leu Val Ala Ala Ser Leu Leu Ala Trp Arg Met
               170
                                   175
Met Lys Tyr Gln Gln Lys Ala Ala Gly Met Ser Pro Glu Gln Val
               185
                                    190
                                                        195
Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala Asp Leu Thr Leu
                                    205
```

```
Gln Leu Ala Gly Thr Ser Pro Arg Lys Ala Thr Thr Lys Leu Ser
                215
                                     220
Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met Ala
                230
                                     235
Ser Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly
                245
                                     250
                                                          255
Ala Glu Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser
                260
                                     265
                                                          270
Ser His Leu Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser
                275
                                    280
Thr Ile Ser Arg Pro
<210> 19
<211> 390
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1618158CD1
<400> 19
Met Phe Ser Thr Asn Tyr Ser His Met Glu Asn Tyr Arg Lys Arg
                                      10
Glu Asp Leu Val Tyr Gln Ser Thr Val Arg Leu Pro Glu Val Arg
                                      25
                                                          30
Ile Ser Asp Asn Gly Pro Tyr Glu Cys His Val Gly Ile Tyr Asp
                 35
                                      40
Arg Ala Thr Arg Glu Lys Val Val Leu Ala Ser Gly Asn Ile Phe
                 50
                                      55
Leu Asn Val Met Ala Pro Pro Thr Ser Ile Glu Val Val Ala Ala
                 65
                                      70
Asp Thr Pro Ala Pro Phe Ser Arg Tyr Gln Ala Gln Asn Phe Thr
                 80
                                      85
                                                          90
Leu Val Cys Ile Val Ser Gly Gly Lys Pro Ala Pro Met Val Tyr
                 95
                                    100
Phe Lys Arg Asp Gly Glu Pro Ile Asp Ala Val Pro Leu Ser Glu
                110
                                     115
                                                         120
Pro Pro Ala Ala Ser Ser Gly Pro Leu Gln Asp Ser Arg Pro Phe
                125
                                    130
                                                         135
Arg Ser Leu Leu His Arg Asp Leu Asp Asp Thr Lys Met Gln Lys
                140
                                    145
Ser Leu Ser Leu Leu Asp Ala Glu Asn Arg Gly Gly Arg Pro Tyr
                155
                                    160
                                                         165
Thr Glu Arg Pro Ser Arg Gly Leu Thr Pro Asp Pro Asn Ile Leu
                170
                                    175
                                                         180
Leu Gln Pro Thr Thr Glu Asn Ile Pro Glu Thr Val Val Ser Arg
                185
                                    190
Glu Phe Pro Arg Trp Val His Ser Ala Glu Pro Thr Tyr Phe Leu
                200
                                    205
                                                         210
Arg His Ser Arg Thr Pro Ser Ser Asp Gly Thr Val Glu Val Arg
                215
                                    220
                                                         225
Ala Leu Leu Thr Trp Thr Leu Asn Pro Gln Ile Asp Asn Glu Ala
                230
                                    235
Leu Phe Ser Cys Glu Val Lys His Pro Ala Leu Ser Met Pro Met
                245
                                    250
                                                         255
Gln Ala Glu Val Thr Leu Val Ala Pro Lys Gly Pro Lys Ile Val
                260
                                    265
                                                         270
Met Thr Pro Ser Arg Ala Arg Val Gly Asp Thr Val Arg Ile Leu
                275
                                    280
                                                         285
Val His Gly Phe Gln Asn Glu Val Phe Pro Glu Pro Met Phe Thr
                290
                                    295
Trp Thr Arg Val Gly Ser Arg Leu Leu Asp Gly Ser Ala Glu Phe
```

```
310
 Asp Gly Lys Glu Leu Val Leu Glu Arg Val Pro Ala Glu Leu Asn
                 320
                                     325
 Gly Ser Met Tyr Arg Cys Thr Ala Gln Asn Pro Leu Gly Ser Thr
                 335
                                     340
                                                          345
 Asp Thr His Thr Arg Leu Ile Val Phe Glu Asn Pro Asn Ile Pro
                350
                                     355
 Arg Gly Thr Glu Asp Ser Asn Gly Ser Ile Gly Pro Thr Gly Ala
                365
                                     370
                                                          375
 Arg Leu Thr Leu Val Leu Ala Leu Thr Val Ile Leu Glu Leu Thr
                                     385
 <210> 20
 <211> 427
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 1656935CD1
<400> 20
Met Asn Val Asn Ser Met Asp Met Thr Gly Gly Leu Ser Val Lys
                                     10
Asp Pro Ser Gln Ser Gln Ser Arg Leu Pro Gln Trp Thr His Pro
                 20
                                      25
Asn Ser Met Asp Asn Leu Pro Ser Ala Ala Ser Pro Leu Glu Gln
                 35
                                      40
Asn Pro Ser Lys His Gly Ala Ile Pro Gly Gly Leu Ser Ile Gly
                 50
                                     55
                                                          60
Pro Pro Gly Lys Ser Ser Ile Asp Asp Ser Tyr Gly Arg Tyr Asp
                 65
                                     70
Leu Ile Gln Asn Ser Glu Ser Pro Ala Ser Pro Pro Val Ala Val
                 80
                                     85
                                                          90
Pro His Ser Trp Ser Arg Ala Lys Ser Asp Ser Asp Lys Ile Ser
                 95
                                    100 ·
Asn Gly Ser Ser Ile Asn Trp Pro Pro Glu Phe His Pro Gly Val
                110
                                    115
Pro Trp Lys Gly Leu Gln Asn Ile Asp Pro Glu Asn Asp Pro Asp
                125
                                    130
                                                         135
Val Thr Pro Gly Ser Val Pro Thr Gly Pro Thr Ile Asn Thr Thr
                140
                                    145
Ile Gln Asp Val Asn Arg Tyr Leu Leu Lys Ser Gly Gly Ser Ser
                155
                                    160
Pro Pro Ser Ser Gln Asn Ala Thr Leu Pro Ser Ser Ser Ala Trp
                170
                                    175
                                                         180
Pro Leu Ser Ala Ser Gly Tyr Ser Ser Ser Phe Ser Ser Ile Ala
                185
                                    190
                                                         195
Ser Ala Pro Ser Val Ala Gly Lys Leu Ser Asp Ile Lys Ser Thr
                200
                                    205
Trp Ser Ser Gly Pro Thr Ser His Thr Gln Ala Ser Leu Ser His
                215
                                    220
Glu Leu Trp Lys Val Pro Arg Asn Ser Thr Ala Pro Thr Arg Pro
               230
                                    235
Pro Pro Gly Leu Thr Asn Pro Lys Pro Ser Ser Thr Trp Gly Ala
               245
                                    250
                                                         255
Ser Pro Leu Gly Trp Thr Ser Ser Tyr Ser Ser Gly Ser Ala Trp
               .260
                                    265
                                                         270
Ser Thr Asp Thr Ser Gly Arg Thr Ser Ser Trp Leu Val Leu Arg
               275
                                    280
Asn Leu Thr Pro Gln Ile Asp Gly Ser Lys Leu Arg Thr Leu Cys
               290
                                    295
                                                        300
Leu Gln His Gly Pro Leu Ile Thr Phe His Leu Asn Leu Thr Gln
```

```
Gly Asn Ala Val Val Arg Tyr Ser Ser Lys Glu Glu Gly Leu Pro
                320
                                     325
Lys Ala Gln Glu Val Leu Cys Thr Ile Val Arg Pro Trp Glu Thr
                335
                                     340
                                                         345
Leu Ser His Ser Leu Gly Pro Ser Phe Arg Leu Val Gly Thr Lys
                350
                                     355
Glu Val Gly Ile Arg Val Ser Phe Lys Pro Pro Glu Gly Pro Gly
                365
                                     370
Arg Ile Gly Gln Ser Thr Ile Phe Gln Gly Leu Ala Gln Phe His
                380
                                     385
Asp Gln Arg Gly Val Ser Lys Leu Thr Gly Arg Gly Gly Ile His
                395
                                     400
Arg Pro Arg Gly Arg Gly Lys Ala Ser His Gln Leu Ala His Met
                410
                                     415
                                                         420
Arg His Cys Glu Leu Thr Phe
                425
<210> 21
<211> 459
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1859305CD1
<400> 21
Met Glu Lys Thr Cys Ile Asp Ala Leu Pro Leu Thr Met Asn Ser
Ser Glu Lys Gln Glu Thr Val Cys Ile Phe Gly Thr Gly Asp Phe
                 20
                                      25
Gly Arg Ser Leu Gly Leu Lys Met Leu Gln Cys Gly Tyr Ser Val
                 35 -
                                     40
Val Phe Gly Ser Arg Asn Pro Gln Lys Thr Thr Leu Leu Pro Ser
                 50
                                     55
Gly Ala Glu Val Leu Ser Tyr Ser Glu Ala Ala Lys Lys Ser Asp
                 65
                                     70
Ile Ile Ile Ala Ile His Arg Glu His Tyr Asp Phe Leu Thr
                 80
                                     85
Glu Leu Thr Glu Val Leu Asn Gly Lys Ile Leu Val Asp Ile Ser
                 95
                                    100
Asn Asn Leu Lys Ile Asn Gln Tyr Pro Glu Ser Asn Ala Glu Tyr
                110
                                    115
                                                         120
Leu Ala His Leu Val Pro Gly Ala His Val Val Lys Ala Phe Asn
               125
                                    130
                                                         135
Thr Ile Ser Ala Trp Ala Leu Gln Ser Gly Ala Leu Asp Ala Ser
               140
                                    145
Arg Gln Val Phe Val Cys Gly Asn Asp Ser Lys Ala Lys Gln Arg
                155
                                    160
                                                         165
Val Met Asp Ile Val Arg Asn Leu Gly Leu Thr Pro Met Asp Gln
                170
                                    175
                                                         180
Gly Ser Leu Met Ala Ala Lys Glu Ile Glu Lys Tyr Pro Leu Gln
               185
                                    190
Leu Phe Pro Met Trp Arg Phe Pro Phe Tyr Leu Ser Ala Val Leu
               200
                                    205
                                                         210
Cys Val Phe Leu Phe Phe Tyr Cys Val Ile Arg Asp Val Ile Tyr
               215
                                    220
                                                         225
Pro Tyr Val Tyr Glu Lys Lys Asp Asn Thr Phe Arg Met Ala Ile
               230
                                    235
                                                         240
Ser Ile Pro Asn Arg Ile Phe Pro Ile Thr Ala Leu Thr Leu Leu
               245
                                    250
Ala Leu Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Leu Gln Leu
               260
                                    265
```

```
Tyr Arg Gly Thr Lys Tyr Arg Arg Phe Pro Asp Trp Leu Asp His
                275
                                    280
Trp Met Leu Cys Arg Lys Gln Leu Gly Leu Val Ala Leu Gly Phe
                290
                                    295
                                                         300
Ala Phe Leu His Val Leu Tyr Thr Leu Val Ile Pro Ile Arg Tyr
                                                         315
                305
                                    310
Tyr Val Arg Trp Arg Leu Gly Asn Leu Thr Val Thr Gln Ala Ile
                320
                                    325
Leu Lys Lys Glu Asn Pro Phe Ser Thr Ser Ser Ala Trp Leu Ser
                                                         345
                                    340
                335
Asp Ser Tyr Val Ala Leu Gly Ile Leu Gly Phe Phe Leu Phe Val
                                    355
Leu Leu Gly Ile Thr Ser Leu Pro Ser Val Ser Asn Ala Val Asn
                                    370
                365
Trp Arg Glu Phe Arg Phe Val Gln Ser Lys Leu Gly Tyr Leu Thr
                380
                                    385
Leu Ile Leu Cys Thr Ala His Thr Leu Val Tyr Gly Gly Lys Arg
                395
                                    400
                                                         405
Phe Leu Ser Pro Ser Asn Leu Arg Trp Tyr Leu Pro Ala Ala Tyr
                                                         420
                                    415
                410
Val Leu Gly Leu Ile Ile Pro Cys Thr Val Leu Val Ile Lys Phe
                425
                                    430
                                                         435
Val Leu Ile Met Pro Cys Val Asp Asn Thr Leu Thr Arg Ile Arg
                440
                                    445
Gln Gly Trp Glu Arg Asn Ser Lys His
                455
<210> 22
<211> 229
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1949083CD1
<400> 22
Met Leu Pro Val Ser Arg Thr Cys Leu Leu Glu Ser Ser Thr Arg
 1
                                     10
Leu Lys Pro His Glu Ala Gln Asn Tyr Arg Lys Lys Ala Leu Trp
                 20
                                     25
Val Ser Trp Phe Ser Ile Ile Val Thr Leu Ala Leu Ala Val Ala
                 35
                                     40
Ala Phe Thr Val Ser Val Met Arg Tyr Ser Ala Ser Ala Phe Gly
                                                          60
                 50
                                     55
Phe Ala Phe Asp Ala Ile Leu Asp Val Leu Ser Ser Ala Ile Val
                 65
                                     70
Leu Trp Arg Tyr Ser Asn Ala Ala Ala Val His Ser Ala His Arg
                 80
                                     85
Glu Tyr Ile Ala Cys Val Ile Leu Gly Val Ile Phe Leu Leu Ser
                 95
                                    100
Ser Ile Cys Ile Val Val Lys Ala Ile His Asp Leu Ser Thr Arg
                110
                                    115
Leu Leu Pro Glu Val Asp Asp Phe Leu Phe Ser Val Ser Ile Leu
                125
                                                         135
                                    130
Ser Gly Ile Leu Cys Ser Ile Leu Ala Val Leu Lys Phe Met Leu
                140
                                    145
                                                         150
Gly Lys Val Leu Thr Ser Arg Ala Leu Ile Thr Asp Gly Phe Asn
                155
                                    160
Ser Leu Val Gly Gly Val Met Gly Phe Ser Ile Leu Leu Ser Ala
                170
                                    175
                                                         180
Glu Val Phe Lys His Asp Ser Ala Val Trp Tyr Leu Asp Gly Ser
                185
                                    190
Ile Gly Val Leu Ile Gly Leu Thr Ile Phe Ala Tyr Gly Val Lys
```

205

```
Leu Leu Ile Asp Met Val Pro Lys Val Arg Gln Thr Arg His Tyr
                215
                                    220
Glu Met Phe Glu
<210> 23
<211> 311
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1996357CD1
Met Ala Val Asp Ile Gln Pro Ala Cys Leu Gly Leu Tyr Cys Gly
                                     10
 1
Lys Thr Leu Leu Phe Lys Asn Gly Ser Thr Glu Ile Tyr Gly Glu
                 20
                                     25
Cys Gly Val Cys Pro Arg Gly Gln Arg Thr Asn Ala Gln Lys Tyr
                 35
                                     40
Cys Gln Pro Cys Thr Glu Ser Pro Glu Leu Tyr Asp Trp Leu Tyr
                 50
                                     55
Leu Gly Phe Met Ala Met Leu Pro Leu Val Leu His Trp Phe Phe
                                     70
Ile Glu Trp Tyr Ser Gly Lys Lys Ser Ser Ser Ala Leu Phe Gln
                 80
                                     85
His Ile Thr Ala Leu Phe Glu Cys Ser Met Ala Ala Ile Ile Thr
                                                         105
                                    100
                 95
Leu Leu Val Ser Asp Pro Val Gly Val Leu Tyr Ile Arg Ser Cys
                110
                                    115
                                                         120
Arg Val Leu Met Leu Ser Asp Trp Tyr Thr Met Leu Tyr Asn Pro
                125
                                    130
Ser Pro Asp Tyr Val Thr Thr Val His Cys Thr His Glu Ala Val
                                                         150
                140 ·
                                    145
Tyr Pro Leu Tyr Thr Ile Val Phe Ile Tyr Tyr Ala Phe Cys Leu
                                    160
                155
Val Leu Met Met Leu Leu Arg Pro Leu Leu Val Lys Lys Ile Ala
                170
                                    175
Cys Gly Leu Gly Lys Ser Asp Arg Phe Lys Ser Ile Tyr Ala Ala
                                                         195
                                    190
                185
Leu Tyr Phe Phe Pro Ile Leu Thr Val Leu Gln Ala Val Gly Gly
                200
                                    205
                                                         210
Gly Leu Leu Tyr Tyr Ala Phe Pro Tyr Ile Ile Leu Val Leu Ser
                215
                                    220
Leu Val Thr Leu Ala Val Tyr Met Ser Ala Ser Glu Ile Glu Asn
                230
                                    235
Cys Tyr Asp Leu Leu Val Arg Lys Lys Arg Leu Ile Val Leu Phe
                                                         255
                                    250
Ser His Trp Leu Leu His Ala Tyr Gly Ile Ile Ser Ile Ser Arg
                260
                                    265
Val Asp Lys Leu Glu Gln Asp Leu Pro Leu Leu Ala Leu Val Pro
                                                         285
                275
                                    280
Thr Pro Ala Leu Phe Tyr Leu Phe Thr Ala Lys Phe Thr Glu Pro
                290
                                    295
                                                         300
Ser Arg Ile Leu Ser Glu Gly Ala Asn Gly His
                305
                                    310
<210> 24
<211> 92
<212> PRT
<213> Homo sapiens
<220>
```

<221> misc\_feature <223> Incyte ID No: 2061330CD1 <400> 24 Met Arg Phe Ile Phe Leu Lys Phe Trp Thr Tyr Thr Val Arg Ala 10 Ser Thr Asp Leu Thr Gln Thr Gly Asp Cys Ser Gln Cys Thr His 20 Gln Val Thr Glu Val Gly Gln Gln Ile Lys Thr Ile Phe Leu Phe 40 Tyr Ser Tyr Tyr Glu Cys Met Glu Thr Ile Lys Glu Thr Cys Leu 55 50 Tyr Asn Ala Thr Gln Tyr Lys Val Cys Ser Pro Arg Asn Asp Arg 70 Pro Asp Val Cys Tyr Asn Pro Ser Glu Pro Pro Ala Pro Pro Phe 85 Leu Lys <210> 25 <211> 258 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte ID No: 2346947CD1 <400> 25 Met Ala Glu Ser Pro Gly Cys Cys Ser Val Trp Ala Arg Cys Leu 10 His Cys Leu Tyr Ser Cys His Trp Arg Lys Cys Pro Arg Glu Arg 20 25 Met Gln Thr Ser Lys Cys Asp Cys Ile Trp Phe Gly Leu Leu Phe 40 . 35 Leu Thr Phe Leu Leu Ser Leu Ser Trp Leu Tyr Ile Gly Leu Val 55 . .50 Leu Leu Asn Asp Leu His Asn Phe Asn Glu Phe Leu Phe Arg Arg 70 Trp Gly His Trp Met Asp Trp Ser Leu Ala Phe Leu Leu Val Ile 85 80 Ser Leu Leu Val Thr Tyr Ala Ser Leu Leu Leu Val Leu Ala Leu 105 100 95 Leu Leu Arg Leu Cys Arg Gln Pro Leu His Leu His Ser Leu His 115 110 Lys Val Leu Leu Leu Ile Met Leu Leu Val Ala Ala Gly Leu 135 130 125 Val Gly Leu Asp Ile Gln Trp Gln Glu Trp His Ser Leu Arg 150 145 140 Val Ser Leu Gln Ala Thr Ala Pro Phe Leu His Ile Gly Ala Ala 160 155 Ala Gly Ile Ala Leu Leu Ala Trp Pro Val Ala Asp Thr Phe Tyr 180 175 170 Arg Ile His Arg Arg Gly Pro Lys Ile Leu Leu Leu Leu Phe 195 190 185 Phe Gly Val Val Leu Val Ile Tyr Leu Ala Pro Leu Cys Ile Ser 210 205 200 Ser Pro Cys Ile Met Glu Pro Arg Asp Leu Pro Pro Lys Pro Gly 225 220 215 Leu Val Gly His Arg Gly Ala Pro Met Leu Ala Pro Glu Asn Thr 240 230 235 Leu Met Ser Leu Arg Lys Thr Ala Glu Cys Gly Leu Leu Cys Leu 245

Arg Leu Met

```
<210> 26
<211> 226
<212> PRT
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: 2795577CD1
<400> 26
Met Lys Met Val Ala Pro Trp Thr Arg Phe Tyr Ser Asn Ser Cys
Cys Leu Cys Cys His Val Arg Thr Gly Thr Ile Leu Leu Gly Val
                                     25
                 20
Trp Tyr Leu Ile Ile Asn Ala Val Val Leu Leu Ile Leu Leu Ser
                 35
                                     40
Ala Leu Ala Asp Pro Asp Gln Tyr Asn Phe Ser Ser Ser Glu Leu
                 50
                                     55
Gly Gly Asp Phe Glu Phe Met Asp Asp Ala Asn Met Cys Ile Ala
                                     70
                 65
Ile Ala Ile Ser Leu Leu Met Ile Leu Ile Cys Ala Met Ala Thr
                 80
                                     85
Tyr Gly Ala Tyr Lys Gln Arg Ala Ala Trp Ile Ile Pro Phe Phe
                 95
                                    100
Cys Tyr Gln Ile Phe Asp Phe Ala Leu Asn Met Leu Val Ala Ile
                110
                                    115
Thr Val Leu Ile Tyr Pro Asn Ser Ile Gln Glu Tyr Ile Arg Gln
                125
                                    130
                                                         135
Leu Pro Pro Asn Phe Pro Tyr Arg Asp Asp Val Met Ser Val Asn
                140
                                    145
Pro Thr Cys Leu Val Leu Ile Ile Leu Leu Phe Ile Ser Ile Ile
                                                         165
                                   160
               .155
Leu Thr Phe Lys Gly Tyr Leu Ile Ser Cys Val Trp Asn Cys Tyr
               170
                                    175
                                                         180
Arg Tyr Ile Asn Gly Arg Asn Ser Ser Asp Val Leu Val Tyr Val
                185
                                    190
Thr Ser Asn Asp Thr Thr Val Leu Leu Pro Pro Tyr Asp Asp Ala
                200
                                    205
Thr Val Asn Gly Ala Ala Lys Glu Pro Pro Pro Pro Tyr Val Ser
Ala
<210> 27
<211> 136
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 3255825CD1
<400> 27
Met Ile Ser Ile Thr Glu Trp Gln Lys Ile Gly Val Gly Ile Thr
                                     10
Gly Phe Gly Ile Phe Phe Ile Leu Phe Gly Thr Leu Leu Tyr Phe
                                                          30
                 20
                                     25
Asp Ser Val Leu Leu Ala Phe Gly Asn Leu Leu Phe Leu Thr Gly
                 35
                                     40
Leu Ser Leu Ile Ile Gly Leu Arg Lys Thr Phe Trp Phe Phe Phe
                                                          60
                 50
                                     55
Gln Arg His Lys Leu Lys Gly Thr Ser Phe Leu Leu Gly Gly Val
```

70

```
Val Ile Val Leu Leu Arg Trp Pro Leu Leu Gly Met Phe Leu Glu
                                      85
Thr Tyr Gly Phe Phe Ser Leu Phe Lys Gly Phe Phe Pro Val Ala
                 95
                                     100
Phe Gly Ser Trp Ala Met Ser Ala Thr Ser Pro Ser Trp Val Arg
                110
                                     115
Cys Ser Gly Asp Phe Lys Ala Leu Ala Arg Trp Ser Glu Lys Gln
                125
                                    130
Arg
<210> 28
<211> 458
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 3393430CD1
<400> 28
Met Ala Trp Ala Ser Arg Leu Gly Leu Leu Leu Ala Leu Leu Leu
Pro Val Val Gly Ala Ser Thr Pro Gly Thr Val Val Arg Leu Asn
                 20
                                     25
Lys Ala Ala Leu Ser Tyr Val Ser Glu Ile Gly Lys Ala Pro Leu
                 35
                                      40
Gln Arg Ala Leu Gln Val Thr Val Pro His Phe Leu Asp Trp Ser
                 50
                                     55
Gly Glu Ala Leu Gln Pro Thr Arg Ile Arg Ile Leu Asn Val His
                                     70
                 65
Val Pro Arg Leu His Leu Lys Phe Ile Ala Gly Phe Gly Val Arg
                 80
                                     85
                                                          90
Leu Leu Ala Ala Ala Asn Phe Thr Phe Lys Val Phe Arg Ala Pro
                 95
                                    100
Glu Pro Leu Glu Leu Thr Leu Pro Val Glu Leu Leu Ala Asp Thr
                110
                                    115
Arg Val Thr Gln Ser Ser Ile Arg Thr Pro Val Val Ser Ile Ser
                125
                                    130
                                                         135
Ala Cys Ser Leu Phe Ser Gly His Ala Asn Glu Phe Asp Gly Ser
                140
                                    145
Asn Ser Thr Ser His Ala Leu Leu Val Leu Val Gln Lys His Ile
                155
                                    160
Lys Ala Val Leu Ser Asn Lys Leu Cys Leu Ser Ile Ser Asn Leu
                170
                                    175
                                                         180
Val Gln Gly Val Asn Val His Leu Gly Thr Leu Ile Gly Leu Asn
                185
                                    190
Pro Val Gly Pro Glu Ser Gln Ile Arg Tyr Ser Met Val Ser Val
                200
                                    205
                                                         210
Pro Thr Val Thr Ser Asp Tyr Ile Ser Leu Glu Val Asn Ala Val
                215
                                    220
                                                         225
Leu Phe Leu Leu Gly Lys Pro Ile Ile Leu Pro Thr Asp Ala Thr
                230
                                    235
Pro Phe Val Leu Pro Arg His Val Gly Thr Glu Gly Ser Met Ala
                245
                                    250
Thr Val Gly Leu Ser Gln Gln Leu Phe Asp Ser Ala Leu Leu Leu
                260
                                    265
Leu Gln Lys Ala Gly Ala Leu Asn Leu Asp Ile Thr Gly Gln Leu
                275
                                    280
Arg Ser Asp Asp Asn Leu Leu Asn Thr Ser Ala Leu Gly Arg Leu
                290
                                    295
                                                         300
Ile Pro Glu Val Ala Arg Gln Phe Pro Glu Pro Met Pro Val Val
                                    310
Leu Lys Val Arg Leu Gly Ala Thr Pro Val Ala Met Leu His Thr
```

```
320
                                     325
 Asn Asn Ala Thr Leu Arg Leu Gln Pro Phe Val Glu Val Leu Ala
                 335
                                     340
 Thr Ala Ser Asn Ser Ala Phe Gln Ser Leu Phe Ser Leu Asp Val
                 350
                                     355
 Val Val Asn Leu Arg Leu Gln Leu Ser Val Ser Lys Val Lys Leu
                 365
                                     370
 Gln Gly Thr Thr Ser Val Leu Gly Asp Val Gln Leu Thr Val Ala
                 380
                                     385
 Ser Ser Asn Val Gly Phe Ile Asp Thr Asp Gln Val Arg Thr Leu
                 395
                                     400
 Met Gly Thr Val Phe Glu Lys Pro Leu Leu Asp His Leu Asn Ala
                 410
                                     415
 Leu Leu Ala Met Gly Ile Ala Leu Pro Gly Val Val Asn Leu His
                 425
                                     430
                                                          435
 Tyr Val Ala Pro Glu Ile Phe Val Tyr Glu Gly Tyr Val Val Ile
                 440
                                     445
 Ser Ser Gly Leu Phe Tyr Gln Ser
 <210> 29
 <211> 368
 <212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 3490990CD1
<400> 29
Met Phe Gly Gln Asn Leu Glu Val Gln Leu Ser Ser Ala Arg Thr
                                     10
Glu Asn Thr Thr Val Val Trp Lys Ser Phe His Asp Ser Ile Thr
                 ·20 ·
                                     25 -
Leu Ile Val Leu Ser Ser Glu Val Gly Ile Ser Glu Leu Arg Leu
                35
                                     .40
Glu Arg Leu Leu Gln Met Val Phe Gly Ala Met Val Leu Leu Val
                 50
                                     55
                                                          60
Gly Leu Glu Glu Leu Thr Asn Ile Arg Asn Val Glu Arg Leu Lys
                 65
                                     70
Lys Asp Leu Arg Ala Ser Tyr Cys Leu Ile Asp Ser Phe Leu Gly
                 80
                                     85
Asp Ser Glu Leu Ile Gly Asp Leu Thr Gln Cys Val Asp Cys Val
                 95
                                    100
Ile Pro Pro Glu Gly Ser Leu Leu Gln Glu Ala Leu Ser Gly Phe
                110
                                    115
Ala Glu Ala Ala Gly Thr Thr Phe Val Ser Leu Val Val Ser Gly
                125
                                    130
Arg Val Val Ala Ala Thr Glu Gly Trp Trp Arg Leu Gly Thr Pro
                140
                                    145
Glu Ala Val Leu Leu Pro Trp Leu Val Gly Ser Leu Pro Pro Gln
                155
                                    160
Thr Ala Arg Asp Tyr Pro Val Tyr Leu Pro His Gly Ser Pro Thr
                170
                                    175
Val Pro His Arg Leu Leu Thr Leu Thr Leu Leu Pro Ser Leu Glu
                185
                                    190
Leu Cys Leu Leu Cys Gly Pro Ser Pro Pro Leu Ser Gln Leu Tyr
                200
                                    205
Pro Gln Leu Leu Glu Arg Trp Trp Gln Pro Leu Leu Asp Pro Leu
                215
                                    220
                                                         225
Arg Ala Cys Leu Pro Leu Gly Pro Arg Ala Leu Pro Ser Gly Phe
                230
                                    235
Pro Leu His Thr Asp Ile Leu Gly Leu Leu Leu His Leu Glu
                                    250
                                                         255
```

```
Leu Lys Arg Cys Leu Phe Thr Val Glu Pro Leu Gly Asp Lys Glu
                 260
                                      265
 Pro Ser Pro Glu Gln Arg Arg Arg Leu Leu Arg Asn Phe Tyr Thr
                 275
                                      280
 Leu Val Thr Ser Thr His Phe Pro Pro Glu Pro Gly Pro Pro Glu
                 290
                                      295
                                                          300
 Lys Thr Glu Asp Glu Val Tyr Gln Ala Gln Leu Pro Arg Ala Cys
                 305
                                     310
                                                          315
 Tyr Leu Val Leu Gly Thr Glu Glu Pro Gly Thr Gly Val Arg Leu
                 320
                                     325
 Val Ala Leu Gln Leu Gly Leu Arg Arg Leu Leu Leu Leu Ser
                 335
                                     340
                                                          345
 Pro Gln Ser Pro Thr His Gly Leu Arg Ser Leu Ala Thr His Thr
                 350
                                     355
 Leu His Ala Leu Thr Pro Leu Leu
                 365
 <210> 30
 <211> 91
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 3635154CD1
 <400> 30
Met Tyr Gly Lys Ile Ile Phe Val Leu Leu Leu Ser Glu Ile Val
                                      10
Ser Ile Ser Ala Ser Ser Thr Thr Gly Val Ala Met His Thr Ser
                 20
                                      25
Thr Ser Ser Ser Val Thr Lys Ser Tyr Ile Ser Ser Gln Thr Asn
                 35
                                      40
Gly Glu Thr Gly Gln Leu Val His Arg Phe Thr Val Pro Ala Pro
                 50
                                      55
                                                           60
Val Val Ile Ile Leu Ile Ile Leu Cys Val Met Ala Gly Ile Ile
                 65
                                     70
Gly Thr Ile Leu Leu Phe Ser Tyr Ser Phe Arg Arg Leu Ile Lys
                                      85
Gly
<210> 31
<211> 295
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 4374347CD1
<400> 31
Met Gly Pro Pro Ser Ala Cys Pro His Arg Glu Cys Ile Pro Trp
                                     10
                                                          15
Gln Gly Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Ala
                 20
                                     25
Pro Thr Thr Ala Trp Leu Phe Ile Ala Ser Ala Pro Phe Glu Val
                 35
                                     40
Ala Glu Gly Glu Asn Val His Leu Ser Val Val Tyr Leu Pro Glu
                 50
                                     55
Asn Leu Tyr Ser Tyr Gly Trp Tyr Lys Gly Lys Thr Val Glu Pro
                 65
                                     70
                                                          75
Asn Gln Leu Ile Ala Ala Tyr Val Ile Asp Thr His Val Arg Thr
                 80
                                     85
Pro Gly Pro Ala Tyr Ser Gly Arg Glu Thr Ile Ser Pro Ser Gly
```

```
100
Asp Leu His Phe Gln Asn Val Thr Leu Glu Asp Thr Gly Tyr Tyr
                 110
                                     115
                                                         120
Asn Leu Gln Val Thr Tyr Arg Asn Ser Gln Ile Glu Gln Ala Ser
                 125
                                     130
                                                         135
His His Leu Arg Val Tyr Glu Ser Val Ala Gln Pro Ser Ile Gln
                140
                                     145
                                                         150
Ala Ser Ser Thr Thr Val Thr Glu Lys Gly Ser Val Val Leu Thr
                155
                                     160
Cys His Thr Asn Asn Thr Gly Thr Ser Phe Gln Trp Ile Phe Asn
                                     175
                                                         180
Asn Gln Arg Leu Gln Val Thr Lys Arg Met Lys Leu Ser Trp Phe
                185
                                     190
                                                         195
Asn His Val Leu Thr Ile Asp Pro Ile Arg Gln Glu Asp Ala Gly
                200
                                     205
Glu Tyr Gln Cys Glu Val Ser Asn Pro Val Ser Ser Asn Arg Ser
                215
                                    220
                                                         225
Asp Pro Leu Lys Leu Thr Val Lys Tyr Asp Asn Thr Leu Gly Ile
                230
                                     235
                                                         240
Leu Ile Gly Val Leu Val Gly Ser Leu Leu Val Ala Ala Leu Val
                245
                                     250
Cys Phe Leu Leu Arg Lys Thr Gly Arg Ala Ser Asp Gln Ser
                260
                                                         270
                                     265
Asp Phe Arg Glu Gln Gln Pro Pro Ala Ser Thr Pro Gly His Gly
                275
                                     280
Pro Ser Asp Ser Ser Asp Ser Ser Ile Ser
                290
<210> 32
<211> 724
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 4596747CD1.
<400> 32
Met Phe Asp Thr Thr Pro His Ser Gly Arg Ser Thr Pro Ser Ser
                                     10
Ser Pro Ser Leu Arg Lys Arg Leu Gln Leu Leu Pro Pro Ser Arg
                 20
                                     25
Pro Pro Pro Glu Pro Glu Pro Gly Thr Met Val Glu Lys Gly Ser
                 35
                                     40
Asp Ser Ser Ser Glu Lys Gly Gly Val Pro Gly Thr Pro Ser Thr
                 50
                                     55
Gln Ser Leu Gly Ser Arg Asn Phe Ile Arg Asn Ser Lys Lys Met
                 65
                                     70
Gln Ser Trp Tyr Ser Met Leu Ser Pro Thr Tyr Lys Gln Arg Asn
                 80
Glu Asp Phe Arg Lys Leu Phe Ser Lys Leu Pro Glu Ala Glu Arg
                 95
                                    100
Leu Ile Val Asp Tyr Ser Cys Ala Leu Gln Arg Glu Ile Leu Leu
                110
                                    115
Gln Gly Arg Leu Tyr Leu Ser Glu Asn Trp Ile Cys Phe Tyr Ser
                125
                                    130
                                                         135
Asn Ile Phe Arg Trp Glu Thr Thr Ile Ser Ile Gln Leu Lys Glu
               140
                                    145
                                                         150
Val Thr Cys Leu Lys Lys Glu Lys Thr Ala Lys Leu Ile Pro Asn
                155
                                    160
Ala Ile Gln Ile Cys Thr Glu Ser Glu Lys His Phe Phe Thr Ser
                170
                                    175
                                                         180
Phe Gly Ala Arg Asp Arg Cys Phe Leu Leu Ile Phe Arg Leu Trp
                185
                                    190
                                                         195
```

Gln Asn Ala Leu Leu Glu Lys Thr Leu Ser Pro Arg Glu Leu Trp His Leu Val His Gln Cys Tyr Gly Ser Glu Leu Gly Leu Thr Ser Glu Asp Glu Asp Tyr Val Ser Pro Leu Gln Leu Asn Gly Leu Gly Thr Pro Lys Glu Val Gly Asp Val Ile Ala Leu Ser Asp Ile Thr Ser Ser Gly Ala Ala Asp Arg Ser Gln Glu Pro Ser Pro Val Gly Ser Arg Arg Gly His Val Thr Pro Asn Leu Ser Arg Ala Ser Ser Asp Ala Asp His Gly Ala Glu Glu Asp Lys Glu Glu Gln Val Asp Ser Gln Pro Asp Ala Ser Ser Ser Gln Thr Val Thr Pro Val Ala Glu Pro Pro Ser Thr Glu Pro Thr Gln Pro Asp Gly Pro Thr Thr Leu Gly Pro Leu Asp Leu Leu Pro Ser Glu Glu Leu Leu Thr Asp Thr Ser Asn Ser Ser Ser Ser Thr Gly Glu Glu Ala Asp Leu Ala Ala Leu Leu Pro Asp Leu Ser Gly Arg Leu Leu Ile Asn Ser Val Phe His Val Gly Ala Glu Arg Leu Gln Gln Met Leu Phe Ser Asp Ser Pro Phe Leu Gln Gly Phe Leu Gln Gln Cys Lys Phe Thr Asp Val Thr Leu Ser Pro Trp Ser Gly Asp Ser Lys Cys His Gln Arg Arg Val Leu Thr Tyr Thr Ile Pro Ile Ser Asn Pro Leu Gly Pro Lys Ser Ala Ser Val Val Glu Thr Gln Thr Leu Phe Arg Arg Gly Pro Gln Ala Gly Gly Cys Val Val Asp Ser Glu Val Leu Thr Gln Gly Ile Pro Tyr Gln Asp Tyr Phe Tyr Thr Ala His Arg Tyr Cys Ile Leu Gly Leu Ala Arg Asn Lys Ala Arg Leu Arg Val Ser Ser Glu Ile Arg Tyr Arg Lys Gln Pro Trp Ser Leu Val Lys Ser Leu Ile Glu Lys Asn Ser Trp Ser Gly Ile Glu Asp Tyr Phe His His Leu Glu Arg Glu Leu Ala Lys Ala Glu Lys Leu Ser Leu Glu Glu Gly Gly Lys Asp Ala Arg Gly Leu Leu Ser Gly Leu Arg Arg Lys Arg Pro Leu Ser Trp Arg Ala His Gly Asp Gly Pro Gln His Pro Asp Pro Asp Pro Cys Ala Arg Ala Gly Ile His Thr Ser Gly Ser Leu Ser Ser Arg Phe Ser Glu Pro Ser Val Asp Gln Gly Pro Gly Ala Gly Ile Pro Ser Ala Leu Val Leu Ile Ser Ile Val Ile Cys Val Ser Leu Ile Ile Leu Ile Ala Leu Asn Val Leu Leu Phe Tyr Arg Leu Trp Ser Leu Glu Arg Thr Ala His Thr Phe Glu Ser Trp His Ser Leu Ala Leu Ala Lys Gly Lys Phe Pro Gln Thr Ala Thr Glu Trp Ala Glu Ile Leu Ala Leu Gln Lys Gln Phe His Ser

```
665
                                     670
Val Glu Val His Lys Trp Arg Gln Ile Leu Arg Ala Ser Val Glu
                680
                                     685
Leu Leu Asp Glu Met Lys Phe Ser Leu Glu Lys Leu His Gln Gly
                695
                                     700
Ile Thr Val Ser Asp Pro Pro Phe Asp Thr Gln Pro Arg Pro Asp
                                     715
                710
Asp Ser Phe Ser
<210> 33
<211> 331
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5052680CD1
<400> 33
Met Arg Pro Ala Leu Ala Val Gly Leu Val Phe Ala Gly Cys Cys
                                      10
Ser Asn Val Ile Phe Leu Glu Leu Leu Ala Arg Lys His Pro Gly
                 20
                                      25
Cys Gly Asn Ile Val Thr Phe Ala Gln Phe Leu Phe Ile Ala Val
Glu Gly Phe Leu Phe Glu Ala Asp Leu Gly Arg Lys Pro Pro Ala
                 50
                                      55
Ile Pro Ile Arg Tyr Tyr Ala Ile Met Val Thr Met Phe Phe Thr
                 65
                                      70
Val Ser Val Val Asn Asn Tyr Ala Leu Asn Leu Asn Ile Ala Met
                 80
                                      85
Pro Leu His Met Ile Phe Arg Ser Gly Ser Leu Ile Ala Asn Met
                 95
                                     100
Ile Leu Gly Ile Ile Ile Leu Lys Lys Arg Tyr Ser Ile Phe Lys
                110
                                     115
                                                         120
Tyr Thr Ser Ile Ala Leu Val Ser Val Gly Ile Phe Ile Cys Thr
                125
                                     130
Phe Met Ser Ala Lys Gln Val Thr Ser Gln Ser Ser Leu Ser Glu
                140
                                     145
Asn Asp Gly Phe Gln Ala Phe Val Trp Trp Leu Leu Gly Ile Gly
                155
                                    160
Ala Leu Thr Phe Ala Leu Leu Met Ser Ala Arg Met Gly Ile Phe
                170
                                    175
Gln Glu Thr Leu Tyr Lys Arg Phe Gly Lys His Ser Lys Glu Ala
                185
                                    190
Leu Phe Tyr Asn His Ala Leu Pro Leu Pro Gly Phe Val Phe Leu
                200
                                    205
Ala Ser Asp Ile Tyr Asp His Ala Val Leu Phe Asn Lys Ser Glu
                                     220
Leu Tyr Glu Ile Pro Val Ile Gly Val Thr Leu Pro Ile Met Trp
                230
                                    235
Phe Tyr Leu Leu Met Asn Ile Ile Thr Gln Tyr Val Cys Ile Arg
                245
                                    250
Gly Val Phe Ile Leu Thr Thr Glu Cys Ala Ser Leu Thr Val Thr
                260
                                    265
                                                         270
Leu Val Val Thr Leu Arg Lys Phe Val Ser Leu Ile Phe Ser Ile
                275
                                    280
                                                         285
Leu Tyr Phe Gln Asn Pro Phe Thr Leu Trp His Trp Leu Gly Thr
                290
                                    295
Leu Phe Val Phe Ile Gly Thr Leu Met Tyr Thr Glu Val Trp Asn
                305
                                    310
                                                         315
Asn Leu Gly Thr Thr Lys Ser Glu Pro Gln Lys Asp Ser Lys Lys
                320
                                    325
```

Asn

<210> 34 <211> 398 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte ID No: 5373575CD1 <400> 34 Met Leu Gly Arg Ser Gly Tyr Arg Ala Leu Pro Leu Gly Asp Phe Asp Arg Phe Gln Gln Ser Ser Phe Gly Phe Leu Gly Ser Gln Lys Gly Cys Leu Ser Pro Glu Arg Gly Gly Val Gly Thr Gly Ala Asp Val Pro Gln Ser Trp Pro Ser Cys Leu Cys His Gly Leu Ile Ser Phe Leu Gly Phe Leu Leu Leu Val Thr Phe Pro Ile Ser Gly Trp Phe Ala Leu Lys Ile Val Pro Thr Tyr Glu Arg Met Ile Val Phe Arg Leu Gly Arg Ile Arg Thr Pro Gln Gly Pro Gly Met Val Leu Leu Pro Phe Ile Asp Ser Phe Gln Arg Val Asp Leu Arg Thr Arg Ala Phe Asn Val Pro Pro Cys Lys Leu Ala Ser Lys Asp Gly Ala Val Leu Ser Val Gly Ala Asp Val Gln Phe Arg Ile Trp Asp Pro Val Leu Ser Val Met Thr Val Lys Asp Leu Asn Thr Ala Thr Arg Met Thr Ala Gln Asn Ala Met Thr Lys Ala Leu Leu Lys .180 Arg Pro Leu Arg Glu Ile Gln Met Glu Lys Leu Lys Ile Ser Asp Gln Leu Leu Glu Ile Asn Asp Val Thr Arg Ala Trp Gly Leu Glu Val Asp Arg Val Glu Leu Ala Val Glu Ala Val Leu Gln Pro Pro Gln Asp Ser Pro Ala Gly Pro Asn Leu Asp Ser Thr Leu Gln Gln Leu Ala Leu His Phe Leu Gly Gly Ser Met Asn Ser Met Ala Gly Gly Ala Pro Ser Pro Gly Pro Ala Asp Thr Val Glu Met Val Ser Glu Val Glu Pro Pro Ala Pro Gln Val Gly Ala Arg Ser Ser Pro Lys Gln Pro Leu Ala Glu Gly Leu Leu Thr Ala Leu Gln Pro Phe Leu Ser Glu Ala Leu Val Ser Gln Val Gly Ala Cys Tyr Gln Phe Asn Val Val Leu Pro Ser Gly Thr Gln Ser Ala Tyr Phe Leu Asp Leu Thr Thr Gly Arg Gly Arg Val Gly His Gly Val Pro Asp Gly Ile Pro Asp Val Val Val Glu Met Ala Glu Ala Asp Leu Arg Ala Leu Leu Cys Arg Glu Leu Arg Pro Leu Gly Ala Tyr Met Ser 

Gly Arg Leu Lys Val Lys Gly Asp Leu Ala Met Ala Met Lys Leu

385

390

```
380
Glu Ala Val Leu Arg Ala Leu Lys
                395
<210> 35
<211> 220
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: 5524468CD1
<400> 35
Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg
                                     10
                 - 5
 1
Val Gly Leu Gly Thr Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala
                                     25
                 20
Leu His Asn Cys Pro Tyr Lys Cys Ile Cys Ala Ala Asp Leu Leu
                                      40
                 35
Ser Cys Thr Gly Leu Gly Leu Gln Asp Val Pro Ala Glu Leu Pro
                                                          60
                                      55
                 50
Ala Ala Thr Ala Asp Leu Asp Leu Ser His Asn Ala Leu Gln Arg
                                     70
                 65
Leu Arg Pro Gly Trp Leu Ala Pro Leu Phe Gln Leu Arg Ala Leu
                                      85
                 80
His Leu Asp His Asn Glu Leu Asp Ala Leu Gly Arg Gly Val Phe
                                                         105
                                     100
                 95
Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu Ser Ser Asn Thr
                                                         120
                                     115
                110
Leu Arg Ala Leu Gly Arg His Asp Leu Asp Gly Leu Gly Ala Leu
                125
                                     130
Glu Lys Leu Leu Phe Asn Asn Arg Leu Val His Leu Asp Glu
                                                         150
               140
                                    145
His Ala Phe His Gly Leu Arg Ala Leu Ser His Leu Tyr Leu Gly
                                                         165
                                 160
               155
Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His Leu His Gly Leu
                                     175
              . 170
Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser Asn Arg Leu
                                                         195
                                     190
                185
Gly His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala Phe Leu
                                     205
                                                         210
                200
Lys Asn Gly Leu Tyr Leu His Asp Asn Thr
                                     220
                 215
<210> 36
<211> 706
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 5944279CD1
 <400> 36
 Met Glu Glu Asn Pro Thr Leu Glu Ser Glu Ala Trp Gly Ser Ser
                                      10
                   5
  1
 Arg Gly Trp Leu Ala Pro Arg Glu Ala Arg Gly Gly Pro Ser Leu
                                                           30
                                      25
                  20
 Ser Ser Val Leu Asn Glu Leu Pro Ser Ala Ala Thr Leu Arg Tyr
                                       40
                  35
 Arg Asp Pro Gly Val Leu Pro Trp Gly Ala Leu Glu Glu Glu Glu
                                       55
                  50
 Glu Asp Gly Gly Arg Ser Arg Lys Ala Phe Thr Glu Val Thr Gln
                                       70
```

Thr	Glu	Leu	Gln	Asp	Pro	His	Pro	Ser	Arg	Glu	Leu	Pro	Trp	Pro
				80					85				_	90
Met	Gln	Ala	Arg	Arg 95	Ala	HIS	Arg	GIN	100	Asn	Ala	ser	Arg	105
Gln	Val	Val	Tyr	Gly 110	Ser	Gly	Thr	Lys	Thr 115	Asp	Arg	Trp	Ala	Arg 120
Leu	Leu	Arg	Arg		Lys	Glu	Lys	Thr	Lys 130	Glu	Gly	Leu	Arg	
Leu	Gln	Pro	Trp		Trp	Thr	Leu	Lys		Ile	Gly	Gly	Gln	
Gly	Ala	Gly	Thr	Glu 155	Ser	Tyr	Phe	Ser	Leu 160	Leu	Arg	Phe	Leu	Leu 165
Leu	Leu	Asn	Val		Ala	Ser	Val	Leu	Met 175	Ala	Суѕ	Met	Thr	
Leu	Pro	Thr	Trp		Gly	Gly	Ala	Pro		Gly	Pro	Pro	Gly	
Asp	Ile	Ser	Ser		Суѕ	Gly	Ser	Tyr		Pro	His	Ser	Gln	_
Leu	Val	Thr	Phe		Thr	Gln	Leu	Phe		Leu	Leu	Ser	Gly	
Gly	Tyr	Leu	Glu		Ser	Pro	Leu	Phe		Gly	Phe	Tyr	Pro	
Arg	Pro	Arg	Leu		Val	Thr	Tyr	Leu		Trp	Ala	Phe	Ala	
Gly	Leu	Ile	Cys		Leu	Leu	Ile	Leu		Arg	Ser	Val	Ser	
Leu	Lys	Gln	Thr		Leu	Ala	Glu	Ser		Ala	Leu	Thr	Ser	
Ser	His	Arg	Val		Ser	Ala	Trp	Asp	_	Gly	Leu	Суѕ	Gly	
Val	His	Val	Arg		Arg	Gln	Arg	Ile		Leu	Tyr	Glu	Leu	
Val	Glu	Leu	Glu		Thr	Val	Val	Arg		Gln	Ala	Ala	Val	
Thr	Leu	Gly	Gln		Ala	Arg	Val	Trp		Val	Arg	Val	Leu	-
Asn	Leu	Leu	Val			Leu	Leu	Gly		Ala	Phe	Tyr	Gly	
Tyr	Trp	Ala	Thr		Cys	Thr	Val	Glu		Gln	Glu	Met	Pro	
Val	Gln	Glu	Leu		Leu	Leu	Lys	Leu		Val	Asn	Tyr	Leu	
Ser	Ile	Phe	Ile		Gly	Val	Asn	Phe		Leu	Pro	Pro	Val	
Lys	Leu	Ile	Ala	,	Leu	Glu	Gly	Tyr		Arg	Ser	Arg	Gln	
Val	Phe	Ile	Leu		Arg	Thr	Val	Phe		Arg	Leu	Ala	Ser	
Val	Val	Leu	Leu		Ser	Leu	Trp	Asn		Ile	Thr	Суз	Gly	
Asp	Ser	Glu	Ala	-	Asp	Cys	Lys	Thr		Gly	Tyr	Asn	Tyr	
Gln	Leu	Pro	Cys		Glu	Thr	Val	Leu		Gln	Glu	Met	Tyr	
Leu	Leu	Leu	Phe		Leu	Leu	Thr	Val		Ala	Val	Ala	Leu	
Ile	Gln	Phe	Pro		Lys	Leu	Leu	Cys		Leu	Cys	Pro	Gly	
Leu	Gly	Arg	Leu		Gly	Thr	Gln	Glu		Gln	Val	Pro	Asp	
Val	Leu	Gly	Leu	Ile	Tyr	Ala	Gln	Thr	Val	Val	Trp	Val	Gly	Ser
Phe	Phe	Cys	Pro	530 Leu	Leu	Pro	Leu	Leu	535 Asn	Thr	Val	Lys	Phe	540 Leu

```
550
Leu Leu Phe Tyr Leu Lys Lys Leu Thr Leu Phe Ser Thr Cys Ser
                560
                                    565
Pro Ala Ala Arg Thr Phe Arg Ala Ser Ala Ala Asn Phe Phe
                575
                                     580
Pro Leu Val Leu Leu Gly Leu Ala Ile Ser Ser Val Pro Leu
                590
                                     595
Leu Tyr Ser Ile Phe Leu Ile Pro Pro Ser Lys Leu Cys Gly Pro
                605
                                     610
Phe Arg Gly Gln Ser Ser Ile Trp Ala Gln Ile Pro Glu Ser Ile
                                     625
Ser Ser Leu Pro Glu Thr Thr Gln Asn Phe Leu Phe Phe Leu Gly
                635
                                     640
Thr Gln Ala Phe Ala Val Pro Leu Leu Leu Ile Ser Ser Ile Leu
                650
                                     655
Met Ala Tyr Thr Val Ala Leu Ala Asn Ser Tyr Gly Arg Leu Ile
                665
                                     670
Ser Glu Leu Lys Arg Gln Arg Gln Thr Glu Ala Gln Asn Lys Val
                680
                                     685
Phe Leu Ala Arg Arg Ala Val Ala Leu Thr Ser Thr Lys Pro Ala
                695
                                    700
Leu
<210> 37
<211> 466
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 6114480CD1
<400> 37 /
Met Ala Phe Val Leu Ile Leu Val Leu Ser Phe Tyr Glu Leu Val
                                     10
Ser Gly Gln Trp Gln Val Thr Gly Pro Gly Lys Phe Val Gln Ala
Leu Val Gly Glu Asp Ala Val Phe Ser Cys Ser Leu Phe Pro Glu
                 35
                                     40
Thr Ser Ala Glu Ala Met Glu Val Arg Phe Phe Arg Asn Gln Phe
                 50
                                     55
His Ala Val Val His Leu Tyr Arg Asp Gly Glu Asp Trp Glu Ser
                 65
                                     70
Lys Gln Met Pro Gln Tyr Arg Gly Arg Thr Glu Phe Val Lys Asp
                 80
                                     85
Ser Ile Ala Gly Gly Arg Val Ser Leu Arg Leu Lys Asn Ile Thr
                 95
                                    100
Pro Ser Asp Ile Gly Leu Tyr Gly Cys Trp Phe Ser Ser Gln Ile
                                    115
                                                         120
Tyr Asp Glu Glu Ala Thr Trp Glu Leu Arg Val Ala Ala Leu Gly
                125
                                    130
                                                         135
Ser Leu Pro Leu Ile Ser Ile Val Gly Tyr Val Asp Gly Gly Ile
                140
                                    145
Gln Leu Leu Cys Leu Ser Ser Gly Trp Phe Pro Gln Pro Thr Ala
                155
                                    160
Lys Trp Lys Gly Pro Gln Gly Gln Asp Leu Ser Ser Asp Ser Arg
               170
                                    175
Ala Asn Ala Asp Gly Tyr Ser Leu Tyr Asp Val Glu Ile Ser Ile
                185
                                    190
Ile Val Gln Glu Asn Ala Gly Ser Ile Leu Cys Ser Ile His Leu
                200
                                    205
                                                        210
Ala Glu Gln Ser His Glu Val Glu Ser Lys Val Leu Ile Gly Glu
                215
```

```
Thr Phe Phe Gln Pro Ser Pro Trp Arg Leu Ala Ser Ile Leu Leu
                 230
                                     235
 Gly Leu Leu Cys Gly Ala Leu Cys Gly Val Val Met Gly Met Ile
                 245
                                     250
 Ile Val Phe Phe Lys Ser Lys Gly Lys Ile Gln Ala Glu Leu Asp
                 260
                                     265
                                                          270
 Trp Arg Arg Lys His Gly Gln Ala Glu Leu Arg Asp Ala Arg Lys
                 275
                                     280
 His Ala Val Glu Val Thr Leu Asp Pro Glu Thr Ala His Pro Lys
                 290
                                     295
                                                          300
Leu Cys Val Ser Asp Leu Lys Thr Val Thr His Arg Lys Ala Pro
                 305
                                     310
                                                          315
Gln Glu Val Pro His Ser Glu Lys Arg Phe Thr Arg Lys Ser Val
                 320
                                     325
                                                          330
Val Ala Ser Gln Gly Phe Gln Ala Gly Arg His Tyr Trp Glu Val
                 335
                                     340
Asp Val Gly Gln Asn Val Gly Trp Tyr Val Gly Val Cys Arg Asp
                350
                                     355
                                                          360
Asp Val Asp Arg Gly Lys Asn Asn Val Thr Leu Ser Pro Asn Asn
                365
                                     370
                                                          375
Gly Tyr Trp Val Leu Arg Leu Thr Thr Glu His Leu Tyr Phe Thr
                 380
                                     385
Phe Asn Pro His Phe Ile Ser Leu Pro Pro Ser Thr Pro Pro Thr
                395
                                     400
                                                          405
Arg Val Gly Val Phe Leu Asp Tyr Glu Gly Gly Thr Ile Ser Phe
                410
                                     415
Phe Asn Thr Asn Asp Gln Ser Leu Ile Tyr Thr Leu Leu Thr Cys
                425
                                     430
                                                          435
Gln Phe Glu Gly Leu Leu Arg Pro Tyr Ile Gln His Ala Met Tyr
                440
                                     445
                                                          450
Asp Glu Glu Lys Gly Thr Pro Ile Phe Ile Cys Pro Val Ser
                                                         Trp
                455
                                     460
                                                          465
Gly
<210> 38 -
<211> 2801
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 112301CB1
<400> 38
cgccttcccc gagcgagacc aaaacaggtg gaatccgggc tggagccgga gctccggcgg 60
cgcgggtggc ggcacgtccc tccagacagt accacaggca cctggagtac cggcatcggt 120
cgctgtggcc cccgagtgtc cgtcagagcc taggggagcc tgccctcccg cgcctcgtcg 180
gggcccggcc aggcaccttg gccgccggcg cacggacgcg ggcacgagca ctagatcacg 240
getgetggac eteggeaegt tgacaagatt tetetggggt acegeggagg attactttga 300
attteggtgg tegeetgtgg tetggeatat ttagaaetta agtetattat ttegggeace 360
atgactttga ggcttttaga agactggtgc agggggatgg acatgaaccc tcggaaagcg 420
ctattgattg ccggcatctc ccagagctgc agtgtggcag aaatcgagga ggctctgcag 480
gctggtttag ctcccttggg ggagtacaga ctgcttggaa ggatgttcag gagggatgag 540
aacaggaaag tagccttagt agggcttact gcggagacta gtcacgccct ggtccctaag 600
gagataccgg gaaaaggggg tatctggaga gtgatcttta agccccctga cccagataat 660
acatttttaa gcagattaaa tgaattttta gcgggagagg gcatgacagt gggtgagttg 720
agcagagete ttggacatga aaatggetee ttagacecag agcagggeat gateeeggaa 780
atgtgggccc ctatgttggc acaggcatta gaggctcttc agcctgccct gcaatgcttg 840
aagtataaaa agctgagagt gttctcgggc agggagtctc cagaaccagg agaagaagaa 900
tttggacgct ggatgtttca tactactcag atgataaagg cgtggcaggt gccagatgta 960
gagaagagaa ggcgattgct agagagcctt cgaggcccag cacttgatgt tattcgtgtc 1020
ctcaagataa acaatcettt aattactgte gatgaatgte tgcaggetet tgaggaggta 1080
tttggggtta cagataatcc tagggagttg caggtcaaat atctaaccac ttaccagaag 1140
```

```
gatgaggaaa agttgtcggc ttatgtacta aggctggagc ctttgttaca gaagctggta 1200
cagagaggag caattgagag agatgctgtg aatcaggccc gcctagacca agtcattgct 1260
ggggcagtcc acaaaacaat tcgcagagag cttaatctgc cagaggatgg cccagcccct 1320
ggtttcttgc agttattggt actaataaag gattatgagg cagctgagga ggaggaggcc 1380
cttctccagg caatattgga aggtaatttc acctgagtct cagggaacca cgaagggata 1440
tggcaatgag tagagcatga aggtagaaca gtctatatac tcttgtgaca catacaatcc 1500
ctaccttgtg ctgccaagta actcattttt gtgcaattct cagtataagc cctttgtcgt 1560
ttctgtgcct atttaaagtc tcctaaaggt gtaattgact aggaaggatg tagttctaca 1620
ctgccattta cctatttaaa ttcatccttg tgaatatctt tgttgttgtt gttgagacag 1680
agtetegete tgteacceag getggagtge agtgaegtga tettggetea etgeateete 1740
cgccttccag gtttaagcta ttctcctgcc tcagttgccc gagtagctgg gactacagga 1800
atgactcacc acacccaget aagttttgca ttatcagtag agacggggtt tetecataet 1860
ggtcaggctg gtctcgaact cctgacctca agtgatccac ctgccttggc ctcccaaagt 1920
gctgggatta caggcgtgag ccaccacacc cagcctcagt tcccttattt taataattgt 1980
cctatttcgt ggggttgcta taaagattac atgagacttt aatgggaaag tatttaggac 2040
agtgtatggg acaaagttag taccagacat gcataaggca tttgaaaacc tgggtgcttt 2100
ctctctcact cttaccattt atagacaggg gtcatataat ttttttgtt gagacggagt 2160
ctcgctctgt ggcccaggct ggagagcagt ggtgtgatct cagctcatgg gttcaagcga 2220
ttctcgtgcc tcagcctccc gagtagctgg gactataggc atgcgccacc aggcccagcc 2280
aatttttata tttttagtag agatggggtt tctccatgtt agccaggcta cccaggctgg 2340
tetegatete etgaceteag gtgatecace cacetgggee teccaaagtg etgggattac 2400
aggogtgage cactgoccce tgccttctta cactttttct ttgagactgg gtcgcacagt 2460
cgcacagtga gactccatct cctatgaaaa aaaagattgg cctagcgtct ggctcaggcc 2520
tgtaatccca gcactttggg aggccaaggc gggcggatca caaggtcagg agatcgaggc 2580
cagcatggcc aacatggtga caccetgttt ctactaaaaa tacaaaaaaa attageeggg 2640
catggtggcg catgcctata gtgtcagcta ctctggagaa tcgcttgaac ccgggaggcg 2700
gaggttgcag tgagccgaga ttgcgtcact gcactacagc ctgggcaaca gagcgagact 2760
cccgtctcag aaaaaaaag ttttggtgcc aaccggacga g
<210> 39
<211> 2656
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 997947CB1
<220>
<221> unsure
<222> 2554, 2587, 2604, 2606, 2611, 2644, 2646-2647, 2651
<223> a, t, c, g, or other
ccacteteta gageteeegg acteetaget etgagaatge etgeggaatg ategeeecee 60
aggccggctg ccgccgctgc cgctgctgct gttattgcta ctgctgctgc cgccgcctct 120
gettecacte ggetetgact ggeaggeaga aagtgeaact gacgagggaa aggtetetge 180
agtgagtgga gagcctacat aaaagagagt aaagaggggc aaaaacccag atcagaatgc 240
aggegacgte caacettete aaceteetge tgetgtettt gtttgeegga ttagateett 300
atgggcggtg catttgcaca gttgttgctc cagaacaaaa cctgtgttcc cgggatgcca 420
aaagcaggca acttcgccaa ctactggaaa aggttcagaa catgtcccag tctattgaag 480
tettaaaett gagaaeteag agagatttee aatatgttt aaaaatggaa acceaaatga 540
aagggctgaa ggcaaaattt cggcagattg aagatgatcg aaagacactt atgaccaagc 600
attttcagga gttgaaagag aaaatggacg agctcctgcc tttgatcccc gtgctggaac 660
agtacaaaac agatgctaag ttaatcaccc agttcaagga ggaaataagg aatctgtctg 720
ctgtcctcac tggtattcag gaggaaattg gtgcctatga ctacgaggaa ctacaccaaa 780
gagtgctgag cttggaaaca agacttcgtg actgcatgaa aaagctaaca tgtggcaaac 840
tgatgaaaat cacaggccca gttacagtca agacatctgg aacccgattt ggtgcttgga 900
tgacagaccc tttagcatct gagaaaaaca acagagtctg gtacatggac agttatacta 960
acaataaaat tgttcgtgaa tacaaatcaa ttgcagactt tgtcagtggg gctgaatcaa 1020
ggacatacaa cetteettte aagtgggeag gaactaacca tgttgtetac aatggeteae 1080
tctattttaa caagtatcag agtaatatca tcatcaaata cagctttgat atggggagag 1140
```

5.3× + +

. . . . . .

30 . A.

```
tgcttgccca acgaagcctg gagtatgctg gttttcataa tgtttacccc tacacatggg 1200
gtggattctc tgacatcgac ctaatggctg atgaaatcgg gctgtgggct gtgtatgcaa 1260
ctaaccagaa tgcaggcaat attgtcatca gccaacttaa ccaagatacc ttggaggtga 1320
tgaagagctg gagcactggc taccccaaga gaagtgcagg ggaatctttc atgatctgtg 1380
ggacactgta tgtcaccaac tcccacttaa ctggagccaa ggtgtattat tcctattcca 1440
ccaaaacctc cacatatgag tacacagaca ttcccttcca taaccaatac tttcacatat 1500
ccatgcttga ctacaatgca agagatcgag ctctctatgc ctggaacaat ggccaccagg 1560
tgctgttcaa tgtcaccctt ttccatatca tcaagacaga ggatgacaca taggcaaatg 1620
tgacatgttt tcattgattt aaacagtgtg atttgtgata aactctataa gaccccttcc 1680
gtttttttct tcactattat ttttcatcat ttctccaaag caaagcattt ttattqtaaa 1740
gttggtgttt caaaaacata gctgagcttg tctaacttac catgttggaa acacatctta 1800
acttctaaat ttacaaggcc tatcatgtcc ttgtcatgaa aagcactaaa aaaaaaaaga 1860
gtttaagtgg ctaaagtcat agttttgcaa gagattaatg atctqcctta tattaqaqtc 1920
agagactaat ggtggcttaa atgcacgaat gtcttttttt tttaaaactg tcatttttta 1980
ctgtcttttg ctccatatca ggaaatattt tggtaggaat taggagaaca aaaagcactt 2040
ttatcccatt tatttcttta aaaaatgtaa ggatttcatt tatattgaaa aataatatta 2100
atcattttgc tgttaacaca attctctgat gcggtgctgt acagtcattt ttaaatctct 2160
tgctaacatt ttattggcag tatgtatttc taccattgta accaccattg tgctattgta 2220
tctcttcact tctgtgaaag taatattttt tataaaatac actgaaattt aacctcagta 2280
attgagtcca ttttcaagtg tggtcaagaa taatcttctt ggcttacccc tttacataag 2340
cattataaac taaaatgaaa accaaaccag acacctgaca tagagtcttt attttacccc 2400
aagttttttg ggccactgac attgaatgca acaactgatt tcatacaact gagttactct 2460
gttcactcca ctgaatgcaa cccatatagt ttcttgcaca aggtgcatct ggattctaaa 2520
tattggattt gagttgactc tactcattta ttanacacta aagaaatttt gttcttcata 2580
gttaaangta ctagcattta attnanattt nacatacaac ttgcaataat gaaattcctt 2640
atgncnngac nctgaa
<210> 40
<211> 968
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1521513CB1
tctacatcta tcggagctga acttcctaaa agacaaagtg tttatctttc aagattcatt 60
ctccctgaat cttaccaaca aaacactcct gaggagaaag aaagagaggg agggagaaa 120
aaagagagag agagaaacaa aaaaccaaag agagagaaaa aatgaattca tctaaatcat 180
ctgaaacaca atgcacagag agaggatgct tctcttccca aatgttctta tggactgttg 240
ctgggatccc catcctattt ctcagtgcct gtttcatcac cagatgtgtt gtgacatttc 300
gcatctttca aacctgtgat gagaaaaagt ttcagctacc tgagaatttc acagagctct 360
cctgctacaa ttatggatca ggttcagtca agaattgttg tccattqaac tqqqaatatt 420
ttcaatccag ctgctacttc ttttctactg acaccatttc ctgggcgtta agtttaaaga 480
actgctcagc catgggggct cacctggtgg ttatcaactc acaggaggag caggaattcc 540
tttcctacaa gaaacctaaa atgagagagt tttttattgg actgtcagac caggttgtcg 600
agggtcagtg gcaatgggtg gacggcacac ctttgacaaa gtctctgagc ttctgggatg 660
taggggagec caacaacata gctaccctgg aggactgtgc caccatgaga gactcttcaa 720
acccaaggca aaattggaat gatgtaacct gtttcctcaa ttattttcgg atttgtgaaa 780
tggtaggaat aaatcctttg aacaaaggaa aatctcttta agaacagaag gcacaactca 840
aatgtgtaaa gaaggaagag caagaacatg gccacaccca ccgccccaca cgagaaattt 900
gtgcgctgaa cttcaaagga cttcataagt atttgttact ctgatataaa taaaaataag 960
tagtttta
<210> 41
<211> 1837
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1863994CB1
```

```
<400> 41
ccccagccc gctcagtccc gagcgcccgc agtcgtcgcg ccgccgcgcc aagcatgcag 60
taaaqqctga aaatctgggt cacagctgag gaagacctca gacatggagt ccaggatgtg 120
gcctgcgctg ctgctgtccc acctcctccc tctctggcca ctgctgttgc tgcccctccc 180
accgcctgct cagggctctt catcctcccc tcgaacccca ccagccccag cccgccccc 240
gtgtgccagg ggaggcccct cggccccacg tcatgtgtgc gtgtgggagc gagcacctcc 300
accaageega teteeteggg teceaagate acgteggeaa gteetgeetg geactgeace 360
cccagccacc ccatcaggct ttgaggaggg gccgccctca tcccaatacc cctgggctat 420
cgtgtggggt cccaccgtgt ctcgagagga tggaggggac cccaactctg ccaatcccgg 480
atttctggac tatggttttg cagcccctca tgggctcgca accccacacc ccaactcaga 540
ctccatgcga ggtgatggag atgggcttat ccttggagag gcacctgcca ccctgcggcc 600
attcctgttc gggggccgtg gggaaggtgt ggacccccag ctctatgtca caattaccat 660
ctccatcatc attgttctcg tggccactgg catcatcttc aagttctgct gggaccgcag 720
ccagaagcga cgcagaccct cagggcagca aggtgccctg aggcaggagg agagccagca 780
qccactgaca gacctgtccc cggctggagt cactgtgctg ggggccttcg gggactcacc 840
tacccccacc cctgaccatg aggagecccg agggggaccc cggcctggga tgccccaccc 900
caagggggct ccagcettee agttgaaceg gtgagggcag gggcaatggg atgggaggge 960
aaagagggaa ggcaacttag gtcttcagag ctggggtggg ggtgccctct ggatgggtag 1020
tgaggaggca ggcgtggcct cccacagccc ctggccctcc caagggggct ggaccagctc 1080
ctctctggga ggcacccttc cttctcccag tctctcagga tctgtgtcct attctctgct 1140
qcccataact ccaactctgc cctctttggt tttttctcat gccaccttgt ctaagacaac 1200
tetgecetet taacettgat tececetett tgtettgaac tteceettet attetggeet 1260
accortingt teetqactqt qeeettteee tetteetete aggatteeee tggtgaatet 1320
gtgatgcccc caatgttggg gtgcagccaa gcaggaggcc aaggggccgg cacagccccc 1380
atcccactga gggtggggca gctgtgggga gctggggcca caggggctcc tggctcctgc 1440
cccttgcaca ccaccoggaa cactcccag ccccacgggc aatcctatct gctcgcctc 1500
ctgcaggtgg gggcctcaca tatctgtgac ttcgggtccc tgtccccacc cttgtgcact 1560
cacatgaaag cettgeacae teaceteeae etteacagge catttgeaca egeteetgea 1620
coetctecce greeataceg etergeteag etgactetea tgtteteteg teteacattt 1680
gcactetete etteccacat tetgtgetea geteacteag tggteagegt tteetgeaca 1740
ctttacctct catgtgcgtt tcccggcctg atgttgtggt ggtgtgcggc gtgctcactc 1800
tctccctcat gaacacccac ccacctcgtt tcgcagc
                                                                  1837
<210> 42
<211> 2124
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2071941CB1
<400> 42
qtqacqcqqc tqcqqaggtg acqcgggagg tcgcgcgccc cttccggcgc ggggagggcg 60
ctgaagatcg gggccgctcg gccgcaggcg cctccagcgc cgcgggatgt agcgcggggg 120
accgcggccc ccagcagagc ccgcctgccc ggcttgtcta ccatcagagg gagatctctg 180
cccctqqqq ctgagagacc ccaacctttc cccaagctga agctgcaggg tattgaggta 240
ccagccagat gtcttcccac aaaggatctg tggtggcaca ggggaatggg gctcctgcca 300
gtaacaggga agctgacacg gtggaactgg ctgaactggg acccctgcta gaagagaagg 360
gcaaacgggt aatcgccaac ccacccaaag ctgaagaaga gcaaacatgc ccagtgcccc 420
aggaagaaga ggaggaggtg cgggtactga cacttcccct gcaagcccac cacgccatgg 480
agaagatgga agagttigtg tacaaggtct gggagggacg ttggagggtc atcccatatg 540
atgtgctccc tgactggcta aaggacaacg actatctgct acatggtcat agacctccca 600
tgccctcctt tcgggcttgc ttcaagagca tcttccgcat tcatacagaa actggcaaca 660
tetggaccca tetgettggt ttegtgetgt ttetettttt gggaatettg accatgetea 720
gaccaaatat gtacttcatg gcccctctac aggagaaggt ggtttttggg atgttcttt 780
tgggtgcagt gctctgcctc agcttctcct ggctctttca caccgtctat tgtcattcag 840
agaaagtctc tcggactttt tccaaactgg actattcagg gattgctctt ctaattatgg 900
ggagetttgt eccetggete tattatteet tetaetgete eccaeageea eggeteatet 960
acctetecat egtetgtgte etgggeattt etgecateat tgtggegeag tgggaeeggt 1020
ttgccactcc taagcaccgg cagacaagag caggcgtgtt cctgggactt ggcttgagtg 1080
gcgtcgtgcc caccatgcac tttactatcg ctgagggctt tgtcaaggcc accacagtgg 1140
gccagatggg ctggttcttc ctcatggctg tgatgtacat cactggagct ggcctttatg 1200
```

: . ...

```
ctgctcgaat tcctgagcgc ttctttcctg gaaaatttga catatggttc cagtctcatc 1260
agattttcca tgtcctggtg gtggcagcag cctttgtcca cttctatgga gtctccaacc 1320
ttcaggaatt ccgttacggc ctagaaggcg gctgtactga tgacaccctt ctctgagcct 1380
tcccacctgc ggggtggagg aggaacttcc caagtgcttt taaaaaataac ttctttgctg 1440
aagtgagagg aagagtctga gttgtctgtt tctagaagaa acctcttaga gaattcagta 1500
ccaaccaage tteageceae ttteacacee aetgggeaat aaaettteea ttteeattet 1560
cctagctggg gatggggcat ggtcaaactt agccatcccc tcctcagcaa ggcatctacc 1620
ggcccctcac agagacagta ctttgaaact catgttgaga ttttaccctc tcctccaacc 1680
attttgggaa aattatggac tgggactett cagaaattet gtettttett etggaagaaa 1740
atgtccctcc cttaccccca tccttaactt tgtatcctgg cttataacag gccatccatt 1800
tttgtagcac acttttcaaa aacaattata taccctggtc ccatctttct agggcctgga 1860
tctgcttata gagcaggaag aataaagcca ccaactttta cctagcccgg ctaatcatgg 1920
aagtgtgtcc aggcttcaag taacttgagt tttaattttt ttttttttt tggcagagta 1980
atgtaaaatt taaatgggga aagatattta atatttaata ctaagcttta aaaagaaacc 2040
tgctatcatt gctatgtatc ttgatgcaaa gactatgatg ttaataaaag aaagtacaga 2100
agagacttgg cattcaaaaa aaaa
<210> 43
<211> 993
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2172512CB1
<400> 43
ccgcgcgctt actttgttta taacttgaaa aatcctctcc gtctcccttc cctgcctcct 60
ttcctttccc tttcctctgc cagtacaact agacccggcg tctggcgtcc ccggtgccca 120
gcattctgcg gggcaggcgg attaattgga attcttcaaa atgtcaggtg tggtacccac 180
agcccctgaa cagcctgcag gtgaaatgga aaatcaaaca aaaccaccag atccaaggcc 240
tgatgeteet cetgaataca gtteteattt tttaccagga ceceetggaa cagetgteec 300
tccacctact ggctacccag gaggcttgcc tatgggatac tacagtccac agcaacccag 360
taccttccct ttgtaccagc cagttggtgg tatccatcct gtccggtatc agcctggcaa 420
atatectatg ccaaatcagt etgttecaat aacatggatg ccagggecaa etectatgge 480
aaactgccct cctggtctgg aatacttagt tcagttggac aacatacatg ttcttcagca 540
ttttgagcct ctggaaatga tgacatgttt tgaaactaat aatagatatg atattaaaaa 600
caactcagac cagatggttt acattgtaac cgaagacaca gatgacttta ccaggaatgc 660
ctateggaca ctaaggeeet tegteeteeg ggteaetgat tgtatgggee gagaaateat 720
gacaatgcag agaccettca gatgcacetg etgttgette tgttgeecet etgeeagaca 780
agagetggag gtgcagtgte eteetggtgt caccattgge tttgttgegg aacattggaa 840
ttccctttag tgaggttaat ttttgggggc atgtgccgtg gcagtgcggt ggtgttggtg 960
gttgtgtggg ggtggggtgg gggttggtgg ggt
<210> 44
<211> 2214
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2483172CB1
<400> 44
ggetetegge ceagegegee tgeettegee geeegeegte geteetegee egetgeaega 60
cgacgcgacg cccctgctgc aggcggcgga cccgaccgga cccagaccca gacgcaagat 120
ggcgacggcc gcgtgactgc ctcagcgtcc ccgagctcgg ctccgagtgc acctacggac 180
tgactgtggg ggcagagaag ggcgagatca ggactctgtc tttgttaatc gtgactgcat 240
gaaggtcgcc tccctcgggc ctacttggtg ggagtgtctg gtattgttct aaggccagga 300
gcacggtgag ccacagtctg ttggtagaat ttggcgtctt gatagttgag aaaatggcga 360
tgacactgtt ggaagactgg tgccggggga tggatgtgaa ctcccagaga gctctgttag 420
tctggggcat cccagtgaac tgtgatgagg ctgaaatcga agagaccctc caggctgcga 480
```

```
tgccccaggt ctcctaccga atgcttggga gaatgttctg gagggaagaa aatgcgaaag 540
cagcettatt agageteact ggegetgtag attacgeege gateeeeagg gagatgeegg 600
gcaaaggagg ggtctggaaa gtgttattta agcccccaac ttctgatgct gaatttttag 660
aaagattgca cctcttccta gctagagagg ggtggaccgt gcaagatgtt gcccgtgtcc 720
ttgggtttca gaaccctact ccgaccccgg gcccagagat gccagcagag atgctaaact 780
atattttgga taatgttatt cagcctcttg ttgagtccat atggtacaag aggctgacac 840
ttttctcggg gagggacatc ccagggcctg gagaggaaac ctttgatccc tggctggagc 900
acactaatga ggtcctagag gagtggcagg tgtccgatgt agaaaagagg cggcggttga 960
tggagagtet tagaggeece geegetgatg ttattegeat cettaagtee aacaaeceeg 1020
cgataaccac tgccgaatgc ctgaaggcgc ttgagcaggt gtttgggagc gttgagagct 1080
ctagggatgc ccagatcaaa tttctgaaca cttatcagaa cccgggagaa aaattgtctg 1140
cttatgtcat tcgtctggag cctctgctac agaaggtggt agagaagggg gccattgata 1200
aagataatgt gaaccaggcc cgcctagagc aggtcattgc cggggccaac cacagcgggg 1260
ccatccgaag gcagctgtgg cttaccgggg ctggggaagg gccagcccca aacctctttc 1320
agttgctggt gcagatccgt gaggaggaag ccaaggagga ggaggaggag gctgaggcca 1380
cccttctgca gttaggcctg gaagggcact tctgagtgcc aggaaaggca gctttagtgc 1440
agacctagat cacagctact tttcttgtcc ctgtggggtc ttacagatgt gtctctgagt 1500
agtaaaggct tagccttgtt ctgttttgtt gttttttgga ggggaaggtt agtcaggcct 1560
gcgggtcttg ctggctaagg taaagggttg gttggacaca gcgcttagtg cacgctgtca 1680
tcatggacat cataatcagt tgtgaaaaac acgcgaacct atgacacttc ttattccaca 1740
ctgaatgtga aattgcatgt tcagatgttt actacgaggc ctggctcaca ggaagtgttc 1800
agtaaaagta tgcactgtta gattactgat aacgcggata gatttttgtt taccataaat 1860
tgttccagat ttatattaat ggaaggaaat gtgcatttat tagctattac tcaactttac 1920
aatgcaaaca tottatttot catotttaaa catgtogacc agtttaattg aaaagtatto 1980
tgagactgca aaatggggtg ttaaaaaata ctgcagttac ggagctgtgt aaaccagttt 2040
ctcattgcat aagatacaga tgtaaattgc atggagaggt tgatatgcac ctgtacagta 2100
attcactccc ccatttcaca tctttgtcag agaatagttc ttgttcatac tgagtgttct 2160
aaatttgaag ttatatatac aaattaaaat attttaaaaa ttcaaaaaaa aaaa
<210> 45
<211> 897
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2656128CB1
<400> 45
gcaaaatgca tgacagtaac aatgtggaga aagacattac accatctgaa ttgcctgcaa 60
acccaggttg totgcattca aaagagcatt ctattaaagc taccttaatt tggcgcttat 120
ttttcttaat catgtttctg acaatcatag tgtgtggaat ggttgctgct ttaagcgcaa 180
taagagctaa ctgccatcaa gagccatcag tatgtcttca agctgcatgc ccagaaagct 240
ggattggttt tcaaagaaag tgtttctatt tttctgatga caccaagaac tggacatcaa 300
gtcagaggtt ttgtgactca caagatgctg atcttgctca ggttgaaagc ttccaggaac 360
tgaatttcct gttgagatat aaaggcccat ctgatcactg gattgggctg agcagagaac 420
aaggccaacc atggaaatgg ataaatggta ctgaatggac aagacagtta gtcatgaaag 480
aagatggtgc caacttgtat gttgcaaagg tttcacaagt tcctcgaatg aatccaagac 540
ctgtcatggt ttcctatcct gggagcagga gagtgtgcct atttgaatga caaaggtgcc 600
agtagtgcca ggcactacac agagaggaag tggatttgtt ccaaatcaga tatacatgtc 660
tagatgttac agcaaagccc caactaatct ttagaagcat attggaactg ataactccat 720
 tttaaaatga gcaaagaatt tatttettat accaacaggt atatgaaaat atgeteaata 780
 tcactaataa ctgggaaaat acaaatcaaa atcatagtaa aatattacct gttttcatgg 840
tgctaatatt acctgttctc ccactgctaa tgacataccc gagactgagt aatttaa
 <210> 46
 <211> 2167
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
```

<223> Incyte ID No: 5855841CB1

```
<400> 46
gccggggccg gagttcgctg caagtcggcg gaaagtttgg ctgcgcgggt tcccccgaag 60
ttcagagtga agacatttcc acctggacac ctgaccatgt gcctgccctg agcagcgagg 120
cccaccaggc atctctgttg tgggcagcag ggccaggtcc tggtctgtgg accctcggca 180
gttggcaggc tccctctgca gtggggtctg ggcctcggcc ccaccatgtc gagcctcggc 240
ggtggctccc aggatgccgg cggcagtagc agcagcagca ccaatggcag cggtggcagt 300
ggcagcagtg gcccaaaggc aggagcagca gacaagagtg cagtggtggc tgccgccgca 360
ccagcctcag tggcagatga cacaccaccc cccgagcgtc ggaacaagag cggtatcatc 420
agtgagecee teaacaagag eetgegeege teeegeeege teteecaeta etettettt 480
ggcagcagtg gtggtagtgg cggtggcagc atgatgggcg gagagtctgc tgacaaggcc 540
actgcggctg cagccgctgc ctccctgttg gccaatgggc atgacctggc ggcggccatg 600
gcggtggaca aaagcaaccc tacctcaaag cacaaaagtg gtgctgtggc cagcctgctg 660
agcaaggcag agcgggccac ggagctggca gccgagggac agctgacgct gcagcagttt 720
gcgcagtcca cagagatgct gaagcgcgtg gtgcaggagc atctcccgct gatgagcgag 780
gcgggtgctg gcctgcctga catggaggct gtggcaggtg ccgaagccct caatggccag 840
tecgaettee ectaeetggg egettteece ateaacceag geetetteat tatgaeeceg 900
gcaggtgtgt tcctggccga gagcgcgctg cacatggcgg gcctggctga gtaccccatg 960
cagggagage tggcctctgc catcagetec ggcaagaaga ageggaaaeg etgeggeatg 1020
tgcgcgccct gccggcggcg catcaactgc gagcagtgca gcagttgtag gaatcgaaag 1080
actggccatc agatttgcaa attcagaaaa tgtgaggaac tcaaaaagaa gccttccgct 1140
gctctggaga aggtgatgct tccgacggga gccgccttcc ggtggtttca gtgacggcgg 1200
cggaacccaa agctgccctc tccgtgcaat gtcactgctc gtgtggtctc cagcaaggga 1260
ttcgggcgaa gacaaacgga tgcacccgtc tttagaacca aaaatattct ctcacagatt 1320
tcattcctgt ttttatatat atattttttg ttgtcgtttt aacatctcca cgtccctagc 1380
ataaaaagaa aaagaaaaaa atttaaactg ctttttcgga agaacaacaa caaaaaagag 1440
gtaaagacga atctataaag taccgagact tcctgggcaa agaatggaca atcagtttcc 1500
ttcctgtgtc gatgtcgatg ttgtctgtgc aggagatgca gtttttgtgt agagaatgta 1560
aattttctgt aaccttttga aatctagtta ctaataagca ctactgtaat ttagcacagt 1620
ttaactccac cctcatttaa acttcctttg attctttccg accatgaaat agtgcatagt 1680
ttgcctggag aatccactca cgttcataaa gagaatgttg atggcgccgt gtagaagccg 1740
ctctgtatcc atccacgcgt gcagagctgc cagcagggag ctcacagaag gggagggagc 1800
accaggecag etgagetgea eccaeagtee egagaetggg atececeace ecaacagtga 1860
ttttggaaaa aaaaatgaaa gttctgttcg tttatccatt gcgatctggg gagccccatc 1920
togatatttc caatcotggc tacttttctt agagaaaata agtcottttt ttctggcctt 1980
ccagggggcc ccctgcggcc tgggcccccc tgcccacggc cagcttcctg ctgatgaaca 2100
tgctgtttgt attgttttag gaaaccaggc tgttttgtga ataaaacgaa tgcatgtttg 2160
tgtcacg
<210> 47
<211> 1235
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 603462CB1
<400> 47
gtggagccgg cgagagagtg gcagcggggg ctgatggaag tgcagtgggg gctggagagg 60
gcaccctact gtatccagca tgctccaagg ccacagctct gtgttccagg ccttgctggg 120
gaccttcttc acctggggga tgacagcagc tggggcagct ctcgtgttcg tattctctag 180
tggacagagg cggatcttag atggaagtct tggctttgct gcaggggtca tgttggcagc 240
ttcctattgg tctcttctgg ccccagcagt tgagatggcc acgtcctctg ggggcttcgg 300
tgcctttgcc ttcttccctg tggctgttgg cttcaccctt ggagcggctt ttgtctactt 360
ggctgacctc ctgatgcctc acttgggtgc agcagaagac ccccagacgg ccctggcact 420
gaacttegge tetaegttga tgaagaagaa gtetgateet gagggteeeg egetgetett 480
ccctgagagt gaactttcca tccggataga caagagtgag aatggtgagg catatcagag 540
aaagaaggcg gcagccactg gccttccaga gggtcctgct gtccctgtgc cttctcgagg 600
gaatctggca cagcccggcg gcagcagctg gaggaggatc gcactgctca tcttggccat 660 cactatacac aacgttccag agggtctcgc tgttggagtt ggatttgggg ctatagaaaa 720
```

```
gacggcatct gctacctttg agagtgccag gaatttggcc attggaatcg ggatccagaa 780
tttccccgag ggcctggctg tcagccttcc cttgcgaggg gcaggcttct ccacctggag 840
agetttetgg tatgggeage tgageggeat ggtggageee etggeegggg tetttggtge 900
ctttgccgtg gtgctggctg agcccatcct gccctacgct ctggcctttg ctgccggtgc 960
catggtctac gtggtcatgg acgacatcat ccccgaagcc cagatcagtg gtaatgggaa 1020
actggcatcc tgggcctcca tcctgggatt tgtagtgatg atgtcactgg acgttggcct 1080
gggctagggc tgagacgctt cggaccccgg gaaaggccat acgaagaaac agcagtggtt 1140
ggcttctatg ggacaacaag cttctttctt cacattaaaa cttttttcct tcctctcttc 1200
ttcatctcat tatcctgatt gactctaatt ataat
<210> 48
<211> 2257
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 747681CB1
ccgagccgag cggaccgaag gcgcgcccga gatgcaggtg agcaagagga tgctggcggg 60
gggcgtgagg agcatgccca gcccctcct ggcctgctgg cagcccatcc tcctgctggt 120
getgggetca gtgctgtcag getcggecac gggetgeeeg ceeegetgeg agtgeteege 180
ccaggaccgc gctgtgctgt gccaccgcaa gcgctttgtg gcagtccccg agggcatccc 240
caccgagacg cgcctgctgg acctaggcaa gaaccgcatc aaaacgctca accaggacga 300
gttcgccagc ttcccgcacc tggaggagct ggagctcaac gagaacatcg tgagcgccgt 360
ggagcccggc gccttcaaca acctcttcaa cctccggacg ctgggtctcc gcagcaaccg 420
cctgaagctc atcccgctag gcgtcttcac tggcctcagc aacctgacca agctggacat 480
cagcgagaac aagattgtta tcctgctgga ctacatgttt caggacctgt acaacctcaa 540
gtcactggag gttggcgaca atgacctcgt ctacatctct caccgcgcct tcagcggcct 600
caacageetg gageagetga egetggagaa atgeaacetg acetecatee ceaecgagge 660
getgteceae etgeaeggee teategteet gaggeteegg caceteaaca teaatgeeat 720
cegggactae teetteaaga ggetetaeeg acteaaggte ttggagatet cecaetggee 780
ctacttggac accatgacac ccaactgcct ctacggcctc aacctgacgt ccctgtccat 840
cacacactgc aatctgaccg ctgtgcccta cctggccgtc cgccacctag tctatctccg 900
cttcctcaac ctctcctaca accccatcag caccattgag ggctccatgt tgcatgagct 960
gctccggctg caggagatcc agctggtggg cgggcagctg gccgtggtgg agccctatgc 1020 cttccgcggc ctcaactacc tgcgcgtgct caatgtctct ggcaaccagc tgaccacact 1080
ggaggaatca gtcttccact cggtgggcaa cctggagaca ctcatcctgg actccaaccc 1140
gctggcctgc gactgtcggc tcctgtgggt gttccggcgc cgctggcggc tcaacttcaa 1200
ccggcagcag cccacgtgcg ccacgcccga gtttgtccag ggcaaggagt tcaaggactt 1260
ccctgatgtg ctactgccca actacttcac ctgccgccgc gcccgcatcc gggaccgcaa 1320
ggcccagcag gtgtttgtgg acgagggcca cacggtgcag tttgtgtgcc gggccgatgg 1380
cgacccgccg cccgccatcc tctggctctc accccgaaag cacctggtct cagccaagag 1440
caatgggcgg ctcacagtct tccctgatgg cacgctggag gtgcgctacg cccaggtaca 1500
ggacaacggc acgtacctgt gcatcgcggc caacgcgggc ggcaacgact ccatgcccgc 1560
ccacctgcat gtgcgcagct actcgcccga ctggccccat cagcccaaca agaccttcgc 1620
tttcatctcc aaccagccgg gcgagggaga ggccaacagc acccgcgcca ctgtgccttt 1680
ccccttcgac atcaagaccc tcatcatcgc caccaccatg ggcttcatct ctttcctggg 1740
cgtcgtcctc ttctgcctgg tgctgctgtt tctctggagc cggggcaagg gcaacacaaa 1800
gcacaacatc gagatcgagt atgtgccccg aaagtcggac gcaggcatca gctccgccga 1860
cgcgcccgc aagttcaaca tgaagatgat atgaggccgg ggcggggggc agggacccc 1920
gggcggccgg gcaggggaag gggcctggcc gccacctgct cactctccag tccttcccac 1980
ctcctccta cccttctaca cacgttctct ttctccctcc cgcctccgtc ccctgctgcc 2040
ccccgccage cctcaccace tgccctcctt ctaccaggac ctcagaagcc cagacctggg 2100
gaccccacct acacaggggc attgacagac tggagttgaa agccgacgaa ccgacacgcg 2160
gcagagtcaa taattcaata aaaaagttac gaactttctc tgtaacttgg gtttcaataa 2220
ttatggattt ttatgaaaac ttgaaataaa aaaaaaa
<210> 49
<211> 2359
<212> DNA
```

<213> Homo sapiens

```
<220>
  <221> misc feature
  <223> Incyte ID No: 919469CB1
 gtgggatttg aagatccact ccacttctgc tcatggcggg ccagggcctg cccctgcacg 60
 tggccacact gctgactggg ctgctggaat gcctgggctt tgctggcgtc ctctttggct 120
 ggccttcact agtgtttgtc ttcaagaatg aagattactt taaggatctg tgtggaccag 180
 atgctgggcc gattggcaat gccacagggc aggctgactg caaagcccag gatgagaggt 240
 teteacteat etteaceetg gggteettea tgaacaactt catgacatte eccaetgget 300
 acatetttga eeggtteaag aceaeegtgg eacgeeteat ageeatattt ttetacacea 360
 ccgccacact catcatagcc ttcacctctg caggctcagc cgtgctgctc ttcctggcca 420
 tgccaatgct caccattggg ggaatcctgt ttctcatcac caacctgcag attgggaacc 480
 tatttggcca acaccgttcg accatcatca ctctgtacaa tggagcattt gactcttcct 540
 cggcagtctt ccttattatt aagcttcttt atgaaaaagg catcagcctc agggcctcct 600
 teatetteat etetgtetge agtacetgge atgtageaeg caettteete etgatgeece 660
 gggggcacat cccataccca ctgcccccca actacagcta tggcctgtgc cctgggaatg 720
 gcaccacaaa ggaagagaag gaaacagctg agcatgaaaa cagggagcta cagtcaaagg 780
 agtteettte agegaaggaa gagaceecag gggcagggca gaagcaggaa eteegeteet 840
 tetggageta egetttetet eggegetttg eetggeacet ggtgtggetg tetgtgatae 900
 agttgtggca ctacctcttc attggcactc tcaactcctt gctgaccaac atggccggtg 960
 gggacatggc acgagtcagc acctacacaa atgcctttgc cttcactcag ttcggagtgc 1020
 tgtgtgcccc ctggaatggc ctgctcatgg accggcttaa acagaagtac cagaaggaag 1080
 caagaaagac aggttcctcc actttggcgg tggccctctg ctcgacggtg ccttcgctgg 1140
 ccctgacatc cctgctgtgc ctgggcttcg ccctctgtgc ctcagtcccc atcctccctc 1200
 tccagtacct caccttcatc ctgcaagtga tcagccgctc cttcctctat gggagcaacg 1260
 eggeetteet caccettget tteeetteag ageaetttgg caagetettt gggetggtga 1320
 tggccttgtc ggctgtggtg tctctgctcc agttccccat cttcaccctc atcaaaggct 1380
 cccttcagaa tgacccattt tacgtgaatg tgatgttcat gcttgccatt cttctgacat 1440
 tettecacce etttetggta tategggaat geegtaettg gaaagaaagt eeetetgeaa 1500
 ttgcatagtt cagaagccct cacttttcag ccccgaggat ggttttgttc atcttccacc 1560
 acctttgagg acctcgtgtc ccaaaagact ttgcctatcc cagcaaaaca cacacaca 1620
 cacacacaca cacaaaataa agacacacaa ggacgtctgc gcagcaagaa aagaatctca 1680
 tcaaaacaga agtgtctcct tgcacttagc cttggcagac ccttgactcc aggggagatg 1800
acctggggga ggaagtgtgt caactatttc tttaggcctg tttggctccg aagcctatat 1860
gtgcctggat cctctgccac gggttaaatt ttcaggtgaa gagtgaggtt gtcatggcct 1920
cagetatget teetggetet ceetcaagag tgeageettg getagagaac teacagetet 1980
gatgacettg geetgaceet ggtetggtet cagaateact ttteceatet gtaaaattga 2100
gatgaatttt ggtgttgaaa gttcttcctg gagcagatgt cctagaaggt tttaggaata 2160
gtgacagagt caggccaccc caagggccat gggagccagc tgacctgctt gaccgaagga 2220
tttctgacag actatctttg gggatgtttt caagaaggga tataagttat ttactttggg 2280
catttaaaag aaaatttctc tcgggaataa ttttatagaa aaataaagct tctgtgtcta 2340
aggcaaaaaa aaaaaaaaa
<210> 50
<211> 2052
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 977658CB1
<400> 50
gggtttgaag ccgcgccgcg agggagcgag gtcgcagtga cagcggcggg cgatcggacc 60
caggetgeec egeegtacee geetgegtee egegeteeeg ecceageatg acageeeegg 120
cgggtccgcg cggctcagag accgagcggc ttctgacccc caaccccggg tatgggaccc 180
aggeggggee tteaceggee ceteegacae ecceagaaga ggaagacett egeegtegte 240
tcaaatactt tttcatgagt ccctgcgaca agtttcgagc caagggccgc aagccctgca 300
agetgatget geaagtggte aagateetgg tggteaeggt geageteate etgtttggge 360
tcagtaatca gctggctgtg acattccggg aagagaacac catcgccttc cgacacctct 420
```

```
tcctgctggg ctactcggac ggagcggatg acaccttcgc agcctacacg cgggagcagc 480
 tgtaccaggc catcttccat gctgtggacc agtacctggc gttgcctgac gtgtcactgg 540
 gccggtatgc gtatgtccgt ggtgggggtg accettggac caatggetca gggcttgctc 600
 totgccagcg gtactaccac cgaggccacg tggacccggc caacgacaca tttgacattg 660
 atccgatggt ggttactgac tgcatccagg tggatccccc cgagcggccc cctccgcccc 720
 ccagcgacga tctcaccctc ttggaaagca gctccagtta caagaacctc acgctcaaat 780
 tccacaaget ggtcaatgtc accatecact tccggctgaa gaccattaac ctccagagcc 840
 tcatcaataa tgagatcccg gactgctata ccttcagcgt cctgatcacg tttgacaaca 900
 aagcacacag tgggcggatc cccatcagcc tggagaccca ggcccacatc caggagtgta 960
 agcaccccag tgtcttccag cacggagaca acagcttccg gctcctgttt gacgtggtgg 1020
 tcatcctcac ctgctccctg tccttcctcc tctgcgcccg ctcactcctt cgaggcttcc 1080
 tgctgcagaa tgagtttgtg gggttcatgt ggcggcagcg gggacgggtc atcagcctgt 1140 gggagcggct ggaatttgtc aatggctggt acatcctgct cgtcaccagc gatgtgctca 1200
 ccatctcggg caccatcatg aagatcggca tcgaggccaa gaacttggcg agctacgacg 1260
 tetgeageat ceteetggge acctegaege tgetggtgtg ggtgggegtg atccgetace 1320
 tgaccttett ccacaactac aatateetea tegecacact gegggtggee etgeceageg 1380
 teatgegett etgetgetge gtggetgtea tetacetggg etactgette tgtggetgga 1440
 tcgtgctggg gccctatcat gtgaagttcc gctcactctc catggtgtct gagtgcctgt 1500
 tetegeteat caatggggac gacatgtttg tgacgttege egecatgeag gegeageagg 1560
 geogrageag cetggtgtgg etettetece agetetacet tracteette ateageetet 1620
 tcatctacat ggtgctcagc ctcttcatcg cgctcatcac cggcgcctac gacaccatca 1680
 agcatecegg eggegeagge geagaggaga gegagetgea ggeetacate geacagtgee 1740
 aggacagece caceteegge aagtteegee gegggagegg eteggeetge ageettetet 1800
 gctgctgcgg aagggacccc tcggaggagc attcgctgct ggtgaattga ttcgacctga 1860
 ctgccgttgg accgtaggcc ctggactgca gagacccccg ccccgaccc cgcttattta 1920
 tttgtagggt ttgcttttaa ggatcggctc cctgtcgcgc ccgaggaggg cctggacctt 1980
 tcgtgtcgga cccttggggg cggggagact gggtggggag ggtgttgaat aaaagggaaa 2040
ataaaaaaaa aa
                                                                    2052
<210> 51
<211> 1939
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1004703CB1
<400> 51
cttgatggcg tcgggctgga gagccgcagt cccggctgca gcacctggga gaaggcagac 60
cgtgtgaggg ggcctgtggc ccagcgtgct gtggcctcgg ggagtgggaa gtggaggcag 120
gageetteet tacaettege catgagttte eteategaet ecageateat gattacetee 180
cagatactat tttttggatt tgggtggctt ttcttcatgc gccaattgtt taaagactat 240
gagatacgtc agtatgttgt acaggtgatc ttctccgtga cgtttgcatt ttcttgcacc 300
atgtttgagc tcatcatctt tgaaatctta ggagtattga atagcagctc ccgttatttt 360
cactggaaaa tgaacctgtg tgtaattctg ctgatcctgg ttttcatggt gcctttttac 420
attggctatt ttattgtgag caatatccga ctactgcata aacaacgact gctttttcc 480
tgtctcttat ggctgacctt tatgtatttc ttctggaaac taggagatct ctttcccatt 540
ctcagcccaa aacatgggat cttatccata gaacagctca tcagccgggt tggtgtgatt 600
ggagtgactc tcatggctct tctttctgga tttggtgctg tcaactgccc atacacttac 660
atgtettaet teeteaggaa tgtgaetgae acggatatte tageeetgga acggegaetg 720
ctgcaaacca tggatatgat cataagcaaa aagaaaagga tggcaatggc acggagaaca 780
atgttccaga agggggaagt gcataacaaa ccatcaggtt tctggggaat gataaaaagt 840
gttaccactt cagcatcagg aagtgaaaat cttactctta ttcaacagga agtggatgct 900
ttggaagaat taagcaggca gctttttctg gaaacagctg atctatatgc taccaaggag 960
agaatagaat actccaaaac cttcaagggg aaatatttta attttcttgg ttactttttc 1020
tctatttact gtgtttggaa aattttcatg gctaccatca atattgtttt tgatcgagtt 1080
gggaaaacgg atcctgtcac aagaggcatt gagatcactg tgaattatct gggaatccaa 1140
tttgatgtga agttttggtc ccaacacatt tccttcattc ttgttggaat aatcatcgtc 1200
acatccatca gaggattgct gatcactctt accaagttct tttatgccat ctctagcagt 1260
aagteeteea atgteattgt eetgetatta geacagataa tgggeatgta etttgtetee 1320
totgtgctgc tgatccgaat gagtatgcct ttagaatacc gcaccataat cactgaagtc 1380
cttggagaac tgcagttcaa cttctatcac cgttggtttg atgtgatctt cctggtcagc 1440
```

```
gctctctcta gcatactctt cctctatttg gctcacaaac aggcaccaga gaagcaaatg 1500
 gcaccttgaa cttaagccta ctacagactg ttagaggcca gtggtttcaa aatttagata 1560
 taagaggggg gaaaaatgga accagggcct gacattttat aaacaaacaa aatgctatgg 1620
 tagcattttt caccttcata gcatactcct tccccgtcag gtgatactat gaccatgagt 1680
 agcatcagcc agaacatgag agggagaact aactcaagac aatactcagc agagagcatc 1740
 ccgtgtggat atgaggctgg tgtagaggcg gagaggagcc aagaaactaa aggtgaaaaa 1800
 tacactggaa ctctggggca agacatgtct atggtagctg agccaaacac gtaggatttc 1860
 cgttttaagg ttcacatgga aaaggttata gctttgcctt gagattgact cattaaaatc 1920
 agagactgta aaaaaaaaa
                                                                   1939
 <210> 52
 <211> 1138
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 1334051CB1
 caaactgcaa cttatatctg caatttattt tggtatagac aagaggtatg ccagtagcac 60
 actggtggct tcagaagaaa ttctcaacac ctagctcgcc agagagtcta tgtatgggat 120
 tgaacaatct gtaaactaaa ggatcctaat catgaaaata agtatgataa attataagtc 180
 actattggca ctgttgttta tattagcctc ctggatcatt tttacagttt tccagaactc 240
 cacaaaggtt tggtctgctc taaacttatc catctccctc cattactgga acaactccac 300
 aaagteetta tteeetaaaa caccactgat ateattaaag ceactaacag agactgaact 360
 cagaataaag gaaatcatag agaaactaga tcagcagatc ccacccagac ctttcaccca 420
 cgtgaacacc accaccagcg ccacacatag cacagccacc atcctcaacc ctcgagatac 480
 gtactgcagg ggagaccagc tgcacatcct gctggaggtg agggaccact tgggacgcag 540
 gaagcaatat ggcggggatt teetgaggge caggatgtet teeccagege tgatggcagg 600
 tgcttcagga aaggtgactg acttcaacaa cggcacctac ctggtcagct tcactctgtt 660
ctgggagggc caggtctctc tgtctctgct gctcatccac cccagtgaag gggtgtcagc 720
tctctggagt gcaaggaacc aaggctatga cagggtgatc ttcactggcc agtttgtcaa 780
tggcacttcc caagtccact ctgaatgtgg cctgatccta aacacaaatg ctgaattgtg 840
ccagtacctg gacaacagag accaagaagg cttctactgt gtgaggcctc aacacatgcc 900
ctgtgctgca ctcactcaca tgtattctaa gaacaagaaa gtttcttatc ttagcaaaca 960
agaaaagagc ctctttgaaa ggtaaaaata attacttctt gagactacct gtgcaaatat 1020
tgtgatttgg cctatatact gatccaaaga aaagtcttgt gagtgtatta attttgggtg 1080
tctttagtaa gagcctttgg ggaaaggatc tgtgaattca tttagagaca gtgcccat
<210> 53
<211> 2117
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1336728CB1
tggccacage aacacccact gagcacgetg ggagctgagt atggcgtccc tggtctcgct 60
ggagctgggg ctgcttctgg ctgtgctggt ggtgacggcg acggcgtccc cgcctgctgg 120
tetgetgage etgeteacet etggeeaggg egetetggat caagaggete tgggeggeet 180
gttaaatacg ctggcggacc gtgtgcactg caccaacggg ccgtgtggaa agtgcctgtc 240
tgtggaggac gccctgggcc tgggcgagcc tgaggggtca gggctgccc cgggcccggt 300
cctggaggcc aggtacgtcg cccgcctcag tgccgccgcc gtcctgtacc tcagcaaccc 360
cgagggcacc tgtgaggaca ctcgggctgg cctctgggcc tctcatgcag accacctcct 420
ggccctgctc gagagcccca aggccctgac cccgggcctg agctggctgc tgcagaggat 480
gcaggcccgg gctgccggcc agacccccaa gacggcctgc gtagatatcc ctcagctgct 540
ggaggaggcg gtgggggggg gggctccggg cagtgctggc ggcgtcctgg ctgccctgct 600
ggaccatgtc aggagcgggt cttgcttcca cgccttgccg agccctcagt acttcgtgga 660
ctttgtgttc cagcagcaca gcagcgaggt ccctatgacg ctggccgagc tgtcagcctt 720
gatgcagcgc ctgggggtgg gcagggaggc ccacagtgac cacagtcatc ggcacagggg 780
```

```
agccagcagc cgggaccctg tgcccctcat cagctccagc aacagctcca gtgtgtggga 840
cacggtatgc ctgagtgcca gggacgtgat ggctgcatat ggactgtcgg aacaggctgg 900
agectgcace teccagteca ggccecegt ceaggaceag etcagecagt cagagaggta 1020
tetgtaegge teeetggeea egetgeteat etgeetetge geggtetttg geeteetget 1080
gctgacctgc actggctgca ggggggtcac ccactacatc ctgcagacct tcctgagcct 1140
ggcagtgggt gcactcactg gggacgctgt cctgcatctg acgcccaagg tgctggggct 1200
gcatacacac agcgaagagg gcctcagccc acagcccacc tggcgcctcc tggctatgct 1260
ggccgggctc tacgccttct tcctqtttqa qaacctcttc aatctcctqc tqcccaggga 1320
cccggaggac ctggaggacg ggcctgcgg ccacagcagc catagccacg ggggccacag 1380
ccacggtgtg tccctgcagc tggcacccag cgagctccgg cagcccaagc cccccacga 1440
gggctcccgc gcagacctgg tggcggagga gagcccggag ctgctgaacc ctgagcccag 1500
gagactgagc ccagagttga ggctactgcc ctatatgatc actctgggcg acgccgtgca 1560
caacttegee gaegggetgg cegtgggege egeettegeg teeteetgga agaeeggget 1620
ggccacctcg ctggccgtgt tctgccacga gttgccacac gagctggggg acttcgccgc 1680
cttgctgcac gcggggctgt ccgtgcgcca agcactgctg ctgaacctgg cctccgcgct 1740
cacggeette getggtetet acgtggeact egeggttgga gteagegagg agagegagge 1800
ctggatcctg gcagtggcca ccggcctgtt cctctacgta gcactctgcg acatgctccc 1860
ggcgatgttg aaagtacggg acccgcggcc ctggctcctc ttcctgctgc acaacgtggg 1920
cctgctgggc ggctggaccg tcctgctgct gctgtccctg tacgaggatg acatcacctt 1980
ctgataccct gccctagtcc cccacctttg acttaagatc ccacacctca caaacctaca 2040
gcccagaaac cagaagcccc tatagaggcc ccagtcccaa ctccagtaaa gacactcttg 2100
tccttggaaa aaaaaaa
<210> 54
<211> 1495
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1452856CB1
<400> 54
ctgaaatccc gcgaggatca accgagctcg ccgaaaggag ggaggaacgt atcccttctg 60
gaggetgtet cagggggcag agggacegga ceggaagtga egtgageggg tteeggttgt 120
ctggagccca gcggcggtg tgagagtccg taaggagcag cttccaggat cctgagatcc 180
ggagcagccg gggtcggagc ggctcctcaa gagttactga tctatgaaat ggcagagaat 240
ggaaaaaatt gtgaccagag acgtgtagca atgaacaagg aacatcataa tggaaatttc 300
acagaccect cttcagtgaa tgaaaagaag aggagggagc gggaagaaag gcagaatatt 360
gtcctgtgga gacagccgct cattaccttg cagtattttt ctctggaaat ccttgtaatc 420
ttgaaggaat ggacctcaaa attatggcat cgtcaaagca ttgtggtgtc ttttttactg 480
ctgcttgctg tgcttatagc tacgtattat gttgaaggag tgcatcaaca gtatgtgcaa 540
cgtatagaga aacagtttct tttgtatgcc tactggatag gcttaggaat tttgtcttct 600
gttgggcttg gaacagggct gcacaccttt ctgctttatc tgggtccaca tatagcctca 660
gttacattag ctgcttatga atgcaattca gttaattttc ccgaaccacc ctatcctgat 720
cagattattt gtccagatga agagggcact gaaggaacca tttctttgtg gagtatcatc 780
tcaaaagtta ggattgaagc ctgcatgtgg ggtatcggta cagcaatcgg agagctgcct 840
ccatatttca tggccagagc agctcgcctc tcaggtgctg aaccagatga tgaagagtat 900
caggaatttg aagagatgct ggaacatgca gagtctgcac aagactttgc ctcccgggcc 960
aaactggcag ttcaaaaact agtacagaaa gttggatttt ttggaatttt ggcctgtgct 1020
tcaattccaa atcetttatt tgatetgget ggaataacgt gtggacaett tetggtacet 1080
ttttggacct tctttggtgc aaccctaatt ggaaaagcaa taataaaaat gcatatccag 1140
aaaatttttg ttataataac attcagcaag cacatagtgg agcaaatggt ggctttcatt 1200
ggtgctgtcc ccggcatagg tccatctctg cagaagccat ttcaggagta cctggaggct 1260
caacggcaga agcttcacca caaaagcgaa atgggcacac cacagggaga aaactggttg 1320
tectggatgt ttgaaaagtt ggtegttgte atggtgtgtt actteatect atetateatt 1380
aactccatgg cacaaagtta tgccaaacga atccagcagc ggttgaactc agaggagaaa 1440
actaaataag tagagaaagt tttaaactgc agaaattgga gtggatgggt tctgc
<210> 55
<211> 1747
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1562471CB1
accagcagaa ggctgggagt ctgtagtttg ttcctgctgc caggctccac tgaggggaac 60
ggggacctgt ctgaagagaa gatqcccctq ctgacactct acctqctcct cttctgqctc 120
teaggetact ccattgecac teaaateace ggtecaacaa cagtgaatgg ettggagegg 180
ggctccttga ccgtgcagtg tgtttacaga tcaggctggg agacctactt gaagtggtgg 240
tgtcgaggag ctatttggcg tgactgcaag atccttgtta aaaccagtgg gtcagagcag 300
gaggtgaaga gggaccgggt gtccatcaag gacaatcaga aaaaccgcac gttcactgtg 360
accatggagg atctcatgaa aactgatgct gacacttact ggtgtggaat tgagaaaact 420
ggaaatgacc ttggggtcac agttcaagtg accattgacc cagcaccagt cacccaagaa 480
gaaactagca gctccccaac tctgaccggc caccacttgg acaacaggca caagctcctg 540
aageteagtg teeteetgee ceteatette accatattge tgetgetttt ggtggeegee 600
tcactcttgg cttggaggat gatgaagtac cagcagaaag cagccgggat gtccccagag 660
caggtactgc agcccctgga gggcgacctc tgctatgcag acctgaccct gcagctggcc 720
ggaacctccc cgcgaaaggc taccacgaag ctttcctctg cccaggttga ccaggtggaa 780
gtggaatatg tcaccatggc ttccttgccg aaggaggaca tttcctatgc atctctgacc 840
ttgggtgctg aggatcagga accqacctac tqcaacatqq qccacctcaq taqccacctc 900
cccggcaggg gccctgagga gcccacggaa tacagcacca tcagcaggcc ttagcctgca 960
ctccaggete ettettggae eccaggetgt gageacacte etgecteate gaeegtetge 1020
cccctgctcc cctcatcagg accaacccgg ggactggtgc ctctgcctga tcagccagca 1080 ttgcccctag ctctgggttg ggcttggggc caagtctcag ggggcttcta ggagttgggg 1140
ttttctaaac gtcccctcct ctcctacata gttgaggagg gggctaggga tatgctctgg 1200
ggctttcatg ggaatgatga agatgataat gagaaaaatg ttatcattat tatcatgaag 1260
taccattatc ataatacaat gaacctttat ttattgccta ccacatgtta tgggctgaat 1320
aatggccccc aaagatatct gtgtcctaat cctcagaact tgtgactgtt accttctgtg 1380
gcagaaaggg acagtgcaga tgtatgtaag ttaaggactt tgagatagag aggttattct 1440
tgctgattca ggtgggccca aaatatcacc acaagggtcc tcataagaaa gaggccagaa 1500
ggtcaaagag gtagagacaa agtgatgatg gaagtggacg tgggtgtgac gtgagcaggg 1560
gccatgaatg ccgcagcett cagatgccag aaaqqqaaaq qaatqqattc ccctgcctgg 1620
agcctccaaa agaaaccagc cctgcccacg ccttgacttg agcccattga aactgatctt 1680
aaaaaaa
<210> 56
<211> 1473
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1618158CB1
acagegggac ageceggeag cettgggett ceagegetgg etteategee aceteeetge 60
cttctccac ttccgcattc ttaggtgacg gatggtggca ccatcaagca aaagatcttc 120 accttcgacg ccatgttctc caccaactac tcacacatgg agaactaccg caagcgagag 180
gacctggtgt accagtccac tgtgaggctg cccgaggtcc ggatctcaga caatggtccc 240
tatgagtgcc atgtgggcat ctacgaccgc gccaccaggg agaaggtggt cctggcatca 300
ggcaacatet teeteaaegt catggeteet eecaceteea tigaagtggt ggetgetgae 360
acaccagece cetteageeg etaccaagee cagaacttea egetggtetg categtgtet 420
ggaggaaaac cagcacccat ggtttatttc aaacgagatg gggaaccaat cgacgcagtg 480
cccctatcag agccaccage tgcgagetec ggcccctac aggacagcag gcccttccgc 540
agcettetge accettgacet ggatgacace aagatgeaga agteaetgte eeteetggae 600
gccgagaacc ggggtgggcg accctacacg gagcgcccct cccgtggcct gaccccagat 660
cccaacatcc tcctccagcc aaccacagag aacataccag agacggtcgt gagccgtgag 720
tttccccgct gggtccacag cgccgagccc acctacttcc tgcgccacag ccgcaccccg 780
agcagtgacg gcactgtgga agtacgtgcc ctgctcacct ggaccctcaa cccacagatc 840
gacaacgagg ccctcttcag ctgcgaggtc aagcacccag ctctgtcgat gcccatgcag 900
```

```
gcagaggtca cgctggttgc ccccaaagga cccaaaattg tgatgacgcc cagcagagcc 960
cgggtagggg acacagtgag gattctggtc catgggtttc agaacgaagt cttcccggag 1020
cccatgttca cgtggacgcg ggttgggagc cgcctcctgg acggcagcgc tgagttcgac 1080
gggaaggagc tggtgctgga gegggttccc gccgagctca atggctccat gtatcgctgc 1140
accgcccaga acccactggg ctccaccgac acgcacaccc ggctcatcgt gtttgaaaac 1200
ccaaatatcc caagaggaac ggaggactct aatggttcca ttggccccac tggtgcccgg 1260
ctcaccttgg tgctcgccct gacagtgatt ctggagctga cgtgaaggca cccgcccgg 1320
cagtettgtt cttagtetet ttecatetgt gtettggett etteagtegg tttaattaaa 1440
acaaacagaa caattttccc caaaaaaaaa aaa
                                                                 1473
<210> 57
<211> 1591
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1656935CB1
<400> 57
attaaacgac tcactatagg gaatttggcc ctcgaggcaa gaattcggca cgagggcttc 60
tataggagag ctttagaatg aagtcattta gaggagcagg cgaatcctaa ccgcatctct 120
ctctttagct ggactgaacc caaacatgaa tgtcaacagc atggacatga ccggtggctt 180
gtcggtgaag gacccatccc agtcccagtc acgcctcccc cagtggacgc accccaactc 240
catggataac ttgcccagtg ccgcttcccc cctggagcag aaccctagca agcatggtgc 300
tatccctgga ggtctaagca ttgggcctcc aggtaagtcc tccattgatg actcctatgg 360
ceggtacgat ttaatecaga acagtgagte accagecagt cetecegtag etgttececa 420
tagctggtca cgtgccaaat ctgacagtga taaaatctca aatggctcta gcatcaactg 480
gcccccagaa ttccatccgg gagttccatg gaaaggactg cagaatattg accctgagaa 540
tgaccctgac gtcactcctg gcagtgtccc cactgggcct accatcaaca ccaccatcca 600
ggatgtcaac cgctacctcc tcaagagtgg agggtcctcc ccgccatcat ctcagaatgc 660
cacgetgeet tettegagtg cetggeeact eagtgeetee ggetaeagta getettteag 720
cagcattgca teegcaecta gtgttgeagg.taaactgtea gacateaaat egacgtggte 780
ctctggccct acctcccaca cgcaagcctc tctgtctcat gaactatgga aggtgcccag 840
aaacagtact gcacccacga ggccacctcc agggttaacc aatcccaagc cctcctccac 900
etggggtgcc agececeteg getggaceag etectaetee tegggttetg cetggageae 960
cgacacctca ggaagaacca gcagctggct cgttcttcga aacctcactc cccagattga 1020
tggttctaaa ctgcggacat tgtgtttgca acatgggcct cttatcacat tccacctgaa 1080
tctgactcaa ggcaatgctg tggtccggta cagctccaag gaggagggct tgccaaaggc 1140
ccaggaagtc ctctgcacaa ttgtgcgtcc ttgggagaca cttagccatt ccttgggccc 1200
gagtttccgc ttggttggaa cgaaggaagt tggaattcgg gtttccttta agccgccaga 1260
gggcccaggc cgcattggcc agagcacaat tttccaaggt ctggcacaat tccacgacca 1320
gaggggcgtt tccaagctca caggacgtgg cgggattcac aggccacgcg ggaggggcaa 1380
ggcttctcac caacttgcac atatgagaca ttgtgaatta acattttaag agcgttgcga 1440
ctaattggga caatcatcgg acaaggaccc tgagttcaat tttgtaaagt gccctgttat 1500
aaatgtttgc cgtgtagaat aaaggtttct ttccactata tcccattgta tcgggatata 1560
tcacatcgta acagtgttat tttgggaaga a
                                                                 1591
<210> 58
<211> 1858
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1859305CB1
gcaggcgcgg cgaaacttcc ctctacccqc ccqqcccqcq qcqcgcaccg ttggcgctgg 60
acgetteete ettggaageg eeteteete aggteteaag aactgttttg agatgeagga 120
attcatctaa ttttcactgc cgggcgaggt gtgagagccc tagcatctga aagtggtcga 180
cttgcgagtt gttatggaga aaacttgtat agatgcactt cctcttacta tgaattcttc 240
```

```
agaaaagcaa gagactgtat gtatttttgg aactggtgat tttggaagat cactgggatt 300
gaaaatgctc cagtgtggtt attctgttgt ttttggaagt cgaaaccccc agaagaccac 360
cctactgccc agtggtgcag aagtcttgag ctattcagaa gcagccaaga agtctgacat 420
cataatcata gcaatccaca gagagcatta tgattttctc acagaattaa ctgaggttct 480
caatggaaaa atattggtag acatcagcaa caacctcaaa atcaatcaat atccagaatc 540
taatgcagag taccttgctc atttggtgcc aggagcccac gtggtaaaag catttaacac 600
catctcagcc tgggctctcc agtcaggagc actggatgca agtcggcagg tgtttgtgtg 660
tggaaatgac agcaaagcca agcaaagagt gatggatatt gttcgtaatc ttggacttac 720
tccaatggat caaggatcac tcatggcagc caaagaaatt gaaaagtacc ccctgcagct 780
atttccaatg tggaggttcc ccttctattt gtctgctgtg ctgtgtgtct tcttgttttt 840
ctattgtgtt ataagagacg taatctaccc ttatgtttat gaaaagaaag ataatacatt 900
togtatggct atttccattc caaatcgtat ctttccaata acagcactta cactgcttgc 960
tttggtttac ctccctggtg ttattgctgc cattctacaa ctgtaccgag gcacaaaata 1020
ccgtcgattc ccagactggc ttgaccactg gatgctttgc cgaaagcagc ttggcttggt 1080
agetetggga tttgccttcc ttcatgtcct ctacacactt gtgattccta ttcgatatta 1140
tgtacgatgg agattgggaa acttaaccgt tacccaggca atactcaaga aggagaatcc 1200
atttagcacc tcctcagcct ggctcagtga ttcatatgtg gctttgggaa tacttgggtt 1260
ttttctgttt gtactcttgg gaatcacttc tttgccatct gttagcaatg cagtcaactg 1320
gagagagttc cgatttgtcc agtccaaact gggttatttg accctgatct tgtgtacagc 1380
ccacaccetg gtgtacggtg ggaagagatt cctcagccet tcaaatetca gatggtatet 1440
tcctgcagcc tacgtgttag ggcttatcat tccttgcact gtgctggtga tcaagtttgt 1500
cctaatcatg ccatgtgtag acaacacct tacaaggatc cgccagggct gggaaaggaa 1560
ctcaaaacac tagaaaaagc attgaatgga aaatcaatat ttgaaacaaa gttcaattta 1620
gctggatttc tgaactatgg ttttgaatgt ttaaagaaga atgatgggta cagttaggaa 1680
agtttttttc ttacaccgtg actgagggaa acattgcttg tctttgagaa attgactgac 1740
atactggaag agaacaccat tttatctcag gttagtgaag aatcagtgca ggtccctgac 1800
tcttattttc ccagaggcca tggagctgag attgagacta gccttgtggt tttcacac
<210> 59
<211> 1454
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: 1949083CB1
<400> 59
caccetggtg tetteceetg tggccetgea aggeatatea tgetteetgt etetaggace 60
tgcttactag aaagcagcac ccgcctgaaa cctcacgaag cccagaacta caggaagaag 120
gcattgtggg tgtcctggtt ctccatcatt gtcaccctgg ccctcgcggt ggctgccttt 180
actgtctccg ttatgaggta cagcgcctct gcttttgggt ttgcatttga tgccatcctg 240
gacgtcctgt catcggcgat tgtcctgtgg cgttacagca acgcggccgc tgtgcactct 300
gcccataggg agtacatagc ctgtgtcatc ttgggggtga tattccttct gtcatccata 360
tgtatagtgg tcaaagccat ccatgacctc tcaactaggc tgctcccaga agtggacgat 420
ttcctgttca gtgtctccat tttaagtggg attctttgca gcatcctggc cgtgttgaag 480
ttcatgctgg ggaaggttct gaccagtaga gcactcataa cagatgggtt taactccctc 540
gtgggtggcg tgatgggctt ctccattctt ctgagcgcgg aagtgttcaa gcatgactcg 600
geggtetggt acctggacgg cagcatagge gttetgateg geeteaceat atttgeetat 660
ggggtcaaac tcctcatcga catggtgccg aaggtgaggc agacacgtca ctacgagatg 720
tttgagtgaa gggggccagc atccgcatga gaccatcgag atgaggagtt cccacatagg 780
caaagggtgc caatatttaa ctgaacatct ggtttctttt tggaagtttt ctttcacatg 840
gtttgtcatt acaagacaag gtctgcccag ccaggtggat ctaccttgcc cccatcacct 900
gccgcccca tcaaacatgt tgggacaatg cccataggaa tggacctcct tccccgtctc 960
cagctgggac tggcgttttt tagtctctgg agtatgatgg ttctcatggg taggatgaga 1020
tctttggcag aaaggtcttc ggtggtgctc tgagcctgcg ctgcatagga ctgagcagac 1080
ccacctcctc cagcttgggt ggccctgcca ctcctggttc caagtctctc ctttcctggc 1140
aggtettaag ggaagattgt accectcace etttacatac ccagaatcat cagtatgtca 1200
cttcctaatt tctatcagtg tatctcatta tttcatactg ttttactaat cctaagtcta 1260
aacagatttg ctcaaaagga gaccattcta ttttttaaag tacttagtga tacacgtata 1320
agetttgeat ggacgaatta aataageaca ttgacetttt ettgtacatt cagaacetga 1380
acatccatgt gaaaactggg tccatttttg agagatgtga aactacagtt tatatgtaat 1440
aaataaatat aata
```

```
<210> 60
<211> 2310
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 1996357CB1
<400> 60
ggcccggatg ttcggtgcag ctgccagatc cgctgatcta gtgcttctcg aaaaaaacct 60
tcaggcggcc catggctgtc gatattcaac cagcatgcct tggactttat tgtgggaaga 120
ccctattatt taaaaatggc tcaactgaaa tatatggaga atgtggggta tgcccaagag 180
gacagagaac gaatgcacag aaatattgtc agccttgcac agaatctcct gaactttatg 240
attggctcta tcttggattt atggcaatgc ttcctctggt tttacattgg ttcttcattg 300
aatggtactc ggggaaaaag agttccagcg cacttttcca acacatcact gcattatttg 360
aatgcagcat ggcagctatt atcaccttac ttgtgagtga tccagttggt gttctttata 420
ttcgttcatg tcgagtattg atgctttctg actggtacac gatgctttac aacccaagtc 480
cagattacgt taccacagta cactgtactc atgaagccgt ctacccacta tataccattg 540
tatttatcta ttacgcattc tgcttggtat taatgatgct gctccgacct cttctggtga 600
agaagattgc atgtgggtta gggaaatctg atcgatttaa aagtatttat gctgcacttt 660
acttetteee aattttaace gtgetteagg cagttggtgg aggeetttta tattaegeet 720
teceatacat tatattagtg ttatetttgg ttaetetgge tgtgtacatg tetgettetg 780
aaatagagaa ctgctatgat cttctggtca gaaagaaaag acttattgtt ctcttcagcc 840
actggttact tcatgcctat ggaataatct ccatttccag agtggataaa cttgagcaag 900
atttgcccct tttggctttg gtacctacac cagccctttt ttacttgttc actgcaaaat 960
ttaccgaacc ttcaaggata ctctcagaag gagccaatgg acactgagtg tagacatgtg 1020
aaatgccaaa aacctgagaa gtgctcctaa taaaaaagta aatcaatctt aacagtgtat 1080
gagaactatt ctatcatata tgggaacaag attgtcagta tatcttaatg tttgggtttg 1140
tetttgtttt gtttatggtt agaettacag aettggaaaa tgeaaaaete tgtaataete 1200
tgttacacag ggtaatatta tctgctacac tggaaggccg ctaggaagcc cttgcttctc 1260
tcaacagttc agctgttctt tagggcaaaa tcatgtttct gtgtacctag caatgtgttc 1320
ccattttatt aagaaaagct ttaacacgtg taatctgcag tccttaacag tggcgtaatt 1380
gtacgtacct gttgtgtttc agtttgtttt tcacctataa tgaattgtaa aaacaaacat 1440
acttgtgggg tctgatagca aacatagaaa tgatgtatat tgttttttgt tatctattta 1500
ttttcatcaa tacagtattt tgatgtattg caaaaataga taataattta tataacaggt 1560
tttctgttta tagattggtt caagatttgt ttggattatt gttcctgtaa agaaaacaat 1620
aataaaaagc ttacctacat aaaatttcaa tgttttgaca cttaattgtt gtttggcaca 1680
atagtatgga agtaattcaa actggtaaat agtttcctct catatctcgg gtatatatac 1740
ataccatatt ttattgatcc agagatactt atttcacttt gtgacatctc tgaattagga 1800
tgcatcttac aactgatggc ttattaggtt taatgaaata cagaagatac acagtataaa 1860
aagggttttc ctgtggttgg tttgtggttt gtgataggtg ttctgtgatg tttatgcttt 1920
gaaggcctta agactcatgg ttgcaaccat ggaagcaaaa tgaaattttt agctcttaac 1980
ctaacaacct gaccatgttt atccattttt attgtttaga agtttattta ctgatacttg 2040
gtggaggttg tgtgaattag ttaaatttta aatgtttaag acttctatta acagctgcaa 2100
aatatgaaag taagtgcact cacttttcct gtagtagtct gtcttttgaa ttcacagcag 2160
ttgtatcctt gagttacttt gttaatgtat ttttctcagt acatttaacc actgggaaat 2220
gaaccettgt acgaatgtgt ttettettet etgtaggaat aaaaaataaa tataaaaatt 2280
ttatttgtat tgcacacaaa aaaaaaaaaa
                                                                  2310
<210> 61
<211> 744
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2061330CB1
<400> 61
agtggtgtgt tacctgccga cagcataaag cgaggcaagg tccagccgtt ccgcccggca 60
tacaagetta tggageagee eeetttgaag ateteeaggt ggaetteaca gagatgteaa 120
agtgtagagg tgatcgagtg tggatcaaga actggaacgt agcctctttg tgtccactgt 180
```

```
ggaaaggacc ccagactgtc gttctgagca ctcccaccgc tgtgaaggta gaaggaatcc 240
cagcctggat ccaccacagc catgtaaaac ctgcagcgcc tgaaacctgg gaggcaagac 300
caagcccaga caacccctgc agagtgaccc tgaagaagac gacaagccct gctccagtca 360
cacceggaag etgactggte cacgeaegge egaageetga ggaageteat catgagatte 420
atttttctta aattttggac ttatacagta agggcttcaa ctgatcttac tcaaactggg 480
gactgttccc agtgtactca tcaggtcacc gaagtaggac agcaaattaa aacaatcttt 540
ctgttctata gttattatga atgtatggaa acaataaaag aaacttgttt gtataatgcc 600
actcagtaca aggtatgtag cccgagaaat gaccgacctg atgtgtgtta taacccatct 660
gagecectg caccacegtt tttgaaataa gaataagaac tggccttttc ctaggtgata 720
caagtaaaat aataactaga acag
<210> 62
<211> 1109
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2346947CB1
<220>
<221> unsure
<222> 30
<223> a, t, c, g, or other
<400> 62
gaagcagtgc agagaggaga gcggagcgcn agtgccgctg agcaaaggcc ttcaccatgg 60
cegagteece eggetgetge teegtetggg eeegetgeet ceaetgeetg tatagetgee 120
actggaggaa atgccccaga gagaggatgc aaaccagcaa gtgcgactgt atctggtttg 180
geetgetett ceteacette eteettteee tgagetgget gtacateggg etegteette 240
tcaatgacct gcacaacttc aatgaattcc tcttccgccg ctggggacac tggatggact 300
ggtccctggc attcctgctg gtcatctctc tactggtcac atatgcatcc ttgctattgg 360
teetggeest geteetgegg etttgtagae ageeetgea tetgeacage etceacaagg 420
tgctgctgct cctcattatg ctgcttgtgg cggctggcct tgtgggactg gacatccaat 480
ggcagcagga gtggcatage ttgcgtgtgt cactgcagge cacageeeca tteetteata 540
ttggagcagc cgctggaatt gccctcctgg cctggcctgt ggctgatacc ttctaccgta 600
tccaccgaag aggtcccaag attctgctac tgctcctatt ttttggagtt gtcctggtca 660
tetaettgge ceceetatge ateteeteae cetgeateat ggaaceeaga gaettaecae 720
ccaagectgg getggtggga cacegagggg cccccatget ggeteeegag aacaeeetga 780
tgtccttgcg gaagacagct gaatgcggac tactgtgttt gagactgatg tgatggtcag 840
ctccgatggg gtccccttcc tcatgcatga tgagcacctc agcaggacca cgaatgtagc 900
gagactcaat gctggatcct ggttcctaga gaggcgaccc ttctgggggg ccaaaccgct 1020
ggcaggccct gatcagaaag aggctgagag tcagtcggta ccagcattag aagagctatt 1080
ggaggaaget gcagecetea accetttea
                                                                 1109
<210> 63
<211> 2511
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 2795577CB1
<400> 63
gragccgtcg ccttcggagc gaagggtacc gacccggcag aagctcggag ctctcggggt 60
atcgaggagg caggcccgcg ggcgcacggg cgagcgggcc gggagccgga gcggcggagg 120
agccggcagc agcggcgcgg cgggctccag gcgaggcggt cgacgctcct gaaaacttgc 180
gegegegete geggeactge geeeggageg atgaagatgg tegegeeetg gaegeggtte 240
tactccaaca getgetgett gtgetgecat gteegcaceg geaceatect geteggegte 300
tggtatctga tcatcaatgc tgtggtactg ttgattttat tgagtgccct ggctgatccg 360
gatcagtata actiticaag tictgaactg ggaggtgact tigagticat ggatgatgcc 420
```

```
aacatgtgca ttgccattgc gatttctctt ctcatgatcc tgatatgtgc tatggctact 480
  tacggagcgt acaagcaacg cgcagcctgg atcatcccat tcttctgtta ccagatcttt 540
  gactttgccc tgaacatgtt ggttgcaatc actgtgctta tttatccaaa ctccattcag 600
  gaatacatac ggcaactgcc tcctaatttt ccctacagag atgatgtcat gtcagtgaat 660
  cctacctgtt tggtccttat tattcttctg tttattagca ttatcttgac ttttaagggt 720
  tacttgatta gctgtgtttg gaactgctac cgatacatca atggtaggaa ctcctctgat 780
  gtcctggttt atgttaccag caatgacact acggtgctgc tacccccgta tgatgatgcc 840
  actgtgaatg gtgctgccaa ggagccaccg ccaccttacg tgtctgccta agccttcaag 900
  tgggcggagc tgagggcagc agcttgactt tgcagacatc tgagcaatag ttctgttatt 960
  tcacttttgc catgagecte tetgagettg titgttgetg aaatgetact ttttaaaatt 1020
  tagatgttag attgaaaact gtagttttca acatatgctt tgctggaaca ctgtgataga 1080
 ttaactgtag aattcttcct gtacgattgg ggatataatg ggcttcacta accttcccta 1140
 ggcattgaaa cttcccccaa atctgatgga cctagaagtc tgcttttgta cctgctgggc 1200
 cccaaagttg ggcatttttc tetetgttcc etetettttg aaaatgtaaa ataaaaccaa 1260
 aaatagacaa ctttttcttc agccattcca gcatagagaa caaaacctta tggaaacagg 1320
 aatgtcaatt gtgtaatcat tgttctaatt aggtaaatag aagtccttat gtatgtgtta 1380
 caagaatttc ccccacaaca tcctttatga ctgaagttca atgacagttt gtgtttggtg 1440
 gtaaaggatt ttctccatgg cctgaattaa gaccattaga aagcaccagg ccgtgggagc 1500
 agtgaccatc tgctgactgt tcttgtggat cttgtgtcca gggacatggg gtgacatgcc 1560
 togtatgtgt tagagggtgg aatggatgtg tttggcgctg catgggatct ggtgccctc 1620
 ttctcctgga ttcacatccc cacccagggc ccgcttttac taagtgttct gccctagatt 1680
 ggttcaagga ggtcatccaa ctgactttat caagtggaat tgggatatat ttgatatact 1740
 totgoctaac aacatggaaa agggttttot tttccctgca agctacatcc tactgctttg 1800
 aacttccaag tatgtctagt caccttttaa aatgtaaaca ttttcagaaa aatgaggatt 1860
 gccttccttg tatgcgcttt ttaccttgac tacctgaatt gcaagggatt tttatatatt 1920
 catatgttac aaagtcagca actctcctgt tggttcatta ttgaatgtgc tgtaaattaa 1980
 aaaaaaaaa aaaaaaaaca caatacgaaa caacaagaac agcaagaatc aaaaagctta 2100
 aaatcctcga gtgcacaatg aagaaaacag gggggcgccc ctctaggggt cccagtttcg 2160
 gtcggggtga ttggggggac tgagcccttc ctatagggac cccctaattc tgatttcagg 2220
 ggcggggcgg tttttaaaaa gcgcggttaa cgggggaaac acccctgggg gttatccccc 2280
 ctettttaag eggegtgttg gtgggaaaga cacegeeett ttttgegeee aagtggggge 2340
 atatatetee eeggtgaggg egeeetetae eegatatetg geettteece agaagttttg 2400
 cccgcgccct ctactttggg gactttgggt gccgccacct ttattaaggg ggcgtttata 2460
 ccagcggcgg gggtttgtgg gcgtcctcgc gcgggaggcc cgctccaccc t
                                                                 2511
                        • • •
                 . .
 <210> 64
 <211> 788
 <212> DNA
 <213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: 3255825CB1
cccacgcgtc cgcagctgcg tcctctgggc cacgctccac ttgcccgctt ccacccggaa 60
agcccccag gctgagtgcg gcatgatctc catcaccgaa tggcagaaga ttggtgtggg 120
gatcaccggt ttcggcatct tcttcatcct ctttggaaca ctcctgtact ttgattccgt 180
geteetggee tttggaaace tgetgtteet gaegggeetg teeetcatea ttggeetgag 240
gaagacettt tggttettet tecaaeggea caaaeteaag ggaaecaget teeteetggg 300
gggtgtggtt atcgtgctcc tacgctggcc cctcctcggc atgttcctgg aaacctacgg 360
attetteage etetttaagg gettttteee tgtegeette ggtteetggg caatgtetge 420
aacatcccct tcctgggtgc gctgttccgg agacttcaag gcactagctc gatggtctga 480
aaaacagaga tgagctcctt gaacttggat cattggttga gggggctaga gggagaatgg 540
gaaccacccc ctcagtcccc tgcactgact cactccccga catatccgga cctccccaag 600
tccagaagga aggaatggag ctgagcaact gacgtcaaat ccccaagtcg actcaagagg 660
ctgccaggaa gcagagatgc agaccccaag gagactgggc tgggggctggt atcacaccct 720
cactctatat ttatgggagg aaaagtgaag attaaattcc caagttgtgc gtgtgtctaa 780
aaaaaaa
<210> 65
```

<211> 1831

```
<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 3393430CB1
 <400> 65
 gccttataaa gtagcctctg catctgcctg cctcgggcag aggagggcta ccctggggct 60
 gagagttcac ctgtctcagg aaccacctga gcccacagat cctgtgggca gcggccaggg 120
 cagccatggc ttgggcaagt aggctgggcc tgctgctggc actgctgctg cccgtggtcg 180
 gtgcctccac gccaggcacc gtggtccgac tcaacaaggc agcattgagc tacgtgtctg 240
 aaattgggaa agcccctctc cagcgggccc tgcaggtcac tgtccctcat ttcctggact 300
 ggagtggaga ggcgcttcag cccaccagga tccggattct gaatgtccat gtgccccgcc 360
 tccacctgaa attcattgct ggtttcggag tgcgcctgct ggcagcagct aattttactt 420
 tcaaggtctt tcgcgcccca gagcccctgg agctgacgct gcctgtggaa ctgctggctg 480
 acaccegegt gacceagage tecateagga eccetgtggt cagcatetet geetgetett 540
 tattctcggg ccacgccaac gagtttgatg gcagtaacag cacctcccac gcgctgctgg 600
 tcctggtgca gaagcacatt aaagctgtct tgagtaacaa gctgtgcctg agcatctcca 660
 acctggtgca gggtgtcaat gtccacctgg gcaccttaat tggcctcaac cccgtgggtc 720
 ctgagtccca gatccgctat tccatggtca gtgtgcccac tgtcaccagt gactacattt 780
 ccctggaagt caatgctgtt ctcttcctgc tgggcaagcc catcatcctg cccacggatg 840
 ccaccccttt tgtgttgcca aggcatgtgg gtaccgaggg ctccatggcc accgtgggcc 900
 teteccagea getgtttgae tetgegetee tgetgetgea gaaggeeggt geeeteaace 960
 tggacatcac agggcagctg aggtcggatg acaacctgct gaacacctct gctctgggcc 1020
 ggctcatccc ggaggtggcc cgccagtttc ccgagcccat gcctgtggtg ctcaaggtgc 1080
ggctgggtgc cacacctgtg gccatgctcc acacaaacaa cgccaccctg cggctgcagc 1140 ccttcgtgga ggtcctggcc acagcctcca actcggcttt ccagtccctc ttctccctgg 1200
atgtggtagt gaacttgaga ctccagctct ctgtgtccaa ggtgaagctt caggggacca 1260
cgtctgtgct gggggatgtc cagctcacgg tggcctcctc caacgtgggc ttcattgata 1320
cagatcaggt gcgcacactg atgggcaccg tttttgagaa gcccctgctg gaccatctca 1380
atgctctctt ggccatggga attgccctcc ctggtgtggt caacctccac tatgtcgccc 1440
ctgagatett tgtetatgag ggetacgtgg tgatatecag tggaetette taccagaget 1500
gaggcaagac cactgggagg cctgagagtg ggccagctcg ctgctcaggc gaatttctca 1560
tttcaagcca ctggggaaac tgaggcaaaa ccatacttag tcatcaccaa caagctggac 1620
tgcttagctg ggctgtttta tcttccctga gtgcctgggt ctccctccct cacttctgcc 1680
ctttcccttc ctcctcctt tctcctcct cttccctcat ctccccctc cttcctctgc 1740
cccaccccag gggggagcag actgctcctc caggctgtat agacctgccc tcttgcatta 1800
aacaacttct cttgagctgc aaaaaaaaa a
                                                                    1831
<210> 66
<211> 1499
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 3490990CB1
tgtttgagtt gggtgaagaa ggcgggaagt taatcctctt ccaatcagct ccccatctcg 60
ccctctggcg gctccggacc acaggccgag ttactctgat taccgccatg ctccaagacc 120
cgcactgaca gtccccacct cccgttctct gtcatcggtt ccctcaatgg agtccacatg 180
tttgggcaga atctggaggt gcagctgagc tctgcgagga ccgagaacac gactgtggtg 240
tggaaaagct tccatgacag catcaccctc attgttctgt catctgaggt gggcatctct 300
gagctgaggc tggagagact actccaaatg gtgtttggag ccatggtcct tcttgtggga 360
cttgaagaac tgaccaatat ccgcaacgtg gagagactga agaaggactt gagggccagt 420
tattgcctca tcgacagctt cctgggggac tcggagctca tcggggacct gacccagtgt 480
gtggactgcg tgattcctcc agaggggtcc ctcttgcagg aagccctctc cgggttcgct 540
gaggccgcgg gcacgacctt cgtcagtctg gtggtgtccg gccgggtggt ggcagcaaca 600
gagggttggt ggcggctggg gacgcccgag gccgtgctgc tcccctggct ggtggggtcc 660
ctgccgccgc agaccgctcg cgactacccg gtgtacctac cgcacgggag ccccacggtc 720
ccacaccggc tcctgaccct gactctgctg ccgagcctgg agctgtgtct actctgcggg 780
```

```
ccgagcccac ccctcagcca gttgtatcca cagcttctgg agcgctggtg gcagccactg 840
 ctggacccgt tgcgggcctg tctgccgttg ggaccccggg cgctgcccag tggcttcccc 900
 cttcacacag acatcctcgg gctgctgctc ctccacctgg aactgaagcg ctgcctcttc 960
 accytggage cettggggga taaagageet teaccagaac agegeeggeg ceteeteega 1020
 aacttctata ccctggtcac ctccacgcac ttcccaccag agccagggcc accagagaag 1080
 acagaagatg aggtctacca ggcccagctg cccagagctt gctacctggt gttggggact 1140
 gaggaaccag gcacaggagt gcgtctggtg gccttgcagc tggggcttcg gcggctgctg 1200
 ctgctgctgt ctccccagag tcccacccat gggctgcgaa gcctggccac ccacactctg 1260
 catgecetea ecceaettet ttgactaeet ageagtgggt gatggacaea gacatgggge 1320
 tgttagcgtc tctctgttta ttcgctcaca ataatacaca gcccctggat ggggaggggg 1380
 taggaggggc tacaacaggg tggggtggga ggggaggaga catccacttc cctggcccct 1440
 cteccetetg tgettggggg ggaaagggag ggagggggac tecceetaac ecceeagaa 1499
 <210> 67
 <211> 365
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 3635154CB1
 <400> 67
 gtttttttgc actaacttca ggagccagct cgtgatctca ggatgtatgg aaaaataatc 60
 tttgtattac tattgtcaga aattgtgagc atatcagcat caagtaccac tggtgtggca 120
atgcacactt caacctcttc ttcagtcaca aagagttaca tctcatcaca gacaaatgga 180
gaaacgggac aacttgtcca tcgtttcact gtaccagctc ctgtagtgat aatactcatt 240
attttgtgtg tgatggctgg tattattgga acgatcctct tattttctta cagttttcgc 300
cgactgataa agggctgagg gtgtagcctg catgctgccg atcttgctct gaaccggccg 360
<210> 68
<211> 1102 :
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 4374347CB1
<400> 68
gaggacagag caggcagcag agaccatggg gccccctca gcttgtcccc acagagaatg 60
cateceetgg caggggetet tgeteacage etcaetttta aetttetgga aegeaceeae 120
cactgcctgg ctctttattg catcagcgcc ctttgaagtt gctgaagggg agaatgttca 180
tctctctgtg gtttatctgc ccgagaatct ttacagctat ggctggtaca aagggaaaac 240
ggtggagccc aaccagctaa tcgcagcata tgtaatagac actcacgtta ggactccagg 300
gcctgcatac agcggtcgag agacaatatc acccagtgga gatctgcatt tccagaacgt 360
caccetagag gacacgggat actacaacct acaagtcaca tacagaaatt ctcagattga 420
acaggeatet caccatetee gtgtataega gteagtgget cageeeteea tecaageeag 480
cagcaccaca gtcacagaga agggctccgt ggtcctgacc tgccacacaa ataacactgg 540
aacctettte cagtggattt teaacaacca gegtetgeag gteacgaaga ggatgaaget 600
gtcctggttt aaccatgtgc tcaccataga ccccatcagg caggaggacg ctggggagta 660
tcagtgtgag gtctccaacc cagtcagctc caacaggagc gaccccctca agctgactgt 720
aaaatatgac aacactctag gcatcctgat cggggtcctg gttgggagtc ttctggtggc 780
tgcacttgtg tgtttcctgc tcctccgaaa aactggcagg gccagcgatc agagtgactt 840
cagggagcag cagccccag cctccacccc cggccatgga ccctctgaca gctctgacag 900
ctccatctcc taggaattgc tacactctga cacaaacatt tactgctgga tcgaccacaa 960
ageagatgtg gettettagg tteetetggg agetgeteet gtgggttgat ggagegteee 1020
tgaagccccc agccctgggg atggggaagg acatggagcc tgagccagag aaccagctct 1080
gagtcctgag gagacacagg cc
<210> 69
<211> 2546
```

4000

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 4596747CB1
<400> 69
cccggggcgc gcccaccgcg ccgcatccat gttcgacacc acaccccact ctggccggag 60
cacgccaagc agctccccat cgctccggaa acggctgcag ctcctgcccc caagccggcc 120
cccacctgag ccagaaccag gcaccatggt ggagaaggga tcagatagct cctcagagaa 180
gggtggggtg cctgggaccc ccagcaccca gagcctaggc agccggaact tcatccgcaa 240
cagcaagaag atgcagagct ggtacagtat gctgagcccc acttataagc agcgtaatga 300
qqacttccqq aaactqttca qcaaactccc cqaaqcaqaa cqcctcattq tqqattactc 360
ctgcgccctg cagcgtgaga tcctgctcca gggccgcctc tacctctctg agaactggat 420
ctgcttctac agcaacatct tccgctggga gaccacgatc tccatccagc tgaaggaagt 480
gacatgtctg aagaaggaaa agacggccaa gctgatcccc aacgccatcc agatctgcac 540
ggagagcgag aagcatttet teaetteett tggggeeegt gaeegetget teeteeteat 600
cttccgcctc tggcagaatg cactgcttga aaagacgctg agtccccgcg agctctggca 660
cctggtgcat cagtgctacg gctcagagct gggcctcacc agtgaggatg aggactatgt 720
ctccccttg cagctgaacg gtctggggac ccccaaggaa gtgggagatg tgatcgccct 780
gagcgacatc acctcctcgg gggcagctga ccgcagccag gagccaagcc cagtgggttc 840
gcgccgtggc catgtcacgc ccaacctttc ccgagccagc agcgacgcag accatggggc 900
agaggaggac aaggaggagc aggtagacag ccagccagac gcctcctcca gccagacagt 960
gaccccggtg gctgaacccc cgagcacaga gcccacccag cctgacgggc ccaccaccct 1020
gggccccttg gatctgctgc ccagtgagga gctattgaca gacacaagta actcctcttc 1080
atccactggg gaggaagcgg acttggctgc cctgcttccc gacctctccg gccgcctcct 1140
catcaactct gtcttccatg tgggcgctga gcggctccag cagatgctct tctcggactc 1200
gecetteete cagggettee tacagcagtg caagtteaca gacgtgacge tgagecectg 1260
gagtggggac agcaagtgcc accagcgccg ggtgctgacg tacaccatcc ccatcagcaa 1320
cccactgggc cccaagagcg cctccgtggt ggagacacag acgctgttcc ggcgcggccc 1380
ccaggccggc gggtgtgtgg tggactccga ggtgctgacg cagggcatcc cctaccagga 1440
ctacttctac actgcccacc gctactgcat cctgggtctg gcccggaaca aggcgcggct 1500
ccgagtgtct tctgagatcc gctaccgaaa gcagccgtgg agcctggtga agtcgctcat 1560
tgagaagaac tcgtggagcg gcattgaaga ctatttccac catctggagc gagagctcgc 1620
caaggctgag aagctgtctc tggaggaagg cgggaaggat gcccggggct tgctatccgg 1680
cctgcggcgg cggaagcggc ccctgagctg gcgggctcac ggggacgggc cccagcaccc 1740
agatectgae cectgtgeec gggeeggeat teacaceteg ggeteetea geteegget 1800 etcegaacea tetgtggaec agggeecegg ggeaggeate eccagtgeec tggtteteat 1860 eageattgtg atetgtgtga geettateat ecteategee etcaaegtee tgetetteta 1920
ccgcctctgg tccctggaaa ggacagccca cacctttgag tcctggcaca gcctggccct 1980
ggccaagggc aagttccccc agacggccac agagtgggcc gagatcctgg cgctgcagaa 2040
gcaattccac agcgtggagg tgcacaagtg gaggcagatc ctgcggggcct ccgtggagct 2100
cctggatgag atgaagttct cgctggagaa gctgcaccaa ggcatcacag tctcagaccc 2160
tccctttgac acccagcccc ggcccgatga cagcttttcc tgaggacccc ggccacgcag 2220
ctgttccccc acatggacag atggacacac agagcctcgg cggccactgc tggcacggtg 2280
tgagcgccag gcatctccca cccgcccctc ccgacggccc aaccaggggc tgtgcagacg 2340
tggggaccac ggaaccgaga tgcactttag accagggage tggcccggcc tctggcagge 2400
ccccactaa cttattttgc ccggctgagg ttgtgggggg cgcctcctgg ggtgcacgat 2460
tccctcagct ctgggtttaa tgtattatat ttatttgggg ccgacagtgc cccaataaag 2520
ggtcagaagt gaaaaataaa aaaaaa
                                                                     2546
<210> 70
<211> 1845
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5052680CB1
<400> 70
ctctggcgga ctgcctggcg gaagcgggaa cgtcgcatcc tgaggtaaag gtgcacggca 60
```

ulija ur Vita saposatar

```
tectgggaca tgtagtetgg eeggggeteg gaegeeeeet eggatgaatg ggaeegaage 120
tgactgcgaa ctacagcttc ttggcagcgt cqqtqttggc cgcgggagaa ggggagaccg 180
cggcggcccc cagtgagagc ggctttccag gacggtgcga tgtgctgcgc agcgaagagg 240 caggaggccg gcttcctggg gtagcggtac aggcgggcgc ttactctgtg cgcttgcttc 300
cccaaccetg caceggecat gegeeeggee ttggeggtgg geetggtgtt egeaggetge 360
tgcagtaacg tgatcttcct agagctcctg gcccggaagc atccaggatg tgggaacatt 420
gtgacatttg cacaattttt atttattgct gtggaaggct tcctctttga agctgatttg 480
ggaaggaagc caccagctat cccaataagg tactatgcca taatggtgac catgttcttc 540
accytgagcy tygtgaacaa ctatycccty aatctcaaca ttyccatycc cctycataty 600
atatttagat ccggttctct aattgccaac atgattctag gaattatcat tttgaagaaa 660
agatacagta tattcaaata tacctccatt gccctggtgt ctgtggggat atttatttgc 720
acttttatgt cagcaaagca ggtgacttcc cagtccagct tgagtgagaa tgatggattc 780
caggcatttg tgtggtggtt actaggtatt ggggcattga cttttgctct tctgatgtca 840
gcaaggatgg ggatattcca agagactctc tacaaacgat ttgggaaaca ctccaaggag 900
gctttgtttt ataatcacgc ccttccactt ccgggtttcg tcttcttggc ttctgatatt 960
tatgaccatg cagttetatt caataagtet gagttatatg aaatteeegt categgagtg 1020
accetgecea teatgtggtt etaceteete atgaacatea teacteagta egtgtgeate 1080
eggggtgtgt ttatecteae caeggaatge geeteeetea eegteaeget egtegtgaee 1140
ctacgcaaat ttgtgagcct catcttttcc atcttgtact tccagaaccc cttcaccctg 1200
tggcactggc tgggcacctt gtttgtcttc attgggacct taatgtacac agaggtgtgg 1260
aacaacctag ggaccacaaa aagtgagcct cagaaggaca gcaagaagaa ctgaggcctg 1320
tctggagtac gtagaccagt gtcgtcgtga gggtgggacc ctgtgaaggt ctgaccaccg 1380
tttcgctttt gttaatgccg agctacccgc agtgctgagc cagccgtgca aaaggaaatc 1440
ttcaggaggg gacttctcac gttgctcaga ctgacacatg tagactaaat agaaacccct 1500
cagccctaaa atagaaaaaa gaacaggtct agactattga acaggcgatt catttatttc 1560
tgttttgttt accgacatat tcagtattat tcttgttttc tgaattctga gtctcctgaa 1620
caaaaggett actatecatg gtettggaaa agattgteee ttetettget gttgtaatge 1680 atetetgeta eageagteat tgteateetg tgaeettate eettttgtet eecateacet 1740
tttccttctt cagcagcacc tcacagtcag tcagacgctg caggcaccac tatcaccagg 1800
agtggccaag taaaccgaga caccagtaac agcagggtgg acttc
<210> 71
<210> /1
<211> 1940
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5373575CB1
<400> 71
gtctcctgtc aaaagccatg ctcggcaggt ctgggtaccg ggcgctgccc ctgggtgatt 60
ttgaccgctt ccagcagtcg agettcggct ttctgggctc gcagaagggc tgcttgtccc 120
cggagcgggg cggcgtgggg acaggggccg atgtacccca gagctggccc tcctgcctct 180
gtcatggcct catcagtttc ctggggttct tgctgctgtt ggtcaccttc cccatttctg 240
gctggtttgc cctgaagatt gtgcccacct acgagcggat gattgtgttc cgcctgggcc 300
ggatccgcac cccccaggga cctggcatgg ttctgctctt gcccttcatt gactcctttc 360
agagggtgga tctgaggaca cgagccttca acgtccctcc ctgcaagctg gcctctaagg 420
acggggctgt gctgtccgtg ggagccgatg tccagtttcg catctgggac ccggtgctgt 480
cggtgatgac tgtgaaagac ctgaacacag ccacacgcat gacagcccag aacgccatga 540
ccaaggccct gctcaagagg ccgctgcggg agatccagat ggagaagctc aagatcagcg 600
accagettet getggagate aacgatgtga ccagggeetg ggggetggag gtagacegeg 660
tggagctggc agtggaggcc gtgctccagc cgcccagga cagcccagct gggcccaacc 720
tggacagcac cctccagcag ctggccctgc acttcctggg aggaagcatg aactcaatgg 780
caggaggtgc cccgtccccg gggccagcag acaccgtgga gatggtgagt gaagttgagc 840
cacctgcccc tcaagttggt gccaggtcca gtccgaagca gcctctggcg gaggggctac 900
tgactgctct acagcccttc ctgtctgagg ccctggtcag ccaagtcggg gcctgctacc 960
agttcaatgt cgtcctgccc agcggcaccc aaagcgccta cttcctggac ctcactacag 1020
gacgaggaag agtgggacac ggggtgcctg atggcatccc tgatgtggtg gtggagatgg 1080
ccgaggcaga cctgcgggcc ctgctatgca gagagctgcg gccctgggg gcctacatga 1140
gtggacgget gaaggtgaag ggcgacctgg ctatggccat gaagctggag gctgtcctca 1200
gggccttgaa gtagcagcct tggctgactt tccaqagccc agtcccaagc ctggcaccaa 1260
gecegagggg cetettggag gaggaggtgt teatetgeae caeagagagt tgaggeeeta 1320
```

```
acaaatttca ggcccagcca agagcccatg aatggaggct gcaggaggct gagtccggct 1380
gccatgcacg tetecectae agtggttete tggacaagge tttgtccate ceggteecca 1440
gctgagtgcc cagcgctgag ctgggtgcac ggtgtgattc caggaggaga gccaggcctg 1500
ccctgccctg ctggcttcct gactggagag acaggaccca cagaaacagc ctgacagcag 1560
ctggtttggt ccttgtgtga gggaccaagc atgtggccca ggctctaagc tctgcgggga 1620
ttggagaggg atggggaggg aagggaaggc agctccaaga agaggtccct gtggcgaagt 1680
tacctgggga tcctggctgg cccaccttcc tggctgcagt ccaggcccgt gctggcggga 1740
ttgggcatgg gaaggagcag ggcctgctgc ttccctggcg ctgctcccaa agatttctga 1800
ctcatctgcc agctctgtcc tgcatgcctg gcgagctggg gcccagggca gcatgaagga 1860
gagecetgeg thetgtgett ettaceagag gtttgeaage etcagacaaa taaatgtggt 1920
gtttacaatg taaaaaaaaa
<210> 72
<211> 880
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5524468CB1
gcgaagccga agggagcgcg gctaagagtg ccgcaccgcc tcacaacctg ggaaccggag 60
agtaggggcc gtcggctggc aagaacccgc cgtgcctcct cggcaagggc catccggtgc 120
cacccatgtc gcactagagc agaagagggt gagtcctgga actgcaacct gcacagagct 180
getetgtact gteectggtg gtegeegeea tgacetggtt ggtgetgetg gggacaetge 240
tetgeatget gegegttggg ttaggeacce eggaeteega gggttteeeg eecegtgege 300
tccacaactg cccctacaaa tgtatctgcg ctgccgacct gctaagctgc actggcctag 360
ggctgcagga cgtgccagcc gagttacctg ccgctactgc ggacctcgac ctgagccaca 420
acgcgctcca gcgcctgcgc cccggctggt tggcgcccct cttccagctg cgcgccctgc 480
acctagacca caacgaacta gatgcgctgg gtcgcggcgt cttcgtcaac gccagcggcc 540
tgaggctgct cgatctatca tctaacacgt tgcgggcgct tggccgccac gacctcgacg 600
ggctgggggc gctggagaag ctgcttctgt tcaataaccg cttggtgcac ttggacgagc 660
atgeetteea eggeetgege gegeteagee atetetacet gggetgeaac gaactegeet 720
cgttctcctt cgaccacctg cacggtctga gcgccaccca cctgcttact ctggacctct 780
cctccaaccg gctgggacac atctccgtac ctgagctggc cgcgctgccg gccttcctca 840
<210> 73
<211> 2403
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: 5944279CB1
agccacctgc tggccaggta cccctccctt acctggggca gtgtctgcct ggtggccact 60
agagacagcc cagcctgggc catggaagaa aacccgacct tggaatcaga agcctggggc 120
tectetaggg ggtggetgge ecceegggag gecagaggag geceateget gtettetgtg 180
ctgaacgagc tgcccagtgc tgccaccctt cggtaccgag accctggggt gctgccttgg 240
ggggcgctgg aggaggagga ggaggatgga ggaaggagca gaaaggcctt cacagaagtc 300
acceagacag agetgeagga ceeteaceet teeegggaac tgeeetggee catgeaggee 360
agacgggcac acaggcaaag aaatgccagc agggaccagg tggtctatgg ctctggaact 420
aagacggacc gatgggcgcg gctacttcgg aggtccaagg agaaaacaaa ggaaggcttg 480
cgaagcctgc agccctgggc gtggacactg aagaggatcg ggggccagtt tggcgccggc 540
acggagteet actteteet getgegette etgeteette ttaaegtget ggeetetgtg 600
ctcatggcct gcatgacgct gctgcccacc tggttgggag gcgctccccc aggccctccc 660
ggccccgaca tctcctcgcc ctgcggctcc tataaccccc actcccaggg cctggtcacc 720
tttgccaccc agctcttcaa cttgctctcg ggtgagggtt acctggaatg gtcccctctc 780
ttctatggct tctacccgcc ccgcccacgc ctggcggtca cctacctgtg ctgggccttt 840
geogttggee teatetgeet cetgeteate etgeateget eggtgtetgg getgaageag 900
```

```
acactgctgg cggagtccga ggctctgacc agctacagcc accgggtgtt ctcggcctgg 960
gactteggte tetgegggga egteeacgtg eggetgegee agegeateat ettgtacgaa 1020
ttaaaggtgg agctggagga gacagtggtg cggcgccagg ctgcggtgcg gacgctgggc 1080
cagcaagcca gggtttggtt ggtgcgggtg ctgctcaacc tgctggtggt cgcgctcctg 1140
qqqqcaqcct tctatggcqt ctactgggct acggggtgca ccgtggagct gcaggagatg 1200
ccccttgtcc aggagttgcc actgctgaag cttggggtga attaccttcc gtccatcttc 1260
atcgctgggg tcaattttgt gctgccgccc gtgttcaagc tcattgctcc actggagggc 1320
tacactegga gtegecagat egtttttate etgeteagga eegtgtttet tegectegee 1380
tccctqqtqq tcctgctctt ctctctctgg aatcagatca cttgtggggg cgactccgag 1440
gctgaggact gcaaaacctg tggctacaat tacaaacaac ttccgtgctg ggagactgtc 1500
ctgggccagg aaatgtacaa acttctgctc tttgatctgc tgactgtctt ggcagtcgcg 1560
ctgctcatcc agtttcctag aaagctcctc tgtggcctct gtcctggggc gctgggtcgt 1620
ctggcgggga cccaggagtt ccaggtgccc gacgaggtgc tggggctcat ctacgcgcag 1680
acggtggtct gggtggggag ttttttctgc cctttactgc ccctgcttaa cacggtcaag 1740
ttcctgctgc ttttctacct gaagaagctt accetcttct ccacctgctc cccggctgcc 1800
cgcaccttcc gggcctccgc ggcgaatttc tttttcccct tggtccttct cctgggtctg 1860
gccatctcca gcgttcccct gctttacagc atcttcctga tcccgccttc taagctttgt 1920
ggtccattcc gggggcagtc gtccatctgg gcccagatcc ctgagtctat ttccagcctc 1980 cctgagacca cccagaattt cctcttcttc ctggggaccc aggcttttgc tgtgcccctt 2040
ctgctgatct ccagcatcct gatggcgtac actgtggctc tggctaactc ctacggacgc 2100
ctcatctctq agctcaaacg tcagagacag acggaggcgc agaataaagt cttcctggca 2160
eggegetgt tggegetgae etceaecaaa eeggetettt gaeeceegea geecaegtee 2220
cgctttcaga ccccaggccc attgtaagcc taggtcacaa catctgtaaa ctaggagaac 2280
tggagaagac tccacgcct tccagctttg gtatctggag atttccaggg cccctcgccg 2340 ccacgtcct gactctcggg tgatcttcct tgtatcaata aatacagccg aggttggtga 2400
                                                                    2403
gcc
<210> 74
<211> 2850
<212> DNA
<213> Homo sapiens
<223> Incyte ID No: 6114480CB1
<400> 74
cggctcgagc ggctcgagtg aagagcctct ccacggctcc tgcgcctgag acagctggcc 60
tgacctccaa atcatccatc caccctgct gtcatctgtt ttcatagtgt gagatcaacc 120
cacaggaata tccatggctt ttgtgctcat tttggttctc agtttctacg agctggtgtc 180
aggacagtgg caagtcactg gaccgggcaa gtttgtccag gccttggtgg gggaggacgc 240
cgtgttctcc tgctccctct ttcctgagac cagtgcagag gctatggaag tgcggttctt 300
caggaatcag ttccatgctg tggtccacct ctacagagat ggggaagact gggaatctaa 360
gcagatgcca cagtatcgag ggagaactga gtttgtgaag gactccattg caggggggcg 420
tgtctctcta aggctaaaaa acatcactcc ctcggacatc ggcctgtatg ggtgctggtt 480
cagttcccag atttacgatg aggaggccac ctgggagctg cgggtggcag cactgggctc 540
acttectete atttecateg tgggatatgt tgacggaggt atccagttae tetgeetgte 600
ctcaggctgg ttcccccagc ccacagccaa gtggaaaggt ccacaaggac aggatttgtc 660
ttcagactcc agagcaaatg cagatgggta cagcctgtat gatgtggaga tctccattat 720
agtocaggaa aatgotggga goatattgtg ttocatocac ottgotgago agagtoatga 780
ggtggaatcc aaggtattga taggagagac gtttttccag ccctcacctt ggcgcctggc 840
ttctatttta ctcgggttac tctgtggtgc cctgtgtggt gttgtcatgg ggatgataat 900
tgttttcttc aaatccaaag ggaaaatcca ggcggaactg gactggagaa gaaagcacgg 960
acaggcagaa ttgagagacg cccggaaaca cgcagtggag gtgactctgg atccagagac 1020
ggctcacccg aagctctgcg tttctgatct gaaaactgta acccatagaa aagctcccca 1080
ggaggtgcct cactctgaga agagatttac aaggaagagt gtggtggctt ctcagggttt 1140
ccaagcaggg agacattact gggaggtgga cgtgggacaa aatgtagggt ggtatgtggg 1200
agtgtgtcgg gatgacgtag acagggggaa gaacaatgtg actttgtctc ccaacaatgg 1260
gtattgggtc ctcagactga caacagaaca tttgtatttc acattcaatc cccattttat 1320
cagectecce eccageace etectacaeg agtaggggte tteetggaet atgagggtgg 1380
gaccatetee ttetteaata caaatgacca gteeettatt tataceetge tgacatgtea 1440
gtttgaaggc ttgttgagac cctatatcca gcatgcgatg tatgacgagg aaaaggggac 1500
tcccatattc atatgtccag tgtcctgggg atgagacaga gaagaccctg cttaaagggc 1560
```

	24244424	acadecaadd	gagagtgctc	ccgacaggtg	gccccagctt	T620
cccacaccac	agacccagac	acagecaagg	gegegeget	ctcctttagg	gagctgaggt	1680
cctctccgga	geetgegeac	agagagccac	gtgagagett	ccadatdadd	ggggattggc	1740
tcttctgccc	tgagccctgc	agcagcggca	gccacagect	addacadaa	tagactcaca	1800
ctgaccctgt	gggagtcaga	agccatggct	gccccgaagc	ttessesset	tagactcaca	1860
ttaggtttag	tttgtgaaaa	ctccatccag	ctaagcyatc	tegaacaage	cacaacctcc	1920
	atttactaat	cacqqacaqt	dattcctqcc	ccacaggiga	agaccaaaga	~~~
	atasatasta	cttacaggtt	Egagggcaca	gigiligila	acgacgegee	
	acattttccc	accataaact	ctatttactt	attecacatt	aacccacccc	2010
	aaatcaccca	tagaatagtt	attgaacacc	Egetttgtga	ggcccaaaga	2100
	aataaaattt	ttcactgatt	ctataagccc	agcallacel	yataccaaaa	2100
	Deeperee	DDSSDDSDSS	aaaactacaq	geccatatee	CCCaccacca	2220
	22++c+222+	aaaattttaa	caaattaaac	taadtaatat	acceauugue	2200
cayacacaaa	tactceauac	aatttateee	acaaatgcag	agttggttta	atatttaaat	2340
gatatataac	tacttagtgt	ggcccgcccc	agtaggaag	aaaccatagg	aaggagagac	2400
atcaaccagt	graatteage	acaccaacay	agtaggaaag	caccccaaaa	attttccggc	2460
gaaggaaaga	gaaaaggggg	cgccccaact	agegageegg	caccccagaa	ctcaaaaaaa	2520
gcggactctc	aggggggtag	cgggtatcga	ageagetteg	aagacggaga	ctcggggggg	2580
gccgggacca	aattccccaa	gaggggcggt	tateggegeg	egetggeete	ggtgttaaac	2640
	7777C777C77	graccaagee	adductidad	Cogacogcac	9	
		SDDSSDss	aactagaggc	Caddatadta	gagagagaac	2.00
242444444	acaaggggaa	atgaggacgc	gaggggagag	atgaggagag	acagagaege	
dacdadcadc	gaggagagcc	gggaccggag	aggcaacgga	gaagtgacga	acgaagaaag	
acasadasas	gaaggaacgc	agaagtggaa				2850
acaagggagc						

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
$\square$ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.